fluorouracil has been researched along with Lymph Node Metastasis in 1896 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to determine the relative efficacy of doxorubicin versus methotrexate in combination with intravenous cyclophosphamide and 5-fluorouracil (FAC versus CMF) as adjuvant chemotherapy for operable breast cancer." | 10.20 | Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a ( Albanell, J; Aranda, J; Campbell, J; Camps, C; Candel, MT; Carrato, A; Casado, A; Diaz-Rubio, E; Gonzalez, R; Lizon, J; Martin, M; Massuti, B; Munarriz, B; Sole-Calvo, A; Villar, A, 2003) |
| "Forty postmenopausal women with non-metastatic ER-positive, HER2-negative invasive breast cancer with a primary tumor > 2 cm or positive axillary lymph node(s) proved by biopsy will be randomly (1:1) enrolled from Sun Yat-Sen Memorial Hospital to receive neoadjuvant everolimus plus letrozole for 18 weeks or fluorouracil, epirubicin plus cyclophosphamide (FEC) for six cycles before surgery." | 9.24 | Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial. ( Cao, M; Deng, H; Liu, J; Rao, N; Wu, W; Yang, Y; You, N, 2017) |
| "Whether addition of fluorouracil to epirubicin, cyclophosphamide, and paclitaxel (EC-P) is favourable in adjuvant treatment of patients with node-positive breast cancer is controversial, as is the benefit of increased density of dosing." | 9.20 | Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. ( Ardizzoni, A; Barni, S; Bighin, C; Bisagni, G; Boni, C; Bruzzi, P; Cavazzini, G; Cognetti, F; Colantuoni, G; De Laurentiis, M; De Placido, S; Del Mastro, L; Durando, A; Forestieri, V; Gamucci, T; Garrone, O; Giuliano, M; Gravina, A; Montemurro, F; Nisticò, C; Papaldo, P; Puglisi, F; Turletti, A; Valle, E, 2015) |
| "The current study aimed to evaluate the short-term efficacy and safety of endostar plus irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) in treatment of advanced colorectal cancer (CRC)." | 9.20 | Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study. ( Hu, XL; Li, BL; Sun, HG; Zhang, Y; Zhao, XH; Zhou, CY, 2015) |
| "To investigate the efficacy and safety of selective radiotherapy after distant metastasis of nasopharyngeal carcinoma (NPC) treated with dose-dense cisplatin plus fluorouracil." | 9.20 | Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil. ( Bu, JG; Chen, BY; Chen, KQ; Cheng, JL; Feng, J; Gao, WW; Liang, WC; Liang, Y; Xu, YC, 2015) |
| "Capecitabine is an active drug in metastatic breast cancer (BC)." | 9.20 | Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. ( Adrover, E; Andrés, R; Baena-Cañada, JM; Ballesteros, AI; Barnadas, A; Calvo, L; Carrasco, EM; Casas, M; de la Haba-Rodríguez, J; Del Barco Berron, S; del Carmen Cámara, M; González, S; Jara, C; Lluch, A; López-Vega, JM; Margelí Vila, M; Martín, M; Martínez de Dueñas, E; Martínez-Jáñez, N; Mendiola Fernández, C; Muñoz-Mateu, M; Plazaola, A; Ramos, M; Ribelles, N; Rodríguez, CA; Rodríguez-Lescure, Á; Ruiz Borrego, M; Ruiz Simón, A; Sánchez-Rovira, P; Santaballa, A, 2015) |
| "Capecitabine and cyclophosphamide are active in patients with advanced breast cancer, have non-overlapping toxic effects and synergy pre-clinically." | 9.17 | A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II. ( Dzhelali, MV; Findlay, MP; Harvey, VJ; Hinder, VA; Isaacs, RJ; Jameson, MB; Jeffery, GM; McLaren, BR; Pollard, S; Riley, GA; Scott, JN; Sharples, KJ; Simpson, AB, 2013) |
| "The aim of this phase II study was to investigate the efficacy and safety of oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic breast cancer (MBC) patients heavily pretreated with anthracyclines, taxanes, vinorelbine, gemcitabine, and capecitabine." | 9.16 | Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients. ( Hu, XC; Jia, Z; Sun, S; Wang, BY; Wang, LP; Yang, XY; Zhang, J; Zhang, QL, 2012) |
| "Women with axillary node-positive or high-risk node-negative breast cancer were randomly assigned to receive either three cycles of docetaxel and capecitabine (TX) followed by three cycles of cyclophosphamide, epirubicin, and capecitabine (CEX; n = 753) or three cycles of docetaxel (T) followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil (CEF; n = 747)." | 9.16 | Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. ( Ahlgren, J; Asola, R; Auvinen, P; Bono, P; Helle, L; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, M; Lindman, H; Nilsson, G; Nyandoto, P; Paija, O; Pajunen, M; Poikonen, P; Tanner, M; Villman, K, 2012) |
| "To explore the impact of dose intensity (DI) in the adjuvant setting of breast cancer, a randomized phase III trial was conducted comparing postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide, methotrexate and fluorouracil (CMF)in high-risk breast cancer patients." | 9.16 | Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. ( Bafaloukos, D; Batistatou, A; Bobos, M; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, MA; Eleftheraki, AG; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Kosmidis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Stathopoulos, GP; Timotheadou, E, 2012) |
| "We previously reported a 35% overall response rate (ORR) with biweekly 5-fluorouracil (5-FU) continuous infusion (TTD [Spanish Cooperative Group for Digestive Tumour Therapy] schedule) plus irinotecan as first-line therapy in elderly patients with metastatic colorectal cancer (mCRC)." | 9.16 | Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors. ( Alfaro, J; Aparicio, J; Aranda, E; Benavides, M; Cabrera, E; Campos, JM; Carrato, A; Dueñas, R; Etxeberría, A; Gil-Calle, S; Gómez, A; Gómez, MJ; González-Flores, E; Guasch, I; Marcuello, E; Massutí, B; Pericay, C; Queralt, B; Reina, JJ; Valladares-Ayerbes, M, 2012) |
| "The initial report from the Programme Action Concertée Sein (PACS) PACS01 trial demonstrated a benefit at 5 years for disease-free survival (DFS) and overall survival (OS) rates with the sequential administration of docetaxel after FEC100 (fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), and cyclophosphamide 500 mg/m(2)) for patients with node-positive, operable breast cancer." | 9.16 | Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial. ( Asselain, B; Audhuy, B; Beauduin, M; Campone, M; Canon, JL; Coudert, B; Eymard, JC; Jerusalem, G; Lévy, C; Machiels, JP; Martin, AL; Orfeuvre, H; Pénault-Llorca, F; Petit, T; Piot, G; Roché, H; Romieu, G; Serin, D; Spielmann, M; Veyret, C, 2012) |
| "Adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) have proven highly effective in rapidly proliferating breast cancer (RPBC)." | 9.15 | Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer. ( Amadori, D; Amaducci, L; Baldini, E; Biglia, N; Boccardo, F; Bonginelli, P; Brandi, M; De Lena, M; Faedi, M; Gianni, L; Maltoni, R; Paradiso, A; Ponzone, R; Rocca, A; Scarpi, E; Schittulli, F; Serra, P; Silvestrini, R; Tienghi, A; Valerio, MR, 2011) |
| "To evaluate the efficacy and safety of docetaxel plus thiotepa(TXT/TSPA) and docetaxel plus capecitabine(TXT/CAPE) in patients with metastatic breast cancer." | 9.15 | [Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer]. ( Che, L; DI, Lj; Jia, J; Jiang, Hf; Liang, X; Ren, J; Song, Gh; Wang, Xl; Yang, Hb; Yu, J; Zhang, J; Zhou, Xn; Zhu, Yl, 2011) |
| "The purpose of this study was to investigate the activity of capecitabine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer resistant to both anthracyclines and taxanes." | 9.14 | Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes. ( Fukushima, M; Ishida, T; Ishioka, C; Ishiwata, R; Kiba, T; Masuda, N; Matsuyama, K; Noguchi, S; Ohuchi, N; Takatsuka, Y; Takeda, M; Teramukai, S, 2009) |
| "The primary aim of this study was to compare the effectiveness of oral uracil-tegafur (UFT) with that of classical cyclophosphamide, methotrexate, and fluorouracil (CMF) given as postoperative adjuvant treatment to women with node-negative, high-risk breast cancer." | 9.14 | Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. ( Iwata, H; Kitaya, T; Kohno, N; Nakagami, K; Ohashi, Y; Sakamoto, G; Sano, M; Shimozuma, K; Sonoo, H; Takashima, S; Tokuda, Y; Tsuda, H; Watanabe, T; Yoshimoto, M, 2009) |
| "A randomized multicenter phase III study was conducted to compare the sequential docetaxel followed by epirubicin/cyclophosphamide combination with that of FEC regimen as adjuvant chemotherapy in women with axillary node-positive early breast cancer." | 9.14 | FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). ( Adamou, A; Athanasiadis, A; Boukovinas, I; Christophyllakis, C; Georgoulias, V; Kakolyris, S; Kalbakis, K; Karvounis, N; Kouroussis, C; Malamos, N; Mavroudis, D; Papakotoulas, P; Polyzos, A; Syrigos, K; Vamvakas, L; Varthalitis, I; Ziras, N, 2010) |
| " Therefore, we compared UFT with a combination therapy of cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients who had undergone curative surgery for axillary lymph node-positive breast cancer." | 9.14 | Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study. ( Asaga, T; Higaki, K; Inaji, H; Ito, T; Koh, J; Kohno, N; Komichi, H; Koyama, H; Kyono, S; Mitsuyama, S; Nishikawa, H; Ogita, M; Okamura, K; Osaki, A; Park, Y; Saito, T; Suzuki, T; Tanaka, F; Yamazaki, K, 2009) |
| "The Lapatinib Expanded Access Program (LEAP) was designed to provide access to lapatinib plus capecitabine for HER2-positive metastatic breast cancer patients who previously received an anthracycline, a taxane, and a trastuzumab and had no other treatment options." | 9.14 | An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. ( Capri, G; Chang, J; Chen, SC; Conte, P; Cwiertka, K; De Placido, S; Jerusalem, G; Jiang, Z; Johnston, S; Kaufman, B; Link, J; Oliva, C; Parikh, R; Preston, A; Ro, J; Rosenlund, J; Schütte, J; Selzer, M; Zembryki, D, 2010) |
| "To compare dose-intensified epirubicin monotherapy with a standard sequential regimen, patients with primary breast cancer and > or =10 involved axillary nodes were randomised to either four 21-day cycles of epirubicin 120 mg/m(2) (E120; n=202) or four 21-day cycles of epirubicin 90 mg/m(2) plus cyclophosphamide 600 mg/m(2) (EC) followed by three 28-day cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF; n=209)." | 9.14 | Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group. ( Ataseven, B; Conrad, B; Eiermann, W; Graf, E; Hilfrich, J; Kaufmann, M; Loibl, S; Massinger-Biebl, H; Schumacher, M; Vescia, S; von Minckwitz, G, 2010) |
| "PURPOSE Cyclophosphamide, epirubicin, and fluorouracil (CEF) and doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) are commonly used adjuvant regimens in women with early breast cancer." | 9.14 | Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. ( Albain, KS; Bramwell, V; Burnell, M; Chalchal, H; Chapman, JA; Gelmon, K; Levine, MN; O'Brien, P; Perez, EA; Pritchard, K; Rugo, H; Shepherd, LE; Vandenberg, T; Walley, B, 2010) |
| "We undertook a phase 3, parallel, randomised trial (SWOG-8814, INT-0100) in postmenopausal women with hormone-receptor-positive, node-positive breast cancer to test two major objectives: whether the primary outcome, disease-free survival, was longer with cyclophosphamide, doxorubicin, and fluorouracil (CAF) given every 4 weeks for six cycles plus 5 years of daily tamoxifen than with tamoxifen alone; and whether disease-free survival was longer with CAF followed by tamoxifen (CAF-T) than with CAF plus concurrent tamoxifen (CAFT)." | 9.14 | Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. ( Abeloff, MD; Albain, KS; Barlow, WE; Burton, GV; Cobau, CD; Farrar, WB; Green, SJ; Henderson, IC; Ingle, JN; Ketchel, SJ; Levine, EG; Lew, D; Lichter, AS; Livingston, RB; Martino, S; Muss, HB; Osborne, CK; Pritchard, KI; Ravdin, PM; Schneider, DJ, 2009) |
| "A weekly administration of alternating irinotecan or oxaliplatin associated to 5-Fluorouracil in advanced colorectal cancer was planned in order to evaluate a new schedule maintaining dose intensities of each drug as in double combinations and tolerability of the triplet association." | 9.14 | Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study. ( Bruera, G; Calista, F; Cannita, K; De Galitiis, F; Ficorella, C; Gebbia, N; Guglielmi, F; Iacobelli, S; Lanfiuti Baldi, P; Mancini, M; Marchetti, P; Martella, F; Morelli, MF; Pelliccione, M; Porzio, G; Ricevuto, E; Russo, A; Santomaggio, A; Tudini, M, 2010) |
| "This study was conducted to determine, in patients with advanced-stage breast cancer, the maximum tolerated dose (MTD) of capecitabine administered orally for 7 days followed by a 7-day rest (7/7), a schedule based on a mathematical method for the optimization of anticancer drug scheduling." | 9.13 | Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. ( Dugan, U; Edwards, C; Feigin, K; Hudis, C; Norton, L; Patil, S; Tan, KL; Theodoulou, M; Traina, TA, 2008) |
| "A pilot phase II study was conducted to evaluate the efficacy and safety of the Japanese intermittent regimen of capecitabine (Xeloda) in patients with advanced or recurrent breast cancer." | 9.12 | A pilot phase II study of capecitabine in advanced or recurrent breast cancer. ( Kimura, T; Saeki, T; Taguchi, T; Toi, M, 2006) |
| "The aim of this study was to evaluate the feasibility of a combination of epirubicin and paclitaxel followed by intravenous (iv) cyclophosphamide, methotrexate, and 5-fluorouracile (CMF) as adjuvant treatment of breast cancer patients with 10 or more metastatic axillary lymph nodes." | 9.12 | Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes. ( Battelli, N; Braconi, C; Cascinu, S; Cobelli, S; Dinota, A; Giacomini, G; Giorgi, F; Manzione, L; Massacesi, C; Morale, D; Pilone, A; Scanni, A; Sturba, F; Tummarello, D, 2006) |
| "We performed a controlled study to compare the response to cyclophosphamide (CPA), adriamycin (ADM), and fluorouracil (5-FU) (CAF therapy) with that to uracil-tegafur (UFT) plus tamoxifen (TAM) (UFT+TAM therapy), when given as postoperative adjuvant therapy to women with breast cancer." | 9.12 | [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set ( Inaji, H; Koyama, H; Mori, T; Nakao, K; Oka, T; Oshima, A; Ozawa, K; Saito, Y; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T, 2006) |
| "The PACS 01 trial compared six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) with a sequential regimen of three cycles of FEC followed by three cycles of docetaxel (FEC-D) as adjuvant treatment for women with node-positive early breast cancer." | 9.12 | Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. ( Asselain, B; Bonneterre, J; Campone, M; Canon, JL; Delozier, T; Eichler, F; Ferrero, JM; Fumoleau, P; Genève, J; Goudier, MJ; Kerbrat, P; Martin, AL; Monnier, A; Roché, H; Serin, D; Soulié, P; Spielmann, M; Symann, M; Viens, P; Vindevoghel, A, 2006) |
| "Paclitaxel and capecitabine have proven activity in the treatment of metastatic breast cancer (MBC)." | 9.12 | Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK. ( Aebi, S; Ballabeni, P; Gick, U; Hess, V; Lanz, D; Mingrone, W; Pestalozzi, B; Rauch, D; Rochlitz, C, 2006) |
| "The combination of docetaxel and capecitabine provides a well-tolerated and active chemotherapy regimen for metastatic breast cancer." | 9.12 | [Efficacy of docetaxel combined capecitabine on metastatic breast cancer]. ( Jiang, WQ; Shi, YX; Wang, XX; Yuan, ZY; Zhang, DS; Zhou, ZM, 2007) |
| "The aim of the study was to compare our reference adjuvant chemotherapy, FEC100 (fluorouracil 500 mg m(-2), epirubicin 100 mg m(-2) and cyclophosphamide 500 mg m(-2), six cycles every 21 days), to an epirubicin-vinorelbine (Epi-Vnr) combination for early, poor-prognosis breast cancer patients." | 9.12 | Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial. ( Audhuy, B; Bonneterre, J; Chollet, P; Clavère, P; Eymard, JC; Fargeot, P; Fumoleau, P; Goudier, MJ; Guastalla, JP; Kerbrat, P; Lortholary, A; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Simon, H; Veyret, C; Walter, S, 2007) |
| "This randomized phase III trial was performed to compare the 3-monthly depot LHRH agonist leuprorelin acetate (LAD-3M; n = 299) and chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF; n = 300) in pre- or perimenopausal patients with ER-positive, node-positive breast cancer." | 9.12 | Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. ( Bondar, G; Kossé, V; Lehmann, U; Maubach, L; Meurer, J; Possinger, K; Schmid, P; Tarutinov, V; Untch, M; Vassiljev, L; Wallwiener, D, 2007) |
| "Sixty-three premenopausal women with Stage 2, 3 breast cancer and > or =4 positive axillary nodes were treated in three successive cohorts with 70 mg/m(2) of epirubicin, 500 mg/m(2) of 5-fluorouracil and G-CSF every 14 days for 12 cycles." | 9.12 | A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes. ( Blackstein, M; Bowman, D; Burnell, M; Crump, M; Findlay, B; Levine, M; Norris, B; Palmer, MJ; Pritchard, KI; Shepherd, L; Skillings, J; Tonkin, K; Trudeau, M; Tu, D; Walde, D, 2007) |
| "Gastric cancer patients with cytologically confirmed malignant ascites were treated with cycles of oxaliplatin at 85 mg/m(2) plus leucovorin 20 mg/m(2) on the first day of treatment, followed by 5-fluorouracil (5-FU) via a 400 mg/m(2) bolus and a 22 h continuous infusion of 600 mg/m(2) 5-FU on Days 1-2 at 2-week intervals." | 9.12 | A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. ( Jang, JS; Jeong, JS; Kim, HJ; Kim, MC; Kim, SH; Kwon, HC; Lee, DM; Lee, S; Oh, SY; Yoo, HS, 2007) |
| "Irinotecan has proven anti-tumor activity as induction treatment in combination with 5-fluorouracil (5-FU) or as second-line treatment after 5-FU in patients with metastatic colorectal cancer." | 9.11 | Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil. ( Batran, SA; Bokemeyer, C; Büchele, T; Haag, C; Hartmann, JT; Hofheinz, RD; Jäger, E; Kanz, L; Niederle, N; Oechsle, K; Pflüger, KH; Reis, HE; Wilke, HJ, 2004) |
| "PURPOSE To evaluate long-term cardiac function in patients without disease who had received six cycles of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2), and cyclophosphamide 500 mg/m(2) (FEC 50) or the same regimen with epirubicin 100 mg/m(2) (FEC 100) as adjuvant chemotherapy for node-positive breast cancer in the French Adjuvant Study Group-05 trial." | 9.11 | Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. ( Barats, JC; Bonneterre, J; Chapelle-Marcillac, I; Clavère, P; Datchary, J; Fargeot, P; Fumoleau, P; Goudier, MJ; Kerbrat, P; Monnier, A; Montcuquet, P; Roché, H; Van Praagh, I; Veyret, C, 2004) |
| "We studied the usefulness of the oral 5-FU anti-cancer drug 1-hexylcarbamoyl-5-fluorouracil (HCFU) + cyclophosphamide (CPM) + tamoxifen (TAM) (HCT group) in comparison with CMF + TAM (CMFT group) in adjuvant therapy for breast cancer by a non-inferiority study based on a multi-institutional joint study." | 9.11 | 1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: a randomized controlled trial. ( Abe, R; Aoyama, H; Asaga, T; Awane, H; Danno, M; Ikeda, T; Kimura, M; Koyama, H; Mitsuyama, S; Nishi, T; Ogita, M; Sano, M; Takashima, S; Takatsuka, Y; Toi, M; Tominaga, T; Wada, T; Yoshida, M, 2004) |
| "To assess patterns of locoregional failure (LRF) in lymph node-positive (LN+) breast cancer patients treated with mastectomy and adjuvant chemotherapy (+/- tamoxifen) and without postmastectomy radiotherapy (PMRT) in five National Surgical Adjuvant Breast and Bowel Project trials." | 9.11 | Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized c ( Anderson, S; Bryant, J; Deutsch, M; Jeong, JH; Mamounas, E; Taghian, A; Wolmark, N, 2004) |
| "Oxaliplatin 100 mg/m(2) iv on day 1, and capecitabine 1,000 mg/m(2) orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma." | 9.11 | Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study. ( Casaretti, R; Cataldis, GD; Comella, P; Farris, A; Lucia, LD; Maiorino, L; Massidda, B; Natale, D; Palmeri, S; Tafuto, S, 2005) |
| "We randomized 1,475 premenopausal women with node-positive breast cancer to three, six, or nine courses of "classical" CMF (cyclophosphamide, methotrexate, and fluorouracil)." | 9.11 | Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Ca ( Bonetti, M; Carbone, A; Castiglione-Gertsch, M; Coates, AS; Collins, J; Crivellari, D; Fey, MF; Gelber, RD; Goldhirsch, A; Golouh, R; Gruber, G; Holmberg, SB; Lindtner, J; Nasi, ML; Price, KN; Rudenstam, CM; Simoncini, E; Thürlimann, B, 2005) |
| "A multicenter phase III randomized study comparing the efficacies of two adjuvant polychemotherapeutic regimens in 145 patients with stage II node-positive breast cancer: the standard chemotherapy combination, CMF (cyclophosphamide, methotrexate, 5-fluorouracil), and an experimental protocol, CNF (cyclophosphamide, mitoxantrone [Novantrone], 5-fluorouracil) in which mitoxantrone replaced methotrexate." | 9.10 | CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroups. ( Borovik, R; Brenner, HJ; Brenner, J; Catane, R; Chaitchik, S; Farbstein, H; Inbar, MJ; Peretz, T; Rizel, S; Ron, IG; Shani, A; Wigler, N, 2002) |
| "Between 1986 and 1990, 621 patients with operable breast cancer were randomly assigned to receive fluorouracil (Roche SA, Basel, Switzerland) 500 mg/m2, epirubicin (Pharmacia SA, Milan, Italy) 50 mg/m2, and cyclophosphamide (Asta Medica AG, Frankfurt, Germany) 500 mg/m2 every 21 days (FEC 50) for six cycles (6 FEC 50); FEC 50 for three cycles (3 FEC 50); or the same regimen with epirubicin 75 mg/m2 (FEC 75) for three cycles (3 FEC 75)." | 9.10 | Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. ( Brémond, A; Clavère, P; Datchary, J; Facchini, T; Fargeot, P; Fumoleau, P; Goudier, MJ; Jacquin, JP; Kerbrat, P; Luporsi, E; Mihura, J; Monnier, A; Namer, M; Pourny, C; Ramos, R; Romestaing, P; Schraub, S; Seffert, P; Serin, D; Sztermer, JF, 2003) |
| "The Zoladex Early Breast Cancer Research Association (ZEBRA) trial compared the efficacy and tolerability of goserelin (Zoladex) with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy in pre-/perimenopausal women with node-positive early breast cancer." | 9.10 | Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. ( Blamey, R; Cuzick, J; de Haes, JC; Fogelman, I; Jonat, W; Kaufmann, M; Namer, M; Sauerbrei, W; Schumacher, M, 2003) |
| "To compare quality of life (QoL) in premenopausal and perimenopausal patients with node-positive, early breast cancer treated with the endocrine agent goserelin (Zoladex; AstraZeneca Pharmaceuticals LP, Wilmington, DE) or cyclophosphamide + methotrexate + fluorouracil (CMF)." | 9.10 | Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group. ( de Haes, H; Jonat, W; Kaufmann, M; Olschewski, M; Sauerbrei, W; Schumacher, M, 2003) |
| "The present study aimed at evaluating the efficacy of Raltitrexed, a specific thymidilate synthase inhibitor, in patients with advanced colorectal cancer (ACC) in relapse (>8 weeks) after a prior response or disease stabilization to first-line chemotherapy combination with lrinotecan+5-Fluorouracil (5-FU)+Leucovorin (LV)." | 9.10 | Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy. ( Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M, 2002) |
| "5-fluorouracil remains the standard therapy for patients with advanced/metastatic colorectal cancer." | 9.10 | Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study. ( Blackstock, AW; Case, D; Higgs, V; Melin, SA; Savage, P; Tomlinson, SK; White, DR, 2002) |
| "Classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) including oral cyclophosphamide is still considered an important adjuvant chemotherapy regimen in patients with early breast cancer (BC)." | 9.10 | The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative dos ( Awada, A; Bartholomeus, S; Beauduin, M; Cardoso, F; Di Leo, A; Dolci, S; Ferreira Filho, AF; Focan, C; Michel, J; Paesmans, M; Piccart, MJ; Vindevoghel, A, 2002) |
| "To evaluate the activity and safety of an alternating schedule of irinotecan (CPT-11) with high-dose 5-fluorouracil (5-FU) given as a weekly 48-hour infusion in combination with leucovorin (LV) in the first-line treatment of metastatic colorectal cancer (MCRC) patients." | 9.10 | A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer. ( Manzione, L; Reggiardo, G; Rosati, G; Rossi, A, 2002) |
| "This phase-II study was conducted to investigate the potential benefit from the addition of mitomycin to a conventional anthracycline-cisplatin- and 5-fluorouracil-based chemotherapy for recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type (UCNT)." | 9.09 | Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. ( Alonso, S; Armand, JP; Chouaki, N; Cortès-Funes, H; Cvitkovic, E; Fandi, A; Hasbini, A; Lianes, P; Mahjoubi, R; Raymond, E; Taamma, A, 1999) |
| "We have investigated the relationship between c-erbB(2) status, estrogen receptor (ER) status and outcome in 274 women with node-positive breast cancer who, following excision and axillary clearance, were randomized to receive either 6 cycles of cyclophosphamide/methotrexate/fluorouracil (CMF) (n = 129) or no such treatment (n = 145)." | 9.09 | Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. ( Barnes, DM; Gillett, CE; Harris, WH; Miles, DW; Smith, P, 1999) |
| "This multicenter phase II study was designed to assess the efficacy of the alternating schedule of tomudex with methotrexate (MTX)/5-fluorouracil (5-FU)/leucovorin (LV) in first-line chemotherapy for metastatic colorectal cancer." | 9.09 | A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. ( Agostinelli, R; Baldelli, AM; Barni, S; Cascinu, S; Catalano, G; Catalano, V; Frontini, L; Gasparini, G; Giuliodori, L; Labianca, R; Martignoni, G; Mattioli, R; Silva, RR, 1999) |
| "To evaluate the outcome in patients with stage II hormone receptor-positive breast cancer treated or not treated with low-dose, short-term chemotherapy in addition to tamoxifen in terms of disease-free and overall survival." | 9.09 | Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer. ( Fridrik, M; Gnant, M; Haider, K; Hausmaninger, H; Jakesz, R; Kolb, R; Kubista, E; Manfreda, D; Mittlböck, M; Mlineritsch, B; Samonigg, H; Steger, G; Steindorfer, P; Stierer, M; Tschurtschenthaler, G, 1999) |
| "A phase II pilot study was carried out on 30 patients to ascertain the toxicity and efficacy of combination chemotherapy with mitoxantrone, methotrexate, 5-fluorouracil (NMF) in the adjuvant setting for axillary lymph node-positive breast cancer." | 9.09 | Adjuvant chemotherapy with a combination of mitoxantrone, methotrexate, 5-fluorouracil for node-positive breast cancer: phase II pilot study. ( Bando, H; Kanno, M; Kawahara, F; Mura, T; Nakamura, S; Noguchi, M; Taniya, T; Tsugawa, K; Uotani, C, 1999) |
| "Following modified radical mastectomy, pre- and perimenopausal (amenorrhoea for < 5 years) patients with stage II or III breast cancer received CMF (cyclophosphamide 600, methotrexate 40, 5-fluorouracil 600 mg/m2 intravenously (i." | 9.09 | Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial. ( Andersen, J; Andersson, M; Cold, S; Dombernowsky, P; Ejlertsen, B; Jensen, MB; Kamby, C; Kjaer, M; Mouridsen, H; Overgaard, M; Rose, C, 1999) |
| "According to one of the most recent key scientific questions concerning the use of biomarkers in clinical trials, we investigated whether node-negative breast cancer patients, defined as high-risk cases on the basis of tumor cell proliferation, could benefit from cyclophosphamide, methotrexate, and fluorouracil (CMF) adjuvant therapy." | 9.09 | Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study. ( Amadori, D; Becciolini, A; Catalano, G; Gambi, A; Giunchi, DC; Marangolo, M; Nanni, O; Pacini, P; Perroni, D; Ravaioli, A; Rossi, A; Scarpi, E; Tienghi, A; Volpi, A, 2000) |
| " Therefore, we developed an individualised fluorouracil, epirubicin, cyclophosphamide (FEC) regimen to improve outcomes in patients with high-risk early breast cancer." | 9.09 | Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. ( Anker, G; Bengtsson, NO; Bergh, J; Blomqvist, C; Erikstein, B; Holte, H; Kellokumpu-Lehtinen, P; Lidbrink, E; Lindman, H; Ljungman, P; Malmström, P; Nilsson, J; Ottosson, S; Salminen, E; Söderlund, G; Wiklund, T; Wilking, N; Wist, E, 2000) |
| "Between April 1990 and July 1993, 565 operable breast cancer patients with either more than three positive nodes or between one and three positive nodes with Scarff Bloom Richardson grade > or = 2 and hormone receptor negativity were randomized after surgery to receive either fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2), and cyclophosphamide 500 mg/m(2) every 21 days for six cycles (FEC 50) or the same regimen except with epirubicin dose of 100 mg/m(2) (FEC 100)." | 9.09 | Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. ( , 2001) |
| "We evaluated the usefulness of adjuvant chemotherapy with low-dose epirubicin (EPI) as a key drug in patients with axially-node positive breast cancer." | 9.09 | [Usefulness of ambulatory adjuvant chemotherapy with low-dose epirubicin in patients with axially-node positive breast cancer: Chiba Epirubicin Cooperative Study Group]. ( Miyauchi, M; Nakajima, N; Ogawa, K; Oheda, Y; Ohno, K; Suzuki, M; Takahashi, M; Tsukamoto, T; Yamamoto, K; Yamamoto, N, 2001) |
| "Adjuvant combination chemotherapy with cyclophosphamide, methotrexate, and fluorouracil was administered after radical mastectomy for primary breast cancer with histologically positive axillary lymph nodes to assess whether it would improve treatment outcome as compared with surgery alone." | 9.08 | Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. ( Bonadonna, G; Brambilla, C; Moliterni, A; Valagussa, P; Zambetti, M, 1995) |
| "A prospective randomized study was conducted to compare the adjuvant efficacy of six cycles of high-dose ACMF (Adriamycin, ADM; cyclophosphamide, CPA; methotrexate, MTX; 5-fluorouracil, 5-FU) with that of 12 cycles of low-dose ACMF in premenopausal, node-positive breast cancer patients." | 9.08 | Adjuvant six cycles of high-dose adriamycin, cyclophosphamide, methotrexate, 5-fluorouracil (ACMF) vs. 12 cycles of low-dose ACMF with tamoxifen for premenopausal, node-positive breast cancer patients: results of a prospective randomized study. ( Akashi, S; Fukutomi, T; Nanasawa, T; Yamamoto, H, 1995) |
| "To determine whether a combination chemotherapy regimen that contains epirubicin (fluorouracil, epirubicin, and cyclophosphamide [FEC]) is superior to the standard cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in premenopausal women with axillary node-positive operable breast cancer." | 9.08 | Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab ( Aapro, M; Amadori, D; Bliss, JM; Chilvers, CE; Coombes, G; Coombes, RC; Espié, M; Ferreira, EP; Gambrosier, P; Marty, M; McArdle, C; Morvan, F; Pérez-López, FR; Richards, M; Vassilopoulos, P; Villar-Grimalt, A; Wils, J; Woods, EM, 1996) |
| "To determine the long-term impact on disease-free survival (DFS) and overall survival (OS) of adjuvant anthracycline-based chemotherapy, when prospectively compared by random allocation with standard cyclophosphamide, methotrexate, and fluorouracil (CMF) in node-positive (N+) breast cancer patients." | 9.08 | Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. ( Belpomme, D; Chollet, P; Delgado, M; di Palma, M; Fargeot, P; Fumoleau, P; Guerrin, J; Hill, C; Ithzaki, M; Le Mevel, B; Mathé, G; Metz, R; Misset, JL; Plagne, R, 1996) |
| "By a collaborative study undertaken by 11 medical institutions in the Kita-Kyushu area, we evaluated the clinical efficacy of the combination of medroxyprogesterone acetate (MPA) and Tamoxifen (TAM) as a postoperative adjuvant endocrine therapy for Stage III breast cancer." | 9.08 | [Administration method and recurrence-preventing effect of medroxyprogesterone acetate (MPA) as a postoperative adjuvant endocrine therapy for stage III breast cancer. Kitakyushu Collaborative Study Group for Breast Cancer]. ( Egami, T; Ikeda, S; Kuroda, Y; Mitsuyama, S; Mori, A; Murakami, F; Nakamura, Y; Nishikata, F; Ohe, H; Ohsato, K, 1996) |
| " In patients with node-positive breast cancer adjuvant chemotherapy with cyclophosphamide+ methotrexate+fluorouracil has been reported to improve survival in comparison with patients who are not given this treatment." | 9.08 | Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer. ( Becagli, P; Messori, A; Tendi, E; Trippoli, S, 1996) |
| "Between July 1986 and April 1993, 1,266 postmenopausal breast cancer patients with node-positive disease were randomly assigned to receive one of four adjuvant therapy regimens: (A) tamoxifen alone for 5 years; (B) tamoxifen plus three courses of early cyclophosphamide, methotrexate, and fluorouracil (CMF) on months 1, 2, and 3; (C) tamoxifen plus delayed single courses of CMF on months 9, 12, and 15; (D) tamoxifen plus early and delayed CMF on months 1, 2, 3, 9, 12, and 15." | 9.08 | Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. ( , 1997) |
| "To compare two adjuvant combination chemotherapies, cyclophosphamide, methotrexate, and fluorouracil (CMF) and chlorambucil, methotrexate, and fluorouracil (LMF), for patients who had undergone potentially curative surgery for unilateral breast cancer, in terms of relapse, survival, and toxicity." | 9.08 | Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82. ( Castiglione, M; Cavalli, F; Jungi, WF; Leyvraz, S; Maibach, R; Obrecht, JP; Schildknecht, O; Senn, HJ; Siegenthaler, P, 1997) |
| "The objective of this study was to compare the antitumor activity of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) with that of the 5-fluorouracil/doxorubicin/cyclophosphamide (FAC) combination by evaluating the extent of residual disease in the breast and regional lymph nodes of patients with breast cancer following four cycles of induction chemotherapy." | 9.08 | Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer. ( Ames, F; Asmar, L; Buzdar, AU; Hortobagyi, GN; McNeese, M; Rahman, Z; Singletary, S; Theriault, RL, 1997) |
| "The B-20 study of the National Surgical Adjuvant Breast and Bowel Project (NSABP) was conducted to determine whether chemotherapy plus tamoxifen would be of greater benefit than tamoxifen alone in the treatment of patients with axillary lymph node-negative, estrogen receptor-positive breast cancer." | 9.08 | Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. ( Abramson, N; Atkins, JN; Bryant, J; DeCillis, A; Deschenes, L; Dignam, J; Dimitrov, NV; Emir, B; Fisher, B; Margolese, RG; Shibata, H; Wickerham, DL; Wolmark, N, 1997) |
| "The Intergroup conducted this breast cancer adjuvant trial to compare an investigational 16-week regimen with cyclophosphamide, doxorubicin, and fluorouracil (5-FU; CAF)." | 9.08 | Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study. ( Abeloff, MD; Cella, D; Citron, ML; Fairclough, DL; Fetting, JH; Gray, R; Grove-Conrad, M; Henderson, IC; Margolin, KA; Osborne, CK; Pandya, K; Robert, N; Smith, TJ, 1998) |
| "To determine the relative efficacy of an intensive cyclophosphamide, epirubicin, and fluorouracil (CEF) adjuvant chemotherapy regimen compared with cyclophosphamide, methotrexate, and fluorouracil (CMF) in node-positive breast cancer." | 9.08 | Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical ( Abu-Zahra, H; Arnold, A; Bowman, D; Bramwell, VH; Burnell, M; Findlay, B; Levine, MN; MacKenzie, R; Myles, J; Norris, BD; Ottaway, J; Pritchard, KI; Robert, J; Shepherd, LE; Tu, D; Vandenberg, T; Warr, D; Williams, CK, 1998) |
| "In 1984, the International Collaborative Cancer Group (ICCG) started a randomised trial comparing adjuvant treatment with cyclophosphamide 100 mg/m2 orally on days 1 to 14, methotrexate 40 mg/m2 intravenously on days 1 and 8 plus fluorouracil 600 mg/m2 intravenously on days 1 and 8 every 4 weeks for 6 cycles (CMF) vs fluorouracil 600 mg/m2, epirubicin 50 mg/m2 and cyclophosphamide 600 mg/m2 (FEC), all given intravenously on day 1 for 8 cycles at 3-week intervals in premenopausal patients with node-positive breast cancer." | 9.07 | Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collaborativ ( Bliss, J; Coombes, RC; Marty, M; Wils, J; Woods, E, 1993) |
| "CMFVP chemotherapy, either alone or in combination with tamoxifen, has not been shown to be superior to tamoxifen alone in the treatment of postmenopausal women with node-positive, ER-positive, operable breast cancer." | 9.07 | Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. ( Abeloff, MD; Costanzi, JJ; Cruz, AB; Farrar, WB; Green, S; Jewell, WR; Metch, B; Minton, JP; Osborne, CK; Rivkin, SE, 1994) |
| "Seventeen patients with either newly diagnosed breast cancer with more than four involved axillary nodes (five patients) or metastatic breast cancer (12 patients) were treated with cyclophosphamide 1 g/m2, doxorubicin 50 mg/m2, and fluorouracil 500 mg/m2 (CAF) intravenously (IV) once every 3 weeks." | 9.07 | Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil. ( Gelmon, KA; O'Reilly, SE; Onetto, N; Page, RA; Parente, J; Plenderleith, IH; Rubinger, M, 1993) |
| "This phase III clinical trial was designed to evaluate the therapeutic efficacy and toxicity of the alkylating agent cyclophosphamide in combination with the antimetabolites methotrexate and fluorouracil adjuvant to breast cancer surgery." | 9.07 | Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes. ( Canellos, GP; Frei, E; Gelman, RS; Hayes, DF; Henderson, IC; Obando, A; Osteen, R; Shapiro, CL, 1993) |
| "Thirty-eight patients with stage II breast cancer with four or more positive axillary lymph nodes were randomized to receive CMF (cyclophosphamide, methotrexate and 5-fluorouracil, every 3 weeks) or CXF (cyclophosphamide, mitoxantrone and 5-fluorouracil, every 3 weeks)." | 9.07 | A preliminary report of a pilot randomized trial comparing cyclophosphamide, methotrexate and 5-fluorouracil with cyclophosphamide, mitoxantrone and 5-fluorouracil in the adjuvant therapy of stage II breast cancer with four or more positive axillary nodes ( Ben-Dor, CG; Brufman, G; Isacson, R; Safra, T; Uziely, B, 1993) |
| "The Comprehensive Cancer Center trial 82-01 is a prospective randomized study to investigate the value of the addition of high-dose medroxyprogesterone acetate (MPA) to chemotherapy in patients with node-positive operable breast cancer." | 9.07 | Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients. ( Bron, H; de Jong, J; Fickers, M; Hupperets, PS; Jager, J; Schouten, HC; Schouten, L; Smeets, J; Volovics, L; Wils, J, 1993) |
| "A multicentre pilot study has been conducted to determine an intensive regimen of cyclophosphamide, epirubicin, and fluorouracil which was tolerable and acceptable to patients with node positive breast cancer." | 9.07 | A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. ( Abu-Zahra, H; Arnold, A; Bramwell, V; Findlay, B; Levine, MN; Perrault, D; Pritchard, K; Skillings, J; Warr, D, 1992) |
| "504 evaluable node positive oestrogen receptor (ER) positive breast cancer patients were randomly allocated to receive either 5 years tamoxifen treatment or chemotherapy [six courses of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) followed by 4 courses of epirubicin] or a combination of both treatments." | 9.07 | Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial. ( Amoroso, D; Boccardo, F; Castagnetta, L; Farris, A; Genta, F; Nenci, I; Piffanelli, A; Rubagotti, A; Sismondi, P; Traina, A, 1992) |
| "To improve current adjuvant results in high-risk breast cancer, in February 1982 we activated a prospective randomized trial using both intravenous cyclophosphamide, methotrexate, and fluorouracil (CMF) and Adriamycin (doxorubicin; Farmitalia-Carlo Erba, Milan, Italy) involving patients with resectable mammary carcinoma and more than three positive axillary lymph nodes." | 9.07 | Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. ( Bonadonna, G; Buzzoni, R; Valagussa, P; Zambetti, M, 1991) |
| "A prospectively controlled randomized trial to compare the adjuvant efficacy of 12 cycles of cyclophosphamide, methotrexate, fluorouracil, prednisone, and tamoxifen (CMFPT) followed by observation or a total of 5 years of continuous tamoxifen versus four cycles of CMFPT followed by observation in postmenopausal women with operable node-positive breast cancer was started by the Eastern Cooperative Oncology Group (ECOG) in 1982." | 9.06 | Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. ( Falkson, G; Falkson, HC; Gillchrist, KW; Gray, R; Harris, JE; Tormey, DC; Wolberg, WH, 1990) |
| "Between November 1, 1983 and June 30, 1987, 510 node-positive, estrogen receptor (ER)-positive breast cancer patients have been randomly allocated to receive either chemotherapy (six intravenous [IV] cyclophosphamide, methotrexate, and fluorouracil [CMF] courses followed by four IV epirubicin courses) or 5 years of tamoxifen treatment or a combination of both therapies." | 9.06 | Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group. ( Boccardo, F; Bruzzi, P; Cappellini, M; Isola, G; Nenci, I; Piffanelli, A; Rubagotti, A; Santi, L; Scanni, A; Sismondi, P, 1990) |
| "We evaluated the postoperative use of sequential methotrexate and fluorouracil followed by leucovorin in 679 patients with primary breast cancer, histologically negative axillary nodes, and estrogen-receptor-negative (less than 10 fmol) tumors." | 9.06 | A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. ( Bowman, D; Dimitrov, NV; Fisher, B; Fisher, ER; Legault-Poisson, S; Margolese, R; Redmond, C; Sutherland, C; Wickerham, DL; Wolmark, N, 1989) |
| "A randomized clinical trial was performed to determine if the addition of hormonal therapy with tamoxifen to a combination chemotherapy regimen was superior to the chemotherapy alone for adjuvant treatment of premenopausal women after mastectomy for node-positive breast cancer." | 9.06 | Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer. ( Cullinan, SA; Everson, LK; Fitzgibbons, RG; Foley, JF; Hagen, JB; Ingle, JN; Krook, JE; Martin, JK; Wieand, HS; Wold, LE, 1989) |
| "Four hundred forty-one women with operable breast cancer with histologically positive axillary nodes were randomized to receive either combination cyclophosphamide (60 mg/m2 orally everyday for 1 year); fluorouracil (300 mg/m2 intravenously [IV] weekly for 1 year); methotrexate (15 mg/m2 IV weekly for 1 year); vincristine (0." | 9.06 | Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study. ( Athens, J; Constanzi, JJ; Gad-el-Mawla, N; Glucksberg, H; Green, S; Hoogstraten, B; Maloney, T; Metch, B; Osborne, CK; Rivkin, SE, 1989) |
| "Treatment with tamoxifen (TM), alone or in combination with cyclophosphamide, methotrexate, and fluorouracil (CMF), was used as an adjuvant to surgery in 433 patients with stage I, II, or III(T3a) breast cancer." | 9.06 | Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study. ( Bianco, AR; D'Istria, M; De Placido, S; Delrio, G; Gallo, C; Marinelli, A; Pagliarulo, C; Petrella, G, 1988) |
| "Between 1974 and 1977, a total of 254 patients with stages T1-3a, N0-1, and M0 operable breast cancer (node negative and node positive, stratified) were randomized to either modified radical mastectomy alone or the same surgery and adjuvant chlorambucil, methotrexate, 5-fluorouracil (LMF) plus BCG." | 9.06 | Swiss adjuvant trial (OSAKO 06/74) with chlorambucil, methotrexate, and 5-fluorouracil plus BCG in node-negative breast cancer patients: nine-year results. ( Amgwerd, R; Ammann, J; Creux, G; Enderlin, F; Engelhart, G; Heinz, C; Hochuli, E; Jungi, WF; Senn, HJ; Wick, A, 1986) |
| "This trial studied the possibility that tamoxifen, added to L-phenylalanine mustard and 5-fluorouracil, enhances the established benefit of the latter two drugs in treatment of women with breast cancer and positive axillary nodes." | 9.05 | Treatment of primary breast cancer with L-PAM/5-FU and tamoxifen: an interim report. ( Fisher, B, 1983) |
| "5 mg daily) to an adjuvant cyclophosphamide-methotrexate-5-fluorouracil chemotherapy regimen was investigated in a randomized trial of 505 pre- and perimenopausal patients with operable breast cancer and one to three axillary lymph node metastases (Ludwig Breast Cancer Study I)." | 9.05 | A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. ( , 1985) |
| "After mastectomy, 265 postmenopausal patients with node-positive breast cancer were stratified according to pathologic nodal status and estrogen-receptor (ER) status and randomized to receive either 12 cycles of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP), or CMFP plus tamoxifen (CMFPT), or observation alone." | 9.05 | Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study. ( Bennett, JM; Carbone, PP; Cummings, F; Falkson, G; Kalish, LA; Olson, JE; Taylor, SG; Tormey, DC, 1985) |
| "Thirty-eight patients with advanced breast cancer were treated with the 'VEMFAH' multiple-drug combination chemotherapy, consisting of vincristine (V), cyclophosphamide (Endoxan; E), methotrexate (M), 5-fluorouracil (F), adriamycin (A), and prednisolone (H)." | 9.05 | The effects of multiple combination chemotherapy with vincristine, cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, adriamycin and prednisolone (VEMFAH) for advanced breast cancer. ( Hoshino, A; Ito, Y; Kamiya, O; Kinoshita, T; Kojima, T; Nagata, K; Ohara, K; Sato, H; Sugiura, I; Yamada, M, 1985) |
| " Ixabepilone is approved by the FDA for treatment of patients with metastatic breast cancer (MBC) progressing after taxanes and anthracyclines, either in combination with capecitabine or as monotherapy if the patient has already progressed on capecitabine." | 8.86 | Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer. ( Egerton, N, 2010) |
| "The impact of microsatellite instability (MSI) on survival in stage III colon cancer treated with adjuvant 5-fluorouracil-oxaliplatin combination (FOLFOX) chemotherapy is not clear." | 7.85 | Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX). ( Hong, YS; Kim, CW; Kim, HJ; Kim, JC; Kim, JE; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lim, SB; Park, IJ; Yoon, YS; Yu, CS, 2017) |
| "We prospectively evaluated the feasibility of XELOX(oxaliplatin 130 mg/m/(2) on day 1 plus capecitabine 1,000 mg/m(2) twice daily on days 1 to 14 every 3 weeks) for adjuvant treatment in 15 patients with stage III/IV (Japanese classification) colorectal cancer and pathological curability A or B after D2-D3 lymph node dissection." | 7.81 | [A feasibility study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for Japanese patients with advanced colorectal cancer]. ( Higashino, K; Noura, S; Ohue, M; Sakai, D; Shingai, T; Sugimoto, N; Takeuchi, Y; Yagi, T; Yamamoto, S; Yano, M; Yoshinami, T, 2015) |
| "Five prognostic factors had been previously identified in patients with metastatic colorectal cancer (MCRC) who received irinotecan-based second-line chemotherapy." | 7.79 | Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. ( Fukushima, H; Komatsu, Y; Muro, K; Naito, Y; Shitara, K; Takano, T; Yamazaki, K; Yasui, H; Yuki, S, 2013) |
| "The authors retrospectively evaluated 3 patients with progressive, metastatic neuroendocrine tumors of the thymus who were treated with a combination of capecitabine and temozolomide." | 7.79 | Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series. ( Centeno, B; Kvols, L; Morse, B; Saranga-Perry, V; Strosberg, J, 2013) |
| " We investigated the clinical significance of miR-10b and its involvement in chemotherapeutic resistance to 5-fluorouracil (5-FU), which is a key component of common chemotherapy regimens in colorectal cancer." | 7.78 | MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. ( Doki, Y; Ishii, H; Mimori, K; Mori, M; Nishida, N; Shibata, K; Sudo, T; Tanaka, F; Yamamoto, H; Yamashita, S, 2012) |
| "We examined the background, survival rates, median survival time and side effects of 15 cases in which systemic chemotherapy using carboplatin and 5-fluorouracil was done (chemotherapy group) and 59 cases in which chemotherapy was not done (non-chemotherapy group) out of a total of 74 cases of patients with extrahepatic metastasis from hepatocellular carcinoma." | 7.78 | Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma. ( Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kunimoto, H; Morihara, D; Sakamoto, M; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takeyama, Y; Ueda, S; Yokoyama, K; Yotsumoto, K, 2012) |
| " In this study, patient-derived tumor tissue (PDTT) xenograft models of primary colon carcinoma and lymphatic and hepatic metastases were established for assessment of the antitumor activity of FP3 in combination with capecitabine." | 7.78 | Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. ( Cao, F; Han, N; He, K; Jin, K; Lan, H; Li, G; Teng, L; Xie, B; Xu, Z, 2012) |
| " The absence of any abnormalities in the infant makes irinotecan and fluorouracil a valid therapeutic option for colon cancer during pregnancy." | 7.78 | Irinotecan during pregnancy in metastatic colon cancer. ( Cassandrini, PA; Cirillo, M; Lunardi, G; Musola, M; Venturini, M, 2012) |
| "There has been limited data on capecitabine monotherapy in metastatic colorectal cancer (CRC) patients who were previously treated with both oxaliplatin/5-fluorouracil(FU)/leucovorin (FOLFOX) and irinotecan/5-FU/leucovorin (FOLFIRI)." | 7.77 | Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. ( Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2011) |
| "A total of 153 breast cancer patients, who were treated with postoperative 5-fluorouracil-based chemotherapies, were randomly selected." | 7.77 | The cell cycle profile test is a prognostic indicator for breast cancer patients treated with postoperative 5-fluorouracil-based chemotherapy. ( Harada, S; Ishihara, H; Kanomata, N; Kawasaki, Y; Kikukawa, N; Kozuka, Y; Kurebayashi, J; Moriya, T; Nakayama, S; Noguchi, S; Sonoo, H; Tamura, S, 2011) |
| "FOLFOX (a combination of leucovorin, fluorouracil and oxaliplatin) has achieved substantial success in the treatment of colorectal cancer (CRC) patients." | 7.77 | Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. ( Eshima, K; Horie, H; Iinuma, H; Ikeuchi, H; Ishihara, S; Kobunai, T; Konishi, T; Matsuda, K; Muto, T; Nozawa, K; Watanabe, T; Yamamoto, Y, 2011) |
| " Toxicity (primarily gastrointestinal) necessitated dosage modification in 10 patients (29%)." | 7.77 | Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review. ( Balaban, EP; Bull, J; Frenkel, EP; Graham, M; Periman, P; Perkins, S; Pruitt, B; Ross, M; Ruud, C; Sheehan, RG, 1994) |
| "Capecitabine is effective and well tolerated in patients with anthracycline- and/or taxane-pre-treated metastatic breast cancer." | 7.76 | Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer. ( Amari, M; Ishida, T; Ohuchi, N; Takeda, M, 2010) |
| "The purpose of the present study is to evaluate what clinical factors affect the efficacy, time to treatment failure (TTF), and overall survival (OS) of oral capecitabine monotherapy in heavily pretreated patients with metastatic breast cancer (MBC)." | 7.75 | Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer. ( Hatake, K; Ito, Y; Iwase, T; Matsuura, M; Osako, T; Sugihara, T; Takahashi, S; Tokudome, N; Ushijima, M, 2009) |
| "We report an 83-year-old female with axillary node metastasis from breast cancer who responded to trastuzumab/ capecitabine combination therapy." | 7.75 | [A patient with axillary node metastasis from breast cancer who responded to trastuzumab/capecitabine combination therapy]. ( Imai, S; Kobayashi, A; Koyama, H; Matsuyama, T; Tokugawa, T, 2009) |
| "This study evaluated whether doxorubicin and cyclophosphamide are superior to cyclophosphamide, methotrexate and 5-fluorouracil as adjuvant chemotherapy in breast cancer patients." | 7.75 | Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer. ( Bianchi, S; Biti, GP; Borghesi, S; Cataliotti, L; De Luca Cardillo, C; Greto, D; Livi, L; Mangoni, M; Paiar, F; Saieva, C; Scotti, V, 2009) |
| "To evaluate the efficacy and safety of docetaxel and capecitabine combination chemotherapy (DC regimen) for patients with anthracycline-resistant metastatic breast cancer." | 7.74 | [Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer]. ( Dong, GL; Hao, CF; He, LH; Li, SF; Shi, YH; Tong, ZS; Wang, C; Wang, X, 2008) |
| "We report two cases of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) and lymph node (LN) metastases successfully treated by hepatic arterial infusion of 5-fluorouracil (5-FU) combined with systemic injection of interferon (IFN)-alpha following hepatic resection for the liver tumor." | 7.74 | Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection. ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Noda, T; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Wakasa, K, 2007) |
| "We report a case of elderly metastatic breast cancer with a complete response to the treatment with XC (X: capecitabine and C: cyclophosphamide)." | 7.74 | [A case of elderly metastatic breast cancer with a complete response to treatment with capecitabine and cyclophosphamide]. ( Furukawa, K; Iida, S; Iwasaki, R; Naito, Z; Noguchi, T; Sugisaki, Y; Tajiri, T; Tsuchiya, S; Yanagihara, K; Yokoyama, T, 2007) |
| "To estimate the Q-TWiST (Quality-Adjusted Time Without Symptoms and Toxicity) for premenopausal women with axillary node-positive breast cancer receiving either cyclophosphamide, epirubicin and fluorouracil (CEF) or cyclophosphamide, methotrexate, and fluorouracil (CMF), using data from a phase III clinical trial (National Cancer Institute of Canada Clinical Trials Group [NCIC-CGT." | 7.73 | Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer. ( Radice, D; Redaelli, A, 2005) |
| "We conducted a retrospective analysis of prognosis factors for survival in breast cancer patients with 1-3 axillary lymph node metastases and tried to identify a subset of patients with good prognosis suitable for cyclophosphamide, methotrexate and 5-fluorouracil (CMF) adjuvant chemotherapy." | 7.73 | Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy. ( Chang, HK; Chen, MF; Chen, SC; Hsueh, S; Hwang, TL; Lin, YC; Lo, YF; Tsai, CS, 2005) |
| "We report a case of complete disappearance of multiple lung metastases and mediastinal lymphnode metastasis by intravenous administration of 5-fluorouracil/cisplatin (FP) after operation for primary hepatocellular carcinoma (HCC)." | 7.73 | [Complete disappearance of metastatic lung tumors and mediastinal lymphnode in a case of hepatocellular carcinoma treated by low-dose 5-fluorouracil/cisplatin therapy]. ( Anami, Y; Izai, J; Komiya, H; Matsuda, Y; Oguma, S; Ota, T; Sazawa, Y; Yamaki, T, 2005) |
| "We evaluated the safety and efficacy of primary systemic chemotherapy (PSC) with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda:XLD) in 10 patients with advanced breast cancer." | 7.73 | [Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer]. ( Hamada, K; Kubota, K; Mori, S; Nakagawa, A; Suzuki, N; Tagaya, N, 2006) |
| "We investigated 29 patients with advanced and recurrent breast cancers who underwent capecitabine therapy in the department." | 7.73 | [Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression]. ( Hironou, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Ookubo, S; Seki, M; Shiiki, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y, 2006) |
| "This study retrospectively evaluates the occurrence of second hematological and solid malignancies in the context of a prospective multicenter phase III trial comparing epirubicin-cyclophosphamide at intermediate doses (EC), or at full doses (HEC), with classical cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in 777 patients with early breast cancer." | 7.72 | Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer ( Accettura, C; Bernard-Marty, C; Cardoso, F; Di Leo, A; Kleiber, K; Larsimont, D; Lobelle, JP; Mano, M; Munoz-Bermeo, R; Paesmans, M; Piccart, MJ; Richard, T, 2003) |
| "Ten cases of advanced and metastatic colorectal cancer treated with irinotecan plus fluorouracil and l-leucovorin systemic chemotherapy (CPT-11/5-FU/l-LV) were investigated." | 7.72 | [Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer]. ( Hidaka, K; Matsukura, S; Samejima, R; Tanaka, M, 2004) |
| "The Zoladex Early Breast Cancer Research Association study assessed the efficacy and tolerability of goserelin (3." | 7.71 | Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. ( Blamey, R; Cuzick, J; de Haes, JC; de Matteis, A; Eiermann, W; Fogelman, I; Geberth, M; Jonat, W; Kaufmann, M; Lisboa, B; Namer, M; Palmer, M; Sauerbrei, W; Schumacher, M; Stewart, A; Szakolczai, I, 2002) |
| "To evaluate safety and efficacy of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer." | 7.70 | [A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer]. ( Dai, A; Feng, J; Zheng, X, 1998) |
| "An association between the overexpression of proto-oncogene HER-2/neu and resistance to tamoxifen in estrogen receptor (ER)-positive primary and metastatic breast cancer has been suggested." | 7.70 | HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. ( Barcos, M; Berry, DA; Broadwater, G; Budman, DR; Dressler, L; Hayes, D; Henderson, IC; Liu, ET; Muss, HB; Norton, L; Thor, AD, 2000) |
| "A 53-year-old female patient was treated with combined radiochemotherapy with 5-fluorouracil (5-FU) because of adenocarcinoma of the lung." | 7.69 | [5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?]. ( Härle, M; Jungius, KP; Maurer, U, 1996) |
| "Between 1994 and 1995, 1 day nocturnal infusion of 5-fluorouracil (5-FU) was performed prior to surgery in 13 primary breast cancer patients; 300 mg/m2 of 5-FU was infused constantly from 2100 h to 0700 h via peripheral vein with a volumetric pump." | 7.69 | Nocturnal 5-fluorouracil infusion to patients with breast cancer prior to surgery: appearance of 5-fluorouracil-induced AgNORs aggregation (FAA). ( Furuya, Y; Kohno, N; Saitoh, Y; Yamamoto, K; Yamamoto, M, 1997) |
| " Our cost-effectiveness study [7] evaluated the pharmacoeconomic profile of adjuvant cyclophosphamide, methotrexate and fluorouracil (CMF) in patients with node-positive breast cancer [13] and utilised a Gompertz analysis to estimate lifetime overall survival (OS), which was 862 and 756 discounted years per 100 patients in the CMF and the control groups, respectively." | 7.69 | Adjuvant cyclophosphamide, methotrexate and fluorouracil for node-positive breast cancer: a lifetime cost-utility analysis based on a modified Q-TWIST method. ( Becagli, P; Messori, A; Trippoli, S, 1997) |
| "Combination chemotherapy with cyclophosphamide (CPA), adriamycin (ADR) and 5-fluorouracil (5-FU) (CAF therapy) was performed in 85 patients with advanced and recurrent breast cancer." | 7.66 | [Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer]. ( Abe, O; Enomoto, K; Izuo, M; Koyama, H; Kubo, K; Nomura, Y; Sakai, K; Terasawa, T; Tominaga, T, 1982) |
| " However,the effect of targeted drugs combined with induction therapy in locally advanced nasopharyngeal carcinoma remains unclear." | 6.90 | Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter rando ( Chen, D; Gao, J; Huang, C; Huang, H; Liang, J; Liu, M; Liu, W; Lu, Y; Luo, Z; Ning, X; Wang, R, 2019) |
| " Because the replacement of 2-day-infusional 5-fluorouracil (5-FU) of FOLFIRI with oral tegafur-uracil/leucovorin (UFT/LV) would be highly beneficial for clinical management, we performed a phase I trial using oral UFT/LV and a pharmacokinetic evaluation." | 6.74 | Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. ( Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009) |
| " Severe taxane-related toxic effects were more frequent in group A, while severe thrombocytopenia was low and present only in group A." | 6.73 | Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. ( Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N, 2008) |
| "Patients were randomly assigned to one of three dosing regimens of CAF." | 6.73 | Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. ( Berry, DA; Broadwater, G; Budman, DR; DiGiovanna, MP; Dressler, LG; Edgerton, S; Hayes, DF; Henderson, IC; Liu, ET; Muss, HB; Norton, L; Stern, DF; Thor, AD, 2008) |
| "Gemcitabine is an active antitumor agent in the treatment of advanced pancreatic cancer, and has shown potential synergistic activity with the oral fluoropyrimidine capecitabine in previous phase I/II trials." | 6.71 | Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. ( Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H, 2003) |
| "In an International Breast Cancer Study Group (IBCSG) randomized clinical trial (Trial VIII) for pre- and perimenopausal women with lymph node-negative breast cancer, we compared sequential chemotherapy followed by the gonadotropin-releasing hormone agonist goserelin with each modality alone." | 6.71 | Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. ( Bonetti, M; Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Gelber, RD; Goldhirsch, A; Nasi, ML; O'Neill, A; Price, KN, 2003) |
| "Node-positive breast carcinoma patients were randomly assigned to receive either no further treatment after radical mastectomy (179 women) or 12 monthly cycles of adjuvant CMF chemotherapy (207 women)." | 6.70 | Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. ( Biganzoli, E; Bonadonna, G; Boracchi, P; Casalini, P; Cascinelli, N; Colnaghi, MI; Gianni, L; Marubini, E; Ménard, S; Pilotti, S; Tomasic, G; Valagussa, P, 2001) |
| "AcF is highly active in breast cancer with acceptable toxicities and can be used before alkylating agent-based high-dose therapy." | 6.68 | Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. ( Cameron, DA; Gabra, H; Lee, LE; Leonard, RC; Mackay, J, 1996) |
| "Treatment with levamisole alone had no detectable effect." | 6.67 | Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. ( Emerson, WA; Fleming, TR; Glick, JH; Goodman, PJ; Haller, DG; Laurie, JA; Macdonald, JS; Moertel, CG; Tormey, DC; Ungerleider, JS, 1990) |
| "The purpose of this study was to determine the relative efficacy of doxorubicin versus methotrexate in combination with intravenous cyclophosphamide and 5-fluorouracil (FAC versus CMF) as adjuvant chemotherapy for operable breast cancer." | 6.20 | Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a ( Albanell, J; Aranda, J; Campbell, J; Camps, C; Candel, MT; Carrato, A; Casado, A; Diaz-Rubio, E; Gonzalez, R; Lizon, J; Martin, M; Massuti, B; Munarriz, B; Sole-Calvo, A; Villar, A, 2003) |
| "Cardiotoxicity is an important side effect in patients receiving chemotherapy and the application of anthracycline drugs for gastric cancer treatment is uncommon." | 5.51 | Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients. ( Bai, Y; Gao, L; Jin, X; Wu, S, 2019) |
| "Because the serum concentration of 5-FU fluctuates and displays various patterns, the dosage should not be based on body surface area." | 5.42 | Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer. ( Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Murakami, H; Okumura, H; Tohyama, K; Tsuruta, A, 2015) |
| "The regimens in both arms A and B were safe regarding adjuvant chemotherapy for early breast cancer." | 5.39 | Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. ( Abe, H; Cho, H; Kawai, Y; Kubota, Y; Kurumi, Y; Mori, T; Tani, T; Umeda, T, 2013) |
| "We compared clinical outcome and pharmacokinetic (pK) parameters of a new pharmacokinetically-guided dosing strategy in two groups of patients (age < or >65 years) with metastatic colorectal cancer (mCRC)." | 5.36 | Clinical impact of intesified 5-Fluorouracil-based chemotherapy using a prospective pharmacokinetically-guided dosing approach: comparative study in elderly and non-elderly patients with metastatic colorectal cancer. ( Abderrahim, AG; Bressolle, F; Duffour, J; Pinguet, F; Poujol, S; Roca, L; Ychou, M, 2010) |
| "Colorectal cancer is one of the leading malignancies in the world." | 5.36 | Oncolytic adenovirus mediated Survivin RNA interference and 5-fluorouracil synergistically suppress the lymphatic metastasis of colorectal cancer. ( Fu, ZX; Shen, W; Tu, JK; Wang, XH, 2010) |
| " Pharmacokinetic analysis was performed on plasma samples collected at the first cycle of treatment." | 5.35 | A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. ( Antonuzzo, A; Bocci, G; Bursi, S; Chiara, S; Del Tacca, M; Di Paolo, A; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Pfanner, E; Vasile, E, 2009) |
| "We diagnosed her tumors as occult breast cancer and its metastasis to lymph nodes (cT0N3cM1, Stage IV)." | 5.35 | [A case of occult breast cancer successfully treated by capecitabine in combination with weekly paclitaxel followed by FEC (75)]. ( Hino, N; Ikushima, Y; Miyake, H; Ogasawara, T; Ohura, R; Sohnaka, Y; Tsuyuguchi, M; Wada, D; Yamamoto, Y; Yamasaki, S, 2008) |
| " In April 2004, she had a recurrence manifesting itself as bone metastasis, partly because of poor compliance with the hospital-visit and dosing schedules." | 5.34 | [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine]. ( Akahane, T; Chiba, T; Hashimoto, Y; Yano, H, 2007) |
| "However, standard treatment for Dukes C colorectal cancer patients currently involves the administration of 5-fluorouracil (5-FU)-based adjuvant chemotherapy after surgery." | 5.33 | SMAD4 levels and response to 5-fluorouracil in colorectal cancer. ( Aaltonen, LA; Alazzouzi, H; Alhopuro, P; Arango, D; Dávalos, V; Hemminki, A; Järvinen, H; Mecklin, JP; Salovaara, R; Sammalkorpi, H; Schwartz, S, 2005) |
| "First-line treatment for metastatic colorectal cancer (mCRC) typically entails a biologic such as bevacizumab (BEV) with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) or 5-fluorouracil/leucovorin/irinotecan (FOLFIRI)." | 5.30 | Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). ( Bendell, J; Hochster, HS; Hurwitz, HI; Lee, JJ; Lenz, HJ; Nicholas, A; Palma, JF; Price, R; Reeves, JA; Scappaticci, F; Somer, B; Sommer, N; Tan, BR; Xiong, H, 2019) |
| " Our results indicate that the dose-response effect remains a crucial factor in adjuvant chemotherapy of breast cancer." | 5.30 | Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. ( Castiglione-Gertsch, M; Coates, A; Colleoni, M; Collins, J; Gelber, RD; Goldhirsch, A; Lindtner, J; Price, K; Rudenstam, CM; Thürlimann, B, 1998) |
| "In evaluating response by sites of metastases, lymph nodes (30%), lung nodules (22%), and subcutaneous deposits (2/3) had the highest incidence of C." | 5.25 | An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer. ( Catalano, RB; Creech, RH; Engstrom, PF; Mastrangelo, MJ, 1975) |
| "The AIO-FLOT3 (Arbeitsgemeinschaft Internistische Onkologie-fluorouracil, leucovorin, oxaliplatin, and docetaxel) trial is a prospective, phase 2 trial of 252 patients with resectable or metastatic gastric or gastroesophageal junction adenocarcinoma." | 5.24 | Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. ( Al-Batran, SE; Arnold, D; Bechstein, W; Berkhoff, S; Egger, M; Fischbach, W; Grimm, K; Hartmann, JT; Höffkes, HG; Hofheinz, RD; Homann, N; Illerhaus, G; Jäger, E; Koenigsmann, M; Kraus, TW; Luley, KB; Martens, UM; Mayer, F; Messmann, H; Moehler, M; Mönig, S; Pauligk, C; Post, S; Prasnikar, N; Probst, S; Ronellenfitsch, U; Schmalenberg, H; Stoehlmacher, J, 2017) |
| "Forty postmenopausal women with non-metastatic ER-positive, HER2-negative invasive breast cancer with a primary tumor > 2 cm or positive axillary lymph node(s) proved by biopsy will be randomly (1:1) enrolled from Sun Yat-Sen Memorial Hospital to receive neoadjuvant everolimus plus letrozole for 18 weeks or fluorouracil, epirubicin plus cyclophosphamide (FEC) for six cycles before surgery." | 5.24 | Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial. ( Cao, M; Deng, H; Liu, J; Rao, N; Wu, W; Yang, Y; You, N, 2017) |
| "In this randomized, non-inferiority, phase III trial, women with HER2-negative invasive breast cancer and at least one positive axillary lymph node were randomized to receive either epirubicin (75 mg/m(2)), 5-fluorouracil (500 mg/m(2)) and cyclophosphamide (500 mg/m(2)) every 2 weeks for four cycles, followed by four cycles of docetaxel (75 mg/m(2)) every 2 weeks with prophylactic G-CSF support (FEC → D) or docetaxel (75 mg/m(2)) and cyclophosphamide (600 mg/m(2)) every 21 days for six cycles (TC)." | 5.22 | Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HOR ( Athanasiadis, A; Boukovinas, I; Georgoulias, V; Kakolyris, S; Katsaounis, P; Kentepozidis, N; Malamos, N; Matikas, A; Mavroudis, D; Papakotoulas, P; Saloustros, E; Ziras, N, 2016) |
| "Whether addition of fluorouracil to epirubicin, cyclophosphamide, and paclitaxel (EC-P) is favourable in adjuvant treatment of patients with node-positive breast cancer is controversial, as is the benefit of increased density of dosing." | 5.20 | Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. ( Ardizzoni, A; Barni, S; Bighin, C; Bisagni, G; Boni, C; Bruzzi, P; Cavazzini, G; Cognetti, F; Colantuoni, G; De Laurentiis, M; De Placido, S; Del Mastro, L; Durando, A; Forestieri, V; Gamucci, T; Garrone, O; Giuliano, M; Gravina, A; Montemurro, F; Nisticò, C; Papaldo, P; Puglisi, F; Turletti, A; Valle, E, 2015) |
| "The current study aimed to evaluate the short-term efficacy and safety of endostar plus irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) in treatment of advanced colorectal cancer (CRC)." | 5.20 | Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study. ( Hu, XL; Li, BL; Sun, HG; Zhang, Y; Zhao, XH; Zhou, CY, 2015) |
| "To investigate the efficacy and safety of selective radiotherapy after distant metastasis of nasopharyngeal carcinoma (NPC) treated with dose-dense cisplatin plus fluorouracil." | 5.20 | Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil. ( Bu, JG; Chen, BY; Chen, KQ; Cheng, JL; Feng, J; Gao, WW; Liang, WC; Liang, Y; Xu, YC, 2015) |
| "Capecitabine is an active drug in metastatic breast cancer (BC)." | 5.20 | Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. ( Adrover, E; Andrés, R; Baena-Cañada, JM; Ballesteros, AI; Barnadas, A; Calvo, L; Carrasco, EM; Casas, M; de la Haba-Rodríguez, J; Del Barco Berron, S; del Carmen Cámara, M; González, S; Jara, C; Lluch, A; López-Vega, JM; Margelí Vila, M; Martín, M; Martínez de Dueñas, E; Martínez-Jáñez, N; Mendiola Fernández, C; Muñoz-Mateu, M; Plazaola, A; Ramos, M; Ribelles, N; Rodríguez, CA; Rodríguez-Lescure, Á; Ruiz Borrego, M; Ruiz Simón, A; Sánchez-Rovira, P; Santaballa, A, 2015) |
| "Patients with previously untreated thoracic AEC who had T4 tumors or M1 lymph node metastasis (M1 LYM), or both, received intravenous infusions of docetaxel (35 mg/m(2)) and cisplatin (40 mg/m(2)) on day 1 and a continuous intravenous infusion of 5-fluorouracil (400 mg/m(2)/day) on days 1 to 5, every 2 weeks, plus concurrent radiation." | 5.19 | Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). ( Azuma, M; Hayakawa, K; Higuchi, K; Ishido, K; Ishiyama, H; Katada, C; Katada, N; Koizumi, W; Komori, S; Sasaki, T; Tanabe, S, 2014) |
| "Capecitabine and cyclophosphamide are active in patients with advanced breast cancer, have non-overlapping toxic effects and synergy pre-clinically." | 5.17 | A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II. ( Dzhelali, MV; Findlay, MP; Harvey, VJ; Hinder, VA; Isaacs, RJ; Jameson, MB; Jeffery, GM; McLaren, BR; Pollard, S; Riley, GA; Scott, JN; Sharples, KJ; Simpson, AB, 2013) |
| "Newer radiation techniques, and the application of continuous 5-FU exposure during radiation therapy using oral capecitabine may improve the treatment of anal cancer." | 5.17 | Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. ( Beijnen, JH; Boot, H; Cats, A; Deenen, MJ; Dewit, L; Schellens, JH, 2013) |
| "This trial compared 6 cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) with a sequential regimen of 3 cycles of FEC followed by 3 cycles of docetaxel (FEC-D) as adjuvant treatment for women with node-positive or/and T3 or T4 breast cancer." | 5.17 | Sequential docetaxel as adjuvant chemotherapy for node-positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). ( Anter, AH; Hamed, RH; Sakr, H; Yossef, T, 2013) |
| "The aim of this phase II study was to investigate the efficacy and safety of oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic breast cancer (MBC) patients heavily pretreated with anthracyclines, taxanes, vinorelbine, gemcitabine, and capecitabine." | 5.16 | Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients. ( Hu, XC; Jia, Z; Sun, S; Wang, BY; Wang, LP; Yang, XY; Zhang, J; Zhang, QL, 2012) |
| "This multisite study sought to optimize the dosing, schedule, and administration of fixed-dose rate (FDR) gemcitabine plus capecitabine for advanced pancreatic and biliary tract cancers using an alternating-week dose schedule of both agents." | 5.16 | Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. ( Bergsland, EK; Coakley, FV; Dito, E; Espinoza, AM; Hanover, CS; Jones, KA; Kelley, RK; Ko, AH; Ong, A; Tempero, MA; Venook, AP, 2012) |
| "Women with axillary node-positive or high-risk node-negative breast cancer were randomly assigned to receive either three cycles of docetaxel and capecitabine (TX) followed by three cycles of cyclophosphamide, epirubicin, and capecitabine (CEX; n = 753) or three cycles of docetaxel (T) followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil (CEF; n = 747)." | 5.16 | Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. ( Ahlgren, J; Asola, R; Auvinen, P; Bono, P; Helle, L; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, M; Lindman, H; Nilsson, G; Nyandoto, P; Paija, O; Pajunen, M; Poikonen, P; Tanner, M; Villman, K, 2012) |
| "To explore the impact of dose intensity (DI) in the adjuvant setting of breast cancer, a randomized phase III trial was conducted comparing postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide, methotrexate and fluorouracil (CMF)in high-risk breast cancer patients." | 5.16 | Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. ( Bafaloukos, D; Batistatou, A; Bobos, M; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, MA; Eleftheraki, AG; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Kosmidis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Stathopoulos, GP; Timotheadou, E, 2012) |
| "We previously reported a 35% overall response rate (ORR) with biweekly 5-fluorouracil (5-FU) continuous infusion (TTD [Spanish Cooperative Group for Digestive Tumour Therapy] schedule) plus irinotecan as first-line therapy in elderly patients with metastatic colorectal cancer (mCRC)." | 5.16 | Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors. ( Alfaro, J; Aparicio, J; Aranda, E; Benavides, M; Cabrera, E; Campos, JM; Carrato, A; Dueñas, R; Etxeberría, A; Gil-Calle, S; Gómez, A; Gómez, MJ; González-Flores, E; Guasch, I; Marcuello, E; Massutí, B; Pericay, C; Queralt, B; Reina, JJ; Valladares-Ayerbes, M, 2012) |
| "The initial report from the Programme Action Concertée Sein (PACS) PACS01 trial demonstrated a benefit at 5 years for disease-free survival (DFS) and overall survival (OS) rates with the sequential administration of docetaxel after FEC100 (fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), and cyclophosphamide 500 mg/m(2)) for patients with node-positive, operable breast cancer." | 5.16 | Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial. ( Asselain, B; Audhuy, B; Beauduin, M; Campone, M; Canon, JL; Coudert, B; Eymard, JC; Jerusalem, G; Lévy, C; Machiels, JP; Martin, AL; Orfeuvre, H; Pénault-Llorca, F; Petit, T; Piot, G; Roché, H; Romieu, G; Serin, D; Spielmann, M; Veyret, C, 2012) |
| "Adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) have proven highly effective in rapidly proliferating breast cancer (RPBC)." | 5.15 | Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer. ( Amadori, D; Amaducci, L; Baldini, E; Biglia, N; Boccardo, F; Bonginelli, P; Brandi, M; De Lena, M; Faedi, M; Gianni, L; Maltoni, R; Paradiso, A; Ponzone, R; Rocca, A; Scarpi, E; Schittulli, F; Serra, P; Silvestrini, R; Tienghi, A; Valerio, MR, 2011) |
| "After stratification by ER status, 1669 postmenopausal patients with operable lymph node-negative breast cancer were randomly assigned to three 28-day courses of 'classical' CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy followed by tamoxifen for 57 months (CMF→tamoxifen) or to tamoxifen alone for 5 years." | 5.15 | Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. ( Aebi, S; Braun, D; Castiglione-Gertsch, M; Coates, AS; Crivellari, D; Gelber, RD; Goldhirsch, A; Gusterson, BA; Karlsson, P; Lindtner, J; Price, KN; Rabaglio, M; Regan, MM; Simoncini, E; Snyder, R; Sun, Z; Viale, G, 2011) |
| "To evaluate the efficacy and safety of docetaxel plus thiotepa(TXT/TSPA) and docetaxel plus capecitabine(TXT/CAPE) in patients with metastatic breast cancer." | 5.15 | [Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer]. ( Che, L; DI, Lj; Jia, J; Jiang, Hf; Liang, X; Ren, J; Song, Gh; Wang, Xl; Yang, Hb; Yu, J; Zhang, J; Zhou, Xn; Zhu, Yl, 2011) |
| "The purpose of this study was to investigate the activity of capecitabine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer resistant to both anthracyclines and taxanes." | 5.14 | Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes. ( Fukushima, M; Ishida, T; Ishioka, C; Ishiwata, R; Kiba, T; Masuda, N; Matsuyama, K; Noguchi, S; Ohuchi, N; Takatsuka, Y; Takeda, M; Teramukai, S, 2009) |
| "A phase II study was performed to assess the activity of oxaliplatin plus 5-fluorouracil (5-FU) modulated by leucovorin, as second-line treatment in locally advanced or metastatic pancreas adenocarcinoma pretreated with gemcitabine-containing schedule." | 5.14 | Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. ( Bellone, G; Bertetto, O; Chiappino, I; Ciuffreda, L; Giacobino, A; Milanesi, E; Novarino, A; Rahimi, F; Satolli, MA, 2009) |
| "The primary aim of this study was to compare the effectiveness of oral uracil-tegafur (UFT) with that of classical cyclophosphamide, methotrexate, and fluorouracil (CMF) given as postoperative adjuvant treatment to women with node-negative, high-risk breast cancer." | 5.14 | Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. ( Iwata, H; Kitaya, T; Kohno, N; Nakagami, K; Ohashi, Y; Sakamoto, G; Sano, M; Shimozuma, K; Sonoo, H; Takashima, S; Tokuda, Y; Tsuda, H; Watanabe, T; Yoshimoto, M, 2009) |
| "A randomized multicenter phase III study was conducted to compare the sequential docetaxel followed by epirubicin/cyclophosphamide combination with that of FEC regimen as adjuvant chemotherapy in women with axillary node-positive early breast cancer." | 5.14 | FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). ( Adamou, A; Athanasiadis, A; Boukovinas, I; Christophyllakis, C; Georgoulias, V; Kakolyris, S; Kalbakis, K; Karvounis, N; Kouroussis, C; Malamos, N; Mavroudis, D; Papakotoulas, P; Polyzos, A; Syrigos, K; Vamvakas, L; Varthalitis, I; Ziras, N, 2010) |
| " Therefore, we compared UFT with a combination therapy of cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients who had undergone curative surgery for axillary lymph node-positive breast cancer." | 5.14 | Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study. ( Asaga, T; Higaki, K; Inaji, H; Ito, T; Koh, J; Kohno, N; Komichi, H; Koyama, H; Kyono, S; Mitsuyama, S; Nishikawa, H; Ogita, M; Okamura, K; Osaki, A; Park, Y; Saito, T; Suzuki, T; Tanaka, F; Yamazaki, K, 2009) |
| "The Lapatinib Expanded Access Program (LEAP) was designed to provide access to lapatinib plus capecitabine for HER2-positive metastatic breast cancer patients who previously received an anthracycline, a taxane, and a trastuzumab and had no other treatment options." | 5.14 | An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. ( Capri, G; Chang, J; Chen, SC; Conte, P; Cwiertka, K; De Placido, S; Jerusalem, G; Jiang, Z; Johnston, S; Kaufman, B; Link, J; Oliva, C; Parikh, R; Preston, A; Ro, J; Rosenlund, J; Schütte, J; Selzer, M; Zembryki, D, 2010) |
| "To compare dose-intensified epirubicin monotherapy with a standard sequential regimen, patients with primary breast cancer and > or =10 involved axillary nodes were randomised to either four 21-day cycles of epirubicin 120 mg/m(2) (E120; n=202) or four 21-day cycles of epirubicin 90 mg/m(2) plus cyclophosphamide 600 mg/m(2) (EC) followed by three 28-day cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF; n=209)." | 5.14 | Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group. ( Ataseven, B; Conrad, B; Eiermann, W; Graf, E; Hilfrich, J; Kaufmann, M; Loibl, S; Massinger-Biebl, H; Schumacher, M; Vescia, S; von Minckwitz, G, 2010) |
| "PURPOSE Cyclophosphamide, epirubicin, and fluorouracil (CEF) and doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) are commonly used adjuvant regimens in women with early breast cancer." | 5.14 | Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. ( Albain, KS; Bramwell, V; Burnell, M; Chalchal, H; Chapman, JA; Gelmon, K; Levine, MN; O'Brien, P; Perez, EA; Pritchard, K; Rugo, H; Shepherd, LE; Vandenberg, T; Walley, B, 2010) |
| "We undertook a phase 3, parallel, randomised trial (SWOG-8814, INT-0100) in postmenopausal women with hormone-receptor-positive, node-positive breast cancer to test two major objectives: whether the primary outcome, disease-free survival, was longer with cyclophosphamide, doxorubicin, and fluorouracil (CAF) given every 4 weeks for six cycles plus 5 years of daily tamoxifen than with tamoxifen alone; and whether disease-free survival was longer with CAF followed by tamoxifen (CAF-T) than with CAF plus concurrent tamoxifen (CAFT)." | 5.14 | Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. ( Abeloff, MD; Albain, KS; Barlow, WE; Burton, GV; Cobau, CD; Farrar, WB; Green, SJ; Henderson, IC; Ingle, JN; Ketchel, SJ; Levine, EG; Lew, D; Lichter, AS; Livingston, RB; Martino, S; Muss, HB; Osborne, CK; Pritchard, KI; Ravdin, PM; Schneider, DJ, 2009) |
| "Accumulating data indicate that docetaxel plus cisplatin and 5-fluorouracil has certain effect on advanced gastric or gastro-oesophageal junction adenocarcinoma." | 5.14 | A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma. ( Guo, JF; Nie, XY; Peng, J; Wang, B; Wu, F; Xing, H; Zhang, B; Zhu, GY, 2010) |
| "A weekly administration of alternating irinotecan or oxaliplatin associated to 5-Fluorouracil in advanced colorectal cancer was planned in order to evaluate a new schedule maintaining dose intensities of each drug as in double combinations and tolerability of the triplet association." | 5.14 | Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study. ( Bruera, G; Calista, F; Cannita, K; De Galitiis, F; Ficorella, C; Gebbia, N; Guglielmi, F; Iacobelli, S; Lanfiuti Baldi, P; Mancini, M; Marchetti, P; Martella, F; Morelli, MF; Pelliccione, M; Porzio, G; Ricevuto, E; Russo, A; Santomaggio, A; Tudini, M, 2010) |
| "Patients with lymph node-positive breast cancer (n = 2887) were randomly assigned to one of four treatments: 1) sequential control (four cycles of doxorubicin at 75 mg/m2, followed by three cycles of cyclophosphamide, methotrexate, and 5-fluorouracil [CMF]); 2) concurrent control (four cycles of doxorubicin at 60 mg/m2 plus cyclophosphamide at 600 mg/m2, followed by three cycles of CMF); 3) sequential docetaxel (three cycles of doxorubicin at 75 mg/m2, followed by three cycles of docetaxel at 100 mg/m2, followed by three cycles of CMF); 4) concurrent docetaxel (four cycles of doxorubicin at 50 mg/m2 plus docetaxel at 75 mg/m2, followed by three cycles of CMF)." | 5.13 | Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. ( Andersson, M; Balil, A; Bendahmane, B; Buyse, M; Castiglione-Gertsch, M; Crown, J; Di Leo, A; Dolci, S; Francis, P; Gelber, RD; Goldhirsch, A; Gutiérrez, J; Jakesz, R; Jamin, S; Lang, I; Nordenskjöld, B; Piccart-Gebhart, M; van Hazel, G; Vorobiof, D, 2008) |
| "Food and Drug Administration reviewed a single, open-label, multicenter trial in which 463 patients with epidermal growth factor receptor-expressing metastatic colorectal cancer who had progressed on or following treatment with a regimen containing a fluoropyrimidine, oxaliplatin, and irinotecan were randomized (1:1) to receive best supportive care (BSC) with or without panitumumab (6 mg/kg every other week) administered until disease progression or intolerable toxicity." | 5.13 | U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. ( Cordoba-Rodriguez, R; Fuchs, C; Giusti, RM; Hughes, M; Keegan, P; Koti, K; Men, AY; Pazdur, R; Pilaro, AM; Rothmann, M; Shastri, K; Weiss, KD; Zhao, H, 2008) |
| "International Breast Cancer Study Group Trial VI accrued 1475 eligible pre- and perimenopausal women with node-positive breast cancer who were randomly assigned to receive three to nine courses of classical combination chemotherapy with cyclophosphamide, methotrexate, and fluorouracil." | 5.13 | Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. ( Castiglione-Gertsch, M; Coates, AS; Cole, BF; Collins, J; Crivellari, D; Fey, MF; Gelber, RD; Goldhirsch, A; Golouh, R; Gruber, G; Gusterson, BA; Holmberg, SB; Lindtner, J; Price, KN; Simoncini, E; Thürlimann, B; Viale, G, 2008) |
| "This study was conducted to determine, in patients with advanced-stage breast cancer, the maximum tolerated dose (MTD) of capecitabine administered orally for 7 days followed by a 7-day rest (7/7), a schedule based on a mathematical method for the optimization of anticancer drug scheduling." | 5.13 | Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. ( Dugan, U; Edwards, C; Feigin, K; Hudis, C; Norton, L; Patil, S; Tan, KL; Theodoulou, M; Traina, TA, 2008) |
| "A pilot phase II study was conducted to evaluate the efficacy and safety of the Japanese intermittent regimen of capecitabine (Xeloda) in patients with advanced or recurrent breast cancer." | 5.12 | A pilot phase II study of capecitabine in advanced or recurrent breast cancer. ( Kimura, T; Saeki, T; Taguchi, T; Toi, M, 2006) |
| "We evaluated the survival benefit, safety, feasibility, and tolerability of dose-dense (DD) adjuvant chemotherapy with epirubicin and paclitaxel for women with node-positive primary breast cancer." | 5.12 | Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. ( Blohmer, JU; Breitbach, GP; Budner, M; Elling, D; Kohls, A; Krocker, J; Kümmel, S; Morack, G, 2006) |
| "The aim of this study was to evaluate the feasibility of a combination of epirubicin and paclitaxel followed by intravenous (iv) cyclophosphamide, methotrexate, and 5-fluorouracile (CMF) as adjuvant treatment of breast cancer patients with 10 or more metastatic axillary lymph nodes." | 5.12 | Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes. ( Battelli, N; Braconi, C; Cascinu, S; Cobelli, S; Dinota, A; Giacomini, G; Giorgi, F; Manzione, L; Massacesi, C; Morale, D; Pilone, A; Scanni, A; Sturba, F; Tummarello, D, 2006) |
| "This study evaluated, in terms of pathological complete response (pCR) and acute toxicity, preoperative concurrent (5-fluorouracil (5-FU)-vinorelbine) chemoradiotherapy for large breast cancers." | 5.12 | Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II study. ( Bollet, MA; Campana, F; Dendale, R; Diéras, V; Extra, JM; Fourquet, A; Gambotti, L; Kirova, YM; Meunier, M; Nos, C; Sigal-Zafrani, B, 2006) |
| "We performed a controlled study to compare the response to cyclophosphamide (CPA), adriamycin (ADM), and fluorouracil (5-FU) (CAF therapy) with that to uracil-tegafur (UFT) plus tamoxifen (TAM) (UFT+TAM therapy), when given as postoperative adjuvant therapy to women with breast cancer." | 5.12 | [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set ( Inaji, H; Koyama, H; Mori, T; Nakao, K; Oka, T; Oshima, A; Ozawa, K; Saito, Y; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T, 2006) |
| "The PACS 01 trial compared six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) with a sequential regimen of three cycles of FEC followed by three cycles of docetaxel (FEC-D) as adjuvant treatment for women with node-positive early breast cancer." | 5.12 | Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. ( Asselain, B; Bonneterre, J; Campone, M; Canon, JL; Delozier, T; Eichler, F; Ferrero, JM; Fumoleau, P; Genève, J; Goudier, MJ; Kerbrat, P; Martin, AL; Monnier, A; Roché, H; Serin, D; Soulié, P; Spielmann, M; Symann, M; Viens, P; Vindevoghel, A, 2006) |
| "Paclitaxel and capecitabine have proven activity in the treatment of metastatic breast cancer (MBC)." | 5.12 | Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK. ( Aebi, S; Ballabeni, P; Gick, U; Hess, V; Lanz, D; Mingrone, W; Pestalozzi, B; Rauch, D; Rochlitz, C, 2006) |
| "The combination of docetaxel and capecitabine provides a well-tolerated and active chemotherapy regimen for metastatic breast cancer." | 5.12 | [Efficacy of docetaxel combined capecitabine on metastatic breast cancer]. ( Jiang, WQ; Shi, YX; Wang, XX; Yuan, ZY; Zhang, DS; Zhou, ZM, 2007) |
| "The aim of the study was to compare our reference adjuvant chemotherapy, FEC100 (fluorouracil 500 mg m(-2), epirubicin 100 mg m(-2) and cyclophosphamide 500 mg m(-2), six cycles every 21 days), to an epirubicin-vinorelbine (Epi-Vnr) combination for early, poor-prognosis breast cancer patients." | 5.12 | Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial. ( Audhuy, B; Bonneterre, J; Chollet, P; Clavère, P; Eymard, JC; Fargeot, P; Fumoleau, P; Goudier, MJ; Guastalla, JP; Kerbrat, P; Lortholary, A; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Simon, H; Veyret, C; Walter, S, 2007) |
| "This randomized phase III trial was performed to compare the 3-monthly depot LHRH agonist leuprorelin acetate (LAD-3M; n = 299) and chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF; n = 300) in pre- or perimenopausal patients with ER-positive, node-positive breast cancer." | 5.12 | Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. ( Bondar, G; Kossé, V; Lehmann, U; Maubach, L; Meurer, J; Possinger, K; Schmid, P; Tarutinov, V; Untch, M; Vassiljev, L; Wallwiener, D, 2007) |
| "Sixty-three premenopausal women with Stage 2, 3 breast cancer and > or =4 positive axillary nodes were treated in three successive cohorts with 70 mg/m(2) of epirubicin, 500 mg/m(2) of 5-fluorouracil and G-CSF every 14 days for 12 cycles." | 5.12 | A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes. ( Blackstein, M; Bowman, D; Burnell, M; Crump, M; Findlay, B; Levine, M; Norris, B; Palmer, MJ; Pritchard, KI; Shepherd, L; Skillings, J; Tonkin, K; Trudeau, M; Tu, D; Walde, D, 2007) |
| "Gastric cancer patients with cytologically confirmed malignant ascites were treated with cycles of oxaliplatin at 85 mg/m(2) plus leucovorin 20 mg/m(2) on the first day of treatment, followed by 5-fluorouracil (5-FU) via a 400 mg/m(2) bolus and a 22 h continuous infusion of 600 mg/m(2) 5-FU on Days 1-2 at 2-week intervals." | 5.12 | A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. ( Jang, JS; Jeong, JS; Kim, HJ; Kim, MC; Kim, SH; Kwon, HC; Lee, DM; Lee, S; Oh, SY; Yoo, HS, 2007) |
| "The present randomized phase III trial was designed to detect a 15% benefit in relapse-free survival (RFS) or overall survival (OS) from the incorporation of adjuvant tamoxifen to the combination of CNF [cyclophosphamide, 500 mg/m2; mitoxantrone (Novantrone), 10 mg/m2; fluorouracil, 500 mg/m2 chemotherapy and ovarian ablation in premenopausal patients with node-positive breast cancer and conversely from the incorporation of CNF chemotherapy to adjuvant tamoxifen in node-positive postmenopausal patients." | 5.11 | Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study. ( Adamou, A; Bafaloukos, D; Ekonomopoulos, T; Fountzilas, G; Georgoulias, V; Kalofonos, HP; Klouvas, G; Kosmidis, P; Koukouras, D; Kouvatseas, G; Kyriakou, K; Pavlidis, N; Pectasidis, D; Polychronis, A; Razis, E; Samantas, E; Skarlos, D; Stathopoulos, G; Zamboglou, N; Zombolas, V, 2004) |
| "Irinotecan has proven anti-tumor activity as induction treatment in combination with 5-fluorouracil (5-FU) or as second-line treatment after 5-FU in patients with metastatic colorectal cancer." | 5.11 | Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil. ( Batran, SA; Bokemeyer, C; Büchele, T; Haag, C; Hartmann, JT; Hofheinz, RD; Jäger, E; Kanz, L; Niederle, N; Oechsle, K; Pflüger, KH; Reis, HE; Wilke, HJ, 2004) |
| "PURPOSE To evaluate long-term cardiac function in patients without disease who had received six cycles of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2), and cyclophosphamide 500 mg/m(2) (FEC 50) or the same regimen with epirubicin 100 mg/m(2) (FEC 100) as adjuvant chemotherapy for node-positive breast cancer in the French Adjuvant Study Group-05 trial." | 5.11 | Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. ( Barats, JC; Bonneterre, J; Chapelle-Marcillac, I; Clavère, P; Datchary, J; Fargeot, P; Fumoleau, P; Goudier, MJ; Kerbrat, P; Monnier, A; Montcuquet, P; Roché, H; Van Praagh, I; Veyret, C, 2004) |
| "We studied the usefulness of the oral 5-FU anti-cancer drug 1-hexylcarbamoyl-5-fluorouracil (HCFU) + cyclophosphamide (CPM) + tamoxifen (TAM) (HCT group) in comparison with CMF + TAM (CMFT group) in adjuvant therapy for breast cancer by a non-inferiority study based on a multi-institutional joint study." | 5.11 | 1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: a randomized controlled trial. ( Abe, R; Aoyama, H; Asaga, T; Awane, H; Danno, M; Ikeda, T; Kimura, M; Koyama, H; Mitsuyama, S; Nishi, T; Ogita, M; Sano, M; Takashima, S; Takatsuka, Y; Toi, M; Tominaga, T; Wada, T; Yoshida, M, 2004) |
| "To assess patterns of locoregional failure (LRF) in lymph node-positive (LN+) breast cancer patients treated with mastectomy and adjuvant chemotherapy (+/- tamoxifen) and without postmastectomy radiotherapy (PMRT) in five National Surgical Adjuvant Breast and Bowel Project trials." | 5.11 | Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized c ( Anderson, S; Bryant, J; Deutsch, M; Jeong, JH; Mamounas, E; Taghian, A; Wolmark, N, 2004) |
| "Oxaliplatin 100 mg/m(2) iv on day 1, and capecitabine 1,000 mg/m(2) orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma." | 5.11 | Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study. ( Casaretti, R; Cataldis, GD; Comella, P; Farris, A; Lucia, LD; Maiorino, L; Massidda, B; Natale, D; Palmeri, S; Tafuto, S, 2005) |
| "We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer." | 5.11 | Adjuvant docetaxel for node-positive breast cancer. ( Al-Tweigeri, T; Blitz, S; Chap, L; Coleman, R; Colwell, B; Fornander, T; Guastalla, JP; Guevin, R; Hainsworth, J; Howell, A; Hugh, J; Jacobs, P; Juhos, E; Loret, C; Mackey, J; Martin, M; Modiano, M; Murawsky, M; Pawlicki, M; Pienkowski, T; Pinter, T; Prady, C; Provencher, L; Riva, A; Rodriguez-Lescure, A; Rupin, M; Tang, SC; Tomiak, E; Vinholes, J; Vogel, C; Walde, D; Weaver, C, 2005) |
| "The present study was conducted to evaluate the efficacy and safety of the combination of Oxaliplatin, Leucovorin and 5-FU as second line therapy, following relapse to Gemcitabine, in patients with advanced adenocarcinoma of the pancreas." | 5.11 | Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. ( Felekouras, E; Gouveris, P; Kopterides, P; Kopteridis, P; Kosmas, C; Loukeris, D; Papalambros, E; Sigala, F; Skopelitis, H; Tsavaris, N; Zorbala-Sypsa, A, 2005) |
| "Premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer (1,503 eligible patients) were randomly assigned to six cycles of cyclophosphamide, doxorubicin, and fluorouracil (CAF), CAF followed by 5 years of monthly goserelin (CAF-Z), or CAF followed by 5 years of monthly goserelin and daily tamoxifen (CAF-ZT)." | 5.11 | Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). ( Abeloff, MD; Davidson, NE; Martino, S; O'Neill, AM; Osborne, CK; Vukov, AM; White, DR, 2005) |
| "We randomized 1,475 premenopausal women with node-positive breast cancer to three, six, or nine courses of "classical" CMF (cyclophosphamide, methotrexate, and fluorouracil)." | 5.11 | Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Ca ( Bonetti, M; Carbone, A; Castiglione-Gertsch, M; Coates, AS; Collins, J; Crivellari, D; Fey, MF; Gelber, RD; Goldhirsch, A; Golouh, R; Gruber, G; Holmberg, SB; Lindtner, J; Nasi, ML; Price, KN; Rudenstam, CM; Simoncini, E; Thürlimann, B, 2005) |
| "Recently, high-dose FEC (fluorouracil, epirubicin, and cyclophosphamide) has been increasingly used in adjuvant chemotherapy for breast cancer in Japan." | 5.11 | [The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients]. ( Kim, SJ; Miyoshi, Y; Noguchi, S; Taguchi, T; Tamaki, Y; Tanji, Y, 2005) |
| "According to the overview of Early Breast Cancer Trialists' Collaborative Group, anthracycline containing regimens are superior to cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) as adjuvant chemotherapy for breast carcinoma, but no comparative information is available in terms of primary chemotherapy." | 5.10 | Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma. ( Bella, M; Bisagni, G; Boni, C; Bruzzi, P; Camisa, R; Ceci, G; Cocconi, G; Di Blasio, B; Leonardi, F; Rondini, E; Savoldi, L, 2002) |
| "A multicenter phase III randomized study comparing the efficacies of two adjuvant polychemotherapeutic regimens in 145 patients with stage II node-positive breast cancer: the standard chemotherapy combination, CMF (cyclophosphamide, methotrexate, 5-fluorouracil), and an experimental protocol, CNF (cyclophosphamide, mitoxantrone [Novantrone], 5-fluorouracil) in which mitoxantrone replaced methotrexate." | 5.10 | CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroups. ( Borovik, R; Brenner, HJ; Brenner, J; Catane, R; Chaitchik, S; Farbstein, H; Inbar, MJ; Peretz, T; Rizel, S; Ron, IG; Shani, A; Wigler, N, 2002) |
| "Between 1986 and 1990, 621 patients with operable breast cancer were randomly assigned to receive fluorouracil (Roche SA, Basel, Switzerland) 500 mg/m2, epirubicin (Pharmacia SA, Milan, Italy) 50 mg/m2, and cyclophosphamide (Asta Medica AG, Frankfurt, Germany) 500 mg/m2 every 21 days (FEC 50) for six cycles (6 FEC 50); FEC 50 for three cycles (3 FEC 50); or the same regimen with epirubicin 75 mg/m2 (FEC 75) for three cycles (3 FEC 75)." | 5.10 | Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. ( Brémond, A; Clavère, P; Datchary, J; Facchini, T; Fargeot, P; Fumoleau, P; Goudier, MJ; Jacquin, JP; Kerbrat, P; Luporsi, E; Mihura, J; Monnier, A; Namer, M; Pourny, C; Ramos, R; Romestaing, P; Schraub, S; Seffert, P; Serin, D; Sztermer, JF, 2003) |
| "Within 7 years 263 women with stage II breast cancer were randomised either to receive 1 cycle of doxorubicin, vinblastine, cyclophosphamide, methotrexate and 5- fluorouracil (AV-CMF) or to receive 6 cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)." | 5.10 | Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients. ( Fridrik, M; Gnant, M; Haider, K; Hausmaninger, H; Jakesz, R; Kolb, R; Kubista, E; Mlineritsch, B; Ploner, F; Samonigg, H; Seifert, M; Steger, G; Steindorfer, P; Stierer, M; Tschurtschenthaler, G, 2003) |
| "We randomly assigned 540 female patients with primary breast cancer and at least 10 involved ipsilateral axillary lymph nodes to receive either six cycles of adjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil (CAF) or the same adjuvant chemotherapy followed by high-dose chemotherapy with cyclophosphamide and thiotepa and autologous hematopoietic stem-cell transplantation." | 5.10 | Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. ( Fetting, J; Gradishar, WJ; Gray, R; Lazarus, HM; LeMaistre, CF; Osborne, CK; Paietta, E; Pisansky, TM; Robert, NJ; Tallman, MS; Vaughan, WP, 2003) |
| "The Zoladex Early Breast Cancer Research Association (ZEBRA) trial compared the efficacy and tolerability of goserelin (Zoladex) with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy in pre-/perimenopausal women with node-positive early breast cancer." | 5.10 | Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. ( Blamey, R; Cuzick, J; de Haes, JC; Fogelman, I; Jonat, W; Kaufmann, M; Namer, M; Sauerbrei, W; Schumacher, M, 2003) |
| "To compare quality of life (QoL) in premenopausal and perimenopausal patients with node-positive, early breast cancer treated with the endocrine agent goserelin (Zoladex; AstraZeneca Pharmaceuticals LP, Wilmington, DE) or cyclophosphamide + methotrexate + fluorouracil (CMF)." | 5.10 | Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group. ( de Haes, H; Jonat, W; Kaufmann, M; Olschewski, M; Sauerbrei, W; Schumacher, M, 2003) |
| "The present study aimed at evaluating the efficacy of Raltitrexed, a specific thymidilate synthase inhibitor, in patients with advanced colorectal cancer (ACC) in relapse (>8 weeks) after a prior response or disease stabilization to first-line chemotherapy combination with lrinotecan+5-Fluorouracil (5-FU)+Leucovorin (LV)." | 5.10 | Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy. ( Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M, 2002) |
| "5-fluorouracil remains the standard therapy for patients with advanced/metastatic colorectal cancer." | 5.10 | Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study. ( Blackstock, AW; Case, D; Higgs, V; Melin, SA; Savage, P; Tomlinson, SK; White, DR, 2002) |
| "Classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) including oral cyclophosphamide is still considered an important adjuvant chemotherapy regimen in patients with early breast cancer (BC)." | 5.10 | The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative dos ( Awada, A; Bartholomeus, S; Beauduin, M; Cardoso, F; Di Leo, A; Dolci, S; Ferreira Filho, AF; Focan, C; Michel, J; Paesmans, M; Piccart, MJ; Vindevoghel, A, 2002) |
| "The aim of this study was to evaluate the toxicity and efficacy of combination chemotherapy with weekly 24-h continuous infusion of 5-fluorouracil (5-FU)/folinic acid, weekly paclitaxel and 3-weekly cisplatin in patients with unresectable, locally advanced or metastatic gastric adenocarcinoma." | 5.10 | Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. ( Baronius, W; Bokemeyer, C; Haag, C; Hartmann, JT; Hempel, V; Honecker, F; Kanz, L; Kollmannsberger, C; Quietzsch, D; Schroeder, M; Spott, C, 2002) |
| "To evaluate the activity and safety of an alternating schedule of irinotecan (CPT-11) with high-dose 5-fluorouracil (5-FU) given as a weekly 48-hour infusion in combination with leucovorin (LV) in the first-line treatment of metastatic colorectal cancer (MCRC) patients." | 5.10 | A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer. ( Manzione, L; Reggiardo, G; Rosati, G; Rossi, A, 2002) |
| "This phase-II study was conducted to investigate the potential benefit from the addition of mitomycin to a conventional anthracycline-cisplatin- and 5-fluorouracil-based chemotherapy for recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type (UCNT)." | 5.09 | Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. ( Alonso, S; Armand, JP; Chouaki, N; Cortès-Funes, H; Cvitkovic, E; Fandi, A; Hasbini, A; Lianes, P; Mahjoubi, R; Raymond, E; Taamma, A, 1999) |
| "We have investigated the relationship between c-erbB(2) status, estrogen receptor (ER) status and outcome in 274 women with node-positive breast cancer who, following excision and axillary clearance, were randomized to receive either 6 cycles of cyclophosphamide/methotrexate/fluorouracil (CMF) (n = 129) or no such treatment (n = 145)." | 5.09 | Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. ( Barnes, DM; Gillett, CE; Harris, WH; Miles, DW; Smith, P, 1999) |
| "The purpose of this study was to examine the association between the leucocyte nadir and prognosis in breast cancer patients receiving adjuvant chemotherapy consisting of cyclophosphamide, methotrexate and fluorouracil (CMF)." | 5.09 | Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. ( Blomqvist, C; Joensuu, H; Lundin, J; Poikonen, P; Saarto, T, 1999) |
| "This multicenter phase II study was designed to assess the efficacy of the alternating schedule of tomudex with methotrexate (MTX)/5-fluorouracil (5-FU)/leucovorin (LV) in first-line chemotherapy for metastatic colorectal cancer." | 5.09 | A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. ( Agostinelli, R; Baldelli, AM; Barni, S; Cascinu, S; Catalano, G; Catalano, V; Frontini, L; Gasparini, G; Giuliodori, L; Labianca, R; Martignoni, G; Mattioli, R; Silva, RR, 1999) |
| "To evaluate the outcome in patients with stage II hormone receptor-positive breast cancer treated or not treated with low-dose, short-term chemotherapy in addition to tamoxifen in terms of disease-free and overall survival." | 5.09 | Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer. ( Fridrik, M; Gnant, M; Haider, K; Hausmaninger, H; Jakesz, R; Kolb, R; Kubista, E; Manfreda, D; Mittlböck, M; Mlineritsch, B; Samonigg, H; Steger, G; Steindorfer, P; Stierer, M; Tschurtschenthaler, G, 1999) |
| "A phase II pilot study was carried out on 30 patients to ascertain the toxicity and efficacy of combination chemotherapy with mitoxantrone, methotrexate, 5-fluorouracil (NMF) in the adjuvant setting for axillary lymph node-positive breast cancer." | 5.09 | Adjuvant chemotherapy with a combination of mitoxantrone, methotrexate, 5-fluorouracil for node-positive breast cancer: phase II pilot study. ( Bando, H; Kanno, M; Kawahara, F; Mura, T; Nakamura, S; Noguchi, M; Taniya, T; Tsugawa, K; Uotani, C, 1999) |
| "Three hundred twenty-eight patients with stage II/IIIA breast cancer who were younger than 66 years of age were randomly allocated to chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide (FAC) or FAC plus pretreatment with ethinyl estradiol (EE(2))." | 5.09 | Value of estrogenic recruitment before chemotherapy: first randomized trial in primary breast cancer. ( Baggen, MG; Beudeker, M; Bontenbal, M; Braun, JJ; Burghouts, JT; Foekens, JA; Helle, P; Janssen, JT; Klijn, JG; Leisink, M; Ras, GJ; Stiegelis, WF; van der Linden, GH; van der Velden, PC; van Geel, AN; van Putten, WL, 2000) |
| "Following modified radical mastectomy, pre- and perimenopausal (amenorrhoea for < 5 years) patients with stage II or III breast cancer received CMF (cyclophosphamide 600, methotrexate 40, 5-fluorouracil 600 mg/m2 intravenously (i." | 5.09 | Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial. ( Andersen, J; Andersson, M; Cold, S; Dombernowsky, P; Ejlertsen, B; Jensen, MB; Kamby, C; Kjaer, M; Mouridsen, H; Overgaard, M; Rose, C, 1999) |
| "Biweekly intravenous infusions of low-dose cisplatin (CDDP) and 5-fluorouracil (5-FU) were evaluated in 80 patients with advanced or recurrent gastric, colorectal, pancreatic or gallbladder adenocarcinoma." | 5.09 | [Biweekly low-dose cisplatin and 5-fluorouracil combination chemotherapy for advanced gastrointestinal carcinoma]. ( Kamata, T; Kanno, M; Koyasaki, N; Morita, A; Nakamoto, A; Onishi, I; Takeda, T, 2000) |
| "To evaluate the toxicity and efficacy of combination chemotherapy with paclitaxel, cisplatin and 24 h continuous infusion of 5-FU/folinic acid in patients (pts) with unresectable, locally advanced or metastatic gastric adenocarcinoma." | 5.09 | A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. ( Baronius, W; Bokemeyer, C; Clemens, M; Haag, C; Hartmann, JT; Hempel, V; Kanz, L; Kollmannsberger, C; Lingenfelser, T; Quietzsch, D; Schroeder, M, 2000) |
| "According to one of the most recent key scientific questions concerning the use of biomarkers in clinical trials, we investigated whether node-negative breast cancer patients, defined as high-risk cases on the basis of tumor cell proliferation, could benefit from cyclophosphamide, methotrexate, and fluorouracil (CMF) adjuvant therapy." | 5.09 | Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study. ( Amadori, D; Becciolini, A; Catalano, G; Gambi, A; Giunchi, DC; Marangolo, M; Nanni, O; Pacini, P; Perroni, D; Ravaioli, A; Rossi, A; Scarpi, E; Tienghi, A; Volpi, A, 2000) |
| " Therefore, we developed an individualised fluorouracil, epirubicin, cyclophosphamide (FEC) regimen to improve outcomes in patients with high-risk early breast cancer." | 5.09 | Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. ( Anker, G; Bengtsson, NO; Bergh, J; Blomqvist, C; Erikstein, B; Holte, H; Kellokumpu-Lehtinen, P; Lidbrink, E; Lindman, H; Ljungman, P; Malmström, P; Nilsson, J; Ottosson, S; Salminen, E; Söderlund, G; Wiklund, T; Wilking, N; Wist, E, 2000) |
| "Between April 1990 and July 1993, 565 operable breast cancer patients with either more than three positive nodes or between one and three positive nodes with Scarff Bloom Richardson grade > or = 2 and hormone receptor negativity were randomized after surgery to receive either fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2), and cyclophosphamide 500 mg/m(2) every 21 days for six cycles (FEC 50) or the same regimen except with epirubicin dose of 100 mg/m(2) (FEC 100)." | 5.09 | Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. ( , 2001) |
| "We evaluated the usefulness of adjuvant chemotherapy with low-dose epirubicin (EPI) as a key drug in patients with axially-node positive breast cancer." | 5.09 | [Usefulness of ambulatory adjuvant chemotherapy with low-dose epirubicin in patients with axially-node positive breast cancer: Chiba Epirubicin Cooperative Study Group]. ( Miyauchi, M; Nakajima, N; Ogawa, K; Oheda, Y; Ohno, K; Suzuki, M; Takahashi, M; Tsukamoto, T; Yamamoto, K; Yamamoto, N, 2001) |
| " As data including pre-and post-treatment samples are lacking, we studied leukocyte telomere length and telomerase activity before and after treatment in breast cancer patients randomized to receive 5 adjuvant courses FEC (5-FU, epirubicin and cyclophosphamide) (n = 17), or 4 x FEC followed by high-dose cyclophosphamide, thiotepa, carboplatin and autologous PBSCT (n = 16)." | 5.09 | Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. ( de Jong, S; de Leij, LF; de Vries, EG; Mulder, NH; Ruiters, MH; Schröder, CP; van der Graaf, WT; van der Zee, AG; Wisman, GB, 2001) |
| "The purpose of this investigation was to study the long-term prognosis of breast cancer patients with 10 or more positive lymph nodes after conventional chemotherapy treatment with cyclophosphamide, methotrexate and 5-fluorouracil (CMF)." | 5.09 | Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF. ( Bastert, G; Bojar, H; Sauerbrei, W; Schmoor, C; Schumacher, M, 2001) |
| "Between June 1985 and July 1992, 600 breast cancer patients, clinical stages T1-3A,N0-2,M0 were randomly assigned to a perioperative cycle (PC) of cyclophosphamide 600 mg/m2, epidoxorubicin 60 mg/m2, and fluorouracil 600 mg/m2 (CEF)." | 5.08 | Randomized cooperative study of perioperative chemotherapy in breast cancer. ( Amoroso, D; Bertelli, G; Bruzzi, P; Campora, E; Del Mastro, L; Pronzato, P; Queirolo, P; Sertoli, MR; Venturini, M; Vigani, A, 1995) |
| "To compare 1 year of therapy with continuous cyclophosphamide, methotrexate, fluorouracil (5-FU), vincristine, and prednisone (CMFVP) with a short course of treatment with a doxorubicin-based regimen in the postsurgical adjuvant treatment of patients with hormone receptor-negative, node-positive breast cancer." | 5.08 | Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an intergroup study. ( Abeloff, MD; Budd, GT; Green, S; Hahn, R; Harris, J; Martino, S; O'Bryan, RM; O'Sullivan, J; Rinehart, JJ; Tormey, D, 1995) |
| "Adjuvant combination chemotherapy with cyclophosphamide, methotrexate, and fluorouracil was administered after radical mastectomy for primary breast cancer with histologically positive axillary lymph nodes to assess whether it would improve treatment outcome as compared with surgery alone." | 5.08 | Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. ( Bonadonna, G; Brambilla, C; Moliterni, A; Valagussa, P; Zambetti, M, 1995) |
| "A prospective randomized study was conducted to compare the adjuvant efficacy of six cycles of high-dose ACMF (Adriamycin, ADM; cyclophosphamide, CPA; methotrexate, MTX; 5-fluorouracil, 5-FU) with that of 12 cycles of low-dose ACMF in premenopausal, node-positive breast cancer patients." | 5.08 | Adjuvant six cycles of high-dose adriamycin, cyclophosphamide, methotrexate, 5-fluorouracil (ACMF) vs. 12 cycles of low-dose ACMF with tamoxifen for premenopausal, node-positive breast cancer patients: results of a prospective randomized study. ( Akashi, S; Fukutomi, T; Nanasawa, T; Yamamoto, H, 1995) |
| "To determine whether a combination chemotherapy regimen that contains epirubicin (fluorouracil, epirubicin, and cyclophosphamide [FEC]) is superior to the standard cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in premenopausal women with axillary node-positive operable breast cancer." | 5.08 | Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab ( Aapro, M; Amadori, D; Bliss, JM; Chilvers, CE; Coombes, G; Coombes, RC; Espié, M; Ferreira, EP; Gambrosier, P; Marty, M; McArdle, C; Morvan, F; Pérez-López, FR; Richards, M; Vassilopoulos, P; Villar-Grimalt, A; Wils, J; Woods, EM, 1996) |
| "After curative resection for gastric adenocarcinoma, 103 patients, all with positive nodes, were randomised so that 48 received adjuvant chemotherapy of epidoxorubicin (EPI) 75 mg m-2 on day 1, leucovorin (LV) 200 mg m-2 on days 1-3 and 5-fluorouracil (5-FU) 450 mg m-2 on days 1-3, every 21 days for 7 months, whereas the remaining 55 did not." | 5.08 | Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. ( Andreoli, F; Borrelli, D; Bruno, L; Cini, G; de Leonardis, V; Fabbroni, S; Intini, C; Neri, B; Pernice, LM; Romano, S; Valeri, A, 1996) |
| "To determine the long-term impact on disease-free survival (DFS) and overall survival (OS) of adjuvant anthracycline-based chemotherapy, when prospectively compared by random allocation with standard cyclophosphamide, methotrexate, and fluorouracil (CMF) in node-positive (N+) breast cancer patients." | 5.08 | Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. ( Belpomme, D; Chollet, P; Delgado, M; di Palma, M; Fargeot, P; Fumoleau, P; Guerrin, J; Hill, C; Ithzaki, M; Le Mevel, B; Mathé, G; Metz, R; Misset, JL; Plagne, R, 1996) |
| "We randomly assigned 1,554 premenopausal breast cancer patients with node-positive disease in a 2 x 2 factorial design to receive the following: (A) cyclophosphamide, methotrexate, and fluorouracil for 6 consecutive courses on months 1 to 6 (CMF x 6); (B) CMFx6 plus three single courses of reintroduction CMF given on months 9, 12, and 15; (C) CMF for three consecutive courses on months 1 to 3 (CMFx3); or (D) CMFx3 plus three single courses of reintroduction CMF given on months 6, 9, and 12." | 5.08 | Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. ( , 1996) |
| "We undertook a randomized trial in patients with advanced colorectal cancer, comparing 5-fluorouracil and leucovorin versus combination of these agents with additional cisplatin." | 5.08 | [Evaluation of chemotherapy in the treatment of advanced colorectal cancer--pilot study of 5-FU by biochemical modulation]. ( Katsumata, K; Ohno, M; Shibata, K; Yamamoto, K; Yamashita, S, 1996) |
| "From July 1986 to April 1993 the International Breast Cancer Study Group (IBCSG) Trial VI randomly assigned 1554 pre/perimenopausal node-positive breast cancer patients to receive cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) for either three consecutive courses on months 1-3, or six consecutive courses on months 1-6, both with or without reintroduction CMF." | 5.08 | Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. International Breast Cancer Study Group. ( Bernier, J; Castiglione-Gertsch, M; Gelber, RD; Goldhirsch, A; Joseph, D; Roncadin, M; Wallgren, A, 1996) |
| "By a collaborative study undertaken by 11 medical institutions in the Kita-Kyushu area, we evaluated the clinical efficacy of the combination of medroxyprogesterone acetate (MPA) and Tamoxifen (TAM) as a postoperative adjuvant endocrine therapy for Stage III breast cancer." | 5.08 | [Administration method and recurrence-preventing effect of medroxyprogesterone acetate (MPA) as a postoperative adjuvant endocrine therapy for stage III breast cancer. Kitakyushu Collaborative Study Group for Breast Cancer]. ( Egami, T; Ikeda, S; Kuroda, Y; Mitsuyama, S; Mori, A; Murakami, F; Nakamura, Y; Nishikata, F; Ohe, H; Ohsato, K, 1996) |
| "To evaluate ambulatory cancer chemotherapy, the clinical response, toxicities and survival time were analysed among 32 patients with non-curative or recurrent colorectal cancer who were treated by l-Leucovorin (l-LV) plus 5-fluorouracil for the past four years." | 5.08 | [Clinical study of ambulatory cancer chemotherapy for advanced colorectal cancer]. ( Kunii, Y; Ota, K; Takahashi, N, 1995) |
| " In patients with node-positive breast cancer adjuvant chemotherapy with cyclophosphamide+ methotrexate+fluorouracil has been reported to improve survival in comparison with patients who are not given this treatment." | 5.08 | Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer. ( Becagli, P; Messori, A; Tendi, E; Trippoli, S, 1996) |
| " High expression of TP in cell lines potentiates the effects of the cytotoxic drugs 5-fluorouracil and methotrexate, both of which are used in the cyclophosphamide, 5-fluorouracil and methotrexate (CMF) treatment regimen of breast cancer." | 5.08 | Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. ( Comley, M; Engels, K; Fox, SB; Gatter, KC; Harris, AL; Turley, H; Whitehouse, RM, 1997) |
| "Between July 1986 and April 1993, 1,266 postmenopausal breast cancer patients with node-positive disease were randomly assigned to receive one of four adjuvant therapy regimens: (A) tamoxifen alone for 5 years; (B) tamoxifen plus three courses of early cyclophosphamide, methotrexate, and fluorouracil (CMF) on months 1, 2, and 3; (C) tamoxifen plus delayed single courses of CMF on months 9, 12, and 15; (D) tamoxifen plus early and delayed CMF on months 1, 2, 3, 9, 12, and 15." | 5.08 | Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. ( , 1997) |
| "To compare two adjuvant combination chemotherapies, cyclophosphamide, methotrexate, and fluorouracil (CMF) and chlorambucil, methotrexate, and fluorouracil (LMF), for patients who had undergone potentially curative surgery for unilateral breast cancer, in terms of relapse, survival, and toxicity." | 5.08 | Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82. ( Castiglione, M; Cavalli, F; Jungi, WF; Leyvraz, S; Maibach, R; Obrecht, JP; Schildknecht, O; Senn, HJ; Siegenthaler, P, 1997) |
| "The objective of this study was to compare the antitumor activity of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) with that of the 5-fluorouracil/doxorubicin/cyclophosphamide (FAC) combination by evaluating the extent of residual disease in the breast and regional lymph nodes of patients with breast cancer following four cycles of induction chemotherapy." | 5.08 | Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer. ( Ames, F; Asmar, L; Buzdar, AU; Hortobagyi, GN; McNeese, M; Rahman, Z; Singletary, S; Theriault, RL, 1997) |
| "The B-20 study of the National Surgical Adjuvant Breast and Bowel Project (NSABP) was conducted to determine whether chemotherapy plus tamoxifen would be of greater benefit than tamoxifen alone in the treatment of patients with axillary lymph node-negative, estrogen receptor-positive breast cancer." | 5.08 | Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. ( Abramson, N; Atkins, JN; Bryant, J; DeCillis, A; Deschenes, L; Dignam, J; Dimitrov, NV; Emir, B; Fisher, B; Margolese, RG; Shibata, H; Wickerham, DL; Wolmark, N, 1997) |
| " For this reason, we have evaluated p53 alterations in 282 consecutive patients with infiltrating node-negative breast cancer who underwent primary surgery and were randomized either to CMF (Cyclophosphamide 400 mg/m2, Fluorouracil 400 mg/m2, and Methotrexate 40 mg/m2) or control arm (no adjuvant therapy) from 1980 to 1989." | 5.08 | Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer? ( Bourstyn, E; de Cremoux, P; de Roquancourt, A; Degeorges, A; Espie, M; Extra, JM; Marty, M; Soussi, T, 1998) |
| "The Intergroup conducted this breast cancer adjuvant trial to compare an investigational 16-week regimen with cyclophosphamide, doxorubicin, and fluorouracil (5-FU; CAF)." | 5.08 | Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study. ( Abeloff, MD; Cella, D; Citron, ML; Fairclough, DL; Fetting, JH; Gray, R; Grove-Conrad, M; Henderson, IC; Margolin, KA; Osborne, CK; Pandya, K; Robert, N; Smith, TJ, 1998) |
| "To determine the relative efficacy of an intensive cyclophosphamide, epirubicin, and fluorouracil (CEF) adjuvant chemotherapy regimen compared with cyclophosphamide, methotrexate, and fluorouracil (CMF) in node-positive breast cancer." | 5.08 | Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical ( Abu-Zahra, H; Arnold, A; Bowman, D; Bramwell, VH; Burnell, M; Findlay, B; Levine, MN; MacKenzie, R; Myles, J; Norris, BD; Ottaway, J; Pritchard, KI; Robert, J; Shepherd, LE; Tu, D; Vandenberg, T; Warr, D; Williams, CK, 1998) |
| "In 1984, the International Collaborative Cancer Group (ICCG) started a randomised trial comparing adjuvant treatment with cyclophosphamide 100 mg/m2 orally on days 1 to 14, methotrexate 40 mg/m2 intravenously on days 1 and 8 plus fluorouracil 600 mg/m2 intravenously on days 1 and 8 every 4 weeks for 6 cycles (CMF) vs fluorouracil 600 mg/m2, epirubicin 50 mg/m2 and cyclophosphamide 600 mg/m2 (FEC), all given intravenously on day 1 for 8 cycles at 3-week intervals in premenopausal patients with node-positive breast cancer." | 5.07 | Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collaborativ ( Bliss, J; Coombes, RC; Marty, M; Wils, J; Woods, E, 1993) |
| "In 1984, the German Breast Cancer Study Group (GBSG) started a multicenter randomized clinical trial to compare the effectiveness of three versus six cycles of 500 mg/m2 cyclophosphamide, 40 mg/m2 methotrexate, and 600 mg/m2 fluorouracil (CMF) on day 1 and 8 starting perioperatively with or without tamoxifen (TAM) (3 x 10 mg/d for 2 years)." | 5.07 | Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study Group. ( Bastert, G; Beyerle, C; Bojar, H; Hübner, K; Neumann, RL; Olschewski, M; Rauschecker, HF; Sauerbrei, W; Schmoor, C; Schumacher, M, 1994) |
| "CMFVP chemotherapy, either alone or in combination with tamoxifen, has not been shown to be superior to tamoxifen alone in the treatment of postmenopausal women with node-positive, ER-positive, operable breast cancer." | 5.07 | Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. ( Abeloff, MD; Costanzi, JJ; Cruz, AB; Farrar, WB; Green, S; Jewell, WR; Metch, B; Minton, JP; Osborne, CK; Rivkin, SE, 1994) |
| "Seventeen patients with either newly diagnosed breast cancer with more than four involved axillary nodes (five patients) or metastatic breast cancer (12 patients) were treated with cyclophosphamide 1 g/m2, doxorubicin 50 mg/m2, and fluorouracil 500 mg/m2 (CAF) intravenously (IV) once every 3 weeks." | 5.07 | Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil. ( Gelmon, KA; O'Reilly, SE; Onetto, N; Page, RA; Parente, J; Plenderleith, IH; Rubinger, M, 1993) |
| "To determine if prolonged adjuvant treatment (2 years v 1 year) with combination chemotherapy (cyclophosphamide, methotrexate, fluorouracil [5-FU], vincristine, and prednisone [CMFVP]) in poor-prognosis breast cancer patients (estrogen receptor [ER]-negative, stage II to IIIA) would result in improved disease-free and overall survival rates." | 5.07 | One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study. ( Altman, SJ; Costanzi, JJ; Green, S; Jewell, WR; Metch, B; Minton, JP; O'Bryan, RM; Osborne, CK; Rivkin, SE, 1993) |
| "This phase III clinical trial was designed to evaluate the therapeutic efficacy and toxicity of the alkylating agent cyclophosphamide in combination with the antimetabolites methotrexate and fluorouracil adjuvant to breast cancer surgery." | 5.07 | Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes. ( Canellos, GP; Frei, E; Gelman, RS; Hayes, DF; Henderson, IC; Obando, A; Osteen, R; Shapiro, CL, 1993) |
| "Thirty-eight patients with stage II breast cancer with four or more positive axillary lymph nodes were randomized to receive CMF (cyclophosphamide, methotrexate and 5-fluorouracil, every 3 weeks) or CXF (cyclophosphamide, mitoxantrone and 5-fluorouracil, every 3 weeks)." | 5.07 | A preliminary report of a pilot randomized trial comparing cyclophosphamide, methotrexate and 5-fluorouracil with cyclophosphamide, mitoxantrone and 5-fluorouracil in the adjuvant therapy of stage II breast cancer with four or more positive axillary nodes ( Ben-Dor, CG; Brufman, G; Isacson, R; Safra, T; Uziely, B, 1993) |
| "The Comprehensive Cancer Center trial 82-01 is a prospective randomized study to investigate the value of the addition of high-dose medroxyprogesterone acetate (MPA) to chemotherapy in patients with node-positive operable breast cancer." | 5.07 | Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients. ( Bron, H; de Jong, J; Fickers, M; Hupperets, PS; Jager, J; Schouten, HC; Schouten, L; Smeets, J; Volovics, L; Wils, J, 1993) |
| "In a prospective study of 622 women with breast cancer, those with one to three histologically positive axillary lymph nodes were randomised after mastectomy to receive cyclophosphamide 100 mg/m2 orally on days 1-14, methotrexate 40 mg/m2 intravenously on days 1 and 8, and fluorouracil 600 mg/m2 intravenously on days 1 and 8 every 28 days for six cycles (CMF x six), or for twelve cycles of the same chemotherapy (CMF x 12)." | 5.07 | Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: a South-Eastern Cancer Study Group (SEG) Trial. ( Bartolucci, AA; Bass, D; Carpenter, JT; Ketcham, A; Marcial, V; Moore, M; Singh, KP; Smalley, R; Vélez-García, E; Vogel, CL, 1992) |
| "A multicentre pilot study has been conducted to determine an intensive regimen of cyclophosphamide, epirubicin, and fluorouracil which was tolerable and acceptable to patients with node positive breast cancer." | 5.07 | A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. ( Abu-Zahra, H; Arnold, A; Bramwell, V; Findlay, B; Levine, MN; Perrault, D; Pritchard, K; Skillings, J; Warr, D, 1992) |
| "504 evaluable node positive oestrogen receptor (ER) positive breast cancer patients were randomly allocated to receive either 5 years tamoxifen treatment or chemotherapy [six courses of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) followed by 4 courses of epirubicin] or a combination of both treatments." | 5.07 | Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial. ( Amoroso, D; Boccardo, F; Castagnetta, L; Farris, A; Genta, F; Nenci, I; Piffanelli, A; Rubagotti, A; Sismondi, P; Traina, A, 1992) |
| "Between 1976 and 1984, 574 patients with operable breast cancer and histologically negative axillary lymph nodes were randomly assigned after mastectomy to receive either no further treatment or chemotherapy with oral LMF (fluorouracil, 500 mg, methotrexate, 25 mg, and chlorambucil, 10 mg, on day 1; fluorouracil, 500 mg, and chlorambucil, 10 mg, on day 2)." | 5.07 | West Midlands Oncology Association trial of adjuvant chemotherapy in node-negative breast cancer. ( Grieve, RJ; Howell, A; Kelly, KA; Monypenny, IJ; Morrison, JM; Walker, RA; Waterhouse, JA, 1992) |
| "A randomised trial has previously been repeated in which 437 women with node positive breast cancer received either a 12-week chemohormonal regimen consisting of cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone, adriamycin and tamoxifen or 36 weeks of CMFVP." | 5.07 | The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation. ( Abu-Zahra, H; Arnold, A; Bramwell, V; Findlay, B; Gent, M; Goodyear, MD; Levine, MN; Skillings, J, 1992) |
| "To improve current adjuvant results in high-risk breast cancer, in February 1982 we activated a prospective randomized trial using both intravenous cyclophosphamide, methotrexate, and fluorouracil (CMF) and Adriamycin (doxorubicin; Farmitalia-Carlo Erba, Milan, Italy) involving patients with resectable mammary carcinoma and more than three positive axillary lymph nodes." | 5.07 | Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. ( Bonadonna, G; Buzzoni, R; Valagussa, P; Zambetti, M, 1991) |
| "This study evaluated combined 5-fluorouracil (5FU) and doxorubicin as postoperative adjuvant chemotherapy for patients who had undergone potentially curative resection of a primary gastric adenocarcinoma." | 5.07 | A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. ( Beart, RW; Foley, JF; Krook, JE; Kugler, JW; Leigh, JE; O'Connell, MJ; Pfeifle, DM; Twito, DI; Wieand, HS, 1991) |
| "The influence of S-phase fraction (SPF), measured by DNA flow cytometry, and histological grade on outcome following adjuvant chemotherapy was analysed for 214 patients with node positive breast cancer treated at Guy's Hospital who were entered into the Guy's/Manchester trial of combination chemotherapy with cyclophosphamide/methotrexate/5-fluorouracil (CMF) vs." | 5.06 | Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer. ( Camplejohn, RS; Millis, RR; O'Reilly, SM; Richards, MA; Rubens, RD, 1990) |
| "A prospectively controlled randomized trial to compare the adjuvant efficacy of 12 cycles of cyclophosphamide, methotrexate, fluorouracil, prednisone, and tamoxifen (CMFPT) followed by observation or a total of 5 years of continuous tamoxifen versus four cycles of CMFPT followed by observation in postmenopausal women with operable node-positive breast cancer was started by the Eastern Cooperative Oncology Group (ECOG) in 1982." | 5.06 | Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. ( Falkson, G; Falkson, HC; Gillchrist, KW; Gray, R; Harris, JE; Tormey, DC; Wolberg, WH, 1990) |
| "Between November 1, 1983 and June 30, 1987, 510 node-positive, estrogen receptor (ER)-positive breast cancer patients have been randomly allocated to receive either chemotherapy (six intravenous [IV] cyclophosphamide, methotrexate, and fluorouracil [CMF] courses followed by four IV epirubicin courses) or 5 years of tamoxifen treatment or a combination of both therapies." | 5.06 | Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group. ( Boccardo, F; Bruzzi, P; Cappellini, M; Isola, G; Nenci, I; Piffanelli, A; Rubagotti, A; Santi, L; Scanni, A; Sismondi, P, 1990) |
| "We evaluated the postoperative use of sequential methotrexate and fluorouracil followed by leucovorin in 679 patients with primary breast cancer, histologically negative axillary nodes, and estrogen-receptor-negative (less than 10 fmol) tumors." | 5.06 | A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. ( Bowman, D; Dimitrov, NV; Fisher, B; Fisher, ER; Legault-Poisson, S; Margolese, R; Redmond, C; Sutherland, C; Wickerham, DL; Wolmark, N, 1989) |
| "A randomized clinical trial was performed to determine if the addition of hormonal therapy with tamoxifen to a combination chemotherapy regimen was superior to the chemotherapy alone for adjuvant treatment of premenopausal women after mastectomy for node-positive breast cancer." | 5.06 | Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer. ( Cullinan, SA; Everson, LK; Fitzgibbons, RG; Foley, JF; Hagen, JB; Ingle, JN; Krook, JE; Martin, JK; Wieand, HS; Wold, LE, 1989) |
| "Four hundred forty-one women with operable breast cancer with histologically positive axillary nodes were randomized to receive either combination cyclophosphamide (60 mg/m2 orally everyday for 1 year); fluorouracil (300 mg/m2 intravenously [IV] weekly for 1 year); methotrexate (15 mg/m2 IV weekly for 1 year); vincristine (0." | 5.06 | Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study. ( Athens, J; Constanzi, JJ; Gad-el-Mawla, N; Glucksberg, H; Green, S; Hoogstraten, B; Maloney, T; Metch, B; Osborne, CK; Rivkin, SE, 1989) |
| "Treatment with tamoxifen (TM), alone or in combination with cyclophosphamide, methotrexate, and fluorouracil (CMF), was used as an adjuvant to surgery in 433 patients with stage I, II, or III(T3a) breast cancer." | 5.06 | Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study. ( Bianco, AR; D'Istria, M; De Placido, S; Delrio, G; Gallo, C; Marinelli, A; Pagliarulo, C; Petrella, G, 1988) |
| "The results after 6 years of a prospective clinical trial of adjuvant chemotherapy with a regimen of two drugs--cyclophosphamide and 5-fluorouracil (CF)-- for 2 years in 97 women with stage II or III breast cancer are reported." | 5.06 | Two years of cyclophosphamide and 5-fluorouracil as adjuvant chemotherapy for stage II and III breast carcinoma. ( Caceres, E; Cotrina, M; Gamboa, M; Leon, L; Lingan, M; Moran, M; Olivares, L; Valdivia, S, 1988) |
| "Three hundred ten patients with Stage II or Stage III breast cancer were entered on an adjuvant protocol consisting of a combination of 5-fluorouracil, doxorubicin, cyclophosphamide, vincristine, and prednisone (FACVP)." | 5.06 | Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs. ( Ames, FC; Buzdar, AU; Fraschini, G; Holmes, FA; Hortobagyi, GN; Hug, V; Kau, S; Marcus, C; Martin, RG; Smith, TL, 1988) |
| "Eight hundred eighteen premenopausal or perimenopausal breast cancer patients with axillary node metastases were treated with adjuvant chemotherapy (CMF) with or without endocrine treatment (prednisone, oophorectomy) in two concurrent prospective trials." | 5.06 | Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. ( Castiglione, M; Gelber, RD; Goldhirsch, A, 1988) |
| "Between 1974 and 1977, a total of 254 patients with stages T1-3a, N0-1, and M0 operable breast cancer (node negative and node positive, stratified) were randomized to either modified radical mastectomy alone or the same surgery and adjuvant chlorambucil, methotrexate, 5-fluorouracil (LMF) plus BCG." | 5.06 | Swiss adjuvant trial (OSAKO 06/74) with chlorambucil, methotrexate, and 5-fluorouracil plus BCG in node-negative breast cancer patients: nine-year results. ( Amgwerd, R; Ammann, J; Creux, G; Enderlin, F; Engelhart, G; Heinz, C; Hochuli, E; Jungi, WF; Senn, HJ; Wick, A, 1986) |
| "Between 1978 and 1981, 463 evaluable postmenopausal patients 65 years of age or younger with operable breast cancer and metastases in axillary lymph nodes were entered in Ludwig Breast Cancer Study III (Ludwig III) and randomly allocated to receive chemoendocrine therapy with cyclophosphamide, methotrexate, 5-fluorouracil, low-dose continuous prednisone, and tamoxifen (CMFp + T) for 12 monthly cycles, or endocrine therapy alone with prednisone and tamoxifen (p + T) for 1 year, or no adjuvant treatment after mastectomy (observation)." | 5.06 | A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. ( Gelber, RD; Goldhirsch, A, 1986) |
| "Adjuvant therapy after total mastectomy and axillary clearance in postmenopausal women with breast cancer and axillary node metastasis was assessed; chemo-endocrine therapy (cyclophosphamide, methotrexate, fluorouracil, prednisone, and tamoxifen; CMFp + T) was compared with endocrine therapy (prednisone and tamoxifen; p + T), and with no adjuvant treatment in 463 patients aged less than or equal to 65 years." | 5.05 | Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. ( , 1984) |
| "The Southwest Oncology Group in a prospective randomized study compared one year of adjuvant combination chemotherapy with continuous CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone) to two years of intermittent L-phenylalanine mustard (L-PAM) in women with operable breast cancer with histologically positive axillary lymph nodes." | 5.05 | Adjuvant therapy of breast cancer: the Southwest Oncology Group experience. ( Athens, JW; Costanzi, JJ; Foulkes, MA; Glucksberg, H; Knight, WA; O'Bryan, RM; Rivkin, SE; Stephens, RL, 1983) |
| "Between September 1976 and June 1982, 308 patients with operable breast cancer with 1-3 involved axillary nodes were stratified according to institution, type of mastectomy, and time from surgery to protocol entry, and then randomized to receive either six or 12 months of adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)." | 5.05 | Postmastectomy adjuvant chemotherapy with or without radiation therapy in women with operable breast cancer and positive axillary lymph nodes: the Southeastern Cancer Study Group experience. ( Bartolucci, A; Ketcham, A; Liu, C; Marcial, V; Moore, M; Smalley, R; Velez-Garcia, E; Vogel, CL, 1983) |
| "Five-year results of a prospective, randomized clinical trial of three treatment regimes--(a) cytoxan, methotrexate, and 5-fluorouracil (CMF); (b) CMF plus the antiestrogen drug, tamoxifen (CMFT); and (c) CMFT plus bacillus Calmette-Guerin (BCG) vaccinations--in 312 women with stage-II breast cancer are reported." | 5.05 | Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage-II breast cancer: five-year results. ( Eckert, C; Flynn, WJ; Gordon, NH; Hermann, RE; Hubay, CA; Jones, JC; Mansour, EG; Marshall, JS; McGuire, WL; Pearson, OH, 1983) |
| "This trial studied the possibility that tamoxifen, added to L-phenylalanine mustard and 5-fluorouracil, enhances the established benefit of the latter two drugs in treatment of women with breast cancer and positive axillary nodes." | 5.05 | Treatment of primary breast cancer with L-PAM/5-FU and tamoxifen: an interim report. ( Fisher, B, 1983) |
| "One hundred seventy-one patients received one year of melphalan or intermittent cyclophosphamide, methotrexate, and fluorouracil after mastectomy for breast cancer with involved axillary nodes." | 5.05 | Favorable factors in the adjuvant therapy of breast cancer. ( Carpenter, JT; Laws, HL; Maddox, WA; Soong, SJ; Wirtschafter, DD, 1982) |
| "5 mg daily) to an adjuvant cyclophosphamide-methotrexate-5-fluorouracil chemotherapy regimen was investigated in a randomized trial of 505 pre- and perimenopausal patients with operable breast cancer and one to three axillary lymph node metastases (Ludwig Breast Cancer Study I)." | 5.05 | A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. ( , 1985) |
| "After mastectomy, 265 postmenopausal patients with node-positive breast cancer were stratified according to pathologic nodal status and estrogen-receptor (ER) status and randomized to receive either 12 cycles of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP), or CMFP plus tamoxifen (CMFPT), or observation alone." | 5.05 | Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study. ( Bennett, JM; Carbone, PP; Cummings, F; Falkson, G; Kalish, LA; Olson, JE; Taylor, SG; Tormey, DC, 1985) |
| "Thirty-eight patients with advanced breast cancer were treated with the 'VEMFAH' multiple-drug combination chemotherapy, consisting of vincristine (V), cyclophosphamide (Endoxan; E), methotrexate (M), 5-fluorouracil (F), adriamycin (A), and prednisolone (H)." | 5.05 | The effects of multiple combination chemotherapy with vincristine, cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, adriamycin and prednisolone (VEMFAH) for advanced breast cancer. ( Hoshino, A; Ito, Y; Kamiya, O; Kinoshita, T; Kojima, T; Nagata, K; Ohara, K; Sato, H; Sugiura, I; Yamada, M, 1985) |
| "Since the initial development of 5-fluorouracil and mitomycin as a standard of care platform for definitive anal cancer chemoradiotherapy, multiple studies have evaluated the optimal chemotherapy regimen, and radiotherapy technique." | 5.01 | Anal Cancer in the Era of Dose Painted Intensity Modulated Radiation Therapy: Implications for Regional Nodal Therapy. ( A Goodman, K; Ladbury, C; Olsen, JR; Schefter, TE, 2019) |
| " Ixabepilone is approved by the FDA for treatment of patients with metastatic breast cancer (MBC) progressing after taxanes and anthracyclines, either in combination with capecitabine or as monotherapy if the patient has already progressed on capecitabine." | 4.86 | Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer. ( Egerton, N, 2010) |
| "The case history is presented of a 46-year-old lady who was treated postoperatively for breast cancer with combination chemotherapy containing the antitumour agent epirubicin." | 4.80 | Recall phenomenon following epirubicin. ( Carder, P; Gooi, J; Nishikawa, H; Wilson, J, 1999) |
| "This study aimed to evaluate the efficacy and the safety of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing neutropenia in metastatic colorectal cancer (mCRC) patients that received fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab (Bev) in clinical practice." | 3.96 | Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study. ( Chin, K; Kitagawa, Y; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Ota, Y; Shinozaki, E; Suenaga, M; Suzuki, T; Takahari, D; Wakatsuki, T; Yamaguchi, K, 2020) |
| " In this study we aim to compare the efficacy and toxicity of two regimens FOLFOX (leucoverin, 5-fluorouracil and oxaliplatin) and modified DCF (mDCF) (docetaxel, cisplatin, and 5-fluorouracil) in patients with advanced gastric adenocarcinoma." | 3.96 | Outcome of FOLFOX and Modified DCF Chemotherapy Regimen in Patients with Advanced Gastric Adenocarcinoma. ( Danandeh Mehr, A; Habibzadeh, A; Molaei, M; Pourghasemian, M, 2020) |
| "We describe a metastatic colorectal cancer patient, treated with first-line 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIr-BFOx) therapy, with aggressive and resistant disease." | 3.88 | KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease. ( Alesse, E; Bruera, G; Calvisi, G; Cannita, K; Cocciolone, V; Cortellini, A; Dal Mas, A; Ficorella, C; Mastroiaco, V; Ricevuto, E; Tessitore, A; Zazzeroni, F, 2018) |
| "The aim of this study was to investigate the efficacy and safety of first-line panitumumab plus folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in patients with wild-type KRAS and wild-type NRAS metastatic colorectal cancer (mCRC)." | 3.88 | FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer. ( Geredeli, C; Yasar, N, 2018) |
| "The impact of microsatellite instability (MSI) on survival in stage III colon cancer treated with adjuvant 5-fluorouracil-oxaliplatin combination (FOLFOX) chemotherapy is not clear." | 3.85 | Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX). ( Hong, YS; Kim, CW; Kim, HJ; Kim, JC; Kim, JE; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lim, SB; Park, IJ; Yoon, YS; Yu, CS, 2017) |
| "We prospectively evaluated the feasibility of XELOX(oxaliplatin 130 mg/m/(2) on day 1 plus capecitabine 1,000 mg/m(2) twice daily on days 1 to 14 every 3 weeks) for adjuvant treatment in 15 patients with stage III/IV (Japanese classification) colorectal cancer and pathological curability A or B after D2-D3 lymph node dissection." | 3.81 | [A feasibility study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for Japanese patients with advanced colorectal cancer]. ( Higashino, K; Noura, S; Ohue, M; Sakai, D; Shingai, T; Sugimoto, N; Takeuchi, Y; Yagi, T; Yamamoto, S; Yano, M; Yoshinami, T, 2015) |
| " The correlation of G1249A ABCC2 polymorphism with the development of colorectal cancer (CRC) and poor prognosis was evaluated in patients who were treated with fluorouracil/-leucovorin (FL) plus oxaliplatin (FOLFOX-4)." | 3.79 | Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy. ( Abdullah, S; Khoshzaban, A; Mirakhorli, M; Rahman, SA; Rozafzon, R; Vakili, M, 2013) |
| "Five prognostic factors had been previously identified in patients with metastatic colorectal cancer (MCRC) who received irinotecan-based second-line chemotherapy." | 3.79 | Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. ( Fukushima, H; Komatsu, Y; Muro, K; Naito, Y; Shitara, K; Takano, T; Yamazaki, K; Yasui, H; Yuki, S, 2013) |
| "A 61-year-old man, with a tuberous sclerosis, experienced severe acute reactions during a concomitant chemoradiotherapy regimen after 22Gy and one cycle of 5-fluorouracil-cisplatinum." | 3.79 | [Hypersensitivity to radiation therapy in a patient with tuberous sclerosis: biological considerations about a clinical case]. ( Baruch-Hennequin, V; Duchemain, B; Duchemann, B; Hennequin, C; Quero, L; Rivera, S; Wong, S, 2013) |
| "The authors retrospectively evaluated 3 patients with progressive, metastatic neuroendocrine tumors of the thymus who were treated with a combination of capecitabine and temozolomide." | 3.79 | Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series. ( Centeno, B; Kvols, L; Morse, B; Saranga-Perry, V; Strosberg, J, 2013) |
| "FOLFOXIRI demonstrated higher efficacy compared to 5-fluorouracil, leucovorin, irinotecan (FOLFIRI) as first-line treatment of metastatic colorectal cancer." | 3.78 | Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen. ( Allegrini, G; Baldi, GG; Brunetti, IM; Cortesi, E; Cremolini, C; Cupini, S; Falcone, A; Fornaro, L; Granetto, C; Loupakis, F; Masi, G; Ricci, S; Salvatore, L; Tuzi, A; Vasile, E, 2012) |
| " We investigated the clinical significance of miR-10b and its involvement in chemotherapeutic resistance to 5-fluorouracil (5-FU), which is a key component of common chemotherapy regimens in colorectal cancer." | 3.78 | MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. ( Doki, Y; Ishii, H; Mimori, K; Mori, M; Nishida, N; Shibata, K; Sudo, T; Tanaka, F; Yamamoto, H; Yamashita, S, 2012) |
| "We examined the background, survival rates, median survival time and side effects of 15 cases in which systemic chemotherapy using carboplatin and 5-fluorouracil was done (chemotherapy group) and 59 cases in which chemotherapy was not done (non-chemotherapy group) out of a total of 74 cases of patients with extrahepatic metastasis from hepatocellular carcinoma." | 3.78 | Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma. ( Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kunimoto, H; Morihara, D; Sakamoto, M; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takeyama, Y; Ueda, S; Yokoyama, K; Yotsumoto, K, 2012) |
| " In this study, patient-derived tumor tissue (PDTT) xenograft models of primary colon carcinoma and lymphatic and hepatic metastases were established for assessment of the antitumor activity of FP3 in combination with capecitabine." | 3.78 | Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. ( Cao, F; Han, N; He, K; Jin, K; Lan, H; Li, G; Teng, L; Xie, B; Xu, Z, 2012) |
| "To evaluate the effect of anthracycline pirarubicin-based regimen in association with different ways of fluorouracil (5-Fu) as neoadjuvant and adjuvant chemotherapy for primary breast cancer." | 3.78 | [Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer]. ( Fan, T; Fan, ZQ; Li, JF; Lin, BY; Ouyang, T; Wang, LZ; Wang, TF; Xie, YT, 2012) |
| " The absence of any abnormalities in the infant makes irinotecan and fluorouracil a valid therapeutic option for colon cancer during pregnancy." | 3.78 | Irinotecan during pregnancy in metastatic colon cancer. ( Cassandrini, PA; Cirillo, M; Lunardi, G; Musola, M; Venturini, M, 2012) |
| " The purpose of this pharmacogenetic trial was to study the relevance of thymidylate synthase (TS) genotyping and of the isoform 1A1 of uridine diphosphate glucuronosyltransferase (UGT1A1) in order to tailor a combination chemotherapy regimen of 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) in metastatic colorectal cancer." | 3.77 | Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study. ( Chatelut, E; Delord, JP; Duret, A; Etienne, MC; Falandry, C; Freyer, G; Lledo, G; Merrouche, Y; Milano, G; Rebischung, C, 2011) |
| "There has been limited data on capecitabine monotherapy in metastatic colorectal cancer (CRC) patients who were previously treated with both oxaliplatin/5-fluorouracil(FU)/leucovorin (FOLFOX) and irinotecan/5-FU/leucovorin (FOLFIRI)." | 3.77 | Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. ( Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2011) |
| "A total of 153 breast cancer patients, who were treated with postoperative 5-fluorouracil-based chemotherapies, were randomly selected." | 3.77 | The cell cycle profile test is a prognostic indicator for breast cancer patients treated with postoperative 5-fluorouracil-based chemotherapy. ( Harada, S; Ishihara, H; Kanomata, N; Kawasaki, Y; Kikukawa, N; Kozuka, Y; Kurebayashi, J; Moriya, T; Nakayama, S; Noguchi, S; Sonoo, H; Tamura, S, 2011) |
| "After resection of CRC and synchronous metastases, 53 (84%) out of 63 patients without chemotherapy, and 38 (83%) out of 46 that received 5-fluorouracil (5-FU) alone or with leucovorin (LV) developed recurrent tumors." | 3.77 | FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer. ( Kanazawa, T; Kawai, K; Kazama, S; Kitayama, J; Mori, K; Nagawa, H; Nozawa, H; Saito, S; Sunami, E; Yazawa, K, 2011) |
| "FOLFOX (a combination of leucovorin, fluorouracil and oxaliplatin) has achieved substantial success in the treatment of colorectal cancer (CRC) patients." | 3.77 | Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. ( Eshima, K; Horie, H; Iinuma, H; Ikeuchi, H; Ishihara, S; Kobunai, T; Konishi, T; Matsuda, K; Muto, T; Nozawa, K; Watanabe, T; Yamamoto, Y, 2011) |
| "The aim of this study was to investigate whether c-myc amplification in human breast cancer is associated with response to neoadjuvant chemotherapy comprising paclitaxel followed by 5-FU/epirubicin/cyclophosphamide (P-FEC)." | 3.77 | Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer. ( Baba, Y; Kim, SJ; Kishi, K; Nakayama, T; Naoi, Y; Noguchi, S; Shimazu, K; Shimomura, A; Tamaki, Y; Yasojima, H, 2011) |
| "For a woman with poorly-differentiated anal canal adenocarcinoma in acknowledgment of metastasis to right inguinal lymph node, we gave radiotherapy combined with capecitabine as chemotherapy." | 3.77 | [Preoperative chemoradiation (XELOX/RT) therapy for anal canal adenocarcinoma with the metastasis to inguinal lymph node]. ( Ide, Y; Makino, S; Murata, K, 2011) |
| " Toxicity (primarily gastrointestinal) necessitated dosage modification in 10 patients (29%)." | 3.77 | Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review. ( Balaban, EP; Bull, J; Frenkel, EP; Graham, M; Periman, P; Perkins, S; Pruitt, B; Ross, M; Ruud, C; Sheehan, RG, 1994) |
| "Capecitabine is effective and well tolerated in patients with anthracycline- and/or taxane-pre-treated metastatic breast cancer." | 3.76 | Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer. ( Amari, M; Ishida, T; Ohuchi, N; Takeda, M, 2010) |
| "The phase 3 trial SWOG-8814 for postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer showed that chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil (CAF) before tamoxifen (CAF-T) added survival benefit to treatment with tamoxifen alone." | 3.76 | Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. ( Albain, KS; Allred, DC; Baehner, FL; Barlow, WE; Bugarini, R; Davidson, NE; Gralow, JR; Hayes, DF; Hortobagyi, GN; Hudis, C; Ingle, JN; Livingston, RB; Osborne, CK; Perez, EA; Pritchard, KI; Ravdin, P; Shak, S; Shepherd, L; Sledge, GW; Winer, EP; Yeh, IT; Yoshizawa, C, 2010) |
| "We examined the pre-treatment tumour biopsies (n=40) obtained from patients with rectal adenocarcinoma (clinical International Union Against Cancer stage ll/III) who were scheduled to receive neoadjuvant 5-fluorouracil-based chemoradiotherapy for EGFR, VEGF and HIF-1 expression by quantitative real-time polymerase chain reaction." | 3.76 | Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surg ( Inoue, Y; Kusunoki, M; Miki, C; Okugawa, Y; Saigusa, S; Tanaka, K; Toiyama, Y; Yokoe, T, 2010) |
| "The continuation of trastuzumab beyond progression in combination with capecitabine as secondary chemotherapy for HER2-positive metastatic breast cancer (MBC) prolongs progression-free survival without a substantial increase in toxicity." | 3.76 | Trastuzumab beyond progression: a cost-utility analysis. ( Brauchli, P; Dedes, KJ; Matter-Walstra, KW; Pestalozzi, BC; Schwenkglenks, M; Szucs, TD, 2010) |
| "The main objective of the present study was to compare the effects of three common chemotherapy regimes in terms of disease-free survival (DFS) of breast cancer (BC) patients; the three explored regimes were taxane-based, anthracycline-based and CMF (cyclophosphamide methotrexate and 5-fluorouracil)." | 3.76 | Comparison of three adjuvant chemotherapy regimes using an extended log-logistic model in women with operable breast cancer. ( Faradmal, J; Gohari, MR; Hajizadeh, E; Kazemnejad, A; Khodabakhshi, R, 2010) |
| "The purpose of the present study is to evaluate what clinical factors affect the efficacy, time to treatment failure (TTF), and overall survival (OS) of oral capecitabine monotherapy in heavily pretreated patients with metastatic breast cancer (MBC)." | 3.75 | Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer. ( Hatake, K; Ito, Y; Iwase, T; Matsuura, M; Osako, T; Sugihara, T; Takahashi, S; Tokudome, N; Ushijima, M, 2009) |
| "The aim of this study was to determine whether the expression of the excision repair cross-complementing 1 (ERCC1), thymidylate synthase (TS) and glutathione S-transferase pi (GSTpi) predict clinical outcome in patients with advanced colorectal cancer treated with fluorouracil (5-FU)/oxaliplatin chemotherapy." | 3.75 | Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. ( Choi, HJ; Kim, DC; Kim, HJ; Kim, SH; Kwon, HC; Lee, DM; Lee, JH; Lee, S; Oh, SY; Park, KJ; Roh, MS, 2009) |
| "We report an 83-year-old female with axillary node metastasis from breast cancer who responded to trastuzumab/ capecitabine combination therapy." | 3.75 | [A patient with axillary node metastasis from breast cancer who responded to trastuzumab/capecitabine combination therapy]. ( Imai, S; Kobayashi, A; Koyama, H; Matsuyama, T; Tokugawa, T, 2009) |
| "Conflicting data exist regarding the relevance of high-frequency microsatellite instability (MSI-H) for predicting the prognosis and benefits of 5-fluorouracil (5-FU)-based chemotherapy." | 3.75 | Chemosensitivity and survival in gastric cancer patients with microsatellite instability. ( Ando, K; Kakeji, Y; Maehara, Y; Masuda, T; Morita, M; Ohgaki, K; Oki, E; Yoshida, R; Zhao, Y, 2009) |
| "One hundred and twenty-one MCRC patients with histologically proven adenocarcinoma and baseline ECOG performance status of < or =2 were treated with oxaplatin and (or) irinotecan-based chemotherapy regimens." | 3.75 | [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy]. ( An, X; Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xiang, XJ; Xu, RH, 2009) |
| "This study evaluated whether doxorubicin and cyclophosphamide are superior to cyclophosphamide, methotrexate and 5-fluorouracil as adjuvant chemotherapy in breast cancer patients." | 3.75 | Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer. ( Bianchi, S; Biti, GP; Borghesi, S; Cataliotti, L; De Luca Cardillo, C; Greto, D; Livi, L; Mangoni, M; Paiar, F; Saieva, C; Scotti, V, 2009) |
| "To evaluate the efficacy and toxicity of perioperative combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP) in bladder cancer patients with regional lymph node metastases treated by radical cystectomy." | 3.74 | Combination chemotherapy of ifosfamide, 5-fluorouracil, etoposide and cisplatin as perioperative treatment in lymph node positive bladder carcinoma patients treated by radical cystectomy. ( Fujii, Y; Fukui, I; Kawakami, S; Komai, Y; Okubo, Y; Yamamoto, S; Yonese, J, 2008) |
| "To evaluate the efficacy and safety of docetaxel and capecitabine combination chemotherapy (DC regimen) for patients with anthracycline-resistant metastatic breast cancer." | 3.74 | [Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer]. ( Dong, GL; Hao, CF; He, LH; Li, SF; Shi, YH; Tong, ZS; Wang, C; Wang, X, 2008) |
| "High-dose toremifene therapy (120 mg/day) is useful for the recurrence of receptor-positive breast cancer." | 3.74 | [Evaluation of combination therapy of high-dose toremifene and oral chemotherapy]. ( Murakami, S; Yamamoto, Y, 2007) |
| "We report two cases of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) and lymph node (LN) metastases successfully treated by hepatic arterial infusion of 5-fluorouracil (5-FU) combined with systemic injection of interferon (IFN)-alpha following hepatic resection for the liver tumor." | 3.74 | Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection. ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Noda, T; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Wakasa, K, 2007) |
| " For this purpose, we assessed the impact of cellular supernatants of the primary adenocarcinoma cell line CCL228, its lymph node metastasis CCL227, and four subclones resistant to different levels of 5-fluorouracil on the growth of microvascular and macrovascular endothelial cells." | 3.74 | Angiogenic effect of naive and 5-fluorouracil resistant colon carcinoma on endothelial cells in vitro. ( Mader, RM; Schönau, KK; Steger, GG, 2007) |
| "We report a case of elderly metastatic breast cancer with a complete response to the treatment with XC (X: capecitabine and C: cyclophosphamide)." | 3.74 | [A case of elderly metastatic breast cancer with a complete response to treatment with capecitabine and cyclophosphamide]. ( Furukawa, K; Iida, S; Iwasaki, R; Naito, Z; Noguchi, T; Sugisaki, Y; Tajiri, T; Tsuchiya, S; Yanagihara, K; Yokoyama, T, 2007) |
| "We report the case of a 38-year-old man with metastatic ductal eccrine adenocarcinoma (DEA) of the left breast responding to 5-flourouracil, epirubicin and cyclophosphamide (FEC) chemotherapy." | 3.74 | Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast. ( Brock, CS; Eccles, S; Francis, N; Lim, A; McLean, SR; Nathan, M; Palmieri, C; Shousha, S, 2007) |
| "To estimate the cost effectiveness of TAC (docetaxel, doxorubicin, and cyclophosphamide) compared with FAC (fluorouracil, doxorubicin, and cyclophosphamide) when administered as adjuvant therapy to women with node-positive early breast cancer in the United Kingdom (UK), both with and without primary prophylaxis with granulocyte colony-stimulating factor (G-CSF)." | 3.74 | Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. ( Bagust, A; Cameron, DA; Tate, HC; Wolowacz, SE, 2008) |
| "To estimate the Q-TWiST (Quality-Adjusted Time Without Symptoms and Toxicity) for premenopausal women with axillary node-positive breast cancer receiving either cyclophosphamide, epirubicin and fluorouracil (CEF) or cyclophosphamide, methotrexate, and fluorouracil (CMF), using data from a phase III clinical trial (National Cancer Institute of Canada Clinical Trials Group [NCIC-CGT." | 3.73 | Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer. ( Radice, D; Redaelli, A, 2005) |
| "A 55-year-old Asian Indian woman who had recurrent sebaceous gland carcinoma of the left lower eyelid with orbital extension and regional lymph node metastasis was treated with neoadjuvant chemotherapy, using a combination of carboplatin and 5-fluorouracil." | 3.73 | Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis. ( Burman, S; Honavar, SG; Murthy, R; Naik, MN; Reddy, VA; Vemuganti, GK, 2005) |
| "We describe our experience with a patient who had undifferentiated gastric carcinoma with extensive lymph node metastasis, including para-aortic lymph-node metastasis, and had a complete response to induction therapy with methotrexate plus 5-fluorouracil (sequential therapy with MTX, 5-FU, and Leucovorin) and secondary treatment with oral TS-1." | 3.73 | [Stage IV gastric cancer patient who underwent palliative gastrectomy showing complete response to induction therapy with methotrexate plus 5-fluorouracil and secondary treatment with oral TS-1]. ( Hiramatsu, K; Mizukami, Y; Momiyama, M; Nagashima, T; Niimi, K; Suzuki, M, 2005) |
| "We conducted a retrospective analysis of prognosis factors for survival in breast cancer patients with 1-3 axillary lymph node metastases and tried to identify a subset of patients with good prognosis suitable for cyclophosphamide, methotrexate and 5-fluorouracil (CMF) adjuvant chemotherapy." | 3.73 | Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy. ( Chang, HK; Chen, MF; Chen, SC; Hsueh, S; Hwang, TL; Lin, YC; Lo, YF; Tsai, CS, 2005) |
| "We report a case of complete disappearance of multiple lung metastases and mediastinal lymphnode metastasis by intravenous administration of 5-fluorouracil/cisplatin (FP) after operation for primary hepatocellular carcinoma (HCC)." | 3.73 | [Complete disappearance of metastatic lung tumors and mediastinal lymphnode in a case of hepatocellular carcinoma treated by low-dose 5-fluorouracil/cisplatin therapy]. ( Anami, Y; Izai, J; Komiya, H; Matsuda, Y; Oguma, S; Ota, T; Sazawa, Y; Yamaki, T, 2005) |
| "We evaluated the safety and efficacy of primary systemic chemotherapy (PSC) with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda:XLD) in 10 patients with advanced breast cancer." | 3.73 | [Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer]. ( Hamada, K; Kubota, K; Mori, S; Nakagawa, A; Suzuki, N; Tagaya, N, 2006) |
| "The 21-gene recurrence score (RS) assay quantifies the likelihood of distant recurrence in women with estrogen receptor-positive, lymph node-negative breast cancer treated with adjuvant tamoxifen." | 3.73 | Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. ( Baehner, FL; Baker, J; Bryant, J; Costantino, JP; Cronin, M; Geyer, CE; Kim, C; Kim, W; Paik, S; Shak, S; Tang, G; Watson, D; Wickerham, DL; Wolmark, N, 2006) |
| "We investigated 29 patients with advanced and recurrent breast cancers who underwent capecitabine therapy in the department." | 3.73 | [Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression]. ( Hironou, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Ookubo, S; Seki, M; Shiiki, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y, 2006) |
| "This study retrospectively evaluates the occurrence of second hematological and solid malignancies in the context of a prospective multicenter phase III trial comparing epirubicin-cyclophosphamide at intermediate doses (EC), or at full doses (HEC), with classical cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in 777 patients with early breast cancer." | 3.72 | Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer ( Accettura, C; Bernard-Marty, C; Cardoso, F; Di Leo, A; Kleiber, K; Larsimont, D; Lobelle, JP; Mano, M; Munoz-Bermeo, R; Paesmans, M; Piccart, MJ; Richard, T, 2003) |
| " Dihydropyrimidine dehydrogenase (DPD) which catalyzes 5-fluorouracil (5-FU), thymidine phosphorylase (TP), responsible for catalyzing doxifluridine to 5-FU, and thymidylate synthase (TS) were estimated for breast cancer." | 3.72 | [Estimation of level of enzyme induction of thymidine phosphorylase, dihydropyrimidine dehydrogenase, and thymidylate synthase in primary and recurrent breast cancer]. ( Koh, M; Morimoto, K, 2004) |
| " We report the 1st case of capecitabine-induced toxic encephalopathy with epilepsy-like symptoms and diffuse white matter alterations on magnetic resonance imaging." | 3.72 | Toxic encephalopathy induced by capecitabine. ( Herrmann, R; Niemann, B; Pless, M; Rochlitz, C, 2004) |
| "Ten cases of advanced and metastatic colorectal cancer treated with irinotecan plus fluorouracil and l-leucovorin systemic chemotherapy (CPT-11/5-FU/l-LV) were investigated." | 3.72 | [Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer]. ( Hidaka, K; Matsukura, S; Samejima, R; Tanaka, M, 2004) |
| "Adjuvant 'classical' oral cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) has long been the mainstay of adjuvant chemotherapy for premenopausal breast cancer patients." | 3.72 | Quality of adjuvant CMF chemotherapy for node-positive primary breast cancer: a population-based study. ( de Vries, EG; Otter, R; Schaapveld, M; van der Graaf, WT; Willemse, PH, 2004) |
| " To evaluate the therapeutic effectiveness and safety of oxaliplatin combined with 5-fluorouracil and leucovorin on the patients with gastric carcinoma after palliative gastric resection, we analyzed all of the cases of gastric adenocarcinoma undergone palliative gastric resection in our Cancer Center in recent years." | 3.72 | [Palliative surgery combined with oxaliplatin-based chemotherapy in treatment of patients with advanced gastric cancer]. ( Chen, YB; Guan, YX; Li, W; Li, YF; Sun, XW; Xu, DZ; Zhan, YQ, 2004) |
| "One patient with pulmonary metastasis from colon cancer and one with para-aortic lymph node metastasis were treated with a combination of irinotecan and UFT." | 3.71 | [Two patients with recurrent colon cancer who underwent surgery following a combination of irinotecan and UFT]. ( Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Saguchi, T; Suzuki, T; Yamamoto, T; Yasuda, S, 2002) |
| "The Zoladex Early Breast Cancer Research Association study assessed the efficacy and tolerability of goserelin (3." | 3.71 | Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. ( Blamey, R; Cuzick, J; de Haes, JC; de Matteis, A; Eiermann, W; Fogelman, I; Geberth, M; Jonat, W; Kaufmann, M; Lisboa, B; Namer, M; Palmer, M; Sauerbrei, W; Schumacher, M; Stewart, A; Szakolczai, I, 2002) |
| "Resection specimens from 47 cases of oesophageal adenocarcinoma treated with preoperative 5-fluorouracil/cisplatin and radiotherapy were reviewed." | 3.71 | A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy. ( Dunne, B; Griffin, M; Kelly, A; Mulligan, E; Reynolds, JV, 2001) |
| "We have experienced a case of advanced gastric cancer with para-aortic lymph node metastasis effectively treated by neoadjuvant continuous low dosage 5-fluorouracil and cisplatin (FP regimen)." | 3.71 | Advanced gastric cancer effectively treated by neoadjuvant continuous low-dosage 5-fluorouracil and cisplatin (FP regimen): a case report. ( Aoyagi, K; Koufuji, K; Miyagi, M; Murakami, N; Shirouzu, K; Takeda, J; Yano, S, 2001) |
| "We determined plasma levels of c-erbB-2 in 79 stages II and III breast cancer patients who received cyclophosphamide, methotrexate, and flourouracil (CMF)/cyclophosphamide, methotrexate, fluorouracil, vincristine, and prednisone (CMFVP) chemotherapy." | 3.70 | Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. ( Das Gupta, TK; Hieken, TJ; Marler, KC; McDermott, JH; Mehta, RR; Patel, MK; Wild, LD, 1998) |
| "An 83-year-old Caucasian man with cutaneous T-cell lymphoma developed an aggressive squamous cell carcinoma of the left forearm, which recurred and metastasized after Mohs micrographic surgery and systemic chemotherapy with cis-platin and 5-fluorouracil." | 3.70 | Invasive squamous cell carcinoma with sporotrichoid metastasis in a patient with cutaneous T cell lymphoma treated with chronic extracorporeal photopheresis. ( Beer, R; Elizeri, Y; Gmyrek, R; Grossman, ME; Oster, MW; Schneiderman, P; Silvers, DN, 1999) |
| "This study involved a subset of 129 patients from a series of 174 with T2-3, N0-1, M0 or T1, N1, M0 breast carcinoma (Stage IIA, IIB, or IIIA ) who were registered in a prospective IC trial using paclitaxel or a combination of fluorouracil, doxorubicin, and cyclophosphamide (FAC)." | 3.70 | The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy. ( Ames, FC; Buzdar, AU; Feig, BW; Hunt, KK; Lenert, JT; Mirza, NQ; Ross, MI; Singletary, SE; Vlastos, G, 2000) |
| "To evaluate safety and efficacy of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer." | 3.70 | [A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer]. ( Dai, A; Feng, J; Zheng, X, 1998) |
| "Two hundred and sixteen T2 breast cancer patients were treated consecutively with surgery followed by 5'DFUR (600 mg/body/day) + tamoxifen (20 mg/body/day) for 2 years." | 3.70 | Intratumoral pyrimidine nucleoside phosphorylase (PyNPase) activity predicts a selective effect of adjuvant 5'-deoxy-5-fluorouridine (5'DFUR) on breast cancer. ( Akasaka, Y; Hata, Y; Nakanishi, Y; Ogita, M; Sasaki, F; Sawada, Y; Takahashi, H; Uchino, J; Yoshimoto, M, 2000) |
| "An association between the overexpression of proto-oncogene HER-2/neu and resistance to tamoxifen in estrogen receptor (ER)-positive primary and metastatic breast cancer has been suggested." | 3.70 | HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. ( Barcos, M; Berry, DA; Broadwater, G; Budman, DR; Dressler, L; Hayes, D; Henderson, IC; Liu, ET; Muss, HB; Norton, L; Thor, AD, 2000) |
| "125 stage III breast cancer patients, including 51 cases of inflammatory carcinoma, were treated with the following combined modality approach: three courses of primary 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) chemotherapy followed by locoregional treatment and subsequent adjuvant chemotherapy consisting of three courses of FAC alternating with three courses of cyclophosphamide, methotrexate, 5-fluorouracil (CMF)." | 3.69 | Locally advanced non-metastatic breast cancer: analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach. ( Campora, E; Canavese, G; Catturich, A; Corvò, R; Gardin, G; Guenzi, M; Naso, C; Pronzato, P; Repetto, L; Rosso, R, 1995) |
| "A study of cardioprotection with ICRF-187 (Cardioxane, Eurocetus) has been performed in 35 patients with metastatic breast cancer treated with the FDC regimen (5-fluorouracil 500 mg/m2 i." | 3.69 | Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen. ( Bosnjak, S; Jelić, S; Kreacić, M; Milanović, N; Nesković-Konstantinović, Z; Radulović, S; Ristović, Z; Vuletić, L, 1995) |
| "Between 1982 and 1992, 139 patients with epidermoid carcinoma of the anal canal were treated by radiation and chemotherapy with 5-fluorouracil (5-Fu) and mitomycin C (MMC)." | 3.69 | [The prognostic factors following the simultaneous radiochemotherapy of anal canal carcinoma in a multicenter series of 139 patients]. ( Budach, V; Döker, R; Grabenbauer, GG; Huber, K; Hültenschmidt, B; Hutter, M; Kuhne-Velte, HJ; Panzer, M; Rühl, U; Wendt, T, 1994) |
| "A 53-year-old female patient was treated with combined radiochemotherapy with 5-fluorouracil (5-FU) because of adenocarcinoma of the lung." | 3.69 | [5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?]. ( Härle, M; Jungius, KP; Maurer, U, 1996) |
| "A case of poorly differentiated adenocarcinoma of the small bowel with extensive lymph node metastases is herein presented, which responded to methotrexate/5-fluorouracil (MTX/5-FU) sequential therapy." | 3.69 | Small intestinal cancer with extensive lymph node metastases showing complete remission by methotrexate/5-fluorouracil sequential therapy: report of a case. ( Imamura, M; Maetani, S; Nishitai, R; Onodera, H; Shimizu, K, 1997) |
| "Between 1994 and 1995, 1 day nocturnal infusion of 5-fluorouracil (5-FU) was performed prior to surgery in 13 primary breast cancer patients; 300 mg/m2 of 5-FU was infused constantly from 2100 h to 0700 h via peripheral vein with a volumetric pump." | 3.69 | Nocturnal 5-fluorouracil infusion to patients with breast cancer prior to surgery: appearance of 5-fluorouracil-induced AgNORs aggregation (FAA). ( Furuya, Y; Kohno, N; Saitoh, Y; Yamamoto, K; Yamamoto, M, 1997) |
| " Our cost-effectiveness study [7] evaluated the pharmacoeconomic profile of adjuvant cyclophosphamide, methotrexate and fluorouracil (CMF) in patients with node-positive breast cancer [13] and utilised a Gompertz analysis to estimate lifetime overall survival (OS), which was 862 and 756 discounted years per 100 patients in the CMF and the control groups, respectively." | 3.69 | Adjuvant cyclophosphamide, methotrexate and fluorouracil for node-positive breast cancer: a lifetime cost-utility analysis based on a modified Q-TWIST method. ( Becagli, P; Messori, A; Trippoli, S, 1997) |
| "In 56 patients with disseminated or locally advanced breast cancer it was attempted to reach a state of no evidence of disease by a remission induction regime containing prednisone, 5-fluorouracil, methotrexate, doxorubicin and vincristine." | 3.68 | Induction chemotherapy and intensification with autologous bone marrow reinfusion in patients with locally advanced and disseminated breast cancer. ( de Vries, EG; Dolsma, WV; Mulder, NH; Mulder, PO; Sleijfer, DT; van der Ploeg, E; Willemse, PH, 1993) |
| "A retrospective analysis of prognostic factors in 214 consecutive node-positive (N+) operable breast cancer patients, receiving Melphalan + 5-fluorouracil adjuvant chemotherapy between 1980 and 1984 was performed." | 3.68 | Prognostic factors in node-positive operable breast cancer patients receiving adjuvant chemotherapy. ( Derazne, E; Kahan, E; Klein, B; Lurie, H; Rakowsky, E, 1992) |
| "A 57-year-old woman developed severe tumor lysis syndrome characterized by acute hyperuricemic nephropathy, hyperphosphatemia, hyperkalemia, and hypocalcemia after therapy with cyclophosphamide, methotrexate, and 5-fluorouracil for metastatic infiltrating ductal carcinoma of the breast involving the chest wall, lungs, pleurae, and liver." | 3.67 | Tumor lysis syndrome in nonhematopoietic neoplasms. ( Barton, JC, 1989) |
| " cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) after surgery for primary breast cancer was analyzed according to three administration-related factors: total number of cycles received, time elapsed between surgery and start of chemotherapy, and dose intensity of treatment." | 3.67 | Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer. ( Amoroso, D; Bertelli, G; Botto, F; Campora, E; Conte, PF; Pronzato, P; Rosso, R; Sertoli, MR, 1989) |
| "A 55-year-old female, in which an unresectable Borrmann II-type gastric cancer (moderately differentiated adenocarcinoma) extending from vicinity of the cardia to the lower portion of the corpus, with direct invasion into the pancreas and extensive lymph node metastases, confirmed by laparotomy, was treated postoperatively by 3 courses of chemotherapy with cisplatinum in combination with mitomycin C and 5-fluorouracil." | 3.67 | Cure of advanced gastric cancer by combined chemotherapy with cisplatinum, mitomycin C, and 5-fluorouracil. ( Azuma, S; Furuta, T; Kawata, R; Ohashi, H; Saji, S; Sakata, K; Shimokawa, K; Suzuki, M; Tanemura, H, 1988) |
| "The efficacy of salvage treatments in 243 patients with operable breast cancer and positive axillary nodes who failed during or after adjuvant chemotherapy with CMF (cyclophosphamide, methotrexate and fluorouracil) was analyzed." | 3.67 | Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. ( Bonadonna, G; Tancini, G; Valagussa, P, 1986) |
| "Risk factors for local-regional recurrence of breast cancer were analyzed in a retrospective review of 117 patients treated with adjuvant CMF (Cytoxan [Mead Johnson & Co, Evansville, Ind], methotrexate, 5-fluorouracil) after radical or modified radical mastectomy at the Vincent T." | 3.67 | Local-regional failure in patients treated with adjuvant chemotherapy for breast cancer. ( Bachenheimer, L; Beiser, C; Byrne, P; Dritschilo, A; Goldberg, R; Smith, F; Smith, L; Stefanik, D; Ueno, W, 1985) |
| "The possible influence of histologic grade, necrosis and size of invasive breast cancers on the five year survival rate of women treated in NSABP clinical trials with regimens of L-PAM (P) and L-PAM + 5-FU (PF) and for four years in those receiving L-PAM + 5-FU + methotrexate (PMF) was investigated." | 3.66 | Pathologic findings from the National Surgical Adjuvant Breast Project. VIII. Relationship of chemotherapeutic responsiveness to tumor differentiation. ( Fisher, B; Fisher, ER; Redmond, C, 1983) |
| "Combination chemotherapy with cyclophosphamide (CPA), adriamycin (ADR) and 5-fluorouracil (5-FU) (CAF therapy) was performed in 85 patients with advanced and recurrent breast cancer." | 3.66 | [Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer]. ( Abe, O; Enomoto, K; Izuo, M; Koyama, H; Kubo, K; Nomura, Y; Sakai, K; Terasawa, T; Tominaga, T, 1982) |
| "A series of 41 patients at the MGH who received 5-drug chemotherapy, cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone, (CMF VP) as adjuvant to surgical treatment of operable breast cancer with 4 or more positive axillary nodes is compared to an analogous group of patients treated with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) reported by Bonadonna et al." | 3.66 | 5-drug adjuvant chemotherapy for breast cancer. ( Carey, RW; Halpern, E; Kaufman, S; Kelley, RM; Lew, RA; Sohier, WD; Weitzman, SA, 1979) |
| "One hundred women with primary breast cancer with 4 or more metastatic axillary nodes were treated for 9 months postoperatively with vincristine, prednisone, cyclophosphamide, methotrexate, and fluorouracil (VPCMF)." | 3.66 | Adjuvant chemotherapy of breast cancer. ( Cooper, RG; Glidewell, O; Holland, JF, 1979) |
| "A combination of 5-fluorouracil, Adriamycin, cyclophosphamide, and BCG (FAC-BCG) was evaluated as adjuvant treatment in breast cancer patients following surgical excision and/or radiation of first site of recurrent disease." | 3.66 | Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). ( Blumenschein, GR; Buzdar, AU; Gehan, EA; Gutterman, JU; Hersh, EM; Hortobagyi, GN; Smith, TL; Tashima, CK; Yap, HY, 1979) |
| "A carcinostatic substance (5-fluorouracil) was instilled into the mediastinal lymph nodes, the pleural cavity or the internal thoracic artery by continuous perfusion before operation on patients with bronchial carcinoma." | 3.65 | [Continuous local application of cytostatics for bronchial carcinoma and mediastinal lymph node metastasisization (author's transl)]. ( Inoguchi, T; Kita, T; Kuwano, K; Yamasaki, I; Yazuka, K, 1976) |
| "Thirty patients with an advanced bronchogenic carcinoma were treated with a combination of adriamycin and 5-fluorouracil; in eight the size of the tumour or its metastases was reduced by over 50%, and eight further patients experienced useful relief of symptoms." | 3.65 | Treatment of advanced bronchogenic carcinoma with adriamycin and 5-fluorouracil. ( Anderson, G; Bugaighis, A; Rees, GJ, 1975) |
| "Prolonged cyclic combination chemotherapy with cyclophosphamide, methotrexate and fluorouracil was evaluated as adjuvant treatment to radical mastectomy in primary breast cancer with positive axillary lymph nodes." | 3.65 | Combination chemotherapy as an adjuvant treatment in operable breast cancer. ( Bajetta, E; Bonadonna, G; Brambilla, C; Brugnatelli, L; Brusamolino, E; De Lena, M; Musumeci, R; Rossi, A; Tancini, G; Valagussa, P; Veronesi, U, 1976) |
| " Patients exhibiting EWL had worse survival and higher frequencies of adverse events." | 3.11 | Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306). ( Algül, H; Decker, T; Erickson, NT; Gesenhues, AB; Heinemann, V; Heintges, T; Höffkes, HG; Holch, JW; Kahl, C; Kaiser, F; Kiani, A; Kullmann, F; Lerch, MM; Link, H; Liu, L; Michl, M; Modest, DP; Moehler, M; Ricard, I; Scheithauer, W; Stintzing, S; Theurich, S; von Weikersthal, LF, 2022) |
| " However,the effect of targeted drugs combined with induction therapy in locally advanced nasopharyngeal carcinoma remains unclear." | 2.90 | Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter rando ( Chen, D; Gao, J; Huang, C; Huang, H; Liang, J; Liu, M; Liu, W; Lu, Y; Luo, Z; Ning, X; Wang, R, 2019) |
| "A radical rectal cancer surgery was performed 6 to 8 weeks after the simultaneous chemoradiotherapy." | 2.90 | Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer. ( Chen, J; Dai, G; Du, X; Feng, L; Jia, B; Liu, H; Liu, Q; Wang, Y; Wen, K; Yang, Y; Zeng, M; Zhu, Y, 2019) |
| "Metastatic colorectal cancer (mCRC) is a heterogeneous disease where prognosis is dependent both on tumor biology and host factors." | 2.90 | Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. ( Dajani, O; Glimelius, B; Guren, TK; Hamfjord, J; Johansen, JS; Kure, EH; Lingjærde, OC; Pallisgaard, N; Pfeiffer, P; Sorbye, H; Spindler, KG; Tveit, KM, 2019) |
| "9%) in arm B experienced grade 3/4 adverse events related to bevacizumab; the most frequent were 2 anastomotic fistulas (both in arm A) and abscesses (1 in arm A and 2 in arm B)." | 2.90 | Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study. ( Adenis, A; André, T; Azria, D; Bachet, JB; Balosso, J; Ben Abdelghani, M; Borg, C; Boudghène, F; Conroy, T; Coudert, M; François, Y; Ghiringhelli, F; Ionescu-Goga, M; Lakkis, Z; Mantion, G; Mornex, F; Quero, L; Rio, E; Roullet, B; Spaëth, D; Tanang, A; Vendrely, V, 2019) |
| "Capecitabine (825 mg/m(2)) was delivered orally twice daily for the duration of radiotherapy." | 2.80 | Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer. ( Fan, YT; Feng, HY; Jin, T; Ju, HX; Li, DC; Liu, LY; Liu, Y; Luo, JL; Zhou, N; Zhu, Y; Zhu, YP, 2015) |
| "Patients with stage III/IV resectable head and neck squamous cell carcinoma were randomized to surgery followed by RT or CCRT." | 2.80 | Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. ( Ang, MK; Hwang, J; Iyer, NG; Lim, WT; Sivanandan, R; Soo, KC; Tan, DS; Tan, EH; Tan, HK; Tan, NC; Tan, VK; Wang, W; Wee, J, 2015) |
| "This multicenter trial included esophageal cancer patients with clinical T4 disease and/or unresectable regional lymph node metastasis." | 2.80 | Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). ( Ando, N; Fukuda, H; Ishikura, S; Kato, H; Kato, K; Kawano, T; Kimura, Y; Kosugi, S; Minashi, K; Nakamura, K; Okabe, H; Shinoda, M; Toh, Y; Tsubosa, Y, 2015) |
| "Thirty-four patients with unresectable esophageal cancer were enrolled and received DNF therapy." | 2.80 | Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer. ( Fukuchi, M; Ieta, K; Inose, T; Kato, H; Kuwano, H; Miyazaki, T; Nakajima, M; Ojima, H; Saito, K; Sakai, M; Sano, A; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T, 2015) |
| "A total of 185 patients with gastric cancer and abdominal lymph node metastasis were enrolled and divided into 2 groups: group A received chemotherapy alone (n = 102); group B received HIFU combined with chemotherapy (n = 83)." | 2.80 | Effects of high-intensity focused ultrasound for treatment of abdominal lymph node metastasis from gastric cancer. ( Liu, L; Liu, P; Lu, K; Shu, Y; Wang, J; Wang, R; Zhang, M, 2015) |
| " After six chemotherapy cycles, the short-term efficacy was evaluated according to the Response Evaluation Criteria in Solid Tumors guidelines and adverse reactions were recorded according to National Cancer Institute Common Toxicity Criteria 2." | 2.79 | Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer. ( Chang, ZW; Dong, L; Han, ZF; Li, J; Lou, XP; Lu, P; Miao, JH, 2014) |
| "An analysis of surgically resected esophageal cancer patients after nCRT was performed to determine an association between the number of LNs resected and survival." | 2.78 | Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy. ( Almhanna, K; Chuong, MD; Hoffe, SE; Karl, RC; Meredith, K; Shridhar, R; Weber, JM, 2013) |
| "Certain somatic alterations in breast cancer can define prognosis and response to therapy." | 2.78 | Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. ( Bono, P; Claes, B; Fumagalli, D; Joensuu, H; Kataja, V; Kellokumpu-Lehtinen, PL; Lambrechts, D; Loi, S; Michiels, S; Piccart, MJ; Sotiriou, C, 2013) |
| "Background In women with node-positive breast cancer, the Breast International Group (BIG) 02-98 tested the incorporation of docetaxel (Taxotere) into doxorubicin (Adriamycin)-based chemotherapy, and compared sequential and concurrent docetaxel." | 2.78 | Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial. ( Andersson, M; Buyse, M; Crown, J; De Azambuja, E; Dell'orto, P; Di Leo, A; Francis, PA; Gelber, RD; Gutiérrez, J; Harvey, V; Jakesz, R; Larsimont, D; Margeli Vila, M; Nordenskjöld, B; Oakman, C; Piccart-Gebhart, M; Punzalan, L; Quinaux, E; Steinberg, I; Thürlimann, B; Viale, G, 2013) |
| " This prospective phase II study evaluated the activity and toxicity of a modified regimen with lower doses of docetaxel and cisplatin combined with oral capecitabine instead of fluorouracil for patients with advanced gastric cancer." | 2.77 | Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study. ( Dimitroulis, D; Felekouras, E; Griniatsos, J; Karatzas, T; Karavokyros, J; Kontzoglou, K; Mantas, D; Nikiteas, N; Polyzos, A; Polyzos, K; Syrigos, K; Tsavaris, N; Vafiadis, I, 2012) |
| "The combination of sorafenib plus gemcitabine and capecitabine is tolerable, but requires attenuation of sorafenib and capecitabine dosing because of the overlapping toxicity of hand-foot syndrome." | 2.76 | A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981. ( Jeske, S; Kung, S; Lehrer, D; Matulich, D; Mazumdar, M; Milowsky, MI; Nanus, DM; Selzer, J; Sung, M; Tagawa, ST; Wright, JJ, 2011) |
| "MAI (≥ 10) was strongly associated with breast cancer-related death in lymph node (LN)-negative patients (hazard ratio (HR): 7." | 2.76 | Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients. ( Baak, JP; Gilje, B; Janssen, EA; Nordgård, O; Smaaland, R; Søiland, H; Tjensvoll, K, 2011) |
| "The international NNBC3 ("Node Negative Breast Cancer 3-Europe") trial compares biological risk assessment (UP) using invasion factors uPA/PAI-1 with a clinical-pathological algorithm (CP)." | 2.76 | Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel. ( Augustin, D; Hanf, V; Harbeck, N; Jaenicke, F; Kantelhardt, EJ; Martin, PM; Meisner, C; Paepke, D; Schmidt, M; Schmitt, M; Sweep, F; Thomssen, C; Vetter, M; Veyret, C; von Minckwitz, G, 2011) |
| "To observe and compare the response rate and toxicity of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer." | 2.76 | [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer]. ( Chen, DY; Qi, Q; Zhao, WY, 2011) |
| "Esophageal squamous cell carcinoma (ESCC) is refractory to current therapeutic regimens and more effective therapies are imperative." | 2.76 | Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. ( Doki, Y; Miyata, H; Mori, M; Motoori, M; Peng, YF; Shiozaki, H; Shiraishi, O; Tanaka, K; Yamasaki, M; Yano, M; Yasuda, T, 2011) |
| "While the most frequent, surgery for colorectal cancer is avoided in patients with metastases to the regional lymph nodes (stage III) or distant ones (stage IV)." | 2.76 | [Results of adjuvant chemotherapy (XELOX) of advanced colorectal cancer]. ( Eropkin, PV; Kashnikov, VN; Panina, MV; Rybakov, EG, 2011) |
| "In locally advanced head and neck cancer, concurrent chemoradiotherapy (CRT) with combined 5-fluorouracil (5-FU) and cisplatin has increased acute toxicities as well as survival." | 2.75 | Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer. ( Cho, BC; Choi, EC; Choi, HJ; Kim, GE; Kim, JH; Lee, CG; Lee, YJ; Sohn, JH, 2010) |
| "Patients with advanced gastric cancer (AGC), clinically unresectable because of local invasion or limited intra-abdominal metastasis in para-aortic lymph nodes and/or the peritoneum based on multidetector row computed tomography, were enrolled." | 2.75 | Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer. ( Chang, HM; Kang, YK; Kim, BS; Kim, TW; Lee, JL; Oh, ST; Ryu, MH; Sym, SJ; Yook, JH, 2010) |
| "Liver perfusion chemotherapy (LPC) for pancreatic cancer has been rarely undertaken in a postoperative adjuvant setting." | 2.74 | Liver perfusion chemotherapy with 5-Fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study. ( Aono, T; Hatakeyama, K; Kawachi, Y; Kurosaki, I; Nihei, K; Shimizu, T; Tsuchiya, Y; Yokoyama, N, 2009) |
| "In the International Breast Cancer Study Group (IBCSG) Trials VII and 12-93, postmenopausal women with node-positive, estrogen receptor (ER)-positive or ER-negative, operable breast cancer were randomized to receive either chemotherapy or endocrine therapy or combined chemoendocrine treatment." | 2.74 | Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. ( Castiglione-Gertsch, M; Coates, AS; Collins, J; Crivellari, D; Fey, MF; Forbes, JF; Gelber, RD; Gelber, S; Goldhirsch, A; Holmberg, SB; Lindtner, J; Murray, E; Pagani, O; Price, KN; Simoncini, E; Thürlimann, B, 2009) |
| "To evaluate the safety and efficacy of preoperative radiotherapy (RT) in combination with cetuximab, capecitabine, and irinotecan in patients with locally advanced rectal cancer." | 2.74 | Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. ( Barreto-Miranda, M; Dinter, D; Erben, P; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kienle, P; Mai, S; Post, S; Ströbel, P; Treschl, A; Wenz, F; Willeke, F; Woernle, C, 2009) |
| " Because the replacement of 2-day-infusional 5-fluorouracil (5-FU) of FOLFIRI with oral tegafur-uracil/leucovorin (UFT/LV) would be highly beneficial for clinical management, we performed a phase I trial using oral UFT/LV and a pharmacokinetic evaluation." | 2.74 | Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. ( Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009) |
| "A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15 mg kg(-1), capecitabine 1300 mg m(-2) daily for 2 weeks and gemcitabine 1000 mg m(-2) weekly 2 times; cycles were repeated every 21 days." | 2.74 | Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. ( Garrett, C; Gibbs, J; Iyer, R; Javle, M; Kuvshinoff, B; Litwin, A; Pande, A; Phelan, J; Yu, J, 2009) |
| "Of the 96 patients with gastric cancers, 21 underwent R0 resection and afterward received adjuvant FOLFOX chemotherapy." | 2.74 | [FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer]. ( Dai, H; Yan, D, 2009) |
| " This study was to investigate the efficacy and safety of oxaliplatin in combination with capecitabine as first-line chemotherapy for AGC patients." | 2.74 | [Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer]. ( Dong, NN; Liu, ZF; Wang, MY; Zhang, Q, 2009) |
| "Patients with advanced esophageal squamous cell carcinoma receive neoadjuvant chemotherapy or chemoradiotherapy to improve survival, but benefits are observed only in those with histologic response." | 2.73 | Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma. ( Doki, Y; Fujiwara, Y; Fukunaga, H; Hatazawa, J; Higuchi, I; Miyata, H; Monden, M; Takiguchi, S; Tatsumi, M; Yano, M; Yasuda, T, 2008) |
| "Capecitabine was given at an oral dosage of 825 mg/m(2)bid on each day of the radiotherapy period with the first daily dose applied 2 h before irradiation, followed by surgery 6 weeks later." | 2.73 | Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial. ( Budach, W; Debus, J; Dunst, J; Hinke, A; Hoelscher, T; Mose, S; Reese, T; Roedel, C; Rudat, V; Wulf, J; Zuehlke, H, 2008) |
| "Capecitabine combined with fractionated cisplatin is highly effective and well tolerated as a first-line treatment for advanced gastric cancer, with comparable results to 5-Fu plus cisplatin combination therapy." | 2.73 | [Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study]. ( Bai, YX; Chen, L; Chen, S; Cheng, Y; Hu, B; Jia, TZ; Jin, ML; Li, J; Liang, J; Shen, L; Shu, YQ; Wan, DS; Wang, BC; Wen, ZZ; Yin, HR; Yu, JR; Zhang, HG; Zhou, Y, 2008) |
| "First-line chemotherapy for 32 advanced squamous cell carcinomas of the esophagus is not effective, and early recurrences after chemotherapy were examined." | 2.73 | [Evaluation of docetaxel, CDDP and 5-FU combined therapy as second-line chemotherapy for esophagus cancer]. ( Aoyama, N; Minamide, J; Oota, Y; Takada, K, 2007) |
| "The International Breast Cancer Study Group (IBCSG) conducted two complementary randomized trials to assess whether a treatment-free gap during adjuvant chemotherapy influenced outcome." | 2.73 | Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. ( Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Gelber, RD; Gelber, S; Goldhirsch, A; Pagani, O; Price, KN; Simoncini, E, 2007) |
| "Grade III mucositis was more frequently observed in test group than in control group (75." | 2.73 | [Concurrent chemoradiotherapy followed by adjuvant chemotherapy for stage III-IVa nasopharyngeal carcinoma]. ( Fu, ZF; Hu, QY; Liu, P; Wang, L, 2007) |
| "From January 1998 to January 2003, 400 gastric cancer patients at high risk for recurrence including patients with serosal invasion (stage pT3 N0) and/or lymph node metastasis (stage pT2 or pT3 N1, N2, or N3), were enrolled in a trial of adjuvant chemotherapies; 201 patients were randomly assigned to receive the PELFw regimen, consisting of eight weekly administrations of cisplatin (40 mg/m2), LV (250 mg/m2), epidoxorubicin (35 mg/m2), 5-FU (500 mg/m2), and glutathione (1." | 2.73 | Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. ( Aitini, E; Ardizzoia, A; Arnoldi, E; Barni, S; Barone, C; Beretta, GD; Bertetto, O; Carnaghi, C; Cascinu, S; Cassano, A; Catalano, V; Chiara, S; Cortesi, E; Floriani, I; Foa, P; Frontini, L; Gasparini, G; Giordani, P; Labianca, R; Mansutti, M; Mosconi, S; Nardi, M; Piazza, E; Pozzo, C; Pucci, F; Rabbi, C; Ravaioli, A; Rimassa, L; Rota, S; Santoro, A; Silva, RR; Sobrero, A; Torri, V, 2007) |
| " Severe taxane-related toxic effects were more frequent in group A, while severe thrombocytopenia was low and present only in group A." | 2.73 | Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. ( Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N, 2008) |
| "Complete surgical resection of gastric cancer is potentially curative, but long-term survival is poor." | 2.73 | Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. ( Antimi, M; Antonuzzo, L; Arcangeli, A; Banducci, S; Bellini, V; Biagioni, F; Bianchini, D; Bilancia, D; Bisagni, G; Biscottini, B; Boni, C; Bracci, R; Bravi, S; Bruno, L; Cabassi, A; Camera, S; Camisa, R; Canaletti, R; Carboni, M; Carlini, P; Carroccio, R; Cascinu, S; Catalano, G; Catalano, V; Cavalli, C; Cesari, M; Cognetti, F; Contu, A; Corgna, E; Cortesi, E; Croce, E; Dalla Mola, A; De Filippis, S; De Stefanis, M; Di Costanzo, F; Dinota, A; Enzo, MR; Farris, A; Figoli, F; Floriani, I; Foa, P; Fornarini, G; Francavilla, F; Frignano, M; Gasperoni, S; Gilli, G; Giunta, A; Grigniani, F; Ionta, MT; Italia, M; Labianca, R; Lastraioli, E; Leoni, M; Lungarotti, F; Luppi, G; Manzione, L; Masoni, L; Massidda, B; Mela, M; Messerini, L; Monzio Compagnoni, B; Muscogiuri, A; Natalini, G; Nelli, F; Nicolosi, A; Oldani, S; Olgiati, A; Olivetti, A; Orselli, G; Pandolfi, U; Papiani, G; Pazzola, A; Piga, A; Pisani Leretti, A; Porrozzi, S; Recchia, F; Romiti, A; Rondini, E; Rossetti, R; Rovei, R; Saggese, M; Sarobba, MG; Scipioni, L; Strafiuso, G; Tomao, S; Tonato, M; Torri, V; Trignano, M; Zironi, S, 2008) |
| "Patients were randomly assigned to one of three dosing regimens of CAF." | 2.73 | Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. ( Berry, DA; Broadwater, G; Budman, DR; DiGiovanna, MP; Dressler, LG; Edgerton, S; Hayes, DF; Henderson, IC; Liu, ET; Muss, HB; Norton, L; Stern, DF; Thor, AD, 2008) |
| "Stage III colon cancer patients were enrolled and were divided into two groups: Group W, in which the histologic type of both primary tumors and metastatic lymph nodes was well-differentiated adenocarcinoma; and Group U, in which the primary tumors and the metastatic lymph nodes were of any type other than well-differentiated." | 2.72 | Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer. ( Hirota, T; Kodaira, S; Mori, T; Ohashi, Y, 2006) |
| "Gemcitabine is an active antitumor agent in the treatment of advanced pancreatic cancer, and has shown potential synergistic activity with the oral fluoropyrimidine capecitabine in previous phase I/II trials." | 2.71 | Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. ( Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H, 2003) |
| "Metastatic gastric cancer is usually treated with cisplatin- and 5-FU-based chemotherapy regimens." | 2.71 | Recurrent gastric adenocarcinoma with unusual metastatic localization and excellent response to docetaxel and 5-FU continuous infusion. ( Dörken, B; Krenn, V; Kretzschmar, A; Reichardt, P; Thuss-Patience, PC, 2003) |
| "Capecitabine is an effective salvage regimen in patients with recurrent and metastatic NPC." | 2.71 | A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. ( Au, GK; Chua, DT; Sham, JS, 2003) |
| "Doxifluridine (5'-DFUR) is an intermediate of capecitabine approved in Europe and USA to treat metastatic colorectal cancer." | 2.71 | A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines. ( Koda, K; Kodaira, S; Miyazaki, M; Nakazato, H; Ogawa, K; Saito, N; Sarashina, H; Suwa, T; Suzuki, M; Watanabe, S, 2003) |
| "In an International Breast Cancer Study Group (IBCSG) randomized clinical trial (Trial VIII) for pre- and perimenopausal women with lymph node-negative breast cancer, we compared sequential chemotherapy followed by the gonadotropin-releasing hormone agonist goserelin with each modality alone." | 2.71 | Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. ( Bonetti, M; Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Gelber, RD; Goldhirsch, A; Nasi, ML; O'Neill, A; Price, KN, 2003) |
| "Japanese women with low-stage cervical cancer receiving radical hysterectomy and radiotherapy have a good 5-year survival rate." | 2.71 | Adjuvant oral 5-fluorouracil for cervical cancer: Japanese Gynecologic Oncology Group report. ( Hasegawa, K; Izumi, R; Kudo, R; Nakajima, H; Ohashi, K; Okuda, H; Origasa, H; Sugimori, H; Takahashi, T; Yamamoto, K, 2004) |
| "Capecitabine was administered orally on day 1 of radiotherapy by an intermittent schedule (14 days treatment; 7-day rest) at 3 weekly intervals for two cycles." | 2.71 | [Phase I study of capecitabine with concurrent radiotherapy in early-stage nasopharyngeal carcinoma]. ( Guo, L; Guo, X; Hong, MH; Li, FY; Li, Q; Lin, HX; Luo, DH; Qiu, F, 2004) |
| "Capecitabine (Xeloda) is a novel, oral, selectively tumor-activated fluoropyrimidine with proven activity in the treatment of advanced colorectal cancer." | 2.71 | A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. ( Cho, JY; Choi, SH; Chung, HC; Han, JY; Hong, YS; Kang, JH; Lee, KS; Lee, SI; Noh, SH; Park, JN; Song, SY, 2004) |
| " Pharmacokinetic analyses for both BAY 12-9566 and 5-fluorouracil were performed." | 2.71 | An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin. ( Agarwal, V; Chouinard, E; Goel, R; Hirte, H; Huan, S; Humphrey, R; Lathia, C; Matthews, S; Roach, J; Seymour, L; Stafford, S; Stewart, DJ; Walsh, W; Waterfield, B, 2005) |
| "For patients with high-risk breast cancer treated with modified radical mastectomy, treatment with radiation therapy (schedule of 16 fractions) and adjuvant chemotherapy leads to better survival outcomes than chemotherapy alone, and it is well tolerated, with acceptable long-term toxicity." | 2.71 | Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. ( Coldman, AJ; Coppin, CM; Durand, R; Gelmon, K; Jackson, SM; Knowling, MA; Le, N; Manji, M; Olivotto, IA; Phillips, N; Ragaz, J; Spinelli, JJ; Weir, L; Wilson, KS, 2005) |
| "In total, 203 renal carcinoma patients' status post radical tumour nephrectomy were stratified into three risk groups: patients with tumour extending into renal vein/vena cava or invading beyond Gerota's fascia (pT3b/c pN0 or pT4pN0), patients with locoregional lymph node infiltration (pN+), and patients after complete resection of tumour relapse or solitary metastasis (R0)." | 2.71 | Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). ( Atzpodien, J; Ecke, M; Fornara, P; Gertenbach, U; Heynemann, H; Jentsch, H; Maskow, A; Reitz, M; Schmitt, E; Wandert, T; Wieland, W; Wöltjen, HH, 2005) |
| "5-Fluorouracil (5-FU) has two major mechanisms by which it exerts its anticancer activity." | 2.71 | Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients. ( Hoshino, S; Maekawa, T; Shirakusa, T; Yamashita, Y, 2005) |
| "For patients with rectal cancer treated with full thickness local excision the risk of mesorectal nodal metastases has to be very low." | 2.71 | Prediction of mesorectal nodal metastases after chemoradiation for rectal cancer: results of a randomised trial: implication for subsequent local excision. ( Bujko, K; Kepka, L; Nasierowska-Guttmejer, A; Nowacki, MP; Oledzki, J; Rogowska, D; Serkies, K; Stryczyńska, G; Suwiński, R; Tokar, P; Wieczorek, A; Winkler-Spytkowska, B, 2005) |
| "Standard chemotherapy for advanced gastric cancer remains undefined." | 2.71 | [A randomized controlled trail of taxol-based combination regimens for advanced gastric cancer]. ( Cai, XC; Chen, Q; Chen, YG; Fan, NF; Guo, ZQ; Lu, X; Ouyang, XN; Wu, XA; Xu, S; Yang, JW; Zhang, YH, 2005) |
| "Patients with resected breast cancer were treated if they were node-positive and estrogen receptor-negative, positive for overexpression of Her-2-neu, or had four or more involved nodes." | 2.70 | Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. ( Ellis, GK; Gralow, JR; Green, SJ; Livingston, RB; Thompson, T, 2002) |
| "Node-positive breast carcinoma patients were randomly assigned to receive either no further treatment after radical mastectomy (179 women) or 12 monthly cycles of adjuvant CMF chemotherapy (207 women)." | 2.70 | Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. ( Biganzoli, E; Bonadonna, G; Boracchi, P; Casalini, P; Cascinelli, N; Colnaghi, MI; Gianni, L; Marubini, E; Ménard, S; Pilotti, S; Tomasic, G; Valagussa, P, 2001) |
| "Histologic slides from selected breast cancer cases entered on node-negative Eastern Cooperative Oncology Group trials were assigned grades." | 2.70 | Prediction of node-negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry: an Eastern Cooperative Oncology Group Study (2192). ( Allred, DC; Dressler, LG; Gray, R; Hatfield, AK; Martino, S; Page, DL; Robert, NJ; Wood, WC, 2001) |
| "For patients with squamous cell carcinoma of the head and neck (HNSCC), persistence of cervical adenopathy following organ-preservation therapy is a strong predictor of locoregional failure." | 2.69 | Squamous cell granulomas of the neck: histologic regression of metastatic squamous cell carcinoma following chemotherapy and/or radiotherapy. ( Eisele, DW; Forastiere, AA; Lee, DJ; Westra, WH, 1998) |
| "The hypothesis that patients whose breast tumors exhibit high erbB-2 expression benefit from dose-intensive CAF should be further validated before clinical implementation." | 2.69 | erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. ( Allred, C; Barcos, M; Berry, DA; Budman, DR; Cirrincione, C; Edgerton, S; Henderson, IC; Kute, T; Liu, ET; Muss, HB; Norton, L; Thor, AD, 1998) |
| "Since the prognosis of patients with T4 squamous cell carcinoma (SCC) of the esophagus is extremely poor, an effective multimodal treatment needs to be established." | 2.69 | Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus. ( Doki, Y; Inoue, M; Inoue, T; Monden, M; Shiozaki, H; Tanaka, E; Tsujinaka, T; Yamamoto, M; Yano, M, 1999) |
| "Patients with inflammatory breast cancer or more than nine ipsilateral lymph node involvement without evidence of distant metastasis were randomized to receive either standard dose 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) every 3 weeks for nine courses (control) or six courses of FAC followed by two courses of cyclophosphamide (5." | 2.69 | A phase III study of high-dose intensification without hematopoietic progenitor cells support for patients with high-risk primary breast carcinoma. ( Aref, IM; Cross, PW; Gertler, SZ; Grimard, LJ; Hanson, J; Huan, SD; Malik, ST; St Cyr, DA; Stewart, DJ; Tomiak, EM; Verma, S; Yau, JC, 2000) |
| "55 patients with advanced renal cell cancer were treated as follows: IL-2 and IFN-alpha according to the schedule originally described by Atzpodien, with PVI 5FU 200 mg m(-2)day(-1)during weeks 5-9." | 2.69 | Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study. ( Ahern, R; Allen, MJ; Bate, S; Eisen, T; Gore, ME; Johnston, S; Moore, J; Savage, P; Vaughan, M; Webb, A, 2000) |
| "Stage II breast cancer patients who were or became node negative by both ultrasonographic and physical examinations after IC had a 48% incidence of nodal metastases." | 2.69 | The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy. ( Ames, FC; Bedi, D; Buzdar, AU; Feig, BW; Fornage, BD; Hunt, KK; Lenert, JT; Mirza, NQ; Ross, MI; Singletary, SE; Tolley, SM; Vlastos, G; Winchester, DJ, 2000) |
| "Patients with stage II or III breast cancer who had undergone doxorubicin-based neoadjuvant chemotherapy before breast surgery were eligible." | 2.69 | Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. ( Ames, FC; Breslin, TM; Buzdar, AU; Cohen, L; Delpassand, ES; Feig, BW; Fleming, JB; Hortobagyi, GN; House, R; Hunt, KK; Kuerer, HM; Newman, LA; Ross, MI; Sahin, A; Singletary, SE, 2000) |
| "The prognosis for patients with primary breast cancer involving multiple axillary lymph nodes is poor." | 2.68 | Randomized, comparative study of high-dose (with autologous bone marrow support) versus low-dose cyclophosphamide, cisplatin, and carmustine as consolidation to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for patients with operable stage II o ( Hurd, DD; Peters, WP, 1995) |
| "The regimens for colon cancer were, Arm I: mitomycin C [intraoperative portal vein bolus (12 mg/m2) + postoperative, twice weekly and then three times bimonthly for six months intermittent i." | 2.68 | Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan. ( , 1995) |
| "Forty-two patients with head and neck cancer were treated with tegafur suppository for 7 days preoperatively and clinical value of this treatment was assessed." | 2.68 | [High tissue concentration of 5-FU reduced local recurrence after administration of tegafur suppositories]. ( Itokazu, T; Kochi, A; Koja, S; Maeda, H; Maeshiro, N; Matsumura, J; Noda, Y; Yasuda, S, 1995) |
| " None of the patients could be administered the initially scheduled dosage of 500 mg/m2 of 5FU." | 2.68 | [Combination therapy with interferon-alpha and continuous infusion of 5-fluorouracil for advanced renal cell carcinoma]. ( Hosaka, M; Kubota, Y; Masuda, M; Noguchi, S; Shuin, T; Yao, M, 1995) |
| "Six patients (21%) had residual cancer in the resected specimen, either at the primary site or--more often--in adjacent lymph nodes." | 2.68 | Treating esophageal cancer with a combination of chemotherapy, radiation, and excision. ( Bates, DM; Clyde, JC; Garcia, JM; Girvin, GW; Lin, PH; Matsumoto, GH, 1995) |
| "Lymphatic metastasis is one of the most important problems in the treatment of gynecologic malignancy." | 2.68 | [Chemotherapy against lymphatic metastases of gynecologic cancer via pelvic retroperitoneal cannulation: a preliminary report]. ( Cao, Z; You, Z; Zhou, S, 1995) |
| " However, considering the fact that toxicity was still considerable despite reducing the dose of chemotherapy by 50%, we believe that conventionally dosed short-term regimens are preferable in the treatment of node-positive breast cancer." | 2.68 | Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: a joint European Organization for Research and Treatment of Cancer-Dutch Breast Cancer Working Party Study. Cooperating Investigator ( Clahsen, PC; Sylvester, RJ; van de Velde, CJ; van Driel, OJ; Welvaart, K, 1995) |
| "Combined chemotherapy and radiotherapy in standard dosage is an acceptable approach following mastectomy for patients with extensive nodal involvement at high risk for local recurrence and distant relapse." | 2.68 | Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement. ( Barraclough, B; Boyages, J; Langlands, AO; Ung, O, 1995) |
| "There were 51 patients with colorectal cancer and 130 patients with appendiceal cancer." | 2.68 | Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. ( Jablonski, KA; Sugarbaker, PH, 1995) |
| "Forty-eight patients with unresectable gastric cancer were enrolled for a randomized trial of FP (n = 24) vs FEP (n = 24) combination chemotherapy with respect to their effects on survival period." | 2.68 | [Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy]. ( Horiuchi, Y; Ina, K; Iwase, H; Kaneko, H; Kuroiwa, A; Kusugami, K; Morise, K; Oka, Y; Shinoda, M; Suga, S, 1995) |
| "Women with resected T1-3N1,2 primary breast cancer and > or = 10 positive axillary lymph nodes referred for possible trial participation were evaluated for this report." | 2.68 | Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. ( Crump, M; Girouard, C; Goss, PE; Prince, M, 1996) |
| "5-fluorouracil (5-FU) is a known radiosensitizer that enhances efficacy, in vivo and in vitro, when administered during radiotherapy." | 2.68 | Brachytherapy and continuous infusion 5-fluorouracil for treatment of locally advanced, lymph node negative, prostate cancer: a phase I trial. ( Dreicer, R; Forest, PK; Loening, S; See, WA; Wheeler, JA, 1996) |
| "A total of 2,795 women with early breast cancer, stage I to IIIA, were randomized onto a trial (European Organization for Research and Treatment of Cancer [EORTC] 10854) to compare surgery followed by one course of perioperative chemotherapy versus surgery alone." | 2.68 | Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer. A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study. ( Clahsen, PC; Delozier, T; Floiras, JL; Julien, JP; Mignolet, FY; Sahmoud, TM; van de Velde, CJ, 1996) |
| "5-FU; and arm III was surgery only." | 2.68 | Prognostic factors of colorectal cancer. Results of multivariate analysis of curative resection cases with or without adjuvant chemotherapy. ( Hamano, K; Kato, T; Kodaira, S; Koyama, Y; Ogawa, N; Sakabe, T; Takahashi, T; Tominaga, T; Yasutomi, M, 1996) |
| "To determine whether, when primary breast cancer is treated by local excision supported by systemic therapy appropriate to the oestrogen receptor status (ER) of the tumour, local radiotherapy can be avoided." | 2.68 | Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group. ( Everington, D; Forrest, AP; George, WD; Harnett, AN; McArdle, CS; Prescott, RJ; Smith, DC; Stewart, HJ, 1996) |
| "AcF is highly active in breast cancer with acceptable toxicities and can be used before alkylating agent-based high-dose therapy." | 2.68 | Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. ( Cameron, DA; Gabra, H; Lee, LE; Leonard, RC; Mackay, J, 1996) |
| "Some 978 patients with colon cancer and 713 patients with rectal cancer were enrolled in the study, 85 (5." | 2.68 | [Prospective controlled study on the usefulness of Carmofur as a postoperative adjuvant chemotherapy for colorectal cancer]. ( Hojo, K; Ichihashi, H; Kato, T; Kikuchi, K; Kodaira, S; Kunii, Y; Ogawa, M; Takahashi, T; Tamada, R; Tominaga, T; Yasutomi, M, 1997) |
| "We studied how gastric cancer tissues and cells changed as a result of preoperative chemotherapy." | 2.68 | [Influence of preoperative on gastric cancer tissues and cells]. ( Chen, Z; Li, G; Liu, F, 1997) |
| " Frequent dosage modifications were required with the dose intensity of 5-FU and alpha interferon of 57% and 58%, respectively." | 2.67 | Phase II trial of 5-fluorouracil and alpha-2b interferon in patients with hormone-refractory metastatic prostate cancer. ( Dreicer, R; Forest, PK; Williams, RD, 1994) |
| "Epirubicin has been found to be as effective as doxorubicin at equimolar doses but significantly better tolerated, especially in terms of alopecia, leucopenia, and cardiac toxicity." | 2.67 | Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles. The French Adjuvant Study Group. ( Devaux, Y; Fargeot, P; Fumoleau, P; Kerbrat, P; Mercier, M; Mihura, J; Namer, M; Schraub, S; Vo Van, ML, 1993) |
| "In 1978 the International (Ludwig) Breast Cancer Study Group (IBCSG) initiated four complementary randomized controlled clinical trials to evaluate the roles of chemo-endocrine combinations or endocrine therapy alone in specific populations defined by risk (for pre- and perimenopausal patients) or by age (for postmenopausal patients)." | 2.67 | The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. ( Castiglione-Gertsch, M; Collins, J; Cortes-Funes, H; Forbes, J; Gelber, RD; Goldhirsch, A; Hacking, A; Johnsen, C; Lindtner, J; Rudenstam, CM, 1994) |
| " There was no clear evidence of a dose-response effect in patients with minimal or no c-erbB-2 expression." | 2.67 | c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. ( Barcos, M; Berry, DA; Budman, DR; Cirrincione, CT; Koerner, F; Kute, T; Liu, ET; Muss, HB; Thor, AD; Wood, WC, 1994) |
| "Fifty-seven Dukes C colorectal cancer patients were given 5-fluorouracil-interferon-alpha 2b adjuvant treatment from October 1986 to September 1990." | 2.67 | 5-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes C colorectal cancer. ( Cremone, L; Espinosa, A; Faiella, F; Frasci, G; Leone, F; Monaco, M; Persico, G; Sapio, U, 1994) |
| "Grade 3 infections were seen in 9 cycles (5%)." | 2.67 | Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. ( Chevallier, B; Chollet, P; Hurteloup, P; Olivier, JP; Roche, H, 1993) |
| "Retinol palmitate was administered at the dose of 15." | 2.67 | [5-fluorouracil, cisplatin and retinol palmitate in the management of advanced cancer of the oral cavity. Phase II study]. ( Di Matteo, G; Frati, L; Lelli, S; Rea, S; Recchia, F, 1993) |
| "A total of 49 patients with metastatic renal cell cancer underwent recombinant interferon-alpha 2a therapy combined with chemotherapy." | 2.67 | Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer. ( Amato, R; Dexeus, FH; Fitz, K; Kilbourn, R; Logothetis, CJ; Sella, A; Wallace, S, 1992) |
| "Women with node-negative breast cancer have a 30% chance of relapse 5 years after mastectomy." | 2.67 | Swiss adjuvant trials in women with node-negative breast cancer. OSAKO. ( Jungi, WF; Senn, HJ, 1992) |
| "Postoperative women with breast cancer but without histopathological evidence of metastases to the axillary lymph nodes or clinical evidence of metastases were studied." | 2.67 | Chemotherapy versus observation in high-risk node-negative breast cancer patients. ( Cooper, MR; Eudey, L; Falkson, G; Gilchrist, KW; Mansour, EG; Osborne, CK; Shatila, AH; Tormey, DC, 1992) |
| "Twenty five patients with gastric cancer were randomly divided into five groups, and 5-FU (250 mg) was given with or without AT-II intraoperatively." | 2.67 | [5-FU concentration in the tissue of gastric cancer, and evaluation of cancer chemotherapy with angiotensin-II]. ( Takahashi, N, 1991) |
| "Significant improvement in dysphagia was recorded in 76% patients with complete response in 47 cases ranging from 6 to 27 months." | 2.67 | The role of intraluminal radiotherapy and concurrent 5-fluorouracil infusion in the management of carcinoma esophagus: a pilot study. ( Desai, PB; Deshpande, R; Dinshaw, KA; Malliat, MK; Pendse, AM; Sharma, V; Telang, CS; Vege, SS, 1991) |
| "Eight patients with untreated squamous cell carcinoma of the esophagus accompanying distant metastases who were treated by one to five cycles of chemotherapy consisting of Cisplatin and 120 hour infusion of 5-Fluorouracil were reported." | 2.67 | [Combined radiotherapy and pre-radiation chemotherapy with cisplatin and 5-fluorouracil for advanced esophageal carcinoma. I. Clinical evaluation in cases with distant metastases]. ( Sueyama, H, 1990) |
| "Treatment with levamisole alone had no detectable effect." | 2.67 | Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. ( Emerson, WA; Fleming, TR; Glick, JH; Goodman, PJ; Haller, DG; Laurie, JA; Macdonald, JS; Moertel, CG; Tormey, DC; Ungerleider, JS, 1990) |
| "Among these are the following." | 2.66 | Prospective computerized simulation of breast cancer: comparison of computer predictions with nine sets of biological and clinical data. ( Headley, DL; Retsky, MW; Swartzendruber, DE; Wardwell, RH, 1987) |
| " The LT 5-FU was given at a dosage of 750 mg/m2 every 2 weeks for 18 months or until progression." | 2.66 | Adjuvant radiotherapy and chemotherapy in resectable gastric cancer. A randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC. ( Bleiberg, H; Buyse, M; Dalesio, O; Gerard, A; Gignoux, M; Goffin, JC; Michel, J; Pector, JC; Roussel, A; Samana, G, 1989) |
| "Tamoxifen was added to the conventionally timed regimen in postmenopausal women." | 2.66 | Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. ( , 1988) |
| " Addition of chemotherapy with doxorubicin and cyclophosphamide significantly increased the proportion of patients with pulmonary fibrosis compared with patients treated with radiotherapy only or radiotherapy combined with cyclophosphamide, methotrexate and 5-fluorouracil." | 2.66 | Tolerance of radiotherapy combined with adjuvant chemotherapy in breast cancer. ( Hrafnkelsson, J; Nilsson, K; Söderberg, M, 1987) |
| "In patients with Stage I-II squamous cell carcinoma of the lung without regional lymph node metastases the used regimen of combined therapy had no significant effect." | 2.66 | Combined treatment including postoperative chemotherapy in lung cancer patients. ( Amiraliev, MA; Barchuk, AS; Glagolev, AN; Grigoryeva, SP; Kovalev, VN; Malay, EF; Trakhtenberg, AKh; Vidyak, IV; Zakharchenkov, AV; Zhiglov, MA, 1988) |
| "In rectosigmoid cancer the group on 5-FU included 26 patients who showed a response rate of 19% (5/26)." | 2.66 | Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer. ( Kolarić, K; Potrebica, V; Stanovnik, M, 1986) |
| "From 1973 to 1980, 701 patients with breast cancer measuring less than 2 cm in pathological diameter and with no palpable axillary lymph nodes were randomized to Halsted mastectomy (349) or to "quadrantectomy" with axillary dissection and radiotherapy to the ipsilateral breast tissue (QUART) (352)." | 2.66 | Local control and survival in early breast cancer: the Milan trial. ( Luini, A; Veronesi, U; Zucali, R, 1986) |
| " This prospective study was undertaken to record possible adverse effects of surgery, external beam radiation therapy, and 5-fluorouracil (5-FU) chemotherapy in the treatment of large bowel cancer." | 2.66 | 5-Fluorouracil chemotherapy and pelvic radiation in the treatment of large bowel cancer. Decreased toxicity in combined treatment with 5-fluorouracil administration through the intraperitoneal route. ( Barofsky, I; Gianola, FJ; Hancock, SL; Sugarbaker, PH; Wesley, R, 1986) |
| "Adjuvant treatment of breast cancer with AVCF gave significantly longer disease-free survival than CMF in the group of patients taken as a whole, in the subgroup with lymph node involvement and in the premenopausal subgroup." | 2.66 | Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results. ( Belpomme, D; Delgado, M; Fumoleau, P; Guerrin, J; Le Mevel, B; Mathé, G; Metz, R; Misset, JL; Plagne, R; Reizenstein, P, 1986) |
| "Women with breast carcinoma and four or more involved ipsilateral axillary lymph nodes were randomly assigned to receive an induction course and 2 yr of maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF, 150 patients), CMF plus vincristine and prednisone (CMFVP, 166 patients), or chemoimmunotherapy with CMF plus the methanol extraction residue of BCG (CMF-MER, 85 patients)." | 2.65 | A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer. ( Falkson, G; Falkson, HC; Glidewell, OJ; Henry, PH; Holland, JF; Leone, LA; Perloff, M; Tormey, DC; Weinberg, VE; Weiss, RB, 1983) |
| "Adjuvant therapy trials in breast cancer have grown steadily more complex since 1971, when the first long-term adjuvant trial in the United States was initiated." | 2.65 | Multiple trials of adjuvant chemohormonal therapy in the treatment of breast cancer: preliminary results--the ECOG experience. ( Carbone, PP, 1983) |
| "A group of 243 patients with gastric cancer was subjected to a prospective randomized trial of adjuvant chemotherapy after curative gastrectomy." | 2.65 | Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. ( Kajitani, T; Kuno, K; Nakajima, T; Takagi, K; Takahashi, T, 1984) |
| "Twenty-six patients with metastatic breast carcinoma who had measurable sites of disease were evaluated." | 2.65 | Combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in advanced breast carcinoma. ( Aroney, RS; Dalley, DN; Levi, JA, 1980) |
| " Both the delay in starting chemotherapy and the significant decrease in percent optimal drug dosage during the first six cycles of therapy are factors that may influence the high frequency of relapse observed in the R." | 2.65 | A randomized comparative trial of chemotherapy and irradiation therapy for stage II breast cancer. ( Cooper, MR; Ferree, C; Howard, V; Jackson, DV; Muss, HB; Rhyne, AL; Richards, F; Shore, A; Spurr, CL; Stuart, JJ; White, DR, 1981) |
| "The age adjusted death rate for ovarian cancer has remained unchanged for the past 20 years." | 2.64 | Advances in the staging and treatment of ovarian cancer. ( Fisher, RI; Young, RC, 1977) |
| "Seventy patients with breast cancer (stage IIIb--IV) were randomized by an "envelope" method into 2 groups, each including 35 persons." | 2.64 | [Combined drug treatment of far-advanced forms of breast cancer]. ( Borisov, AI, 1978) |
| "Antibody against a breast carcinoma antigen was present in patients with breast carcinoma and other cancer more often (P less than ." | 2.64 | Immunology and adjuvant chemoimmunotherapy of breast cancer. ( Morton, DL; Ramming, KP; Silver, HK; Sparks, FC; Wile, AG; Wolk, RW, 1976) |
| "Capecitabine+Bmab treatment was also administered for 11 courses due to an adverse event of peripheral neuropathy." | 2.50 | [A case of cecum colon cancer with lymph node metastasis successfully treated with XELOX plus bevacizumab]. ( Aoki, J; Goto, M; Honjo, K; Ichikawa, R; Ishiyama, S; Ito, S; Kawai, M; Kojima, Y; Komiyama, H; Kure, K; Mizukoshi, K; Okazawa, Y; Okubo, H; Ro, H; Sakamoto, K; Sugimoto, K; Takahashi, M; Takehara, K; Tomiki, Y; Yaginuma, Y, 2014) |
| "For cT2 N0 esophageal cancer patients, the benefit of neoadjuvant therapy is still unclear." | 2.48 | Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging. ( Brock, MV; Franco, N; Hooker, CM; How, R; Hulbert, A; Lee, S; Prevas, H; Shin, J; Yang, SC; Zhang, JQ, 2012) |
| "The standard treatment for colon cancer is surgical excision." | 2.47 | Adjuvant chemotherapy for localised colon cancer. Fluorouracil + folinic acid for node-positive, non-metastatic disease. ( , 2011) |
| "Patients with UICC stage II colon cancer and microsatellite instability (MSI) apparently experience a better prognosis but do not profit from an adjuvant CT with 5-FU/FA alone." | 2.47 | [Multimodal therapy for colon cancer: state of the art]. ( Link, KH; Weber, T, 2011) |
| "From a global perspective, gastric cancer including cancer of the esophago-gastric junction is the fourth most common malignant tumor and the second-most common cause of cancer-related death." | 2.46 | [Diagnosis and treatment of gastric cancer]. ( Ebert, M; Grenacher, L; Lordick, F; Moehler, M; Röcken, C; Schumacher, G, 2010) |
| "Many patients with early-stage colon cancer are cured with surgery alone, even if the standard of care remains an uniform approach to adjuvant chemotherapy based primarily on tumour stage." | 2.46 | Adjuvant colon cancer chemotherapy: where we are and where we'll go. ( Cinieri, S; Colucci, G; Fazio, N; Lombardi, L; Maiello, E; Morelli, F; Orlando, L; Santini, D; Silvestris, N; Tonini, G, 2010) |
| "We relate 2 cases reports about rectal cancer and pregnancy." | 2.43 | [Management of rectal cancer in pregnant women]. ( Benouna, J; Classe, JM; Dravet, F; Dupré, PF; Mahé, MA; Pigeau, H; Pioud, R, 2005) |
| "Adjuvant chemotherapy for breast cancer patients has been derived from the results of various clinical studies and metaanalysis." | 2.43 | [Adjuvant chemotherapy based on evidence-based medicine for breast cancer patients]. ( Ito, Y; Tokudome, N, 2006) |
| "5-Fluorouracil has been the mainstay of therapy for the last four decades." | 2.43 | Surgical adjuvant therapy for colorectal cancer: current approaches and future directions. ( Monga, DK; O'Connell, MJ, 2006) |
| "In patients with resectable pancreatic cancer, particularly in UICC-stage II neoadjuvant radiochemotherapy, this results in an improvement in survival: the median survival is between 15 and 30 months." | 2.42 | [Pancreatic cancer. The relative importance of neoadjuvant therapy]. ( Beger, HG; Gansauge, F; Poch, B; Schwarz, M, 2003) |
| "Case 2: A 74-year-old female with anal squamous cell carcinoma Stage II was treated by chemoradiotherapy with tegafur/uracil, external irradiation (30 Gy) and interstitial irradiation (24 Gy)." | 2.42 | [Effectiveness of chemoradiotherapy for three cases of squamous cell anal carcinoma]. ( Fujitani, K; Hirao, M; Ikenaga, M; Kashiwazaki, M; Masuda, N; Mishima, H; Sawamura, T; Takeda, Y; Takeno, A; Tsujinaka, T, 2004) |
| "Epirubicin is a unique anthracycline whose introduction to the US market represents a significant advance in breast cancer treatment." | 2.41 | The worldwide perspective in the adjuvant treatment of primary lymph node positive breast cancer. ( Glück, S, 2001) |
| "Advanced extramammary Paget's disease is also adenocarcinoma of the skin." | 2.40 | [Chemotherapy for advanced adenocarcinoma of the skin: experience with combination chemotherapy and a review of the literature]. ( Yamazaki, N, 1997) |
| "In addition, the PHREG analysis in 1453 gastric cancer patients showed that MF therapy (mitomycin C i." | 2.40 | Selection of adjuvant chemotherapy for gastric cancer using objective criteria. ( Nishiyama, M; Toge, T, 1997) |
| "The main therapy for primary breast cancer is not surgery, but a systemic therapy involving administration of cytotoxic chemotherapy or the use of ablative or additive endocrine therapy to control disseminated micrometastasis." | 2.40 | [Benefits of adjuvant chemotherapy for breast cancer]. ( Inaji, H; Koyama, H; Motomura, K; Noguchi, S, 1997) |
| "In patients with Dukes' B or C rectal cancer, combined radiation and FU increase survival and decrease local and distal recurrence." | 2.40 | Adjuvant therapy of colorectal cancer. ( Cohen, A; Kemeny, N; Saltz, L, 1997) |
| " Optimal dosing and administration strategies remain to be determined." | 2.40 | A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. ( Machover, D, 1997) |
| "The recurrence rate of resected gastric cancer with curative intent was around 20%." | 2.40 | [Treatment of recurrent gastric cancer]. ( Sakata, Y; Tsushima, K, 1998) |
| "Locally advanced, fungating breast cancers pose particularly difficult management problems for which intra-arterial drug delivery may be appropriate in carefully, selected cases." | 2.39 | Intra-arterial chemotherapy for palliation of fungating breast cancer. A case report and review of the literature. ( Bufill, JA; Grace, WR; Neff, R, 1994) |
| "In the treatment of stages 2 and 3 rectal cancer, significant reductions in local recurrence and death rates have been achieved with the combination of 5-fluorouracil and radiation therapy." | 2.39 | Role of adjuvant therapy in surgically resected colorectal carcinoma. ( Sinicrope, FA; Sugarman, SM, 1995) |
| "Dystrophic epidermolysis bullosa is associated with a high incidence of cutaneous squamous cell carcinoma." | 2.38 | Squamous cell carcinoma in epidermolysis bullosa. Treatment with systemic chemotherapy. ( Lentz, SR; Marion, JM; Orlowski, EP; Raish, RJ, 1990) |
| "After treatment of early breast carcinoma (stage I, II, and some III), the recurrent lesion can be classified as local, regional, distant, or combinations thereof." | 2.37 | Patterns of metastasis and natural courses of breast carcinoma. ( Lee, YT, 1985) |
| "By using the Korean Pancreatic Cancer (K-PaC) registry, we compared the clinical outcomes of FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GNP) in patients with metastatic pancreatic cancer (MPC)." | 1.56 | Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry. ( Cha, HS; Hwang, JH; Kim, J; Kim, JW; Kim, MJ; Lee, JC; Lee, WJ; Park, P; Shin, DW; Woo, SM; Yang, SY, 2020) |
| "From our established gastric cancer database, patients with pathological stage II and III gastric cancer who received adjuvant chemotherapy after D2 gastrectomy at Zhongshan Hospital of Fudan University were analyzed." | 1.51 | The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study. ( Cheng, X; Cui, Y; Ji, Y; Jiang, H; Li, W; Liu, F; Liu, TS; Shen, Z; Sun, Y; Tang, C; Wang, X; Wang, Y; Yu, S; Yu, Y, 2019) |
| "Breast cancer is the most common female-specific malignancy in Taiwan and developed countries worldwide, and its incidence continues to grow." | 1.51 | YWHAE promotes proliferation, metastasis, and chemoresistance in breast cancer cells. ( Hou, MF; Lee, YC; Wang, CH; Wang, YY; Yang, YF; Yuan, SF, 2019) |
| "Management of advanced intrahepatic cholangiocarcinoma (iCCA) is challenging and overall survival is poor." | 1.51 | Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden. ( Gbolahan, O; Hashemi-Sadraei, N; O'Neil, B, 2019) |
| "Cardiotoxicity is an important side effect in patients receiving chemotherapy and the application of anthracycline drugs for gastric cancer treatment is uncommon." | 1.51 | Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients. ( Bai, Y; Gao, L; Jin, X; Wu, S, 2019) |
| " We report 2 patients with para-aortic lymph node metastasis treated with 4 courses each of FOLFOX6 and FOLFIRI in combination with bevacizumab, which led to a complete response." | 1.48 | [Five-Year Survival of Two Patients with Para-Aortic Lymph Node Metastasis Treated with Four FOLFOX6and Four FOLFIRI Courses in Combination with Bevacizumab]. ( Ohara, H; Yamamoto, H, 2018) |
| "Patients with rectal cancer treated with chemoradiotherapy and radical surgery from 2003 to 2015 (N = 222) were included." | 1.46 | Oncological Outcomes of Lateral Pelvic Lymph Node Metastasis in Rectal Cancer Treated With Preoperative Chemoradiotherapy. ( Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Morikawa, T; Nozawa, H; Tanaka, T; Watanabe, T, 2017) |
| "Esophageal cancer is the eighth most common cancer worldwide." | 1.46 | Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience. ( Chen, Y; Hao, D; He, C; Liu, J; Wang, J; Wang, W; Wu, X; Xing, W; Yang, Y, 2017) |
| "It has rarely been associated with disseminated intravascular coagulation (DIC) with only 3 previously reported cases." | 1.46 | Acute Disseminated Intravascular Coagulation after Oxaliplatin Infusion. ( Ailawadhi, S; Arthurs, JR; Fischer, DL; Gannon, NA; Gibbs, M; Gupta, E; Irvin, M; Kakar, TS; Waddle, M, 2017) |
| "Stage IV squamous cell carcinoma of the anus outcomes are poor, but first-line chemotherapy can enable good response rates." | 1.46 | Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience. ( Benezery, K; Cavaglione, G; Doyen, J; Evesque, L; Follana, P; François, E; Reure, J; Tuan Falk, A, 2017) |
| "We report a case of perianal squamous cell carcinoma and left inguinal lymph node metastasis that showed a complete response more than 5 years after chemotherapy and concomitant proton beam therapy." | 1.46 | [A Case of Perianal Squamous Cell Carcinoma with Left Inguinal Lymph Node Metastasis That Showed a Complete Response More Than Five Years after Chemotherapy and Concomitant Proton Beam Therapy]. ( Abe, T; Azami, A; Honda, M; Nakamura, T; Sato, A; Suzuki, N; Tada, T; Takano, Y; Teranishi, Y; Todate, Y; Waragai, M, 2017) |
| "5-Fluorouracil (5-FU) has been identified as one of the standard first-line chemotherapy drugs for locally advanced or metastatic gastric cancer." | 1.46 | Combination of NRP1-mediated iRGD with 5-fluorouracil suppresses proliferation, migration and invasion of gastric cancer cells. ( Cao, G; Gao, Q; Sun, X; Xing, Y; Zhang, D; Zhang, L, 2017) |
| "A 67-year-old woman was diagnosed with cecal cancer, para-aortic lymph node metastasis, peritoneum dissemination, and left breast cancer." | 1.46 | [A Case of Cecal Cancer with Para-Aortic Lymph Node Metastasis and Peritoneum Dissemination Treated with Curative Resection after mFOLFOX6 plus Panitumumab Chemotherapy]. ( Babaya, A; Hamanaka, M; Ikeda, M; Imada, A; Kimura, K; Kobayashi, M; Noda, M; Song, J; Tomita, N; Tsukamoto, K; Yamano, T, 2017) |
| "Locally advanced unresectable pancreatic cancer (LAPC) historically portends a poor prognosis." | 1.46 | Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes? ( Bahary, N; Bednar, F; Hogg, ME; Ocuin, LM; Steve, J; Winters, S; Zeh, HJ; Zenati, MS; Zureikat, AH, 2017) |
| "Patients with ypN0 rectal cancer who have received preoperative chemoradiotherapy can be divided into those who initially were node negative and those whose positive nodes have been sterilized by preoperative therapy." | 1.46 | Prognostic Value of Sterilized Lymph Nodes After Preoperative Chemoradiotherapy for Patients with ypN0 Rectal Cancer. ( Agostini, J; Benoist, S; Boige, V; Brouquet, A; Dartigues, P; Dumont, F; Goéré, D; Julié, C; Lazure, T; Penna, C; Peschaud, F; Vychnevskaia, K, 2017) |
| "50 patients with advanced esophageal cancer were treated with a continuous infusion of CF, 5-FU, and CDDP, and the short-term effects, adverse reactions, and survival periods after treatment were analyzed." | 1.46 | Continuous infusion of a large dose of CF (folinic acid) and 5-FU combined with CDDP in the treatment of advanced esophageal cancer. ( Cai, HX; Zhu, ZA; Zhu, ZQ, 2017) |
| "PTBP3 mRNA levels in human gastric cancer and adjuvant non-tumour tissues were detected." | 1.46 | Inhibition of polypyrimidine tract-binding protein 3 induces apoptosis and cell cycle arrest, and enhances the cytotoxicity of 5- fluorouracil in gastric cancer cells. ( Li, J; Liang, X; Lin, S; Liu, J; Qi, Y; Qiu, C; Shi, H; Yang, L; Zhao, A, 2017) |
| "Patients with locally advanced colon cancer (LACC) have a relatively poor prognosis despite radical resection and adjuvant chemotherapy." | 1.46 | Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer. ( Huang, CJ; Huang, CM; Huang, CW; Huang, MY; Ma, CJ; Tsai, HL; Wang, JY; Yeh, Y-, 2017) |
| "The correlation was confirmed in gastric cancer cell lines, analyzed further by gene overexpression and silencing analysis, a cell invasion assay, and a chemosensitivity test." | 1.43 | Inverse association between Bmi-1 and RKIP affecting clinical outcome of gastric cancer and revealing the potential molecular mechanisms underlying tumor metastasis and chemotherapy resistance. ( Chen, J; Chen, S; Chen, Y; Huang, K; Li, H; Li, J; Lian, G; Ou, G; Yang, K; Zeng, L, 2016) |
| "Metastatic and refractory gastric cancer (GC) are associated with a poor prognosis; therefore, the identification of prognostic factors and chemosensitivity markers is extremely important." | 1.43 | Nuclear PRMT1 expression is associated with poor prognosis and chemosensitivity in gastric cancer patients. ( Altan, B; Asao, T; Bai, T; Bao, P; Hara, K; Ide, M; Kimura, A; Kogure, N; Kuwano, H; Mochiki, E; Nishiyama, M; Ogata, K; Oyama, T; Suzuki, M; Toyomasu, Y; Yokobori, T, 2016) |
| "Esophageal squamous cell carcinoma (ESCC) contains genomic alterations of undefined clinical significance." | 1.43 | Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China. ( Bi, Y; Chen, X; Chen, Y; Cheng, C; Cheng, X; Cui, H; Cui, Y; Guo, J; Guo, S; Hu, X; Jia, J; Jia, Z; Kong, P; Li, G; Li, H; Li, Q; Li, Y; Liang, J; Liu, H; Liu, J; Qian, Y; Shi, R; Song, B; Wang, C; Wang, F; Wang, J; Wang, T; Xi, Y; Xu, E; Yan, T; Yang, B; Yang, J; Zhan, Q; Zhang, L; Zhang, Y; Zhao, Z; Zhou, Y, 2016) |
| "Advanced gastric cancer patients with PALM can obtain a survival benefit from neoadjuvant chemotherapy, subsequent surgery and radiotherapy." | 1.43 | A pilot study of an individualized comprehensive treatment for advanced gastric cancer with para-aortic lymph node metastasis. ( He, Q; Li, G; Li, Y; Ma, L, 2016) |
| "She was diagnosed with descending colon cancer with lymph node and liver metastases." | 1.43 | [A Case of Liver Metastasis of Descending Colon Cancer with a Pathological Complete Response to mFOLFOX6]. ( Ito, T; Kawamoto, K; Kawamoto, Y; Koda, Y; Ome, Y; Saga, K, 2016) |
| "A pathologic cervical residual tumor was observed in 16 patients (35." | 1.43 | [Stage IB2, IIA and IIB cervical carcinoma without lymph node extension treated with neoadjuvant chemoradiotherapy]. ( Ballester, M; Daraï, E; Huguet, F; Lauratet, B; Lefranc, JP; Monnier, L; Touboul, E, 2016) |
| "Although squamous cell carcinoma (SCC) is the second most common nonmelanoma skin cancer, clinicians have difficulty diagnosing SCC of the toe because its clinical features can mimic other less serious diseases." | 1.43 | A Digital Squamous Cell Carcinoma Mimicking a Diabetic Foot Ulcer, With Early Inguinal Metastasis and Cancer-Related Lymphedema. ( Kim, HW; Kim, JE; Ko, JY; Kwon, HI; Park, HC; Ro, YS, 2016) |
| "In patients with rectal cancer who have already received neoadjuvant chemoradiotherapy and undergone curative resection, adding oxaliplatin to 5-FU could prolong OS in patients aged < 73 years and ypN+ category." | 1.43 | Impact of age on efficacy of postoperative oxaliplatin-based chemotherapy in patients with rectal cancer after neoadjuvant chemoradiotherapy. ( Chen, XW; Gao, P; Huang, XZ; Ma, B; Song, YX; Sun, JX; Wang, J; Wang, ZN; Zhao, JH, 2016) |
| "The histological diagnosis was tubular adenocarcinoma (tub2-1), int, INF a, pMP, ly0, v0, pDM0, pPM0, R0." | 1.43 | [A Case of Advanced Rectal Cancer Resected Successfully after Induction Chemotherapy with Modified FOLFOX6 plus Panitumumab]. ( Aomatsu, N; Dozaiku, T; Hanno, H; Hirakawa, T; Hirooka, T; Iwauchi, T; Kawamura, M; Morimoto, J; Nakazawa, K; Nishii, T; Takayanagi, S; Takeda, O; Takeuchi, K; Uchima, Y; Yukawa, Y, 2016) |
| "To determine the function of WEE1 in gastric cancer cells, we determined that WEE1 ablation decreased the proliferation, migration, and invasion, while overexpression of WEE1 increased these effects in gastric cancer cells." | 1.43 | Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer. ( Cho, Y; Chun, KH; Kang, H; Kim, HY; Kim, SJ; Song, J; Yim, YS, 2016) |
| "45 patients with anal cancer who underwent pre-treatment FDG-PET/CT were included." | 1.43 | Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival. ( Behrendt, FF; Eble, MJ; Heinzel, A; Mohammadkhani Shali, S; Mottaghy, FM; Schmitt, V; Verburg, FA; Winz, OH, 2016) |
| "Gastric cancer is considered the fourth most common cancer and second most common cause of cancerrelated mortalities worldwide." | 1.43 | Oxaliplatin, 5Fluorouracil and Leucovorin (FOLFOX4) as First Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer. ( Esmaeilpour, K; Haghighi, S; Kasbkar, H; Yasaei, M, 2016) |
| "We report 2 cases of metastatic rectal cancer patients who received chemotherapy with FOLFOXIRI plus bevacizumab(Bev)." | 1.43 | [Two Cases of Metastatic Rectal Cancer Patients Who Received Chemotherapy with FOLFOXIRI plus Bevacizumab]. ( Aomatsu, N; Hirakawa, T; Iwauchi, T; Morimoto, J; Nagashima, D; Nakazawa, K; Nishii, T; Takeuchi, K; Tei, S; Uchima, Y; Wang, E; Yamakoshi, Y, 2016) |
| "Indications for surgery for esophageal cancer often do not include cases with SCLN metastasis because the latter is considered distant metastasis." | 1.42 | Clinical Importance of Supraclavicular Lymph Node Metastasis After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. ( Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M, 2015) |
| "We aimed to identify esophageal squamous cell carcinoma (ESCC) stem-like cells, the epigenetic mechanism and identify novel biomarkers for targeting ESCC CSCs." | 1.42 | Epigenetic regulation of CD271, a potential cancer stem cell marker associated with chemoresistance and metastatic capacity. ( Chen, X; Gao, Q; Huang, L; Li, F; Li, J; Li, S; Ping, Y; Wang, D; Wang, L; Yang, L; Yue, D; Zhang, T; Zhang, Y, 2015) |
| "Patients with KRAS wild-type metastatic colorectal cancer in the CORECT registry who initiated treatment with bevacizumab between 2008 and 2012 were enrolled." | 1.42 | Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data. ( Bortlíček, Z; Kubáčková, K; Linke, Z; Pikus, T; Pokorná, P; Prausová, J; Vyzula, R, 2015) |
| "In recent decades, the management of rectal cancer has been significantly improved by optimizing the surgical treatment with the total mesorectal excision and the development of neoadjuvant radiotherapy with or without chemotherapy." | 1.42 | [Preoperative chemoradiotherapy for rectal cancer: experience from one centre]. ( Bednarek, C; Bosset, JF; Cerda, T; Guimas, V; Lepinoy, A; Lescut, N; Schipman, B, 2015) |
| "The authors conclude that multiple synchronous neoplasms can be treated with individualized chemotherapeutic protocol with good efficacy and few adverse reactions." | 1.42 | [Individualized therapy of synchronous ovarian and colon cancers with lymph]. ( Bishr, AM; Deme, D; Nizar, J; Telekes, A, 2015) |
| "Primary rectal cancer patients with synchronous distant metastases between September 2001 and August 2011 were enrolled." | 1.42 | Comparison of oncologic outcomes of metastatic rectal cancer patients with or without neoadjuvant chemoradiotherapy. ( Jung, SH; Kim, JH; Kim, SH, 2015) |
| "Pancreatic cancer is the fourth leading cause of cancer related death with median survival ranging from 3 to 6 months for metastatic disease." | 1.42 | Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country. ( Jabbar, AA; Zahir, MN, 2015) |
| "Because the serum concentration of 5-FU fluctuates and displays various patterns, the dosage should not be based on body surface area." | 1.42 | Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer. ( Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Murakami, H; Okumura, H; Tohyama, K; Tsuruta, A, 2015) |
| "Transfection of miR-125b sensitizes gastric cancer cells to 5-FU-induced apoptosis." | 1.42 | miR-125b Suppresses Proliferation and Invasion by Targeting MCL1 in Gastric Cancer. ( He, X; Liu, F; Lv, X; Peng, Y; Wu, S; Xie, L; Zhang, Z; Zhu, Y, 2015) |
| "Nasopharyngeal carcinoma is an extremely rare pediatric malignancy predominantly occurring in adolescent males." | 1.42 | Pediatric advanced stage nasopharyngeal carcinoma - case report. ( Mascarin, M; Matijašić, N; Roganović, J, 2015) |
| "The clinicopathological data of 110 gastric cancer patients who developed recurrence or second primary malignancies after radical gastrectomy and adjuvant chemotherapy with FOLFOX4 regimen or docetaxel plus FOLFOX4 regimen were analyzed retrospectively." | 1.42 | [Characteristics of recurrence in patients with gastric cancer after radical gastrectomy and adjuvant chemotherapy]. ( Du, C; Guo, C; Wang, J; Xu, Q; Zhou, A, 2015) |
| "After disease progression, a second line based on FOLFIRI-aflibercept was started achieving an initial partial response followed by a long-lasting disease stability with a good tolerability." | 1.42 | [Efficacy and safety of antivascular drugs after anti-EFGR: aflibercept after cetuximab, a clinical case]. ( Aroldi, F; Zaniboni, A, 2015) |
| "We report a case of regional recurrence of esophageal cancer after curative esophagectomy." | 1.42 | [A Case of Salvage Chemoradiotherapy for Regional Recurrence after Curative Esophagectomy]. ( Imanishi, T; Kakeji, Y; Kanaji, S; Kanemitsu, K; Nakamura, T; Okuno, T; Sumi, Y; Suzuki, S; Yamamoto, M; Yamashita, K, 2015) |
| "We present a case of sigmoid colon cancer with isolated para-aortic lymph node metastasis in a 67-year-old male patient." | 1.42 | [A Case of Para-Aortic Lymph Node Metastases of Sigmoid Colon Cancer Treated with Complete Resection]. ( Fukuda, M; Fukunari, H; Hayashi, T; Kato, T; Nakao, K; Okajima, C; Shitara, K; Yamamoto, Y, 2015) |
| "This was a rare case of rectal cancer with submucosal invasion that showed recurrence in the bone and lymph nodes 78 months after the additional resection." | 1.42 | [Recurrence of Rectal Cancer with Submucosal Invasion in the Bone and Lymph Nodes 89 Months after Surgery--A Case Report]. ( Amikura, K; Asayama, M; Fukuda, T; Ishikawa, H; Kawashima, Y; Kazama, S; Kurozumi, M; Mori, Y; Nishimura, Y; Nishizawa, Y; Sakamoto, H; Takano, M; Takenoya, T; Tanaka, Y, 2015) |
| "A patient in his 70s was diagnosed with rectal cancer (pT3, pN1, cM0, and pStage IIIa) for which he underwent low anterior resection of the rectum and received adjuvant therapy with UFT/LV." | 1.42 | [A Case of Rectal Cancer with Multiple Liver, Lung, and Para-Aortic Lymph Node Metastases Successfully Treated with FOLFOX4 plus Bevacizumab]. ( Goya, T; Hanaka, J; Kanamura, S; Nakayama, H; Takahashi, M; Takahashi, S; Wakamatsu, T, 2015) |
| "Human colorectal cancer specimens (n=94) and human colorectal cancer cell lines HRT18 and HT115 were used." | 1.40 | Death associated protein 1 is correlated with the clinical outcome of patients with colorectal cancer and has a role in the regulation of cell death. ( Davies, ML; Hargest, R; Ji, J; Ji, K; Jia, Y; Jiang, WG; Ruge, F; Toms, AM; Ye, L, 2014) |
| "Between 1998 and 2012, 56 patients with squamous cell carcinoma were treated at our institution and included in the analysis." | 1.40 | [Results of definitive radiotherapy for squamous cell carcinomas of the larynx patients with subglottic extension]. ( Blanchard, P; Bourhis, J; Daly-Schveitzer, N; Janot, F; Lévy, A; Tao, Y; Temam, S, 2014) |
| "We found that S100P expression of colorectal cancer tissue was significantly higher than that of normal colorectal mucosal tissues." | 1.40 | Overexpression of S100P promotes colorectal cancer metastasis and decreases chemosensitivity to 5-FU in vitro. ( Chen, L; Dong, L; Jiang, L; Jin, R; Li, G; Lin, F; Ni, W; Wang, F; Wu, J; Yin, X, 2014) |
| "However, the number of long-term esophageal cancer survivors has been increasing due to advances in early detection and therapy." | 1.40 | Second primary pancreatic adenocarcinoma three years after successfully treated index esophageal cancer. ( Dasanu, CA; Nandy, N, 2014) |
| "Metastasized rectal cancer has long been considered incurable." | 1.40 | A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach. ( Albertsson, M; Holmqvist, A; Jung, M; Sun, XF, 2014) |
| "Fibrolamellar variant of hepatocellular carcinoma (FLHCC) does not have a favorable prognosis than conventional HCC, and there is no difference regarding the response to chemotherapy and the degree of surgical resectability." | 1.40 | Successful multimodal treatment for aggressive metastatic and recurrent fibrolamellar hepatocellular carcinoma in a child. ( Akdemir, ÜÖ; Akyol, G; Boyunağa, Ö; Dalgiç, A; Demiroğullari, B; Eser, EP; Karadeniz, C; Oğuz, A; Okur, A; Pinarli, FG; Yilmaz, G, 2014) |
| "Hepatic resection of metastatic colorectal cancer (CRC) has become the treatment of choice for patients after resection of the primary CRC." | 1.40 | Extracapsular lymph node involvement is associated with colorectal liver metastases and impact outcome after hepatectomy for colorectal metastases. ( Araki, K; Asao, T; Fujii, T; Kubo, N; Kuwano, H; Suzuki, H; Tsukagoshi, M; Tsutsumi, S; Wada, S; Watanabe, A, 2014) |
| "Abdominal pain was the most frequent symptom (36." | 1.40 | Retrospective analysis of 119 small bowel adenocarcinoma in Chinese patients. ( Bai, L; Guo, XC; Mao, ZY; Su, D; Wang, LJ; Zhang, TT, 2014) |
| "DCF has strong antitumor activity for esophageal cancer and may confer survival benefits when used as preoperative chemotherapy." | 1.40 | Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer. ( Baba, H; Baba, Y; Ishimoto, T; Iwagami, S; Iwatsuki, M; Nagai, Y; Watanabe, M; Yoshida, N, 2014) |
| " Our chemoradiotherapy protocol was as follows: (i) alternating chemoradiotherapy with 5-fluorouracil and nedaplatin; (ii) whole pelvic radiotherapy with the dynamic conformal technique combined with intracavitary brachytherapy; (iii) prophylactic irradiation to the para-aortic region for International Federation of Gynecology and Obstetrics III/IVA or positive pelvic node and full-dose radiotherapy for positive para-aortic node." | 1.40 | Clinical efficacy of alternating chemoradiotherapy by conformal radiotherapy combined with intracavitary brachytherapy for high-risk cervical cancer. ( Fuwa, N; Hirata, K; Ito, J; Kodaira, T; Nakanishi, T; Ohshima, Y; Tachibana, H; Tomita, N, 2014) |
| "Distant metastasis accounted for the predominant cause of death." | 1.40 | [Outcome and prognostic factors of 125 loco-regionally advanced head and neck squamous cell carcinoma treated with multi-modality treatment]. ( Guo, Y; Ji, Q; Qian, W; Wang, Y; Zhu, G, 2014) |
| "Inguinal lymph node metastasis is predictive of locoregional recurrence and poor overall survival in anal carcinoma." | 1.40 | Inguinal lymph node recurrence in the untreated groin of patients with anal carcinoma. ( Blinde, SE; Mens, JW; Nuyttens, JJ; Olofsen, M; Schasfoort, R; Verhoef, C, 2014) |
| "Out of 322 patients with breast cancer registered in our institute, 80 patients received neoadjuvant chemotherapy." | 1.40 | The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India. ( Babu, S; Das, U; Govind Babu, K; Jacob, L; Lakshmaiah, KC; Lokanatha, D; Suresh, TM, 2014) |
| "Three and five years survival of gastric cancer patients subjected to adjuvant chemoradiotherapy was 53 and 41% respectively." | 1.40 | [Adjuvant chemoradiotherapy in advanced gastric cancer: experience in 168 patients]. ( Isa O, N; López V, H; Russo N, M, 2014) |
| "Grade 2 anorexia was the most frequent chemotherapy-related toxicity and no toxic death was noted." | 1.40 | Intraarterial chemotherapy as the first-line therapy in penile cancer. ( Chen, CH; Chiang, PH; Shen, YC, 2014) |
| "Chemoimmunotherapy has been used to treat intrahepatic cholangiocarcinoma (ICC)." | 1.40 | Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy. ( Gong, J; Homma, S; Ito, M; Kajihara, M; Kan, S; Koido, S; Namiki, Y; Odahara, S; Ohkusa, T; Okamoto, M; Sugiyama, H; Tajiri, H; Takakura, K; Tsukinaga, S; Yoshida, K; Yoshizaki, S; Yusa, S, 2014) |
| "The study included 405 gastric cancer patients who underwent curative gastrectomy with D2 lymph node dissection and received adjuvant therapy between January 2008 and July 2009." | 1.40 | Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study. ( Bae, JM; Choi, MG; Kang, WK; Kim, S; Lee, J; Lee, JH; Lee, SJ; Lim, DH; Lim, HY; Park, JO; Park, SH; Park, YS; Sohn, TS, 2014) |
| "A 77-year-old woman was diagnosed with gastric cancer complicated by multiple liver metastases and peritoneal dissemination." | 1.40 | [Gastric cancer with liver metastasis and peritoneal dissemination treated with conversion surgery to achieve r0 resection after capecitabine, cisplatin, and trastuzumab chemotherapy-a case report]. ( Choda, Y; Harano, M; Idani, H; Kanazawa, T; Matsukawa, H; Ninomiya, M; Ojima, Y; Okajima, M; Sato, D; Shiozaki, S; Tokumoto, N, 2014) |
| "Two patients presented with brain metastases, while one demonstrated lymphangitic spread to lungs." | 1.40 | A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma. ( Calkins, SM; Cinar, P; Kelley, RK; Venook, AP, 2014) |
| " Therefore, we aimed to assess the clinical effect of XELOX neoadjuvant chemotherapy on AGC when combined with laparoscopic surgery." | 1.40 | Treatment of locally advanced gastric cancer with the XELOX program of neoadjuvantchemotherapy combined with laparoscopic surgery: the experience in China. ( Huang, CM; Li, P; Lin, JX; Lu, J; Wang, JB; Xie, JW; Zheng, CH, 2014) |
| "Metastatic gastric cancer is uncommon, and metastasis of colorectal cancer to the stomach is extremely rare." | 1.40 | [A case of metastatic gastric cancer originating from transverse colon cancer]. ( Doi, S; Kan, K; Maruyama, H; Murata, K; Nakaguchi, K; Nakano, K; Nushijima, Y; Okamura, S; Sugimoto, K, 2014) |
| "A 62-year-old man presented with type 3 gastric cancer (tub1, HER2 positive) in the cardia, with 10-cm direct invasion into the lower esophagus, and extensive lymph node metastasis (Virchow and paraaortic nodes)." | 1.40 | [A case of HER2-positive advanced gastric cancer with extensive lymph node metastasis treated via chemotherapy with a trastuzumab-containing regimen followed by conversion surgery]. ( Asaoka, T; Fujitani, K; Fukuda, Y; Haraguchi, N; Hirao, M; Ikeda, M; Miyake, M; Miyamoto, A; Nakamori, S; Nishikawa, K; Omiya, H; Sekimoto, M; Takami, K; Tsujinaka, T; Yamamoto, K, 2014) |
| "Six months after surgery, recurrence was detected in the para-aortic lymph node." | 1.40 | [A case of gastric cancer showing response to first-line XP regimen after lymph node recurrence during the administration of S-1 as postoperative adjuvant chemotherapy]. ( Egawa, T; Ito, Y; Kemmochi, T; Mihara, K; Nagashima, A; Nishiya, S; Yamashiro, N, 2014) |
| "In patients with metastatic gastric cancer, the prognosis is poor with a median overall survival of 11 months since curative treatments are excluded; however, this case illustrated that a personalized treatment with chemotherapy and surgery can allow a curative strategy in selected patients with HER2-negative advanced gastric cancer." | 1.40 | Advanced gastric cancer with liver and lymph node metastases successfully resected after induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil. ( Anselmi, E; Banchini, F; Bodini, FC; Capelli, P; Cavanna, L; Michieletti, E; Stroppa, EM; Zangrandi, A, 2014) |
| "The aim is to evaluate the preliminary efficacy and side effects of paclitaxel, 5-fluorouracil, and leucovorin intravenous chemotherapy in combination with cisplatin hyperthermic intraperitoneal perfusion chemotherapy (HIPEC) as postoperative adjuvant therapy for patients of locally advanced gastric cancer (GC) at high risk for recurrence after curative resection." | 1.40 | Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer. ( Chen, S; Deng, Q; Jing, S; Li, J; Li, X; Ma, S; Tang, R; Wu, K; Wu, Z; Zheng, Z, 2014) |
| "Our findings suggest that BCS after NCT in clinical stage III patients is oncologically safe in terms of LR if breast tumor size is ≤4 cm after NCT and Ki-67 is a predictor of LR after NCT." | 1.39 | Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients. ( Han, W; Im, SA; Moon, HG; Moon, WK; Noh, DY; Park, IA; Park, SJ; Shin, HC, 2013) |
| "He had squamous cell carcinoma diagnosed by biopsy specimens, found in the esophagogastric junction by esophagogastroduodenoscopy." | 1.39 | [A case of squamous cell carcinoma of the esophagogastric junction with bulky no.7-metastatic node successfully treatedby chemoradiation followed by surgery]. ( Koide, N; Miyagawa, S; Shinoda, A; Suzuki, A; Takeuchi, D; Yoshizawa, J, 2013) |
| "Ninety-five patients with esophageal cancer were retrospectively analyzed." | 1.39 | Endoscopic ultrasound in staging esophageal cancer after neoadjuvant chemotherapy--results of a multicenter cohort analysis. ( Domagk, D; Domschke, W; Heinzow, HS; Kucharzik, T; Meister, T; Seifert, H; Tsepetonidis, S; Wolters, H, 2013) |
| "We retrospectively analyzed esophageal squamous cell carcinoma (SCC) patients with e-CR after nCRT between 1999 and 2006." | 1.39 | Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy. ( Chang, HK; Chang, WC; Chao, YK; Chiu, CT; Liu, YH; Tseng, CK; Wan, YL; Wen, YW, 2013) |
| "Oral squamous cell carcinoma (OSCC) is a common malignant tumor of the head and neck, and recurrence is an important prognostic factor in patients with OSCC." | 1.39 | The recurrence and survival of oral squamous cell carcinoma: a report of 275 cases. ( Wang, B; Wang, XD; Yue, K; Zhang, S, 2013) |
| "Carbon monoxide was a mediator of HMOX1 effects on proliferation, migration, and miR-378 expression." | 1.39 | Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis. ( Boczkowski, J; Ciesla, M; Collet, G; Dulak, J; Gil, T; Golda, S; Guichard, A; Jozkowicz, A; Kieda, C; Kozakowska, M; Kuzdzal, J; Loboda, A; Muchova, L; Skrzypek, K; Tertil, M; Vitek, L; Was, H; Weglarczyk, K, 2013) |
| "Here, we present a case of recurrent gastric cancer during S-1 adjuvant therapy that showed partial response to CDDP + capecitabine therapy." | 1.39 | [A case of mediastinal lymph node gastric cancer recurrence during S-1 adjuvant therapy successfully treated with cisplatin + capecitabine as second-line chemotherapy]. ( Ebata, T; Fukaya, M; Hirata, A; Igami, T; Itatsu, K; Nagino, M; Sugawara, G; Tsunoda, N; Uehara, K; Usui, H; Yokoyama, Y; Yoshioka, Y, 2013) |
| "About 9% of node positive T0-2 breast cancer will have residual positive node in level III region after neoadjuvant chemotherapy." | 1.39 | Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy. ( Fan, T; Fan, Z; Li, J; Lin, B; Ouyang, T; Wang, T; Xie, Y, 2013) |
| "A 69-year-old man diagnosed with lower rectal cancer was referred to our hospital." | 1.39 | [A case of pathological complete response with neoadjuvant mFOLFOX6 chemotherapy for advanced lower rectal cancer]. ( Fujiwara, Y; Gotoh, K; Ishikawa, O; Kishi, K; Marubashi, S; Motoori, M; Noura, S; Ohigashi, H; Ohue, M; Shingai, T; Sueda, T; Takahashi, H; Tomita, Y; Yano, M, 2013) |
| "Colonoscopy revealed a lower rectal cancer just above the dentate line, and its biopsy showed endocrine cell carcinoma." | 1.39 | [A case of rectal endocrine cell carcinoma treated by laparoscopic assisted intersphincteric resection after neoadjuvant chemotherapy]. ( Arai, S; Kataoka, M; Miyazawa, K; Oeda, Y; Shiobara, M; Tonooka, T; Wakatsuki, K; Yoshioka, S, 2013) |
| "The regimens in both arms A and B were safe regarding adjuvant chemotherapy for early breast cancer." | 1.39 | Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. ( Abe, H; Cho, H; Kawai, Y; Kubota, Y; Kurumi, Y; Mori, T; Tani, T; Umeda, T, 2013) |
| "By this stage of esophageal cancer, surgery, although very invasive, is the standard radical therapy for the patients." | 1.39 | Clinical outcome of endoscopic mucosal resection for esophageal squamous cell cancer invading muscularis mucosa and submucosal layer. ( Kameda, Y; Ohkawa, S; Tamai, S; Yoshii, T, 2013) |
| "Median age at gastric cancer diagnosis was 48." | 1.39 | Chemosensitivity in ovarian metastases from gastric cancer: a case series. ( Berger, A; Brieau, B; Dubreuil, O; Landi, B; Lepère, C; Markoutsaki, T; Rougier, P; Roussel, H; Taieb, J; Trouilloud, I; Vaillant, JN; Zaanan, A, 2013) |
| "In locally advanced rectal cancer (LARC) patients, major response to neoadjuvant radiotherapy (NR) has been associated with favorable long-term outcomes." | 1.39 | What is the incidence of metastatic lymph node involvement after significant pathologic response of primary tumor following neoadjuvant treatment for locally advanced rectal cancer? ( Flejou, JF; Lefèvre, JH; Parc, Y; Svrcek, M; Tiret, E; Tranchart, H, 2013) |
| "To assess the outcome of esophageal cancer according to therapeutic strategy." | 1.39 | [Esophageal cancer: outcome according to therapeutic strategy]. ( Capitain, O; Cellier, P; Denis, F; Girault, S; Hamy, A; Mahé, MA; Mesgouez-Nebout, N; Paumier, A; Poirier, AL; Rousseau, D, 2013) |
| "Peritoneal carcinomatosis (PC), considered to have a dismal prognosis, is exclusively sub-classified into stage IVB, even though other metastases to a sole organ are sub-classified into stage IVA, which is considered to be associated with better survival." | 1.39 | Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy? ( Baba, H; Haga, N; Hatano, S; Ishibashi, K; Ishida, H; Kumagai, Y; Kumamoto, K; Matsuzawa, T; Okada, N, 2013) |
| "Data from 199 stage II-III breast cancer patients who failed to achieve pCR after NCT were used." | 1.38 | A prognostic model to predict outcome of patients failing to achieve pathological complete response after anthracycline-containing neoadjuvant chemotherapy for breast cancer. ( Chen, CM; Chen, S; Shao, ZM; Yang, WT; Yu, KD, 2012) |
| "We obtained total RNA from residual cancer cells using microdissection from a total of 52 rectal cancer specimens from patients who underwent preoperative CRT." | 1.38 | Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy. ( Fujikawa, H; Inoue, Y; Kusunoki, M; Matsushita, K; Okugawa, Y; Saigusa, S; Tanaka, K; Toiyama, Y; Uchida, K, 2012) |
| "Patients with locally unresectable pancreatic cancer (AJCC stage III) have a median survival of 10-14 months." | 1.38 | Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. ( Allen, PJ; Bickenbach, KA; Brennan, MF; D'Angelica, MI; Dematteo, RP; Fong, Y; Gonen, M; Goodman, K; Jarnagin, WR; O'Reilly, E; Tang, LH, 2012) |
| "In pN0 gastric cancers, prognostic factors differed significantly between early stage and advanced stage." | 1.38 | Prognostic significance of intraoperative chemotherapy and extensive lymphadenectomy in patients with node-negative gastric cancer. ( Kang, WM; Ma, ZQ; Wang, J; Yu, JC, 2012) |
| "Pre- and post-treatment staging of anal cancer are often inaccurate." | 1.38 | Role of positron emission tomography-computed tomography in the management of anal cancer. ( Baccega, M; Bellò, M; Cassoni, P; Cravero, F; Filippini, C; Fora, G; Lesca, A; Milanesi, E; Mistrangelo, M; Morino, M; Munoz, FH; Pelosi, E; Racca, P; Ricardi, U; Skanjeti, A, 2012) |
| " Boosted high dosing to metastatic lymph nodes can increase the relapse-free survival rate." | 1.38 | Efficacy analysis of simplified intensity-modulated radiotherapy with high or conventional dose and concurrent chemotherapy for patients with neck and upper thoracic esophageal carcinoma. ( Chen, XF; Han, JH; Li, T; Yu, CH; Zhou, K; Zhu, WG, 2012) |
| "A total of 182 breast carcinoma specimens were included." | 1.38 | Clinicopathological significance of mesothelin expression in invasive breast cancer. ( Li, F; Liu, X; Niu, Z; Wang, L; Wang, X; Wang, Y; Zhang, L, 2012) |
| "Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease." | 1.37 | Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin. ( Peters, GJ; Schneiders, FL; van den Berg, HP; van der Vliet, HJ; Verheul, HM, 2011) |
| "All of the patients had squamous cell carcinoma." | 1.37 | Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. ( Ahn, SD; Choi, EK; Kim, JH; Kim, SB; Lee, SW; Lee, YS; Park, JW; Park, SI; Song, SY; Yoon, SM, 2011) |
| "We studied 26 gastric cancer patients with lymph node metastasis who underwent gastric resection at the Korea University Guro Hospital from Feb 2007 to July 2008." | 1.37 | Metastatic lymph node targeted chemosensitivity test for gastric cancer. ( Jang, YJ; Kim, CS; Kim, JH; Kim, SJ; Mok, YJ; Park, SH; Park, SS, 2011) |
| "Even after curative resection of pancreatic cancer, there is a high probability of systemic recurrence." | 1.37 | Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer. ( Baba, H; Beppu, T; Hirota, M; Ikeda, O; Kanemitsu, K; Oya, N; Takamori, H; Tanaka, H; Yamashita, Y, 2011) |
| "In patients with Stage III-IV (M0) gastric cancer, adjuvant 5-fluorouracil/cisplatin chemotherapy was tolerable, but did not seem to confer survival advantage." | 1.37 | Increasing nodal ratio is a poor prognostic factor for survival in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant chemotherapy: a retrospective study. ( Bang, YJ; Choe, KJ; Heo, DS; Im, SA; Kim, DW; Kim, JS; Kim, MA; Kim, NK; Kim, TM; Kim, TY; Kim, WH; Lee, KU; Lee, SH; Oh, DY; Yang, HK, 2011) |
| "A cohort of 148 patients with esophageal cancer received cisplatin-based CCRT (concurrently combined with 40 Gy irradiation) and subsequent esophagectomy." | 1.37 | Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery. ( Chen, JS; Cheng, JC; Chuang, TH; Hsu, CH; Hsu, HH; Huang, PM; Kuo, SW; Lee, JM; Lee, YC; Lin, CC; Shun, CT; Wang, YH; Wu, MT; Yang, PW; Yang, SY, 2011) |
| "Gastric cancer is the second most common cause of cancer deaths worldwide and due to its poor prognosis, it is important that specific biomarkers are identified to enable its early detection." | 1.37 | Identification of 14-3-3β in human gastric cancer cells and its potency as a diagnostic and prognostic biomarker. ( Chang, KJ; Chen, CN; Chuang, KN; Huang, HC; Juan, HF; Lai, HS; Lee, PH; Lin, CC; Tseng, CW; Yang, JC, 2011) |
| "The finding that some rectal cancers respond to neoadjuvant chemoradiation is broadening new surgical options for the treatment of some of these tumors that, until now, required a total mesorectal excision." | 1.37 | Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: can we trust the findings? ( Arbea, L; Aristu, J; Baixauli, J; Beorlegui, C; Hernandez-Lizoain, JL; Pastor, C; Sola, J; Subtil, JC, 2011) |
| "One hundred and fourteen cases of breast cancer with NA therapy were analyzed and clinical data were collected from March 2007 to December 2010." | 1.37 | [Primary systemic therapy in breast cancer patients (2007-2010)]. ( Farkas, R; Horváth, OP; Kálmán, E; Kovács, G; Kövér, E; Pavlovics, G; Szalai, G; Tizedes, G; Zapf, I, 2011) |
| "FOLFIRI was effective for recurrent rectal cancer with paraaortic LN metastasis." | 1.37 | [A case of recurrent rectal cancer with paraaortic lymph node metastasis treated by FOLFIRI therapy leading to complete response]. ( Nishimura, Y; Sakamoto, H; Tanaka, Y; Yamaguchi, K; Yatsuoka, T, 2011) |
| "We report a resected case of ascending colon cancer with left supraclavicular and paraaortic lymph nodes and liver metastases which completely responded in terms of metastases but not the primary tumor to FOLFOX4 therapy." | 1.36 | [A case of advanced ascending colon cancer, curatively resected after complete response in left supraclavicular and paraaortic lymph nodes and liver metastases to FOLFOX4 therapy]. ( Fuji, H; Furumoto, K; Ito, D; Kogire, M; Kojima, H; Mizuno, R; Mori, T; Okuno, M; Takaya, H, 2010) |
| "Obesity is associated with an increased risk of colon cancer." | 1.36 | Obesity is an independent prognostic variable in colon cancer survivors. ( Foster, NR; O'Connell, MJ; Rankin, C; Sargent, DJ; Sinicrope, FA, 2010) |
| "Patients with deeply invading (T3-T4) oesophageal cancers usually receive chemoradiotherapy with or without surgery." | 1.36 | Pre- and post-therapy nodal status equally affects survival of patients with oesophageal squamous cell carcinoma receiving preoperative chemoradiation. ( Doki, Y; Fujiwara, Y; Miyata, H; Mori, M; Nakajima, K; Takiguchi, S; Yamasaki, M, 2010) |
| "Our diagnosis was penile cancer with bilateral inguinal lymph node metastasis and clinical staging T4N3M0." | 1.36 | A case of local advanced penile cancer treated with multimodality therapy. ( Arima, K; Kato, M; Soga, N; Sugimura, Y, 2010) |
| "In patients with stage IV colorectal cancer, liver metastases exhibit a better histological response than primary tumors to OCFL neoadjuvant chemotherapy." | 1.36 | Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes. ( Andres, A; Gervaz, P; Majno, P; Mentha, G; Morel, P; Roth, A; Rubbia-Brandt, L, 2010) |
| " When chemotherapy with S-1 or UFT/LV started from the micrometastasis stage, not the advanced macroscopic metastasis stage, anti-LNM efficacy of S-1 was significantly higher than that of UFT/LV at the dosage in which antitumor activity of the two drugs against primary subcutaneous tumor was comparable." | 1.36 | Characterization of a novel lymph node metastasis model from human colonic cancer and its preclinical use for comparison of anti-metastatic efficacy between oral S-1 and UFT/ LV. ( Hirai, T; Ito, Y; Kato, T; Kodera, Y; Nakanishi, H; Nakao, A, 2010) |
| "We compared clinical outcome and pharmacokinetic (pK) parameters of a new pharmacokinetically-guided dosing strategy in two groups of patients (age < or >65 years) with metastatic colorectal cancer (mCRC)." | 1.36 | Clinical impact of intesified 5-Fluorouracil-based chemotherapy using a prospective pharmacokinetically-guided dosing approach: comparative study in elderly and non-elderly patients with metastatic colorectal cancer. ( Abderrahim, AG; Bressolle, F; Duffour, J; Pinguet, F; Poujol, S; Roca, L; Ychou, M, 2010) |
| "Patients with gallbladder cancer at T2N0M0, T2N1M0, T3N0M0, and T3N1M0 stages were enrolled in this study." | 1.36 | Adjuvant chemoradiation therapy in gallbladder cancer. ( Cho, SY; Han, SS; Kim, SH; Kim, TH; Kim, YK; Lee, KW; Lee, WJ; Park, SJ; Woo, SM, 2010) |
| "Colorectal cancer is one of the leading malignancies in the world." | 1.36 | Oncolytic adenovirus mediated Survivin RNA interference and 5-fluorouracil synergistically suppress the lymphatic metastasis of colorectal cancer. ( Fu, ZX; Shen, W; Tu, JK; Wang, XH, 2010) |
| "We report here a case of recurrent esophageal cancer successfully treated by cervical lymph node dissection and chemo-radiation therapy." | 1.36 | [A case of recurrent esophageal cancer successfully treated by combined therapies]. ( Andoh, S; Kitamura, Y; Tokunou, K; Toshimitsu, H; Tsushimi, K; Yamamoto, T, 2010) |
| "Sigmoidectomy was performed for sigmoid colon cancer in January 2002." | 1.36 | [A case of recurrent sigmoid colon cancer with adrenal and para-aortic lymph node metastasis successfully treated by operation and chemotherapy]. ( Doki, Y; Hirose, H; Ikeda, M; Kim, HM; Miyoshi, N; Mizushima, T; Mori, M; Okano, M; Sekimoto, M; Takemasa, I; Yamamoto, H; Yamashita, S, 2010) |
| "A 42-year-old man with advanced rectal cancer underwent a low anterior resection with TME and pelvic lateral lymph-node and paraaortic lymph-node dissections." | 1.36 | [A long-term disease-free survival case of advanced rectal cancer with massive metastasis to the lateral pelvic and para-aortic lymph nodes]. ( Gotoh, K; Ishikawa, O; Kano, S; Kishi, K; Miyashiro, I; Motoori, M; Noura, S; Ohigashi, H; Ohue, M; Shingai, T; Takahashi, H; Yamada, T; Yano, M, 2010) |
| "A colonoscopy revealed primary rectal cancer." | 1.36 | [A case of successfully treated lower rectal cancer with both inguinal lymph nodes by chemoradiotherapy]. ( Danno, K; Imaoka, S; Inatome, J; Kagara, N; Kanoh, T; Kim, C; Kimura, Y; Monden, T; Nakamura, H; Nakano, Y; Ohnishi, T; Taniguchi, H; Tono, T; Tsukao, Y; Watanabe, A, 2010) |
| "Recurrent lymph node metastasis was detected in 68 patients with thoracic esophageal carcinoma after curative esophagectomy (R0, International Union Against Cancer criteria)." | 1.35 | Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection. ( Mitsuhashi, N; Nakamura, T; Narumiya, K; Ohki, T; Ota, M; Sato, T; Yamamoto, M, 2008) |
| "Patients with locally advanced breast carcinoma (LABC) receive preoperative chemotherapy to provide early systemic treatment and assess in vivo tumor response." | 1.35 | Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. ( Barlow, WE; Doot, RK; Dunnwald, LK; Ellis, GK; Gralow, JR; Kurland, BF; Lawton, TJ; Linden, HM; Livingston, RB; Mankoff, DA; Schubert, EK; Specht, JM, 2008) |
| "To investigate the effect of Endostatin and SU6668 combined with 5-FU on the growth and metastasis of human colon cancer in vivo and its mechanism." | 1.35 | [Effect of Endostatin and SU6668 combined with 5-FU on human colon cancer xenograft in nude mice]. ( Chu, ZH; Luo, XJ; Zeng, QL; Zhou, K, 2008) |
| "The human colon cancer cell line LoVo was injected subcutaneously into the necks of five mice to generate a solid tumor." | 1.35 | A simple colostomy implantation model for evaluating colon cancer. ( Ding, Y; Jin, H; Li, VK; Liu, F; Liu, X; Ni, M; Song, Y; Yun, S; Zhou, S, 2009) |
| " Pharmacokinetic analysis was performed on plasma samples collected at the first cycle of treatment." | 1.35 | A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. ( Antonuzzo, A; Bocci, G; Bursi, S; Chiara, S; Del Tacca, M; Di Paolo, A; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Pfanner, E; Vasile, E, 2009) |
| "Hepatic metastasis from colorectal cancer (mCRC) is best treated with a multidisciplinary approach." | 1.35 | Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. ( Campbell, ML; Landry, CS; Martin, RC; McMasters, KM; Scoggins, CR; Slomiany, BA; Woodall, CE, 2009) |
| "A 63-year-old man who was diagnosed T1b esophageal cancer, for which transthoracic esophagectomy was indicated, received mediastinoscopy-assisted transhiatal esophagectomy because of the previous right thoracotomy for pulmonary tuberculosis." | 1.35 | [A case of esophageal cancer with recurrent lymph-node metastasis successfully treated with chemo-radiotherapy after mediastinoscopy-assisted transhiatal esophagectomy]. ( Nishimura, T; Oka, M; Takeda, S; Tokunou, K; Yoshino, S, 2008) |
| "Sixty-eight consecutive patients with pancreatic cancer who underwent pancreatic resection were included." | 1.35 | Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer. ( Kitade, H; Kwon, AH; Matsui, Y; Mergental, H; Satoi, S; Takahashi, K; Takai, S; Tanigawa, N; Toyokawa, H; Yanagimoto, H, 2009) |
| "104 patients with advanced gastric cancers were treated with capecitabine-based chemotherapy regimens from Sept." | 1.35 | [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer]. ( Li, J; Li, Y; Lu, M; Shen, L; Xiao, Y; Zhang, J; Zhang, XD, 2009) |
| "From April 1998 to April 2004, 112 breast cancer patients were treated with neoadjuvant chemotherapy." | 1.35 | [Efficacy of neoadjuvant chemotherapy with FEC and TEC regimen on breast cancer]. ( Fu, JF; Hong, ZW; Wang, B, 2009) |
| "SS in cervical cancer is a feasible and safe pretreatment procedure, and when associated with CT, it improves OS and DFS." | 1.35 | Impact of surgical staging in locally advanced cervical cancer and subsequent chemotherapy. ( Clagnan, WS; de Andrade, JM; Dos Reis, FJ; Garieri, AP; Marana, HR; Tiezzi, DG; Zola, FE, 2009) |
| "Thirty-three patients with rectal cancer underwent preoperative CRT." | 1.35 | Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. ( Ioue, Y; Kusunoki, M; Miki, C; Okugawa, Y; Saigusa, S; Tanaka, K; Toiyama, Y; Yokoe, T, 2009) |
| "Prognosis of stage II colorectal cancer varies." | 1.35 | [Prognostic analysis of 443 cases of stage II colorectal cancer and the value of adjuvant chemotherapy]. ( Ding, PR; Li, LR; Lin, JZ; Pan, ZZ; Peng, ZH; Wan, DS; Wu, XJ; Zhou, ZG, 2009) |
| "The presence of ECE in breast cancer is positively related with tumor size and the number of positive lymph nodes." | 1.35 | [Clinical impact of extracapsular extension of axillary lymph node metastases in breast cancer]. ( Cao, WF; Cao, XC; Hao, XS; Ning, LS; Niu, Y; Song, YQ; Zhang, B; Zhao, HM, 2009) |
| "A 63-year-old female diagnosed as rectal cancer underwent low anterior resection and received adjuvant chemotherapy (folinate/tegafur/uracil therapy)." | 1.35 | [A case of surgical approach to the recurrence of the para-aortic lymph nodes after resection of rectal cancer]. ( Endo, W; Fujie, Y; Fukunaga, H; Hojou, S; Kakutani, A; Maeura, Y; Ogino, T; Ota, H; Shimizu, K; Toyoda, Y; Yoshioka, A; Yoshioka, S, 2009) |
| "A 45-year-old male patient with right colonic cancer, of which clinical finding was SIM1 (No." | 1.35 | [A case of advanced right colonic cancer successfully treated by surgery and post operative chemotherapy]. ( Inoue, S; Nasu, K; Noda, K; Umekita, N, 2009) |
| "We report a case of transverse colon cancer with gastric regional lymph node metastasis." | 1.35 | [Extended lymphadenectomy for gastric regional lymph node metastasis from transverse colon cancer--a case report]. ( Hazama, S; Nakatsu, H; Oka, M; Sakamoto, K; Tomochika, S; Yoshino, S, 2009) |
| "Gastrointestinal perforation is a known risk factor of unknown etiology associated with the use of bevacizumab." | 1.35 | [Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery]. ( Abbrederis, K; Kremer, M; Schuhmacher, C, 2008) |
| "Breast cancer is a very heterogeneous disease, and markers for disease subtypes and therapy response remain poorly defined." | 1.35 | Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen. ( Bataille, R; Campion, L; Campone, M; Charbonnel, C; Genève, J; Gouraud, W; Jézéquel, P; Magrangeas, F; Martin, AL; Minvielle, S; Roché, H, 2008) |
| "Early relapse in colorectal cancer (CRC) patients is attributed mainly to the higher malignant entity (such as an unfavorable genotype, deeper tumor invasion, lymph node metastasis and advance cancer stage) and poor response to chemotherapy." | 1.35 | ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study. ( Cheng, TL; Fang, WY; Huang, MY; Lee, SC; Lin, SR; Wang, JY, 2008) |
| "From 1998 to 2006, 370 primary breast cancer patients underwent curative surgical treatment after NAC containing both anthracycline and taxane at the National Cancer Center Hospital." | 1.35 | Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome. ( Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kohno, T; Seki, K; Shibata, T; Shien, T; Shimizu, C, 2009) |
| "We reported a case of sigmoid colon cancer with left supraclavicular lymph node involvement that completely responded to FOLFOX4 therapy following laparoscopy-assisted colectomy (LAC)." | 1.35 | [A case of complete response in supraclavicular lymph node involvement from cancer of the sigmoid colon to FOLFOX4 therapy after laparoscopy-assisted colectomy]. ( Ito, N; Nakamura, SI; Obuchi, T; Sugai, T; Suto, T; Uesugi, N; Wakabayashi, G, 2008) |
| "We diagnosed her tumors as occult breast cancer and its metastasis to lymph nodes (cT0N3cM1, Stage IV)." | 1.35 | [A case of occult breast cancer successfully treated by capecitabine in combination with weekly paclitaxel followed by FEC (75)]. ( Hino, N; Ikushima, Y; Miyake, H; Ogasawara, T; Ohura, R; Sohnaka, Y; Tsuyuguchi, M; Wada, D; Yamamoto, Y; Yamasaki, S, 2008) |
| "Between 1974 and 1988, 31 male breast cancer patients were prospectively enrolled on study MB-82 in the National Cancer Institute." | 1.34 | A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up. ( Anderson, WF; Berman, AW; Lippman, ME; Steinberg, SM; Swain, SM; Vatas, U; Walshe, JM, 2007) |
| "Breast cancer is a heterogeneous disease and it is of importance to select patients with regard to different prognosis and treatment sensitivity to individualize treatment regimes." | 1.34 | Proteomic analysis identifies candidate proteins associated with distant recurrences in breast cancer after adjuvant chemotherapy. ( Fernö, M; Johnsson, A; Malmström, J; Marko-Varga, G; Niméus, E, 2007) |
| "Neoadjuvant treatment modalities for esophageal cancer were developed to improve local tumor control as well as to reduce lymph node metastases and distant metastases in patients with locally advanced esophageal cancer." | 1.34 | Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer. ( Baldus, SE; Bollschweiler, E; Dienes, HP; Hölscher, AH; Izbicki, JR; König, A; Mueller, RP; Prenzel, KL; Schneider, PM; Schnickmann, C; Schröder, W, 2007) |
| " In April 2004, she had a recurrence manifesting itself as bone metastasis, partly because of poor compliance with the hospital-visit and dosing schedules." | 1.34 | [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine]. ( Akahane, T; Chiba, T; Hashimoto, Y; Yano, H, 2007) |
| "50 patients diagnosed as advanced gastric cancer were administered continuous infusion of 5-FU (300 mg/m(2)/day, x 14 days) and intermittent infusion of CDDP (3 mg/m(2)/day, day 1-5 and 8-12) before surgery." | 1.34 | [Pathological evaluation of neoadjuvant chemotherapy with low-dose FP therapy for advanced gastric cancer]. ( Koda, K; Miyazaki, M; Oda, K; Seike, K; Takano, S; Takiguchi, N, 2007) |
| "In cases of esophageal cancer, a different pattern of tumor shrinkage is often observed between primary tumors and metastatic lymph nodes (MLNs)." | 1.34 | Reduction rate of lymph node metastasis as a significant prognostic factor in esophageal cancer patients treated with neoadjuvant chemoradiation therapy. ( Aiko, S; Ishizuka, T; Kumano, I; Maehara, T; Sakano, T; Sugiura, Y; Yoshizumi, Y, 2007) |
| "Thoracic esophageal cancers frequently metastasize to the right recurrent nerve nodes (RRNNs)." | 1.34 | Salvage lymphadenectomy of the right recurrent nerve node with tracheal involvement after definitive chemoradiation therapy for esophageal squamous cell carcinoma: report of two cases. ( Doki, Y; Fujiwara, Y; Makari, Y; Masuoka, T; Matsuyama, J; Miyata, H; Monden, M; Takiguchi, S; Yamasaki, M; Yasuda, T, 2007) |
| "Grade 3/4 neutropenia was seen in 12 patients (60%), and neuropathy was observed in 11 patients (55%)." | 1.34 | Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer. ( Kasai, M; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Shitara, K, 2007) |
| "Basaloid squamous cell carcinoma (BSC) of the esophagus is a rare malignant disease." | 1.34 | Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin. ( Arita, S; Ariyama, H; Baba, E; Kusaba, H; Miki, R; Mitsugi, K; Nakano, S; Noshiro, H; Ogami, N; Qin, B; Shibata, Y; Yao, T, 2007) |
| "We evaluated 81 patients with uterine cervical cancer who underwent three serial MR examinations, i." | 1.34 | The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI. ( Ahn, YC; Bae, DS; Han, Y; Huh, SJ; Kim, BG; Lee, JH; Lee, JW; Lim, DH; Nam, H; Park, HC; Park, W, 2007) |
| "All cases of breast carcinoma diagnosed during the period from 1989 to 2001 were retrospectively reviewed." | 1.34 | [Diagnosis and prognosis study of breast carcinoma with micropapillary component]. ( Chen, L; Fan, Y; Fu, L; Guo, XJ; Lang, RG; Sun, YL, 2007) |
| "The data of 114 breast cancer patients treated with adjuvant dose dense chemotherapy was retrospectively analyzed." | 1.34 | [Dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer]. ( Guan, JH; Huan, HY; Mao, F; Sun, Q; Zhou, YD, 2007) |
| "101 patients with cervical cancer FIGO IB1-IVB underwent chemoradiation after transperitoneal laparoscopic staging." | 1.34 | Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging. ( Bischoff, A; Budach, V; Füller, J; Köhler, C; Marnitz, S; Roth, C; Schneider, A; Wendt, T, 2007) |
| "Patients with esophageal cancer often develop metastatic disease after esophageal resection and generally receive cisplatin-based chemotherapy or chemoradiotherapy." | 1.34 | Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience. ( Fujita, H; Mori, N; Nagano, T; Sasahara, H; Shirouzu, K; Sueyoshi, S; Tanaka, T; Tanaka, Y; Yamana, H, 2007) |
| " 60Co gamma-irradiation or 6MVX-ray with conventional fraction were used for radiotherapy with a total volume dosage of 55-70 Gy." | 1.34 | [Clinical analysis of 108 cases with adenocarcinoma Barretts's esophagus]. ( Han, JQ; Li, XQ; Liang, RX; Liu, Q; Qu, FS; Sun, YH; Yan, TX, 2007) |
| "In Europe and America, breast cancer commonly occurs in women of middle and old age, the median age of patients is about 57 years old." | 1.33 | [Clinical analysis of resectable breast cancer: a report of 6 263 cases]. ( Fu, JH; Huang, ZF; Lin, P; Long, H; Rong, TH; Tang, J; Wang, SY; Wang, X; Yang, MT; Zeng, CG, 2005) |
| "Patients with rectal cancer treated by preoperative chemoradiation showed a surprisingly low rate of micrometastasis detection (7%), even in high-risk patients (T3 and T4 tumors)." | 1.33 | Lymph node micrometastasis in stage II distal rectal cancer following neoadjuvant chemoradiation therapy. ( Coelho Siqueira, SA; Gama-Rodrigues, JJ; Habr-Gama, A; Kiss, DR; Nishida Arazawa, ST; Perez, RO; Rawet, V, 2005) |
| "It seems that the quality of life for breast cancer patients was affected by the extent of the alopecia." | 1.33 | [A case of advanced breast cancer markedly responding to chemo-endocrine therapy with only slight alopecia]. ( Iwakuma, N; Nagamatsu, H; Ono, H; Shirouzu, K; Terazaki, Y, 2005) |
| "Based on laboratory data, we diagnosed acute renal failure caused by MTX and added the infusion of Ringer and LV." | 1.33 | [A case of head and neck squamous cell carcinoma suffering from acute renal failure after methotrexate administrator]. ( Matsuda, H; Mikami, Y; Nagao, J; Sakuma, N; Tsukuda, M; Yoshida, T, 2005) |
| " These data suggest that 5-FU/l-LV can be given in the outpatient and yields improved prognosis and minimal adverse reactions even in patients in reduced dose or prolonged interval." | 1.33 | [Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer]. ( Chiba, N; Ishioka, C; Kakudo, Y; Kato, S; Ohori, H; Otsuka, K; Sakayori, M; Shibata, H; Takahashi, M; Takahashi, S; Yamaura, G; Yasuda, K; Yoshioka, T, 2005) |
| "Twenty-two patients with localized esophageal cancer suitable for curative chemoradiation therapy and 24 patients suitable for palliative therapy were enrolled." | 1.33 | Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin. ( Burmeister, BH; Burmeister, EA; Gotley, DC; Harvey, JA; Mark Smithers, B; Thomas, J; Thomson, DB; Walpole, ET, 2005) |
| "The lymph node status of 73 resectable gastric cancer patients was analyzed preoperatively by computed tomography (CT), ultrasonography and magnetic resonance, and the OPRT activity of collected tumor tissue was measured." | 1.33 | Impact of orotate phosphoribosyl transferase activity as a predictor of lymph node metastasis in gastric cancer. ( Futagawa, S; Kitajima, M; Nishimura, K; Noguchi, H; Ochiai, T; Okada, T; Ouchi, M; Sugitani, M; Takahashi, Y; Tsuruoka, Y; Yamada, M, 2005) |
| "However, standard treatment for Dukes C colorectal cancer patients currently involves the administration of 5-fluorouracil (5-FU)-based adjuvant chemotherapy after surgery." | 1.33 | SMAD4 levels and response to 5-fluorouracil in colorectal cancer. ( Aaltonen, LA; Alazzouzi, H; Alhopuro, P; Arango, D; Dávalos, V; Hemminki, A; Järvinen, H; Mecklin, JP; Salovaara, R; Sammalkorpi, H; Schwartz, S, 2005) |
| "Endpoints were recurrence and distant metastasis rates, overall survival (OS) and disease-free survival (DFS) at 5 and 10 years." | 1.33 | Long-term survival after concomitant chemoradiotherapy prior to surgery in advanced cervical carcinoma. ( Buttarelli, M; Goncalves, A; Gonzague-Casabianca, L; Houvenaeghel, G; Lelievre, L; Moutardier, V; Resbeut, M, 2006) |
| "In 140 patients with primary squamous cell carcinoma (SCC) of the tongue, intratumoural TS expression was evaluated by immunohistochemistry." | 1.33 | Intratumoural expression of thymidylate synthase is an independent predictor of prognosis in patients with squamous cell carcinoma of the tongue: results from a retrospective study. ( Fukuda, J; Goto, H; Goto, M; Ikemura, K; Inokuchi, T; Kawano, K; Kusukawa, J; Mimura, T; Oishi, M; Shiba, R; Shinohara, M; Sugihara, K; Sunagawa, H; Takahashi, T; Yanagisawa, S, 2006) |
| "This is the first study investigating neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with chemotherapy in patients with breast cancer." | 1.33 | Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer. ( Baltas, D; Filipowicz, I; Hoffmann, G; Kolotas, C; Kontova, M; Kuner, RP; Kurek, R; Martin, T; Pollow, B; Roddiger, SJ; Rogge, B; Zamboglou, N, 2006) |
| " In patients with Grade 3 or more, leukocytopenia was observed in 7 patients and diarrhea in 1 as adverse events." | 1.33 | [Clinical examination of safety and effectiveness of primary chemotherapy with CEF followed by docetaxel in preoperative breast cancer]. ( Dohden, K; Hattori, M; Hayashi, H; Hosokawa, O; Kaizaki, Y; Kiya, T; Morishita, M; Morita, M; Ohta, K, 2006) |
| "(1) The standard treatment for colon cancer is surgical excision, but without additional treatment nearly 50% of surgically treated patients die from relapse and metastatic disease progression." | 1.33 | Adjuvant chemotherapy of colon cancer: lymph node involvement without metastases. ( , 2006) |
| "Twenty-five chemonaive patients with AGC have been treated with FOLFIRI regimen consisting of irinotecan 180 mg/m(2) over 30 min on day 1 combined with leucovorin 200 mg/m(2) over 2 h followed by 5-fluorouracil 400 mg/m(2) as bolus and 600 mg/m(2) as a 22-hour infusion on day 1 and 2." | 1.33 | Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy. ( Alacacioglu, A; Oztop, I; Somali, I; Tarhan, O; Yaren, A; Yilmaz, U, 2006) |
| "Forty patients with rectal cancer pretherapeutic UICC stage II/III, receiving preoperative FU-based CT/RT (CAO/ARO/AIO-94 trial) followed by standardized surgery, including total mesorectal excision, were investigated." | 1.33 | Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. ( Aust, DE; Baretton, GB; Becker, H; Ghadimi, BM; Häusler, P; Jakob, C; Kulle, B; Langer, C; Liersch, T; Schwabe, W, 2006) |
| " We designed a new regimen to evaluate the efficacy and feasibility of weekly low dose CPT-11 combined with 5-FU/l-LV therapy based on an RPMI regimen against advanced and recurrent colorectal cancer." | 1.33 | [Evaluation of weekly low-dose CPT-11 combined with 5-FU/l-LV therapy for advanced and recurrent colorectal cancer--preliminary study]. ( Deguchi, Y; Kaneko, I; Kii, E; Murata, T; Sonoda, K; Tsubono, M; Yasuda, K, 2006) |
| "Breast cancer is a heterogeneous disease, so therapeutic predictive biological markers need to be identified." | 1.33 | Difference in Ki67 and thymidylate synthase expression in primary tumour compared with metastatic nodes in breast cancer patients. ( Aragona, F; Barresi, E; Cabibi, D; Calascibetta, A; Martorana, A; Rausa, L; Sanguedolce, R, 2006) |
| "The majority of deaths due to breast cancer occur in the context of complications secondary to metastatic disease." | 1.33 | A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy. ( Carrato Mena, A; Guillén Ponce, C; Maciá Escalante, S; Martínez Banaclocha, N; Pons Sanz, V; Rodríguez Lescure, A, 2006) |
| "Type IV advanced gastric cancer was diagnosed on upper gastrointestinal endoscopy." | 1.33 | [A case of long-term survival of 3-years 4 months after combination chemotherapy of MTX, 5-FU and low-dose CDDP (MFP) for type 4 gastric cancer with pleuritis, peritoneal dissemination and Krukenberg tumor]. ( Higuchi, K; Kobayashi, N; Koizumi, W; Mitomi, H; Nakatani, K; Nakayama, N; Nishimura, K; Saigenji, K; Sasaki, T; Shimoda, T; Tanabe, S, 2006) |
| "She was first diagnosed as intrahepatic cholangiocarcinoma with hepatic, paraaortic lymphnodal and bone metastasis." | 1.33 | [A case of intrahepatic cholangiocarcinoma effectively treated by hepatic arterial infusion chemotherapy]. ( Hibi, T; Higuchi, H; Hisamatsu, T; Iizuka, H; Iwasaki, E; Izumiya, M; Masaoka, T; Nagata, H; Nishizawa, T; Suzuki, H; Takaishi, H; Yamagishi, Y, 2006) |
| "Simultaneous presentation of breast cancer and malignant phyllodes tumour is rare." | 1.33 | Infiltrating ductal carcinoma and synchronous malignant phyllodes tumour. Diagnostic and therapeutic approaches. ( Calpena, R; Cansado Martínez, P; Lacueva Gómez, FJ; Martínez Banaclocha, N; Merck, B; Pérez Ramos, M, 2006) |
| "Clinical presentation and outcome of breast cancer in our young patients aged under 35 years seems not to be different from that in older patients." | 1.33 | [Breast cancer in young women in the south of Tunisia]. ( Boudawara, T; Daoud, J; Frikha, M; Kallel, F; Khanfir, A; Meziou, M; Mnif, J; Trabelsi, K, 2006) |
| "A remission of lymph node metastasis was accurately shown by rES in 17/19 cases (90%) and by CT in 10/12 cases (83%)." | 1.32 | [Preoperative diagnostic procedures in locally advanced rectal carcinoma (> or =T3 or N+). What does endoluminal ultrasound achieve at staging and restaging (after neoadjuvant radiochemotherapy) in contrast to computed tomography?]. ( Becker, H; Füzesi, L; Ghadimi, BM; Jakob, C; Langer, C; Liersch, T; Markus, PM; Müller, D; Siemer, A, 2003) |
| "Nine (18%) have died of anal cancer." | 1.32 | Concurrent chemoradiotherapy for squamous cell carcinoma of the anus using a shrinking field radiotherapy technique without a boost. ( Melcher, AA; Sebag-Montefiore, D, 2003) |
| " One course of nedaplatin, 5-FU and LV combined with radiation was performed alternatively." | 1.32 | [Effect of nedaplatin, 5-FU, and leucovorin combined with radiation therapy in unresectable esophageal carcinoma]. ( Futami, R; Makino, H; Maruyama, H; Miyashita, M; Miyashita, T; Nomura, T; Sasajima, K; Tajiri, T; Tateno, A, 2003) |
| " Furthermore, he was administered tegafur/uracil (400 mg/day) 5 days weekly as pharmacokinetic modulating chemotherapy (PMC)." | 1.32 | [A case of advanced gastric cancer with liver and intra-abdominal lymph node metastasis treated by hypertensive selective chemotherapy with pharmacokinetic modulating chemotherapy]. ( Baba, Y; Hayashi, S; Ishikawa, T; Kamimura, T; Nomura, K; Oota, H; Yoshida, T, 2003) |
| "Case 1 A 40-year-old female with gastric cancer located in the MULE area underwent total gastrectomy with D3 lymph node dissection on June 2, 1989." | 1.32 | [Two patients with metastatic ovarian tumor (Krukenberg's tumor) of gastric origin who underwent oophorectomy with paraaortic and intrapelvic lymph node dissection]. ( Arai, K; Horiguchi, S; Iwasaki, Y; Katayanagi, S; Matsumoto, H; Miyamoto, H; Nishioka, K; Takahashi, K; Yamaguchi, T, 2003) |
| "Ten patients with recurrent esophageal cancer were treated with the combination of docetaxel 60 mg/m2 (day 1), CDDP 10 mg/body (days 1-5) and 5-FU 500 mg/body (days 1-5) at intervals of 2-3 weeks." | 1.32 | [Preliminary evaluation of chemotherapy with docetaxel, 5-FU, CDDP for recurrent esophageal cancer--a pilot study]. ( Fujita, H; Matono, S; Sasahara, H; Shirouzu, K; Sueyoshi, S; Tanaka, T; Yamana, H, 2003) |
| "We report a case of advanced gastric cancer that responded to docetaxel with low-dose 5-FU and cisplatin combination chemotherapy after becoming chemoresistant to M-FLP." | 1.32 | [A case of advanced gastric cancer that responded to docetaxel with low-dose 5-FU and cisplatin combination chemotherapy after becoming chemoresistant to M-FLP]. ( Akiyama, N; Arai, F; Funakoshi, K; Inayoshi, J; Kato, T; Motoyama, H; Tasaki, A, 2003) |
| " Pharmacokinetic modulating chemotherapy (PMC), a combination of infused 5-fluorouracil and oral uracil-tegafur, has been proven to be highly effective for the treatment of colorectal carcinoma." | 1.32 | Modified pharmacokinetic modulating chemotherapy using 5-fluorouracil, UFT, and taxotere (docetaxel) for advanced gastric cancer. ( Kobayashi, M; Konishi, N; Kusunoki, M; Mohri, Y; Ohmori, Y; Tanaka, K; Tonouchi, H, 2003) |
| "Bioluminescent PC-3M-luc-C6 human prostate cancer cells were implanted subcutaneously into SCID-beige mice and were monitored for tumor growth and response to 5-FU and mitomycin C treatments." | 1.32 | Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. ( Contag, PR; Dusich, J; Hornig, YS; Jenkins, DE; Oei, Y; Purchio, T; Yu, SF, 2003) |
| " After the operation, weekly bolus of 5-fluorouracil combined with levofolinate was carried out." | 1.32 | [A case of rectal cancer with distant lymph node metastases completely responding to postoperative chemotherapy with levofolinate combined with 5-fluorouracil]. ( Inoue, M; Jingu, K; Nakajima, Y; Ochiai, T, 2004) |
| "In the majority of patients with rectal cancer invading perirectal tissues or lymph nodes, lesions downstages by preoperative chemo radiotherapy." | 1.32 | [Preoperative radiation with chemotherapy for rectal cancer: its impact on downstaging of disease and the role of endorectal ultrasound]. ( Juska, P; Pavalkis, D; Pranys, D, 2004) |
| "A total of 145 rectal cancer patients were treated with surgery and postoperative radiochemotherapy." | 1.32 | Extracapsular spread of nodal metastasis as a prognostic factor in rectal cancer. ( Berger, J; Heide, J; Krüll, A, 2004) |
| "Under a diagnosis of advanced ileocecal colon cancer with metastases to Virchow's and the paraaortic lymph nodes, ileocecal resection was performed." | 1.32 | [A case of advanced colon cancer with metastases to both the Virchow's and the paraaortic lymph nodes that achieved complete long-term response with levofolinate.5-FU therapy]. ( Kathou, T; Maruyama, H; Mio, H; Sekiya, M; Yamada, T, 2004) |
| "Patients with locally advanced squamous carcinoma of the head and neck who also presented with nodal disease and underwent hyperfractionated radiotherapy and concurrent cisplatin/5-fluorouracil chemotherapy constituted the study population." | 1.32 | Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. ( Brizel, DM; Clough, RL; Downey, MA; Fisher, SR; Hunter, S; Prosnitz, RG; Scher, RL, 2004) |
| "In poor prognosis breast carcinomas (PPBCs) treated by intensive preoperative CT, we compared the predictive value of S phase fraction (SPF), mitotic index (MI) and Ki67." | 1.32 | Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. ( Al Ghuzlan, A; Beuzeboc, P; Campana, F; Fréneaux, P; Jouve, M; Klijanienko, J; Nos, C; Rosty, C; Rousseau, A; Sastre-Garau, X; Sigal-Zafrani, B; Vincent-Salomon, A, 2004) |
| " This could account for both the toxic effects and the response." | 1.32 | Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer?--a prospective clinical study. ( Bansal, A; Lyall, A; Saxena, S; Singh, JP; Singhal, V, 2004) |
| "The treated breast carcinoma cells were tubulin-positive but the proliferating histiocytes were tubulin-negative." | 1.32 | Pseudoneoplastic proliferation of histiocytes with paclitaxel-induced ultrastructural changes in a mastectomy specimen. ( Garg, K; Lemos, LB; Papasozomenos, S; Qu, Z, 2004) |
| "The prognosis of gastric cancer with liver metastasis is very poor." | 1.32 | [Gastric cancer with liver metastasis effectively treated by intra-hepatic arterial infusion]. ( Aoyagi, K; Imaizumi, T; Koufuji, K; Miyagi, M; Shirouzu, K; Takeda, J; Yano, S, 2004) |
| "Advanced pancreatic cancer is mainly treated by chemotherapy with poor prognosis." | 1.32 | [Efficacy of selective continuous transarterial infusion chemotherapy on advanced pancreatic cancer]. ( Chen, YT; Hong, GB; Jiang, RJ; Luo, JH; Xu, LF; Xu, LY; Zhou, JX, 2004) |
| "Twenty-four patients with advanced gastric cancer who had been treated by multiple chemotherapy regimens presenting poor responses were allotted." | 1.32 | [Oxaliplatin plus capecitabine as a second line chemotherapy for patients with advanced gastric cancer]. ( Chen, YX; He, ZM; Mei, JF; Qian, J; Qin, SK; Shao, ZJ, 2004) |
| "We report a patient with esophageal cancer with concomitant liver metastasis in whom complete response was achieved by chemoradiation therapy." | 1.31 | Complete regression of esophageal cancer with concomitant liver metastasis achieved by concurrent chemoradiation therapy. ( Hiramoto, J; Murakami, S; Nagayama, K; Nakada, T; Sakabe, S; Tsuruta, Y, 2002) |
| "The follow up didn't show a relapse of breast carcinoma after 5 years." | 1.31 | [Breast carcinoma in accessory gland: a case report]. ( Arcuri, MF; Corcione, L; Del Rio, P; Sivelli, R, 2002) |
| "Advanced esophageal cancer patients with extensive lymph node metastases show extremely poor prognosis and the long-term outcome is poorer with the involvement of more lymph nodes." | 1.31 | A case of advanced esophageal cancer with extensive lymph node metastases successfully treated with multimodal therapy. ( Gunduz, M; Haisa, M; Naomoto, Y; Shigemitsu, K; Shirakawa, Y; Tanaka, N, 2002) |
| "Diarrhea was the major adverse effect of UFT/LV that made patients reduce dosage." | 1.31 | Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer. ( Chen, JS; Hsu, KC; Tang, R; Wang, JY; Yang, TS, 2002) |
| "Six patients with gastric cancer, stage IIIA to IV, received intraabdominal cisplatin (CDDP) at laporotomy." | 1.31 | [Postoperative adjuvant immunochemotherapy using Lentinan for advanced gastric carcinoma patients with metastasis in the regional lymph nodes and serosal invasion]. ( Kagawa, R; Nakayama, N; Sakata, S; Tada, M; Yamaguchi, T, 2002) |
| "We report a case of primary liver carcinoid." | 1.31 | [A case report of primary hepatic carcinoid with lymph node metastasis--treatment of hepatic arterial infusion to post-reoperative liver and radiation to metastasis of para-aortic lymph nodes]. ( Hasuike, Y; Takeda, Y; Tujinaka, T; Ueda, S; Yoshida, K, 2002) |
| "Ovarian metastasis is frequent." | 1.31 | Adenocarcinoid of the appendix vermiformis: complete and persistent remission after chemotherapy (folfox) of a metastatic case. ( Blanchot, J; Boucher, E; Corbinais, S; Garin, L; Le Guilcher, P; Raoul, JL, 2002) |
| "The long term outcome of women with breast carcinoma and isolated SCN metastases whose disease is sensitive to CT appears to be favorable; whether this result is superior to that achieved with standard therapy alone remains to be confirmed in prospective, randomized trials." | 1.31 | High dose chemotherapy and autologous blood stem cell support in women with breast carcinoma and isolated supraclavicular lymph node metastases. ( Abraham, R; Crump, M; Goss, PE; Nagy, T, 2000) |
| " Radiotherapy was administered twice per day on dosing days 1 through 42 to a total dose of 7200 cGy to the primary tumor and 6000 cGy to the involved lymph nodes." | 1.31 | Nodal volume reduction after concurrent chemo- and radiotherapy: correlation between initial CT and histopathologic findings. ( Labadie, RF; Mukherji, SK; Pillsbury, HC; Weissler, MC; Yarbrough, WG, 2000) |
| "We report a case of far advanced breast cancer showing an excellent response to chemo-endocrine therapy." | 1.31 | [A case of far advanced breast cancer with distant metastases which had mostly disappeared after chemoendocrine therapy]. ( Hayashi, K; Kasuga, Y; Kondo, R; Munakata, Y; Nishimura, H; Takasuna, K, 2000) |
| "Twenty-three premenopausal breast cancer patients received 6 cycles of adjuvant CMF intravenously on days 1 and 8 every 3 weeks and granulocyte colony-stimulating factor days 9-18." | 1.31 | Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer. ( Bos, AM; de Graaf, H; de Vries, EG; Piersma, H; Willemse, PH, 2000) |
| "225 patients with squamous cell carcinoma of the oesophagus were prospectively studied." | 1.31 | Epithelial cells in bone marrow of oesophageal cancer patients: a significant prognostic factor in multivariate analysis. ( Busch, R; Roder, RJ; Rosenberg, R; Thorban, S, 2000) |
| "Six nonoperated esophageal cancer patients were treated by daily concurrent CRT, which consisted of continuous 5-fluorouracil administration with leucovorin, combined with a low dose of daily cisplatin administration before each fraction of radiation." | 1.31 | Feasibility of daily concurrent chemoradiation therapy as nonsurgical management for esophageal cancer: our experience and theoretical background. ( Aoki, F; Kaminishi, M; Murakami, T; Shimoyama, S; Toyoda, K, 2000) |
| "Lymph node metastasis was not present." | 1.31 | [Lymph node and peritoneum metastases of bile duct cancer responding to chronochemotherapy--a case report]. ( Iesato, H; Morishita, Y; Nakagami, K; Ohwada, S; Ohya, T; Sasaki, T; Sugitani, K; Takahashi, T; Yokomori, T, 2000) |
| "In the patients with squamous cell carcinoma, 100 mg/m2 of cisplatin was infused intravenously, followed immediately by five consecutive daily administrations of 5-fluorouracil, 1,000 mg/m2/day, each infused intravenously over 24 hr." | 1.31 | Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors. ( Kim, GE; Kim, SN; Kim, SW; Park, TK; Suh, CO, 2000) |
| "Under a diagnosis of locally advanced breast cancer (T4bN2M1, stage IV) with liver metastases, we attempted sequential neoadjuvant chemotherapy." | 1.31 | [A case of effective chemotherapy using CAF followed by docetaxel for advanced breast cancer]. ( Fukuda, H; Fukuda, K; Kim, YH; Kitano, H; Kokufu, I; Taniguchi, H; Yamada, K; Yamamoto, M; Yano, T, 2000) |
| "In stage 3 gastric cancer, the overall survival rates following surgery was significantly (p < 0." | 1.31 | Postsurgical sequential methotrexate, fluorouracil, and leucovorin for stages 3 and 4 gastric carcinoma: A preliminary study. ( Kitaoka, A; Ohsumi, K; Tokuka, A; Tokunaga, Y; Yagi, T, 2000) |
| "5-Fluorouracil and cisplatin were administered intraperitoneally on postoperative days 1-4, and this was repeated at 4-week intervals." | 1.31 | Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer. ( Chung, HC; Min, JS; Noh, SH; Roh, JK; Shin, DW; Yoo, CH, 2001) |
| "As an outpatient without recurrence he has received oral administration of uracil plus tegafur." | 1.31 | [A patient with obstructive jaundice due to recurrence after gastric cancer surgery responding remarkably to FLP combination therapy]. ( Kawahara, M; Nashimoto, A; Yabusaki, H, 2001) |
| "In node-positive colon cancer, we assessed the S-phase fraction (SPF) index, the vascular endothelial growth factor (VEGF) expression and the TS levels." | 1.31 | Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. ( Baldelli, AM; Cascinu, S; Catalano, G; Catalano, V; Giordani, P; Graziano, F; Grianti, C; Muretto, P; Rossi, C; Staccioli, MP; Valentini, M, 2001) |
| "The diagnosis was advanced gall bladder cancer of Stage IVa (S2, N3, P0, H0, Hinf1, Dinf1)." | 1.31 | [A case of inoperable advanced gall bladder cancer responding to intra-arterial infusion of 5-fluorouracil (5-FU) and leucovorin (LV)]. ( Kim, R; Miyahara, E; Ohta, K; Sawamura, A; Toge, T, 2001) |
| "Human colon cancer cells (KM12SM) were injected into the cecal wall of the nude rats." | 1.31 | [Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats]. ( Akagi, Y; Kobayashi, H; Matono, K; Miyagi, Y; Nakagawa, M; Nozoe, Y; Ogata, Y; Sasatomi, T; Shirouzu, K, 2001) |
| "Leser-Trélat-syndrome is characterized as the eruptive appearance of multiple seborrheic keratoses in association with underlying malignant disease." | 1.31 | [Clinical and histopathological characteristics of early Leser-Trélat syndrome]. ( Barth, G; Basten, O; Rompel, R; Rüschoff, J, 2001) |
| "We reported a case of hepatocellular carcinoma (HCC) with multiple lymph node metastases." | 1.31 | [Lymph node excision with laparotomy and chemo-radiation therapy for a hepatocellular carcinoma patient with multiple lymph node metastases]. ( Beppu, T; Fujiyama, S; Hirota, M; Ishiko, T; Ishiodori, H; Matsuda, T; Ogawa, M; Omuraya, M; Yamashita, Y, 2001) |
| "Skin biopsy confirmed the diagnosis of extramammary Paget's disease, and a CT scan revealed multiple metastases to the lymph nodes along the iliac artery and aorta." | 1.31 | Docetaxel induced durable response in advanced extramammary Paget's disease: a case report. ( Kaneko, M; Oguchi, S; Saida, T; Uhara, H, 2002) |
| "We experienced a case of recurrent gastric cancer with a long-term survival." | 1.31 | [Dormant chemotherapy by low-dose FP and low-dose UFT-E in recurrent gastric cancer with long-term survival--a case report]. ( Koyama, S; Shimoda, S; Takeda, N; Tanaka, N; Tsukahara, A; Yajima, K, 2002) |
| "A total of 119 women with breast cancer undergoing surgery between 1985 and 1996 were included in this study." | 1.31 | Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer. ( Horiguchi, J; Iijima, K; Iino, Y; Koibuchi, Y; Morishita, Y; Ninomiya, J; Ochiai, R; Takei, H; Uchida, K; Yokoe, T; Yoshida, M, 2002) |
| "A clinically important myelosuppression due to adjuvant chemotherapy is seen more frequently as dosage is intensified and new drugs are used." | 1.31 | [Chemotherapy-associated myelosuppression in gynecological oncology]. ( Bergauer, F; Dimpfl, T; Janni, W; Kaestner, R; Linka, F; Rack, B; Rjosk, D; Schindlbeck, C; Sommer, H; Strobl, B, 2001) |
| " The dosage of cisplatin was 20 mg/m2/d on every day and 5-FU was given as a 120-h infusion with 600 mg/m2/d." | 1.31 | [Adjuvant simultaneous radiochemotherapy after operated uterine cervix carcinoma in high risk situation. Results of a pilot study]. ( Dunst, J; Hänsgen, G; Kuhnt, T; Pigorsch, S; Strauss, H, 2002) |
| "We report three patients with recurrent gastric cancer responding to TS-1 therapy after combination chemotherapy with 5-fluorouracil, mitomycin C and cisplatin." | 1.31 | [Three cases of recurrent gastric cancer responding to TS-1 therapy following combination therapy with 5-fluorouracil, mitomycin C and cisplatin]. ( Hayashi, K; Iijima, S; Koyama, Y; Miyazawa, K; Morikawa, A; Murakami, M; Okabe, R; Ozaki, K; Sugiyama, A; Suzuki, A, 2002) |
| " Patients in the P+M group who received a 5-fluorouracil (5-FU) dosage of more than 3500 mg had a better 5-year local control rate than patients who received a 5-FU dosage of less than 3500 mg (p = 0." | 1.31 | Trimodal combination therapy for maxillary sinus carcinoma. ( Amagasa, T; Enomoto, S; Kishimoto, S; Miura, M; Ogura, I; Shibuya, H; Yoshimura, R, 2002) |
| "Advanced gastric cancer was found in 12 cases (operation performed in 9 cases and 7 cases resectable) and recurrent in 5 cases." | 1.30 | [Clinical analysis of adjuvant chemotherapy using 5-fluorouracil, leucovorin and cis-diamminedichloroplatinum for patients with advanced and recurrent gastric cancer]. ( Katsumata, K; Kohno, M; Koyanagi, Y; Moriwaki, R; Ohno, M; Shibata, K; Tadatomo, H; Yamamoto, K; Yamashita, S, 1997) |
| "152 of 211 breast cancer patients received post-operatively a combination chemotherapy including the anthracycline analog mitoxantrone, while 59 patients were treated with conventional CMF therapy." | 1.30 | Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. ( Fehm, T; Jäger, W; Katalinic, A; Maimonis, P; Teramoto, Y; Weitz, S, 1997) |
| "Ten patients with advanced esophageal cancer were enrolled for this regimen consisting of 5-FU; 500 mg/day x 5/w x 4, CDDP; 10 mg/day x 5/w x 4 and radiation; 2 Gy x 5/w x 4." | 1.30 | [Preoperative synchronized chemoradiation therapy for advanced esophageal cancer]. ( Iihara, K; Kimura, M; Kitada, M; Murotani, M; Niinobu, T; Nose, T; Ogawa, M; Shibata, T; Takada, T; Takami, M; Tsujinaka, T; Tsukahara, Y; Tsukamoto, F, 1997) |
| "Though treatment of recurrent gastric cancer with liver metastasis is often ineffective, this case suggests that a combination therapy of cisplatin and carmofur might be effective." | 1.30 | [A case of recurrent gastric cancer with liver metastasis responding to combination chemotherapy with cisplatin and carmofur]. ( Inomata, Y; Inoue, K; Kuroda, T; Mizutani, H; Sakuyama, T; Tadaoka, N; Takahashi, N; Yamada, T; Yoshinaga, K, 1997) |
| "Endoscopic study revealed an advanced gastric cancer in the upper body of her stomach." | 1.30 | [A case of advanced gastric cancer with carcinomatosa peritonitis effectively treated by 5-FU and low-dose CDDP therapy]. ( Kunii, Y; Saito, E; Sakakibara, N; Tsuchiya, S; Wada, G; Yamasaki, T, 1997) |
| "Most of them (n = 40) were squamous cell carcinomas." | 1.30 | [Therapy pf cervical lymph node metastases of unknown primary tumor]. ( Fietkau, R; Iro, H; Kirschner, MJ; Sauer, R; Waldfahrer, F, 1997) |
| "We retrospectively examined the acute toxicity of (neo-)adjuvant combined treatment for rectal cancer in an attempt to evaluate potential factors that influence the severity of toxic side effects." | 1.30 | [The acute toxicity of the simultaneous radiochemotherapy of rectal carcinoma]. ( Fietkau, R; Grabenbauer, GG; Keilholz, L; Kessler, H; Martus, P; Rödel, C; Sauer, R, 1997) |
| "Merkel cell carcinoma is a rare and highly aggressive skin tumor." | 1.30 | The role of radiation therapy and chemotherapy in the treatment of Merkel cell carcinoma. ( Brenner, B; Fenig, E; Hana, MB; Katz, A; Rakovsky, E; Sulkes, A, 1997) |
| "Three rectal cancer patients were treated with arterial infusion chemotherapy through the internal iliac artery." | 1.30 | [Arterial infusion chemotherapy in pelvic space for advanced rectal cancer]. ( Aoyama, H; Fukunaga, T; Imazeki, H; Isono, K; Iwasaki, K; Maeda, T; Matsuzaki, H; Miyazaki, S; Nakajima, K; Okazumi, S; Shinotou, K; Shutou, K; Takayama, W; Takeda, A, 1997) |
| "We diagnosed the patient as recurrent breast cancer metastatic to liver, 14 years postoperatively." | 1.30 | [Liver metastases from breast cancer 14 years after radical mastectomy; successful treatment with hepatic arterial infusion chemotherapy and systemic endocrine therapy--a case report]. ( Arai, K; Imai, R; Ito, K; Kojima, K; Muro, H; Nakagami, K; Nakajima, N; Nishimura, K; Onogawa, S; Suzuki, M; Tohyama, K; Umeda, Y, 1997) |
| "A 57-year-old man suffering from gastric cancer with esophageal invasion and liver and paraaortic lymph nodes metastases was treated with continuous 5-FU injection and intra-hepatic arterial infusion of low-dose cisplatin following non-curative surgery." | 1.30 | [A case of far-advanced gastric cancer treated with continuous 5-fluorouracil injection and intrahepatic arterial infusion of low-dose cisplatin]. ( Oka, M; Ueno, T, 1997) |
| "The histopathological diagnosis was squamous cell carcinoma of the ureter, G1 INF beta, pT2, pR0, pV1 and pL0." | 1.30 | [A case of advanced primary ureteral squamous cell carcinoma responding to combination chemotherapy with cisplatin and 5-fluorouracil]. ( Fujita, T; Mori, H; Nakamura, Y; Noguchi, M; Okada, K, 1997) |
| "Although gallbladder cancer (GBC) is believed to be chemoresistant, the effectiveness of chemotherapy against lymph node metastasis has been reported." | 1.30 | Lymph node recurrence of gallbladder carcinoma successfully managed by systemic chemotherapy with 5-fluorouracil and mitomycin C: report of a 5-year survivor. ( Hatakeyama, K; Ohtani, T; Shirai, Y; Tsukada, K, 1997) |
| " Furthermore, the effectiveness of this therapy is greatly anticipated for the unresectable abdominal cancer, evaluating the selection of anti-cancer drugs and their administration dosage etc." | 1.30 | [Aortic stop flow and hypoxic perfusion chemotherapy for unresectable gallbladder cancer]. ( Aoki, T; Asami, K; Inoue, K; Kasuya, K; Koyanagi, Y; Masuhara, S; Ozawa, T; Tsuchida, A; Uda, O, 1998) |
| "Treatment of bladder cancer by TURB and RT/RCT is an alternative to primary cystectomy." | 1.30 | Radiotherapy alone or radiochemotherapy with platin derivatives following transurethral resection of the bladder. Organ preservation and survival after treatment of bladder cancer. ( Birkenhake, S; Kühn, R; Martus, P; Sauer, R; Schrott, KM, 1998) |
| "The most common histologic type is squamous cell carcinoma (82%)." | 1.30 | Squamous cell carcinoma of the vulva in the south of Israel: a study of 50 cases. ( Cohen, Y; Friger, M; Glezerman, M; Piura, B; Rabinovich, A, 1998) |
| "An advanced gastric cancer patient with T3N1M0 successfully underwent a curatively total gastrectomy combined with distal pancreatectomy and lymphnode dissection following ELF-P combined chemotherapy." | 1.30 | [Advanced gastric cancer curatively resected following combined neoadjuvant chemotherapy--report of a case]. ( Kamiyama, H; Kawashima, K; Koike, N; Morishita, Y; Ogawa, T; Ohwada, S; Sato, Y; Takeyoshi, I, 1998) |
| "Fifteen patients with squamous cell carcinoma arising in the gingiva (8), tongue (3), floor of the mouth (1), or maxillary sinus (3) were enrolled." | 1.30 | Intranodal injection of anticancer drugs into fixed cervical metastatic lymph nodes. ( Osaki, T; Ueta, E; Yamamoto, T; Yoneda, K, 1997) |
| "Of 125 cases of advanced gastric cancer, 41 cases received intraarterial chemotherapy (A group) and the rest were given systemic infusion (S group)." | 1.30 | [Evaluation of intra-arterial infusion chemotherapy for advanced gastric cancer]. ( Akiyama, T; Kita, I; Kosaka, T; Nakano, Y; Saito, H; Sugaya, J; Takashima, S; Tomita, F; Ueshige, N, 1998) |
| "Bone metastasis of breast cancer generally tends to be multiple." | 1.30 | [Significance of full-thickness chest wall resection as a local treatment for sternum metastasis of breast cancer]. ( Hamazoe, R; Hirooka, Y; Kinugasa, Y; Murata, Y; Shiota, S; Sumi, K; Takahashi, S, 1998) |
| "Patients with metastatic breast cancer (MBC) have variable clinical courses." | 1.30 | Clinical characteristics of patients with metastatic breast cancer with complete remission following systemic treatment. ( Adachi, I; Ando, M; Katsumata, N; Narabayashi, M; Omuro, Y; Watanabe, T; Yamamoto, N, 1998) |
| " Our results indicate that the dose-response effect remains a crucial factor in adjuvant chemotherapy of breast cancer." | 1.30 | Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. ( Castiglione-Gertsch, M; Coates, A; Colleoni, M; Collins, J; Gelber, RD; Goldhirsch, A; Lindtner, J; Price, K; Rudenstam, CM; Thürlimann, B, 1998) |
| "A patient with advanced gastric cancer was treated with combined administration of CPT-11 CDDP and 5-FU before operation." | 1.30 | [A case of advanced gastric cancer successfully treated by neoadjuvant chemotherapy with CPT-11, CDDP and 5-FU]. ( Fukuda, S; Kume, S; Nagamoto, N; Okamura, K; Sakaguchi, T; Tanabe, D, 1999) |
| " The findings indicate that a method is available to rationally address the design of dosing schedules in concurrent therapy regimens." | 1.30 | Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy. ( Bachert, P; Becker, M; Dietz, A; Knopp, MV; Rudat, V; Schlemmer, HP; van Kaick, G; Vanselow, B; Wannenmacher, M; Weidauer, H; Wollensack, P; Zuna, I, 1999) |
| "Metaplastic breast cancer is a rare disease with little information available to guide therapy." | 1.30 | Metaplastic breast cancer: prognosis and response to systemic therapy. ( Adjei, AA; Ingle, JN; Rayson, D; Suman, VJ; Wold, LE, 1999) |
| "Local control of esophageal cancer is excellent following neoadjuvant chemotherapy and radiation therapy." | 1.30 | Resectable esophageal carcinoma: local control with neoadjuvant chemotherapy and radiation therapy. ( Adelstein, DJ; Becker, M; Chidel, MA; Kupelian, PA; Rice, TW; Suh, JH, 1999) |
| "He was diagnosed as having advanced esophageal cancer (Stage IV) with a massive supraclavicular lymph node metastasis, and the lesion was thought to be unresectable." | 1.30 | [A case of stage IV esophageal cancer successfully treated by chemoradiation]. ( Isogaki, J; Kawabe, A; Kazui, T; Kobayashi, T; Nishimura, T; Nozue, M; Wada, H; Yoshida, M, 1999) |
| "A 64-year-old man with unresectable esophageal cancer (A3, N1, M0) was treated with concurrent chemoradiotherapy." | 1.30 | [A case of stage IV (A3) cervical and upper thoracic esophageal adenocarcinoma successfully treated with concurrent chemoradiotherapy]. ( Inoue, H; Ise, H; Matsumoto, G; Matsuo, S; Suzuki, N, 1999) |
| "Fluorouracil (5-FU) was repeatedly injected into the pelvic retroperitoneal space of 43 patients and the abdominal cavity of 11 patients." | 1.30 | [The contrast between chemotherapy via pelvic retroperitoneal cannulation and intraperitoneal chemotherapy in gynecological malignancies cancers with lymph node metastases]. ( Cao, Z; Peng, Z; Zhang, D, 1999) |
| "The major limitation in the treatment of malignant melanoma is the lack of availability of effective agents for treatment." | 1.29 | Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity. ( Algermissen, B; Czarnetzki, BM; Kohlmus, CM; Schadendorf, D; Worm, M, 1994) |
| "Primary hepatocellular carcinoma is a very rare disease, especially in association with a pregnancy." | 1.29 | [Hepatocellular carcinoma in pregnancy]. ( Brucker, C; Debus-Thiede, G; Genz, T; Maassen, V; Schweiberer, L; Weiss, M, 1994) |
| "The response of gastric cancer to intravenous application of low-dose CDDP plus 5-fluorouracil (FP) was assessed by changes in DNA indices (DIs) and PCNA labeling indices (LIs) by flow cytometry, and by the thymidylate synthetase inhibition rate (TSIR)." | 1.29 | [Effect of low dose CDDP/5-fluorouracil therapy on PCNA labeling index and TS inhibition rate of gastric cancer]. ( Akiyama, T; Kiriyama, M; Kita, I; Kosaka, T; Nakano, Y; Saito, H; Sugaya, J; Takano, Y; Tomita, F; Yoshida, S, 1995) |
| "Histologically, aneuploidy was detected in 71." | 1.29 | [Flow cytometric DNA analysis and chemosensitivity in squamous cell carcinoma of the head and neck]. ( Miyagi, M; Nakashima, T; Soda, T, 1994) |
| "The tegafur suppository was useful because of the high concentration in cancer tissue and metastatic lymph nodes without any obvious side effects in the head and neck region." | 1.29 | [Tissue concentration of tegafur suppository in patients with head and neck cancer--concentration of 5-FU in cancer tissue]. ( Esu, H; Itokazu, T; Kamiya, S; Kanazawa, T; Koja, S; Maeshiro, N; Noda, Y; Simoji, Y; Yamauchi, M, 1994) |
| "Because locally advanced infiltrating breast carcinomas are frequently diagnosed by fine-needle aspiration, histologic grade can be determined in the mastectomy specimens only after chemotherapy." | 1.29 | Histologic grade of locally advanced infiltrating ductal carcinoma after treatment with induction chemotherapy. ( Fechner, RE; Frierson, HF, 1994) |
| " Increasing the dosage by boost technique above 50." | 1.29 | [Simultaneous radiochemotherapy in locoregional recurrent breast carcinoma after mastectomy. Results in patients with macroscopic residual tumor R2]. ( Renner, H; van Kampen, M, 1994) |
| "Three cases of postoperative gastric cancer with peritoneal dissemination were treated by combined administration of CDDP, 5-FU and Lentinan." | 1.29 | [Postoperative immunochemotherapy for gastric carcinoma with peritoneal dissemination--the effects with the combination of CDDP, 5-FU and lentinan]. ( Mio, H; Terabe, K, 1994) |
| "Patients with breast cancer and a high number of involved axillary lymph nodes have a poor prognosis, despite adjuvant chemotherapy." | 1.29 | Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes. ( de Graaf, H; de Vries, EG; Dolsma, WV; Mulder, NH; Mulder, PO; Sleijfer, DT; Smit Sibinga, CT; van der Graaf, WT; van der Ploeg, E; Willemse, PH, 1994) |
| "Eighty-one laryngeal cancer patients treated at our clinic during the past ten years were studied clinically." | 1.29 | Results of treatment of laryngeal cancer. ( Hasegawa, T; Kim, Y; Sano, R; Suzuki, H, 1994) |
| "An advanced gastric cancer patient with multiple retroperitoneal lymph node metastases and bone metastases was treated with sequential MTX and 5-FU." | 1.29 | [A case of nonresectable gastric cancer treated by sequential methotrexate and 5-fluorouracil]. ( Anai, H; Furuyama, M; Ikejiri, K; Maekawa, S; Muranaka, T; Saku, M; Takeo, S; Yakabe, S, 1994) |
| "This case suggested that respiratory failure due to lymphangitis carcinomatosis can be a treatable condition." | 1.29 | Respiratory failure due to pulmonary lymphangitis carcinomatosis. ( Fujita, J; Kubo, A; Takahara, J; Takigawa, K; Yamagishi, Y; Yamaji, Y, 1993) |
| "An experience with an advanced gastric cancer patient with metastases to bilateral breasts, uterus, abdominal lymph nodes, bilateral axillary and supraclavicular lymph nodes, and bone marrow, responded extremely well to an FAP combined chemotherapy as reported here." | 1.29 | [A case of advanced gastric cancer responding to an FAP (5-FU, ADM, platinum compounds) combined chemotherapy]. ( Azuma, T; Doihara, H; Kirihara, Y; Miyahara, E; Ohashi, R; Sakamoto, N; Soga, H; Takiyama, W; Tanada, M; Yokoyama, N, 1993) |
| "The patient was a 44-year-old male with gastric cancer accompanied by pancreatic invasion and metastasis to the periaortic lymph nodes." | 1.29 | [A patient with stage IV gastric cancer responding to combination chemotherapy with 5-FU, leucovorin and CDDP]. ( Kobayashi, O; Motohashi, H; Okada, K; Okugawa, T; Rino, Y; Sairenji, M, 1993) |
| "Multiple lymph node metastasis were detected by CT scan." | 1.29 | [A case of advanced esophageal cancer showing good partial response by combination therapy of low dose 5-FU and low dose CDDP]. ( Aisawa, T; Akagi, T; Fukushi, M; Ishiguro, Y; Kimura, S; Kudoh, I; Osanai, S; Sakata, Y; Suzuki, H; Takemori, H; Yoshiike, M, 1996) |
| "Patients with inflammatory breast cancer have a high risk of developing a local recurrence and/or distant metastases." | 1.29 | Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy. ( Arriagada, R; Fontaine, F; Le Chevalier, T; Mouriesse, H; Spielmann, M; Thomas, F; Tursz, T, 1995) |
| "In the majority of patients with rectal cancer invading perirectal tissues or lymph nodes, lesions may be downstaged by preoperative adjuvant therapy." | 1.29 | Preoperative adjuvant radiation with chemotherapy for rectal cancer: its impact on stage of disease and the role of endorectal ultrasound. ( Bernini, A; Deen, KI; Madoff, RD; Wong, WD, 1996) |
| "Mitomycin C 26 mg was given intravenously on the day of operation and 5-fluorouracil (5-FU) 150 mg/day orally since postoperative 14th day as adjuvant chemotherapy." | 1.29 | [A case of advanced gastric cancer with liver metastasis with no recurrence and long survival]. ( Kajiura, Y; Kondo, Y; Mitomi, T; Miyaji, M; Nakamura, K; Ogoshi, K; Tajima, T, 1996) |
| "We described a case of advanced gastric cancer accompanied by metastasis to the periaortic lymph node." | 1.29 | [Successful neoadjuvant chemotherapy in a patient with advanced gastric cancer with periaortic lymph node metastasis]. ( Horiuchi, H; Hyodo, S; Kakegawa, T; Nozoe, Y; Sasatomi, T; Takeuchi, K; Tanaka, T, 1996) |
| " In CCR managed with EC, the independent factors of age, tumor classification, exact tumor location, true vocal cord motion, arytenoid cartilage motion, total dosage of drugs delivered, and number of courses received were tested for potential correlation with survival, local recurrence, nodal recurence, and distant metastasis." | 1.29 | Cisplatin-fluorouracil exclusive chemotherapy for T1-T3N0 glottic squamous cell carcinoma complete clinical responders: five-year results. ( Bassot, V; Brasnu, D; Khayat, D; Laccourreye, H; Laccourreye, O; Ménard, M, 1996) |
| "There were 43 colorectal and 104 appendiceal cancer patients." | 1.29 | Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy. ( Chang, D; Koslowe, P; Sugarbaker, PH, 1996) |
| "To identify appropriate candidates with rectal cancer for preoperative chemoradiation therapy, the local recurrence rate and clinicopathological characteristics of 232 patients with rectal cancer undergoing curative resection in our department were investigated." | 1.29 | [Preoperative chemoradiation therapy for lower rectal cancer]. ( Iihara, K; Kimura, M; Kitada, M; Murotani, M; Niinobu, T; Nose, T; Ogawa, M; Shibata, T; Takada, T; Takami, M; Tsujinaka, T; Tsukahara, Y; Tsukamoto, F, 1996) |
| "The chemosensitivity of various head and neck cancers was investigated with the 5-day rapid thymidine incorporation assay in soft agar culture." | 1.28 | Chemosensitivity of head and neck cancer with the rapid thymidine incorporation assay and its clinical application. ( Fujieda, S; Ohtsubo, T; Saito, H; Tanigawa, N, 1992) |
| "Twenty-two cases of early squamous cell carcinoma of the arytenoid cartilage staged as T1 according to the 1983 American Joint Committee for Cancer Staging Classification system were reviewed." | 1.28 | T1 squamous cell carcinoma of the arytenoid. ( Brasnu, D; Chabardes, E; Housset, M; Laccourreye, H; Laccourreye, O; Weinstein, G, 1992) |
| "Ten patients with squamous cell carcinoma of the cervix metastatic to periaortic lymph nodes were treated with external-beam radiation therapy and synchronous infusion of intravenous 5-fluorouracil (5-FU) chemotherapy at doses of 350 mg/m2/day." | 1.28 | Continuous infusion of low-dose 5-fluorouracil and radiation therapy for poor-prognosis squamous cell carcinoma of the uterine cervix. ( Drescher, CW; Hopkins, MP; Perez-Tamayo, C; Reid, GC; Roberts, JA; Schoeppel, SL; Terada, K, 1992) |
| "Ten patients with non-resectable gastric cancer were subjected to a neo-adjuvant chemotherapy (FLEP therapy), consisting of 4 drugs (leucovorin and 5-FU i." | 1.28 | [Evaluation of effective neo-adjuvant chemotherapy (FLEP therapy) in the treatment of advanced gastric cancer]. ( Ishihara, S; Mizuno, S; Nakajima, T; Nishi, M; Ohashi, Y; Ohta, K; Okumura, S; Toyoda, S; Tsuchiya, S, 1991) |
| "Stage II patients with breast carcinoma who had undergone lumpectomy." | 1.28 | Adjuvant therapy of stage II breast cancer treated with CMFVP, radiation therapy and VATH following lumpectomy. A pilot trial. ( Allen, S; Bosworth, H; Budman, D; Lehrman, D; Lichtman, SM; Schulman, P; Vinciguerra, V; Weiselberg, L; Weiss, R, 1991) |
| "5-Fluorouracil (5-FU) was administered by arterial continuous infusion, Adriamycin (ADM) and mitomycin C (MMC) were given by bolus infusion in the hospital, and continuous arterial 5-FU infusion and ADM low-dose intermittent bolus infusion chemotherapy (AF therapy) were used for outpatients at home." | 1.28 | [Long-term arterial infusion chemotherapy in advanced and recurrent gastric cancer patients at home and an interesting autopsy case]. ( Saito, K; Sato, M; Takagane, A; Terashima, M, 1990) |
| "In 14 gastric cancer and 15 colonic cancer cases, to which UFT 400 mg/day and OK-432 2KE 2/W were administered orally and intra-muscularly for 2 weeks preoperatively until surgical treatment, intratumor 5-fluorouracil (5-FU) concentration was measured and compared with that of patients who given UFT 400 mg/day orally for 2 weeks (15 gastric cancer and 15 colonic cancer cases)." | 1.28 | [Influence of OK-432 on intratumor 5-fluorouracil concentration in cases given UFT]. ( Hosoi, H; Kitagawa, M; Sinmyo, K; Susaki, H; Suwa, H; Yamaguchi, K, 1989) |
| "Spontaneous metastasis of highly metastatic variants, B16 melanoma BL-6 and colon adenocarcinoma 26 NL-22, was examined." | 1.27 | Spontaneous metastasis of highly metastatic variants of mouse tumors and the effect of drugs on the metastasis. ( Iida, H; Kawabata, H; Naganuma, K; Oh-Hara, T; Sakurai, Y; Tsukagoshi, S; Tsuruo, T; Yamori, T, 1984) |
| "Five-year results in 60 oral and pharyngeal cancer patients treated with combined approach chemoradiotherapy (39 patients) and chemoradiotherapy plus lymph node surgery (21 patients) are reported." | 1.27 | Oral and pharyngeal cancer: combined approach for multimodal therapy. ( Airoldi, M; Badellino, F; Fazio, M; Gandolfo, S; Manca, A; Sannazzari, GL; Vercellino, V, 1983) |
| "In advanced breast cancer it has been hypothesized that the presence of progesterone receptor (PR) might be a more sensitive marker for predicting response to endocrine therapy (2, 3)." | 1.27 | Prognostic factors in primary breast cancer. ( Clark, GM; McGuire, WL, 1983) |
| "A case of extramammary Paget's disease is reported." | 1.27 | Metastatic extramammary Paget's disease: dramatic response to combined modality treatment. ( Athar, M; Balducci, L; Crawford, ED; Khansur, T; McKenzie, D; Smith, GF, 1988) |
| "Investigations were made on 76 cases of scirrhous carcinoma of the stomach in the care of our department, and the treatment methods in these cases were as follows: 1) Lymph node dissection: Lymphadenectomy of over R2 is performed." | 1.27 | [Treatment methods for scirrhous carcinoma of the stomach--with special reference to total gastrectomy and chemotherapy in early postoperative period]. ( Hamakubo, S; Higashino, K; Nabeya, K; Nyumura, T, 1988) |
| "Lymph node metastasis was not related to the concentration of 5-FU in the lymph nodes." | 1.27 | [Serum and tissue concentrations of UFT in patients with lung cancer]. ( Aota, M; Daitoh, N; Jinno, K; Nakayama, S; Yokomise, H, 1986) |
| "One hundred forty-three patients with pancreatic cancer were treated with a number of chemotherapeutic agents, while ninety-eight patients did not receive any chemotherapy." | 1.27 | [Clinical study on the effect of chemotherapy in the treatment of pancreatic cancer]. ( Fujimoto, T; Ishida, T; Kurogoh, F; Ohyanagi, H; Okumura, S; Saitoh, Y; Shimada, Y; Tagashira, Y; Uchida, K; Yamamoto, M, 1988) |
| "The treatment schedule for disseminated breast carcinoma has been developed." | 1.27 | [4-component chemotherapy and radiation therapy of breast cancer]. ( Aplevich, NN; Gritsaĭ, AA; Kondrat'eva, AP; Lichinitser, MR; Vyshinskaia, GV, 1986) |
| "One hundred and eight patients with squamous cell carcinoma of the upper aerodigestive tract (UADT) (T3, T4, NO-N3; 17% stage II, 54% stage III, 27% stage IV) were given three courses of chemotherapy before any local treatment." | 1.27 | Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. ( Caldani, C; Chauvel, P; Demard, F; Santini, J; Schneider, M; Thyss, A; Vallicioni, J, 1986) |
| "As far as squamous cell carcinoma is concerned, the post-therapeutic courses of our combination therapy have been satisfactory." | 1.27 | Analysis of the long-term results of our combination therapy for maxillary cancer, with particular reference to treatment of T4 and N1-3 maxillary cancer. ( Hanazawa, S; Konno, A; Okamoto, Y; Togawa, K, 1985) |
| "Although the mean size of breast tumors among the Hispanic patients was smaller than that of our black patients, Hispanic patients are more likely to have higher numbers of positive axillary lymph nodes." | 1.27 | Surgical treatment of carcinoma of the breast. V. Changes in patient population and therapeutic modalities at a metropolitan hospital (1971-1980). ( Lee, YT, 1985) |
| "Sixteen patients with dermal lymphatic carcinomatosis and 10 patients with negative skin biopsies had median RFS of 31 and 46 months, respectively (p = 0." | 1.27 | Management of inflammatory carcinoma of the breast. A combined modality approach. ( Blumenschein, GR; Buzdar, AU; Fastenberg, NA; Hortobagyi, GN; Jessup, JM; Martin, RG; Montague, ED, 1985) |
| "Preoperative cancer chemotherapy for gastric cancer was reviewed with special emphasis on histologic findings and survival." | 1.27 | [Preoperative cancer chemotherapy for gastric cancer]. ( Endoh, F; Fujimoto, S; Kawata, S; Kurihara, M; Miyazaki, M; Ohta, M; Shimura, T; Sugasawa, H; Takahashi, O; Udagawa, I, 1985) |
| "Multimodality therapy for colorectal cancer is composed of surgery, chemotherapy and irradiation; and hyperthermia joins them recently." | 1.27 | [Multimodality therapy of colorectal cancer]. ( Fujimoto, S; Miyazaki, M; Okui, K, 1985) |
| "In group A for gastric cancer and in group C for colon cancer, the histological response was stronger at the edge of the cancer than at its surface." | 1.27 | [Preoperative treatment with 5-fluorouracil (5-FU) in gastric and colorectal cancer]. ( Hashizume, Y; Hirano, M; Iwa, T; Kawaura, Y; Ohmura, K; Sakatoku, M; Takayama, K; Yamada, T, 1985) |
| "In the total 70 cases including those of undifferentiated carcinoma and adenocarcinoma, the 3-year and 5-year actual survival rates were 75." | 1.26 | Analysis of the results of our combined therapy for maxillary cancer. ( Inoue, S; Konno, A; Togawa, K, 1980) |
| "Patients without lymph node metastases were not treated." | 1.26 | [Ancillary chemotherapy with trofosfamid, methotrexate and fluoro-uracil in cancer of the breast (author's transl)]. ( Albrecht, M; Jepsen, G; Thomsen, K; Trams, G, 1981) |
| " While earlier results suggested that adjuvant chemotherapy is especially effective in premenopausal women, newer studies and analyses indicate that appropriate dosage and consistent administration of chemotherapy are of decisive importance." | 1.26 | [Results of, and indications for adjuvant chemotherapy in breast cancer]. ( Brunner, KW; Goldhirsch, A; Joss, R; Sonntag, RW; Tschopp, L, 1981) |
| "58 women with metastatic breast cancer, non-responsive to hormone therapy, were treated with a modified CMF regimen." | 1.26 | [Encouraging results with cytostatic therapy in metastasizing breast cancer (author's transl)]. ( Denz, H; Huber, H; Kratzer, H; Michlmayr, G, 1981) |
| "46 patients with rectal cancer were treated preoperatively with intrarectal administration of 5-FU emulsion (25 cases) or 5-FU suppositories (21 cases) for a period of 10 days before surgery, and the histological effect of this regimen on the metastatic lesion in the lymph nodes, as well as in the primary tumor was examined." | 1.26 | Clinical studies of intrarectal administration of 5-FU emulsion as an adjunct to surgical treatment of rectal cancer. ( Fijita, Y; Kojima, O; Majima, S; Morisawa, K; Nishioka, B; Umehara, M; Watanabe, S; Yamane, E, 1980) |
| "Three patients with metastatic breast carcinoma who had untreated locally advanced primary tumors were treated initially with combination chemotherapy followed by hygienic mastectomy." | 1.26 | Mastectomy as an adjunct to combination chemotherapy. ( Aisner, J; Elias, EG; Morris, D; Wiernik, PH, 1978) |
| "In additional 13 cases with gastric cancer, the active 5-FU concentrations in the regional lymph nodes were determined." | 1.26 | Histological evaluation of the effect of 5-FU emulsion on lymph node metastasis of stomach cancer. ( Cho, K; Fujita, Y; Majima, S; Morisawa, K; Nakao, E; Nishioka, B; Takahashi, T; Ueda, T; Watanabe, S, 1978) |
| "In evaluating response by sites of metastases, lymph nodes (30%), lung nodules (22%), and subcutaneous deposits (2/3) had the highest incidence of C." | 1.25 | An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer. ( Catalano, RB; Creech, RH; Engstrom, PF; Mastrangelo, MJ, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 309 (16.30) | 18.7374 |
| 1990's | 399 (21.04) | 18.2507 |
| 2000's | 604 (31.86) | 29.6817 |
| 2010's | 553 (29.17) | 24.3611 |
| 2020's | 31 (1.64) | 2.80 |
| Authors | Studies |
|---|---|
| Garnier, J | 2 |
| Magallon, C | 1 |
| Ewald, J | 2 |
| Palen, A | 1 |
| Marchese, U | 2 |
| Delpero, JR | 3 |
| Turrini, O | 2 |
| Okadome, K | 1 |
| Baba, Y | 7 |
| Yasuda-Yoshihara, N | 1 |
| Nomoto, D | 1 |
| Yagi, T | 3 |
| Toihata, T | 1 |
| Ogawa, K | 5 |
| Sawayama, H | 2 |
| Ishimoto, T | 2 |
| Iwatsuki, M | 3 |
| Iwagami, S | 3 |
| Miyamoto, Y | 4 |
| Yoshida, N | 3 |
| Watanabe, M | 6 |
| Komohara, Y | 1 |
| Baba, H | 11 |
| Yoshida, T | 8 |
| Nishino, T | 1 |
| Goto, M | 5 |
| Inoue, S | 3 |
| Fujiwara, S | 1 |
| Takizawa, H | 1 |
| Tangoku, A | 2 |
| Uehara, H | 1 |
| Bando, Y | 1 |
| Sukhbaatar, A | 2 |
| Kodama, T | 2 |
| Matsuki, G | 1 |
| Nakajima, T | 5 |
| Ichise, N | 1 |
| Nomura, K | 2 |
| Fujikawa, M | 1 |
| Kasai, M | 2 |
| Okamoto, R | 1 |
| Ikuta, S | 1 |
| Nakamoto, Y | 1 |
| Aihara, T | 1 |
| Kajimoto, N | 1 |
| Kakuno, A | 1 |
| Yanagi, H | 1 |
| Yamanaka, N | 1 |
| Yuan, P | 1 |
| Kang, Y | 1 |
| Ma, F | 1 |
| Fan, Y | 2 |
| Wang, J | 14 |
| Wang, X | 9 |
| Yue, J | 2 |
| Luo, Y | 1 |
| Zhang, P | 3 |
| Li, Q | 4 |
| Xu, B | 1 |
| Huang, B | 1 |
| He, Z | 1 |
| Manceau, G | 1 |
| Margot, N | 1 |
| Augustin, J | 1 |
| Bardier, A | 1 |
| Simon, JM | 2 |
| Bachet, JB | 2 |
| Spano, JP | 2 |
| Maingon, P | 1 |
| Vaillant, JC | 1 |
| Karoui, M | 1 |
| Sahu, KK | 1 |
| Pandey, D | 1 |
| Mishra, AK | 1 |
| O'Shea, J | 1 |
| Chen, Y | 6 |
| McGregor, B | 1 |
| Sugimura, K | 1 |
| Miyata, H | 11 |
| Shinno, N | 1 |
| Ushigome, H | 1 |
| Asukai, K | 2 |
| Yanagimoto, Y | 1 |
| Hasegawa, S | 2 |
| Takahashi, Y | 4 |
| Yamada, D | 1 |
| Yamamoto, K | 9 |
| Nishimura, J | 2 |
| Motoori, M | 6 |
| Wada, H | 4 |
| Takahashi, H | 6 |
| Yasui, M | 2 |
| Omori, T | 1 |
| Ohue, M | 6 |
| Yano, M | 14 |
| Taieb, J | 5 |
| Geissler, M | 1 |
| Rivera, F | 2 |
| Karthaus, M | 1 |
| Wilson, R | 1 |
| Loupakis, F | 6 |
| Price, T | 1 |
| Tracy, M | 1 |
| Burdon, P | 1 |
| Peeters, M | 1 |
| Igarashi, H | 1 |
| Taniguchi, H | 4 |
| Nosho, K | 1 |
| Ishigami, K | 1 |
| Koide, H | 1 |
| Mitsuhashi, K | 1 |
| Okita, K | 1 |
| Takemasa, I | 4 |
| Imai, K | 2 |
| Nakase, H | 1 |
| Wattenberg, MM | 1 |
| Asch, D | 1 |
| Yu, S | 2 |
| O'Dwyer, PJ | 1 |
| Domchek, SM | 1 |
| Nathanson, KL | 1 |
| Rosen, MA | 1 |
| Beatty, GL | 1 |
| Siegelman, ES | 1 |
| Reiss, KA | 1 |
| Abdel Raouf, SM | 1 |
| Ibrahim, TR | 1 |
| Abdelaziz, LA | 1 |
| Farid, MI | 1 |
| Mohamed, SY | 1 |
| Akiyoshi, T | 2 |
| Toda, S | 2 |
| Tominaga, T | 8 |
| Oba, K | 3 |
| Tomizawa, K | 2 |
| Hanaoka, Y | 2 |
| Nagasaki, T | 1 |
| Konishi, T | 4 |
| Matoba, S | 2 |
| Fukunaga, Y | 2 |
| Ueno, M | 2 |
| Kuroyanagi, H | 2 |
| Medrano, J | 1 |
| Gilabert, M | 1 |
| Launay, S | 1 |
| Poizat, F | 1 |
| Giovannini, M | 2 |
| Lu, Y | 1 |
| Chen, D | 1 |
| Liang, J | 4 |
| Gao, J | 1 |
| Luo, Z | 1 |
| Wang, R | 3 |
| Liu, W | 2 |
| Huang, C | 1 |
| Ning, X | 1 |
| Liu, M | 4 |
| Huang, H | 1 |
| Steenbruggen, TG | 1 |
| Steggink, LC | 1 |
| Seynaeve, CM | 1 |
| van der Hoeven, JJM | 1 |
| Hooning, MJ | 1 |
| Jager, A | 2 |
| Konings, IR | 1 |
| Kroep, JR | 1 |
| Smit, WM | 1 |
| Tjan-Heijnen, VCG | 1 |
| van der Wall, E | 3 |
| Bins, AD | 1 |
| Linn, SC | 1 |
| Schaapveld, M | 2 |
| Jacobse, JN | 1 |
| van Leeuwen, FE | 1 |
| Schröder, CP | 2 |
| van Tinteren, H | 1 |
| de Vries, EGE | 1 |
| Sonke, GS | 1 |
| Gietema, JA | 1 |
| Hayashi, Y | 2 |
| Nakatsuka, R | 1 |
| Nishizawa, Y | 2 |
| Komatsu, H | 1 |
| Miyazaki, S | 4 |
| Tomokuni, A | 1 |
| Komori, T | 1 |
| Iwase, K | 2 |
| Fujitani, K | 3 |
| Kazakov, OV | 2 |
| Kabakov, AV | 2 |
| Poveshchenko, AF | 2 |
| Raiter, TV | 2 |
| Strunkin, DN | 2 |
| Bogachev, SS | 1 |
| Lykov, AP | 2 |
| Konenkov, VI | 2 |
| Fukui, K | 1 |
| Nagasawa, S | 1 |
| Hanasaki, T | 1 |
| Ueda, Y | 3 |
| Aihara, K | 1 |
| Kokura, K | 1 |
| Matsuo, S | 3 |
| Zozumi, M | 1 |
| Tsukamoto, Y | 1 |
| Kim, S | 5 |
| Buecher, B | 1 |
| André, T | 2 |
| Jary, M | 2 |
| Bidard, FC | 2 |
| Ghiringhelli, F | 3 |
| François, É | 3 |
| Smith, D | 2 |
| de la Fouchardière, C | 1 |
| Desramé, J | 1 |
| Samalin, E | 2 |
| Parzy, A | 1 |
| Baba-Hamed, N | 1 |
| Bouché, O | 3 |
| Tougeron, D | 3 |
| Dahan, L | 4 |
| El Hajbi, F | 1 |
| Jacquin, M | 1 |
| Rebucci-Peixoto, M | 1 |
| Spehner, L | 1 |
| Vendrely, V | 3 |
| Vernerey, D | 1 |
| Borg, C | 4 |
| Palma, S | 1 |
| Raffa, CI | 1 |
| Garcia-Fabiani, MB | 1 |
| Ferretti, VA | 1 |
| Zwenger, A | 1 |
| Perez Verdera, PV | 1 |
| Llontop, A | 1 |
| Rojas Bilbao, E | 1 |
| Cuartero, V | 1 |
| Abba, MC | 1 |
| Lacunza, E | 1 |
| Kitagawa, Y | 4 |
| Osumi, H | 1 |
| Shinozaki, E | 2 |
| Ota, Y | 1 |
| Nakayama, I | 1 |
| Suzuki, T | 9 |
| Wakatsuki, T | 1 |
| Ogura, M | 2 |
| Ooki, A | 1 |
| Takahari, D | 3 |
| Suenaga, M | 3 |
| Chin, K | 4 |
| Yamaguchi, K | 6 |
| Bockorny, B | 1 |
| Semenisty, V | 1 |
| Macarulla, T | 1 |
| Borazanci, E | 1 |
| Wolpin, BM | 1 |
| Stemmer, SM | 1 |
| Golan, T | 1 |
| Geva, R | 1 |
| Borad, MJ | 1 |
| Pedersen, KS | 1 |
| Park, JO | 4 |
| Ramirez, RA | 1 |
| Abad, DG | 1 |
| Feliu, J | 2 |
| Muñoz, A | 1 |
| Ponz-Sarvise, M | 2 |
| Peled, A | 1 |
| Lustig, TM | 1 |
| Bohana-Kashtan, O | 1 |
| Shaw, SM | 1 |
| Sorani, E | 1 |
| Chaney, M | 1 |
| Kadosh, S | 1 |
| Vainstein Haras, A | 1 |
| Von Hoff, DD | 1 |
| Hidalgo, M | 1 |
| Sakr, A | 1 |
| Elsherbiny, M | 1 |
| Abdel Moneim, R | 1 |
| Shaaban, S | 1 |
| Aldaly, M | 1 |
| Pourghasemian, M | 1 |
| Danandeh Mehr, A | 1 |
| Molaei, M | 1 |
| Habibzadeh, A | 1 |
| Lee, JC | 2 |
| Woo, SM | 2 |
| Shin, DW | 2 |
| Kim, J | 3 |
| Yang, SY | 2 |
| Kim, MJ | 2 |
| Kim, JW | 4 |
| Lee, WJ | 2 |
| Cha, HS | 1 |
| Park, P | 1 |
| Hwang, JH | 1 |
| Woo, IT | 1 |
| Park, JS | 1 |
| Kang, BW | 1 |
| Park, SY | 1 |
| Kim, HJ | 6 |
| Choi, GS | 1 |
| Gwang Kim, J | 1 |
| Tanishima, Y | 1 |
| Nishikawa, K | 4 |
| Arakawa, Y | 1 |
| Matsumoto, A | 1 |
| Yuda, M | 1 |
| Tanaka, Y | 8 |
| Mitsumori, N | 1 |
| Yanaga, K | 1 |
| Koizumi, M | 2 |
| Yamada, T | 9 |
| Shinji, S | 1 |
| Matsuda, A | 2 |
| Yokoyama, Y | 2 |
| Takahashi, G | 1 |
| Iwai, T | 1 |
| Takeda, K | 3 |
| Hara, K | 3 |
| Yoshida, H | 3 |
| Cai, Z | 1 |
| Ma, J | 2 |
| Li, S | 3 |
| Fingerhut, A | 1 |
| Sun, J | 2 |
| Zang, L | 1 |
| Yan, C | 1 |
| Zhu, Z | 2 |
| Zheng, M | 2 |
| Zhu, H | 1 |
| Rivin Del Campo, E | 1 |
| Ye, J | 1 |
| Simone, CB | 1 |
| Zhao, W | 2 |
| Amini, A | 1 |
| Zhou, J | 1 |
| Wu, C | 2 |
| Tang, H | 1 |
| Fan, M | 1 |
| Li, L | 2 |
| Lin, Q | 1 |
| Xia, Y | 1 |
| Li, Y | 8 |
| Li, J | 15 |
| Mo, M | 1 |
| Jia, H | 1 |
| Lu, S | 1 |
| Nie, Y | 1 |
| Chen, J | 4 |
| Wu, S | 5 |
| Hamaji, M | 1 |
| Haque, W | 1 |
| Jeong, BK | 1 |
| Shridhar, R | 2 |
| Zhang, Z | 4 |
| Zhao, K | 3 |
| Voogt, ELK | 1 |
| Schaap, DP | 1 |
| van den Berg, K | 1 |
| Nieuwenhuijzen, GAP | 1 |
| Bloemen, JG | 1 |
| Creemers, GJ | 1 |
| Willems, J | 1 |
| Cnossen, JS | 1 |
| Peulen, HMU | 1 |
| Nederend, J | 1 |
| van Lijnschoten, G | 1 |
| Burger, JWA | 1 |
| Rutten, HJT | 1 |
| Peng, J | 2 |
| Pu, H | 1 |
| Jia, Y | 2 |
| Chen, C | 1 |
| Ke, XK | 1 |
| Zhou, Q | 1 |
| Lutsyk, M | 1 |
| Awawda, M | 1 |
| Gourevich, K | 1 |
| Ben Yosef, R | 1 |
| Shu, C | 1 |
| Zhang, X | 1 |
| Wen, H | 1 |
| Tian, Z | 1 |
| Wu, X | 3 |
| Yang, J | 2 |
| Gou, G | 1 |
| Liu, L | 3 |
| Erickson, NT | 1 |
| Ricard, I | 1 |
| von Weikersthal, LF | 1 |
| Lerch, MM | 1 |
| Decker, T | 1 |
| Kiani, A | 1 |
| Kaiser, F | 1 |
| Heintges, T | 1 |
| Kahl, C | 1 |
| Kullmann, F | 1 |
| Scheithauer, W | 2 |
| Link, H | 1 |
| Höffkes, HG | 2 |
| Moehler, M | 3 |
| Gesenhues, AB | 1 |
| Theurich, S | 1 |
| Michl, M | 1 |
| Modest, DP | 1 |
| Algül, H | 1 |
| Stintzing, S | 2 |
| Heinemann, V | 3 |
| Holch, JW | 1 |
| Ishihara, S | 3 |
| Kawai, K | 2 |
| Tanaka, T | 9 |
| Kiyomatsu, T | 1 |
| Hata, K | 1 |
| Nozawa, H | 4 |
| Morikawa, T | 2 |
| Watanabe, T | 8 |
| Zhang, Y | 7 |
| Liu, J | 7 |
| Zhang, W | 2 |
| Deng, W | 1 |
| Al-Batran, SE | 1 |
| Homann, N | 1 |
| Pauligk, C | 1 |
| Illerhaus, G | 1 |
| Martens, UM | 1 |
| Stoehlmacher, J | 1 |
| Schmalenberg, H | 1 |
| Luley, KB | 1 |
| Prasnikar, N | 1 |
| Egger, M | 1 |
| Probst, S | 1 |
| Messmann, H | 1 |
| Fischbach, W | 1 |
| Hartmann, JT | 4 |
| Mayer, F | 1 |
| Koenigsmann, M | 1 |
| Arnold, D | 2 |
| Kraus, TW | 1 |
| Grimm, K | 1 |
| Berkhoff, S | 1 |
| Post, S | 2 |
| Jäger, E | 2 |
| Bechstein, W | 1 |
| Ronellenfitsch, U | 1 |
| Mönig, S | 1 |
| Hofheinz, RD | 4 |
| Hao, D | 1 |
| Xing, W | 1 |
| Yang, Y | 3 |
| He, C | 1 |
| Wang, W | 2 |
| Waddle, M | 1 |
| Irvin, M | 1 |
| Gupta, E | 1 |
| Gibbs, M | 1 |
| Kakar, TS | 1 |
| Gannon, NA | 1 |
| Arthurs, JR | 1 |
| Fischer, DL | 1 |
| Ailawadhi, S | 1 |
| Badakhshi, H | 1 |
| Ismail, M | 1 |
| Boskos, C | 1 |
| Kaul, D | 1 |
| Baggio, R | 1 |
| Chavel, P | 1 |
| Tisseau, L | 1 |
| Darrieux, L | 1 |
| Safa, G | 1 |
| Honma, Y | 1 |
| Hokamura, N | 2 |
| Nagashima, K | 1 |
| Sudo, K | 1 |
| Shoji, H | 2 |
| Iwasa, S | 2 |
| Takashima, A | 1 |
| Kato, K | 3 |
| Hamaguchi, T | 2 |
| Boku, N | 6 |
| Umezawa, R | 2 |
| Ito, Y | 9 |
| Itami, J | 1 |
| Koyanagi, K | 2 |
| Igaki, H | 2 |
| Tachimori, Y | 1 |
| Evesque, L | 1 |
| Benezery, K | 1 |
| Follana, P | 1 |
| Tuan Falk, A | 1 |
| Doyen, J | 1 |
| Reure, J | 1 |
| Cavaglione, G | 1 |
| Suzuki, N | 4 |
| Azami, A | 1 |
| Todate, Y | 1 |
| Tada, T | 1 |
| Waragai, M | 1 |
| Honda, M | 2 |
| Sato, A | 2 |
| Takano, Y | 3 |
| Abe, T | 1 |
| Nakamura, T | 9 |
| Teranishi, Y | 1 |
| Zhang, L | 8 |
| Xing, Y | 1 |
| Gao, Q | 2 |
| Sun, X | 1 |
| Zhang, D | 3 |
| Cao, G | 1 |
| Okamura, A | 1 |
| Mine, S | 1 |
| Kurogochi, T | 1 |
| Yamashita, K | 8 |
| Hayami, M | 1 |
| Imamura, Y | 3 |
| Ichimura, T | 1 |
| Sellick, MJ | 1 |
| Michaud, M | 1 |
| Wong, S | 2 |
| Candler, D | 1 |
| Watanabe, SM | 1 |
| Noble, F | 3 |
| Lloyd, MA | 1 |
| Turkington, R | 1 |
| Griffiths, E | 1 |
| O'Donovan, M | 1 |
| O'Neill, JR | 1 |
| Mercer, S | 1 |
| Parsons, SL | 1 |
| Fitzgerald, RC | 1 |
| Underwood, TJ | 3 |
| Ma, S | 2 |
| Ling, F | 1 |
| Gui, A | 1 |
| Chen, S | 5 |
| Sun, Y | 2 |
| Li, Z | 1 |
| Berger, MD | 1 |
| Yang, D | 1 |
| Cao, S | 1 |
| Sunakawa, Y | 1 |
| Ning, Y | 1 |
| Matsusaka, S | 1 |
| Okazaki, S | 1 |
| Schirripa, M | 1 |
| Soni, S | 1 |
| Falcone, A | 5 |
| Lenz, HJ | 3 |
| Berriochoa, CA | 1 |
| Abdel-Wahab, M | 1 |
| Leyrer, CM | 1 |
| Khorana, A | 1 |
| Matthew Walsh, R | 1 |
| Kumar, AMS | 1 |
| Tate, T | 1 |
| Fukui, Y | 1 |
| Wu, W | 1 |
| Deng, H | 1 |
| Rao, N | 1 |
| You, N | 1 |
| Cao, M | 1 |
| Ji, WB | 1 |
| Hong, KD | 2 |
| Kim, JS | 4 |
| Joung, SY | 1 |
| Um, JW | 1 |
| Min, BW | 1 |
| Kozak, GM | 1 |
| Epstein, JD | 1 |
| Deshmukh, SP | 1 |
| Scott, BB | 1 |
| Keith, SW | 1 |
| Lavu, H | 1 |
| Yeo, CJ | 4 |
| Winter, JM | 2 |
| Ishchenko, IY | 1 |
| Michurina, SV | 1 |
| Tsai, HL | 2 |
| Chen, YT | 2 |
| Yeh, YS | 1 |
| Huang, CW | 2 |
| Ma, CJ | 2 |
| Wang, JY | 4 |
| He, J | 1 |
| Blair, AB | 1 |
| Groot, VP | 1 |
| Javed, AA | 1 |
| Burkhart, RA | 1 |
| Gemenetzis, G | 1 |
| Hruban, RH | 4 |
| Waters, KM | 1 |
| Poling, J | 1 |
| Zheng, L | 1 |
| Laheru, D | 2 |
| Herman, JM | 5 |
| Makary, MA | 2 |
| Weiss, MJ | 1 |
| Cameron, JL | 6 |
| Wolfgang, CL | 3 |
| Nakajima, M | 2 |
| Muroi, H | 1 |
| Kikuchi, M | 1 |
| Takahashi, M | 9 |
| Ihara, K | 1 |
| Shida, Y | 1 |
| Kurayama, E | 1 |
| Ogata, H | 1 |
| Yamaguchi, S | 2 |
| Sasaki, K | 7 |
| Sakai, M | 2 |
| Sohda, M | 2 |
| Miyazaki, T | 3 |
| Kuwano, H | 7 |
| Kato, H | 6 |
| Kimura, K | 1 |
| Noda, M | 1 |
| Imada, A | 1 |
| Song, J | 2 |
| Babaya, A | 1 |
| Hamanaka, M | 1 |
| Kobayashi, M | 4 |
| Tsukamoto, K | 1 |
| Yamano, T | 1 |
| Ikeda, M | 7 |
| Tomita, N | 2 |
| Odagiri, K | 1 |
| Yamazaki, M | 1 |
| Tanaka, K | 10 |
| Miyazaki, Y | 2 |
| Makino, T | 1 |
| Takahashi, T | 19 |
| Kurokawa, Y | 4 |
| Nakajima, K | 6 |
| Mori, M | 12 |
| Doki, Y | 18 |
| Tessitore, A | 1 |
| Bruera, G | 2 |
| Mastroiaco, V | 1 |
| Cannita, K | 3 |
| Cortellini, A | 1 |
| Cocciolone, V | 1 |
| Dal Mas, A | 1 |
| Calvisi, G | 1 |
| Zazzeroni, F | 1 |
| Ficorella, C | 3 |
| Ricevuto, E | 3 |
| Alesse, E | 1 |
| Burgy, M | 1 |
| Leblanc, J | 1 |
| Borel, C | 1 |
| Mayanagi, S | 1 |
| Kashiwabara, K | 1 |
| Aoyama, T | 1 |
| Kanda, M | 1 |
| Maeda, H | 4 |
| Hamada, C | 2 |
| Sadahiro, S | 3 |
| Sakamoto, J | 5 |
| Saji, S | 2 |
| Yoshikawa, T | 1 |
| Kim, SM | 1 |
| An, JY | 2 |
| Lee, J | 6 |
| Sohn, TS | 2 |
| Goense, L | 1 |
| van Rossum, PSN | 1 |
| Xi, M | 1 |
| Maru, DM | 1 |
| Carter, BW | 1 |
| Meijer, GJ | 1 |
| Ho, L | 1 |
| van Hillegersberg, R | 2 |
| Hofstetter, WL | 1 |
| Lin, SH | 1 |
| Geredeli, C | 1 |
| Yasar, N | 1 |
| Cloyd, JM | 1 |
| Omichi, K | 1 |
| Mizuno, T | 1 |
| Kawaguchi, Y | 3 |
| Tzeng, CD | 1 |
| Conrad, C | 1 |
| Chun, YS | 1 |
| Aloia, TA | 1 |
| Katz, MHG | 1 |
| Lee, JE | 2 |
| Halperin, D | 1 |
| Yao, J | 1 |
| Vauthey, JN | 3 |
| Dasari, A | 1 |
| Greally, M | 1 |
| Pilson, K | 1 |
| Linehan, A | 1 |
| O'Keane, C | 1 |
| Shields, CJ | 1 |
| Conneely, JB | 1 |
| McCaffrey, JA | 1 |
| Chen, EY | 1 |
| Blanke, CD | 1 |
| Haller, DG | 2 |
| Benson, AB | 2 |
| Dragovich, T | 1 |
| Robles, C | 1 |
| Li, H | 5 |
| Mattek, N | 1 |
| Sanborn, RE | 1 |
| Lopez, CD | 1 |
| Kopetz, S | 2 |
| Murakami, Y | 1 |
| Hamai, Y | 1 |
| Emi, M | 1 |
| Hihara, J | 1 |
| Imano, N | 1 |
| Takeuchi, Y | 2 |
| Takahashi, I | 2 |
| Nishibuchi, I | 1 |
| Kimura, T | 2 |
| Okada, M | 1 |
| Nagata, Y | 1 |
| Ohara, H | 1 |
| Yamamoto, H | 7 |
| Collot, T | 1 |
| Fumet, JD | 1 |
| Klopfenstein, Q | 1 |
| Vincent, J | 1 |
| Bengrine, L | 1 |
| Kim, WR | 1 |
| Han, YD | 1 |
| Min, BS | 2 |
| Touchefeu, Y | 1 |
| Guimbaud, R | 1 |
| Louvet, C | 3 |
| Barbier, E | 1 |
| Le Malicot, K | 1 |
| Cohen, R | 1 |
| Gornet, JM | 2 |
| Aparicio, T | 2 |
| Nguyen, S | 1 |
| Azzedine, A | 1 |
| Etienne, PL | 3 |
| Phelip, JM | 1 |
| Hammel, P | 1 |
| Chapelle, N | 1 |
| Sefrioui, D | 1 |
| Mineur, L | 1 |
| Lepage, C | 1 |
| Mondaca, S | 1 |
| Chatila, WK | 1 |
| Bates, D | 1 |
| Hechtman, JF | 1 |
| Cercek, A | 1 |
| Segal, NH | 1 |
| Stadler, ZK | 1 |
| Varghese, AM | 1 |
| Kundra, R | 1 |
| Capanu, M | 1 |
| Shia, J | 2 |
| Schultz, N | 1 |
| Saltz, L | 3 |
| Yaeger, R | 1 |
| Rhoades, K | 1 |
| Smith, B | 1 |
| Honaker, MD | 1 |
| Cheng, X | 3 |
| Wang, Y | 9 |
| Cui, Y | 3 |
| Li, W | 2 |
| Yu, Y | 3 |
| Tang, C | 1 |
| Jiang, H | 1 |
| Ji, Y | 1 |
| Shen, Z | 2 |
| Liu, F | 5 |
| Liu, TS | 1 |
| Que, WC | 1 |
| Huang, YF | 1 |
| Lin, XY | 1 |
| Lan, YQ | 1 |
| Gao, XY | 1 |
| Wang, XL | 2 |
| Wu, RP | 1 |
| Du, B | 1 |
| Huang, XB | 1 |
| Qiu, HQ | 1 |
| Zhong, DT | 1 |
| Hurwitz, HI | 2 |
| Tan, BR | 1 |
| Reeves, JA | 1 |
| Xiong, H | 1 |
| Somer, B | 1 |
| Hochster, HS | 2 |
| Scappaticci, F | 1 |
| Palma, JF | 1 |
| Price, R | 1 |
| Lee, JJ | 2 |
| Nicholas, A | 1 |
| Sommer, N | 1 |
| Bendell, J | 1 |
| Gabrielson, S | 1 |
| Tsai, JA | 2 |
| Celebioglu, F | 1 |
| Nilsson, M | 2 |
| Rouvelas, I | 1 |
| Lindblad, M | 1 |
| Bjäreback, A | 1 |
| Tomson, A | 1 |
| Axelsson, R | 1 |
| Pietrantonio, F | 1 |
| Roviello, G | 1 |
| Petrioli, R | 1 |
| Rosellini, P | 1 |
| Multari, AG | 1 |
| Conca, R | 2 |
| Paganini, G | 1 |
| Chiriacò, G | 1 |
| Aieta, M | 1 |
| Huang, WC | 1 |
| Jang, TH | 1 |
| Tung, SL | 1 |
| Yen, TC | 1 |
| Chan, SH | 1 |
| Wang, LH | 1 |
| Akhter, K | 1 |
| Enamur Rashid, M | 1 |
| Liu, Q | 2 |
| Jia, B | 1 |
| Du, X | 1 |
| Dai, G | 1 |
| Liu, H | 10 |
| Zeng, M | 1 |
| Wen, K | 1 |
| Zhu, Y | 3 |
| Feng, L | 1 |
| Ladbury, C | 1 |
| A Goodman, K | 1 |
| Schefter, TE | 1 |
| Olsen, JR | 1 |
| Cleary, JM | 1 |
| Horick, NK | 1 |
| McCleary, NJ | 1 |
| Abrams, TA | 1 |
| Yurgelun, MB | 1 |
| Azzoli, CG | 1 |
| Rubinson, DA | 1 |
| Brooks, GA | 1 |
| Chan, JA | 1 |
| Blaszkowsky, LS | 1 |
| Clark, JW | 1 |
| Goyal, L | 1 |
| Meyerhardt, JA | 2 |
| Ng, K | 1 |
| Schrag, D | 1 |
| Savarese, DMF | 1 |
| Graham, C | 1 |
| Fitzpatrick, B | 1 |
| Gibb, KA | 1 |
| Boucher, Y | 1 |
| Duda, DG | 1 |
| Jain, RK | 1 |
| Fuchs, CS | 1 |
| Enzinger, PC | 1 |
| Liang, Y | 2 |
| Xie, X | 3 |
| Xia, L | 1 |
| Meng, J | 1 |
| Xu, R | 2 |
| He, D | 1 |
| Fujii, H | 2 |
| Horie, S | 1 |
| Mishra, R | 1 |
| Sakamoto, M | 2 |
| Mori, S | 3 |
| Yang, YF | 1 |
| Lee, YC | 3 |
| Wang, YY | 1 |
| Wang, CH | 2 |
| Hou, MF | 1 |
| Yuan, SF | 1 |
| Hamfjord, J | 1 |
| Guren, TK | 1 |
| Dajani, O | 1 |
| Johansen, JS | 1 |
| Glimelius, B | 3 |
| Sorbye, H | 1 |
| Pfeiffer, P | 2 |
| Lingjærde, OC | 1 |
| Tveit, KM | 2 |
| Kure, EH | 1 |
| Pallisgaard, N | 1 |
| Spindler, KG | 1 |
| Degirmencioglu, S | 1 |
| Tanrıverdi, O | 1 |
| Demiray, AG | 1 |
| Senol, H | 1 |
| Dogu, GG | 1 |
| Yaren, A | 2 |
| Oguma, J | 1 |
| Ozawa, S | 2 |
| Kazuno, A | 1 |
| Yamamoto, M | 7 |
| Ninomiya, Y | 1 |
| Yatabe, K | 1 |
| Gbolahan, O | 1 |
| Hashemi-Sadraei, N | 1 |
| O'Neil, B | 1 |
| Jin, X | 1 |
| Bai, Y | 1 |
| Gao, L | 1 |
| Mantion, G | 1 |
| Boudghène, F | 1 |
| Mornex, F | 2 |
| Adenis, A | 1 |
| Azria, D | 1 |
| Balosso, J | 1 |
| Ben Abdelghani, M | 1 |
| François, Y | 1 |
| Conroy, T | 1 |
| Rio, E | 1 |
| Roullet, B | 1 |
| Spaëth, D | 1 |
| Quero, L | 2 |
| Lakkis, Z | 1 |
| Coudert, M | 1 |
| Ionescu-Goga, M | 1 |
| Tanang, A | 1 |
| Cabau, M | 1 |
| Luc, G | 1 |
| Terrebonne, E | 1 |
| Belleanne, G | 1 |
| Sa Cunha, A | 1 |
| Collet, D | 1 |
| Migita, K | 1 |
| Takayama, T | 2 |
| Saeki, K | 1 |
| Matsumoto, S | 1 |
| Wakatsuki, K | 2 |
| Enomoto, K | 3 |
| Ito, M | 3 |
| Kurumatani, N | 1 |
| Nakajima, Y | 3 |
| Harvey, VJ | 1 |
| Sharples, KJ | 1 |
| Isaacs, RJ | 1 |
| Jameson, MB | 1 |
| Jeffery, GM | 1 |
| McLaren, BR | 1 |
| Pollard, S | 1 |
| Riley, GA | 1 |
| Simpson, AB | 1 |
| Hinder, VA | 1 |
| Scott, JN | 1 |
| Dzhelali, MV | 1 |
| Findlay, MP | 1 |
| Shin, HC | 1 |
| Han, W | 1 |
| Moon, HG | 1 |
| Im, SA | 7 |
| Moon, WK | 1 |
| Park, IA | 1 |
| Park, SJ | 2 |
| Noh, DY | 1 |
| Shibata, T | 7 |
| Ando, N | 3 |
| Seki, S | 2 |
| Mukaida, H | 1 |
| Fukuda, H | 5 |
| Yoshizawa, J | 1 |
| Koide, N | 1 |
| Takeuchi, D | 1 |
| Suzuki, A | 3 |
| Shinoda, A | 1 |
| Miyagawa, S | 2 |
| Deenen, MJ | 1 |
| Dewit, L | 1 |
| Boot, H | 3 |
| Beijnen, JH | 2 |
| Schellens, JH | 1 |
| Cats, A | 2 |
| Kim, K | 7 |
| Min, HS | 1 |
| Chie, EK | 5 |
| Jang, JY | 5 |
| Kim, SW | 6 |
| Han, SW | 3 |
| Oh, DY | 6 |
| Kim, TY | 6 |
| Bang, YJ | 6 |
| Jang, JJ | 1 |
| Ha, SW | 5 |
| Heinzow, HS | 1 |
| Seifert, H | 1 |
| Tsepetonidis, S | 1 |
| Wolters, H | 1 |
| Kucharzik, T | 1 |
| Domschke, W | 1 |
| Domagk, D | 1 |
| Meister, T | 1 |
| Lin, SC | 1 |
| Chen, PC | 1 |
| Lee, CT | 1 |
| Tsai, HM | 1 |
| Lin, PC | 1 |
| Chen, HH | 1 |
| Wu, YH | 1 |
| Lin, BW | 1 |
| Su, WP | 1 |
| Chao, YK | 2 |
| Tseng, CK | 2 |
| Wen, YW | 2 |
| Liu, YH | 2 |
| Wan, YL | 1 |
| Chiu, CT | 1 |
| Chang, WC | 1 |
| Chang, HK | 4 |
| Polysalov, VN | 1 |
| Veriasova, NN | 1 |
| Dolgikh, SD | 1 |
| Gapbarov, ACh | 1 |
| Wang, B | 4 |
| Zhang, S | 1 |
| Yue, K | 1 |
| Wang, XD | 1 |
| Skrzypek, K | 1 |
| Tertil, M | 1 |
| Golda, S | 1 |
| Ciesla, M | 1 |
| Weglarczyk, K | 1 |
| Collet, G | 1 |
| Guichard, A | 1 |
| Kozakowska, M | 1 |
| Boczkowski, J | 1 |
| Was, H | 1 |
| Gil, T | 1 |
| Kuzdzal, J | 1 |
| Muchova, L | 1 |
| Vitek, L | 1 |
| Loboda, A | 1 |
| Jozkowicz, A | 1 |
| Kieda, C | 1 |
| Dulak, J | 1 |
| Zhang, SS | 1 |
| Yang, H | 1 |
| Luo, KJ | 1 |
| Wen, J | 1 |
| Bella, AE | 1 |
| Hu, Y | 5 |
| Yang, F | 1 |
| Fu, JH | 2 |
| Hoffe, SE | 1 |
| Almhanna, K | 1 |
| Weber, JM | 1 |
| Chuong, MD | 1 |
| Karl, RC | 1 |
| Meredith, K | 1 |
| Yin, L | 1 |
| Luo, C | 1 |
| Zhang, H | 2 |
| Le Fur, E | 1 |
| Chatellier, G | 1 |
| Berger, A | 3 |
| Emile, JF | 1 |
| Dousset, B | 1 |
| Nordlinger, B | 3 |
| Berges, O | 1 |
| Deberne, M | 1 |
| Dessard-Diana, B | 1 |
| Henni, M | 1 |
| Giraud, P | 1 |
| Housset, M | 2 |
| Durdux, C | 1 |
| Sato, Y | 3 |
| Motoyama, S | 1 |
| Nanjo, H | 1 |
| Ito, S | 3 |
| Yoshino, K | 1 |
| Sasaki, T | 8 |
| Kuribayashi, K | 1 |
| Nagaki, Y | 1 |
| Saito, H | 6 |
| Minamiya, Y | 1 |
| Ogawa, J | 1 |
| Elezkurtaj, S | 1 |
| Moser, L | 1 |
| Budczies, J | 1 |
| Müller, AJ | 1 |
| Bläker, H | 1 |
| Buhr, HJ | 1 |
| Dietel, M | 1 |
| Kruschewski, M | 1 |
| Musio, D | 1 |
| De Felice, F | 1 |
| Bulzonetti, N | 1 |
| Guarnaccia, R | 1 |
| Caiazzo, R | 1 |
| Bangrazi, C | 1 |
| Raffetto, N | 1 |
| Tombolini, V | 1 |
| Xiang, H | 1 |
| He, XM | 1 |
| Yang, HJ | 1 |
| Zong, XY | 1 |
| Loi, S | 2 |
| Michiels, S | 2 |
| Lambrechts, D | 1 |
| Fumagalli, D | 1 |
| Claes, B | 1 |
| Kellokumpu-Lehtinen, PL | 2 |
| Bono, P | 2 |
| Kataja, V | 2 |
| Piccart, MJ | 5 |
| Joensuu, H | 3 |
| Sotiriou, C | 3 |
| Ohchi, T | 2 |
| Akagi, Y | 2 |
| Kinugasa, T | 1 |
| Ishibashi, Y | 1 |
| Tanaka, N | 7 |
| Fujino, S | 1 |
| Kibe, S | 1 |
| Yuge, K | 1 |
| Sasatomi, T | 3 |
| Mizobe, T | 1 |
| Oka, Y | 3 |
| Shirouzu, K | 8 |
| Cutilli, T | 1 |
| Leocata, P | 1 |
| Dolo, V | 1 |
| Altobelli, E | 1 |
| Gerber, N | 1 |
| Ilson, DH | 1 |
| Wu, AJ | 1 |
| Janjigian, YY | 1 |
| Kelsen, DP | 1 |
| Zheng, J | 1 |
| Bains, MS | 1 |
| Rizk, N | 1 |
| Rusch, VW | 1 |
| Goodman, KA | 2 |
| Trusilova, EV | 1 |
| Besova, NS | 2 |
| Bagrova, SG | 1 |
| Gorbunova, VA | 1 |
| Stilidi, IS | 1 |
| Nered, SN | 1 |
| Tezuka, T | 1 |
| Ishida, H | 4 |
| Ooshiro, M | 1 |
| Matsuoka, H | 1 |
| Kawasaki, S | 3 |
| Mishima, H | 4 |
| Maeda, K | 3 |
| Koda, K | 4 |
| Ahn, JS | 1 |
| Jeon, JR | 1 |
| Yoo, HS | 2 |
| Park, TK | 2 |
| Park, CK | 1 |
| Sinn, DH | 1 |
| Paik, SW | 1 |
| Yamamoto, Y | 10 |
| Konishi, H | 2 |
| Ichikawa, D | 3 |
| Arita, T | 2 |
| Shoda, K | 1 |
| Komatsu, S | 2 |
| Shiozaki, A | 3 |
| Ikoma, H | 1 |
| Fujiwara, H | 4 |
| Okamoto, K | 3 |
| Ochiai, T | 7 |
| Inoue, J | 1 |
| Inazawa, J | 1 |
| Otsuji, E | 3 |
| Hirata, A | 1 |
| Itatsu, K | 1 |
| Fukaya, M | 1 |
| Ebata, T | 1 |
| Tsunoda, N | 1 |
| Igami, T | 1 |
| Sugawara, G | 1 |
| Uehara, K | 2 |
| Yoshioka, Y | 1 |
| Usui, H | 1 |
| Nagino, M | 2 |
| Matsumoto, K | 2 |
| Shioyama, Y | 1 |
| Nakamura, K | 6 |
| Atsumi, K | 1 |
| Nonoshita, T | 1 |
| Ooga, S | 1 |
| Yoshitake, T | 1 |
| Uehara, S | 3 |
| Hirata, H | 1 |
| Honda, H | 2 |
| Lupinacci, RM | 1 |
| Menegaux, F | 1 |
| Labianca, R | 6 |
| Beretta, GD | 4 |
| Mosconi, S | 3 |
| Mandalà, M | 1 |
| Cervantes, A | 2 |
| Fan, Z | 1 |
| Wang, T | 3 |
| Xie, Y | 1 |
| Fan, T | 2 |
| Lin, B | 2 |
| Ouyang, T | 2 |
| Madbouly, KM | 1 |
| Abbas, KS | 1 |
| Hussein, AM | 2 |
| Mansi, L | 1 |
| Benzidane, B | 1 |
| Cazorla, A | 1 |
| Demarchi, M | 1 |
| Nguyen, T | 1 |
| Kaliski, A | 1 |
| Delabrousse, E | 1 |
| Bonnetain, F | 3 |
| Letondal, P | 1 |
| Bosset, JF | 2 |
| Valmary-Degano, S | 1 |
| Genovesi, D | 1 |
| Myerson, RJ | 1 |
| Cèfaro, GA | 1 |
| Vinciguerra, A | 1 |
| Augurio, A | 1 |
| Trignani, M | 1 |
| DI Tommaso, M | 1 |
| Nuzzo, M | 1 |
| Lupattelli, M | 1 |
| Aristei, C | 1 |
| Bellavita, R | 1 |
| Scandolaro, L | 2 |
| Cosentino, D | 2 |
| Pani, G | 1 |
| Ziccarelli, L | 1 |
| Gambacorta, MA | 2 |
| Barba, MC | 1 |
| Maranzano, E | 1 |
| Trippa, F | 1 |
| Sciacero, P | 1 |
| Niespolo, R | 1 |
| Leonardi, C | 1 |
| Iannone, T | 1 |
| Rosetto, ME | 1 |
| Fusco, V | 1 |
| Sanpaolo, P | 1 |
| Melano, A | 1 |
| Valvo, F | 1 |
| Capirci, C | 1 |
| DE Paoli, A | 1 |
| DI Nicola, M | 1 |
| Mantello, G | 1 |
| Valentini, V | 4 |
| Lee, YY | 1 |
| Park, W | 2 |
| Huh, SJ | 2 |
| Yoon, A | 1 |
| Park, JY | 1 |
| Choi, CH | 1 |
| Kim, TJ | 1 |
| Lee, JW | 3 |
| Kim, BG | 2 |
| Bae, DS | 2 |
| Kaira, K | 1 |
| Sunose, Y | 1 |
| Ohshima, Y | 2 |
| Ishioka, NS | 1 |
| Arakawa, K | 1 |
| Ogawa, T | 4 |
| Sunaga, N | 1 |
| Shimizu, K | 3 |
| Tominaga, H | 1 |
| Oriuchi, N | 1 |
| Itoh, H | 1 |
| Nagamori, S | 1 |
| Kanai, Y | 1 |
| Yamaguchi, A | 1 |
| Segawa, A | 1 |
| Ide, M | 3 |
| Oyama, T | 3 |
| Takeyoshi, I | 3 |
| Delbaldo, C | 1 |
| Serin, D | 6 |
| Mousseau, M | 1 |
| Greget, S | 1 |
| Audhuy, B | 3 |
| Priou, F | 1 |
| Berdah, JF | 1 |
| Teissier, E | 1 |
| Laplaige, P | 1 |
| Zelek, L | 1 |
| Quinaux, E | 3 |
| Buyse, M | 4 |
| Piedbois, P | 1 |
| Shimada, K | 2 |
| Ishikawa, T | 2 |
| Yoneyama, S | 2 |
| Kita, K | 1 |
| Narui, K | 1 |
| Sugae, S | 1 |
| Shimizu, D | 2 |
| Tanabe, M | 1 |
| Chishima, T | 1 |
| Ichikawa, Y | 1 |
| Endo, I | 1 |
| Le Naourès, C | 1 |
| Guilloit, JM | 1 |
| Capovilla, M | 1 |
| Buzdar, AU | 17 |
| Suman, VJ | 2 |
| Meric-Bernstam, F | 2 |
| Leitch, AM | 1 |
| Ellis, MJ | 1 |
| Boughey, JC | 1 |
| Unzeitig, G | 1 |
| Royce, M | 1 |
| McCall, LM | 1 |
| Ewer, MS | 1 |
| Hunt, KK | 7 |
| Curtis, NJ | 1 |
| Bailey, IS | 2 |
| Kelly, JJ | 2 |
| Byrne, JP | 2 |
| Wu, H | 1 |
| Wang, L | 5 |
| He, YL | 1 |
| Xu, JB | 1 |
| Cai, SR | 1 |
| Ma, JP | 1 |
| Chen, CQ | 1 |
| Zhang, XH | 1 |
| Zhan, WH | 1 |
| Ye, L | 1 |
| Ji, K | 1 |
| Toms, AM | 1 |
| Davies, ML | 1 |
| Ruge, F | 1 |
| Ji, J | 1 |
| Hargest, R | 1 |
| Jiang, WG | 1 |
| Calvo, FA | 2 |
| Sole, CV | 1 |
| Serrano, J | 2 |
| Del Valle, E | 1 |
| Rodriguez, M | 2 |
| Muñoz-Calero, A | 1 |
| García-Sabrido, JL | 1 |
| Garcia-Alfonso, P | 1 |
| Peligros, I | 1 |
| Alvarez, E | 1 |
| Stiekema, J | 1 |
| Trip, AK | 1 |
| Jansen, EP | 1 |
| Ponz, OB | 1 |
| Verheij, M | 1 |
| van Sandick, JW | 1 |
| Lévy, A | 1 |
| Blanchard, P | 1 |
| Janot, F | 4 |
| Temam, S | 1 |
| Bourhis, J | 1 |
| Daly-Schveitzer, N | 1 |
| Tao, Y | 1 |
| Leone, JP | 1 |
| Leone, J | 1 |
| Vallejo, CT | 1 |
| Pérez, JE | 1 |
| Romero, AO | 1 |
| Machiavelli, MR | 1 |
| Romero Acuña, L | 1 |
| Domínguez, ME | 1 |
| Langui, M | 1 |
| Fasce, HM | 1 |
| Leone, BA | 1 |
| Ortiz, E | 1 |
| Iturbe, J | 1 |
| Zwenger, AO | 1 |
| Oashi, K | 1 |
| Tsutsumida, A | 1 |
| Namikawa, K | 1 |
| Tanaka, R | 1 |
| Omata, W | 1 |
| Yamazaki, N | 2 |
| Dong, L | 2 |
| Wang, F | 5 |
| Yin, X | 1 |
| Chen, L | 4 |
| Li, G | 5 |
| Lin, F | 1 |
| Ni, W | 1 |
| Wu, J | 1 |
| Jin, R | 1 |
| Jiang, L | 1 |
| Yasui, T | 1 |
| Mukubo, H | 1 |
| Nakanuma, S | 1 |
| Sato, N | 4 |
| Kita, I | 4 |
| Ojima, E | 1 |
| Nakano, T | 1 |
| Kanamoto, A | 1 |
| Sasaki, S | 1 |
| Sueda, T | 1 |
| Noura, S | 4 |
| Shingai, T | 5 |
| Gotoh, K | 2 |
| Kishi, K | 5 |
| Marubashi, S | 3 |
| Fujiwara, Y | 13 |
| Ohigashi, H | 3 |
| Tomita, Y | 1 |
| Ishikawa, O | 3 |
| Tsukiyama, G | 1 |
| Hasegawa, M | 3 |
| Yabuki, S | 1 |
| Tanaka, H | 3 |
| Tanahashi, C | 1 |
| Yoshioka, S | 4 |
| Shiobara, M | 1 |
| Kataoka, M | 1 |
| Arai, S | 1 |
| Tonooka, T | 1 |
| Miyazawa, K | 2 |
| Oeda, Y | 1 |
| Deguchi, K | 1 |
| Kawada, J | 1 |
| Aono, T | 2 |
| Nomura, M | 2 |
| Tamagawa, H | 2 |
| Matsuda, C | 1 |
| Deguchi, T | 1 |
| Higashi, S | 1 |
| Okumura, Y | 1 |
| Noguchi, Y | 2 |
| Takagi, M | 1 |
| Fukui, A | 1 |
| Kawasaki, K | 2 |
| Iwasaki, Y | 5 |
| Yajima, K | 2 |
| Oohinata, R | 1 |
| Yuu, K | 1 |
| Iwanaga, T | 3 |
| Karasawa, K | 2 |
| Maeda, Y | 3 |
| Kaczmarek, K | 1 |
| Wiącek, MP | 1 |
| Sulewski, A | 1 |
| Kubaszewski, Ł | 1 |
| Kaczmarczyk, J | 1 |
| Nowakowski, A | 1 |
| Hirata, K | 7 |
| Nagata, N | 1 |
| Kato, T | 11 |
| Okuyama, Y | 1 |
| Andoh, H | 1 |
| Takahashi, K | 7 |
| Hazama, S | 2 |
| Nolan, L | 1 |
| Bateman, AC | 1 |
| Sharland, DM | 1 |
| Rees, CN | 1 |
| Iveson, TJ | 1 |
| Bateman, AR | 1 |
| Nandy, N | 1 |
| Dasanu, CA | 1 |
| Balermpas, P | 1 |
| Bauer, C | 1 |
| Fraunholz, I | 1 |
| Ottinger, A | 1 |
| Wagenblast, J | 1 |
| Stöver, T | 1 |
| Seitz, O | 1 |
| Fokas, E | 1 |
| Rödel, C | 3 |
| Weiss, C | 1 |
| Huh, JW | 1 |
| Lee, WY | 3 |
| Park, YA | 1 |
| Cho, YB | 1 |
| Yun, SH | 1 |
| Kim, HC | 1 |
| Chun, HK | 1 |
| Nagano, I | 1 |
| Yamada, I | 1 |
| Niwa, M | 2 |
| Kanazawa, H | 1 |
| Sato, T | 3 |
| Matsumoto, N | 1 |
| Yoshinaka, H | 1 |
| Maggiori, L | 1 |
| Bretagnol, F | 1 |
| Aslam, MI | 1 |
| Guedj, N | 1 |
| Zappa, M | 1 |
| Ferron, M | 1 |
| Panis, Y | 1 |
| Jung, M | 1 |
| Holmqvist, A | 1 |
| Sun, XF | 1 |
| Albertsson, M | 1 |
| Takahashi, N | 4 |
| Aoyama, F | 1 |
| Hiyoshi, M | 1 |
| Kataoka, H | 1 |
| Sawaguchi, A | 1 |
| Wu, CE | 1 |
| Chen, SC | 3 |
| Lin, YC | 2 |
| Lo, YF | 2 |
| Hsueh, S | 2 |
| Kawasaki, Y | 2 |
| Okumura, H | 6 |
| Uchikado, Y | 3 |
| Kita, Y | 3 |
| Owaki, T | 3 |
| Ishigami, S | 4 |
| Natsugoe, S | 5 |
| Okur, A | 1 |
| Eser, EP | 1 |
| Yilmaz, G | 1 |
| Dalgiç, A | 1 |
| Akdemir, ÜÖ | 1 |
| Oğuz, A | 1 |
| Karadeniz, C | 1 |
| Akyol, G | 1 |
| Demiroğullari, B | 1 |
| Boyunağa, Ö | 1 |
| Pinarli, FG | 1 |
| Suzuki, H | 7 |
| Fujii, T | 4 |
| Asao, T | 2 |
| Tsutsumi, S | 1 |
| Wada, S | 1 |
| Araki, K | 1 |
| Kubo, N | 1 |
| Watanabe, A | 2 |
| Tsukagoshi, M | 1 |
| Matsuda, N | 1 |
| Hayashi, N | 4 |
| Ohde, S | 1 |
| Yagata, H | 1 |
| Kajiura, Y | 2 |
| Yoshida, A | 1 |
| Suzuki, K | 3 |
| Nakamura, S | 7 |
| Tsunoda, H | 1 |
| Yamauchi, H | 2 |
| Guo, XC | 1 |
| Mao, ZY | 1 |
| Su, D | 1 |
| Wang, LJ | 1 |
| Zhang, TT | 1 |
| Bai, L | 1 |
| Sonoda, H | 1 |
| Shimizu, T | 5 |
| Mekata, E | 1 |
| Endo, Y | 2 |
| Ishida, M | 1 |
| Tani, T | 4 |
| Peguero, J | 1 |
| Khanfar, A | 1 |
| Mannem, S | 1 |
| Willis, M | 1 |
| Markowtiz, A | 1 |
| Dorth, JA | 1 |
| Pura, JA | 1 |
| Palta, M | 1 |
| Willett, CG | 3 |
| Uronis, HE | 1 |
| D'Amico, TA | 1 |
| Czito, BG | 2 |
| Nagai, Y | 3 |
| Lou, XP | 1 |
| Miao, JH | 1 |
| Lu, P | 1 |
| Chang, ZW | 1 |
| Han, ZF | 1 |
| Martin, M | 6 |
| Brase, JC | 1 |
| Calvo, L | 2 |
| Krappmann, K | 1 |
| Ruiz-Borrego, M | 1 |
| Fisch, K | 1 |
| Ruiz, A | 1 |
| Weber, KE | 1 |
| Munarriz, B | 2 |
| Petry, C | 1 |
| Rodriguez, CA | 2 |
| Kronenwett, R | 1 |
| Crespo, C | 1 |
| Alba, E | 1 |
| Carrasco, E | 1 |
| Casas, M | 2 |
| Caballero, R | 1 |
| Rodriguez-Lescure, A | 3 |
| Omoto, I | 2 |
| Arigami, T | 1 |
| Uenosono, Y | 1 |
| Matsushita, D | 2 |
| Hiraki, Y | 3 |
| Fushimi, K | 1 |
| Tanabe, N | 1 |
| Takami, M | 4 |
| Kodaira, T | 2 |
| Ito, J | 1 |
| Tachibana, H | 1 |
| Nakanishi, T | 1 |
| Fuwa, N | 1 |
| Qian, W | 1 |
| Zhu, G | 1 |
| Ji, Q | 1 |
| Guo, Y | 1 |
| Wei, L | 1 |
| Liang, X | 3 |
| Blinde, SE | 1 |
| Schasfoort, R | 1 |
| Mens, JW | 1 |
| Verhoef, C | 2 |
| Olofsen, M | 1 |
| Nuyttens, JJ | 1 |
| Hur, H | 2 |
| Kim, NK | 2 |
| Baik, SH | 1 |
| Lee, KY | 1 |
| Koom, WS | 1 |
| Ahn, JB | 2 |
| Kim, H | 1 |
| van Bunderen, CC | 1 |
| de Weger, VA | 1 |
| Griffioen-Keijzer, A | 1 |
| Rack, B | 3 |
| Schindlbeck, C | 2 |
| Jückstock, J | 1 |
| Andergassen, U | 1 |
| Hepp, P | 1 |
| Zwingers, T | 2 |
| Friedl, TW | 2 |
| Lorenz, R | 1 |
| Tesch, H | 1 |
| Fasching, PA | 1 |
| Fehm, T | 2 |
| Schneeweiss, A | 1 |
| Lichtenegger, W | 3 |
| Beckmann, MW | 1 |
| Friese, K | 1 |
| Pantel, K | 1 |
| Janni, W | 3 |
| Higuchi, K | 3 |
| Komori, S | 2 |
| Tanabe, S | 4 |
| Katada, C | 3 |
| Azuma, M | 1 |
| Ishiyama, H | 2 |
| Ishido, K | 1 |
| Katada, N | 2 |
| Hayakawa, K | 2 |
| Koizumi, W | 5 |
| Morillo, V | 1 |
| Santos, M | 1 |
| Gomez-Espí, M | 1 |
| Del Vale, E | 1 |
| Gracia-Sabrido, JL | 1 |
| Ferrer, C | 1 |
| Sole, C | 1 |
| Tashiro, J | 1 |
| Ishii, T | 1 |
| Kondo, H | 1 |
| Morita, Y | 1 |
| Koyama, I | 3 |
| Huang, RW | 1 |
| Chan, SC | 1 |
| Das, U | 1 |
| Lakshmaiah, KC | 1 |
| Govind Babu, K | 1 |
| Suresh, TM | 1 |
| Lokanatha, D | 1 |
| Jacob, L | 1 |
| Babu, S | 1 |
| Eikesdal, HP | 1 |
| Knappskog, S | 1 |
| Aas, T | 1 |
| Lønning, PE | 1 |
| Cihan, YB | 1 |
| Isa O, N | 1 |
| Russo N, M | 1 |
| López V, H | 1 |
| Deng, Z | 1 |
| Kiyuna, A | 1 |
| Ganaha, A | 1 |
| Yamashita, Y | 7 |
| Matayoshi, S | 1 |
| Agena, S | 1 |
| Toita, T | 1 |
| Uehara, T | 1 |
| Suzuki, M | 8 |
| Siegel, EM | 1 |
| Eschrich, S | 1 |
| Winter, K | 1 |
| Riggs, B | 1 |
| Berglund, A | 2 |
| Ajidahun, A | 1 |
| Simko, J | 1 |
| Moughan, J | 1 |
| Ajani, J | 1 |
| Magliocco, A | 1 |
| Elahi, A | 1 |
| Hoffe, S | 1 |
| Shibata, D | 1 |
| Zhu, X | 1 |
| Zhao, X | 1 |
| Peng, W | 1 |
| Sun, S | 2 |
| Cao, J | 1 |
| Ji, D | 1 |
| Liu, X | 4 |
| Wang, C | 3 |
| Huang, M | 1 |
| Yu, H | 1 |
| Guo, W | 1 |
| Yin, J | 2 |
| Chiang, PH | 1 |
| Chen, CH | 1 |
| Shen, YC | 1 |
| De Stefano, A | 1 |
| Moretto, R | 1 |
| Bucci, L | 1 |
| Pepe, S | 1 |
| Romano, FJ | 1 |
| Cella, AC | 1 |
| Attademo, L | 1 |
| Rosanova, M | 1 |
| De Falco, S | 1 |
| Fiore, G | 1 |
| Raimondo, L | 1 |
| De Placido, S | 5 |
| Carlomagno, C | 1 |
| Schwameis, M | 1 |
| Thaler, J | 1 |
| Schober, A | 1 |
| Schörgenhofer, C | 1 |
| Kulinna-Cosentini, C | 1 |
| Laggner, A | 1 |
| Röggla, M | 1 |
| Jilma, B | 1 |
| Ijichi, K | 1 |
| Hanai, N | 1 |
| Kawakita, D | 1 |
| Ozawa, T | 2 |
| Hirakawa, H | 2 |
| Murakami, S | 3 |
| Hasegawa, Y | 1 |
| Cienfuegos, JA | 1 |
| Rotellar, F | 1 |
| Baixauli, J | 2 |
| Beorlegui, C | 2 |
| Sola, JJ | 2 |
| Arbea, L | 3 |
| Pastor, C | 2 |
| Arredondo, J | 1 |
| Hernández-Lizoáin, JL | 2 |
| Silvestris, N | 2 |
| Simone, G | 2 |
| Partipilo, G | 1 |
| Scarpi, E | 3 |
| Lorusso, V | 3 |
| Brunetti, AE | 1 |
| Maiello, E | 2 |
| Paradiso, A | 3 |
| Mangia, A | 1 |
| Yamasaki, M | 8 |
| Takiguchi, S | 10 |
| Dong, CX | 1 |
| Fu, JF | 2 |
| Ye, XY | 1 |
| Li, XF | 1 |
| Zhong, X | 1 |
| Yuan, Y | 1 |
| Sinha, R | 1 |
| Larkin, J | 1 |
| Fearfield, L | 1 |
| Izawa, N | 1 |
| Onozawa, Y | 2 |
| Hikosaka, T | 1 |
| Hamauchi, S | 1 |
| Tsushima, T | 2 |
| Todaka, A | 1 |
| Machida, N | 1 |
| Haraguchi, Y | 1 |
| Ogawa, H | 1 |
| Nishimura, T | 3 |
| Nakagawa, M | 2 |
| Fuke, T | 1 |
| Iida, Y | 1 |
| Kamijo, T | 1 |
| Onitsuka, T | 1 |
| Yasui, H | 3 |
| Yokota, T | 4 |
| Nishida, T | 1 |
| Tsujii, M | 1 |
| Tsutsui, S | 1 |
| Isohashi, F | 1 |
| Kato, M | 2 |
| Shinzaki, S | 1 |
| Iijima, H | 2 |
| Takehara, T | 1 |
| Yu, P | 2 |
| Du, Y | 1 |
| Yu, Q | 1 |
| Huang, L | 3 |
| Dong, R | 1 |
| Yue, D | 1 |
| Chen, X | 2 |
| Ping, Y | 1 |
| Wang, D | 2 |
| Zhang, T | 1 |
| Li, F | 2 |
| Yang, L | 2 |
| Koido, S | 1 |
| Kan, S | 1 |
| Yoshida, K | 8 |
| Yoshizaki, S | 1 |
| Takakura, K | 1 |
| Namiki, Y | 1 |
| Tsukinaga, S | 1 |
| Odahara, S | 1 |
| Kajihara, M | 1 |
| Okamoto, M | 2 |
| Yusa, S | 1 |
| Gong, J | 1 |
| Sugiyama, H | 1 |
| Ohkusa, T | 1 |
| Homma, S | 1 |
| Tajiri, H | 1 |
| Lee, SJ | 3 |
| Park, SH | 3 |
| Lim, DH | 3 |
| Park, YS | 3 |
| Lim, HY | 2 |
| Choi, MG | 1 |
| Lee, JH | 4 |
| Bae, JM | 1 |
| Kang, WK | 4 |
| Perez, K | 1 |
| Safran, H | 1 |
| Sikov, W | 1 |
| Vrees, M | 1 |
| Klipfel, A | 1 |
| Shah, N | 1 |
| Schechter, S | 1 |
| Oldenburg, N | 1 |
| Pricolo, V | 1 |
| Rosati, K | 1 |
| Dipetrillo, T | 1 |
| Choda, Y | 1 |
| Ninomiya, M | 1 |
| Kanazawa, T | 5 |
| Sato, D | 1 |
| Tokumoto, N | 1 |
| Harano, M | 1 |
| Matsukawa, H | 1 |
| Ojima, Y | 1 |
| Idani, H | 1 |
| Shiozaki, S | 1 |
| Okajima, M | 1 |
| Ichikawa, R | 1 |
| Kure, K | 1 |
| Honjo, K | 1 |
| Aoki, J | 1 |
| Okazawa, Y | 1 |
| Mizukoshi, K | 1 |
| Ro, H | 1 |
| Kawai, M | 3 |
| Takehara, K | 1 |
| Okubo, H | 1 |
| Ishiyama, S | 2 |
| Sugimoto, K | 3 |
| Komiyama, H | 2 |
| Yaginuma, Y | 2 |
| Kojima, Y | 2 |
| Tomiki, Y | 2 |
| Sakamoto, K | 3 |
| Moorcraft, SY | 1 |
| Khan, K | 1 |
| Peckitt, C | 2 |
| Watkins, D | 1 |
| Rao, S | 2 |
| Cunningham, D | 4 |
| Chau, I | 2 |
| Uetake, H | 2 |
| Yasuno, M | 2 |
| Ishiguro, M | 1 |
| Kameoka, S | 1 |
| Shimada, Y | 5 |
| Muro, K | 5 |
| Yamamoto, J | 1 |
| Mizunuma, N | 3 |
| Mochizuki, I | 1 |
| Kinugasa, Y | 2 |
| Kikuchi, T | 3 |
| Sugihara, K | 3 |
| Yamashita, H | 2 |
| Omori, M | 1 |
| Takenaka, R | 1 |
| Okuma, K | 1 |
| Kobayashi, R | 1 |
| Ohtomo, K | 1 |
| Nakagawa, K | 5 |
| Leon, O | 1 |
| Guren, M | 1 |
| Hagberg, O | 1 |
| Dahl, O | 2 |
| Havsteen, H | 1 |
| Naucler, G | 1 |
| Svensson, C | 1 |
| Jakobsen, A | 4 |
| Wanderås, E | 1 |
| Ekman, T | 1 |
| Lindh, B | 1 |
| Balteskard, L | 1 |
| Frykholm, G | 1 |
| Johnsson, A | 2 |
| Cinar, P | 1 |
| Calkins, SM | 1 |
| Venook, AP | 3 |
| Kelley, RK | 2 |
| Yasuda, T | 9 |
| Sun, Z | 2 |
| Zhang, N | 1 |
| Jin, T | 1 |
| Luo, JL | 1 |
| Zhou, N | 2 |
| Li, DC | 1 |
| Ju, HX | 1 |
| Fan, YT | 1 |
| Liu, Y | 4 |
| Zhu, YP | 1 |
| Feng, HY | 1 |
| Liu, LY | 1 |
| Mombelli, S | 1 |
| Kwiatkowski, F | 2 |
| Abrial, C | 1 |
| Wang-Lopez, Q | 1 |
| de Boissieu, P | 1 |
| Garbar, C | 1 |
| Bensussan, A | 1 |
| Curé, H | 1 |
| Kubáčková, K | 1 |
| Bortlíček, Z | 1 |
| Pikus, T | 1 |
| Linke, Z | 1 |
| Pokorná, P | 1 |
| Vyzula, R | 1 |
| Prausová, J | 1 |
| Kim, SY | 2 |
| Choi, YY | 1 |
| Shin, HB | 1 |
| Jo, A | 1 |
| Choi, H | 1 |
| Seo, SH | 1 |
| Bang, HJ | 1 |
| Cheong, JH | 1 |
| Hyung, WJ | 1 |
| Noh, SH | 3 |
| Yossi, S | 1 |
| El Alouani, C | 1 |
| Pointreau, Y | 1 |
| Laccourreye, L | 1 |
| Capitain, O | 2 |
| Gustin, P | 1 |
| Peyraga, G | 1 |
| Septans, AL | 1 |
| Jadaud, É | 1 |
| Vinchon-Petit, S | 1 |
| Cellier, P | 2 |
| Autret, D | 1 |
| Tuchais, C | 1 |
| Iyer, NG | 1 |
| Tan, DS | 1 |
| Tan, VK | 1 |
| Hwang, J | 1 |
| Tan, NC | 1 |
| Sivanandan, R | 1 |
| Tan, HK | 1 |
| Lim, WT | 2 |
| Ang, MK | 1 |
| Wee, J | 2 |
| Soo, KC | 1 |
| Tan, EH | 2 |
| Shinoda, M | 3 |
| Ishikura, S | 5 |
| Tsubosa, Y | 3 |
| Minashi, K | 2 |
| Okabe, H | 3 |
| Kimura, Y | 5 |
| Kawano, T | 1 |
| Kosugi, S | 1 |
| Toh, Y | 1 |
| Kozak, MM | 1 |
| von Eyben, R | 1 |
| Pai, J | 1 |
| Vossler, SR | 1 |
| Limaye, M | 1 |
| Jayachandran, P | 1 |
| Anderson, EM | 1 |
| Shaffer, JL | 1 |
| Longacre, T | 1 |
| Pai, RK | 1 |
| Koong, AC | 1 |
| Chang, DT | 1 |
| Ojima, H | 2 |
| Fukuchi, M | 1 |
| Suzuki, S | 7 |
| Ieta, K | 1 |
| Saito, K | 4 |
| Sano, A | 1 |
| Yokobori, T | 2 |
| Inose, T | 1 |
| Zheng, CH | 1 |
| Lu, J | 2 |
| Huang, CM | 2 |
| Li, P | 1 |
| Xie, JW | 1 |
| Wang, JB | 1 |
| Lin, JX | 1 |
| Yamashita, M | 1 |
| Takenaka, HY | 1 |
| Zhang, M | 1 |
| Lu, K | 1 |
| Shu, Y | 2 |
| Liu, P | 4 |
| Nushijima, Y | 1 |
| Nakano, K | 2 |
| Nakaguchi, K | 2 |
| Kan, K | 1 |
| Maruyama, H | 5 |
| Doi, S | 1 |
| Okamura, S | 1 |
| Murata, K | 2 |
| Tsujinaka, T | 8 |
| Hirao, M | 2 |
| Fukuda, Y | 3 |
| Haraguchi, N | 1 |
| Miyake, M | 2 |
| Asaoka, T | 1 |
| Miyamoto, A | 2 |
| Omiya, H | 1 |
| Takami, K | 1 |
| Nakamori, S | 2 |
| Sekimoto, M | 3 |
| Mihara, K | 1 |
| Yamashiro, N | 1 |
| Nishiya, S | 1 |
| Kemmochi, T | 1 |
| Egawa, T | 1 |
| Nagashima, A | 1 |
| Del Mastro, L | 2 |
| Bruzzi, P | 4 |
| De Laurentiis, M | 2 |
| Boni, C | 3 |
| Cavazzini, G | 1 |
| Durando, A | 1 |
| Turletti, A | 1 |
| Nisticò, C | 1 |
| Valle, E | 1 |
| Garrone, O | 1 |
| Puglisi, F | 1 |
| Montemurro, F | 1 |
| Barni, S | 3 |
| Ardizzoni, A | 2 |
| Gamucci, T | 1 |
| Colantuoni, G | 1 |
| Giuliano, M | 1 |
| Gravina, A | 1 |
| Papaldo, P | 1 |
| Bighin, C | 1 |
| Bisagni, G | 3 |
| Forestieri, V | 1 |
| Cognetti, F | 2 |
| Sakai, D | 1 |
| Sugimoto, N | 1 |
| Yoshinami, T | 1 |
| Yamamoto, S | 4 |
| Higashino, K | 2 |
| Hwang, JE | 1 |
| Hong, JY | 1 |
| Kim, JE | 3 |
| Shim, HJ | 1 |
| Bae, WK | 1 |
| Hwang, EC | 1 |
| Jeong, O | 1 |
| Park, YK | 1 |
| Lee, KH | 2 |
| Cho, SH | 2 |
| Chung, IJ | 1 |
| Lian, G | 1 |
| Ou, G | 1 |
| Yang, K | 1 |
| Zeng, L | 1 |
| Huang, K | 1 |
| Lescut, N | 1 |
| Lepinoy, A | 1 |
| Schipman, B | 1 |
| Cerda, T | 1 |
| Guimas, V | 1 |
| Bednarek, C | 1 |
| Drooger, JC | 1 |
| van Pelt-Sprangers, JM | 1 |
| Leunis, C | 1 |
| de Jongh, FE | 1 |
| Takácsi-Nagy, Z | 1 |
| Hitre, E | 2 |
| Remenár, É | 1 |
| Oberna, F | 1 |
| Polgár, C | 1 |
| Major, T | 1 |
| Gödény, M | 1 |
| Fodor, J | 1 |
| Kásler, M | 1 |
| Endo, S | 1 |
| Okuyama, M | 1 |
| Hiraoka, K | 1 |
| Konishi, K | 1 |
| Kim, C | 3 |
| Nakagawa, T | 2 |
| Nishijima, J | 1 |
| Hassan, AS | 1 |
| Naicker, M | 1 |
| Yusof, KH | 1 |
| Wan Ishak, WZ | 1 |
| Senfter, D | 1 |
| Holzner, S | 1 |
| Kalipciyan, M | 1 |
| Staribacher, A | 1 |
| Walzl, A | 1 |
| Huttary, N | 1 |
| Krieger, S | 1 |
| Brenner, S | 1 |
| Jäger, W | 2 |
| Krupitza, G | 1 |
| Dolznig, H | 1 |
| Mader, RM | 2 |
| Ozaslan, E | 2 |
| Duran, AO | 2 |
| Bozkurt, O | 2 |
| Inanc, M | 2 |
| Ucar, M | 1 |
| Berk, V | 2 |
| Karaca, H | 2 |
| Elmali, F | 1 |
| Ozkan, M | 2 |
| Ma, SR | 2 |
| Wang, WM | 1 |
| Huang, CF | 2 |
| Zhang, WF | 2 |
| Sun, ZJ | 2 |
| Cavanna, L | 1 |
| Bodini, FC | 1 |
| Stroppa, EM | 1 |
| Banchini, F | 1 |
| Michieletti, E | 1 |
| Capelli, P | 1 |
| Zangrandi, A | 1 |
| Anselmi, E | 1 |
| Li, BL | 1 |
| Hu, XL | 1 |
| Zhao, XH | 1 |
| Sun, HG | 1 |
| Zhou, CY | 1 |
| Takahama, T | 1 |
| Takeda, M | 3 |
| Nishina, S | 1 |
| Iwayama, Y | 1 |
| Tsuruma, T | 1 |
| Mizuguchi, T | 1 |
| Furuhata, T | 2 |
| Toyota, N | 2 |
| Matsumura, M | 1 |
| Torigoe, T | 1 |
| Xie, Q | 1 |
| Rao, Q | 1 |
| Li, R | 2 |
| Zhou, H | 1 |
| Han, J | 2 |
| Yao, T | 2 |
| Lin, Z | 1 |
| Amankwatia, EB | 1 |
| Chakravarty, P | 1 |
| Carey, FA | 1 |
| Weidlich, S | 1 |
| Steele, RJ | 1 |
| Munro, AJ | 1 |
| Wolf, CR | 1 |
| Smith, G | 1 |
| Ayez, N | 1 |
| van der Stok, EP | 1 |
| Grünhagen, DJ | 1 |
| Rothbarth, J | 1 |
| van Meerten, E | 1 |
| Eggermont, AM | 1 |
| Hecht, JR | 1 |
| Cohn, A | 1 |
| Dakhil, S | 1 |
| Saleh, M | 1 |
| Piperdi, B | 1 |
| Cline-Burkhardt, M | 1 |
| Tian, Y | 1 |
| Go, WY | 1 |
| Yang, N | 1 |
| Zhu, L | 1 |
| Tan, T | 1 |
| Hou, C | 1 |
| Deme, D | 1 |
| Bishr, AM | 1 |
| Nizar, J | 1 |
| Telekes, A | 1 |
| Zheng, W | 1 |
| Xu, YJ | 1 |
| Qiu, SF | 1 |
| Zong, JF | 1 |
| Huang, LL | 1 |
| Huang, CB | 1 |
| Lin, SJ | 1 |
| Pan, JJ | 1 |
| Schneitler, S | 1 |
| Kröpil, P | 1 |
| Riemer, J | 1 |
| Antoch, G | 1 |
| Knoefel, WT | 1 |
| Häussinger, D | 1 |
| Graf, D | 1 |
| Kim, SH | 5 |
| Kim, JH | 11 |
| Jung, SH | 1 |
| Chang, KH | 1 |
| Kelly, NP | 1 |
| Duff, GP | 1 |
| Condon, ET | 1 |
| Waldron, D | 1 |
| Coffey, JC | 1 |
| Wu, Z | 1 |
| Jing, S | 1 |
| Deng, Q | 1 |
| Zheng, Z | 1 |
| Wu, K | 1 |
| Tang, R | 2 |
| Li, X | 3 |
| Ohtsuka, M | 1 |
| Hata, T | 2 |
| Hiraki, M | 1 |
| Takeyama, H | 1 |
| Nonaka, R | 1 |
| Uemura, M | 2 |
| Mizushima, T | 3 |
| Garde-Noguera, J | 1 |
| Gil-Raga, M | 1 |
| Evgenyeva, E | 1 |
| García, JA | 1 |
| Llombart-Cussac, A | 1 |
| Camps-Herrero, C | 1 |
| Zahir, MN | 1 |
| Jabbar, AA | 1 |
| Bu, JG | 1 |
| Cheng, JL | 1 |
| Gao, WW | 1 |
| Xu, YC | 1 |
| Feng, J | 2 |
| Chen, BY | 1 |
| Liang, WC | 1 |
| Chen, KQ | 1 |
| Deniz, K | 1 |
| Maruo, H | 1 |
| Ishikawa, S | 1 |
| Higashi, Y | 2 |
| Shoji, T | 1 |
| Nishiyama, R | 1 |
| Kubota, H | 2 |
| Nicolai, N | 2 |
| Sangalli, LM | 1 |
| Necchi, A | 2 |
| Giannatempo, P | 1 |
| Paganoni, AM | 1 |
| Colecchia, M | 2 |
| Piva, L | 2 |
| Catanzaro, MA | 1 |
| Biasoni, D | 1 |
| Stagni, S | 1 |
| Torelli, T | 2 |
| Raggi, D | 1 |
| Faré, E | 1 |
| Pizzocaro, G | 1 |
| Salvioni, R | 2 |
| Zheng, H | 1 |
| Nong, Z | 1 |
| Lu, G | 1 |
| Ruiz Simón, A | 1 |
| Ruiz Borrego, M | 1 |
| Ribelles, N | 1 |
| Muñoz-Mateu, M | 1 |
| González, S | 1 |
| Margelí Vila, M | 2 |
| Barnadas, A | 1 |
| Ramos, M | 1 |
| Del Barco Berron, S | 1 |
| Jara, C | 1 |
| Martínez-Jáñez, N | 1 |
| Mendiola Fernández, C | 1 |
| Martínez de Dueñas, E | 1 |
| Andrés, R | 1 |
| Plazaola, A | 1 |
| de la Haba-Rodríguez, J | 1 |
| López-Vega, JM | 1 |
| Adrover, E | 1 |
| Ballesteros, AI | 1 |
| Santaballa, A | 1 |
| Sánchez-Rovira, P | 1 |
| Baena-Cañada, JM | 1 |
| del Carmen Cámara, M | 1 |
| Carrasco, EM | 1 |
| Lluch, A | 2 |
| Altan, B | 1 |
| Mochiki, E | 1 |
| Toyomasu, Y | 1 |
| Kogure, N | 1 |
| Kimura, A | 1 |
| Bai, T | 1 |
| Bao, P | 1 |
| Ogata, K | 1 |
| Nishiyama, M | 2 |
| Matsumoto, H | 2 |
| Murakami, H | 1 |
| Higashida, M | 1 |
| Tsuruta, A | 1 |
| Tohyama, K | 2 |
| Hirai, T | 2 |
| Xie, L | 1 |
| Peng, Y | 1 |
| Lv, X | 1 |
| He, X | 1 |
| Song, B | 1 |
| Cui, H | 1 |
| Cheng, C | 1 |
| Yang, B | 1 |
| Kong, P | 1 |
| Jia, Z | 2 |
| Bi, Y | 1 |
| Zhou, Y | 3 |
| Zhao, Z | 1 |
| Hu, X | 1 |
| Shi, R | 1 |
| Yan, T | 1 |
| Xu, E | 1 |
| Qian, Y | 1 |
| Xi, Y | 1 |
| Guo, S | 1 |
| Jia, J | 2 |
| Guo, J | 2 |
| Zhan, Q | 1 |
| Hoffman, RM | 4 |
| Sasaki, H | 1 |
| Kaneto, H | 1 |
| Iida, T | 1 |
| Naganawa, Y | 1 |
| Satoh, S | 1 |
| Shimizu, H | 1 |
| Konishi, Y | 2 |
| Kon, S | 1 |
| Bian, Z | 1 |
| Feng, Y | 1 |
| Xue, Y | 1 |
| Wang, Q | 1 |
| Zhou, L | 1 |
| Liu, Z | 3 |
| Zhang, J | 4 |
| Yin, Y | 2 |
| Gu, B | 1 |
| Huang, Z | 1 |
| Jiang, CF | 1 |
| Li, DM | 1 |
| Ge, X | 1 |
| Shi, ZM | 1 |
| Li, CY | 2 |
| Zhen, L | 1 |
| Liu, LZ | 1 |
| Jiang, BH | 1 |
| Roganović, J | 1 |
| Matijašić, N | 1 |
| Mascarin, M | 1 |
| Du, C | 1 |
| Guo, C | 2 |
| Xu, Q | 2 |
| Zhou, A | 1 |
| Jeannin, G | 1 |
| Merle, P | 1 |
| Janicot, H | 1 |
| Thibonnier, L | 1 |
| Naame, A | 1 |
| Chadeyras, JB | 1 |
| Galvaing, G | 1 |
| Belliere, A | 1 |
| Filaire, M | 1 |
| Verrelle, P | 1 |
| Orlandi, A | 1 |
| Calegari, MA | 1 |
| Martini, M | 1 |
| Cocomazzi, A | 1 |
| Bagalà, C | 1 |
| Indellicati, G | 1 |
| Zurlo, V | 1 |
| Basso, M | 1 |
| Cassano, A | 2 |
| Larocca, LM | 1 |
| Barone, C | 3 |
| de Oliveira, SF | 1 |
| Ganzinelli, M | 1 |
| Chilà, R | 1 |
| Serino, L | 1 |
| Maciel, ME | 1 |
| Urban, Cde A | 1 |
| de Lima, RS | 1 |
| Cavalli, IJ | 1 |
| Generali, D | 1 |
| Broggini, M | 1 |
| Damia, G | 1 |
| Ribeiro, EM | 1 |
| Aroldi, F | 2 |
| Zaniboni, A | 3 |
| He, Q | 1 |
| Ma, L | 1 |
| Klevebro, F | 1 |
| Alexandersson von Döbeln, G | 1 |
| Wang, N | 2 |
| Johnsen, G | 1 |
| Jacobsen, AB | 1 |
| Friesland, S | 1 |
| Hatlevoll, I | 1 |
| Glenjen, NI | 1 |
| Lind, P | 1 |
| Lundell, L | 1 |
| Okuno, T | 3 |
| Imanishi, T | 1 |
| Kanaji, S | 1 |
| Kanemitsu, K | 4 |
| Sumi, Y | 1 |
| Kakeji, Y | 3 |
| Fukunari, H | 1 |
| Nakao, K | 2 |
| Okajima, C | 1 |
| Shitara, K | 4 |
| Hayashi, T | 3 |
| Fukuda, M | 1 |
| Takenoya, T | 1 |
| Nishimura, Y | 3 |
| Asayama, M | 1 |
| Takano, M | 1 |
| Mori, Y | 1 |
| Ishikawa, H | 2 |
| Fukuda, T | 1 |
| Kazama, S | 2 |
| Amikura, K | 1 |
| Kurozumi, M | 1 |
| Kawashima, Y | 4 |
| Sakamoto, H | 2 |
| Takahashi, S | 8 |
| Hanaka, J | 1 |
| Kanamura, S | 1 |
| Wakamatsu, T | 1 |
| Nakayama, H | 2 |
| Goya, T | 1 |
| Kawamoto, Y | 1 |
| Ome, Y | 1 |
| Koda, Y | 1 |
| Saga, K | 1 |
| Kawamoto, K | 1 |
| Ito, T | 4 |
| Kakuta, S | 1 |
| Takayama, W | 3 |
| Kou, T | 1 |
| Satou, M | 1 |
| Sugaya, M | 1 |
| Monnier, L | 1 |
| Touboul, E | 3 |
| Daraï, E | 1 |
| Lefranc, JP | 1 |
| Lauratet, B | 1 |
| Ballester, M | 1 |
| Huguet, F | 2 |
| Park, HC | 2 |
| Kwon, HI | 1 |
| Kim, HW | 1 |
| Ro, YS | 1 |
| Ko, JY | 2 |
| Hamamoto, Y | 1 |
| Mizusawa, J | 2 |
| Katayama, H | 2 |
| Tebbutt, NC | 1 |
| Price, TJ | 1 |
| Ferraro, DA | 1 |
| Wong, N | 1 |
| Veillard, AS | 1 |
| Hall, M | 1 |
| Sjoquist, KM | 1 |
| Pavlakis, N | 1 |
| Strickland, A | 1 |
| Varma, SC | 1 |
| Cooray, P | 2 |
| Young, R | 1 |
| Underhill, C | 1 |
| Shannon, JA | 1 |
| Ganju, V | 1 |
| Gebski, V | 1 |
| Liu, S | 1 |
| Qi, H | 1 |
| Sun, MZ | 1 |
| Huang, XZ | 1 |
| Gao, P | 1 |
| Song, YX | 1 |
| Sun, JX | 1 |
| Chen, XW | 1 |
| Zhao, JH | 1 |
| Ma, B | 1 |
| Wang, ZN | 1 |
| Matsuda, S | 1 |
| Sato, H | 4 |
| Takebayashi, K | 1 |
| Kawamorita, K | 1 |
| Mori, K | 4 |
| Niihara, M | 1 |
| Takeuchi, H | 1 |
| Sakanaka, K | 1 |
| Ishida, Y | 1 |
| Itasaka, S | 1 |
| Ezoe, Y | 1 |
| Aoyama, I | 1 |
| Miyamoto, S | 2 |
| Horimatsu, T | 1 |
| Muto, M | 4 |
| Hiraoka, M | 1 |
| Kamiya, T | 2 |
| Nakayama, G | 1 |
| Ishigure, K | 1 |
| Kobayashi, S | 3 |
| Hiramatsu, K | 2 |
| Sakamoto, E | 1 |
| Tojima, Y | 1 |
| Kawai, S | 1 |
| Kodera, Y | 2 |
| Calderon, B | 1 |
| Guerder, C | 1 |
| Resbeut, M | 3 |
| Fakhry, N | 1 |
| Dupuis, C | 1 |
| Cowen, D | 1 |
| Tan, F | 1 |
| Yue, W | 1 |
| Wang, H | 5 |
| Xue, H | 1 |
| Wen, Z | 1 |
| Gluz, O | 1 |
| Liedtke, C | 2 |
| Huober, J | 2 |
| Peyro-Saint-Paul, H | 1 |
| Kates, RE | 1 |
| Kreipe, HH | 1 |
| Hartmann, A | 2 |
| Pelz, E | 1 |
| Erber, R | 1 |
| Mohrmann, S | 1 |
| Möbus, V | 1 |
| Augustin, D | 3 |
| Hoffmann, G | 2 |
| Thomssen, C | 2 |
| Jänicke, F | 1 |
| Kiechle, M | 2 |
| Wallwiener, D | 2 |
| Kuhn, W | 1 |
| Nitz, U | 2 |
| Harbeck, N | 4 |
| Stein, SM | 1 |
| James, ES | 1 |
| Deng, Y | 1 |
| Cong, X | 1 |
| Kortmansky, JS | 1 |
| Staugaard, C | 1 |
| Indukala, D | 1 |
| Boustani, AM | 1 |
| Patel, V | 1 |
| Cha, CH | 1 |
| Salem, RR | 1 |
| Chang, B | 1 |
| Lacy, J | 1 |
| Jueckstock, J | 1 |
| Wischnik, A | 1 |
| Annecke, K | 1 |
| Scholz, C | 1 |
| Wang, ZX | 1 |
| Yang, XL | 1 |
| He, MM | 1 |
| Zhang, DS | 2 |
| Li, YH | 4 |
| Zhou, ZW | 1 |
| Zhan, YQ | 2 |
| Xu, RH | 4 |
| Zhao, ZL | 1 |
| Bu, LL | 1 |
| Liu, JF | 1 |
| Yu, GT | 1 |
| Liu, B | 2 |
| Gutkind, JS | 1 |
| Kulkarni, AB | 1 |
| Jung, SM | 1 |
| Yu, CS | 2 |
| Park, IJ | 2 |
| Kim, TW | 4 |
| Yoon, YS | 2 |
| Lim, SB | 2 |
| Kim, JC | 2 |
| Yukawa, Y | 1 |
| Uchima, Y | 2 |
| Kawamura, M | 1 |
| Takeda, O | 1 |
| Hanno, H | 1 |
| Takayanagi, S | 1 |
| Hirooka, T | 2 |
| Dozaiku, T | 1 |
| Aomatsu, N | 2 |
| Hirakawa, T | 2 |
| Iwauchi, T | 2 |
| Nishii, T | 2 |
| Morimoto, J | 2 |
| Nakazawa, K | 2 |
| Takeuchi, K | 3 |
| Sasaki, M | 2 |
| Kouyama, M | 1 |
| Tazaki, T | 1 |
| Sugiyama, Y | 1 |
| Nakamura, H | 3 |
| Kuroo, Y | 1 |
| Nakamitsu, A | 1 |
| Daimaru, Y | 1 |
| Yabuta, Y | 1 |
| Shirai, A | 1 |
| Uzuhashi, K | 1 |
| Pan, W | 1 |
| Smyth, EC | 1 |
| Fassan, M | 1 |
| Allum, WH | 1 |
| Okines, AF | 1 |
| Lampis, A | 1 |
| Hahne, JC | 1 |
| Rugge, M | 2 |
| Nankivell, M | 1 |
| Langley, R | 1 |
| Ghidini, M | 1 |
| Braconi, C | 2 |
| Wotherspoon, A | 1 |
| Grabsch, HI | 1 |
| Valeri, N | 1 |
| Chen, G | 1 |
| Zhang, R | 1 |
| Lu, Z | 1 |
| Ding, P | 1 |
| Pan, Z | 1 |
| Wan, D | 1 |
| Kim, HY | 2 |
| Cho, Y | 1 |
| Kang, H | 1 |
| Yim, YS | 1 |
| Kim, SJ | 4 |
| Chun, KH | 1 |
| Mohammadkhani Shali, S | 1 |
| Schmitt, V | 1 |
| Behrendt, FF | 1 |
| Winz, OH | 1 |
| Heinzel, A | 1 |
| Mottaghy, FM | 1 |
| Eble, MJ | 2 |
| Verburg, FA | 1 |
| Stanisavljević, L | 1 |
| Myklebust, MP | 1 |
| Leh, S | 1 |
| Zanoni, A | 1 |
| Verlato, G | 1 |
| Giacopuzzi, S | 1 |
| Motton, M | 1 |
| Casella, F | 1 |
| Weindelmayer, J | 1 |
| Ambrosi, E | 1 |
| Di Leo, A | 7 |
| Vassiliadis, A | 1 |
| Ricci, F | 1 |
| Rice, TW | 2 |
| de Manzoni, G | 1 |
| Mavroudis, D | 2 |
| Matikas, A | 1 |
| Malamos, N | 2 |
| Papakotoulas, P | 2 |
| Kakolyris, S | 2 |
| Boukovinas, I | 2 |
| Athanasiadis, A | 2 |
| Kentepozidis, N | 1 |
| Ziras, N | 2 |
| Katsaounis, P | 1 |
| Saloustros, E | 1 |
| Georgoulias, V | 3 |
| Haghighi, S | 1 |
| Kasbkar, H | 1 |
| Esmaeilpour, K | 1 |
| Yasaei, M | 1 |
| Martin-Romano, P | 1 |
| Diaz-Gonzalez, JA | 1 |
| Chopitea, A | 1 |
| Iragorri, Y | 1 |
| Martínez-Regueira, F | 1 |
| Subtil, JC | 2 |
| Cano, D | 1 |
| Ceniceros, L | 1 |
| Legaspi, J | 1 |
| Hernandez, JL | 1 |
| Rodríguez, J | 1 |
| Kawaguchi, T | 1 |
| Takeshita, H | 1 |
| Miyamae, M | 1 |
| Ohashi, T | 1 |
| Okajima, W | 1 |
| Imamura, T | 1 |
| Kiuchi, J | 1 |
| Wang, Z | 3 |
| Liang, L | 1 |
| Zhuang, R | 1 |
| Liu, T | 1 |
| Choi, Y | 1 |
| Lee, KW | 2 |
| Oh, HK | 1 |
| Kim, DW | 2 |
| Kang, SB | 2 |
| Song, C | 3 |
| Kanemitsu, Y | 1 |
| Shiozawa, M | 1 |
| Díez de Corcuera, I | 1 |
| Manzano, JL | 1 |
| Valladares-Ayerbes, M | 2 |
| Alcaide, J | 1 |
| García García, T | 1 |
| Vera, R | 1 |
| Sastre, J | 1 |
| Hann, A | 1 |
| Bohle, W | 1 |
| Egger, J | 1 |
| Zoller, WG | 1 |
| Huang, PM | 2 |
| Chu, PY | 1 |
| Chen, PM | 3 |
| Lin, MW | 1 |
| Kuo, SW | 2 |
| Lee, JM | 2 |
| Hong, YS | 2 |
| Kim, KP | 1 |
| Kim, CW | 1 |
| DeWitt, JM | 1 |
| Murthy, SK | 1 |
| Ardhanari, R | 1 |
| DuVall, GA | 1 |
| Wallner, G | 1 |
| Litka, P | 1 |
| Daugherty, C | 1 |
| Fowers, K | 1 |
| Bednar, F | 1 |
| Zenati, MS | 1 |
| Steve, J | 1 |
| Winters, S | 1 |
| Ocuin, LM | 1 |
| Bahary, N | 1 |
| Hogg, ME | 1 |
| Zeh, HJ | 1 |
| Zureikat, AH | 1 |
| Cao, Y | 1 |
| Lin, C | 1 |
| He, H | 1 |
| Xu, J | 1 |
| Hong, S | 1 |
| Vychnevskaia, K | 1 |
| Dumont, F | 2 |
| Agostini, J | 1 |
| Julié, C | 1 |
| Dartigues, P | 2 |
| Lazure, T | 1 |
| Boige, V | 2 |
| Goéré, D | 2 |
| Brouquet, A | 1 |
| Penna, C | 1 |
| Peschaud, F | 1 |
| Benoist, S | 1 |
| Bertocchi, P | 1 |
| Prochilo, T | 1 |
| Meriggi, F | 1 |
| Ren, HY | 1 |
| Huang, GL | 1 |
| Shen, JX | 1 |
| Zhou, P | 1 |
| Liu, WM | 1 |
| Shen, DY | 1 |
| Su, J | 1 |
| Zhu, S | 1 |
| Zhao, Y | 2 |
| Hosoda, K | 1 |
| Moriya, H | 1 |
| Sugawara, M | 1 |
| Mieno, H | 1 |
| Yamakoshi, Y | 1 |
| Wang, E | 1 |
| Nagashima, D | 1 |
| Tei, S | 1 |
| Noro, H | 1 |
| Hirao, T | 1 |
| Takaichi, S | 1 |
| Son, C | 1 |
| Iwamoto, K | 1 |
| Kono, E | 1 |
| Yasumasa, K | 1 |
| Mizuno, H | 1 |
| Morimoto, Y | 1 |
| Hatanaka, N | 1 |
| Yamasaki, Y | 1 |
| Katsumi, C | 1 |
| Bamba, T | 1 |
| Nakagawa, S | 2 |
| Aizawa, M | 1 |
| Matsuki, A | 1 |
| Yabusaki, H | 6 |
| Homma, K | 1 |
| Zhu, ZQ | 1 |
| Zhu, ZA | 1 |
| Cai, HX | 1 |
| Shi, H | 1 |
| Qiu, C | 1 |
| Lin, S | 1 |
| Qi, Y | 1 |
| Zhao, A | 1 |
| Huang, MY | 2 |
| Yeh, Y- | 1 |
| Huang, CJ | 1 |
| Bird, T | 1 |
| Michael, M | 1 |
| Bressel, M | 1 |
| Chu, J | 1 |
| Chander, S | 1 |
| McKendrick, J | 1 |
| Jefford, M | 1 |
| Heriot, A | 1 |
| Steel, M | 1 |
| Leong, T | 1 |
| Ngan, S | 1 |
| Cellini, N | 2 |
| Smaniotto, D | 1 |
| Scambia, G | 1 |
| Luzi, S | 1 |
| Balducci, M | 1 |
| Ferrandina, G | 1 |
| Corvari, B | 1 |
| Margariti, PA | 1 |
| D'Agostino, G | 1 |
| Lin, SS | 1 |
| Tai, CJ | 1 |
| Lee, WR | 1 |
| Chu, JS | 1 |
| Wang, KH | 1 |
| Lindebjerg, J | 2 |
| Spindler, KL | 1 |
| Ploen, J | 1 |
| Fujita, T | 3 |
| Ota, M | 1 |
| Narumiya, K | 1 |
| Ohki, T | 1 |
| Mitsuhashi, N | 2 |
| Higuchi, I | 2 |
| Tatsumi, M | 1 |
| Fukunaga, H | 2 |
| Hatazawa, J | 1 |
| Monden, M | 10 |
| Leong, SS | 1 |
| Rajan, S | 1 |
| Toh, CK | 1 |
| Hee, SW | 1 |
| Tay, MH | 1 |
| Poon, D | 1 |
| Dunnwald, LK | 1 |
| Gralow, JR | 3 |
| Ellis, GK | 2 |
| Livingston, RB | 4 |
| Linden, HM | 1 |
| Specht, JM | 1 |
| Doot, RK | 1 |
| Lawton, TJ | 1 |
| Barlow, WE | 3 |
| Kurland, BF | 1 |
| Schubert, EK | 1 |
| Mankoff, DA | 1 |
| Zeng, QL | 1 |
| Chu, ZH | 1 |
| Zhou, K | 2 |
| Luo, XJ | 1 |
| Lee, JL | 2 |
| Kang, YK | 2 |
| Kang, HJ | 1 |
| Zang, DY | 1 |
| Ryoo, BY | 1 |
| Kim, JG | 1 |
| Park, SR | 1 |
| Shin, DB | 1 |
| Ryu, MH | 2 |
| Chang, HM | 2 |
| Baek, JH | 1 |
| Min, YJ | 1 |
| Osako, T | 1 |
| Ushijima, M | 1 |
| Tokudome, N | 2 |
| Sugihara, T | 1 |
| Iwase, T | 1 |
| Matsuura, M | 1 |
| Hatake, K | 2 |
| Jin, H | 1 |
| Li, VK | 1 |
| Ding, Y | 1 |
| Yun, S | 1 |
| Zhou, S | 2 |
| Song, Y | 1 |
| Ni, M | 1 |
| Yano, T | 2 |
| Hattori, S | 1 |
| Onozawa, M | 1 |
| Nihei, K | 2 |
| Ohtsu, A | 5 |
| Yoshida, S | 6 |
| Komai, Y | 1 |
| Fujii, Y | 1 |
| Okubo, Y | 1 |
| Kawakami, S | 1 |
| Yonese, J | 2 |
| Fukui, I | 2 |
| Kurosaki, I | 1 |
| Kawachi, Y | 2 |
| Tsuchiya, Y | 5 |
| Yokoyama, N | 5 |
| Hatakeyama, K | 4 |
| Bollschweiler, E | 3 |
| Metzger, R | 2 |
| Drebber, U | 2 |
| Baldus, S | 1 |
| Vallböhmer, D | 3 |
| Kocher, M | 1 |
| Hölscher, AH | 3 |
| Harshman, LC | 1 |
| Li, M | 1 |
| Srinivas, S | 1 |
| Kinsella, TJ | 1 |
| Seo, Y | 1 |
| Willis, J | 1 |
| Stellato, TA | 1 |
| Siegel, CT | 1 |
| Harpp, D | 1 |
| Willson, JK | 1 |
| Gibbons, J | 1 |
| Sanabria, JR | 1 |
| Hardacre, JM | 1 |
| Schulak, JP | 1 |
| Fornaro, L | 4 |
| Masi, G | 4 |
| Bursi, S | 1 |
| Vasile, E | 4 |
| Antonuzzo, A | 1 |
| Chiara, S | 2 |
| Pfanner, E | 1 |
| Di Paolo, A | 1 |
| Bocci, G | 1 |
| Del Tacca, M | 1 |
| Gu, Y | 1 |
| Pagani, O | 4 |
| Gelber, S | 2 |
| Simoncini, E | 7 |
| Castiglione-Gertsch, M | 11 |
| Price, KN | 7 |
| Gelber, RD | 15 |
| Holmberg, SB | 4 |
| Crivellari, D | 6 |
| Collins, J | 6 |
| Lindtner, J | 7 |
| Thürlimann, B | 7 |
| Fey, MF | 3 |
| Murray, E | 1 |
| Forbes, JF | 1 |
| Coates, AS | 7 |
| Goldhirsch, A | 17 |
| Wang, ZH | 2 |
| Chen, Z | 4 |
| Li, CZ | 1 |
| Sheng, LJ | 1 |
| Zhou, DG | 1 |
| Wang, QC | 1 |
| Zhang, EN | 1 |
| Scoggins, CR | 1 |
| Campbell, ML | 1 |
| Landry, CS | 1 |
| Slomiany, BA | 1 |
| Woodall, CE | 1 |
| McMasters, KM | 1 |
| Martin, RC | 2 |
| Dunst, J | 5 |
| Debus, J | 3 |
| Rudat, V | 5 |
| Wulf, J | 1 |
| Budach, W | 2 |
| Hoelscher, T | 1 |
| Reese, T | 1 |
| Mose, S | 1 |
| Roedel, C | 1 |
| Zuehlke, H | 1 |
| Hinke, A | 1 |
| Jézéquel, P | 2 |
| Campone, M | 5 |
| Roché, H | 8 |
| Gouraud, W | 2 |
| Charbonnel, C | 2 |
| Ricolleau, G | 1 |
| Magrangeas, F | 2 |
| Minvielle, S | 2 |
| Genève, J | 3 |
| Martin, AL | 5 |
| Bataille, R | 2 |
| Campion, L | 2 |
| Hakenberg, OW | 1 |
| Ishida, T | 3 |
| Kiba, T | 1 |
| Matsuyama, K | 1 |
| Teramukai, S | 1 |
| Ishiwata, R | 1 |
| Masuda, N | 2 |
| Takatsuka, Y | 3 |
| Noguchi, S | 6 |
| Ishioka, C | 4 |
| Fukushima, M | 2 |
| Ohuchi, N | 2 |
| Asiyanbola, B | 1 |
| Gleisner, A | 1 |
| Choti, MA | 2 |
| Swartz, M | 1 |
| Edil, BH | 1 |
| Schulick, RD | 3 |
| Pawlik, TM | 3 |
| Tausch, C | 1 |
| Konstantiniuk, P | 1 |
| Kugler, F | 1 |
| Reitsamer, R | 1 |
| Roka, S | 1 |
| Pöstlberger, S | 1 |
| Haid, A | 1 |
| Yoshino, S | 2 |
| Takeda, S | 2 |
| Tokunou, K | 2 |
| Oka, M | 3 |
| Ishiguro, T | 1 |
| Kitaoka, T | 1 |
| Sakimoto, T | 1 |
| Yokoyama, M | 2 |
| Ishibashi, K | 3 |
| Matsuki, M | 1 |
| Inoue, N | 1 |
| Sano, M | 5 |
| Horisberger, K | 1 |
| Treschl, A | 1 |
| Mai, S | 1 |
| Barreto-Miranda, M | 1 |
| Kienle, P | 1 |
| Ströbel, P | 1 |
| Erben, P | 1 |
| Woernle, C | 1 |
| Dinter, D | 1 |
| Kähler, G | 1 |
| Hochhaus, A | 2 |
| Willeke, F | 1 |
| Wenz, F | 1 |
| Satoi, S | 1 |
| Yanagimoto, H | 1 |
| Toyokawa, H | 1 |
| Matsui, Y | 1 |
| Kitade, H | 1 |
| Mergental, H | 1 |
| Tanigawa, N | 2 |
| Takai, S | 1 |
| Kwon, AH | 1 |
| Zhang, GQ | 1 |
| Han, F | 1 |
| Sun, W | 1 |
| Pang, ZL | 1 |
| SiKanDaer, AB | 1 |
| Wang, HJ | 1 |
| Hu, B | 1 |
| Yu, JR | 1 |
| Wen, ZZ | 1 |
| Shu, YQ | 2 |
| Wang, BC | 1 |
| Yin, HR | 1 |
| Bai, YX | 1 |
| Cheng, Y | 1 |
| Shen, L | 3 |
| Zhang, HG | 1 |
| Wan, DS | 5 |
| Jia, TZ | 1 |
| Jin, ML | 1 |
| Li, SF | 1 |
| He, LH | 1 |
| Shi, YH | 1 |
| Hao, CF | 1 |
| Dong, GL | 1 |
| Tong, ZS | 1 |
| Kwon, HC | 2 |
| Oh, SY | 2 |
| Lee, DM | 2 |
| Lee, S | 4 |
| Roh, MS | 1 |
| Kim, DC | 1 |
| Park, KJ | 1 |
| Choi, HJ | 4 |
| Novarino, A | 1 |
| Satolli, MA | 1 |
| Chiappino, I | 1 |
| Giacobino, A | 1 |
| Bellone, G | 1 |
| Rahimi, F | 1 |
| Milanesi, E | 2 |
| Bertetto, O | 2 |
| Ciuffreda, L | 1 |
| Chayahara, N | 1 |
| Tamura, T | 3 |
| Yamamori, M | 2 |
| Kadowaki, Y | 1 |
| Miki, I | 1 |
| Tsuda, M | 1 |
| Nishisaki, H | 2 |
| Maeda, T | 5 |
| Inoue, Y | 3 |
| Okumura, K | 1 |
| Azuma, T | 2 |
| Kasuga, M | 2 |
| Sakaeda, T | 2 |
| Hirai, M | 1 |
| Takashima, S | 6 |
| Kitaya, T | 1 |
| Tokuda, Y | 1 |
| Yoshimoto, M | 2 |
| Kohno, N | 3 |
| Nakagami, K | 3 |
| Iwata, H | 1 |
| Shimozuma, K | 1 |
| Sonoo, H | 3 |
| Tsuda, H | 1 |
| Sakamoto, G | 1 |
| Ohashi, Y | 4 |
| Park, D | 1 |
| Kåresen, R | 1 |
| Naume, B | 1 |
| Synnestvedt, M | 1 |
| Beraki, E | 1 |
| Sauer, T | 1 |
| Kim, YS | 2 |
| Ahn, SD | 2 |
| Lee, SW | 2 |
| Shin, SS | 1 |
| Nam, JH | 1 |
| Kim, YT | 2 |
| Kim, YM | 1 |
| Choi, EK | 2 |
| Pollina, L | 1 |
| Cupini, S | 3 |
| Ricci, S | 2 |
| Brunetti, IM | 2 |
| Ferraldeschi, R | 1 |
| Naso, G | 1 |
| Filipponi, F | 1 |
| Pietrabissa, A | 1 |
| Goletti, O | 1 |
| Baldi, G | 1 |
| Andreuccetti, M | 1 |
| Saha, AK | 1 |
| Sutton, C | 1 |
| Rotimi, O | 1 |
| Dexter, S | 1 |
| Sue-Ling, H | 1 |
| Sarela, AI | 1 |
| Tokugawa, T | 1 |
| Kobayashi, A | 1 |
| Matsuyama, T | 2 |
| Imai, S | 3 |
| Koyama, H | 11 |
| Lee, YJ | 2 |
| Lee, HJ | 1 |
| Jeong, KC | 1 |
| Kang, JG | 1 |
| Lee, SH | 3 |
| Hohenberger, W | 1 |
| Lahmer, G | 1 |
| Fietkau, R | 4 |
| Croner, RS | 1 |
| Merkel, S | 1 |
| Göhl, J | 1 |
| Sauer, R | 9 |
| Segami, K | 1 |
| Sakurai, J | 1 |
| Noda, A | 1 |
| Suwa, T | 2 |
| Enomoto, T | 1 |
| Makizumi, R | 1 |
| Tsukikawa, S | 1 |
| Yamada, K | 2 |
| Miyajima, N | 1 |
| Otsubo, T | 1 |
| Safar, B | 1 |
| Wexner, S | 1 |
| Zhao, R | 1 |
| Cruz-Correa, M | 1 |
| Berho, M | 1 |
| Javle, M | 1 |
| Yu, J | 2 |
| Garrett, C | 1 |
| Pande, A | 1 |
| Kuvshinoff, B | 1 |
| Litwin, A | 1 |
| Phelan, J | 1 |
| Gibbs, J | 1 |
| Iyer, R | 1 |
| He, LR | 1 |
| Liu, MZ | 4 |
| Li, BK | 1 |
| Rao, HL | 1 |
| Deng, HX | 1 |
| Guan, XY | 1 |
| Zeng, YX | 2 |
| Xie, D | 1 |
| Boeck, S | 1 |
| Bruns, CJ | 1 |
| Sargent, M | 1 |
| Schafer, C | 1 |
| Seufferlein, T | 1 |
| Jauch, KW | 1 |
| Oki, E | 1 |
| Yoshida, R | 1 |
| Ando, K | 1 |
| Masuda, T | 4 |
| Ohgaki, K | 1 |
| Morita, M | 2 |
| Maehara, Y | 2 |
| Lee, CG | 1 |
| Cho, BC | 2 |
| Kim, GE | 2 |
| Choi, EC | 1 |
| Sohn, JH | 2 |
| Kimura, M | 7 |
| Toi, M | 3 |
| Abe, R | 3 |
| Nomura, Y | 4 |
| Miura, S | 2 |
| Kimijima, I | 1 |
| Tashiro, H | 1 |
| Yan, D | 1 |
| Dai, H | 1 |
| Xiao, Y | 1 |
| Lu, M | 1 |
| Zhang, XD | 1 |
| Hong, ZW | 1 |
| Dong, NN | 1 |
| Wang, MY | 1 |
| Zhang, Q | 1 |
| Liu, ZF | 1 |
| Qiu, MZ | 1 |
| Teng, KY | 1 |
| Ruan, DY | 1 |
| Chen, XQ | 1 |
| Pan, ZZ | 3 |
| He, YJ | 3 |
| Barrett-Lee, P | 2 |
| Pierga, JY | 3 |
| Polyzos, A | 2 |
| Adamou, A | 2 |
| Kalbakis, K | 1 |
| Syrigos, K | 2 |
| Kouroussis, C | 1 |
| Karvounis, N | 1 |
| Vamvakas, L | 1 |
| Christophyllakis, C | 1 |
| Varthalitis, I | 2 |
| Park, Y | 1 |
| Okamura, K | 2 |
| Mitsuyama, S | 3 |
| Saito, T | 1 |
| Koh, J | 1 |
| Kyono, S | 1 |
| Higaki, K | 1 |
| Ogita, M | 3 |
| Asaga, T | 2 |
| Inaji, H | 3 |
| Komichi, H | 1 |
| Yamazaki, K | 2 |
| Tanaka, F | 2 |
| Nishikawa, H | 2 |
| Osaki, A | 1 |
| Swartz, MJ | 2 |
| Hsu, CC | 2 |
| Winter, J | 1 |
| Guler, M | 1 |
| Laheru, DA | 3 |
| Marana, HR | 1 |
| de Andrade, JM | 1 |
| Dos Reis, FJ | 1 |
| Tiezzi, DG | 1 |
| Zola, FE | 1 |
| Clagnan, WS | 1 |
| Garieri, AP | 1 |
| Kersting, S | 1 |
| Konopke, R | 1 |
| Dittert, D | 1 |
| Distler, M | 1 |
| Rückert, F | 1 |
| Gastmeier, J | 1 |
| Baretton, GB | 2 |
| Saeger, HD | 1 |
| Saigusa, S | 3 |
| Toiyama, Y | 3 |
| Yokoe, T | 4 |
| Okugawa, Y | 3 |
| Ioue, Y | 1 |
| Miki, C | 2 |
| Kusunoki, M | 4 |
| Schmidt, C | 1 |
| Ge, J | 1 |
| Rougier, P | 4 |
| Raoul, JL | 2 |
| Gamelin, E | 1 |
| Cadiot, G | 1 |
| Mitry, E | 4 |
| Cvitkovic, F | 1 |
| Coudert, B | 3 |
| Ricard, F | 1 |
| Bedenne, L | 1 |
| Seitz, JF | 3 |
| Zhou, ZG | 2 |
| Li, LR | 2 |
| Wu, XJ | 3 |
| Ding, PR | 2 |
| Lin, JZ | 2 |
| Peng, ZH | 1 |
| Zeng, ZF | 1 |
| Lu, ZH | 1 |
| Kong, LH | 1 |
| An, X | 2 |
| Xiang, XJ | 1 |
| Wang, ZQ | 1 |
| Wang, FH | 1 |
| Feng, F | 1 |
| Jiang, WQ | 3 |
| Power, DG | 1 |
| Kemeny, NE | 1 |
| Li, BS | 1 |
| Zhou, T | 1 |
| Wang, ZT | 1 |
| Li, HS | 1 |
| Sun, HF | 1 |
| Zhang, ZC | 1 |
| Lin, HQ | 1 |
| Wei, YM | 1 |
| Gong, HY | 1 |
| Huang, W | 2 |
| Yi, Y | 2 |
| Wang, LY | 1 |
| Miller, RC | 2 |
| Iott, MJ | 1 |
| Corsini, MM | 1 |
| Schrohl, AS | 1 |
| Look, MP | 1 |
| Meijer-van Gelder, ME | 1 |
| Foekens, JA | 2 |
| Brünner, N | 1 |
| Marks, LB | 1 |
| Cirrincione, C | 2 |
| Fitzgerald, TJ | 1 |
| Laurie, F | 1 |
| Glicksman, AS | 1 |
| Vredenburgh, J | 1 |
| Prosnitz, LR | 2 |
| Shpall, EJ | 1 |
| Crump, M | 4 |
| Richardson, PG | 1 |
| Schuster, MW | 1 |
| Peterson, BL | 1 |
| Norton, L | 8 |
| Seagren, S | 1 |
| Henderson, IC | 11 |
| Hurd, DD | 2 |
| Peters, WP | 2 |
| Soto Iglesias, S | 1 |
| Baltar Arias, R | 1 |
| Vázquez Rodríguez, S | 1 |
| Alvarez, M | 1 |
| Gómez Martínez, P | 1 |
| Alvarez Sánchez, MV | 1 |
| Vázquez Astray, E | 1 |
| Capri, G | 1 |
| Chang, J | 1 |
| Conte, P | 1 |
| Cwiertka, K | 1 |
| Jerusalem, G | 2 |
| Jiang, Z | 1 |
| Johnston, S | 2 |
| Kaufman, B | 1 |
| Link, J | 1 |
| Ro, J | 1 |
| Schütte, J | 1 |
| Oliva, C | 1 |
| Parikh, R | 1 |
| Preston, A | 1 |
| Rosenlund, J | 1 |
| Selzer, M | 1 |
| Zembryki, D | 1 |
| Sprenger, T | 3 |
| Rothe, H | 2 |
| Homayounfar, K | 2 |
| Beissbarth, T | 2 |
| Ghadimi, BM | 4 |
| Becker, H | 5 |
| Liersch, T | 5 |
| Baldi, GG | 2 |
| Stasi, I | 1 |
| Salvatore, L | 2 |
| Eiermann, W | 3 |
| Graf, E | 1 |
| Ataseven, B | 1 |
| Conrad, B | 1 |
| Hilfrich, J | 2 |
| Massinger-Biebl, H | 1 |
| Vescia, S | 1 |
| Loibl, S | 1 |
| von Minckwitz, G | 2 |
| Schumacher, M | 6 |
| Kaufmann, M | 6 |
| Amari, M | 1 |
| Yu, Z | 1 |
| Luo, W | 1 |
| Zhou, QC | 1 |
| Zhang, QH | 1 |
| Kang, DH | 1 |
| Arimura, Y | 1 |
| Okahara, S | 1 |
| Tanuma, T | 1 |
| Kodaira, J | 1 |
| Hokari, K | 1 |
| Tsukagoshi, H | 1 |
| Shinomura, Y | 1 |
| Hosokawa, M | 1 |
| Burnell, M | 3 |
| Levine, MN | 4 |
| Chapman, JA | 1 |
| Bramwell, V | 3 |
| Gelmon, K | 2 |
| Walley, B | 1 |
| Vandenberg, T | 2 |
| Chalchal, H | 1 |
| Albain, KS | 5 |
| Perez, EA | 2 |
| Rugo, H | 1 |
| Pritchard, K | 2 |
| O'Brien, P | 1 |
| Shepherd, LE | 2 |
| Wang, TS | 2 |
| Ding, QQ | 1 |
| Guo, RH | 1 |
| Shen, H | 1 |
| Lu, KH | 1 |
| You, SH | 2 |
| Ge, HM | 2 |
| Spielmann, M | 4 |
| Delozier, T | 3 |
| Canon, JL | 3 |
| Romieu, G | 2 |
| Bourgeois, H | 1 |
| Extra, JM | 4 |
| Kerbrat, P | 6 |
| Machiels, JP | 2 |
| Lortholary, A | 2 |
| Orfeuvre, H | 2 |
| Hardy-Bessard, AC | 1 |
| Maerevoet, M | 1 |
| Piot, G | 2 |
| Kramar, A | 1 |
| Penault-Llorca, F | 2 |
| Ozmen, V | 1 |
| Unal, ES | 1 |
| Muslumanoglu, ME | 1 |
| Igci, A | 1 |
| Canbay, E | 1 |
| Ozcinar, B | 1 |
| Mudun, A | 1 |
| Tunaci, M | 1 |
| Tuzlali, S | 1 |
| Kecer, M | 1 |
| Livi, L | 1 |
| Saieva, C | 1 |
| Borghesi, S | 1 |
| De Luca Cardillo, C | 1 |
| Scotti, V | 1 |
| Mangoni, M | 1 |
| Greto, D | 1 |
| Cataliotti, L | 1 |
| Paiar, F | 1 |
| Bianchi, S | 1 |
| Biti, GP | 1 |
| Habr-Gama, A | 2 |
| Perez, RO | 2 |
| Sabbaga, J | 1 |
| Nadalin, W | 1 |
| São Julião, GP | 1 |
| Gama-Rodrigues, J | 1 |
| Sym, SJ | 1 |
| Yook, JH | 1 |
| Oh, ST | 1 |
| Kim, BS | 2 |
| Zhu, WG | 2 |
| Yu, CH | 2 |
| Han, JH | 2 |
| Li, T | 2 |
| Zhou, XL | 1 |
| Tao, GZ | 1 |
| Ravdin, PM | 1 |
| Farrar, WB | 4 |
| Burton, GV | 1 |
| Ketchel, SJ | 2 |
| Cobau, CD | 1 |
| Levine, EG | 1 |
| Ingle, JN | 5 |
| Pritchard, KI | 4 |
| Lichter, AS | 1 |
| Schneider, DJ | 1 |
| Abeloff, MD | 8 |
| Muss, HB | 8 |
| Green, SJ | 3 |
| Lew, D | 2 |
| Martino, S | 5 |
| Osborne, CK | 14 |
| Shak, S | 2 |
| Hortobagyi, GN | 14 |
| Yeh, IT | 1 |
| Ravdin, P | 1 |
| Bugarini, R | 1 |
| Baehner, FL | 2 |
| Davidson, NE | 3 |
| Sledge, GW | 2 |
| Winer, EP | 1 |
| Hudis, C | 2 |
| Shepherd, L | 2 |
| Yoshizawa, C | 1 |
| Allred, DC | 2 |
| Hayes, DF | 5 |
| Andre, F | 2 |
| Delaloge, S | 1 |
| Timovska, YO | 1 |
| Pivnyuk, VM | 1 |
| Oliynichenko, GP | 1 |
| Anikushko, MF | 1 |
| Zachartseva, LM | 1 |
| Chekhun, VF | 1 |
| Zhang, B | 3 |
| Cao, WF | 1 |
| Zhao, HM | 1 |
| Song, YQ | 1 |
| Ning, LS | 1 |
| Niu, Y | 1 |
| Hao, XS | 1 |
| Cao, XC | 1 |
| Li, GL | 1 |
| Fan, CG | 1 |
| Bao, Y | 1 |
| Jiang, J | 1 |
| Li, N | 1 |
| Li, JS | 2 |
| Ota, H | 1 |
| Fujie, Y | 1 |
| Ogino, T | 3 |
| Toyoda, Y | 1 |
| Yoshioka, A | 1 |
| Hojou, S | 1 |
| Endo, W | 1 |
| Kakutani, A | 1 |
| Maeura, Y | 1 |
| Hasegawa, K | 3 |
| Matsumoto, R | 1 |
| Yamada, H | 3 |
| Kuroda, T | 3 |
| Mamiya, Y | 1 |
| Kon, A | 1 |
| Noda, K | 1 |
| Umekita, N | 2 |
| Nasu, K | 1 |
| Nakatsu, H | 1 |
| Tomochika, S | 1 |
| Yoshitani, S | 1 |
| Hosokawa, K | 2 |
| Yokoi, M | 1 |
| Kinami, S | 1 |
| Omote, K | 1 |
| Ueda, N | 1 |
| Nakano, Y | 5 |
| Kosaka, T | 4 |
| Tomimaru, Y | 1 |
| Nagano, H | 4 |
| Murakami, M | 2 |
| Eguchi, H | 1 |
| Takeda, Y | 5 |
| Tanemura, M | 1 |
| Umeshita, K | 3 |
| Wakasa, K | 2 |
| Lee, GW | 1 |
| Go, SI | 1 |
| Kim, HG | 1 |
| Kang, JH | 3 |
| Honda, S | 1 |
| Toyama, E | 1 |
| Takamori, H | 4 |
| Beppu, T | 7 |
| Furukawa, MK | 1 |
| Furukawa, M | 1 |
| Kanagavel, D | 1 |
| Pokataev, IA | 1 |
| Fedyanin, MY | 1 |
| Tryakin, AA | 1 |
| Bazin, IS | 1 |
| Narimanov, MN | 1 |
| Yakovleva, ES | 1 |
| Garin, AM | 2 |
| Tjulandin, SA | 1 |
| Shimakawa, T | 1 |
| Naritaka, Y | 1 |
| Asaka, S | 1 |
| Isohata, N | 1 |
| Murayama, M | 1 |
| Konno, S | 1 |
| Katsube, T | 1 |
| Ide, H | 2 |
| Furumoto, K | 1 |
| Kojima, H | 2 |
| Takaya, H | 1 |
| Okuno, M | 1 |
| Fuji, H | 1 |
| Mizuno, R | 1 |
| Mori, T | 6 |
| Ito, D | 1 |
| Kogire, M | 3 |
| Lu, JC | 1 |
| Kong, C | 1 |
| Tao, H | 1 |
| Sato, S | 6 |
| Mukai, M | 8 |
| Seront, E | 1 |
| Marot, L | 1 |
| Coche, E | 1 |
| Gala, JL | 1 |
| Sempoux, C | 1 |
| Humblet, Y | 1 |
| Maillard, S | 1 |
| Merol, JC | 1 |
| Chays, A | 1 |
| Nguyen, TD | 1 |
| Guo, JF | 1 |
| Wu, F | 1 |
| Xing, H | 1 |
| Zhu, GY | 1 |
| Nie, XY | 1 |
| Sinicrope, FA | 2 |
| Foster, NR | 1 |
| Sargent, DJ | 1 |
| O'Connell, MJ | 4 |
| Rankin, C | 1 |
| Zaanan, A | 2 |
| Costes, L | 1 |
| Gauthier, M | 1 |
| Malka, D | 2 |
| Locher, C | 1 |
| Lecomte, T | 2 |
| Sobhani, I | 1 |
| Moulin, V | 1 |
| Afchain, P | 1 |
| Ishihara, Y | 1 |
| Matsunaga, K | 1 |
| Hasegawa, G | 1 |
| Kobayashi, T | 5 |
| Yang, M | 1 |
| Mesía, R | 1 |
| Kawecki, A | 1 |
| Rottey, S | 1 |
| Hitt, R | 1 |
| Kienzer, H | 1 |
| Cupissol, D | 1 |
| De Raucourt, D | 1 |
| Benasso, M | 3 |
| Koralewski, P | 1 |
| Delord, JP | 3 |
| Bokemeyer, C | 4 |
| Curran, D | 1 |
| Gross, A | 1 |
| Vermorken, JB | 1 |
| Frikha, M | 2 |
| Toumi, N | 1 |
| Ghorbel, L | 1 |
| Ben Salah, H | 1 |
| Khabir, A | 1 |
| Karray, H | 1 |
| Gargouri, R | 1 |
| Boudawara, T | 2 |
| Ghorbel, A | 1 |
| Daoud, J | 2 |
| Wright, JL | 1 |
| Patil, SM | 1 |
| Temple, LK | 1 |
| Minsky, BD | 2 |
| Saltz, LB | 2 |
| Soga, N | 1 |
| Arima, K | 1 |
| Sugimura, Y | 1 |
| Gervaz, P | 1 |
| Rubbia-Brandt, L | 1 |
| Andres, A | 1 |
| Majno, P | 1 |
| Roth, A | 1 |
| Morel, P | 1 |
| Mentha, G | 1 |
| Morelli, MF | 2 |
| Santomaggio, A | 1 |
| De Galitiis, F | 2 |
| Tudini, M | 1 |
| Mancini, M | 1 |
| Pelliccione, M | 1 |
| Calista, F | 1 |
| Guglielmi, F | 1 |
| Martella, F | 1 |
| Lanfiuti Baldi, P | 1 |
| Porzio, G | 2 |
| Russo, A | 2 |
| Gebbia, N | 2 |
| Iacobelli, S | 2 |
| Marchetti, P | 2 |
| Matter-Walstra, KW | 1 |
| Dedes, KJ | 1 |
| Schwenkglenks, M | 1 |
| Brauchli, P | 1 |
| Szucs, TD | 1 |
| Pestalozzi, BC | 1 |
| Gor, PP | 1 |
| Su, HI | 1 |
| Gray, RJ | 1 |
| Gimotty, PA | 1 |
| Horn, M | 1 |
| Aplenc, R | 1 |
| Vaughan, WP | 2 |
| Tallman, MS | 2 |
| Rebbeck, TR | 1 |
| DeMichele, A | 1 |
| Spanos, CP | 1 |
| Syrakos, T | 1 |
| Lorenzen, S | 2 |
| Panzram, B | 1 |
| Rosenberg, R | 2 |
| Nekarda, H | 1 |
| Becker, K | 1 |
| Schenk, U | 1 |
| Höfler, H | 1 |
| Siewert, JR | 2 |
| Jäger, D | 1 |
| Ott, K | 2 |
| Li, B | 1 |
| Sun, H | 1 |
| Gong, H | 1 |
| Ciocca, O | 1 |
| Vassallo, C | 1 |
| Brazzelli, V | 1 |
| Fiandrino, G | 1 |
| Rosso, R | 3 |
| Borroni, G | 1 |
| Kefeli, U | 1 |
| Bilici, A | 1 |
| Ustaalioglu, BB | 1 |
| Kefeli, AU | 1 |
| Yildirim, ME | 1 |
| Seker, M | 1 |
| Gumus, M | 1 |
| Nakanishi, H | 1 |
| Nakao, A | 1 |
| Duffour, J | 1 |
| Roca, L | 1 |
| Bressolle, F | 1 |
| Abderrahim, AG | 1 |
| Poujol, S | 1 |
| Pinguet, F | 1 |
| Ychou, M | 2 |
| Tashiro, Y | 1 |
| Nagayasu, K | 1 |
| Niwa, K | 1 |
| Ono, S | 1 |
| Hata, M | 1 |
| Tanaka, M | 2 |
| Sengoku, H | 1 |
| Okuzawa, A | 1 |
| Schneiders, FL | 1 |
| van den Berg, HP | 1 |
| Peters, GJ | 1 |
| Verheul, HM | 1 |
| van der Vliet, HJ | 1 |
| Dumontet, C | 1 |
| Krajewska, M | 1 |
| Treilleux, I | 1 |
| Mackey, JR | 1 |
| Rupin, M | 2 |
| Lafanechère, L | 1 |
| Reed, JC | 1 |
| Cho, SY | 1 |
| Han, SS | 1 |
| Kim, YK | 1 |
| Kim, TH | 1 |
| Besch, S | 1 |
| Schröder, W | 2 |
| Mönig, SP | 1 |
| Baldus, SE | 2 |
| Horowitz, DP | 1 |
| Robinson, R | 1 |
| Kuwahara, A | 1 |
| Fujita, M | 3 |
| Kadoyama, K | 1 |
| Okamura, N | 1 |
| Matsukawa, S | 1 |
| Shiratori, T | 3 |
| Kugimiya, M | 1 |
| Kaji, S | 1 |
| Aoyama, Y | 1 |
| Kuroki, M | 1 |
| Hiramoto, K | 1 |
| Matsumura, Y | 2 |
| Miura, A | 1 |
| Kikuchi, Y | 1 |
| Lordick, F | 2 |
| Grenacher, L | 1 |
| Röcken, C | 1 |
| Ebert, M | 1 |
| Schumacher, G | 1 |
| Thompson, SK | 1 |
| Bartholomeusz, D | 1 |
| Devitt, PG | 1 |
| Lamb, PJ | 1 |
| Ruszkiewicz, AR | 1 |
| Jamieson, GG | 1 |
| Wolthuis, AM | 1 |
| Penninckx, F | 1 |
| Haustermans, K | 1 |
| Ectors, N | 1 |
| Van Cutsem, E | 1 |
| D'Hoore, A | 1 |
| Faradmal, J | 1 |
| Kazemnejad, A | 1 |
| Khodabakhshi, R | 1 |
| Gohari, MR | 1 |
| Hajizadeh, E | 1 |
| Tamandl, D | 1 |
| Klinger, M | 1 |
| Eipeldauer, S | 1 |
| Herberger, B | 1 |
| Kaczirek, K | 1 |
| Gruenberger, B | 1 |
| Gruenberger, T | 1 |
| Spigel, DR | 2 |
| Greco, FA | 3 |
| Waterhouse, D | 1 |
| Shipley, D | 1 |
| Lane, CM | 1 |
| Vazquez, ER | 1 |
| Clark, BL | 1 |
| Infante, JR | 2 |
| Bendell, JC | 3 |
| Burris, HA | 2 |
| Hainsworth, JD | 2 |
| Shen, W | 1 |
| Tu, JK | 1 |
| Wang, XH | 1 |
| Fu, ZX | 1 |
| Lee, JY | 1 |
| Kim, YH | 3 |
| Chung, HH | 1 |
| Park, NH | 1 |
| Song, YS | 1 |
| Tagawa, ST | 1 |
| Milowsky, MI | 1 |
| Jeske, S | 1 |
| Mazumdar, M | 2 |
| Kung, S | 1 |
| Sung, M | 1 |
| Lehrer, D | 1 |
| Matulich, D | 1 |
| Selzer, J | 1 |
| Wright, JJ | 1 |
| Nanus, DM | 1 |
| Egerton, N | 1 |
| Park, JW | 1 |
| Yoon, SM | 1 |
| Song, SY | 3 |
| Lee, YS | 1 |
| Kim, SB | 1 |
| Park, SI | 1 |
| Jang, YJ | 1 |
| Park, SS | 1 |
| Kim, CS | 1 |
| Mok, YJ | 1 |
| Hirota, M | 3 |
| Ikeda, O | 1 |
| Oya, N | 1 |
| Kim, MA | 1 |
| Kim, WH | 1 |
| Yang, HK | 1 |
| Heo, DS | 1 |
| Lee, KU | 1 |
| Kim, TM | 1 |
| Choe, KJ | 1 |
| Xia, LP | 1 |
| Wu, PH | 1 |
| Xia, JC | 1 |
| Guan, ZZ | 1 |
| Guo, GF | 1 |
| Xu, BH | 1 |
| Lombardi, L | 1 |
| Morelli, F | 1 |
| Cinieri, S | 1 |
| Santini, D | 1 |
| Fazio, N | 1 |
| Orlando, L | 1 |
| Tonini, G | 2 |
| Colucci, G | 2 |
| Amadori, D | 3 |
| Silvestrini, R | 3 |
| De Lena, M | 4 |
| Boccardo, F | 4 |
| Rocca, A | 1 |
| Schittulli, F | 2 |
| Brandi, M | 2 |
| Maltoni, R | 1 |
| Serra, P | 1 |
| Ponzone, R | 1 |
| Biglia, N | 1 |
| Gianni, L | 3 |
| Tienghi, A | 2 |
| Valerio, MR | 2 |
| Bonginelli, P | 1 |
| Amaducci, L | 1 |
| Faedi, M | 1 |
| Baldini, E | 1 |
| Amonkar, SJ | 1 |
| Cain, HJ | 1 |
| Hughes, T | 1 |
| Hemming, JD | 1 |
| Browell, DA | 1 |
| Yamaoka, K | 1 |
| Inatsugi, N | 1 |
| Yoshikawa, S | 1 |
| Uchida, H | 1 |
| Kuge, H | 1 |
| Yokotani, T | 1 |
| Yamaguchi, T | 10 |
| Kawaguchi, C | 1 |
| Shimobayashi, T | 1 |
| Inagaki, M | 1 |
| Matsuoka, M | 1 |
| Tatsumi, K | 1 |
| Saraya, T | 1 |
| Otsuji, T | 1 |
| Yamochi, Y | 1 |
| Yamanishi, K | 1 |
| Enomoto, Y | 1 |
| Nonomura, A | 1 |
| Sho, M | 1 |
| Yamamoto, T | 3 |
| Toshimitsu, H | 1 |
| Kitamura, Y | 1 |
| Andoh, S | 1 |
| Tsushimi, K | 1 |
| Hirose, H | 2 |
| Miyoshi, N | 2 |
| Kim, HM | 2 |
| Okano, M | 2 |
| Yamashita, S | 5 |
| Ishii, H | 2 |
| Kano, S | 1 |
| Miyashiro, I | 2 |
| Kanoh, T | 1 |
| Ohnishi, T | 1 |
| Danno, K | 1 |
| Tsukao, Y | 1 |
| Inatome, J | 1 |
| Kagara, N | 1 |
| Tono, T | 1 |
| Monden, T | 1 |
| Imaoka, S | 1 |
| Okubo, K | 1 |
| Nakanishi, M | 1 |
| Maekawa, T | 2 |
| Hama, N | 1 |
| Kashiwazaki, M | 2 |
| Taniguchi, M | 2 |
| Tsujie, M | 2 |
| Konishi, M | 1 |
| Yano, K | 1 |
| Fujimoto, T | 3 |
| Jansen, JF | 1 |
| Schöder, H | 1 |
| Lee, NY | 1 |
| Stambuk, HE | 1 |
| Fury, MG | 1 |
| Patel, SG | 1 |
| Pfister, DG | 1 |
| Shah, JP | 1 |
| Koutcher, JA | 1 |
| Shukla-Dave, A | 1 |
| Kinoshita, K | 1 |
| Saito, S | 2 |
| Kurashige, J | 1 |
| Karashima, R | 1 |
| Hirashima, K | 1 |
| Hiyoshi, Y | 1 |
| Freyer, G | 1 |
| Duret, A | 1 |
| Milano, G | 1 |
| Chatelut, E | 1 |
| Rebischung, C | 1 |
| Merrouche, Y | 1 |
| Lledo, G | 1 |
| Etienne, MC | 1 |
| Falandry, C | 1 |
| Aebi, S | 3 |
| Braun, D | 1 |
| Rabaglio, M | 1 |
| Snyder, R | 2 |
| Karlsson, P | 1 |
| Gusterson, BA | 2 |
| Viale, G | 4 |
| Regan, MM | 1 |
| Yang, PW | 1 |
| Shun, CT | 1 |
| Wu, MT | 1 |
| Hsu, CH | 1 |
| Lin, CC | 2 |
| Cheng, JC | 1 |
| Wang, YH | 1 |
| Chuang, TH | 1 |
| Chen, JS | 3 |
| Hsu, HH | 1 |
| Wang, LP | 1 |
| Yang, XY | 1 |
| Zhang, QL | 1 |
| Hu, XC | 1 |
| Wang, BY | 1 |
| Clavel, S | 1 |
| Charron, MP | 1 |
| Bélair, M | 1 |
| Delouya, G | 1 |
| Fortin, B | 1 |
| Després, P | 1 |
| Soulières, D | 1 |
| Filion, E | 1 |
| Guertin, L | 1 |
| Nguyen-Tan, PF | 1 |
| DI, Lj | 1 |
| Song, Gh | 1 |
| Che, L | 1 |
| Jiang, Hf | 1 |
| Zhu, Yl | 1 |
| Yang, Hb | 1 |
| Zhou, Xn | 1 |
| Ren, J | 1 |
| Kim, ST | 1 |
| Choi, YJ | 1 |
| Park, KH | 1 |
| Oh, SC | 1 |
| Seo, JH | 1 |
| Shin, SW | 1 |
| Uncu, D | 2 |
| Ozdemir, NY | 1 |
| Aksoy, S | 2 |
| Abali, H | 2 |
| Oksuzoglu, BC | 1 |
| Budakoglu, B | 1 |
| Yildiz, R | 1 |
| Aslan, N | 1 |
| Zengin, N | 1 |
| Conradi, LC | 2 |
| Bleckmann, A | 1 |
| Schirmer, M | 1 |
| Jo, P | 1 |
| Wolff, HA | 1 |
| Middel, P | 1 |
| Ghadimi, MB | 1 |
| Goldberg, RM | 1 |
| Ryan, DP | 1 |
| Sawaki, A | 1 |
| Tajika, M | 1 |
| Kawai, H | 1 |
| Ura, T | 1 |
| Kusumoto, M | 1 |
| Toyoda, S | 2 |
| Ishikawa, N | 1 |
| Matsumoto, T | 3 |
| Kusumoto, C | 1 |
| Doi, F | 1 |
| Tandon, M | 1 |
| Mishra, A | 1 |
| Agarwal, U | 1 |
| Saxena, S | 2 |
| Bossi, P | 1 |
| Orlandi, E | 1 |
| Bergamini, C | 1 |
| Locati, LD | 1 |
| Granata, R | 1 |
| Mirabile, A | 1 |
| Parolini, D | 1 |
| Franceschini, M | 1 |
| Fallai, C | 1 |
| Olmi, P | 1 |
| Quattrone, P | 1 |
| Potepan, P | 1 |
| Gloghini, A | 1 |
| Miceli, R | 1 |
| Mattana, F | 1 |
| Scaramellini, G | 1 |
| Licitra, L | 1 |
| Klaver, YL | 1 |
| de Hingh, IH | 1 |
| Verwaal, VJ | 1 |
| Shigaki, N | 1 |
| Yokoyama, S | 1 |
| Sugita, H | 1 |
| Arima, N | 1 |
| Radhakrishnan, V | 1 |
| Bakhshi, S | 1 |
| Gilje, B | 1 |
| Nordgård, O | 1 |
| Tjensvoll, K | 1 |
| Janssen, EA | 1 |
| Søiland, H | 1 |
| Smaaland, R | 1 |
| Baak, JP | 1 |
| Leibold, T | 1 |
| Akhurst, TJ | 1 |
| Chessin, DB | 1 |
| Yeung, HW | 1 |
| Macapinlac, H | 1 |
| Riedel, E | 1 |
| Paty, PB | 1 |
| Weiser, MR | 1 |
| Wong, WD | 2 |
| Larson, SM | 1 |
| Guillem, JG | 1 |
| Ferreira, A | 1 |
| Vieira, C | 1 |
| Rodrigues, A | 1 |
| Pereira, D | 1 |
| Rodrigues, H | 1 |
| Dávila, C | 1 |
| Bento, S | 1 |
| Kantelhardt, EJ | 1 |
| Vetter, M | 1 |
| Schmidt, M | 1 |
| Veyret, C | 4 |
| Hanf, V | 1 |
| Meisner, C | 1 |
| Paepke, D | 1 |
| Schmitt, M | 1 |
| Sweep, F | 1 |
| Martin, PM | 1 |
| Jaenicke, F | 1 |
| Showalter, TN | 1 |
| Zhan, T | 1 |
| Anne, PR | 1 |
| Chervoneva, I | 1 |
| Mitchell, EP | 1 |
| Rosato, EL | 1 |
| Kennedy, EP | 1 |
| Berger, AC | 1 |
| Kurebayashi, J | 2 |
| Kanomata, N | 1 |
| Kozuka, Y | 1 |
| Moriya, T | 1 |
| Kikukawa, N | 1 |
| Harada, S | 1 |
| Tamura, S | 1 |
| Nakayama, S | 2 |
| Ishihara, H | 1 |
| Liu, JH | 3 |
| Xiong, Y | 1 |
| Li, JD | 1 |
| Huang, X | 1 |
| He, L | 2 |
| Ren, YF | 1 |
| Wang, HY | 3 |
| Ko, AH | 1 |
| Espinoza, AM | 1 |
| Jones, KA | 1 |
| Bergsland, EK | 1 |
| Dito, E | 1 |
| Ong, A | 1 |
| Hanover, CS | 1 |
| Coakley, FV | 1 |
| Tempero, MA | 1 |
| Castoro, C | 1 |
| Scarpa, M | 1 |
| Cagol, M | 1 |
| Ruol, A | 1 |
| Cavallin, F | 1 |
| Alfieri, R | 1 |
| Zanchettin, G | 1 |
| Ancona, E | 1 |
| Negri, FV | 1 |
| Bozzetti, C | 1 |
| Lagrasta, C | 1 |
| Crafa, P | 1 |
| Silini, EM | 1 |
| Cao, KJ | 2 |
| Zhang, AL | 1 |
| Ma, WJ | 1 |
| Huang, PY | 2 |
| Luo, DH | 2 |
| Xia, WX | 1 |
| Zhao, WY | 1 |
| Chen, DY | 1 |
| Qi, Q | 1 |
| Tseng, CW | 1 |
| Yang, JC | 1 |
| Chen, CN | 1 |
| Huang, HC | 1 |
| Chuang, KN | 1 |
| Lai, HS | 1 |
| Lee, PH | 1 |
| Chang, KJ | 1 |
| Juan, HF | 1 |
| Delpeuch, A | 1 |
| Leveque, D | 1 |
| Rob, L | 1 |
| Bergerat, JP | 1 |
| Lu, L | 1 |
| Zhu, Q | 1 |
| Hao, Y | 1 |
| Mo, Y | 1 |
| Cui, N | 1 |
| Rong, T | 1 |
| Catanzaro, M | 1 |
| Nishiyama, K | 2 |
| Miyagi, K | 1 |
| Suzuki, O | 1 |
| Kitayama, J | 1 |
| Sunami, E | 1 |
| Yazawa, K | 1 |
| Nagawa, H | 2 |
| Kobunai, T | 1 |
| Matsuda, K | 1 |
| Nozawa, K | 1 |
| Iinuma, H | 1 |
| Horie, H | 1 |
| Ikeuchi, H | 2 |
| Eshima, K | 1 |
| Muto, T | 4 |
| Meng, H | 1 |
| Fong, Y | 2 |
| Zhang, ZT | 1 |
| Bolton, JS | 1 |
| Mahoney, MR | 1 |
| Farr, GH | 1 |
| Fitch, TR | 1 |
| Maples, WJ | 1 |
| Nagorney, DM | 1 |
| Rubin, J | 2 |
| Fuloria, J | 1 |
| Steen, PD | 1 |
| Alberts, SR | 1 |
| Yasojima, H | 1 |
| Shimomura, A | 1 |
| Naoi, Y | 2 |
| Shimazu, K | 1 |
| Nakayama, T | 1 |
| Tamaki, Y | 2 |
| Kawaguchi, K | 2 |
| Sato, K | 2 |
| Horie, A | 1 |
| Nomura, T | 5 |
| Iketani, S | 1 |
| Kanai, I | 1 |
| Nakatani, Y | 2 |
| Hamada, Y | 1 |
| Cohen, DJ | 1 |
| Newman, E | 1 |
| Iqbal, S | 1 |
| Chang, RY | 1 |
| Potmesil, M | 1 |
| Ryan, T | 1 |
| Donahue, B | 1 |
| Chandra, A | 1 |
| Utate, M | 1 |
| Hiotis, S | 1 |
| Pachter, LH | 1 |
| Hochster, H | 1 |
| Muggia, F | 1 |
| Izumiya, M | 2 |
| Yamagishi, Y | 3 |
| Sakai, G | 1 |
| Funakoshi, S | 1 |
| Adachi, M | 1 |
| Higuchi, H | 2 |
| Takaishi, H | 2 |
| Sugiura, J | 1 |
| Irie, E | 1 |
| Ohmori, T | 1 |
| Hibi, T | 2 |
| Shiraishi, O | 1 |
| Peng, YF | 1 |
| Shiozaki, H | 4 |
| He, Y | 1 |
| Bennouna, J | 1 |
| Husseini, F | 1 |
| Trillet-Lenoir, V | 1 |
| Faroux, R | 1 |
| Goldwasser, F | 1 |
| Senellart, H | 1 |
| Kraemer, S | 1 |
| Douillard, JY | 1 |
| Eropkin, PV | 1 |
| Rybakov, EG | 1 |
| Kashnikov, VN | 1 |
| Panina, MV | 1 |
| Sola, J | 1 |
| Aristu, J | 1 |
| Suzuki, C | 1 |
| Blomqvist, L | 1 |
| Sundin, A | 1 |
| Jacobsson, H | 1 |
| Byström, P | 1 |
| Nygren, P | 1 |
| Verhage, RJ | 1 |
| van der Horst, S | 1 |
| van der Sluis, PC | 1 |
| Lolkema, MP | 1 |
| McCleod, M | 1 |
| Shipley, DL | 1 |
| Arrowsmith, E | 1 |
| Barnes, EK | 1 |
| Gujral, DM | 1 |
| Hawkins, MA | 1 |
| Leonulli, BG | 1 |
| Ashley, S | 1 |
| Tait, D | 1 |
| Ferrarotto, R | 1 |
| Pathak, P | 1 |
| Maru, D | 1 |
| Agarwal, A | 1 |
| Overman, M | 1 |
| Hoff, PM | 3 |
| Nitzkorski, JR | 1 |
| Farma, JM | 1 |
| Watson, JC | 1 |
| Siripurapu, V | 1 |
| Zhu, F | 1 |
| Matteotti, RS | 1 |
| Sigurdson, ER | 1 |
| Weber, T | 1 |
| Link, KH | 1 |
| Chen, SF | 1 |
| Gong, C | 1 |
| Luo, M | 1 |
| Yao, HR | 1 |
| Zeng, YJ | 1 |
| Su, FX | 1 |
| Allegrini, G | 1 |
| Cremolini, C | 1 |
| Cortesi, E | 3 |
| Tuzi, A | 1 |
| Granetto, C | 1 |
| Tsuboi, K | 1 |
| Kawase, Y | 1 |
| Okochi, O | 1 |
| Hattori, M | 2 |
| Takami, Y | 1 |
| Mizuno, A | 1 |
| Uno, Y | 2 |
| Sasada, Y | 1 |
| Takamura, S | 1 |
| Kozaki, K | 1 |
| Muratore, A | 1 |
| Zimmitti, G | 1 |
| Ribero, D | 1 |
| Mellano, A | 1 |
| Viganò, L | 1 |
| Capussotti, L | 1 |
| Hattersley, SM | 1 |
| Sylvester, DC | 1 |
| Dyer, CE | 1 |
| Stafford, ND | 1 |
| Haswell, SJ | 1 |
| Greenman, J | 1 |
| Zapf, I | 1 |
| Tizedes, G | 1 |
| Pavlovics, G | 1 |
| Kovács, G | 1 |
| Kálmán, E | 1 |
| Szalai, G | 1 |
| Kövér, E | 1 |
| Farkas, R | 1 |
| Horváth, OP | 1 |
| Dalmases, M | 1 |
| Lucena, CM | 1 |
| Cano-Jiménez, E | 1 |
| Xaubet, A | 1 |
| Agustí, C | 1 |
| Katz, MH | 1 |
| Balachandran, A | 1 |
| Bhosale, P | 1 |
| Crane, CH | 2 |
| Pisters, PW | 1 |
| Abdalla, EK | 1 |
| Wolff, R | 3 |
| Abbruzzese, J | 3 |
| Varadhachary, G | 1 |
| Chopin-Laly, X | 1 |
| Charnsangavej, C | 1 |
| Fleming, JB | 2 |
| Chen, CM | 2 |
| Yu, KD | 1 |
| Yang, WT | 1 |
| Shao, ZM | 1 |
| Fujikawa, H | 1 |
| Matsushita, K | 2 |
| Uchida, K | 3 |
| Jingu, K | 2 |
| Ariga, H | 1 |
| Nemoto, K | 1 |
| Narazaki, K | 1 |
| Koto, M | 1 |
| Sugawara, T | 1 |
| Kubozono, M | 1 |
| Miyata, G | 1 |
| Onodera, K | 1 |
| Yamada, S | 3 |
| Huovinen, R | 1 |
| Jukkola-Vuorinen, A | 1 |
| Tanner, M | 1 |
| Kokko, R | 1 |
| Ahlgren, J | 1 |
| Auvinen, P | 1 |
| Paija, O | 1 |
| Helle, L | 1 |
| Villman, K | 1 |
| Nyandoto, P | 1 |
| Nilsson, G | 1 |
| Pajunen, M | 1 |
| Asola, R | 1 |
| Poikonen, P | 2 |
| Leinonen, M | 1 |
| Lindman, H | 2 |
| Scotté, M | 1 |
| Hamidou, H | 1 |
| Di Fiore, F | 1 |
| Paillot, B | 1 |
| Michot, F | 1 |
| Michel, P | 1 |
| Rosenberg, L | 1 |
| Weissler, M | 1 |
| Hayes, DN | 1 |
| Shockley, W | 1 |
| Zanation, A | 1 |
| Rosenman, J | 1 |
| Chera, B | 1 |
| Bickenbach, KA | 1 |
| Gonen, M | 1 |
| Tang, LH | 1 |
| O'Reilly, E | 1 |
| Goodman, K | 1 |
| Brennan, MF | 1 |
| D'Angelica, MI | 1 |
| Dematteo, RP | 1 |
| Jarnagin, WR | 1 |
| Allen, PJ | 1 |
| Gogas, H | 2 |
| Dafni, U | 2 |
| Karina, M | 2 |
| Papadimitriou, C | 2 |
| Batistatou, A | 1 |
| Bobos, M | 1 |
| Kalofonos, HP | 3 |
| Eleftheraki, AG | 1 |
| Timotheadou, E | 1 |
| Bafaloukos, D | 3 |
| Christodoulou, C | 1 |
| Markopoulos, C | 2 |
| Briasoulis, E | 2 |
| Papakostas, P | 2 |
| Samantas, E | 3 |
| Kosmidis, P | 2 |
| Stathopoulos, GP | 2 |
| Karanikiotis, C | 2 |
| Pectasides, D | 2 |
| Dimopoulos, MA | 1 |
| Fountzilas, G | 4 |
| Li, ZY | 1 |
| Koh, CE | 1 |
| Bu, ZD | 1 |
| Wu, AW | 1 |
| Zhang, LH | 1 |
| Wu, Q | 1 |
| Zong, XL | 1 |
| Ren, H | 1 |
| Tang, L | 1 |
| Zhang, XP | 1 |
| Li, JY | 1 |
| Ji, JF | 1 |
| Makino, S | 2 |
| Ide, Y | 1 |
| Yatsuoka, T | 1 |
| Urakawa, M | 1 |
| Murakami, T | 4 |
| Amano, K | 1 |
| Ohsawa, T | 1 |
| Okada, N | 2 |
| Kumamoto, K | 2 |
| Umemoto, S | 1 |
| Kawamoto, S | 1 |
| Shi, M | 1 |
| Hsia, Y | 1 |
| Luo, S | 1 |
| Zhao, L | 1 |
| Xu, M | 1 |
| Xiao, F | 1 |
| Fu, X | 1 |
| Zhou, B | 1 |
| Long, X | 1 |
| Hotta, T | 1 |
| Takifuji, K | 1 |
| Kobayashi, Y | 2 |
| Tabuse, K | 1 |
| Fukiage, O | 1 |
| Yamaue, H | 4 |
| Gehoff, A | 1 |
| Basten, O | 2 |
| Bismarck, C | 1 |
| Bandorski, D | 1 |
| Merkelbach-Bruse, S | 1 |
| Schneider-Stock, R | 1 |
| Stoehr, R | 1 |
| Wirtz, RM | 1 |
| Kitz, J | 1 |
| Müller, A | 1 |
| Rüschoff, J | 2 |
| Gong, L | 1 |
| Lou, JY | 1 |
| Wang, P | 1 |
| Zhang, JW | 1 |
| Peng, ZL | 1 |
| Zhang, JQ | 1 |
| Hooker, CM | 1 |
| Brock, MV | 1 |
| Shin, J | 1 |
| How, R | 1 |
| Franco, N | 1 |
| Prevas, H | 1 |
| Hulbert, A | 1 |
| Yang, SC | 1 |
| Saito, M | 1 |
| Hirowatari, H | 1 |
| Izawa, H | 2 |
| Furuya, T | 1 |
| Ito, K | 3 |
| Yovino, S | 1 |
| Maidment, BW | 1 |
| Pandya, N | 1 |
| Goloubeva, O | 1 |
| Wolfgang, C | 1 |
| Schulick, R | 1 |
| Hanna, N | 1 |
| Alexander, R | 1 |
| Regine, WF | 1 |
| Wu, ZM | 1 |
| Teng, RY | 1 |
| Shen, JG | 1 |
| Xie, SD | 1 |
| Xu, CY | 1 |
| Wang, LB | 1 |
| Ishihara, R | 1 |
| Yu, JC | 1 |
| Kang, WM | 1 |
| Ma, ZQ | 1 |
| Nishida, N | 1 |
| Mimori, K | 1 |
| Sudo, T | 1 |
| Shibata, K | 4 |
| Matsumoto, M | 3 |
| Sakurai, T | 1 |
| Setoyama, T | 2 |
| Nabeki, B | 1 |
| Nakajo, M | 2 |
| Hirano, G | 1 |
| Sakurai, K | 1 |
| Sohda, T | 1 |
| Kunimoto, H | 1 |
| Yotsumoto, K | 1 |
| Fukunaga, A | 1 |
| Iwashita, H | 1 |
| Ueda, S | 4 |
| Yokoyama, K | 1 |
| Morihara, D | 1 |
| Takeyama, Y | 1 |
| Irie, M | 1 |
| Iwata, K | 1 |
| Shakado, S | 1 |
| Sakisaka, S | 1 |
| Kucukoner, M | 1 |
| Isikdogan, A | 1 |
| Arpaci, E | 1 |
| Bilici, M | 1 |
| Cetin, B | 1 |
| Dane, F | 1 |
| Inane, M | 1 |
| Kaplan, MA | 1 |
| Cayir, K | 1 |
| Yetisyigit, T | 1 |
| Ozdemir, N | 1 |
| Inal, A | 1 |
| Alkis, N | 1 |
| Tekin, SB | 1 |
| Eroglu, C | 1 |
| Turhal, S | 1 |
| Benekli, M | 1 |
| Buyukberber, S | 1 |
| Blank, S | 1 |
| Chu, E | 1 |
| Baehring, JM | 1 |
| Ferrand, FR | 1 |
| Gontier, E | 1 |
| Guymar, S | 1 |
| Fagot, T | 1 |
| Ceccaldi, B | 1 |
| Malfuson, JV | 1 |
| de Revel, T | 1 |
| Benavides, M | 1 |
| Pericay, C | 1 |
| Gil-Calle, S | 1 |
| Massutí, B | 2 |
| Aparicio, J | 1 |
| Dueñas, R | 1 |
| González-Flores, E | 1 |
| Carrato, A | 3 |
| Marcuello, E | 1 |
| Gómez, A | 1 |
| Cabrera, E | 1 |
| Queralt, B | 1 |
| Gómez, MJ | 1 |
| Guasch, I | 1 |
| Etxeberría, A | 1 |
| Alfaro, J | 1 |
| Campos, JM | 1 |
| Reina, JJ | 1 |
| Aranda, E | 2 |
| Seshimo, K | 1 |
| Oishi, M | 2 |
| Toshima, T | 1 |
| Ikeda, H | 1 |
| Yamamura, M | 2 |
| Kodera, M | 1 |
| Fujita, H | 5 |
| Shibagaki, K | 1 |
| Matsuki, T | 1 |
| Kobayashi, K | 2 |
| Takita, K | 1 |
| Del Vescovo, R | 1 |
| Trodella, LE | 1 |
| Sansoni, I | 1 |
| Cazzato, RL | 1 |
| Battisti, S | 1 |
| Giurazza, F | 1 |
| Ramella, S | 1 |
| Cellini, F | 2 |
| Grasso, RF | 1 |
| Trodella, L | 2 |
| Beomonte Zobel, B | 1 |
| Yi, JH | 1 |
| Yim, DS | 1 |
| Schönekaes, K | 1 |
| Rübe, C | 1 |
| Sulkowski, U | 1 |
| Preusser, P | 1 |
| Prott, FJ | 1 |
| Willich, N | 1 |
| Abe, H | 2 |
| Kawai, Y | 1 |
| Cho, H | 1 |
| Kubota, Y | 3 |
| Umeda, T | 1 |
| Kurumi, Y | 1 |
| Joerger, M | 1 |
| Ess, S | 1 |
| Dehler, S | 1 |
| Savidan, A | 1 |
| Bouchardy, C | 1 |
| Frick, H | 1 |
| Konzelmann, I | 1 |
| Zhang, HQ | 1 |
| Wang, RB | 1 |
| Yan, HJ | 1 |
| Zhu, KL | 1 |
| Jiang, SM | 1 |
| Hu, XG | 1 |
| Yu, JM | 1 |
| Mistrangelo, M | 1 |
| Pelosi, E | 1 |
| Bellò, M | 1 |
| Ricardi, U | 1 |
| Cassoni, P | 1 |
| Baccega, M | 1 |
| Filippini, C | 1 |
| Racca, P | 1 |
| Lesca, A | 1 |
| Munoz, FH | 1 |
| Fora, G | 1 |
| Skanjeti, A | 1 |
| Cravero, F | 1 |
| Morino, M | 1 |
| Asselain, B | 3 |
| Lévy, C | 1 |
| Petit, T | 2 |
| Beauduin, M | 2 |
| Eymard, JC | 2 |
| Jin, K | 1 |
| Lan, H | 1 |
| Xie, B | 1 |
| He, K | 1 |
| Xu, Z | 1 |
| Han, N | 1 |
| Teng, L | 1 |
| Cao, F | 1 |
| Chen, XF | 1 |
| Yoshii, T | 1 |
| Ohkawa, S | 1 |
| Tamai, S | 4 |
| Kameda, Y | 2 |
| Yeh, J | 1 |
| Hastings, J | 1 |
| Rao, A | 1 |
| Abbas, MA | 1 |
| Nishino, H | 2 |
| Takanosawa, M | 1 |
| Kawada, K | 1 |
| Ichimura, K | 1 |
| Nakazawa, M | 1 |
| Wang, LZ | 1 |
| Wang, TF | 1 |
| Xie, YT | 2 |
| Fan, ZQ | 1 |
| Lin, BY | 1 |
| Li, JF | 1 |
| Da Mosto, MC | 1 |
| Lupato, V | 1 |
| Romeo, S | 1 |
| Spinato, G | 1 |
| Addonisio, G | 1 |
| Baggio, V | 1 |
| Gava, A | 1 |
| Boscolo-Rizzo, P | 1 |
| Kim, JY | 2 |
| Yoon, MS | 1 |
| Niu, Z | 1 |
| Shi, X | 1 |
| Guo, X | 2 |
| Yao, W | 1 |
| Jiang, GL | 1 |
| Eveno, C | 1 |
| Honoré, C | 1 |
| Tzanis, D | 1 |
| Benhaim, L | 1 |
| Elias, D | 2 |
| Pavlidis, N | 3 |
| Felekouras, E | 2 |
| Karatzas, T | 1 |
| Griniatsos, J | 1 |
| Dimitroulis, D | 1 |
| Polyzos, K | 1 |
| Kontzoglou, K | 1 |
| Mantas, D | 1 |
| Karavokyros, J | 1 |
| Nikiteas, N | 1 |
| Tsavaris, N | 3 |
| Vafiadis, I | 1 |
| Shah, SM | 1 |
| Drage, MG | 1 |
| Lichtman, AH | 1 |
| Haddad, RI | 2 |
| Glynne-Jones, R | 2 |
| Sebag-Montefiore, D | 2 |
| Adams, R | 1 |
| Gollins, S | 1 |
| Harrison, M | 2 |
| Meadows, HM | 1 |
| Jitlal, M | 1 |
| Tenti, S | 1 |
| Correale, P | 1 |
| Pastina, P | 1 |
| Fioravanti, A | 1 |
| Okada, K | 5 |
| Nakamura, Y | 4 |
| Bano, N | 1 |
| Najam, R | 1 |
| Mateen, A | 1 |
| Qazi, F | 1 |
| Xuan, Y | 1 |
| Kim, YB | 1 |
| Lee, G | 1 |
| Shim, W | 1 |
| Yun, J | 1 |
| Ham, IH | 1 |
| Han, SU | 1 |
| Wu, M | 1 |
| Ren, T | 1 |
| Wan, XR | 1 |
| Feng, FZ | 1 |
| Huang, HF | 1 |
| Yang, JX | 1 |
| Shen, K | 2 |
| Xiang, Y | 1 |
| Brieau, B | 1 |
| Roussel, H | 1 |
| Markoutsaki, T | 1 |
| Dubreuil, O | 1 |
| Trouilloud, I | 1 |
| Landi, B | 1 |
| Lepère, C | 1 |
| Vaillant, JN | 2 |
| Furusaka, T | 1 |
| Tanaka, A | 1 |
| Matsuda, H | 2 |
| Tranchart, H | 1 |
| Lefèvre, JH | 1 |
| Svrcek, M | 1 |
| Flejou, JF | 1 |
| Tiret, E | 3 |
| Parc, Y | 1 |
| Iwata, T | 1 |
| Chung, K | 1 |
| Hanada, S | 1 |
| Toda, M | 1 |
| Nakata, K | 1 |
| Miura, T | 1 |
| Mirakhorli, M | 1 |
| Rahman, SA | 1 |
| Abdullah, S | 1 |
| Vakili, M | 1 |
| Rozafzon, R | 1 |
| Khoshzaban, A | 1 |
| Mukai, T | 1 |
| Koga, R | 1 |
| Arita, J | 1 |
| Saiura, A | 1 |
| Ikeda, A | 1 |
| Nagasue, Y | 1 |
| Oikawa, Y | 1 |
| Yamakawa, K | 1 |
| Fujimoto, Y | 3 |
| Nagayama, S | 1 |
| Yamamoto, C | 1 |
| Ozturk, MA | 1 |
| Ozveren, O | 1 |
| Cinar, V | 1 |
| Erdik, B | 1 |
| Oyan, B | 1 |
| Yuki, S | 1 |
| Naito, Y | 1 |
| Fukushima, H | 1 |
| Komatsu, Y | 1 |
| Takano, T | 1 |
| Duchemann, B | 1 |
| Duchemain, B | 1 |
| Baruch-Hennequin, V | 1 |
| Rivera, S | 1 |
| Hennequin, C | 1 |
| Rousseau, D | 1 |
| Denis, F | 1 |
| Girault, S | 1 |
| Poirier, AL | 1 |
| Paumier, A | 1 |
| Hamy, A | 1 |
| Mahé, MA | 2 |
| Mesgouez-Nebout, N | 1 |
| Oakman, C | 1 |
| Francis, PA | 1 |
| Crown, J | 6 |
| De Azambuja, E | 2 |
| Andersson, M | 4 |
| Nordenskjöld, B | 2 |
| Jakesz, R | 4 |
| Gutiérrez, J | 3 |
| Harvey, V | 1 |
| Punzalan, L | 1 |
| Dell'orto, P | 1 |
| Larsimont, D | 3 |
| Steinberg, I | 1 |
| Piccart-Gebhart, M | 2 |
| Saranga-Perry, V | 1 |
| Morse, B | 1 |
| Centeno, B | 1 |
| Kvols, L | 1 |
| Strosberg, J | 1 |
| Sakr, H | 1 |
| Hamed, RH | 1 |
| Anter, AH | 1 |
| Yossef, T | 1 |
| Corry, J | 1 |
| Peters, L | 1 |
| Kleid, S | 1 |
| Rischin, D | 1 |
| Sirtaine, N | 1 |
| Piette, F | 1 |
| Salgado, R | 1 |
| Van Eenoo, F | 1 |
| Rouas, G | 1 |
| Francis, P | 2 |
| Crown, JP | 1 |
| Amajoyi, R | 1 |
| Lee, Y | 1 |
| Recio, PJ | 1 |
| Kondylis, PD | 1 |
| Wood, MD | 1 |
| Zaki, BI | 1 |
| Gordon, SR | 1 |
| Sutton, JE | 1 |
| Lisovsky, M | 1 |
| Gui, J | 1 |
| Bubis, JA | 1 |
| Dragnev, KH | 1 |
| Rigas, JR | 1 |
| Hatano, S | 1 |
| Matsuzawa, T | 1 |
| Kumagai, Y | 1 |
| Haga, N | 1 |
| Cirillo, M | 1 |
| Musola, M | 1 |
| Cassandrini, PA | 1 |
| Lunardi, G | 1 |
| Venturini, M | 2 |
| Nakada, T | 2 |
| Nagayama, K | 2 |
| Hiramoto, J | 1 |
| Tsuruta, Y | 1 |
| Sakabe, S | 1 |
| Cocconi, G | 1 |
| Di Blasio, B | 1 |
| Ceci, G | 1 |
| Rondini, E | 2 |
| Bella, M | 1 |
| Leonardi, F | 1 |
| Savoldi, L | 1 |
| Camisa, R | 2 |
| Hehr, T | 1 |
| Classen, J | 1 |
| Schreck, U | 1 |
| Glocker, S | 1 |
| Koitschev, A | 1 |
| Bamberg, M | 1 |
| Artru, P | 2 |
| Ezenfis, J | 1 |
| Clavero-Fabri, MC | 1 |
| Ducreux, M | 2 |
| Thompson, T | 1 |
| Toba, T | 1 |
| Ohga, S | 1 |
| Urashima, Y | 1 |
| Terashima, H | 2 |
| Masuda, K | 1 |
| Sivelli, R | 1 |
| Del Rio, P | 1 |
| Arcuri, MF | 1 |
| Corcione, L | 1 |
| Moreno, A | 1 |
| Escobedo, A | 1 |
| Benito, E | 1 |
| Serra, JM | 1 |
| Gumà, A | 1 |
| Riu, F | 1 |
| Takizawa, M | 1 |
| Hirano, M | 2 |
| Murakami, N | 2 |
| Hara, T | 1 |
| Asaumi, Y | 1 |
| Kikkawa, H | 1 |
| Ron, IG | 2 |
| Wigler, N | 2 |
| Borovik, R | 2 |
| Peretz, T | 1 |
| Rizel, S | 2 |
| Shani, A | 2 |
| Brenner, J | 2 |
| Farbstein, H | 2 |
| Brenner, HJ | 2 |
| Chaitchik, S | 3 |
| Catane, R | 2 |
| Inbar, MJ | 2 |
| Mikami, Y | 2 |
| Kubozoe, T | 3 |
| Urakami, A | 1 |
| Kimoto, M | 3 |
| Tsunoda, T | 4 |
| Shigemitsu, K | 1 |
| Naomoto, Y | 1 |
| Shirakawa, Y | 1 |
| Haisa, M | 1 |
| Gunduz, M | 1 |
| Yang, TS | 2 |
| Hsu, KC | 1 |
| Münter, MW | 1 |
| Hof, H | 1 |
| Nill, S | 1 |
| Häring, P | 1 |
| Bortfeld, T | 1 |
| Wannenmacher, M | 4 |
| Onda, M | 1 |
| Sasajima, K | 3 |
| Makino, H | 5 |
| Hagiwara, N | 2 |
| Takubo, K | 2 |
| Miyashita, M | 4 |
| Elsaleh, H | 1 |
| Iacopetta, B | 1 |
| Kempin, S | 1 |
| Wilson, E | 1 |
| Lowery, C | 1 |
| Diasio, R | 1 |
| Ichikawa, W | 2 |
| Shirota, Y | 2 |
| Nihei, Z | 2 |
| Hirayama, R | 1 |
| Cameron, DA | 4 |
| Anderson, A | 1 |
| Toy, E | 1 |
| Evans, TR | 1 |
| Le Vay, JH | 1 |
| Kennedy, IC | 1 |
| Grieve, RJ | 2 |
| Perren, TJ | 1 |
| Jones, A | 1 |
| Mansi, J | 1 |
| Leonard, RC | 4 |
| Kagawa, R | 1 |
| Nakayama, N | 2 |
| Sakata, S | 1 |
| Tada, M | 1 |
| Ishikawa, K | 2 |
| Saguchi, T | 1 |
| Yasuda, S | 2 |
| Makuuchi, H | 6 |
| Murayama, C | 1 |
| Dietz, A | 5 |
| Vanselow, B | 3 |
| Conradt, C | 1 |
| Weidauer, H | 2 |
| Kallinowski, F | 1 |
| Dollner, R | 1 |
| Ebisui, C | 1 |
| Souma, I | 1 |
| Fukuchi, N | 1 |
| Sakita, I | 1 |
| Kanai, T | 2 |
| Kouro, T | 1 |
| Hasuike, Y | 1 |
| Tujinaka, T | 1 |
| Schüll, B | 1 |
| Ulrich-Pur, H | 1 |
| Schmid, K | 1 |
| Raderer, M | 1 |
| Haider, K | 3 |
| Kwasny, W | 1 |
| Depisch, D | 1 |
| Schneeweiss, B | 1 |
| Lang, F | 1 |
| Kornek, GV | 1 |
| Jonat, W | 4 |
| Sauerbrei, W | 6 |
| Blamey, R | 2 |
| Cuzick, J | 2 |
| Namer, M | 6 |
| Fogelman, I | 2 |
| de Haes, JC | 2 |
| de Matteis, A | 1 |
| Stewart, A | 1 |
| Szakolczai, I | 1 |
| Palmer, M | 1 |
| Geberth, M | 1 |
| Lisboa, B | 1 |
| Rivkin, SE | 8 |
| Costanzi, JJ | 5 |
| Athens, JW | 2 |
| Vaughn, CB | 1 |
| Garin, L | 1 |
| Corbinais, S | 1 |
| Boucher, E | 1 |
| Blanchot, J | 1 |
| Le Guilcher, P | 1 |
| Shimizu, C | 2 |
| Ohta, K | 4 |
| Ohyama, S | 1 |
| Chiba, N | 3 |
| Yonekawa, H | 1 |
| Fumoleau, P | 8 |
| Romestaing, P | 3 |
| Fargeot, P | 5 |
| Brémond, A | 1 |
| Schraub, S | 2 |
| Goudier, MJ | 5 |
| Mihura, J | 2 |
| Monnier, A | 5 |
| Clavère, P | 3 |
| Seffert, P | 1 |
| Pourny, C | 1 |
| Facchini, T | 1 |
| Jacquin, JP | 2 |
| Sztermer, JF | 1 |
| Datchary, J | 2 |
| Ramos, R | 1 |
| Luporsi, E | 2 |
| Niki, T | 1 |
| Matsumoto, I | 1 |
| Inoue, H | 2 |
| Hamano, K | 3 |
| Okutani, T | 1 |
| Hirohata, S | 1 |
| Nakashima, T | 2 |
| Yasutake, K | 1 |
| Sashikata, T | 1 |
| Nishizawa, S | 2 |
| Sano, K | 1 |
| Ogasawara, T | 2 |
| Nakamura, M | 2 |
| Sadato, N | 1 |
| Yoshida, M | 6 |
| Yonekura, Y | 1 |
| Papagikos, M | 1 |
| Skibber, J | 4 |
| Janjan, NA | 5 |
| Feig, B | 1 |
| Rodriguez-Bigas, MA | 1 |
| Hung, A | 1 |
| Wolff, RA | 1 |
| Delclos, M | 1 |
| Lin, E | 2 |
| Cleary, K | 2 |
| Inaba, S | 1 |
| Nakata, M | 1 |
| Matsushita, Y | 1 |
| Araki, Y | 1 |
| Ogino, A | 1 |
| Yamada, E | 1 |
| Sawada, M | 1 |
| Ono, Y | 1 |
| Nakagoe, T | 1 |
| Yamaguchi, E | 1 |
| Sawai, T | 1 |
| Tsuji, T | 1 |
| Shibasaki, S | 1 |
| Nanashima, A | 1 |
| Yamaguchi, H | 1 |
| Yasutake, T | 1 |
| Ayabe, H | 1 |
| Thuss-Patience, PC | 1 |
| Kretzschmar, A | 1 |
| Krenn, V | 1 |
| Dörken, B | 1 |
| Reichardt, P | 1 |
| Bonneterre, J | 5 |
| Beger, HG | 1 |
| Poch, B | 1 |
| Schwarz, M | 1 |
| Gansauge, F | 1 |
| Langer, C | 2 |
| Jakob, C | 2 |
| Müller, D | 1 |
| Siemer, A | 1 |
| Markus, PM | 1 |
| Füzesi, L | 1 |
| Chua, DT | 1 |
| Sham, JS | 2 |
| Au, GK | 1 |
| Bernard-Marty, C | 1 |
| Mano, M | 2 |
| Paesmans, M | 3 |
| Accettura, C | 1 |
| Munoz-Bermeo, R | 1 |
| Richard, T | 1 |
| Kleiber, K | 1 |
| Cardoso, F | 2 |
| Lobelle, JP | 1 |
| Weiss, RB | 3 |
| Woolf, SH | 1 |
| Demakos, E | 1 |
| Holland, JF | 9 |
| Berry, DA | 7 |
| Falkson, G | 7 |
| Cirrincione, CT | 3 |
| Robbins, A | 1 |
| Bothun, S | 1 |
| Fritz, P | 1 |
| Stoll, P | 1 |
| Zierhut, D | 1 |
| Colleoni, M | 5 |
| Ploner, F | 1 |
| Hausmaninger, H | 2 |
| Kolb, R | 2 |
| Stierer, M | 2 |
| Fridrik, M | 2 |
| Steindorfer, P | 2 |
| Gnant, M | 2 |
| Mlineritsch, B | 2 |
| Tschurtschenthaler, G | 2 |
| Steger, G | 2 |
| Seifert, M | 1 |
| Kubista, E | 3 |
| Samonigg, H | 2 |
| Weisser, A | 1 |
| Willer, A | 1 |
| Hehlmann, R | 1 |
| Emi, Y | 1 |
| Sakurai, M | 1 |
| Yonemura, Y | 2 |
| Usuki, H | 1 |
| Ishimura, K | 1 |
| Yachida, S | 1 |
| Hagiike, M | 1 |
| Okano, K | 1 |
| Izuishi, K | 1 |
| Karasawa, Y | 1 |
| Goda, F | 1 |
| Maeta, H | 1 |
| Terashima, M | 3 |
| Takagane, A | 2 |
| Abe, K | 1 |
| Irinoda, T | 1 |
| Nakaya, T | 1 |
| Yonezawa, H | 1 |
| Oyama, K | 3 |
| Kanzaki, N | 1 |
| Ohtani, S | 1 |
| Nemoto, T | 1 |
| Hoshino, Y | 1 |
| Kogure, M | 1 |
| Gotoh, M | 1 |
| Melcher, AA | 1 |
| Lin, JC | 1 |
| Jan, JS | 1 |
| Chen, KY | 1 |
| Hsu, CY | 1 |
| Liang, WM | 1 |
| Wang, WY | 1 |
| Miyazaki, M | 5 |
| Sarashina, H | 1 |
| Saito, N | 1 |
| Watanabe, S | 8 |
| Kodaira, S | 4 |
| Nakazato, H | 2 |
| Futami, R | 2 |
| Tajiri, T | 4 |
| Tateno, A | 1 |
| Miyashita, T | 1 |
| Noguchi, T | 3 |
| Kikuchi, R | 1 |
| Toyoda, H | 1 |
| Okada, S | 1 |
| Uchida, Y | 1 |
| Villar, A | 1 |
| Sole-Calvo, A | 1 |
| Gonzalez, R | 1 |
| Lizon, J | 1 |
| Camps, C | 1 |
| Casado, A | 1 |
| Candel, MT | 1 |
| Albanell, J | 1 |
| Aranda, J | 1 |
| Campbell, J | 1 |
| Diaz-Rubio, E | 2 |
| Gray, R | 7 |
| Robert, NJ | 2 |
| LeMaistre, CF | 1 |
| Gradishar, WJ | 1 |
| Pisansky, TM | 1 |
| Fetting, J | 1 |
| Paietta, E | 1 |
| Lazarus, HM | 1 |
| Nahon, P | 1 |
| Tournigand, C | 1 |
| Krulik, M | 2 |
| De Gramont, A | 2 |
| Yusa, H | 1 |
| Noguchi, M | 3 |
| Ohara, K | 2 |
| An, FS | 1 |
| Huang, JQ | 1 |
| Chen, SH | 1 |
| Rong, TH | 2 |
| Hayashi, S | 2 |
| Oota, H | 1 |
| Kamimura, T | 1 |
| Tachibana, M | 1 |
| Yoshimura, H | 1 |
| Kinugasa, S | 1 |
| Shibakita, M | 1 |
| Dhar, DK | 1 |
| Nagasue, N | 1 |
| Nakamori, M | 1 |
| Iwahashi, M | 2 |
| McHam, SA | 1 |
| Adelstein, DJ | 2 |
| Rybicki, LA | 1 |
| Lavertu, P | 1 |
| Esclamado, RM | 1 |
| Wood, BG | 1 |
| Strome, M | 1 |
| Carroll, MA | 1 |
| TAYLOR, SG | 4 |
| ANSFIELD, FJ | 6 |
| CURRERI, AR | 4 |
| MOERTEL, CG | 4 |
| REITEMEIER, RJ | 1 |
| HAHN, RG | 1 |
| GOLLIN, FF | 1 |
| VERMUND, H | 1 |
| MCCAFFERY, JF | 1 |
| BAKER, RR | 1 |
| GAERTNER, RA | 1 |
| Tanguay, JS | 1 |
| Shrihari, N | 1 |
| Warren, RE | 1 |
| Dummer, R | 1 |
| Beyeler, M | 1 |
| Morcinek, J | 1 |
| Burg, G | 1 |
| Semiglazov, VF | 4 |
| Maksimov, SIa | 1 |
| Semiglazov, VV | 1 |
| Kosnikov, AG | 1 |
| Helbig, M | 1 |
| Schlemmer, HP | 2 |
| Lumer, M | 1 |
| Knopp, MV | 2 |
| de Haes, H | 1 |
| Olschewski, M | 2 |
| Okamoto, N | 1 |
| Maruta, M | 1 |
| Masumori, K | 1 |
| Kato, R | 1 |
| Kikkawa, N | 1 |
| Iijima, S | 3 |
| Handa, R | 1 |
| Ohshima, S | 1 |
| Kurokawa, E | 1 |
| Nishioka, K | 1 |
| Arai, K | 5 |
| Katayanagi, S | 2 |
| Miyamoto, H | 1 |
| Horiguchi, S | 1 |
| Chauveinc, L | 1 |
| Buthaud, X | 1 |
| Falcou, MC | 1 |
| Mosseri, V | 1 |
| De la Rochefordière, A | 1 |
| Girodet, J | 1 |
| Salmon, RJ | 1 |
| Sueyoshi, S | 3 |
| Sasahara, H | 2 |
| Matono, S | 2 |
| Yamana, H | 3 |
| Takada, T | 4 |
| Saito, E | 2 |
| Hiraide, Y | 1 |
| Funakoshi, K | 1 |
| Tasaki, A | 1 |
| Inayoshi, J | 1 |
| Arai, F | 1 |
| Motoyama, H | 1 |
| Akiyama, N | 2 |
| Konishi, N | 1 |
| Ohmori, Y | 2 |
| Mohri, Y | 1 |
| Tonouchi, H | 1 |
| O'Neill, A | 2 |
| Nasi, ML | 2 |
| Bonetti, M | 2 |
| Furusawa, J | 1 |
| Mizumati, T | 1 |
| Iizuka, K | 1 |
| Jenkins, DE | 1 |
| Oei, Y | 1 |
| Hornig, YS | 1 |
| Yu, SF | 1 |
| Dusich, J | 1 |
| Purchio, T | 1 |
| Contag, PR | 1 |
| Ottevanger, PB | 1 |
| De Mulder, PH | 1 |
| Grol, RP | 1 |
| van Lier, H | 1 |
| Beex, LV | 1 |
| Okushiba, S | 1 |
| Kondo, S | 1 |
| Katoh, H | 1 |
| Inoue, M | 3 |
| Stathopoulos, G | 1 |
| Kouvatseas, G | 1 |
| Polychronis, A | 1 |
| Klouvas, G | 1 |
| Zamboglou, N | 2 |
| Kyriakou, K | 1 |
| Pectasidis, D | 1 |
| Ekonomopoulos, T | 1 |
| Razis, E | 1 |
| Koukouras, D | 1 |
| Zombolas, V | 1 |
| Skarlos, D | 2 |
| Juska, P | 1 |
| Pavalkis, D | 1 |
| Pranys, D | 1 |
| Ernst, MF | 1 |
| Voogd, AC | 1 |
| Coebergh, JW | 1 |
| Poortmans, PM | 1 |
| Roukema, JA | 1 |
| Heide, J | 1 |
| Krüll, A | 1 |
| Berger, J | 1 |
| Ushijima, T | 1 |
| Sasako, M | 3 |
| Mio, H | 2 |
| Sekiya, M | 1 |
| Kathou, T | 1 |
| Brizel, DM | 1 |
| Prosnitz, RG | 1 |
| Hunter, S | 1 |
| Fisher, SR | 1 |
| Clough, RL | 1 |
| Downey, MA | 1 |
| Scher, RL | 1 |
| Izumi, R | 1 |
| Nakajima, H | 1 |
| Ohashi, K | 2 |
| Kudo, R | 1 |
| Okuda, H | 1 |
| Origasa, H | 1 |
| Sugimori, H | 1 |
| Gruber, G | 3 |
| Greiner, RH | 1 |
| Hlushchuk, R | 1 |
| Aebersold, DM | 1 |
| Altermatt, HJ | 1 |
| Berclaz, G | 1 |
| Djonov, V | 1 |
| Calais, G | 1 |
| Claude, L | 1 |
| Carrie, C | 1 |
| Newlin, HE | 1 |
| Zlotecki, RA | 1 |
| Morris, CG | 1 |
| Hochwald, SN | 1 |
| Riggs, CE | 1 |
| Mendenhall, WM | 1 |
| Morimoto, K | 1 |
| Koh, M | 1 |
| Peiffert, D | 1 |
| Oechsle, K | 1 |
| Reis, HE | 1 |
| Haag, C | 3 |
| Niederle, N | 1 |
| Wilke, HJ | 1 |
| Pflüger, KH | 1 |
| Batran, SA | 1 |
| Büchele, T | 1 |
| Kanz, L | 3 |
| Vincent-Salomon, A | 2 |
| Rousseau, A | 1 |
| Jouve, M | 2 |
| Beuzeboc, P | 2 |
| Sigal-Zafrani, B | 2 |
| Fréneaux, P | 1 |
| Rosty, C | 1 |
| Nos, C | 2 |
| Campana, F | 2 |
| Klijanienko, J | 1 |
| Al Ghuzlan, A | 1 |
| Sastre-Garau, X | 1 |
| Niemann, B | 1 |
| Rochlitz, C | 2 |
| Herrmann, R | 2 |
| Pless, M | 1 |
| Simizu, M | 1 |
| Matsukura, S | 1 |
| Samejima, R | 1 |
| Hidaka, K | 1 |
| Ema, T | 1 |
| de Vries, EG | 5 |
| van der Graaf, WT | 3 |
| Otter, R | 1 |
| Willemse, PH | 4 |
| Lind, M | 1 |
| Twelves, C | 1 |
| Coleman, R | 2 |
| van Belle, S | 1 |
| Wilson, C | 1 |
| Ledermann, J | 1 |
| Kennedy, I | 1 |
| Perren, T | 1 |
| Verrill, M | 1 |
| Cameron, D | 1 |
| Foster, E | 1 |
| Yellowlees, A | 1 |
| Takemura, M | 2 |
| Osugi, H | 2 |
| Kaneko, M | 2 |
| Iwasaki, H | 1 |
| Ishiyama, T | 1 |
| Inazawa, K | 1 |
| Montcuquet, P | 2 |
| Barats, JC | 1 |
| Van Praagh, I | 1 |
| Chapelle-Marcillac, I | 1 |
| Ninomiya, I | 1 |
| Terada, I | 1 |
| Yoshizumi, T | 1 |
| Takino, T | 1 |
| Nagai, N | 1 |
| Morita, A | 2 |
| Fushida, S | 2 |
| Nishimura, G | 2 |
| Fujimura, T | 2 |
| Ohta, T | 2 |
| Miwa, K | 2 |
| Singhal, V | 1 |
| Singh, JP | 1 |
| Lyall, A | 1 |
| Bansal, A | 1 |
| Jiang, ZF | 1 |
| Song, ST | 1 |
| Zhang, SH | 1 |
| Shen, G | 1 |
| Yu, JX | 1 |
| Guo, L | 1 |
| Lin, HX | 3 |
| Li, FY | 1 |
| Qiu, F | 1 |
| Hong, MH | 1 |
| Lee, SI | 2 |
| Chung, HC | 2 |
| Choi, SH | 2 |
| Park, JN | 1 |
| Han, JY | 1 |
| Lee, KS | 3 |
| Cho, JY | 3 |
| Awane, H | 1 |
| Ikeda, T | 2 |
| Aoyama, H | 2 |
| Nishi, T | 2 |
| Wada, T | 2 |
| Danno, M | 2 |
| Hanasawa, K | 1 |
| Naitoh, H | 1 |
| Kushima, R | 1 |
| Fujio, N | 2 |
| Ihara, T | 2 |
| Terakura, M | 1 |
| Takatori, H | 2 |
| Tsukazaki, T | 2 |
| Tsukazaki, Y | 2 |
| Taghian, A | 1 |
| Jeong, JH | 2 |
| Mamounas, E | 1 |
| Anderson, S | 3 |
| Bryant, J | 3 |
| Deutsch, M | 1 |
| Wolmark, N | 10 |
| Imdahl, A | 1 |
| Schöffel, U | 1 |
| Ruf, G | 1 |
| Hopf, UT | 1 |
| Lemos, LB | 1 |
| Qu, Z | 1 |
| Garg, K | 1 |
| Papasozomenos, S | 1 |
| Nikkuni, K | 1 |
| Nagahashi, M | 1 |
| Nishimura, A | 1 |
| Bonnen, M | 1 |
| Crane, C | 1 |
| Delclos, ME | 1 |
| Rodriguez-Bigas, M | 1 |
| Eng, C | 1 |
| Wong, A | 2 |
| Feig, BW | 7 |
| Goel, R | 1 |
| Chouinard, E | 1 |
| Stewart, DJ | 2 |
| Huan, S | 1 |
| Hirte, H | 1 |
| Stafford, S | 1 |
| Waterfield, B | 1 |
| Roach, J | 1 |
| Lathia, C | 1 |
| Agarwal, V | 1 |
| Humphrey, R | 1 |
| Walsh, W | 1 |
| Matthews, S | 1 |
| Seymour, L | 1 |
| Mochizuki, R | 1 |
| Gunji, Y | 2 |
| Miyauchi, H | 1 |
| Chiba, S | 1 |
| Aoyagi, K | 2 |
| Koufuji, K | 2 |
| Yano, S | 2 |
| Miyagi, M | 3 |
| Imaizumi, T | 1 |
| Takeda, J | 2 |
| Takeno, A | 1 |
| Ikenaga, M | 1 |
| Sawamura, T | 1 |
| Wu, XQ | 1 |
| Cui, HJ | 1 |
| Tan, HY | 1 |
| Chen, YB | 1 |
| Guan, YX | 1 |
| Sun, XW | 1 |
| Li, YF | 1 |
| Xu, DZ | 1 |
| Kobayashi, H | 4 |
| Koike, T | 2 |
| Nakatsuka, A | 1 |
| Kurita, H | 2 |
| Sagara, J | 1 |
| Taniguchi, S | 1 |
| Kurashina, K | 2 |
| Zhou, JX | 1 |
| Hong, GB | 1 |
| Xu, LY | 1 |
| Xu, LF | 1 |
| Jiang, RJ | 1 |
| Luo, JH | 1 |
| Fisher, B | 17 |
| Miyata, Y | 3 |
| Shirao, K | 3 |
| Hyodo, I | 3 |
| Kurihara, M | 2 |
| Taylor, I | 1 |
| Patonay, P | 1 |
| Naszály, A | 1 |
| Mayer, A | 1 |
| Pócza, K | 1 |
| Kovács, L | 1 |
| Ragaz, J | 4 |
| Olivotto, IA | 2 |
| Spinelli, JJ | 2 |
| Phillips, N | 1 |
| Jackson, SM | 1 |
| Wilson, KS | 1 |
| Knowling, MA | 1 |
| Coppin, CM | 1 |
| Weir, L | 1 |
| Le, N | 1 |
| Durand, R | 1 |
| Coldman, AJ | 1 |
| Manji, M | 1 |
| D'Aprile, M | 2 |
| Pistillucci, G | 1 |
| Farris, A | 5 |
| Sarobba, MG | 2 |
| Palazzo, S | 1 |
| Manzione, L | 5 |
| Adamo, V | 2 |
| Palmeri, S | 2 |
| Ferraù, F | 2 |
| Lauria, R | 1 |
| Pagliarulo, C | 2 |
| Petrella, G | 2 |
| Limite, G | 1 |
| Costanzo, R | 1 |
| Bianco, AR | 2 |
| Gohongi, T | 2 |
| Tokuuye, K | 1 |
| Iida, H | 4 |
| Nakai, R | 2 |
| Gunji, N | 2 |
| Akine, Y | 1 |
| Orii, K | 2 |
| Bonneterre, JM | 1 |
| Radice, D | 1 |
| Redaelli, A | 1 |
| Chan, AK | 1 |
| Jenken, D | 1 |
| Heine, J | 1 |
| Buie, D | 1 |
| Johnson, D | 1 |
| Persiani, R | 1 |
| D'Ugo, D | 1 |
| Rausei, S | 1 |
| Sermoneta, D | 1 |
| Pozzo, C | 2 |
| Ricci, R | 3 |
| La Torre, G | 1 |
| Picciocchi, A | 2 |
| Qian, J | 1 |
| Qin, SK | 1 |
| Mei, JF | 1 |
| Chen, YX | 1 |
| Shao, ZJ | 1 |
| He, ZM | 1 |
| Sagara, H | 1 |
| Okayama, H | 1 |
| Ohtake, T | 1 |
| Yasuda, M | 2 |
| Watanabe, K | 1 |
| Takenoshita, S | 1 |
| Atzpodien, J | 1 |
| Schmitt, E | 1 |
| Gertenbach, U | 1 |
| Fornara, P | 1 |
| Heynemann, H | 1 |
| Maskow, A | 1 |
| Ecke, M | 1 |
| Wöltjen, HH | 1 |
| Jentsch, H | 1 |
| Wieland, W | 1 |
| Wandert, T | 1 |
| Reitz, M | 1 |
| Yamagishi, H | 1 |
| Itoi, H | 1 |
| Kikuchi, S | 1 |
| Fuji, N | 1 |
| Sonoyama, T | 1 |
| Yang, MT | 1 |
| Huang, ZF | 1 |
| Zeng, CG | 1 |
| Long, H | 1 |
| Lin, P | 2 |
| Wang, SY | 1 |
| Tang, J | 1 |
| Nishida Arazawa, ST | 1 |
| Rawet, V | 1 |
| Coelho Siqueira, SA | 1 |
| Kiss, DR | 1 |
| Gama-Rodrigues, JJ | 1 |
| Hayashi, H | 3 |
| Doi, K | 1 |
| Ishiko, T | 4 |
| Sumitsuzi, A | 1 |
| Kamohara, H | 1 |
| Kuwahara, N | 1 |
| Morinaga, H | 1 |
| Egami, H | 1 |
| Chen, EC | 2 |
| Hu, YH | 2 |
| Li, QQ | 2 |
| Cai, L | 2 |
| Huang, Y | 2 |
| Cui, NJ | 2 |
| Mazeron, JJ | 2 |
| González-Moreno, S | 1 |
| Brun, E | 1 |
| Sugarbaker, PH | 6 |
| Ji, SH | 1 |
| Park, BB | 1 |
| Park, KW | 1 |
| Kim, WS | 1 |
| Jung, CW | 1 |
| Im, YH | 1 |
| Park, K | 2 |
| Mermershtain, W | 1 |
| Gluzman, A | 1 |
| Gusakova, I | 1 |
| Walfish, S | 1 |
| Cohen, Y | 3 |
| Ariad, S | 1 |
| Hundahl, SA | 1 |
| Comella, P | 1 |
| Massidda, B | 2 |
| Lucia, LD | 1 |
| Natale, D | 1 |
| Maiorino, L | 1 |
| Tafuto, S | 1 |
| Cataldis, GD | 1 |
| Casaretti, R | 1 |
| Terazaki, Y | 1 |
| Nagamatsu, H | 1 |
| Ono, H | 2 |
| Iwakuma, N | 1 |
| Pessi, MA | 1 |
| Milesi, L | 1 |
| Bazan, V | 1 |
| Agnese, V | 1 |
| Corsale, S | 1 |
| Calò, V | 1 |
| Latteri, MA | 1 |
| Vieni, S | 1 |
| Grassi, N | 1 |
| Cicero, G | 1 |
| Dardanoni, G | 1 |
| Tomasino, RM | 1 |
| Pienkowski, T | 1 |
| Mackey, J | 1 |
| Pawlicki, M | 1 |
| Guastalla, JP | 3 |
| Weaver, C | 1 |
| Tomiak, E | 1 |
| Al-Tweigeri, T | 1 |
| Chap, L | 1 |
| Juhos, E | 1 |
| Guevin, R | 1 |
| Howell, A | 4 |
| Fornander, T | 1 |
| Hainsworth, J | 2 |
| Vinholes, J | 1 |
| Modiano, M | 1 |
| Pinter, T | 1 |
| Tang, SC | 1 |
| Colwell, B | 1 |
| Prady, C | 1 |
| Provencher, L | 1 |
| Walde, D | 2 |
| Hugh, J | 1 |
| Loret, C | 1 |
| Blitz, S | 1 |
| Jacobs, P | 1 |
| Murawsky, M | 1 |
| Riva, A | 2 |
| Vogel, C | 2 |
| Erman, M | 1 |
| Baltali, E | 1 |
| Karaoglu, A | 1 |
| Engin, H | 1 |
| Ozisik, Y | 1 |
| Guler, N | 1 |
| Altundag, K | 1 |
| Tekuzman, G | 1 |
| Atahan, IL | 1 |
| Onat, D | 1 |
| Sayek, I | 1 |
| Hoshino, S | 1 |
| Shirakusa, T | 1 |
| Muneoka, K | 2 |
| Shirai, Y | 3 |
| Wakai, T | 2 |
| Okumura, S | 3 |
| Nagao, J | 1 |
| Tsukuda, M | 1 |
| Sakuma, N | 1 |
| Shindo, H | 1 |
| Tonouchi, A | 1 |
| Yamamori, H | 1 |
| Dressler, LG | 3 |
| Broadwater, G | 3 |
| Cowan, D | 1 |
| Cox, K | 1 |
| Griffin, S | 1 |
| Miller, A | 1 |
| Tse, J | 1 |
| Novotny, D | 1 |
| Persons, DL | 1 |
| Barcos, M | 4 |
| Liu, ET | 5 |
| Thor, A | 1 |
| Budman, D | 2 |
| Muss, H | 1 |
| Hikino, H | 1 |
| Johbara, K | 1 |
| Obayashi, N | 1 |
| Ozaki, N | 1 |
| Hakamada, Y | 1 |
| Tsuchida, A | 2 |
| Arima, M | 1 |
| Kubouchi, T | 1 |
| Tokita, H | 1 |
| Ota, D | 1 |
| Kaise, H | 1 |
| Aoki, T | 7 |
| Kusama, M | 1 |
| Kosmas, C | 2 |
| Skopelitis, H | 1 |
| Gouveris, P | 1 |
| Kopterides, P | 1 |
| Kopteridis, P | 1 |
| Loukeris, D | 1 |
| Sigala, F | 1 |
| Zorbala-Sypsa, A | 1 |
| Papalambros, E | 1 |
| Engstrom, PF | 2 |
| Chen, YJ | 1 |
| Dilawari, RA | 1 |
| Enke, CA | 1 |
| Fakih, MG | 1 |
| Fuchs, C | 2 |
| Kiel, K | 1 |
| Knol, JA | 1 |
| Leong, LA | 1 |
| Ludwig, KA | 1 |
| Martin, EW | 1 |
| Saif, MW | 1 |
| Skibber, JM | 2 |
| Yeatman, TJ | 1 |
| Yoshioka, T | 3 |
| Kato, S | 4 |
| Shibata, H | 4 |
| Sakayori, M | 2 |
| Otsuka, K | 1 |
| Kakudo, Y | 2 |
| Ohori, H | 2 |
| Yamaura, G | 2 |
| Yasuda, K | 3 |
| Mitomi, T | 2 |
| Noto, T | 1 |
| Kumada, K | 1 |
| Hiki, Y | 1 |
| Yamakawa, T | 1 |
| Amano, T | 1 |
| Oki, S | 1 |
| Otani, Y | 1 |
| Oka, H | 1 |
| Takemiya, S | 4 |
| Yamamura, T | 1 |
| Tsuchiya, S | 4 |
| Ogawa, N | 2 |
| Harada, N | 1 |
| Takeo, Y | 1 |
| Tanaka, S | 4 |
| Hanyu, F | 2 |
| Murthy, R | 1 |
| Honavar, SG | 1 |
| Burman, S | 1 |
| Vemuganti, GK | 1 |
| Naik, MN | 1 |
| Reddy, VA | 1 |
| Guadagnolo, BA | 1 |
| Posner, MR | 1 |
| Weeks, L | 1 |
| Wirth, LJ | 1 |
| Norris, CM | 1 |
| Sullivan, CA | 1 |
| Goguen, L | 1 |
| Busse, PM | 1 |
| Tishler, R | 1 |
| Yom, SS | 1 |
| Machtay, M | 1 |
| Biel, MA | 1 |
| Sinard, RJ | 1 |
| El-Naggar, AK | 1 |
| Weber, RS | 1 |
| Rosenthal, DI | 1 |
| Puri, DR | 1 |
| Chou, W | 1 |
| Lee, N | 1 |
| O'Neill, AM | 1 |
| Vukov, AM | 1 |
| White, DR | 5 |
| Mizukami, Y | 1 |
| Momiyama, M | 1 |
| Niimi, K | 1 |
| Nagashima, T | 2 |
| Ahluwalia, MS | 1 |
| Daw, HA | 1 |
| Burmeister, BH | 1 |
| Walpole, ET | 1 |
| Burmeister, EA | 1 |
| Thomas, J | 1 |
| Thomson, DB | 1 |
| Harvey, JA | 1 |
| Mark Smithers, B | 1 |
| Gotley, DC | 1 |
| Noronha, V | 1 |
| Sugitani, M | 1 |
| Nishimura, K | 3 |
| Noguchi, H | 1 |
| Okada, T | 1 |
| Ouchi, M | 1 |
| Yamada, M | 2 |
| Kitajima, M | 1 |
| Tsuruoka, Y | 1 |
| Futagawa, S | 1 |
| Alhopuro, P | 1 |
| Alazzouzi, H | 1 |
| Sammalkorpi, H | 1 |
| Dávalos, V | 1 |
| Salovaara, R | 1 |
| Hemminki, A | 1 |
| Järvinen, H | 1 |
| Mecklin, JP | 1 |
| Schwartz, S | 1 |
| Aaltonen, LA | 1 |
| Arango, D | 1 |
| Beresford, M | 1 |
| Richman, P | 1 |
| Makris, A | 1 |
| Mawdsley, S | 1 |
| Stott, D | 1 |
| Osborne, M | 1 |
| Ashford, R | 1 |
| Grainger, J | 1 |
| Al-Jabbour, J | 1 |
| Talbot, I | 1 |
| Mitchell, IC | 1 |
| Meyrick Thomas, J | 1 |
| Livingstone, JI | 1 |
| McCue, J | 1 |
| MacDonald, P | 1 |
| Northover, JA | 1 |
| Windsor, A | 1 |
| Novell, R | 1 |
| Wallace, M | 1 |
| Harrison, RA | 1 |
| Matsumoto, G | 2 |
| Tsurta, K | 1 |
| Okamoto, A | 1 |
| Rudenstam, CM | 4 |
| Golouh, R | 2 |
| Carbone, A | 1 |
| Sanuki-Fujimoto, N | 1 |
| Tsai, CS | 1 |
| Hwang, TL | 1 |
| Chen, MF | 1 |
| Ninomiya, H | 6 |
| Wakui, K | 5 |
| Komatsu, N | 5 |
| Tsuchiya, K | 5 |
| Nakasaki, H | 5 |
| Houvenaeghel, G | 2 |
| Lelievre, L | 1 |
| Gonzague-Casabianca, L | 1 |
| Buttarelli, M | 1 |
| Moutardier, V | 1 |
| Goncalves, A | 1 |
| Bamias, A | 1 |
| Basdanis, G | 1 |
| Xanthakis, I | 1 |
| Naito, H | 1 |
| Hamada, T | 1 |
| Shinohara, T | 1 |
| Mino, K | 1 |
| Shibazaki, W | 1 |
| Minagawa, N | 1 |
| Orimo, T | 1 |
| Ichimura, W | 1 |
| Kuru, B | 1 |
| Camlibel, M | 1 |
| Dinc, S | 1 |
| Gulcelik, MA | 1 |
| Atalay, C | 1 |
| Alagol, H | 1 |
| Tajima, T | 4 |
| Bujko, K | 2 |
| Nowacki, MP | 2 |
| Nasierowska-Guttmejer, A | 2 |
| Kepka, L | 2 |
| Winkler-Spytkowska, B | 1 |
| Suwiński, R | 1 |
| Oledzki, J | 1 |
| Stryczyńska, G | 1 |
| Wieczorek, A | 1 |
| Serkies, K | 1 |
| Rogowska, D | 1 |
| Tokar, P | 2 |
| Kawano, K | 1 |
| Yanagisawa, S | 1 |
| Kusukawa, J | 1 |
| Sunagawa, H | 1 |
| Shiba, R | 1 |
| Shinohara, M | 1 |
| Fukuda, J | 1 |
| Ikemura, K | 1 |
| Inokuchi, T | 1 |
| Mimura, T | 1 |
| Goto, H | 2 |
| Taguchi, T | 5 |
| Miyoshi, Y | 1 |
| Tanji, Y | 1 |
| Anami, Y | 1 |
| Oguma, S | 1 |
| Matsuda, Y | 1 |
| Yamaki, T | 1 |
| Sazawa, Y | 1 |
| Komiya, H | 1 |
| Izai, J | 1 |
| Ota, T | 1 |
| Paik, YH | 2 |
| Chang, YS | 1 |
| Lee, DK | 2 |
| Chung, JB | 2 |
| Park, MS | 1 |
| Yu, JS | 1 |
| Yoon, DS | 2 |
| Altinyollar, H | 1 |
| Dingil, G | 1 |
| Berberoglu, U | 1 |
| Pigeau, H | 1 |
| Dupré, PF | 1 |
| Benouna, J | 1 |
| Classe, JM | 1 |
| Pioud, R | 1 |
| Dravet, F | 1 |
| Nabeya, Y | 2 |
| Matsubara, H | 2 |
| Okazumi, S | 3 |
| Shuto, K | 1 |
| Uno, T | 2 |
| Ito, H | 2 |
| Shimada, H | 2 |
| Yang, JW | 1 |
| Chen, YG | 1 |
| Chen, Q | 1 |
| Fan, NF | 1 |
| Guo, ZQ | 1 |
| Cai, XC | 1 |
| Wu, XA | 1 |
| Xu, S | 1 |
| Lu, X | 1 |
| Zhang, YH | 1 |
| Ouyang, XN | 1 |
| Marutaka, M | 1 |
| Suguri, T | 1 |
| Yoshimura, K | 1 |
| Canning, CA | 1 |
| Gubbels, S | 1 |
| Chinn, C | 1 |
| Wax, M | 1 |
| Holland, JM | 1 |
| Urba, S | 1 |
| Wolf, G | 1 |
| Eisbruch, A | 1 |
| Worden, F | 1 |
| Bradford, C | 1 |
| Teknos, T | 1 |
| Chepeha, D | 1 |
| Prince, M | 2 |
| Hogikyan, N | 1 |
| Taylor, J | 1 |
| Kümmel, S | 3 |
| Krocker, J | 3 |
| Kohls, A | 3 |
| Breitbach, GP | 2 |
| Morack, G | 2 |
| Budner, M | 2 |
| Blohmer, JU | 2 |
| Elling, D | 3 |
| Kuramochi, H | 1 |
| Danenberg, KD | 1 |
| Nielsen, JN | 1 |
| Danenberg, PV | 1 |
| Roddiger, SJ | 1 |
| Kolotas, C | 1 |
| Filipowicz, I | 1 |
| Kurek, R | 1 |
| Kuner, RP | 1 |
| Martin, T | 1 |
| Baltas, D | 1 |
| Rogge, B | 1 |
| Kontova, M | 1 |
| Pollow, B | 1 |
| Tagaya, N | 1 |
| Nakagawa, A | 1 |
| Hamada, K | 1 |
| Kubota, K | 1 |
| Ohsugi, H | 1 |
| Kondo, K | 2 |
| Yamamura, Y | 2 |
| Pergolizzi, S | 1 |
| Russi, E | 1 |
| Santacaterina, A | 1 |
| Maisano, R | 1 |
| Numico, G | 1 |
| Palazzolo, C | 1 |
| Settineri, N | 1 |
| Altavilla, G | 1 |
| Girlando, A | 1 |
| Spadaro, P | 1 |
| Cascinu, S | 6 |
| Kim, CB | 1 |
| Cheng, SH | 1 |
| Horng, CF | 1 |
| Clarke, JL | 1 |
| Tsou, MH | 1 |
| Tsai, SY | 1 |
| Jian, JJ | 1 |
| Liu, MC | 1 |
| West, M | 1 |
| Huang, AT | 1 |
| Dohden, K | 1 |
| Morishita, M | 1 |
| Hosokawa, O | 1 |
| Kaizaki, Y | 1 |
| Kiya, T | 1 |
| Saeki, T | 1 |
| Islam, S | 1 |
| Cole, CV | 1 |
| Hoffman, GR | 1 |
| Brennan, PA | 1 |
| Morese, R | 1 |
| Cianci, G | 1 |
| Di Rocco, ZC | 1 |
| De Tursi, M | 1 |
| Tinari, N | 1 |
| Hirota, T | 1 |
| Abad, A | 1 |
| Tabernero, J | 1 |
| Zhang, ZG | 1 |
| Panasci, LC | 1 |
| Paik, S | 1 |
| Tang, G | 1 |
| Baker, J | 1 |
| Kim, W | 1 |
| Cronin, M | 1 |
| Watson, D | 1 |
| Costantino, JP | 2 |
| Geyer, CE | 1 |
| Wickerham, DL | 7 |
| Melloni, G | 1 |
| Doglioni, C | 2 |
| Bandiera, A | 1 |
| Carretta, A | 1 |
| Ciriaco, P | 1 |
| Arrigoni, G | 1 |
| Zannini, P | 1 |
| Barten, M | 1 |
| Klautke, G | 1 |
| Klar, E | 1 |
| Ludwig, K | 1 |
| Thomas, H | 1 |
| Brinckmann, W | 1 |
| Friedrich, A | 1 |
| Prall, F | 1 |
| Hartung, G | 1 |
| Küchenmeister, U | 1 |
| Kundt, G | 1 |
| Sakata, J | 1 |
| Elliott, KS | 1 |
| Borowsky, ME | 1 |
| Malka, ES | 1 |
| Scudder, SA | 1 |
| Leiserowitz, GS | 1 |
| Russell, AH | 1 |
| Doi, T | 1 |
| Arai, Y | 2 |
| Takiuchi, H | 1 |
| Miyazawa, H | 1 |
| Bhatia, S | 1 |
| Haddock, MG | 1 |
| Donohue, JH | 1 |
| Krishnan, S | 1 |
| Yilmaz, U | 1 |
| Oztop, I | 1 |
| Alacacioglu, A | 1 |
| Tarhan, O | 1 |
| Somali, I | 1 |
| Feng, FY | 1 |
| Wu, LY | 1 |
| Liu, JW | 1 |
| Gao, YJ | 1 |
| Guan, XQ | 1 |
| Nan, KJ | 1 |
| Suo, AL | 1 |
| Wang, XW | 1 |
| Zhang, MH | 1 |
| Zhang, WD | 1 |
| Li, CW | 1 |
| Zhao, JB | 1 |
| Battelli, N | 1 |
| Massacesi, C | 1 |
| Pilone, A | 1 |
| Dinota, A | 3 |
| Cobelli, S | 1 |
| Scanni, A | 2 |
| Sturba, F | 1 |
| Giacomini, G | 1 |
| Morale, D | 1 |
| Giorgi, F | 1 |
| Tummarello, D | 1 |
| Bollet, MA | 1 |
| Gambotti, L | 1 |
| Meunier, M | 1 |
| Dendale, R | 1 |
| Kirova, YM | 1 |
| Diéras, V | 2 |
| Fourquet, A | 1 |
| Monga, DK | 1 |
| Tomono, H | 1 |
| Nashimoto, A | 5 |
| Johnston, PG | 1 |
| Kulle, B | 1 |
| Aust, DE | 1 |
| Schwabe, W | 1 |
| Häusler, P | 1 |
| Jiang, Y | 1 |
| Qiu, XH | 1 |
| Yang, YX | 1 |
| Zhang, SQ | 1 |
| Chen, ZM | 1 |
| Tsubono, M | 1 |
| Kaneko, I | 1 |
| Kii, E | 1 |
| Murata, T | 1 |
| Deguchi, Y | 1 |
| Sonoda, K | 1 |
| Ratto, C | 2 |
| Castri, F | 1 |
| Parello, A | 1 |
| Vecchio, FM | 2 |
| Doglietto, GB | 3 |
| Kodama, H | 1 |
| Nio, Y | 1 |
| Iguchi, C | 1 |
| Kan, N | 1 |
| Sakai, K | 4 |
| Oka, T | 1 |
| Ozawa, K | 1 |
| Saito, Y | 2 |
| Senoo, T | 1 |
| Terasawa, T | 3 |
| Oshima, A | 1 |
| Shiiki, S | 1 |
| Seki, M | 1 |
| Hironou, M | 1 |
| Ookubo, S | 1 |
| Udagawa, K | 1 |
| Nakashima, K | 1 |
| Gordon, NH | 2 |
| Silverman, P | 1 |
| Lasheen, W | 1 |
| Meinert, J | 1 |
| Siminoff, LA | 1 |
| Walshe, JM | 1 |
| Berman, AW | 1 |
| Vatas, U | 1 |
| Steinberg, SM | 2 |
| Anderson, WF | 1 |
| Lippman, ME | 2 |
| Swain, SM | 2 |
| Calascibetta, A | 1 |
| Cabibi, D | 1 |
| Rausa, L | 1 |
| Aragona, F | 1 |
| Barresi, E | 1 |
| Martorana, A | 1 |
| Sanguedolce, R | 1 |
| Maciá Escalante, S | 1 |
| Rodríguez Lescure, A | 1 |
| Pons Sanz, V | 1 |
| Martínez Banaclocha, N | 2 |
| Guillén Ponce, C | 1 |
| Carrato Mena, A | 1 |
| Niméus, E | 1 |
| Malmström, J | 1 |
| Marko-Varga, G | 1 |
| Fernö, M | 1 |
| Karakuzu, A | 1 |
| Koc, M | 1 |
| Ozdemir, S | 1 |
| Prenzel, KL | 1 |
| König, A | 1 |
| Schneider, PM | 1 |
| Schnickmann, C | 1 |
| Dienes, HP | 1 |
| Mueller, RP | 2 |
| Izbicki, JR | 1 |
| Honma, H | 1 |
| Nakatani, K | 1 |
| Shimoda, T | 1 |
| Kobayashi, N | 1 |
| Mitomi, H | 1 |
| Saigenji, K | 1 |
| Nishizawa, T | 1 |
| Iizuka, H | 2 |
| Hisamatsu, T | 1 |
| Masaoka, T | 1 |
| Iwasaki, E | 1 |
| Nagata, H | 1 |
| Deniaud-Alexandre, E | 1 |
| Sezeur, A | 1 |
| Hannoun, L | 1 |
| Houry, S | 1 |
| Pène, F | 2 |
| Parc, R | 2 |
| Schlienger, M | 2 |
| da Silva, RG | 1 |
| Symann, M | 1 |
| Soulié, P | 1 |
| Eichler, F | 1 |
| Viens, P | 1 |
| Vindevoghel, A | 2 |
| Ferrero, JM | 1 |
| Michalski, W | 1 |
| Dymecki, D | 1 |
| Pawlak, M | 1 |
| Lesniak, T | 1 |
| Richter, P | 1 |
| Wojnar, A | 1 |
| Chmielik, E | 1 |
| Merck, B | 1 |
| Cansado Martínez, P | 1 |
| Pérez Ramos, M | 1 |
| Lacueva Gómez, FJ | 1 |
| Calpena, R | 1 |
| Khanfir, A | 1 |
| Kallel, F | 1 |
| Meziou, M | 1 |
| Trabelsi, K | 1 |
| Mnif, J | 1 |
| Takenobu, T | 1 |
| Kokubo, M | 1 |
| Taniike, N | 1 |
| Nagano, M | 1 |
| Furutani, M | 1 |
| Ohnishi, M | 1 |
| Nakahara, O | 1 |
| Mizumoto, T | 2 |
| Hosaka, S | 1 |
| Maruyama, M | 3 |
| Nagahama, T | 2 |
| Maruyama, S | 2 |
| Okabe, K | 1 |
| Hiroto, M | 1 |
| Minamide, J | 2 |
| Aoyama, N | 1 |
| Takada, K | 1 |
| Oota, Y | 1 |
| Isobe, K | 1 |
| Kawakami, H | 1 |
| Ueno, N | 1 |
| Kawata, T | 1 |
| Hughes, MA | 2 |
| Frassica, DA | 2 |
| Riall, TS | 2 |
| Lillemoe, KD | 2 |
| Donehower, RC | 3 |
| Abrams, RA | 2 |
| Wang, CT | 1 |
| Xie, GF | 1 |
| Jensen, SA | 1 |
| Vilmar, A | 1 |
| Sørensen, JB | 1 |
| Overgaard, M | 3 |
| Nielsen, HM | 1 |
| Overgaard, J | 2 |
| Truong, PT | 1 |
| Woodward, WA | 1 |
| Thames, HD | 1 |
| Buchholz, TA | 2 |
| Shen, J | 1 |
| Gilcrease, MZ | 1 |
| Babiera, GV | 1 |
| Ross, MI | 6 |
| Kuerer, HM | 4 |
| Francis, A | 1 |
| Ames, FC | 10 |
| Gick, U | 1 |
| Mingrone, W | 1 |
| Pestalozzi, B | 1 |
| Rauch, D | 1 |
| Ballabeni, P | 1 |
| Lanz, D | 1 |
| Hess, V | 1 |
| Kamoshita, N | 1 |
| Makita, F | 1 |
| Matsuzaki, Y | 1 |
| Kabeya, K | 1 |
| Akahane, T | 1 |
| Chiba, T | 1 |
| Yano, H | 1 |
| Hashimoto, Y | 1 |
| Herman, J | 1 |
| Hu, QY | 1 |
| Fu, ZF | 1 |
| Wang, XX | 1 |
| Zhou, ZM | 1 |
| Yuan, ZY | 1 |
| Shi, YX | 2 |
| Takano, S | 1 |
| Oda, K | 2 |
| Seike, K | 1 |
| Takiguchi, N | 2 |
| Tsukamoto, G | 1 |
| Ibaragi, S | 1 |
| Shimo, T | 1 |
| Kishimoto, K | 1 |
| Mese, H | 1 |
| Aoe, M | 1 |
| Kiura, K | 1 |
| Sasaki, A | 2 |
| Minami, K | 1 |
| Kameda, A | 1 |
| Tsutani, Y | 1 |
| Miyahara, E | 3 |
| Noso, Y | 1 |
| Aiko, S | 1 |
| Yoshizumi, Y | 1 |
| Ishizuka, T | 1 |
| Sakano, T | 1 |
| Kumano, I | 1 |
| Sugiura, Y | 1 |
| Maehara, T | 1 |
| Santoro, A | 1 |
| Carnaghi, C | 2 |
| Catalano, V | 4 |
| Frontini, L | 3 |
| Aitini, E | 1 |
| Rota, S | 1 |
| Torri, V | 2 |
| Floriani, I | 2 |
| Rimassa, L | 1 |
| Giordani, P | 2 |
| Ardizzoia, A | 1 |
| Foa, P | 2 |
| Rabbi, C | 1 |
| Gasparini, G | 3 |
| Nardi, M | 1 |
| Mansutti, M | 1 |
| Arnoldi, E | 1 |
| Piazza, E | 1 |
| Pucci, F | 1 |
| Silva, RR | 2 |
| Sobrero, A | 1 |
| Ravaioli, A | 3 |
| Abbrederis, K | 1 |
| Kremer, M | 1 |
| Schuhmacher, C | 1 |
| Bendardaf, R | 1 |
| Elzagheid, A | 1 |
| Lamlum, H | 1 |
| Algars, A | 1 |
| Korkeila, E | 1 |
| Ristamäki, R | 1 |
| Collan, Y | 1 |
| Syrjänen, K | 1 |
| Pyrhönen, S | 1 |
| Matsuyama, J | 2 |
| Makari, Y | 2 |
| Matsuura, N | 1 |
| Chollet, P | 3 |
| Simon, H | 1 |
| Walter, S | 1 |
| Koda, M | 1 |
| Sulkowska, M | 1 |
| Kanczuga-Koda, L | 1 |
| Tomaszewski, J | 1 |
| Kucharczuk, W | 1 |
| Lesniewicz, T | 1 |
| Cymek, S | 1 |
| Sulkowski, S | 1 |
| Henry, NL | 1 |
| Schmid, P | 1 |
| Untch, M | 2 |
| Kossé, V | 1 |
| Bondar, G | 1 |
| Vassiljev, L | 1 |
| Tarutinov, V | 1 |
| Lehmann, U | 1 |
| Maubach, L | 1 |
| Meurer, J | 1 |
| Possinger, K | 2 |
| Rosati, G | 2 |
| Bilancia, D | 2 |
| Germano, D | 1 |
| Romano, R | 1 |
| Reggiardo, G | 2 |
| Masuoka, T | 1 |
| Sautter-Bihl, ML | 1 |
| Cole, BF | 2 |
| Panzini, I | 1 |
| Byrne, M | 1 |
| Munakata, M | 1 |
| Muto, O | 1 |
| Okada, R | 1 |
| Mitobe, S | 1 |
| Sakata, Y | 4 |
| Takeno, S | 1 |
| Fumoto, S | 1 |
| Kawahara, K | 1 |
| Hoshina, K | 1 |
| Kobayashi, I | 2 |
| Kurita, M | 1 |
| Shida, D | 1 |
| Shinkai, H | 1 |
| Shimomatsuya, T | 1 |
| Mitsudou, Y | 1 |
| Yonezawa, K | 1 |
| Shiraishi, S | 1 |
| Fujino, M | 1 |
| Maruhashi, K | 1 |
| Shibata, Y | 1 |
| Baba, E | 1 |
| Ariyama, H | 1 |
| Miki, R | 1 |
| Ogami, N | 1 |
| Arita, S | 1 |
| Qin, B | 1 |
| Kusaba, H | 1 |
| Mitsugi, K | 1 |
| Noshiro, H | 1 |
| Nakano, S | 1 |
| Harrop, R | 1 |
| Drury, N | 1 |
| Shingler, W | 1 |
| Chikoti, P | 1 |
| Redchenko, I | 1 |
| Carroll, MW | 1 |
| Kingsman, SM | 1 |
| Naylor, S | 1 |
| Melcher, A | 1 |
| Nicholls, J | 1 |
| Wassan, H | 1 |
| Habib, N | 1 |
| Anthoney, A | 1 |
| Noda, T | 1 |
| Damdinsuren, B | 1 |
| Dono, K | 2 |
| Sakon, M | 2 |
| Nam, H | 1 |
| Han, Y | 1 |
| Ahn, YC | 1 |
| Schönau, KK | 1 |
| Steger, GG | 1 |
| Nishino, Y | 1 |
| Ohtsuka, K | 2 |
| Shimodaira, H | 1 |
| Murakawa, Y | 2 |
| Gamoh, M | 1 |
| Seike, J | 1 |
| Honda, J | 1 |
| Miyoshi, T | 1 |
| Umemoto, A | 1 |
| Hanazono, K | 1 |
| Oowaki, T | 1 |
| Arimura, K | 1 |
| Nakamura, F | 1 |
| Aikou, T | 2 |
| Kelsey, CR | 1 |
| Nelson, JW | 1 |
| Chino, JP | 1 |
| Clough, RW | 1 |
| Tyler, DS | 1 |
| Morse, MA | 1 |
| Clary, BM | 1 |
| Pappas, TN | 1 |
| Xie, FY | 1 |
| Qi, SN | 1 |
| Hu, WH | 1 |
| Zou, GR | 1 |
| Peng, M | 1 |
| Luo, HY | 1 |
| Lang, RG | 1 |
| Guo, XJ | 1 |
| Sun, YL | 1 |
| Fu, L | 1 |
| Findlay, B | 4 |
| Tonkin, K | 1 |
| Norris, B | 1 |
| Trudeau, M | 1 |
| Blackstein, M | 1 |
| Skillings, J | 3 |
| Bowman, D | 4 |
| Levine, M | 1 |
| Palmer, MJ | 1 |
| Tu, D | 2 |
| Zhou, YD | 1 |
| Sun, Q | 1 |
| Huan, HY | 1 |
| Mao, F | 1 |
| Guan, JH | 1 |
| Marnitz, S | 1 |
| Köhler, C | 1 |
| Roth, C | 1 |
| Füller, J | 1 |
| Bischoff, A | 1 |
| Wendt, T | 2 |
| Schneider, A | 1 |
| Budach, V | 2 |
| Heidenreich, A | 1 |
| Jakse, G | 1 |
| Zabel-du Bois, A | 1 |
| Milker-Zabel, S | 1 |
| Iida, S | 1 |
| Furukawa, K | 2 |
| Yokoyama, T | 1 |
| Yanagihara, K | 1 |
| Iwasaki, R | 1 |
| Sugisaki, Y | 1 |
| Naito, Z | 1 |
| Sujendran, V | 1 |
| Wheeler, J | 1 |
| Baron, R | 1 |
| Warren, BF | 1 |
| Maynard, N | 1 |
| Wada, Y | 2 |
| Ohara, T | 1 |
| Okuda, Y | 1 |
| Kiguchi, K | 1 |
| Ishizuka, B | 1 |
| Mori, N | 1 |
| Nagano, T | 1 |
| Han, JQ | 1 |
| Liang, RX | 1 |
| Qu, FS | 1 |
| Yan, TX | 1 |
| Sun, YH | 1 |
| Li, XQ | 1 |
| McLean, SR | 1 |
| Shousha, S | 1 |
| Francis, N | 1 |
| Lim, A | 1 |
| Eccles, S | 1 |
| Nathan, M | 1 |
| Brock, CS | 1 |
| Palmieri, C | 1 |
| Linardou, H | 1 |
| Pisanidis, N | 1 |
| Tzorakoeleftherakis, E | 1 |
| Dimitrakakis, K | 1 |
| Makrantonakis, P | 1 |
| Xiros, N | 1 |
| Polichronis, A | 1 |
| Dimopoulos, AM | 1 |
| Lin, D | 1 |
| Glastonbury, CM | 1 |
| Rafaelian, O | 1 |
| Eisele, DW | 2 |
| Wang, SJ | 1 |
| Balil, A | 1 |
| Lang, I | 1 |
| Vorobiof, D | 1 |
| van Hazel, G | 1 |
| Dolci, S | 3 |
| Jamin, S | 1 |
| Bendahmane, B | 1 |
| Jang, JS | 1 |
| Kim, MC | 1 |
| Jeong, JS | 1 |
| Fang, WY | 1 |
| Lee, SC | 1 |
| Cheng, TL | 1 |
| Lin, SR | 1 |
| Wolowacz, SE | 1 |
| Tate, HC | 1 |
| Bagust, A | 1 |
| Shien, T | 1 |
| Seki, K | 1 |
| Hojo, T | 1 |
| Ando, M | 2 |
| Kohno, T | 1 |
| Katsumata, N | 2 |
| Akashi-Tanaka, S | 1 |
| Kinoshita, T | 2 |
| Giusti, RM | 1 |
| Shastri, K | 1 |
| Pilaro, AM | 1 |
| Cordoba-Rodriguez, R | 1 |
| Koti, K | 1 |
| Rothmann, M | 1 |
| Men, AY | 1 |
| Zhao, H | 1 |
| Hughes, M | 1 |
| Keegan, P | 1 |
| Weiss, KD | 1 |
| Pazdur, R | 5 |
| Lim, JY | 1 |
| Park, HJ | 1 |
| Di Costanzo, F | 2 |
| Gasperoni, S | 1 |
| Bravi, S | 1 |
| Carlini, P | 1 |
| Bracci, R | 1 |
| Tomao, S | 1 |
| Messerini, L | 1 |
| Arcangeli, A | 1 |
| Tonato, M | 1 |
| Strafiuso, G | 1 |
| Corgna, E | 1 |
| Porrozzi, S | 1 |
| Giunta, A | 1 |
| Monzio Compagnoni, B | 1 |
| Biagioni, F | 1 |
| Cesari, M | 1 |
| Fornarini, G | 1 |
| Nelli, F | 1 |
| Carboni, M | 1 |
| Enzo, MR | 1 |
| Piga, A | 1 |
| Romiti, A | 1 |
| Olivetti, A | 1 |
| Masoni, L | 1 |
| De Stefanis, M | 1 |
| Dalla Mola, A | 1 |
| Camera, S | 1 |
| Recchia, F | 2 |
| De Filippis, S | 1 |
| Scipioni, L | 1 |
| Zironi, S | 1 |
| Luppi, G | 1 |
| Italia, M | 1 |
| Banducci, S | 1 |
| Pisani Leretti, A | 1 |
| Ionta, MT | 1 |
| Nicolosi, A | 1 |
| Canaletti, R | 1 |
| Biscottini, B | 1 |
| Grigniani, F | 1 |
| Rovei, R | 1 |
| Croce, E | 1 |
| Carroccio, R | 1 |
| Gilli, G | 1 |
| Cavalli, C | 1 |
| Olgiati, A | 1 |
| Pandolfi, U | 1 |
| Rossetti, R | 1 |
| Natalini, G | 1 |
| Oldani, S | 1 |
| Bruno, L | 2 |
| Catalano, G | 4 |
| Lungarotti, F | 1 |
| Trignano, M | 1 |
| Muscogiuri, A | 1 |
| Francavilla, F | 1 |
| Figoli, F | 1 |
| Leoni, M | 1 |
| Papiani, G | 1 |
| Orselli, G | 1 |
| Antimi, M | 1 |
| Bellini, V | 1 |
| Cabassi, A | 1 |
| Contu, A | 1 |
| Pazzola, A | 1 |
| Frignano, M | 1 |
| Lastraioli, E | 1 |
| Saggese, M | 1 |
| Bianchini, D | 1 |
| Antonuzzo, L | 1 |
| Mela, M | 1 |
| Tani, M | 2 |
| Miyazawa, M | 1 |
| Hirono, S | 1 |
| Ina, S | 1 |
| Nishioka, R | 1 |
| Fujita, Y | 8 |
| Uchiyama, K | 1 |
| Gensheimer, M | 1 |
| Jones, CA | 1 |
| Graves, CR | 1 |
| Merchant, NB | 1 |
| Lockhart, AC | 1 |
| Yokoi, K | 1 |
| Seya, T | 1 |
| Kanazawa, Y | 1 |
| Ohaki, Y | 1 |
| DiGiovanna, MP | 1 |
| Stern, DF | 1 |
| Edgerton, S | 2 |
| Budman, DR | 5 |
| Thor, AD | 4 |
| Traina, TA | 1 |
| Theodoulou, M | 1 |
| Feigin, K | 1 |
| Patil, S | 1 |
| Tan, KL | 1 |
| Edwards, C | 1 |
| Dugan, U | 1 |
| Suto, T | 1 |
| Ito, N | 1 |
| Obuchi, T | 1 |
| Uesugi, N | 1 |
| Sugai, T | 1 |
| Nakamura, SI | 1 |
| Wakabayashi, G | 1 |
| Vigo, V | 1 |
| Bacigalupo, A | 2 |
| Ponzanelli, A | 1 |
| Marcenaro, M | 1 |
| Corvò, R | 3 |
| Margarino, G | 2 |
| Tordai, A | 1 |
| Yan, K | 1 |
| Symmans, WF | 1 |
| Pusztai, L | 1 |
| Ejlertsen, B | 2 |
| Mouridsen, HT | 4 |
| Jensen, MB | 3 |
| Su, YR | 1 |
| Wu, GH | 1 |
| Zeng, ZY | 1 |
| Guo, ZM | 1 |
| Chen, WK | 1 |
| Wei, MW | 1 |
| Chen, YF | 1 |
| Hino, N | 1 |
| Ikushima, Y | 1 |
| Tsuyuguchi, M | 1 |
| Sohnaka, Y | 1 |
| Wada, D | 1 |
| Yamasaki, S | 1 |
| Miyake, H | 1 |
| Ohura, R | 1 |
| Furuta, R | 1 |
| Ina, K | 2 |
| Kataoka, T | 1 |
| Nagao, S | 1 |
| Kayukawa, S | 1 |
| Mori, F | 1 |
| Masaki, A | 1 |
| Ando, T | 3 |
| Ide, T | 1 |
| Kitajima, Y | 1 |
| Ohtaka, K | 1 |
| Mitsuno, M | 1 |
| Nakafusa, Y | 1 |
| Miyazaki, K | 1 |
| Pennathur, A | 1 |
| Luketich, JD | 1 |
| Landreneau, RJ | 1 |
| Ward, J | 1 |
| Christie, NA | 1 |
| Gibson, MK | 1 |
| Schuchert, M | 1 |
| Cooper, K | 1 |
| Land, SR | 1 |
| Belani, CP | 1 |
| Stehlin, JS | 1 |
| Hills, WJ | 1 |
| Rufino, C | 1 |
| Bush, H | 2 |
| George, WD | 3 |
| Howat, JM | 2 |
| Crowther, D | 2 |
| Sellwood, RA | 2 |
| Rubens, RD | 3 |
| Hayward, JL | 2 |
| Bulbrook, RD | 2 |
| Fentiman, IS | 1 |
| Deregibus, P | 1 |
| Battezzati, G | 1 |
| Gilbert, JM | 1 |
| Kawagoe, K | 1 |
| Sasaki, J | 2 |
| Edsmyr, F | 1 |
| Andersson, L | 1 |
| Esposti, PL | 1 |
| Cieplinski, W | 1 |
| Waddell, WR | 1 |
| Gerner, RE | 1 |
| Reich, MP | 1 |
| Weltz, MD | 1 |
| Perry, DJ | 1 |
| Blom, J | 1 |
| Butler, WM | 1 |
| Konno, A | 2 |
| Togawa, K | 2 |
| Ikegami, H | 1 |
| Horai, T | 1 |
| Matsuda, M | 1 |
| Abitbol, A | 1 |
| Straus, MJ | 1 |
| Sedlis, A | 1 |
| Davidian, M | 1 |
| Spehn, J | 1 |
| Beyer, JH | 1 |
| von Franqué, U | 1 |
| Schmieder, A | 1 |
| Holzmann, K | 1 |
| Abel, U | 2 |
| Redmond, C | 7 |
| Wieand, HS | 5 |
| Tormey, DC | 9 |
| Weinberg, VE | 1 |
| Glidewell, OJ | 1 |
| Perloff, M | 1 |
| Falkson, HC | 3 |
| Henry, PH | 1 |
| Leone, LA | 1 |
| Carbone, PP | 3 |
| Wood, WC | 4 |
| Knight, WA | 2 |
| Glucksberg, H | 4 |
| Foulkes, MA | 1 |
| Stephens, RL | 1 |
| O'Bryan, RM | 3 |
| Velez-Garcia, E | 3 |
| Moore, M | 3 |
| Vogel, CL | 2 |
| Marcial, V | 3 |
| Ketcham, A | 2 |
| Bartolucci, A | 1 |
| Liu, C | 1 |
| Smalley, R | 2 |
| Pearson, OH | 1 |
| Hubay, CA | 1 |
| Marshall, JS | 1 |
| McGuire, WL | 3 |
| Mansour, EG | 3 |
| Hermann, RE | 1 |
| Jones, JC | 1 |
| Flynn, WJ | 1 |
| Eckert, C | 1 |
| Jungi, WF | 10 |
| Beadle, GF | 1 |
| Harris, JR | 1 |
| Olson, JE | 2 |
| Rose, C | 4 |
| Brincker, H | 2 |
| Thorpe, SM | 1 |
| Rank, F | 2 |
| Fischerman, K | 1 |
| Andersen, KW | 2 |
| Jones, SE | 4 |
| Brooks, RJ | 1 |
| Takasugi, BJ | 1 |
| Garewal, HS | 1 |
| Giordano, GF | 1 |
| Jackson, R | 1 |
| Heusinkveld, RS | 1 |
| Kemmer, SR | 1 |
| Moon, TE | 4 |
| Smith, TL | 4 |
| Marcus, CE | 1 |
| Blumenschein, GR | 4 |
| Tormey, C | 1 |
| Foulkes, M | 1 |
| Alberto, P | 1 |
| Brunner, KW | 3 |
| Mermillod, B | 1 |
| Barrelet, L | 1 |
| Cavalli, F | 3 |
| Rossi, A | 12 |
| Brambilla, C | 6 |
| Valagussa, P | 19 |
| Bonadonna, G | 22 |
| Wallgren, A | 2 |
| Baral, E | 1 |
| Beling, U | 1 |
| Carstensen, J | 1 |
| Friberg, S | 1 |
| Glas, U | 1 |
| Kaigas, M | 1 |
| Skoog, L | 1 |
| Knight, RK | 1 |
| Machida, T | 2 |
| Kano, K | 1 |
| Miura, Y | 1 |
| Akiyama, J | 1 |
| Sagara, Y | 1 |
| Yamazaki, Y | 2 |
| Amano, H | 1 |
| Hiura, T | 1 |
| Oda, S | 1 |
| Namiki, S | 1 |
| Nagao, K | 2 |
| Takagi, K | 2 |
| Kuno, K | 1 |
| Kajitani, T | 1 |
| Tsuruo, T | 2 |
| Naganuma, K | 2 |
| Yamori, T | 1 |
| Kawabata, H | 1 |
| Oh-Hara, T | 1 |
| Tsukagoshi, S | 2 |
| Sakurai, Y | 1 |
| Ohta, H | 1 |
| Ohashi, I | 1 |
| Takekoshi, T | 1 |
| Kato, Y | 4 |
| Voznyĭ, EK | 2 |
| Kurkina, TV | 1 |
| Al'tshtuller, IuB | 1 |
| Senn, HJ | 11 |
| Amgwerd, R | 5 |
| Hochuli, E | 3 |
| Ammann, J | 3 |
| Engelhart, G | 4 |
| Heinz, C | 4 |
| Wick, A | 4 |
| Enderlin, F | 4 |
| Creux, G | 4 |
| Fornasiero, A | 1 |
| Cartei, G | 1 |
| Daniele, O | 1 |
| Fosser, V | 1 |
| Fiorentino, MV | 1 |
| Tancini, G | 6 |
| Veronesi, U | 8 |
| Cazzaniga, F | 1 |
| Marelli, M | 1 |
| Sgro, M | 1 |
| Clerici, R | 1 |
| Gallosi, D | 1 |
| Lattuada, N | 1 |
| Sussi, PL | 1 |
| Albrecht, M | 2 |
| Kleinkauf-Houken, A | 1 |
| Trams, G | 3 |
| Thomsen, K | 2 |
| Ringborg, U | 1 |
| Ewert, G | 1 |
| Kinnman, J | 1 |
| Lundquist, PG | 1 |
| Strander, H | 1 |
| Smalley, RV | 1 |
| Bartolucci, AA | 2 |
| Carpenter, J | 1 |
| Perez, CA | 1 |
| Lefante, J | 1 |
| Wittliff, J | 1 |
| Nishioka, B | 6 |
| Kojima, O | 3 |
| Ohuchi, T | 1 |
| Yahata, K | 2 |
| Muto, F | 2 |
| Umehara, M | 3 |
| Yamane, E | 3 |
| Majima, S | 5 |
| Gattoni, F | 1 |
| Mazzoni, R | 1 |
| Moro, E | 1 |
| Uslenghi, C | 1 |
| De Luca, L | 1 |
| Marsilio, P | 1 |
| Bian, AR | 1 |
| Geatti, O | 1 |
| Englaro, E | 1 |
| Nadalin, L | 1 |
| Englaro, GC | 1 |
| Fazio, M | 2 |
| Badellino, F | 1 |
| Sannazzari, GL | 1 |
| Vercellino, V | 2 |
| Airoldi, M | 2 |
| Manca, A | 1 |
| Gandolfo, S | 2 |
| Clark, GM | 2 |
| Bedikian, AY | 1 |
| Chen, TT | 1 |
| Khankhanian, N | 2 |
| Heilbrun, LK | 1 |
| McBride, CM | 3 |
| McMurtrey, MJ | 1 |
| Bodey, GP | 1 |
| Arndt, D | 1 |
| Higi, M | 1 |
| Heuser, L | 1 |
| Schmitt, G | 2 |
| Takayama, K | 2 |
| Eguchi, S | 1 |
| Yanagita, T | 1 |
| Sakita, M | 2 |
| Yamane, T | 2 |
| Torii, T | 1 |
| Imai, H | 2 |
| Kageyama, N | 1 |
| Ouchi, T | 1 |
| Nomiyama, S | 1 |
| Pankov, AK | 1 |
| Sidorenko, IuS | 1 |
| Il'inskaia, EG | 1 |
| Ogorodnikova, LS | 1 |
| Zubkova, TV | 1 |
| Miwa, H | 1 |
| Ono, F | 1 |
| Orita, K | 1 |
| Kondo, T | 1 |
| Inokuchi, K | 1 |
| Hattori, T | 1 |
| Inoue, K | 5 |
| Akiyama, H | 1 |
| Abe, O | 3 |
| Ito, I | 1 |
| Kikuchi, K | 2 |
| Kasai, Y | 1 |
| Sugie, S | 1 |
| Hayasaka, A | 1 |
| Suemasu, K | 1 |
| Nomoto, C | 1 |
| Masuda, F | 1 |
| Fisher, ER | 5 |
| Nivinskaia, MM | 1 |
| Abramova, NA | 2 |
| Klykova, ID | 1 |
| Tess, JD | 1 |
| Banfi, A | 3 |
| Mavligit, GM | 2 |
| Dalley, DN | 1 |
| Levi, JA | 1 |
| Aroney, RS | 1 |
| Cooper, MR | 4 |
| Rhyne, AL | 1 |
| Ferree, C | 2 |
| Richards, F | 3 |
| Stuart, JJ | 1 |
| Jackson, DV | 2 |
| Howard, V | 1 |
| Shore, A | 1 |
| Spurr, CL | 2 |
| von Maillot, K | 1 |
| Egger, H | 1 |
| Gunselmann, W | 1 |
| Levitt, SH | 1 |
| Potish, RA | 1 |
| Bajetta, E | 3 |
| Marchini, S | 2 |
| Tesoro Tess, JD | 1 |
| Hochuli, R | 1 |
| Simon, B | 1 |
| Lanz, R | 2 |
| Bigler, R | 2 |
| Seiler, S | 1 |
| Carpenter, JT | 2 |
| Maddox, WA | 1 |
| Laws, HL | 1 |
| Wirtschafter, DD | 1 |
| Soong, SJ | 1 |
| Rasmussen, S | 1 |
| Tranum, B | 1 |
| Gad-el-Mawla, N | 2 |
| Costanzi, J | 1 |
| Hoogstraten, B | 2 |
| Athens, J | 2 |
| Maloney, T | 2 |
| McCracken, J | 1 |
| Vaughn, C | 1 |
| Kukleta, JF | 1 |
| Altorfer, J | 1 |
| Akovbiantz, A | 1 |
| Izuo, M | 1 |
| Kubo, K | 1 |
| Jepsen, G | 1 |
| Fennelly, JJ | 1 |
| Cantwell, B | 1 |
| Jones, M | 1 |
| Wanebo, HJ | 1 |
| Futrell, W | 1 |
| Constable, W | 1 |
| Joss, R | 1 |
| Sonntag, RW | 1 |
| Tschopp, L | 1 |
| Michlmayr, G | 1 |
| Kratzer, H | 1 |
| Denz, H | 1 |
| Huber, H | 1 |
| Glidewell, O | 2 |
| Cooper, RG | 2 |
| Melchert, F | 1 |
| Kreienberg, R | 2 |
| von Nathusius, U | 1 |
| Gerinshteĭn, IG | 1 |
| Kislichenko, VA | 1 |
| Tarkhanova, MV | 1 |
| Pashchenko, NS | 1 |
| Kolesnikova, GS | 1 |
| Ermilova, VD | 1 |
| Sokolova, IG | 1 |
| Fijita, Y | 1 |
| Morisawa, K | 2 |
| Neubauer, BL | 1 |
| Best, KL | 1 |
| Counts, DF | 1 |
| Goode, RL | 1 |
| Hoover, DM | 1 |
| Jones, CD | 1 |
| Sarosdy, MF | 1 |
| Shaar, CJ | 1 |
| Tanzer, LR | 1 |
| Merriman, RL | 1 |
| Schadendorf, D | 1 |
| Worm, M | 1 |
| Algermissen, B | 1 |
| Kohlmus, CM | 1 |
| Czarnetzki, BM | 1 |
| Pache, L | 1 |
| Bufill, JA | 1 |
| Grace, WR | 1 |
| Neff, R | 1 |
| Brucker, C | 1 |
| Weiss, M | 1 |
| Schweiberer, L | 1 |
| Genz, T | 2 |
| Maassen, V | 1 |
| Debus-Thiede, G | 1 |
| Dreicer, R | 2 |
| Forest, PK | 2 |
| Williams, RD | 1 |
| Marsh, RW | 1 |
| Agaliotis, D | 1 |
| Killeen, R | 1 |
| Moriyama, A | 1 |
| Murata, I | 1 |
| Yoshikawa, I | 1 |
| Tabaru, A | 1 |
| Ogami, Y | 1 |
| Otsuki, M | 1 |
| Berkowitz, LD | 1 |
| Love, N | 1 |
| Takamatsu, S | 1 |
| Sugano, N | 1 |
| Katada, M | 1 |
| Ebuchi, M | 2 |
| Terada, J | 1 |
| Mizuno, I | 1 |
| Ueda, T | 3 |
| Mohri, N | 1 |
| Inagaki, H | 1 |
| Manabe, T | 1 |
| Gardin, G | 1 |
| Campora, E | 3 |
| Repetto, L | 1 |
| Naso, C | 1 |
| Canavese, G | 1 |
| Catturich, A | 1 |
| Guenzi, M | 1 |
| Pronzato, P | 3 |
| Sertoli, MR | 2 |
| Queirolo, P | 1 |
| Amoroso, D | 4 |
| Vigani, A | 1 |
| Bertelli, G | 2 |
| Ohwada, S | 3 |
| Izumi, M | 1 |
| Hosomura, Y | 1 |
| Joshita, T | 1 |
| Lino, Y | 1 |
| Morishita, Y | 6 |
| Sack, H | 1 |
| Koja, S | 2 |
| Itokazu, T | 2 |
| Maeshiro, N | 2 |
| Matsumura, J | 1 |
| Kochi, A | 1 |
| Noda, Y | 2 |
| Adachi, Y | 1 |
| Matsukuma, A | 1 |
| Sakino, I | 1 |
| Konishi, J | 1 |
| Funahashi, S | 1 |
| Yo, R | 1 |
| Iso, Y | 1 |
| Ayabe, K | 1 |
| Moriyama, M | 1 |
| Sugaya, J | 2 |
| Akiyama, T | 3 |
| Kiriyama, M | 2 |
| Tomita, F | 3 |
| Jelić, S | 1 |
| Radulović, S | 1 |
| Nesković-Konstantinović, Z | 2 |
| Kreacić, M | 1 |
| Ristović, Z | 1 |
| Bosnjak, S | 1 |
| Milanović, N | 1 |
| Vuletić, L | 1 |
| Sugarman, SM | 1 |
| Nishino, N | 1 |
| Aoki, K | 2 |
| Konno, H | 1 |
| Maruo, Y | 1 |
| Matsuda, I | 1 |
| Baba, S | 2 |
| Maoleekoonpairoj, S | 1 |
| Shuin, T | 1 |
| Masuda, M | 1 |
| Yao, M | 1 |
| Hosaka, M | 1 |
| Devaux, Y | 1 |
| Vo Van, ML | 1 |
| Mercier, M | 2 |
| Wils, J | 3 |
| Coombes, RC | 2 |
| Marty, M | 4 |
| Bliss, J | 1 |
| Woods, E | 1 |
| Gérard, JP | 3 |
| Héry, M | 1 |
| Gedouin, D | 2 |
| Plat, F | 1 |
| Cabarrot, E | 1 |
| Budd, GT | 1 |
| Green, S | 6 |
| Rinehart, JJ | 1 |
| Hahn, R | 1 |
| Harris, J | 1 |
| Tormey, D | 1 |
| O'Sullivan, J | 3 |
| Di Bartolomeo, M | 1 |
| Bochicchio, AM | 1 |
| Somma, L | 1 |
| Mazzaferro, V | 1 |
| Visini, M | 1 |
| Gebbia, V | 1 |
| Tumolo, S | 1 |
| Ballatore, P | 1 |
| Hayashi, K | 3 |
| Eguchi, R | 1 |
| Girvin, GW | 1 |
| Matsumoto, GH | 1 |
| Bates, DM | 1 |
| Garcia, JM | 1 |
| Clyde, JC | 1 |
| Lin, PH | 1 |
| Wiltschke, C | 1 |
| Krainer, M | 1 |
| Budinsky, AC | 1 |
| Müller, C | 2 |
| Zeillinger, R | 1 |
| Speiser, P | 1 |
| Eibl, M | 1 |
| Zielinski, CC | 1 |
| Hao, C | 1 |
| Gao, F | 1 |
| Cao, Z | 3 |
| You, Z | 1 |
| Clahsen, PC | 3 |
| van de Velde, CJ | 3 |
| Welvaart, K | 1 |
| van Driel, OJ | 1 |
| Sylvester, RJ | 1 |
| Braun, EM | 1 |
| Kikot', VA | 1 |
| Iugrinov, OG | 1 |
| Sorokin, BV | 1 |
| Mochizuki, F | 2 |
| Tomioka, K | 1 |
| Mizuno, Y | 1 |
| Sato, F | 1 |
| Yamagata, T | 1 |
| Nagakawa, Y | 1 |
| Kobari, Y | 1 |
| Fujii, M | 2 |
| Iwai, S | 2 |
| Chung, YS | 3 |
| Nakata, B | 2 |
| Nitta, A | 1 |
| Inoue, T | 4 |
| Hirayama, K | 1 |
| Ogawa, M | 8 |
| Kubo, T | 1 |
| Shirasaka, T | 2 |
| Johnsen, C | 1 |
| Hacking, A | 1 |
| Cortes-Funes, H | 3 |
| Forbes, J | 1 |
| Zambetti, M | 6 |
| Imai, T | 1 |
| Kodama, S | 1 |
| Yanase, T | 1 |
| Ikarashi, H | 1 |
| Kazama, Y | 1 |
| Ung, O | 1 |
| Langlands, AO | 2 |
| Barraclough, B | 1 |
| Boyages, J | 2 |
| Umehara, Y | 1 |
| Okubo, T | 1 |
| Sano, Y | 1 |
| Sakamoto, R | 1 |
| Nagato, Y | 1 |
| Moriyama, R | 1 |
| Jablonski, KA | 1 |
| Soda, T | 1 |
| Reisser, C | 1 |
| Haberkorn, U | 1 |
| Dimitrakopoulou-Strauss, A | 1 |
| Seifert, E | 1 |
| Strauss, LG | 1 |
| Moliterni, A | 2 |
| Morise, K | 1 |
| Kusugami, K | 1 |
| Iwase, H | 1 |
| Kaneko, H | 1 |
| Horiuchi, Y | 1 |
| Kuroiwa, A | 1 |
| Suga, S | 1 |
| Kute, T | 2 |
| Koerner, F | 1 |
| Bastert, G | 2 |
| Bojar, H | 2 |
| Hübner, K | 1 |
| Schmoor, C | 2 |
| Beyerle, C | 1 |
| Neumann, RL | 1 |
| Rauschecker, HF | 1 |
| Metch, B | 3 |
| Cruz, AB | 2 |
| Jewell, WR | 3 |
| Minton, JP | 2 |
| Kolesnik, EA | 1 |
| Cherny?, VA | 1 |
| Kikot, VA | 1 |
| Haruta, A | 1 |
| Umeno, T | 1 |
| Toriya, H | 1 |
| Jyozaki, H | 1 |
| Ikeda, S | 2 |
| Laccourreye, O | 3 |
| Weinstein, G | 2 |
| Brasnu, D | 4 |
| Bassot, V | 3 |
| Cauchois, R | 1 |
| Jouffre, V | 1 |
| Garcia, D | 1 |
| Laccourreye, H | 4 |
| Sauter, C | 1 |
| Takamuro, T | 1 |
| Takada, Y | 1 |
| Sueyama, H | 3 |
| Tsuchida, E | 1 |
| Sugita, T | 2 |
| Higuchi, S | 1 |
| Fujita, K | 1 |
| Ebeling, O | 2 |
| Eckel, HE | 2 |
| Volling, P | 3 |
| Heitmann, K | 1 |
| Vössing, M | 1 |
| Kamiya, S | 1 |
| Yamauchi, M | 1 |
| Esu, H | 1 |
| Simoji, Y | 1 |
| Witzigmann, H | 1 |
| Sagasser, J | 1 |
| Meyer, FM | 1 |
| Witte, J | 1 |
| Frasci, G | 1 |
| Leone, F | 1 |
| Monaco, M | 1 |
| Cremone, L | 1 |
| Sapio, U | 1 |
| Faiella, F | 1 |
| Espinosa, A | 1 |
| Persico, G | 1 |
| Kawahara, H | 1 |
| Hirai, K | 1 |
| Ashikaga, K | 1 |
| Yamada, Y | 3 |
| Kimura, C | 1 |
| Kuroda, H | 1 |
| Ono, M | 1 |
| Asaishi, K | 2 |
| Okazaki, M | 2 |
| Okazaki, A | 2 |
| Toda, K | 2 |
| Masuoka, H | 2 |
| Narimatsu, E | 1 |
| Frierson, HF | 1 |
| Fechner, RE | 1 |
| Grabenbauer, GG | 4 |
| Panzer, M | 1 |
| Hültenschmidt, B | 1 |
| Döker, R | 2 |
| Huber, K | 1 |
| Kuhne-Velte, HJ | 1 |
| Hutter, M | 1 |
| Rühl, U | 1 |
| Aizawa, K | 1 |
| Muto, I | 1 |
| Katayanagi, N | 1 |
| Tanaka, O | 3 |
| Vorob'eva, LI | 1 |
| Galakhin, KA | 1 |
| Koval'chuk, EN | 1 |
| Renner, H | 1 |
| van Kampen, M | 1 |
| Jessup, JM | 3 |
| Steele, G | 1 |
| Mayer, RJ | 1 |
| Posner, M | 1 |
| Busse, P | 1 |
| Cady, B | 1 |
| Stone, M | 1 |
| Jenkins, R | 1 |
| Osteen, R | 2 |
| Terabe, K | 1 |
| Le Prise, E | 1 |
| Meunier, B | 1 |
| Maddern, G | 1 |
| Ben Hassel, M | 1 |
| Boutin, D | 1 |
| Campion, JP | 1 |
| Launois, B | 1 |
| de Graaf, H | 2 |
| Sleijfer, DT | 2 |
| Mulder, PO | 2 |
| Smit Sibinga, CT | 1 |
| van der Ploeg, E | 2 |
| Dolsma, WV | 2 |
| Mulder, NH | 3 |
| Buffat, L | 1 |
| Lefkopoulos, D | 1 |
| Gallot, D | 1 |
| Malafosse, M | 1 |
| Laugier, A | 1 |
| Husseinzadeh, N | 1 |
| Shrake, P | 1 |
| DeEulis, T | 1 |
| Rowley, K | 1 |
| Aron, B | 1 |
| Hagiwara, A | 1 |
| Nomura, N | 1 |
| Yamada, A | 1 |
| Saitou, F | 1 |
| Tsuzawa, T | 1 |
| Yamashita, I | 1 |
| Sakakibara, T | 1 |
| Sakamoto, T | 2 |
| Karaki, Y | 1 |
| Tazawa, K | 2 |
| Hasegawa, T | 2 |
| Sano, R | 1 |
| Kim, Y | 1 |
| Depondt, J | 1 |
| Gehanno, P | 1 |
| Lelievre, G | 1 |
| Guerrier, B | 1 |
| Peytral, C | 1 |
| Schott, H | 1 |
| Pellae-Cosset, B | 1 |
| O'Reilly, SE | 1 |
| Gelmon, KA | 1 |
| Onetto, N | 1 |
| Parente, J | 1 |
| Rubinger, M | 1 |
| Page, RA | 1 |
| Plenderleith, IH | 1 |
| Jaiyesimi, IA | 2 |
| Au, JL | 2 |
| Wientjes, MG | 2 |
| Rosol, TJ | 1 |
| Koolemans-Beynen, A | 1 |
| Goebel, EA | 1 |
| Schuller, DE | 1 |
| Shamseddine, AI | 1 |
| Khalil, AM | 1 |
| Wehbeh, MH | 1 |
| Balaban, EP | 1 |
| Graham, M | 1 |
| Perkins, S | 1 |
| Sheehan, RG | 1 |
| Frenkel, EP | 1 |
| Ross, M | 2 |
| Bull, J | 1 |
| Pruitt, B | 1 |
| Periman, P | 1 |
| Ruud, C | 1 |
| Oda, Y | 1 |
| Koba, I | 1 |
| Ohnaka, O | 1 |
| Shimizu, W | 1 |
| Anai, H | 1 |
| Muranaka, T | 1 |
| Takeo, S | 1 |
| Maekawa, S | 1 |
| Ikejiri, K | 1 |
| Yakabe, S | 1 |
| Furuyama, M | 1 |
| Saku, M | 1 |
| Schneider, IH | 1 |
| Gall, FP | 1 |
| Isono, K | 2 |
| Koide, Y | 1 |
| Nagai, K | 1 |
| Endoh, M | 1 |
| Chevallier, B | 1 |
| Olivier, JP | 1 |
| Hurteloup, P | 1 |
| Lelli, S | 1 |
| Di Matteo, G | 1 |
| Rea, S | 1 |
| Frati, L | 1 |
| Itaya, S | 1 |
| Tsuge, I | 1 |
| Matsuda, T | 4 |
| Motai, H | 1 |
| Shimada, J | 1 |
| Gion, M | 1 |
| Mione, R | 1 |
| Pappagallo, GL | 1 |
| Gatti, C | 1 |
| Nascimben, O | 1 |
| Bari, M | 1 |
| Leon, AE | 1 |
| Vinante, O | 1 |
| Bruscagnin, G | 1 |
| Altman, SJ | 1 |
| Koizumi, H | 1 |
| Ozawa, Y | 1 |
| Fukano, F | 1 |
| Tokunaga, M | 1 |
| Moriwaki, R | 2 |
| Ajani, JA | 2 |
| Patt, YZ | 1 |
| Gomez, J | 1 |
| Bready, B | 1 |
| Levin, B | 2 |
| Caffier, H | 2 |
| Brunnert, K | 1 |
| Schermann, J | 1 |
| Kleine, W | 1 |
| Fujita, J | 1 |
| Kubo, A | 1 |
| Takigawa, K | 1 |
| Yamaji, Y | 1 |
| Takahara, J | 1 |
| Keane, TJ | 1 |
| Cummings, BJ | 2 |
| O'Sullivan, B | 1 |
| Payne, D | 1 |
| Rawlinson, E | 1 |
| MacKenzie, R | 2 |
| Danjoux, C | 1 |
| Hodson, I | 1 |
| Takiyama, W | 1 |
| Sakamoto, N | 1 |
| Ohashi, R | 1 |
| Kirihara, Y | 1 |
| Doihara, H | 1 |
| Tanada, M | 1 |
| Soga, H | 1 |
| Shapiro, CL | 1 |
| Gelman, RS | 1 |
| Obando, A | 1 |
| Canellos, GP | 1 |
| Frei, E | 2 |
| Arrigoni, F | 1 |
| Ventriglia, L | 1 |
| Saturno, F | 1 |
| Poletti, EM | 1 |
| Sacco, R | 1 |
| Isacson, R | 1 |
| Safra, T | 1 |
| Ben-Dor, CG | 1 |
| Uziely, B | 1 |
| Brufman, G | 2 |
| Fung, CY | 1 |
| Kaufman, DS | 1 |
| Efird, J | 1 |
| Shellito, PC | 1 |
| Gilchrist, K | 1 |
| Okugawa, T | 1 |
| Rino, Y | 1 |
| Kobayashi, O | 3 |
| Sairenji, M | 3 |
| Motohashi, H | 3 |
| Hupperets, PS | 1 |
| Volovics, L | 1 |
| Schouten, L | 1 |
| Fickers, M | 1 |
| Bron, H | 1 |
| Schouten, HC | 1 |
| Jager, J | 1 |
| Smeets, J | 1 |
| de Jong, J | 1 |
| Toki, T | 1 |
| Okazaki, Y | 2 |
| Ogoshi, S | 1 |
| Ogawa, Y | 1 |
| Akagi, T | 1 |
| Takemori, H | 1 |
| Kimura, S | 1 |
| Kudoh, I | 1 |
| Fukushi, M | 1 |
| Aisawa, T | 1 |
| Ishiguro, Y | 1 |
| Yoshiike, M | 1 |
| Osanai, S | 1 |
| Somekawa, Y | 1 |
| Asano, K | 1 |
| Taira, A | 1 |
| Imai, R | 2 |
| Fukutomi, T | 1 |
| Akashi, S | 1 |
| Nanasawa, T | 1 |
| Bliss, JM | 1 |
| Morvan, F | 1 |
| Espié, M | 3 |
| Gambrosier, P | 1 |
| Richards, M | 1 |
| Aapro, M | 1 |
| Villar-Grimalt, A | 1 |
| McArdle, C | 1 |
| Pérez-López, FR | 1 |
| Vassilopoulos, P | 1 |
| Ferreira, EP | 1 |
| Chilvers, CE | 1 |
| Coombes, G | 1 |
| Woods, EM | 1 |
| Goss, PE | 2 |
| Girouard, C | 1 |
| Neri, B | 1 |
| de Leonardis, V | 1 |
| Romano, S | 1 |
| Andreoli, F | 1 |
| Pernice, LM | 1 |
| Borrelli, D | 1 |
| Valeri, A | 1 |
| Fabbroni, S | 1 |
| Intini, C | 1 |
| Cini, G | 1 |
| Cheng, LC | 1 |
| Chiu, CS | 1 |
| Fu, KH | 1 |
| Mok, CK | 1 |
| See, WA | 1 |
| Wheeler, JA | 1 |
| Loening, S | 1 |
| Wust, P | 1 |
| Stahl, H | 1 |
| Dieckmann, K | 1 |
| Scheller, S | 1 |
| Löffel, J | 1 |
| Riess, H | 1 |
| Bier, J | 1 |
| Jahnke, V | 1 |
| Felix, R | 1 |
| Julien, JP | 1 |
| Floiras, JL | 1 |
| Mignolet, FY | 1 |
| Sahmoud, TM | 1 |
| Rutgers, EJ | 1 |
| Holtkamp, MJ | 1 |
| Baars, JW | 2 |
| Schornagel, JH | 2 |
| Peterse, JL | 2 |
| Rodenhuis, S | 2 |
| Johnson, JT | 3 |
| Wagner, RL | 3 |
| Myers, EN | 3 |
| Maurer, U | 1 |
| Härle, M | 1 |
| Jungius, KP | 1 |
| Thomas, F | 1 |
| Arriagada, R | 1 |
| Mouriesse, H | 1 |
| Le Chevalier, T | 1 |
| Fontaine, F | 1 |
| Tursz, T | 1 |
| Bernini, A | 1 |
| Deen, KI | 1 |
| Madoff, RD | 1 |
| Misset, JL | 3 |
| di Palma, M | 1 |
| Delgado, M | 2 |
| Plagne, R | 2 |
| Le Mevel, B | 2 |
| Belpomme, D | 2 |
| Guerrin, J | 2 |
| Metz, R | 2 |
| Ithzaki, M | 1 |
| Hill, C | 1 |
| Mathé, G | 2 |
| Estes, NC | 1 |
| Giri, S | 1 |
| Fabian, C | 1 |
| Andreyev, HJ | 1 |
| Norman, AR | 1 |
| Padhani, AR | 1 |
| Hill, AS | 1 |
| Ross, PJ | 1 |
| Webb, A | 2 |
| Guillot, T | 1 |
| Bernal, ET | 1 |
| Sigal, R | 1 |
| Domenge, C | 2 |
| Wibault, P | 2 |
| Armand, JP | 2 |
| Cvitkovic, E | 2 |
| Plasswilm, L | 1 |
| Seegenschmiedt, MH | 1 |
| Ganssauge, F | 1 |
| Koyama, Y | 2 |
| Sakabe, T | 1 |
| Yasutomi, M | 3 |
| Katsumata, K | 2 |
| Ohno, M | 3 |
| Kumegawa, H | 1 |
| Kanazawa, M | 1 |
| Morinaga, K | 1 |
| Tanemura, H | 2 |
| Oshita, H | 1 |
| Miyaji, M | 1 |
| Ogoshi, K | 2 |
| Kondo, Y | 1 |
| Horiuchi, H | 1 |
| Nozoe, Y | 2 |
| Hyodo, S | 1 |
| Kakegawa, T | 1 |
| van Slooten, HJ | 1 |
| van Dierendonck, JH | 1 |
| Duval, C | 1 |
| Pallud, C | 1 |
| Mandard, AM | 1 |
| Delobelle-Deroide, A | 1 |
| van de Vijver, MJ | 1 |
| Hudis, CA | 1 |
| Dignam, J | 2 |
| Mamounas, EP | 1 |
| Dimitrov, NV | 5 |
| Bowman, DM | 1 |
| Glass, AG | 2 |
| Atkins, JN | 3 |
| Abramson, N | 3 |
| Sutherland, CM | 1 |
| Aron, BS | 1 |
| Margolese, RG | 4 |
| Kwan, WH | 2 |
| Teo, PM | 3 |
| Chow, LT | 1 |
| Choi, PH | 1 |
| Johnson, PJ | 2 |
| Bernier, J | 1 |
| Roncadin, M | 1 |
| Joseph, D | 1 |
| Ardiet, JM | 2 |
| Sentenac, I | 1 |
| Mahé, M | 1 |
| Ménard, M | 2 |
| Khayat, D | 2 |
| Barthel, A | 1 |
| Leonhardt, U | 1 |
| Stöckmann, F | 1 |
| Ramadori, G | 1 |
| Leung, TW | 2 |
| Chan, AT | 2 |
| Leung, SF | 1 |
| Johnson, P | 1 |
| Kuroda, Y | 2 |
| Ohsato, K | 1 |
| Murakami, F | 1 |
| Nishikata, F | 1 |
| Egami, T | 1 |
| Mori, A | 1 |
| Ohe, H | 1 |
| Forrest, AP | 1 |
| Stewart, HJ | 1 |
| Everington, D | 1 |
| Prescott, RJ | 1 |
| McArdle, CS | 2 |
| Harnett, AN | 1 |
| Smith, DC | 1 |
| Chang, D | 1 |
| Koslowe, P | 1 |
| Kunii, Y | 3 |
| Ota, K | 1 |
| Maeshiro, T | 1 |
| Yamada, F | 1 |
| Awane, Y | 1 |
| Murotani, M | 3 |
| Kitada, M | 3 |
| Tsukahara, Y | 3 |
| Niinobu, T | 3 |
| Iihara, K | 3 |
| Tsukamoto, F | 2 |
| Nose, T | 3 |
| Sanchez, W | 1 |
| Luna-Perez, P | 2 |
| Alvarado, I | 1 |
| Labastida, S | 2 |
| Herrera, L | 1 |
| Messori, A | 2 |
| Becagli, P | 2 |
| Trippoli, S | 2 |
| Tendi, E | 1 |
| Martus, P | 3 |
| Zeyi, C | 1 |
| Zongbing, Y | 1 |
| Shiying, Z | 1 |
| Zhilan, P | 1 |
| Jinghua, W | 1 |
| Peiyi, L | 1 |
| Gabra, H | 1 |
| Lee, LE | 1 |
| Mackay, J | 1 |
| Noda, N | 2 |
| Sano, T | 2 |
| Katai, H | 2 |
| Maruyama, K | 2 |
| Onodera, H | 1 |
| Nishitai, R | 1 |
| Maetani, S | 1 |
| Imamura, M | 3 |
| Dimpfl, T | 2 |
| Stumpfe, M | 1 |
| Baltzer, J | 1 |
| Kohno, M | 2 |
| Tadatomo, H | 1 |
| Koyanagi, Y | 2 |
| Maimonis, P | 1 |
| Weitz, S | 1 |
| Teramoto, Y | 1 |
| Katalinic, A | 1 |
| Willers, H | 1 |
| Würschmidt, F | 1 |
| Janik, I | 1 |
| Bünemann, H | 1 |
| Heilmann, HP | 1 |
| Ueyama, N | 1 |
| Miyata, M | 1 |
| Kitamura, K | 1 |
| Tadaoka, N | 1 |
| Yoshinaga, K | 1 |
| Mizutani, H | 1 |
| Inomata, Y | 1 |
| Sakuyama, T | 1 |
| Fox, SB | 1 |
| Engels, K | 1 |
| Comley, M | 1 |
| Whitehouse, RM | 1 |
| Turley, H | 1 |
| Gatter, KC | 1 |
| Harris, AL | 1 |
| Furuya, Y | 1 |
| Saitoh, Y | 2 |
| Matsuoka, T | 1 |
| Onoda, N | 1 |
| Sawada, T | 1 |
| Sowa, M | 1 |
| Kitamura, M | 1 |
| Toge, T | 2 |
| Maibach, R | 1 |
| Castiglione, M | 3 |
| Leyvraz, S | 2 |
| Obrecht, JP | 1 |
| Schildknecht, O | 1 |
| Siegenthaler, P | 1 |
| Lerner-Tung, MB | 1 |
| Chang, AY | 1 |
| Ong, LS | 1 |
| Kreiser, D | 1 |
| Honda, I | 1 |
| Wada, G | 1 |
| Yamasaki, T | 1 |
| Sakakibara, N | 1 |
| Fishman, A | 1 |
| Chiu, JK | 1 |
| Girtanner, RE | 1 |
| Dennis, W | 1 |
| Carpenter, LS | 1 |
| Lu, HH | 1 |
| Woo, SY | 1 |
| Kerley, JM | 1 |
| Kaplan, AL | 1 |
| Kirschner, MJ | 1 |
| Waldfahrer, F | 1 |
| Iro, H | 1 |
| Motomura, K | 1 |
| Keilholz, L | 1 |
| Kessler, H | 1 |
| Lévi, F | 1 |
| Zidani, R | 1 |
| Fenig, E | 1 |
| Brenner, B | 1 |
| Katz, A | 1 |
| Rakovsky, E | 1 |
| Hana, MB | 1 |
| Sulkes, A | 1 |
| Kemeny, N | 1 |
| Cohen, A | 1 |
| Machover, D | 1 |
| Kling, KM | 1 |
| Ostrzega, N | 1 |
| Schmit, P | 1 |
| Dees, EC | 1 |
| Shulman, LN | 1 |
| Souba, WW | 1 |
| Smith, BL | 1 |
| Hojo, K | 1 |
| Ichihashi, H | 1 |
| Tamada, R | 1 |
| Iwamoto, S | 2 |
| Mure, T | 2 |
| Fujimori, Y | 1 |
| Onuma, E | 2 |
| Iki, K | 2 |
| Tadaoka, Y | 2 |
| Takeo, T | 1 |
| Loyer, E | 1 |
| David, C | 1 |
| Sella, A | 2 |
| Ellerhorst, J | 1 |
| Asmar, L | 2 |
| Theriault, RL | 3 |
| Rahman, Z | 1 |
| McNeese, M | 2 |
| Singletary, S | 1 |
| Ames, F | 2 |
| Solano, C | 1 |
| Sola, C | 1 |
| Hornedo, J | 1 |
| López, J | 1 |
| García-Conde, J | 1 |
| Imazeki, H | 1 |
| Takeda, A | 1 |
| Fukunaga, T | 1 |
| Iwasaki, K | 2 |
| Shutou, K | 1 |
| Shinotou, K | 1 |
| Matsuzaki, H | 1 |
| Onogawa, S | 1 |
| Umeda, Y | 1 |
| Kojima, K | 1 |
| Nakajima, N | 2 |
| Muro, H | 1 |
| Ueno, T | 1 |
| Hanada, M | 1 |
| Mori, H | 1 |
| Imoto, S | 2 |
| Akasu, T | 1 |
| Moriya, Y | 1 |
| DeCillis, A | 1 |
| Emir, B | 1 |
| Deschenes, L | 1 |
| Uemastu, T | 1 |
| Nishimaki, T | 1 |
| Kaizu, M | 1 |
| Ohtani, T | 1 |
| Tsukada, K | 1 |
| Hansen, PS | 1 |
| Bach, F | 1 |
| Kjaer, M | 2 |
| Gadeberg, CC | 1 |
| Zedeler, K | 1 |
| Rubagotti, A | 3 |
| Perrotta, A | 1 |
| Sismondi, P | 3 |
| Mesiti, M | 1 |
| Gallo, L | 1 |
| Pacini, P | 2 |
| Villa, E | 1 |
| Agostara, B | 1 |
| Wollensack, P | 2 |
| Bettscheider, C | 1 |
| Sakai, Y | 1 |
| Miyasaka, Y | 1 |
| Yo, S | 1 |
| Fukasaku, T | 1 |
| Kusano, F | 1 |
| Sakuma, I | 1 |
| Maekawa, N | 1 |
| Sazaki, N | 1 |
| Tazawa, J | 1 |
| Asami, K | 1 |
| Uda, O | 1 |
| Masuhara, S | 1 |
| Kasuya, K | 1 |
| Murata, A | 1 |
| Takei, H | 2 |
| Iino, Y | 3 |
| Horiguchi, J | 2 |
| Maemura, M | 1 |
| Koibuchi, Y | 2 |
| Nagaoka, H | 1 |
| Arcangeli, G | 2 |
| Micheli, A | 1 |
| D'Angelo, L | 1 |
| Giovinazzo, G | 1 |
| Tersigni, R | 1 |
| Comandini, E | 1 |
| Scala, T | 1 |
| Lopez, M | 2 |
| Mauri, M | 1 |
| Tsushima, K | 2 |
| Ishida, K | 1 |
| Ikeda, K | 1 |
| Koeda, K | 1 |
| Ogasawara, S | 1 |
| Iwaya, T | 1 |
| Degeorges, A | 1 |
| de Roquancourt, A | 1 |
| Bourstyn, E | 1 |
| de Cremoux, P | 1 |
| Soussi, T | 1 |
| Ahnen, DJ | 1 |
| Feigl, P | 1 |
| Quan, G | 1 |
| Fenoglio-Preiser, C | 1 |
| Lovato, LC | 1 |
| Bunn, PA | 1 |
| Stemmerman, G | 1 |
| Wells, JD | 1 |
| Macdonald, JS | 2 |
| Meyskens, FL | 1 |
| Birkenhake, S | 1 |
| Kühn, R | 2 |
| Schrott, KM | 2 |
| Hongo, H | 1 |
| Akamine, T | 1 |
| Hanada, N | 1 |
| Yoshioka, M | 1 |
| Tabira, Y | 1 |
| Hiraoka, T | 1 |
| Kitamura, N | 1 |
| Majima, T | 1 |
| Kajihara, K | 1 |
| Akama, F | 1 |
| Shigeta, K | 1 |
| Sano, I | 1 |
| Kasakura, Y | 1 |
| Kanamori, N | 1 |
| Kasahara, M | 1 |
| Yamagata, M | 1 |
| Piura, B | 1 |
| Rabinovich, A | 1 |
| Friger, M | 1 |
| Glezerman, M | 1 |
| Catino, A | 1 |
| Longo, S | 1 |
| Racanelli, A | 1 |
| Timurian, A | 1 |
| Marzullo, F | 1 |
| Roppongi, T | 1 |
| Kanno, K | 1 |
| Ogata, T | 1 |
| Ayzac, L | 1 |
| Hun, D | 1 |
| Coquard, R | 1 |
| Heidemann, E | 1 |
| Koike, N | 1 |
| Kawashima, K | 1 |
| Kamiyama, H | 1 |
| Peng, Z | 2 |
| Osaki, T | 1 |
| Ueta, E | 1 |
| Yoneda, K | 1 |
| Grigsby, PW | 3 |
| Lu, JD | 1 |
| Mutch, DG | 3 |
| Kim, RY | 2 |
| Eifel, PJ | 2 |
| Fetting, JH | 2 |
| Fairclough, DL | 1 |
| Smith, TJ | 1 |
| Margolin, KA | 1 |
| Citron, ML | 1 |
| Grove-Conrad, M | 1 |
| Cella, D | 1 |
| Pandya, K | 1 |
| Robert, N | 1 |
| Mehta, RR | 1 |
| McDermott, JH | 1 |
| Hieken, TJ | 1 |
| Marler, KC | 1 |
| Patel, MK | 1 |
| Wild, LD | 1 |
| Das Gupta, TK | 1 |
| Hara, A | 1 |
| Matsubara, T | 1 |
| Satake, K | 1 |
| Miyazaki, H | 1 |
| Westra, WH | 1 |
| Forastiere, AA | 1 |
| Lee, DJ | 1 |
| Ueshige, N | 1 |
| Hamazoe, R | 1 |
| Sumi, K | 1 |
| Murata, Y | 1 |
| Shiota, S | 1 |
| Hirooka, Y | 1 |
| Bramwell, VH | 1 |
| Norris, BD | 1 |
| Abu-Zahra, H | 3 |
| Warr, D | 2 |
| Myles, J | 1 |
| Arnold, A | 3 |
| Robert, J | 1 |
| Ottaway, J | 1 |
| Williams, CK | 1 |
| Coates, A | 2 |
| Fey, M | 1 |
| Price, K | 2 |
| Richel, DJ | 1 |
| Koning, CC | 1 |
| Borger, JH | 1 |
| Nooijen, WJ | 1 |
| Bakx, R | 1 |
| Dalesio, O | 2 |
| Rutgers, E | 1 |
| Ferree, CR | 1 |
| Green, MR | 1 |
| Yamamoto, N | 2 |
| Omuro, Y | 1 |
| Narabayashi, M | 1 |
| Adachi, I | 1 |
| Allred, C | 1 |
| Stadler, P | 1 |
| Feldmann, HJ | 1 |
| Creighton, C | 1 |
| Kau, R | 1 |
| Molls, M | 1 |
| Kitsukawa, S | 1 |
| Kinn, T | 1 |
| Izutami, T | 1 |
| Ishikawa, Y | 1 |
| Tsuchiyama, T | 1 |
| Iida, A | 1 |
| Katayama, SK | 1 |
| Hirose, K | 1 |
| Yamaguch, A | 1 |
| Nakagawara, G | 1 |
| Spitz, FR | 1 |
| Giacco, GG | 1 |
| Hess, K | 1 |
| Larry, L | 1 |
| Rich, TA | 2 |
| Janjan, N | 1 |
| Cleary, KR | 2 |
| Giaretti, W | 1 |
| Sanguineti, G | 1 |
| Geido, E | 1 |
| Orecchia, R | 1 |
| Numico, GM | 1 |
| Merlano, M | 1 |
| Vitale, V | 1 |
| Barbareschi, M | 1 |
| Palma, PD | 1 |
| Mauri, FA | 1 |
| Boracchi, P | 2 |
| Bevilacqua, P | 1 |
| Caffo, O | 1 |
| Morelli, L | 1 |
| Verderio, P | 1 |
| Atkins, CD | 1 |
| Varia, MA | 1 |
| Bundy, BN | 1 |
| Deppe, G | 1 |
| Mannel, R | 1 |
| Averette, HE | 2 |
| Rose, PG | 1 |
| Connelly, P | 1 |
| Patiutko, IuI | 1 |
| Kotel'nikov, AG | 1 |
| Badalian, KhV | 1 |
| Sagaĭdak, IV | 1 |
| Suwa, H | 2 |
| Hosotani, R | 2 |
| Okino, T | 1 |
| Monden, K | 1 |
| Arii, S | 1 |
| Ohshio, G | 1 |
| Fukumoto, M | 1 |
| Newman, LA | 3 |
| Dhingra, K | 1 |
| Binkley, SM | 1 |
| Singletary, SE | 7 |
| Tanaka, E | 1 |
| Mikhak, B | 1 |
| Zahurak, M | 1 |
| Waterfield, W | 1 |
| Kennedy, MJ | 1 |
| Kume, S | 1 |
| Tanabe, D | 1 |
| Sakaguchi, T | 1 |
| Nagamoto, N | 1 |
| Fukuda, S | 1 |
| Corral, P | 1 |
| Rodríguez-Coria, D | 1 |
| Delgado, S | 1 |
| Schwartzberg, LS | 1 |
| Birch, R | 1 |
| Tauer, KW | 1 |
| Leff, R | 1 |
| Raefsky, E | 1 |
| McAneny, B | 1 |
| Weaver, Z | 1 |
| West, J | 1 |
| Buckner, CD | 1 |
| Weaver, CH | 1 |
| Morris, M | 1 |
| Levenback, C | 1 |
| Stevens, RE | 1 |
| Rotman, M | 1 |
| Gershenson, DM | 1 |
| Taniguchi, K | 1 |
| Bando, E | 1 |
| Michiwa, Y | 1 |
| Masaki, T | 1 |
| Becker, M | 2 |
| Bachert, P | 1 |
| Zuna, I | 1 |
| van Kaick, G | 1 |
| Rayson, D | 1 |
| Adjei, AA | 1 |
| Wold, LE | 2 |
| Hasbini, A | 1 |
| Mahjoubi, R | 1 |
| Fandi, A | 1 |
| Chouaki, N | 1 |
| Taamma, A | 1 |
| Lianes, P | 1 |
| Alonso, S | 1 |
| Raymond, E | 1 |
| Sahin, AA | 1 |
| Breslin, TM | 2 |
| Miles, DW | 1 |
| Harris, WH | 1 |
| Gillett, CE | 1 |
| Smith, P | 1 |
| Barnes, DM | 1 |
| Khoo, VS | 1 |
| Dubrow, R | 2 |
| Allen, PK | 1 |
| Lynch, PM | 1 |
| Glober, G | 1 |
| Ping, B | 1 |
| Rudroff, C | 1 |
| Altendorf-Hoffmann, A | 1 |
| Stangl, R | 1 |
| Scheele, J | 1 |
| Howell, JD | 1 |
| Warren, HW | 1 |
| Anderson, JH | 1 |
| Kerr, DJ | 1 |
| Görlich, M | 2 |
| Jandrig, B | 1 |
| Fujiwara, T | 1 |
| Iwata, R | 1 |
| Ido, T | 1 |
| Gamo, M | 1 |
| Kanamaru, R | 1 |
| Saarto, T | 1 |
| Lundin, J | 1 |
| Blomqvist, C | 2 |
| Nekhme, A | 1 |
| Furukawa, J | 1 |
| Azama, T | 1 |
| Katsumoto, Y | 1 |
| Morimoto, T | 2 |
| Okajima, S | 1 |
| Sue, F | 1 |
| Tsujitani, S | 1 |
| Oka, S | 2 |
| Kondo, A | 1 |
| Ikeguchi, M | 1 |
| Maeta, M | 1 |
| Kaibara, N | 1 |
| Mattioli, R | 1 |
| Martignoni, G | 1 |
| Baldelli, AM | 2 |
| Giuliodori, L | 1 |
| Agostinelli, R | 1 |
| Chidel, MA | 1 |
| Kupelian, PA | 1 |
| Suh, JH | 1 |
| Gmyrek, R | 1 |
| Beer, R | 1 |
| Elizeri, Y | 1 |
| Oster, MW | 1 |
| Silvers, DN | 1 |
| Schneiderman, P | 1 |
| Grossman, ME | 1 |
| Schröder, M | 1 |
| Eckel, H | 1 |
| Stennert, E | 1 |
| Sano, O | 1 |
| Yamanaka, T | 1 |
| Manfreda, D | 1 |
| Mittlböck, M | 1 |
| Satake, M | 2 |
| Kaneko, K | 1 |
| Nakamura, A | 1 |
| Tocchi, A | 1 |
| Lepre, L | 1 |
| Costa, G | 1 |
| Liotta, G | 1 |
| Mazzoni, G | 1 |
| Agostini, N | 1 |
| Miccini, M | 1 |
| Huang, XY | 1 |
| Sasagawa, I | 1 |
| Ishigooka, M | 1 |
| Haie-Meder, C | 1 |
| Fervers, B | 1 |
| Chauvergne, J | 1 |
| Fondrinier, E | 1 |
| Lhommé, C | 1 |
| Faivre, C | 1 |
| Lusinchi, A | 1 |
| Lasser, P | 1 |
| Eschwege, F | 1 |
| Tanabe, T | 1 |
| Tsutsui, M | 1 |
| Carr, JA | 1 |
| Ajlouni, M | 1 |
| Wollner, I | 1 |
| Wong, D | 1 |
| Velanovich, V | 1 |
| Davidson, NG | 1 |
| Davis, AS | 1 |
| Woods, J | 1 |
| Snooks, S | 1 |
| Cheverton, PD | 1 |
| Peracchia, A | 1 |
| Bonavina, L | 1 |
| Via, A | 1 |
| Incarbone, R | 1 |
| Kanno, M | 2 |
| Uotani, C | 1 |
| Taniya, T | 1 |
| Mura, T | 1 |
| Bando, H | 1 |
| Kawahara, F | 1 |
| Tsugawa, K | 1 |
| Ohsawa, H | 1 |
| Aiba, K | 1 |
| Sugiyama, K | 1 |
| Horikoshi, N | 2 |
| Kawabe, A | 1 |
| Isogaki, J | 1 |
| Kazui, T | 1 |
| Nozue, M | 1 |
| Ise, H | 1 |
| Valero, V | 2 |
| Frye, D | 2 |
| Booser, DJ | 2 |
| Holmes, FA | 3 |
| Giralt, S | 1 |
| Khouri, I | 1 |
| Andersson, B | 1 |
| Gajewski, JL | 1 |
| Rondon, G | 1 |
| Sneige, N | 1 |
| Strom, EA | 1 |
| McNeese, MD | 3 |
| Deisseroth, AB | 1 |
| Champlin, RE | 1 |
| Samli, B | 1 |
| Celik, S | 1 |
| Evrensel, T | 1 |
| Orhan, B | 1 |
| Tasdelen, I | 1 |
| Wilson, J | 1 |
| Carder, P | 1 |
| Gooi, J | 1 |
| Bontenbal, M | 1 |
| van Putten, WL | 1 |
| Burghouts, JT | 1 |
| Baggen, MG | 1 |
| Ras, GJ | 1 |
| Stiegelis, WF | 1 |
| Beudeker, M | 1 |
| Janssen, JT | 1 |
| Braun, JJ | 1 |
| van der Linden, GH | 1 |
| van der Velden, PC | 1 |
| van Geel, AN | 1 |
| Helle, P | 1 |
| Leisink, M | 1 |
| Klijn, JG | 1 |
| Kamby, C | 1 |
| Mouridsen, H | 1 |
| Dombernowsky, P | 2 |
| Cold, S | 1 |
| Andersen, J | 1 |
| Takenoue, T | 1 |
| Akiyama, Y | 1 |
| Koyama, K | 1 |
| Abraham, R | 1 |
| Nagy, T | 1 |
| Labadie, RF | 1 |
| Yarbrough, WG | 1 |
| Weissler, MC | 1 |
| Pillsbury, HC | 1 |
| Mukherji, SK | 1 |
| Iwatani, Y | 1 |
| Kamigaki, T | 1 |
| Suzuki, Y | 1 |
| Iwasaki, T | 1 |
| Sinmaru, H | 1 |
| Vlastos, G | 2 |
| Mirza, NQ | 2 |
| Lenert, JT | 2 |
| Jabro, G | 1 |
| Wazer, DE | 1 |
| Ruthazer, R | 1 |
| Lum, R | 1 |
| Sklar, N | 1 |
| Goldman, D | 1 |
| Enegess, D | 1 |
| Erban, J | 1 |
| Nogaret, JM | 1 |
| Duffy, K | 1 |
| Bartholomeus, S | 2 |
| Rowan, S | 1 |
| O'Higgins, N | 1 |
| Wang, WS | 2 |
| Lin, JK | 2 |
| Chiou, TJ | 2 |
| Fan, FS | 2 |
| Yen, CC | 2 |
| Lin, TC | 2 |
| Jiang, JK | 2 |
| Yang, SH | 2 |
| Wang, HS | 2 |
| Blohmer, J | 1 |
| Heinrich, J | 1 |
| Quass, J | 1 |
| Breitbach, P | 1 |
| Köhler, U | 1 |
| Nishimura, H | 1 |
| Takasuna, K | 1 |
| Kondo, R | 1 |
| Munakata, Y | 1 |
| Kasuga, Y | 1 |
| Crane, CN | 1 |
| Curley, SA | 1 |
| Ellis, LM | 1 |
| Vauthey, J | 1 |
| Lenzi, R | 1 |
| Lynch, P | 1 |
| Brown, T | 1 |
| Allen, P | 1 |
| Brown, B | 1 |
| Palermo, JA | 1 |
| Lohman, KK | 1 |
| Lovelace, JV | 1 |
| Atkinson, J | 1 |
| Case, LD | 1 |
| Blackstock, AW | 2 |
| Juvekar, AS | 1 |
| Amonkar, AJ | 1 |
| D'cruz, AK | 1 |
| Saikaia, T | 1 |
| Pradhan, S | 1 |
| Yau, JC | 1 |
| Gertler, SZ | 1 |
| Hanson, J | 1 |
| Verma, S | 1 |
| Grimard, LJ | 1 |
| Malik, ST | 1 |
| Aref, IM | 1 |
| Cross, PW | 1 |
| Tomiak, EM | 1 |
| St Cyr, DA | 1 |
| Huan, SD | 1 |
| Tang, SG | 1 |
| See, LC | 1 |
| Chen, WC | 1 |
| Tsang, S | 1 |
| Chang, JT | 1 |
| Hong, JH | 1 |
| Bos, AM | 1 |
| Piersma, H | 1 |
| Rashidi, B | 2 |
| An, Z | 2 |
| Sun, FX | 2 |
| Moossa, AR | 2 |
| Thorban, S | 1 |
| Busch, R | 1 |
| Roder, RJ | 1 |
| Gregory, WM | 1 |
| Bowman, A | 1 |
| Anderson, ED | 1 |
| Levack, P | 1 |
| Forouhi, P | 1 |
| Song, S | 1 |
| Gan, Y | 1 |
| Luisi, A | 1 |
| Cipriani, S | 1 |
| Daidone, MG | 2 |
| Kamata, T | 1 |
| Nakamoto, A | 1 |
| Onishi, I | 1 |
| Takeda, T | 1 |
| Koyasaki, N | 1 |
| Takasaka, H | 1 |
| Kawasaki, H | 1 |
| Matsunaga, T | 1 |
| Nakagawa, N | 1 |
| Yabana, T | 1 |
| Yasojima, T | 1 |
| Hata, F | 1 |
| Shimoyama, S | 1 |
| Aoki, F | 1 |
| Toyoda, K | 1 |
| Kaminishi, M | 2 |
| Han, Q | 1 |
| Zheng, X | 1 |
| Dai, A | 1 |
| Tamura, H | 1 |
| Kojima, M | 1 |
| Ando, J | 1 |
| Fujisaki, M | 1 |
| Wada, N | 1 |
| Joly, F | 1 |
| Héron, JF | 1 |
| Henry-Amar, M | 1 |
| Kollmannsberger, C | 2 |
| Quietzsch, D | 2 |
| Lingenfelser, T | 1 |
| Schroeder, M | 3 |
| Baronius, W | 2 |
| Hempel, V | 2 |
| Clemens, M | 1 |
| Ezekiel, G | 1 |
| Walfisch, S | 1 |
| Nanni, O | 1 |
| Marangolo, M | 1 |
| Gambi, A | 1 |
| Perroni, D | 1 |
| Giunchi, DC | 1 |
| Becciolini, A | 1 |
| Volpi, A | 1 |
| Sugitani, K | 1 |
| Yokomori, T | 2 |
| Iesato, H | 2 |
| Ohya, T | 1 |
| Mizutani, S | 1 |
| Inada, T | 1 |
| Fukutomi, K | 1 |
| Igarashi, S | 1 |
| Ogata, Y | 2 |
| Ohashi, M | 1 |
| Kim, SN | 1 |
| Suh, CO | 1 |
| Allen, MJ | 1 |
| Vaughan, M | 1 |
| Savage, P | 2 |
| Eisen, T | 1 |
| Bate, S | 1 |
| Moore, J | 1 |
| Ahern, R | 1 |
| Gore, ME | 1 |
| Nakashima, S | 1 |
| Miyazono, F | 1 |
| Kijima, F | 1 |
| Aridome, K | 1 |
| Kusano, C | 1 |
| Baba, M | 1 |
| Takao, S | 1 |
| Fornage, BD | 1 |
| Bedi, D | 1 |
| Winchester, DJ | 1 |
| Tolley, SM | 1 |
| Graeven, U | 1 |
| Schmiegel, W | 1 |
| Kokufu, I | 1 |
| Fukuda, K | 1 |
| Kitano, H | 1 |
| Tokunaga, Y | 1 |
| Kitaoka, A | 1 |
| Tokuka, A | 1 |
| Ohsumi, K | 1 |
| Hata, Y | 1 |
| Sasaki, F | 1 |
| Uchino, J | 1 |
| Akasaka, Y | 1 |
| Nakanishi, Y | 2 |
| Sawada, Y | 1 |
| Uchida, N | 1 |
| Tsuzuki, Y | 1 |
| Mochida, Y | 1 |
| Yoshikawa, M | 1 |
| Sekihara, M | 1 |
| Ohno, Y | 1 |
| Dressler, L | 1 |
| Hayes, D | 1 |
| Cohen, L | 1 |
| Sahin, A | 1 |
| Delpassand, ES | 1 |
| House, R | 1 |
| Bergh, J | 1 |
| Wiklund, T | 1 |
| Erikstein, B | 1 |
| Lidbrink, E | 1 |
| Malmström, P | 1 |
| Kellokumpu-Lehtinen, P | 1 |
| Bengtsson, NO | 1 |
| Söderlund, G | 1 |
| Anker, G | 1 |
| Wist, E | 1 |
| Ottosson, S | 1 |
| Salminen, E | 1 |
| Ljungman, P | 1 |
| Holte, H | 1 |
| Nilsson, J | 1 |
| Wilking, N | 1 |
| Kajiyama, Y | 1 |
| Tsurumaru, M | 1 |
| Montana, GS | 1 |
| Thomas, GM | 1 |
| Moore, DH | 1 |
| Saxer, A | 1 |
| Mangan, CE | 1 |
| Lentz, SS | 1 |
| Mouret, E | 1 |
| Laurence, V | 1 |
| Dorval, T | 1 |
| Palangié, T | 1 |
| Scholl, S | 1 |
| Pouillart, P | 1 |
| Sumi, H | 1 |
| Nagashima, F | 1 |
| León, X | 1 |
| Quer, M | 1 |
| Orús, C | 1 |
| de Dios, E | 1 |
| Recher, K | 1 |
| Lammering, G | 1 |
| Hartmann, KA | 1 |
| Frenken, M | 1 |
| Aryus, B | 1 |
| Ulrich, B | 1 |
| Okumoto, T | 1 |
| Ino, H | 1 |
| Kanaya, Y | 1 |
| Otani, J | 1 |
| Soda, M | 1 |
| Ida, K | 1 |
| Swiatkowska-Freund, M | 1 |
| Preis, K | 1 |
| Emerich, J | 1 |
| Tang, ZY | 1 |
| Yoo, CH | 1 |
| Roh, JK | 2 |
| Min, JS | 2 |
| Brito, RA | 1 |
| Strom, E | 1 |
| Kau, SW | 2 |
| Benoit, R | 1 |
| Grobost, O | 1 |
| Chalmet, P | 1 |
| Tan-Chiu, E | 1 |
| Merajver, S | 1 |
| Romond, EH | 1 |
| Kardinal, CG | 1 |
| Shibata, HR | 1 |
| Miyauchi, M | 1 |
| Ohno, K | 1 |
| Tsukamoto, T | 1 |
| Oheda, Y | 1 |
| Kamiya, N | 1 |
| Asano, S | 1 |
| Shinya, F | 1 |
| Kawahara, M | 2 |
| Berner, J | 1 |
| Tenderenda, M | 1 |
| Pasz, S | 1 |
| Berner, A | 1 |
| Piekarski, J | 1 |
| Popiela, T | 1 |
| Kulig, J | 1 |
| Kołodziejczyk, P | 1 |
| Ménard, S | 1 |
| Pilotti, S | 1 |
| Biganzoli, E | 1 |
| Tomasic, G | 1 |
| Casalini, P | 1 |
| Marubini, E | 1 |
| Colnaghi, MI | 1 |
| Cascinelli, N | 3 |
| Page, DL | 1 |
| Hatfield, AK | 1 |
| Shinners, MJ | 1 |
| Brodner, DC | 1 |
| Amedee, RG | 1 |
| Khoubehi, B | 1 |
| Schofield, A | 1 |
| Leslie, M | 1 |
| Slevin, ML | 2 |
| Talbot, IC | 1 |
| Northover, JM | 1 |
| Graziano, F | 1 |
| Valentini, M | 1 |
| Staccioli, MP | 1 |
| Rossi, C | 2 |
| Grianti, C | 1 |
| Muretto, P | 1 |
| Sekikawa, T | 2 |
| Tsukui, H | 1 |
| Kina, S | 1 |
| Kawahara, T | 1 |
| Ono, K | 1 |
| Kishida, Y | 1 |
| Yakumaru, K | 1 |
| Kagami, H | 1 |
| Sawamura, A | 1 |
| Kim, R | 1 |
| Wang, HM | 1 |
| Ng, SH | 1 |
| Liaw, CT | 1 |
| Chen, IH | 1 |
| Schultze, J | 1 |
| Kimmig, B | 1 |
| Chen, WS | 1 |
| Noël, G | 1 |
| Wisman, GB | 1 |
| de Jong, S | 1 |
| Ruiters, MH | 1 |
| de Leij, LF | 1 |
| van der Zee, AG | 1 |
| Miyagi, Y | 1 |
| Matono, K | 1 |
| Baeza, MR | 1 |
| Giannini T, O | 1 |
| Rivera S, R | 1 |
| González, P | 1 |
| González, J | 1 |
| Vergara, E | 1 |
| del Castillo, C | 1 |
| Madrid, J | 1 |
| Vinés, E | 1 |
| Szatkowska, L | 1 |
| Mazurkiewicz, M | 1 |
| Brzozowska, A | 1 |
| Jiao, X | 1 |
| Krasna, MJ | 1 |
| Sonett, J | 1 |
| Gamliel, Z | 1 |
| Suntharalingam, M | 1 |
| Doyle, A | 1 |
| Greenwald, B | 1 |
| Mayers, C | 1 |
| Panzarella, T | 1 |
| Tannock, IF | 1 |
| Bédard, EL | 1 |
| Inculet, RI | 1 |
| Malthaner, RA | 1 |
| Brecevic, E | 1 |
| Vincent, M | 1 |
| Dar, R | 1 |
| Dale, A | 1 |
| Barth, G | 1 |
| Rompel, R | 1 |
| Staar, S | 1 |
| Stuetzer, H | 1 |
| Flentje, M | 1 |
| Abzumanov, AS | 1 |
| Bozhok, AA | 1 |
| Ivanov, VG | 1 |
| Ivanova, OA | 2 |
| Barash, NIu | 1 |
| Topuzov, EE | 2 |
| Seleznev, IK | 2 |
| Migmanova, NSh | 2 |
| Popova, RT | 1 |
| Nurgaziev, KSh | 1 |
| Yukiiri, K | 1 |
| Mizushige, K | 1 |
| Ishii, R | 1 |
| Kammori, M | 1 |
| Seto, Y | 1 |
| Haniuda, N | 1 |
| Endo, H | 1 |
| Hutchins, LF | 1 |
| Arick, CL | 1 |
| Murabayashi, K | 1 |
| Kusta, T | 1 |
| Onishi, H | 1 |
| Saegusa, S | 1 |
| Okanami, Y | 1 |
| Nakamura, I | 1 |
| Dunne, B | 1 |
| Reynolds, JV | 1 |
| Mulligan, E | 1 |
| Kelly, A | 1 |
| Griffin, M | 1 |
| Heydon, K | 1 |
| Eifel, P | 1 |
| Okada, A | 1 |
| Omuraya, M | 1 |
| Ishiodori, H | 1 |
| Fujiyama, S | 1 |
| Tokairin, Y | 1 |
| Kure, N | 1 |
| Asano, T | 1 |
| Fujiwara, J | 1 |
| Hong, RL | 1 |
| Ting, LL | 1 |
| Hsu, MM | 1 |
| Sheen, TS | 1 |
| Lou, PJ | 1 |
| Wang, CC | 1 |
| Chung, NN | 1 |
| Lui, LT | 1 |
| Morii, Y | 1 |
| Aramaki, M | 1 |
| Kitano, S | 1 |
| Haensgen, G | 1 |
| Glück, S | 1 |
| Duffaud, F | 1 |
| Ries, P | 1 |
| Ville, E | 1 |
| Laugier, R | 1 |
| Hathaway, B | 1 |
| Piccirillo, JF | 1 |
| Snyderman, CH | 1 |
| Labriola, S | 1 |
| Han, S | 1 |
| Ahn, SH | 1 |
| Bae, BN | 1 |
| Kim, KH | 1 |
| Kim, YD | 1 |
| Wichmann, MW | 1 |
| Meyer, G | 1 |
| Strauss, T | 1 |
| Hornung, HM | 1 |
| Lau-Werner, U | 1 |
| Angele, MK | 1 |
| Schildberg, FW | 1 |
| Amin, R | 1 |
| Oguchi, S | 1 |
| Uhara, H | 1 |
| Saida, T | 1 |
| Papadopoulos, T | 1 |
| Vadiaka, M | 1 |
| Koufos, C | 1 |
| Branković-Magić, M | 1 |
| Janković, R | 1 |
| Nikolić-Vukosavljević, D | 1 |
| Shimoda, S | 1 |
| Takeda, N | 1 |
| Koyama, S | 1 |
| Tsukahara, A | 1 |
| Iijima, K | 1 |
| Ninomiya, J | 1 |
| Ochiai, R | 1 |
| Sundararajan, V | 1 |
| Mitra, N | 1 |
| Jacobson, JS | 1 |
| Grann, VR | 1 |
| Heitjan, DF | 1 |
| Neugut, AI | 1 |
| Hartman, AR | 1 |
| Fleming, GF | 1 |
| Dillon, JJ | 1 |
| Rjosk, D | 1 |
| Strobl, B | 1 |
| Bergauer, F | 1 |
| Linka, F | 1 |
| Kaestner, R | 1 |
| Sommer, H | 1 |
| Hänsgen, G | 1 |
| Kuhnt, T | 1 |
| Pigorsch, S | 1 |
| Strauss, H | 1 |
| Oliver, L | 1 |
| Cordel, S | 1 |
| Barbieux, I | 1 |
| LeCabellec, MT | 1 |
| Meflah, K | 1 |
| Grégoire, M | 1 |
| Vallette, FM | 1 |
| Rhein, B | 1 |
| Koka, VN | 1 |
| Bessede, JP | 1 |
| Marandas, P | 1 |
| Schwaab, G | 1 |
| Luboinski, B | 1 |
| Kleeberg, UR | 1 |
| Ost, E | 1 |
| Illiger, HJ | 1 |
| Takemura, N | 1 |
| Osaka, Y | 1 |
| Sako, H | 1 |
| Ioka, Z | 1 |
| Nakane, Y | 1 |
| Tomlinson, SK | 1 |
| Melin, SA | 1 |
| Higgs, V | 1 |
| Case, D | 1 |
| Ferreira Filho, AF | 1 |
| Michel, J | 2 |
| Focan, C | 1 |
| Awada, A | 1 |
| Misawa, K | 1 |
| Sano, H | 1 |
| Naka, M | 1 |
| Okawa, Y | 1 |
| Takada, A | 1 |
| Morikawa, A | 1 |
| Okabe, R | 1 |
| Ozaki, K | 1 |
| Sugiyama, A | 1 |
| Honecker, F | 1 |
| Spott, C | 1 |
| Kono, K | 1 |
| Takahashi, A | 1 |
| Ichihara, F | 1 |
| Amemiya, H | 1 |
| Matsumoto, Y | 1 |
| Yoshimura, R | 1 |
| Shibuya, H | 1 |
| Ogura, I | 1 |
| Miura, M | 1 |
| Amagasa, T | 1 |
| Enomoto, S | 1 |
| Kishimoto, S | 1 |
| Coco, C | 1 |
| Morganti, AG | 1 |
| Ciabattoni, A | 1 |
| Barbaro, B | 1 |
| Cogliandolo, S | 1 |
| Nuzzo, G | 1 |
| Ambesi-Impiombato, F | 1 |
| Cosimelli, M | 1 |
| Morelli, U | 1 |
| Ohta, Y | 1 |
| Shuto, T | 1 |
| Takemura, S | 1 |
| Kawasaki, M | 1 |
| Shibata, J | 1 |
| El-Domeiri, AA | 1 |
| Chaudhuri, P | 1 |
| Just-Viera, JO | 1 |
| Silva, JE | 1 |
| Goldsmith, MA | 1 |
| Carter, SK | 2 |
| Gutterman, JU | 2 |
| Burgess, MA | 1 |
| Seibert, GB | 1 |
| Speer, JF | 1 |
| Jubert, AV | 1 |
| Copeland, EM | 2 |
| Gehan, EA | 2 |
| Hersh, EM | 2 |
| Wasserman, TH | 1 |
| Rose, DP | 1 |
| Davis, TE | 1 |
| Ruffner, BW | 1 |
| Fisher, RI | 1 |
| Young, RC | 1 |
| Kitade, F | 2 |
| Mabuchi, A | 1 |
| Osawa, N | 2 |
| Yagi, A | 2 |
| Sakuramoto, K | 2 |
| Okajima, K | 2 |
| Kita, R | 1 |
| Sumida, T | 1 |
| Kasagawa, O | 1 |
| Shiian, DN | 2 |
| Golden, GT | 1 |
| Rosenthal, JD | 1 |
| Shaw, A | 1 |
| Otto, R | 1 |
| Zwicker, H | 1 |
| Engeler, V | 1 |
| Glass, A | 2 |
| Barton, B | 1 |
| Such, E | 1 |
| Carbone, P | 1 |
| Economou, S | 1 |
| Foster, R | 1 |
| Frelick, R | 1 |
| Lerner, H | 1 |
| Levitt, M | 1 |
| Margolese, R | 3 |
| MacFarlane, J | 1 |
| Plotkin, D | 1 |
| Volk, H | 1 |
| Morris, D | 1 |
| Aisner, J | 1 |
| Elias, EG | 1 |
| Wiernik, PH | 1 |
| Slack, NH | 3 |
| Bross, ID | 2 |
| Prout, GR | 1 |
| Rotte, K | 1 |
| Sprenger, F | 1 |
| Hochueli, R | 1 |
| Simeon, B | 1 |
| Borisov, AI | 1 |
| Schaake, C | 1 |
| Engelsman, E | 1 |
| Hamersma, E | 1 |
| Grage, TB | 1 |
| Dietz, R | 1 |
| Tkocz, HJ | 1 |
| Sekimoto, T | 1 |
| Carey, RW | 2 |
| Sohier, WD | 1 |
| Kaufman, S | 1 |
| Weitzman, SA | 1 |
| Kelley, RM | 1 |
| Lew, RA | 1 |
| Halpern, E | 1 |
| Heise, E | 1 |
| Számel, I | 1 |
| Kerpel-Fronius, S | 1 |
| Tashima, CK | 1 |
| Yap, HY | 1 |
| Nakao, E | 1 |
| Cho, K | 1 |
| Block, GE | 1 |
| Ellis, RS | 1 |
| DeSombre, E | 1 |
| Jensen, E | 1 |
| von der Maase, H | 1 |
| Sveinsson, T | 1 |
| Poser, H | 1 |
| Quäck, J | 1 |
| Jacobsen, J | 1 |
| Inoguchi, T | 2 |
| Yamasaki, I | 1 |
| Yazuka, K | 1 |
| Kita, T | 1 |
| Kuwano, K | 2 |
| Collier, D | 1 |
| Soloway, MS | 1 |
| Sparks, FC | 2 |
| Wile, AG | 1 |
| Ramming, KP | 1 |
| Silver, HK | 1 |
| Wolk, RW | 1 |
| Morton, DL | 2 |
| Band, PR | 1 |
| Gallmeier, WM | 1 |
| Bruntsch, U | 1 |
| Schmidt, CG | 1 |
| Creech, RH | 1 |
| Catalano, RB | 1 |
| Mastrangelo, MJ | 1 |
| Aoki, Y | 1 |
| Rees, GJ | 1 |
| Bugaighis, A | 1 |
| Anderson, G | 1 |
| Mallo, N | 1 |
| Vincente, J | 1 |
| Iaremenko, KV | 1 |
| Kharitonenko, TS | 1 |
| Golubeva, TA | 1 |
| Schimmel, DH | 1 |
| Julien, PJ | 1 |
| Gamsu, G | 1 |
| Brusamolino, E | 1 |
| Brugnatelli, L | 1 |
| Musumeci, R | 1 |
| Taniguchi, T | 1 |
| Saito, A | 1 |
| Kobayashi, J | 1 |
| Owada, S | 1 |
| Ohtsubo, T | 1 |
| Fujieda, S | 1 |
| Congy, F | 1 |
| Pelletier, S | 1 |
| Langlois, P | 1 |
| Homsi, T | 1 |
| Emerit, J | 1 |
| Bavli, IaL | 2 |
| Golubeva, OM | 1 |
| Orlov, AA | 1 |
| Chepik, OF | 1 |
| Kuusk, U | 1 |
| Basco, V | 1 |
| Rebbeck, P | 1 |
| Hihara, T | 1 |
| Nishiumi, T | 1 |
| Yoneyama, T | 1 |
| Singh, KP | 1 |
| Bass, D | 1 |
| LeBlanc, M | 1 |
| Rivkin, S | 2 |
| Salvadori, B | 1 |
| Rovini, D | 1 |
| Squicciarini, P | 1 |
| Conti, R | 1 |
| Cusumano, F | 1 |
| Grassi, M | 1 |
| Perrault, D | 1 |
| Sfedj, D | 1 |
| Chabardes, E | 1 |
| Wolf, GT | 1 |
| Fisher, SG | 1 |
| Kakizaki, K | 1 |
| Logothetis, CJ | 1 |
| Fitz, K | 1 |
| Dexeus, FH | 1 |
| Amato, R | 1 |
| Kilbourn, R | 1 |
| Wallace, S | 1 |
| Drescher, CW | 1 |
| Reid, GC | 1 |
| Terada, K | 1 |
| Roberts, JA | 1 |
| Hopkins, MP | 1 |
| Perez-Tamayo, C | 1 |
| Schoeppel, SL | 1 |
| Maruyama, Y | 1 |
| Ishizuka, K | 1 |
| Smith, IM | 1 |
| Poulsen, M | 1 |
| Jackson, M | 1 |
| Robinson, D | 1 |
| Thomson, D | 1 |
| Coman, WB | 1 |
| Negri, L | 2 |
| Calabrese, F | 1 |
| Correggia, F | 1 |
| Miozzo, S | 1 |
| Giacomasso, S | 1 |
| Genta, F | 1 |
| Nenci, I | 2 |
| Piffanelli, A | 2 |
| Castagnetta, L | 1 |
| Traina, A | 1 |
| Lindeman, GJ | 1 |
| Driessen, C | 1 |
| Coradini, D | 1 |
| Bignami, P | 1 |
| Contesso, G | 1 |
| Morrison, JM | 1 |
| Kelly, KA | 1 |
| Monypenny, IJ | 1 |
| Walker, RA | 1 |
| Waterhouse, JA | 1 |
| Eudey, L | 1 |
| Shatila, AH | 2 |
| Gilchrist, KW | 2 |
| Rakowsky, E | 1 |
| Klein, B | 1 |
| Kahan, E | 1 |
| Derazne, E | 1 |
| Lurie, H | 1 |
| Içli, F | 2 |
| Günel, N | 1 |
| Dinçol, D | 2 |
| Karaoğuz, H | 1 |
| Demirkazik, A | 1 |
| Greco, M | 2 |
| Morabito, A | 1 |
| Bufalino, R | 1 |
| Testori, A | 1 |
| Baldini, MT | 1 |
| Andreola, S | 1 |
| Leo, E | 2 |
| Galluzzo, D | 1 |
| Rilke, F | 1 |
| Kirita, T | 1 |
| Ihara, H | 1 |
| Nishiyama, T | 1 |
| Kon, M | 1 |
| Mueller, CB | 1 |
| Lesperance, ML | 1 |
| Natali, M | 1 |
| Di Lauro, L | 1 |
| Carpano, S | 1 |
| Vici, P | 1 |
| Conti, EM | 1 |
| Aoki, H | 1 |
| Mieno, K | 1 |
| Amino, K | 1 |
| Ohtaki, K | 1 |
| Satoi, Y | 1 |
| Shikata, J | 1 |
| Goodyear, MD | 1 |
| Gent, M | 1 |
| Schaldenbrand, JD | 1 |
| Siders, DB | 1 |
| Zainea, GG | 1 |
| Thieme, ET | 1 |
| Brockschmidt, JK | 1 |
| Tamburini, M | 1 |
| Ferrari, L | 2 |
| Bombino, T | 1 |
| Gangeri, L | 1 |
| Rosso, S | 1 |
| Bonomi, P | 2 |
| Gale, M | 1 |
| Rowland, K | 2 |
| Purl, S | 1 |
| Reddy, S | 2 |
| Lee, MS | 2 |
| Phillips, A | 1 |
| Kittle, CF | 2 |
| Warren, W | 2 |
| Bonaventura, A | 1 |
| Stewart, JF | 1 |
| Mizuno, S | 1 |
| Nishi, M | 1 |
| Takemori, S | 1 |
| Arai, H | 1 |
| Fujimaki, M | 1 |
| Ota, DM | 1 |
| McBride, C | 1 |
| Boddie, A | 1 |
| Jackson, DE | 1 |
| Roh, M | 1 |
| Hohn, D | 1 |
| Dobrowsky, W | 2 |
| Dobrowsky, E | 1 |
| Strassl, H | 1 |
| Braun, O | 1 |
| Gritzmann, N | 1 |
| Scheiber, V | 1 |
| Nigro, ND | 1 |
| Lichtman, SM | 1 |
| Bosworth, H | 1 |
| Allen, S | 1 |
| Schulman, P | 1 |
| Weiselberg, L | 1 |
| Weiss, R | 1 |
| Lehrman, D | 1 |
| Vinciguerra, V | 1 |
| Watanabe, Y | 1 |
| Mikami, T | 1 |
| Ohba, S | 1 |
| Johnson, PW | 1 |
| Thompson, PI | 1 |
| Seymour, MT | 1 |
| Deasy, NP | 1 |
| Thuraisingham, RC | 1 |
| Wrigley, PF | 1 |
| Raabe, NK | 1 |
| Buzzoni, R | 1 |
| Schreer, I | 1 |
| Frischbier, HJ | 1 |
| Maass, H | 1 |
| Stegner, HE | 1 |
| Krook, JE | 5 |
| Gunderson, LL | 1 |
| Collins, RT | 1 |
| Beart, RW | 2 |
| Kubista, TP | 1 |
| Poon, MA | 1 |
| Meyers, WC | 1 |
| Mailliard, JA | 1 |
| Leigh, JE | 2 |
| Kugler, JW | 1 |
| Foley, JF | 2 |
| Pfeifle, DM | 1 |
| Twito, DI | 1 |
| Perey, L | 1 |
| Pasche, P | 1 |
| Bauer, J | 1 |
| Capasso, P | 1 |
| Savary, M | 1 |
| Demuynck, B | 1 |
| Maisani, JE | 1 |
| Lagadec, B | 1 |
| Delfau, S | 1 |
| Varette, C | 1 |
| Gonzalez-Canali, G | 1 |
| Shanta, V | 1 |
| Krishnamurthi, S | 1 |
| Dinshaw, KA | 1 |
| Sharma, V | 1 |
| Pendse, AM | 1 |
| Telang, CS | 1 |
| Vege, SS | 1 |
| Malliat, MK | 1 |
| Deshpande, R | 1 |
| Desai, PB | 1 |
| Solsona, E | 1 |
| Iborra, I | 1 |
| Ricós, JV | 1 |
| Monrós, JL | 1 |
| Dumont, R | 1 |
| Guillem, V | 1 |
| Ota, J | 1 |
| Sugimoto, T | 1 |
| Sakamoto, Y | 1 |
| Tanimura, H | 1 |
| Terashita, S | 1 |
| Tamai, M | 1 |
| O'Reilly, SM | 1 |
| Camplejohn, RS | 1 |
| Millis, RR | 1 |
| Richards, MA | 1 |
| Danforth, DN | 1 |
| McDonald, H | 1 |
| Bader, J | 1 |
| Egan, E | 1 |
| Lampert, M | 1 |
| Recine, D | 1 |
| Taylor, S | 1 |
| Faber, LP | 1 |
| Hendrickson, FR | 1 |
| Wolberg, WH | 1 |
| Gillchrist, KW | 1 |
| Harris, JE | 1 |
| Youn, JK | 1 |
| Lee, YB | 1 |
| Lee, DW | 1 |
| Park, IS | 1 |
| Legault-Poisson, S | 2 |
| Brown, AM | 1 |
| Brown, A | 1 |
| Dimitrov, N | 1 |
| Pilch, Y | 1 |
| Cappellini, M | 1 |
| Isola, G | 1 |
| Santi, L | 1 |
| Camoriano, JK | 1 |
| Loprinzi, CL | 1 |
| Therneau, TM | 1 |
| Veeder, MH | 1 |
| Lentz, SR | 1 |
| Raish, RJ | 1 |
| Orlowski, EP | 1 |
| Marion, JM | 1 |
| Porschen, R | 1 |
| Stremmel, W | 1 |
| Fujimoto, M | 1 |
| Benedetto, P | 1 |
| Sridhar, KS | 1 |
| Fleming, TR | 2 |
| Laurie, JA | 2 |
| Goodman, PJ | 1 |
| Ungerleider, JS | 1 |
| Emerson, WA | 1 |
| Glick, JH | 1 |
| Kaern, J | 1 |
| Tropé, C | 1 |
| Abeler, V | 1 |
| Iversen, T | 1 |
| Kjørstad, K | 1 |
| Zampa, G | 1 |
| Andriani, A | 1 |
| Beni, A | 1 |
| Patino, N | 1 |
| Rinaldi, P | 1 |
| Merkle, E | 1 |
| Seidl, C | 1 |
| Fuchs, U | 1 |
| Wirtz, PM | 1 |
| Clark, JL | 1 |
| Barcewicz, P | 1 |
| Nava, HR | 1 |
| Goodwin, PS | 1 |
| Douglass, HO | 1 |
| Isikman, E | 1 |
| Unal, M | 1 |
| Meshcheriakova, NG | 1 |
| Melent'eva, EG | 1 |
| Al'tshuler, IuB | 1 |
| Sato, M | 1 |
| Nunnink, JC | 1 |
| Krusinski, PA | 1 |
| Yates, JW | 1 |
| Retsky, MW | 1 |
| Wardwell, RH | 1 |
| Swartzendruber, DE | 1 |
| Headley, DL | 1 |
| Klausner, JM | 1 |
| Gutman, M | 1 |
| Rozin, RR | 1 |
| Lelcuk, S | 1 |
| Inbar, M | 1 |
| Warshaw, AL | 1 |
| Swanson, RS | 1 |
| Bonfils, P | 1 |
| Fabre, A | 1 |
| Lele, SB | 1 |
| Piver, MS | 1 |
| Barton, JC | 1 |
| Namba, M | 1 |
| Muto, K | 1 |
| Ikeguchi, S | 1 |
| Shida, S | 1 |
| Sinmyo, K | 1 |
| Hosoi, H | 1 |
| Kitagawa, M | 1 |
| Susaki, H | 1 |
| Arima, S | 1 |
| Futami, K | 1 |
| Yoshimura, S | 1 |
| Shimura, H | 1 |
| Tamura, Y | 1 |
| Ogasawara, H | 1 |
| Itoh, T | 1 |
| Furukohri, N | 1 |
| Saitoh, S | 1 |
| Baba, T | 1 |
| Munakata, A | 1 |
| Yoshida, Y | 1 |
| Cheson, BD | 1 |
| Apple, JS | 1 |
| Paulson, DF | 1 |
| Baber, C | 1 |
| Putman, CE | 1 |
| Botto, F | 1 |
| Conte, PF | 1 |
| Nissen-Meyer, R | 1 |
| Høst, H | 1 |
| Kjellgren, K | 1 |
| Sutherland, C | 1 |
| Everson, LK | 1 |
| Cullinan, SA | 1 |
| Hagen, JB | 1 |
| Martin, JK | 1 |
| Fitzgibbons, RG | 1 |
| Mukaiyama, T | 1 |
| Kuraishi, Y | 1 |
| Constanzi, JJ | 1 |
| Bleiberg, H | 1 |
| Goffin, JC | 1 |
| Pector, JC | 1 |
| Gignoux, M | 1 |
| Roussel, A | 1 |
| Samana, G | 1 |
| Gerard, A | 1 |
| Scheurlen, H | 1 |
| Barett-Mahler, AR | 1 |
| McCormack, GW | 1 |
| Gerstner, JB | 1 |
| Malliard, J | 1 |
| Chernyĭ, VA | 1 |
| Shchepotin, IB | 1 |
| Ngan, HY | 1 |
| Wong, LC | 1 |
| Chan, SY | 1 |
| Ma, HK | 1 |
| Balducci, L | 1 |
| Athar, M | 1 |
| Smith, GF | 1 |
| Khansur, T | 1 |
| McKenzie, D | 1 |
| Crawford, ED | 1 |
| Nyumura, T | 1 |
| Nabeya, K | 1 |
| Hamakubo, S | 1 |
| Serrano Migallón, JA | 1 |
| Sandoval Guerrero, F | 1 |
| Miranda Hernández, H | 1 |
| de la Garza Navarro, JM | 1 |
| Gallo, C | 1 |
| Marinelli, A | 1 |
| D'Istria, M | 1 |
| Delrio, G | 1 |
| Norton, JA | 1 |
| Doppman, JL | 1 |
| Wesley, RA | 1 |
| Maton, PN | 1 |
| Gardner, JD | 1 |
| Jensen, RT | 1 |
| Linsk, JA | 1 |
| Bruckner, HW | 1 |
| McKenna, A | 1 |
| Hart, R | 1 |
| Caceres, E | 1 |
| Valdivia, S | 1 |
| Cotrina, M | 1 |
| Lingan, M | 1 |
| Leon, L | 1 |
| Gamboa, M | 1 |
| Olivares, L | 1 |
| Moran, M | 1 |
| Paulus, D | 1 |
| Hug, V | 2 |
| Romsdahl, MM | 1 |
| Fraschini, G | 2 |
| Nishimura, M | 1 |
| Yasui, K | 1 |
| Yasue, M | 1 |
| Kito, T | 1 |
| Miyaishi, S | 1 |
| John, M | 1 |
| Flam, M | 1 |
| Wittlinger, P | 1 |
| Podolsky, W | 1 |
| Padmanabhan, A | 1 |
| Mowry, PA | 1 |
| Kakuta, T | 1 |
| Kido, C | 1 |
| Endo, T | 1 |
| Aota, M | 1 |
| Yokomise, H | 1 |
| Jinno, K | 1 |
| Daitoh, N | 1 |
| Jain, S | 1 |
| Seymour, AE | 1 |
| Hrafnkelsson, J | 1 |
| Nilsson, K | 1 |
| Söderberg, M | 1 |
| Ohyanagi, H | 1 |
| Tagashira, Y | 1 |
| Kurogoh, F | 1 |
| Kawata, R | 1 |
| Shimokawa, K | 1 |
| Azuma, S | 1 |
| Furuta, T | 1 |
| Ohashi, H | 1 |
| Sakata, K | 1 |
| Fowble, B | 1 |
| Glick, J | 1 |
| Goodman, R | 1 |
| Peek, U | 1 |
| Kau, S | 1 |
| Marcus, C | 1 |
| Martin, RG | 2 |
| Buzdar, A | 2 |
| Montague, E | 2 |
| Powles, T | 2 |
| Panduro, J | 1 |
| Büyükünal, E | 1 |
| Derman, U | 1 |
| Serdengecti, S | 1 |
| Berkarda, B | 1 |
| Sugimasa, Y | 2 |
| Okamoto, T | 2 |
| Iimori, K | 2 |
| Murakami, K | 2 |
| Iwasa, Z | 1 |
| Matsunami, N | 1 |
| Saeki, Y | 1 |
| Kurooka, K | 1 |
| Yamato, M | 1 |
| Okuno, K | 1 |
| Sagara, N | 1 |
| Mizusawa, H | 1 |
| Trakhtenberg, AKh | 1 |
| Zakharchenkov, AV | 1 |
| Zhiglov, MA | 1 |
| Glagolev, AN | 1 |
| Kovalev, VN | 1 |
| Amiraliev, MA | 1 |
| Barchuk, AS | 1 |
| Malay, EF | 1 |
| Vidyak, IV | 1 |
| Grigoryeva, SP | 1 |
| Kies, MS | 1 |
| Rosen, ST | 1 |
| Tsang, TK | 1 |
| Shetty, R | 1 |
| Schneider, PA | 1 |
| Wallemark, CB | 1 |
| Shields, TW | 1 |
| Kolarić, K | 1 |
| Potrebica, V | 1 |
| Stanovnik, M | 1 |
| Zucali, R | 1 |
| Luini, A | 1 |
| Gianola, FJ | 1 |
| Barofsky, I | 1 |
| Hancock, SL | 1 |
| Wesley, R | 1 |
| Giuliano, AE | 1 |
| Patterson, K | 1 |
| Spears, I | 1 |
| Reizenstein, P | 1 |
| Appelqvist, P | 1 |
| Salmo, M | 1 |
| Leivonen, M | 1 |
| Kalima, T | 1 |
| Saario, I | 1 |
| Tolppanen, EM | 1 |
| Dmitrieva, NV | 1 |
| Vyshinskaia, GV | 3 |
| Lichintser, MR | 1 |
| Schwartz, GF | 1 |
| Cantor, RI | 1 |
| Biermann, WA | 1 |
| Bassalyk, LS | 1 |
| Vasil'ev, SA | 1 |
| Gromova, NV | 1 |
| Nadezhdina, TM | 1 |
| Ekberg, H | 1 |
| Tranberg, KG | 1 |
| Lundstedt, C | 1 |
| Hanff, G | 1 |
| Ranstam, J | 1 |
| Jeppsson, B | 1 |
| Bengmark, S | 1 |
| Jakse, R | 2 |
| Scherlacher, A | 2 |
| Lehnert, M | 2 |
| Haas, J | 1 |
| Michel, U | 1 |
| Schwarz, R | 1 |
| Montague, ED | 2 |
| Oswald, MJ | 1 |
| Sauer, HJ | 1 |
| Wilmanns, W | 1 |
| Gritsaĭ, AA | 1 |
| Lichinitser, MR | 1 |
| Kondrat'eva, AP | 1 |
| Aplevich, NN | 1 |
| Thyss, A | 1 |
| Schneider, M | 1 |
| Santini, J | 1 |
| Caldani, C | 1 |
| Vallicioni, J | 1 |
| Chauvel, P | 1 |
| Demard, F | 1 |
| Okamoto, Y | 1 |
| Hanazawa, S | 1 |
| Huntington, MO | 1 |
| Ozzello, F | 1 |
| Pedani, F | 1 |
| Camoletto, D | 1 |
| Sauerwein, W | 1 |
| Rehwald, U | 1 |
| Lapukins, Z | 1 |
| Scherer, E | 2 |
| Boidi Trotti, A | 1 |
| Lee, YT | 2 |
| Fastenberg, NA | 1 |
| Srodes, CH | 1 |
| Mayernik, DG | 1 |
| Sigler, BA | 1 |
| Schramm, VL | 1 |
| Nolan, TA | 1 |
| Kalish, LA | 1 |
| Cummings, F | 1 |
| Bennett, JM | 1 |
| Prorokov, VV | 1 |
| Ozhiganov, EL | 1 |
| Kojima, T | 1 |
| Hoshino, A | 1 |
| Kamiya, O | 1 |
| Nagata, K | 1 |
| Sugiura, I | 1 |
| Posada, JG | 1 |
| Marantz, AB | 1 |
| Yeung, KY | 1 |
| Smith, FP | 1 |
| Delgado, G | 1 |
| Edwards, BK | 1 |
| Schein, PS | 1 |
| Shank, B | 1 |
| Ryu, S | 1 |
| Ariga, T | 1 |
| Koh, Z | 1 |
| Odaka, M | 1 |
| Satoh, H | 1 |
| Fujimoto, S | 2 |
| Endoh, F | 1 |
| Shimura, T | 1 |
| Sugasawa, H | 1 |
| Takahashi, O | 1 |
| Kawata, S | 1 |
| Ohta, M | 1 |
| Udagawa, I | 1 |
| Okui, K | 1 |
| Shiba, E | 1 |
| Sasaki, Y | 1 |
| Wada, A | 1 |
| Greenall, MJ | 1 |
| Quan, SH | 1 |
| Urmacher, C | 1 |
| DeCosse, JJ | 1 |
| Moiseenko, VM | 1 |
| Rzhankov, SV | 1 |
| Kawaura, Y | 1 |
| Ohmura, K | 1 |
| Hashizume, Y | 1 |
| Sakatoku, M | 1 |
| Iwa, T | 1 |
| Stefanik, D | 1 |
| Goldberg, R | 1 |
| Byrne, P | 1 |
| Smith, F | 1 |
| Ueno, W | 1 |
| Smith, L | 1 |
| Bachenheimer, L | 1 |
| Beiser, C | 1 |
| Dritschilo, A | 1 |
| Hellriegel, W | 1 |
| Southwick, HW | 1 |
| Sievers, DB | 1 |
| Donovan, AJ | 1 |
| Costanza, ME | 1 |
| Dayal, Y | 1 |
| Binder, S | 1 |
| Nathanson, L | 1 |
| Mackman, S | 3 |
| Wise, L | 1 |
| Vikmanis, UE | 1 |
| Sviatukhina, OV | 1 |
| Lun'kova, EF | 1 |
| Oberfield, RA | 1 |
| Komatsu, K | 1 |
| Hiratsuka, H | 1 |
| Kamisasa, A | 1 |
| Inaba, Y | 1 |
| Moskalik, KG | 1 |
| Kozlov, AP | 1 |
| Akimov, AA | 1 |
| Linder, GT | 1 |
| Crook, JN | 1 |
| Cohn, I | 1 |
| Gnatyshak, AI | 1 |
| Ramirez, G | 2 |
| Knock, FE | 1 |
| Galt, RM | 1 |
| Oester, YT | 1 |
| Sylvester, R | 1 |
| Goepfert, H | 1 |
| Jesse, RH | 1 |
| Lindberg, RD | 1 |
| Hsu, CT | 1 |
| Cheng, YS | 1 |
| Su, SC | 1 |
| Sasatomi, N | 1 |
| Kumaoka, S | 1 |
| Takeda, H | 1 |
| Mizuno, M | 1 |
| Dean, RE | 1 |
| Taylor, ES | 1 |
| Weisbrod, DM | 1 |
| Martin, JW | 1 |
| Nitze, HR | 1 |
| Ganzer, U | 1 |
| Vosteen, KH | 1 |
| Ravdin, RG | 1 |
| Ausman, RK | 1 |
| Moore, GE | 1 |
| Noer, RJ | 1 |
| Blumenson, LE | 1 |
| Rassow, J | 1 |
| Karev, NI | 1 |
| Blokhina, NG | 1 |
| Vozny, EK | 1 |
| Pershin, MP | 1 |
| Nakao, I | 1 |
| Furue, H | 1 |
| Kanko, T | 1 |
| Harashima, S | 1 |
| Hillemand, P | 1 |
| Roux, M | 1 |
| Muller, JM | 1 |
| Bernard, HJ | 1 |
| Delavierre, P | 1 |
| Zeligman, I | 1 |
| Lutzner, MA | 1 |
| Scott, CI | 1 |
| Sheehe, PR | 1 |
| Graham, S | 1 |
| Deemarsky, LY | 1 |
| Chernomordikova, MF | 1 |
| Milonov, BV | 1 |
| Kosarev, VA | 1 |
| Nikiforov, AM | 1 |
| Horsley, JS | 1 |
| Rowe, DS | 1 |
| Bryan, GT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colore[NCT00819780] | Phase 2 | 285 participants (Actual) | Interventional | 2009-04-24 | Completed | ||
| A Single Arm Multicentre Phase II Study of Panitumumab in Combination With Irinotecan/5-fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer[NCT00508404] | Phase 2 | 154 participants (Actual) | Interventional | 2007-05-09 | Completed | ||
| A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Oxaliplatin/ 5-fluorouracil/ Leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ Leucovorin Alone in Patients With Previously Untreated Metastatic C[NCT00364013] | Phase 3 | 1,183 participants (Actual) | Interventional | 2006-08-01 | Completed | ||
| High-dose Chemotherapy With Hematopoietic Stem-cell Rescue for High-risk Breast Cancer: Long-term Follow-up of a Randomized Phase III Study[NCT03087409] | 885 participants (Actual) | Observational | 2016-07-31 | Completed | |||
| Spartalizumab, mDCF (Docetaxel, Cisplatin and 5-fluorouracil) and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma. A Phase IIA Study[NCT04894370] | Phase 2 | 34 participants (Anticipated) | Interventional | 2022-06-09 | Recruiting | ||
| A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma[NCT03519295] | Phase 2 | 99 participants (Anticipated) | Interventional | 2018-07-22 | Active, not recruiting | ||
| A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study[NCT02826486] | Phase 2 | 80 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Survival Rate and Treatment Cost in Patients With Pancreatic Cancer With the Advent of New Chemotherapeutic Agents in Korea: An Analysis Using NHIS Database and K-PaC Registry Focusing on the Newest One, Liposomal Irinotecan[NCT04984174] | 54,000 participants (Anticipated) | Observational | 2021-08-04 | Recruiting | |||
| MAgnetic Resonance Imaging Guided LAteral Lymph Node Dissection in Lower REctal Cancer - A Multicenter, Prospective, Registry Study (MALAREC)[NCT04850027] | 268 participants (Anticipated) | Observational [Patient Registry] | 2021-01-01 | Recruiting | |||
| A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined With Sintilimab in Gastric Cancer With Peritoneal Metastasis[NCT05648487] | Phase 2 | 46 participants (Anticipated) | Interventional | 2023-01-01 | Not yet recruiting | ||
| Clinical Study of CT and MR in Staging and Prediction of Response in Patients With Gastric Cancer[NCT04028375] | 400 participants (Anticipated) | Observational | 2019-09-01 | Recruiting | |||
| A Prospective Multicenter Study With 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction[NCT00849615] | Phase 2 | 252 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Radiotherapy, Chemotherapy and Anti-PD-1 Immunotherapy Followed by Surgical Resection in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Prospective, Single Arm, Phase II Trial[NCT06121700] | Phase 2 | 55 participants (Anticipated) | Interventional | 2023-01-01 | Recruiting | ||
| Adjuvant Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) During Laparoscopic Resection in High-risk Gastric Cancer Patients: A Multicentre Phase-I Study (the PIPAC-OPC4 Study)[NCT04047004] | Phase 1 | 20 participants (Actual) | Interventional | 2020-03-11 | Completed | ||
| Prospective Randomized Controlled Trial of Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy[NCT03734952] | 537 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | |||
| A Randomised Pilot Study of Neoadjuvant Everolimus Plus Letrozole Compared With FEC in Postmenopausal Patients With ER-positive, HER2-negative Breast Cancer[NCT02742051] | Phase 2 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| A Phase II Study of Efficacy and Safety of Induction Modified TPF (mTPF) Followed by Concurrent Chemoradiotherapy (CCRT) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LASCCHN)[NCT05527782] | Phase 2 | 40 participants (Anticipated) | Interventional | 2019-05-01 | Recruiting | ||
| Steam (Sequencing Triplet With Avastin and Maintenance): FOLFOXIRI/Bevacizumab Regimens (Concurrent and Sequential) vs. FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer[NCT01765582] | Phase 2 | 280 participants (Actual) | Interventional | 2013-01-23 | Terminated | ||
| Phase II Trial of CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer[NCT01191697] | Phase 2 | 37 participants (Actual) | Interventional | 2011-02-28 | Active, not recruiting | ||
| 5-Fluorouracil/Folinate/Oxaliplatin (Eloxatin) (FLOX Regimen), Given Continuously or Intermittently, in Combination With Cetuximab (Erbitux), in First-line Treatment of Metastatic Colorectal Cancer. A Phase III Multicenter Trial.[NCT00145314] | Phase 3 | 571 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| The Effect of Postoperative Supplemental Parenteral Nutrition (SPN) in Gastric Cancer Patients Who Underwent Gastrectomy: A Multicenter Prospective Randomized Controlled Trial[NCT04607057] | Phase 4 | 224 participants (Anticipated) | Interventional | 2020-12-22 | Recruiting | ||
| Prospective Clinical Trial to Assess a Mini-invasive Pre-surgical Procedure to Detect Residual Breast or Axillary Disease in Patients With cT1-T2-T3 cN0/N1 Breast Cancer in Complete Clinical/Radiological Remission After Primary Chemotherapy[NCT05951699] | 105 participants (Anticipated) | Observational | 2022-04-28 | Recruiting | |||
| A Phase II, Randomised Study of Nivolumab as Consolidation Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent C[NCT04085250] | Phase 2 | 264 participants (Actual) | Interventional | 2019-11-28 | Active, not recruiting | ||
| A Phase II Exploratory, Open-label, Single Arm Study of BYL719 Monotherapy, a Selective Phosphatidylinositol 3-kinase (PI3K) Alpha Inhibitor, in Adult Patients With Advanced Breast Cancer Progressing After First Line Therapy.[NCT02506556] | Phase 2 | 38 participants (Actual) | Interventional | 2015-09-07 | Completed | ||
| Age, Body Mass Index and Tumor Sidedness in Metastatic Colorectal Cancer Patients as Predictive Factors for Systemic Therapy Outcome[NCT04543019] | 50 participants (Anticipated) | Observational | 2020-12-31 | Not yet recruiting | |||
| Assessment of the Clinical Value of a Docetaxel, Cisplatin and 5-fluorouracil (DCF) Strategy Adapted to Patients for the Management of Metastatic or Locally Advanced Anal Resistant Radiochemotherapy Squamous Cell Anal Carcinoma.[NCT02402842] | Phase 2 | 70 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review[NCT05931042] | 1,209 participants (Actual) | Observational | 2023-06-01 | Completed | |||
| A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed by Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients With HER-2 Positive Operable Breast Ca[NCT00513292] | Phase 3 | 280 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Prospective Assessment of Disease Progression in Primary Breast Cancer Patients Undergoing EndoPredict® Gene Expression Testing - a Care Research Study[NCT03503799] | 1,191 participants (Actual) | Observational [Patient Registry] | 2018-07-17 | Active, not recruiting | |||
| Phase III Study to Compare 6 Courses of FEC (Fluorouracil, Epirubicin and Cyclophosphamide) vs. 4 Courses of FEC Followed by 8 Weekly Paclitaxel Administrations, as Adjuvant Treatment for Node Positive Operable BC Patients[NCT00129922] | Phase 3 | 1,289 participants (Actual) | Interventional | 1999-11-30 | Completed | ||
| Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With Intensity-modulated Radiotherapy in High Risk Locregionally Advanced Nasopharyngeal Carcinoma: a Phase 2 Randomized Controlled Trial[NCT02610556] | Phase 2 | 130 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Efficacy and Safety of Dose-dense Epirubicin and Cyclophosphamide Plus Paclitaxel as Neoadjuvant Chemotherapy for HER2-negative Early Breast Cancer：a Multicenter Randomized Controlled Trial[NCT04576143] | Phase 2/Phase 3 | 260 participants (Anticipated) | Interventional | 2020-09-20 | Recruiting | ||
| A Phase III Randomized Study of EC Followed by Paclitaxel Versus FEC Followed by Paclitaxel, All Given Either Every 3 Weeks or 2 Weeks Supported by Pegfilgrastim, for Node Positive Breast Cancer Patients[NCT00433420] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 2003-04-30 | Active, not recruiting | ||
| A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI With Either Panitumumab or Bevacizumab as Second-Line Treatment in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Tumors[NCT00418938] | Phase 2 | 266 participants (Actual) | Interventional | 2006-11-01 | Completed | ||
| Phase III Trial to Compare Epirubicin and Cyclophosphamide (EC) Followed by Docetaxel (T) to Epirubicin and Docetaxel (ET) Followed by Capecitabine (X) as Adjuvant Treatment, Node Positive Breast Cancer Patients[NCT00129935] | Phase 3 | 1,384 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Randomized, Controlled Clinical Trial (HCHTOG1903)[NCT04138212] | Phase 3 | 456 participants (Anticipated) | Interventional | 2019-10-22 | Recruiting | ||
| Adjuvant Treatment of Cancer of the Esophagus or Cardia Before Resection With Curative Intent. Comparative Study Between Chemotherapy and Radiochemotherapy[NCT01362127] | Phase 2 | 181 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Adjuvant Chemotherapy of Breast Cancer: Sequential Chemotherapy vs. Standard Therapy. Prospective Randomised Comparison of 4 x Epirubicin and Cyclophosphamide (EC) --> 4 x Docetaxel (Doc) vs. 6 x CMF / CEF in Patients With 1 to 3 Positive Lymph Nodes[NCT02115204] | Phase 3 | 2,011 participants (Actual) | Interventional | 2000-06-30 | Completed | ||
| Phase II Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer[NCT01523457] | Phase 2 | 75 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Pilot Study in Gastric Cancer of Assignment to Postoperative Chemoradiation or Chemotherapy Based Upon Surgical Lymph Node Assessment After Preoperative Chemotherapy, With Gene Assay as Correlate of Biologic Response[NCT03515941] | Early Phase 1 | 6 participants (Actual) | Interventional | 2018-06-22 | Terminated (stopped due to The PI has decided to close the study due to the outdated study design.) | ||
| A Multicenter Randomized Study Comparing the Dose Dense, G-CSF-supported Sequential Administration of FE75C Followed by Docetaxel Versus Docetaxel/Cyclophosphamide Doublet as Adjuvant Chemotherapy in Women With HER-2 Negative, Axillary Lymph Node Positive[NCT01985724] | Phase 3 | 650 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| A Randomized Study of the Efficacy and Safety of OncoGel™ Treatment as an Adjunctive Therapy to Systemic Chemotherapy and Concurrent External Beam Radiation Prior to Surgery in Subjects With Localized or Loco-regional Esophageal Cancer[NCT00573131] | Phase 2 | 137 participants (Actual) | Interventional | 2008-01-31 | Terminated (stopped due to OncoGel did not show any impact on overall tumor response) | ||
| Chemotherapy-based Split Stereotactic Body Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: Study Protocol of a Prospective, Single-arm Phase II Trial[NCT04289792] | Phase 2 | 27 participants (Anticipated) | Interventional | 2020-05-09 | Recruiting | ||
| Concurrent Radiotherapy and Weekly Chemotherapy of 5-fluorouracil and Cisplatin for Postoperative Locoregional Recurrence of Oesophageal Squamous Cell Carcinoma[NCT02325986] | Phase 2 | 46 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
| Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma: a Multicenter, Randomised, Phase 3 Study.[NCT02460419] | Phase 3 | 104 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Comparison of Efficacy and Tolerance Between Combination Therapy and Monotherapy as a First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer; Multicenter Randomized Phase 3 Study[NCT02114359] | Phase 3 | 111 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)[NCT01917552] | Phase 3 | 870 participants (Anticipated) | Interventional | 2013-08-19 | Recruiting | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Prospective Study to Analyze the Predictive Role of Factors Implicated in the Signaling Pathway of ERCC1 in Response to Treatment With Neoadjuvant Radiochemotherapy in Patients With Esophageal Cancer[NCT00953511] | 80 participants (Actual) | Interventional | 2009-08-31 | Completed | |||
| Adjuvant Therapy for Post/Perimenopausal Patients With Node Positive Breast Cancer Who Are Suitable for Endocrine Therapy Alone.[NCT00002529] | Phase 3 | 452 participants (Actual) | Interventional | 1993-05-31 | Completed | ||
| Phase II Study of Trastuzumab (Herceptin) and Capecitabine (Xeloda) in Women With Taxanes and Anthracyclines Refractory Metastatic Breast Cancer and HER2 Over-Expression[NCT00107393] | Phase 2 | 75 participants (Anticipated) | Interventional | 2003-06-30 | Completed | ||
| A Randomized Controlled Study of Postoperative Adjuvant Therapy of UFT Compared With CMF in High-risk Women With Axillary Node-negative Breast Cancer (NSAS-BC)[NCT00152191] | Phase 3 | 1,300 participants (Anticipated) | Interventional | 1996-10-31 | Completed | ||
| [NCT01849107] | 49 participants (Actual) | Interventional | 2013-04-30 | Completed | |||
| A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639] | Phase 2 | 8 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.) | ||
| Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) as First-line Treatment for Metastatic Colorectal Cancer[NCT01219920] | Phase 3 | 244 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer[NCT00100815] | Phase 2 | 50 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)[NCT00152178] | Phase 3 | 680 participants (Anticipated) | Interventional | 1996-07-31 | Completed | ||
| A Pilot Study to Test the Feasibility of the Combination of Gemcitabine and Anti-PD1 Monoclonal Antibody (CT-011) in the Treatment of Resected Pancreatic Cancer[NCT01313416] | Phase 2 | 2 participants (Actual) | Interventional | 2012-09-30 | Terminated (stopped due to Drug supply issues) | ||
| Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC II-IV, With a 5-FU-based Standard Radiochemotherapy Followed by Total Mesorectal Excision.[NCT03034473] | 200 participants (Actual) | Interventional | 2011-08-31 | Active, not recruiting | |||
| Randomized And Multicentric Opened Phase III Study Evaluating The Concomitant Administration Of Docetaxel 75MG/M2 and Epirubicine 75MG/M2 Versus FEC 100 In Non Metastatic With Positive Lymphatic Nodes Breast Cancer Subjects, And The Sequential Addition Of[NCT00054587] | Phase 3 | 3,010 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Induction Chemotherapy, Preoperative Radiochemotherapy, Consolidation Chemotherapy, Operation and Adjuvant Chemotherapy in the Treatment of Locally Advanced Rectal Cancer- OIGIT 5-01 Phase II Trial[NCT01489332] | Phase 2 | 60 participants (Anticipated) | Interventional | 2011-10-31 | Recruiting | ||
| Maintenance of Chemotherapy Following Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer[NCT01613469] | Phase 2 | 5 participants (Actual) | Interventional | 2011-08-31 | Terminated (stopped due to Re-eval of patient population) | ||
| A Randomized Phase II Study of Capecitabine and Cisplatin (XP) +/- Sorafenib (Nexavar®) in Patients With Advanced Gastric Cancer[NCT01187212] | Phase 2 | 195 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Phase III Comparison of Adjuvant Chemoendocrine Therapy With CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients With Involved Axillary Lymph Nodes and Positive Receptors[NCT00929591] | Phase 3 | 1,558 participants (Actual) | Interventional | 1989-05-31 | Completed | ||
| Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck[NCT00122460] | Phase 3 | 442 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| A Randomized Phase II Study of Modified FOLFOX6 (Infusional 5-Fluorouracil/Leucovorin, Oxaliplatin) and Bevacizumab With or Without Cetuximab in Patients With Metastatic Colorectal Cancer[NCT00193219] | Phase 2 | 36 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| A Randomized, Open-label, Multicenter Trial of the Chemoradiation Versus Standard Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Cancer in Chinese Patients[NCT02972372] | 196 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | |||
| Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer[NCT02607540] | Phase 3 | 210 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial[NCT02604615] | Phase 3 | 60 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| [NCT02603159] | Phase 3 | 200 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer[NCT02025036] | Phase 3 | 249 participants (Actual) | Interventional | 2014-10-31 | Active, not recruiting | ||
| Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy[NCT02644408] | Phase 3 | 184 participants (Actual) | Interventional | 2014-10-01 | Completed | ||
| A Randomized Non-inferiority Trial of Radiotherapy Plus Nimotuzumab or Cisplatin in Patients With Favorable Response to Induction Chemotherapy for Low-risk Locoregionally Advanced-Staged Nasopharyngeal Carcinoma[NCT04456322] | Phase 3 | 326 participants (Anticipated) | Interventional | 2020-07-06 | Recruiting | ||
| Randomized Phase II Trial of Concurrent Chemoradiotherapy With or Without Nimotuzumab for High Risk Nasopharyngeal Carcinoma After Induction Chemotherapy[NCT04223024] | Phase 2 | 246 participants (Actual) | Interventional | 2019-12-12 | Active, not recruiting | ||
| Randomized Multicenter Study Comparing 6xFEC With 3xFEC-3xDoc in High-risk Node-negative Patients With Operable Breast Cancer: Comparison of Efficacy and Evaluation of Clinico-pathological and Biochemical Markers as Risk Selection Criteria[NCT01222052] | Phase 3 | 4,150 participants (Actual) | Interventional | 2002-01-31 | Active, not recruiting | ||
| A Phase II Study of 5-Fluorouracil, Bevacizumab (Avastin), and Radiation in the Preoperative or Adjuvant Treatment of Patients With Stage II / III Rectal Cancer[NCT00308516] | Phase 2 | 66 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Efficacy and Safety of Supplement Adjuvant Capecitabine in Postoperative Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative High-risk Breast Cancer Patients: a Multicenter, Single-arm Clinical Trial[NCT05212454] | Phase 3 | 400 participants (Anticipated) | Interventional | 2023-03-15 | Recruiting | ||
| A Phase II Study of Neoadjuvant Chemotherapy With Modified FOLFOX6 Regimen and Effects of Tumor Regression in Locally Advanced Gastric Cancer[NCT02226380] | Phase 2 | 75 participants (Anticipated) | Interventional | 2013-10-31 | Recruiting | ||
| The Effect of ATP-Binding Cassette C2 (ABCC2) Transporter Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin -Based Chemotherapy[NCT05494320] | 120 participants (Anticipated) | Observational | 2021-08-15 | Recruiting | |||
| Study of the Modifications of the Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative Breast Cancers[NCT04368468] | 100 participants (Actual) | Observational | 2020-06-15 | Completed | |||
| A Phase Ib/II Trial Evaluating the Efficacy of MK-3475 and Trastuzumab in Patients With Trastuzumab-resistant, HER2-positive Metastatic Breast Cancers[NCT02129556] | Phase 1/Phase 2 | 58 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| Phase Ib Study of Neoadjuvant DPX-Survivac, Aromatase Inhibition, and With/Without Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer[NCT04895761] | Phase 1 | 6 participants (Actual) | Interventional | 2021-09-10 | Active, not recruiting | ||
| Comparison of Hypnotherapy Versus Gabapentin in the Treatment of Hot Flashes in Breast Cancer Survivors or Women at Risk of Developing Breast Cancer.[NCT00711529] | Phase 3 | 27 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Randomized Trial to Evaluate Therapeutic Gain by Changing Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma[NCT00379262] | Phase 3 | 803 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer[NCT01291407] | Phase 1 | 27 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Long-term Results of Plasma Epstein-Barr Virus DNA Monitoring In Nasopharyngeal Carcinoma After Curative Treatment[NCT03973723] | 441 participants (Actual) | Observational | 2011-08-01 | Completed | |||
| A Prospective Randomized Feasibility and Phase II Adjuvant Breast Cancer Study of the Netherlands Working Party for Autotransplantation in Solid Tumors.[NCT00851110] | Phase 2 | 50 participants (Anticipated) | Interventional | 2004-10-31 | Terminated | ||
| Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity in Women With Breast Cancer in China[NCT02518191] | Phase 3 | 345 participants (Actual) | Interventional | 2015-09-01 | Completed | ||
| The Effects of Exercise Training on Tumor Vascularity and Response to Neoadjuvant Therapy in Operable Breast Cancer: A Phase I-II Study[NCT00405678] | Phase 1/Phase 2 | 23 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer[NCT01045538] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas[NCT00447330] | Phase 2 | 60 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| OPTimizing Irradiation Through Molecular Assessment of Lymph Node (OPTIMAL)[NCT02335957] | 489 participants (Actual) | Interventional | 2015-04-30 | Completed | |||
| Intensity Modulated Radiation Therapy for Breast Cancer: A Phase I Feasibility Study[NCT00594477] | Phase 1 | 100 participants (Actual) | Interventional | 2008-01-04 | Completed | ||
| A Multi-Center, Randomized Study of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Neoadjuvant Treatment of Triple-Negative or Her2 Positive Breast Cancer[NCT00912444] | Phase 3 | 102 participants (Actual) | Interventional | 2009-07-31 | Terminated (stopped due to TAC treatment was associated with better survial outcome compared with TC treatment, we terminated recruiting and waiting for longer follow up period.) | ||
| A Chinese Multi-Center,Randomized Study of Combination or Sequential Use of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy for Node Positive Breast Cancer[NCT00525642] | Phase 2/Phase 3 | 603 participants (Actual) | Interventional | 2003-06-30 | Active, not recruiting | ||
| A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide (TAC) Versus 5-fluorouracil in Combination With Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of Operable Breast Cancer Patien[NCT00688740] | Phase 3 | 1,491 participants (Actual) | Interventional | 1997-06-30 | Completed | ||
| Adjuvant Dose-dense Sequential Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer: A Hellenic Cooperative Oncology Group (HeCOG) Study[NCT04829890] | 89 participants (Actual) | Observational | 2004-02-29 | Completed | |||
| Phase III Randomized Comparing Docetaxel, Doxorubicin and Cyclophosphamide (TAC) vs 5-Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of High Risk Operable Breast Cancer Patients With Negative Axillary Lymph Nodes[NCT00121992] | Phase 3 | 1,060 participants (Actual) | Interventional | 1999-07-31 | Completed | ||
| RecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast Cancer[NCT04069884] | 540 participants (Anticipated) | Interventional | 2019-08-20 | Recruiting | |||
| LA LEAST- Luminal A, Limited Endocrine Adjuvant Systemic Therapy. A Trial of Abbreviated Hormone Therapy for Low Risk Hormone Receptor Positive, HER2 Negative Early Breast Cancer[NCT03917082] | Phase 2 | 290 participants (Anticipated) | Interventional | 2019-09-23 | Active, not recruiting | ||
| Effect Study of Clinical Outcomes of Traditional Chinese Medicine to Advanced Gastric Cancer by Propensity Score Through Registration[NCT02781285] | 1,500 participants (Anticipated) | Observational [Patient Registry] | 2014-12-31 | Recruiting | |||
| Effect of Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: Clinical Outcome and Correlation to Biological Parameters[NCT01167192] | Phase 2 | 10 participants (Actual) | Interventional | 2011-02-28 | Terminated | ||
| Effect of Neoadjuvant Cisplatin Based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: Clinical Outcome and Correlation to Biological Parameters[NCT00603408] | Phase 2 | 5 participants (Actual) | Interventional | 2007-12-31 | Terminated (stopped due to Study was discontinued due to lack of accrual.) | ||
| A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer[NCT01642771] | Phase 3 | 636 participants (Anticipated) | Interventional | 2012-06-30 | Active, not recruiting | ||
| Phase I/II Trial of Capecitabine With Weekly Paclitaxel for Advanced Breast Cancer[NCT00031876] | Phase 1/Phase 2 | 34 participants (Actual) | Interventional | 2000-05-31 | Completed | ||
| Tailored Neoadjuvant Epirubicin and Cyclophosphamide (EC) and Nanoparticle Albumin Bound (Nab) Paclitaxel for Newly Diagnosed Breast Cancer[NCT01830244] | Phase 2 | 60 participants (Anticipated) | Interventional | 2013-04-30 | Active, not recruiting | ||
| Prospective, Randomised and Multi-centric Therapy Optimisation Study for Examining the Influence of Surgical Staging on the Oncological Results for Patients With Cervix Carcinoma of the FIGO Stages IIB-IV After Chemoradiation[NCT01049100] | 250 participants (Anticipated) | Interventional | 2009-04-30 | Recruiting | |||
| A Phase II Study of Docetaxel and Epirubicin Combination in Patients With Advanced Gastric Cancer.[NCT00375999] | Phase 2 | 34 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Clinical Trial Of Safety Of Robot-assisted Thoracic Approach Verus Open Transthoracic Esophagectomy in Esophageal Cancer.[NCT04652180] | 108 participants (Anticipated) | Interventional | 2020-11-06 | Recruiting | |||
| A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer[NCT00001498] | Phase 2 | 55 participants | Interventional | 1996-02-29 | Completed | ||
| Evaluation of the Technique of Axillary Sentinel Lymph Node (SLN) Detection in Breast Cancers > 2 cm[NCT00636467] | Phase 2 | 249 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| A Phase II Trial of Gemcitabine, Herceptin, and Radiation for Regionally Confined Adenocarcinoma of the Pancreas[NCT00005926] | Phase 2 | 50 participants | Interventional | 2000-06-30 | Completed | ||
| Phase II Trial of Neoadjuvant Chemotherapy for HPV-Associated Squamous Cell Carcinoma of the Oropharynx Followed by Reduced Dose Radiotherapy/Chemoradiotherapy for Responders or Standard Dose Chemoradiotherapy for Non-Responders[NCT01525927] | Phase 2 | 2 participants (Actual) | Interventional | 2010-08-31 | Terminated (stopped due to Principal Investigator left institution. IRB approval lapsed.) | ||
| First Line Infusional 5-Fluorouracil, Folinic Acid and Oxaliplatin for Metastatic Colorectal Cancer or Loco-Regional Recurrency - Role of Chronomodulated Delivery Upon Survival - A Multicenter Randomized Phase III Trial[NCT00003287] | Phase 3 | 554 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
| Proton Therapy for Peripheral Lymph Nodes in Breast Cancer[NCT01365845] | 18 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| Phase I Trial of Dose Escalated IMRT to the Para-aortic Nodes With Concurrent Cisplatin and Amifostine in Locally Advanced Cervical Cancer[NCT00137358] | Phase 1 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to unable to obtain funding to conduct study) | |||
| Phase III Study Comparing Neoadjuvant Chemotherapy With Carboplatin and Paclitaxel Followed by Standard Therapy, With Standard Therapy Alone in Women With Cervical Cancer and Para Aortic Positive Lymph Node.[NCT03534713] | Phase 3 | 310 participants (Anticipated) | Interventional | 2020-07-17 | Recruiting | ||
| A Randomized Comparison of Radiation vs Radiation Plus Weekly Cisplatin vs Radiation Plus PVI (Protracted Venous Infusion) 5-FU in Patients With Stage II-B, III-B, and IV-A Carcinoma of the Cervix With Negative Paraaortic Nodes[NCT00003078] | Phase 3 | 870 participants (Anticipated) | Interventional | 1997-10-31 | Completed | ||
| A Clinical Outcomes Protocol of Photon/Proton Beam Radiation Therapy for Carcinoma of the Nasopharynx[NCT00797290] | 9 participants (Actual) | Observational | 2008-06-30 | Terminated (stopped due to Slow enrollment, Feasibility issues) | |||
| Phase II Randomized Controlled Trial of Concomitant Chemoradiotherapy With Standard Fractionation Compared to Hypofractionated Concomitant Chemoradiotherapy Followed by Brachytherapy, for Clinical Stage III Cervical Cancer Patients[NCT04070976] | 82 participants (Anticipated) | Interventional | 2019-07-01 | Recruiting | |||
| Prospective Study for the Validation of the Genetic Signature 354849 to Predict the Response to Standard Treatment in Patients With Locally Advanced Cervical Cancer[NCT04067882] | 189 participants (Anticipated) | Observational | 2019-09-30 | Recruiting | |||
| CRP on Radiobiological and Clinical Studies on Viral-induced Cancer's Response to Radiotherapy With Comprehensive Morbidity Assessment[NCT00122772] | Phase 3 | 601 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Phase II Trial of Weekly Carboplatin-Paclitaxel Adjuvant Chemotherapy After Intensity Modulated Extended-field Chemoradiation in the Treatment of Locally Advanced Cervical Cancer With Para-aortic Positive Nodes[NCT04016142] | Phase 2 | 21 participants (Actual) | Interventional | 2020-07-15 | Active, not recruiting | ||
| A Phase III Randomized Clinical Trial to Study the Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Uterine Cervix.[NCT03256916] | Phase 3 | 348 participants (Anticipated) | Interventional | 2018-01-16 | Recruiting | ||
| Phase II Trial To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix[NCT04789941] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | ||
| Safety and Efficacy of Gemcitabine Based Neoadjuvant Chemotherapy Followed by Chemoradiation in Locally Advanced Cervical Cancer Patients and Association With Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression[NCT02309658] | Phase 2 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Randomized Phase III Clinical Trial of Weekly Versus Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer[NCT01561586] | Phase 3 | 374 participants (Anticipated) | Interventional | 2012-03-31 | Recruiting | ||
| Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC)[NCT05660083] | Phase 2 | 36 participants (Anticipated) | Interventional | 2023-01-12 | Recruiting | ||
| Sentinel Node Biopsy Before and/or After Neoadjuvant Chemotherapy in Breast Cancer[NCT02031042] | 224 participants (Actual) | Observational | 2010-10-31 | Completed | |||
| Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma: a Phase II Randomized Controlled Trial[NCT02969473] | Phase 2 | 120 participants (Anticipated) | Interventional | 2010-10-31 | Active, not recruiting | ||
| Pharmacogenetic and Pharmacokinetic Aspects of the Response to Chemotherapy Induction Using Docetaxel, Cisplatin and 5-Fluorouracile (TPF)in ORL Cancers[NCT01104714] | 90 participants (Actual) | Observational | 2010-04-30 | Completed | |||
| Profiling Neutrophil Counts in Patients With Cancer During Cycle One of Chemotherapy[NCT02806557] | 200 participants (Anticipated) | Observational | 2016-09-30 | Not yet recruiting | |||
| A Randomized Trial With Factorial Design Comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in Metastatic Breast Cancer Progressing After Aromatase Inhibitor Therapy[NCT02394496] | Phase 3 | 396 participants (Anticipated) | Interventional | 2007-11-30 | Recruiting | ||
| Phase Ⅲ Study of Prophylactic Postoperative Intensity Modulated Radiation Therapy in Stage T2-3N0M0 Disease of Thoracic Esophageal Squamous Cell Carcinoma;[NCT01745107] | Phase 3 | 240 participants (Anticipated) | Interventional | 2012-10-31 | Active, not recruiting | ||
| Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| Quarterback 22: A Phase II Clinical Trial of Sequential Therapy and De-Intensified Chemoradiotherapy for Locally Advanced HPV Positive Oropharynx Cancer[NCT02945631] | 43 participants (Actual) | Interventional | 2016-04-25 | Active, not recruiting | |||
| The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer[NCT01706939] | Phase 3 | 23 participants (Actual) | Interventional | 2012-09-01 | Active, not recruiting | ||
| Phase I Study of Preoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients[NCT01584544] | Phase 1 | 24 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| KCSP Trial of cONsolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After neoadjUvant Concurrent chemoraDiothErapy: A Multicenter, Randomized Controlled Trial (KONCLUDE Trial)[NCT02843191] | Phase 3 | 358 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| Preoperative Induction Chemotherapy in Combination With Bevacizumab Followed by Combined Chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk of Recurrence- Phase II Pilot Study With Preoperative Administration of Capecitabine (Xeloda), Oxal[NCT01434147] | Phase 2 | 25 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer[NCT00001338] | Phase 3 | 65 participants | Interventional | 1993-06-30 | Completed | ||
| Phase 1 Study of Postoperative Capecitabine With Concurrent Radiation in Elderly With Stage II/III Rectal Cancer[NCT01268943] | Phase 1 | 18 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Prospective Randomized Phase III Study of Concurrent Capecitabine and Radiotherapy With or Without Oxaliplatin as Adjuvant Treatment for Stage II and III Rectal Cancer[NCT00714077] | 570 participants (Anticipated) | Observational | 2008-04-30 | Recruiting | |||
| Evaluation of Eating Habits and Dysgeusia During Chemotherapy Treatment: a Prospective Cohort Study on Patients Affected by Breast Cancer[NCT03210441] | 204 participants (Anticipated) | Observational | 2014-05-06 | Recruiting | |||
| A Phase II Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis[NCT03114254] | Phase 2 | 17 participants (Actual) | Interventional | 2014-12-05 | Completed | ||
| Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC): an Open-label, Single-center, Phase 2, Single-arm Trial (CaboPen)[NCT03943602] | Phase 2 | 37 participants (Anticipated) | Interventional | 2019-08-01 | Recruiting | ||
| Effect of Short-duration Preoperative Neoadjuvant Therapy With FOLFOX Based Therapy on Morbidity After Liver Resection for Colorectal Cancer Metastases[NCT00537823] | Phase 2 | 9 participants (Actual) | Interventional | 2007-06-30 | Terminated (stopped due to Poor accrual.) | ||
| Prospective, Randomized Study Aiming to Assess the Benefit of Autohypnosis Learning in the Care of Patients Treated by Adjuvant Chemotherapy for Colorectal or Breast Cancer.[NCT03429296] | 120 participants (Actual) | Interventional | 2018-05-23 | Completed | |||
| Primary Chemotherapy Combined With Perioperative Chemotherapy In Operable Breast Cancer[NCT00301548] | Phase 2 | 172 participants | Interventional | 2000-02-29 | Completed | ||
| Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients Undergoing Adjuvant Chemotherapy: An Open Label, Randomised, Multi-Centre, Phase IIIb Study[NCT00888082] | Phase 3 | 102 participants (Anticipated) | Interventional | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For participants with a confirmed objective response, the time from first confirmed objective response to radiologic disease progression per modified RECIST 1.0 criteria or death. For participants who responded and have not progressed or died, duration of response was censored at their last evaluable disease assessment date. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 10.0 |
| Bevacizumab Plus mFOLFOX6 | 9.0 |
Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | NA |
| Bevacizumab Plus mFOLFOX6 | 25.4 |
Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | NA |
| Bevacizumab Plus mFOLFOX6 | 29.0 |
Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | NA |
| Bevacizumab Plus mFOLFOX6 | 29.0 |
Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 57.75 |
| Bevacizumab Plus mFOLFOX6 | 53.52 |
"Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met.~Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions." (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 63.64 |
| Bevacizumab Plus mFOLFOX6 | 60.49 |
Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 63.64 |
| Bevacizumab Plus mFOLFOX6 | 61.54 |
PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 10.9 |
| Bevacizumab Plus mFOLFOX6 | 10.1 |
PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 13.1 |
| Bevacizumab Plus mFOLFOX6 | 9.7 |
PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 13.0 |
| Bevacizumab Plus mFOLFOX6 | 9.5 |
The resection rate was defined as the percentage of participants with a surgical procedure that resulted in partial reduction or complete eradication of all metastatic disease. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 12.68 |
| Bevacizumab Plus mFOLFOX6 | 11.19 |
Time to progression (TTP) is defined as the time from randomization to the date of radiologic disease progression per modified RECIST 1.0 criteria. Participants not meeting criteria for disease progression by the analysis data cutoff date were censored at their last evaluable disease assessment date. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 11.0 |
| Bevacizumab Plus mFOLFOX6 | 11.1 |
For participants with a confirmed objective response, the time from randomization to the date of first confirmed objective response. Assessments are based on the investigator's review of scans using a modified-RECIST v1.0. An objective response is defined as a best tumor response of complete or partial response. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 1.8 |
| Bevacizumab Plus mFOLFOX6 | 1.9 |
Severity was graded using Common Terminology Criteria for Adverse Events (CTCAE) v3.0, with the exception of some dermatology/skin adverse events that were graded using CTCAE v3.0 with modifications. Fatal adverse events are classified as grade 5. Serious adverse events include any event that is fatal, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or other significant medical hazard. Treatment-related AEs were those that the investigator considered a reasonable possibility that might have been caused by study drug. (NCT00819780)
Timeframe: The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus mFOLFOX arm and 7.3 months for Bevacizumab Plus mFOLFOX6 arm.
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any adverse event (AE) | AE with worst grade of 3 | AE with worst grade of 4 | AE with worst grade of 5 | Serious adverse event (SAE) | AE leading to discontinuation of study drug | Any treatment-related adverse event (TRAE) | Treatment-related AE with worst grade of 3 | Treatment-related AE with worst grade of 4 | Treatment-related AE with worst grade of 5 | Serious treatment-related adverse event | TRAE leading to discontinuation of study drug | |
| Bevacizumab Plus mFOLFOX6 | 139 | 78 | 28 | 9 | 53 | 37 | 136 | 77 | 25 | 2 | 28 | 29 |
| Panitumumab Plus mFOLFOX6 | 139 | 88 | 31 | 7 | 61 | 34 | 138 | 92 | 24 | 3 | 37 | 28 |
"The percentage of participants whose best response was either a complete or partial response or stable disease, based on modified RECIST v1.0 criteria as assessed by the Investigator.~Stable diease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD of target lesions and no progression of existing non-target lesions and no new lesions, or, the persistence of 1 or more non-target lesions not qualifying for either CR or PD if no target lesions were identified at Baseline." (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS | 90.59 |
| Mutant KRAS | 89.66 |
Duration of response was calculated only for those participants who had a confirmed complete or partial response, and is defined as the time from first confirmed response to first observed progression. For participants who responded and did not progress by the analysis data cut-off date, duration of response was censored at their last evaluable disease assessment date. Duration of response was analyzed using the Kaplan-Meier method. (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS | 13.0 |
| Mutant KRAS | 7.4 |
Duration of stable disease was calculated only for participants with a best response of stable disease and is defined as the time from enrollment to first observed PD. For participants who did not progress by the analysis data cut-off date, duration of SD was censored at their last evaluable disease assessment date. Duration of stable disease was estimated using Kaplan-Meier methods. (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS | 5.9 |
| Mutant KRAS | 6.1 |
The percentage of participants with a best response of complete response or partial response by Week 17. Disease assessments are based on investigator review of scans using modified RECIST V1.0 criteria. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Participants with no post-baseline assessment were considered non-responders. (NCT00508404)
Timeframe: Up to Week 17
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS | 49.41 |
| Mutant KRAS | 34.48 |
"Objective response rate is defined as the percentage of participants with a best response of complete response or partial response. Disease assessments are based on investigator review of scans using modified Response Evaluation Criteria in Solid Tumors (RECIST) V1.0 criteria. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Participants with no post-baseline assessment were considered non-responders.~Complete Response (CR): disappearance of all target and non-target lesions and no new lesions.~Partial Response (PR): At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or progressive disease (PD) and no new lesions." (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS | 56.47 |
| Mutant KRAS | 37.93 |
Progression-free survival is the time from the date of enrollment to the date of first observed progression or death, whichever comes first. Participants who were alive and did not progress by the analysis data cut-off date were censored at the last evaluable disease assessment date. Progression-free survival was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS | 8.9 |
| Mutant KRAS | 7.2 |
The percentage of participants who underwent a surgical procedure that resulted in partial reduction or complete eradication of all metastatic disease. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS | 15.12 |
| Mutant KRAS | 6.78 |
Time to progression is the time from the enrollment date to the date of first observed progression. For participants who had not progressed by the analysis data cutoff date, time to progressive disease was censored at their last evaluable disease assessment date. Time to disease progression was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS | 11.2 |
| Mutant KRAS | 7.3 |
Calculated only for those participants who underwent surgical intervention, and defined as the time from the date of first post-intervention radiographic disease assessment to the date of first observed PD. Participants with no post-intervention disease assessment had their time to relapse set to zero and censored in the analysis. Participants that had evidence of progression / recurrence at their first post-intervention disease assessment had a time to relapse of zero. For participants who had not progressed by the analysis data cut-off date, time to relapse was censored at the date of their last evaluable disease assessment. Time to relapse was analyzed using Kaplan-Meier metjhods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS | NA |
| Mutant KRAS | NA |
Time to response is the time from the date of enrollment to the date of first confirmed complete or partial response. Participants with a best response of stable disease at the analysis data cut-off date were censored at their last assessment of SD and participants with all other categories of best response were censored at the maximum observed time to a first confirmed response among all responders. Time to initial objective response was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS | 3.8 |
| Mutant KRAS | NA |
Time to treatment failure is defined as the time from enrollment to the date the decision was made to end the treatment phase for any reason. For participants who remained in the treatment phase at the analysis data cut-off date, time to treatment failure was censored at the date of their last on-study assessment. Time to treatment failure was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS | 6.9 |
| Mutant KRAS | 5.8 |
Duration of response was calculated only for those participants with a confirmed CR or PR, as the time from the first CR or PR (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified RECIST criteria, based on a blinded central review. (NCT00364013)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 11.1 |
| Wild-type KRAS - FOLFOX | 8.8 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.4 |
| Mutant KRAS - FOLFOX | 8.0 |
The definition of overall survival is the time from randomization to death; participants who were alive at the analysis data cutoff were censored at their last contact date. (NCT00364013)
Timeframe: From randomization until the data cutoff date of 28 August 2009. Maximum time on follow-up was 153 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 23.9 |
| Wild-type KRAS - FOLFOX | 19.7 |
| Mutant KRAS - FOLFOX + Panitumumab | 15.5 |
| Mutant KRAS - FOLFOX | 19.3 |
Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response by central radiological assessment was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on the first-line treatment, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders. (NCT00364013)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 55.21 |
| Wild-type KRAS - FOLFOX | 47.68 |
| Mutant KRAS - FOLFOX + Panitumumab | 39.53 |
| Mutant KRAS - FOLFOX | 40.28 |
Progression-free survival (PFS), assessed by central radiological assessment, was defined as the time from randomization to disease progression per modified response evaluation criteria in solid tumors (RECIST) criteria or death. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions. (NCT00364013)
Timeframe: From randomization until the data cutoff date of 30 September 2008. Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 9.6 |
| Wild-type KRAS - FOLFOX | 8.0 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.3 |
| Mutant KRAS - FOLFOX | 8.8 |
Time to progression was defined as time from randomization date to date of disease progression per the modified RECIST criteria. (NCT00364013)
Timeframe: From randomization until the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 10.8 |
| Wild-type KRAS - FOLFOX | 9.2 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.5 |
| Mutant KRAS - FOLFOX | 9.0 |
"A serious adverse event (SAE) is defined as an AE that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: Is there a reasonable possibility that the event may have been caused by the study treatment?" (NCT00364013)
Timeframe: From randomization until the data cut-off date of 28 August 2009; Maximum time on follow-up was 153 weeks.
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any adverse event | Serious adverse event | Leading to discontinuation of any study drug | Treatment-related adverse event (TRAE) | Serious treatment-related adverse event | TRAE leading to discontinuation of any study drug | |
| FOLFOX + Panitumumab | 583 | 262 | 136 | 581 | 162 | 117 |
| FOLFOX Alone | 579 | 198 | 84 | 565 | 89 | 63 |
OS was defined as the time from the date of randomization to the date of death from any cause. (NCT01765582)
Timeframe: Randomization until death due to any cause (up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Arm A: Concurrent FOLFOXIRI + Bevacizumab | 33.97 |
| Arm B: Sequential FOLFOXIRI + Bevacizumab | 28.32 |
| Arm C: FOLFOX + Bevacizumab | 30.65 |
| Arms A + B: Pooled FOLFOXIRI + Bevacizumab | 28.32 |
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. (NCT01765582)
Timeframe: Randomization up to approximately 3 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Arm A: Concurrent FOLFOXIRI + Bevacizumab | 100 |
| Arm B: Sequential FOLFOXIRI + Bevacizumab | 98.9 |
| Arm C: FOLFOX + Bevacizumab | 100 |
| Arms A + B: Pooled FOLFOXIRI + Bevacizumab | 99.4 |
ORR1 was the percentage of participants with complete response (CR) or partial response (PR) during first-line therapy as assessed by investigator according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v.1.1). CR was defined as disappearance of all extranodal target lesions and all pathological lymph nodes had to have decreased to <10 millimeter (mm) in short axis. PR was defined as at least a 30% decrease in the sum of longest diameters of target lesions, taking as reference the baseline sum diameters. ORR1 = CR + PR (NCT01765582)
Timeframe: Randomization up to disease progression during first-line therapy or death, whichever occurs first (up to approximately 3 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Arm A: Concurrent FOLFOXIRI + Bevacizumab | 72.0 |
| Arm B: Sequential FOLFOXIRI + Bevacizumab | 72.8 |
| Arm C: FOLFOX + Bevacizumab | 62.1 |
| Arms A + B: Pooled FOLFOXIRI + Bevacizumab | 72.4 |
PFS1 was defined as time from randomization to the first occurrence of disease progression during first-line therapy, as assessed by the Investigator using RECIST v1.1, or death from any cause, whichever occurs first. Disease progression was defined as sum of longest diameters increased by at least 20% from the smallest value on study. The sum of longest diameters must also demonstrate an absolute increase of at least 5 mm. (NCT01765582)
Timeframe: Randomization up to disease progression during first-line therapy or death, whichever occurs first (up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Arm A: Concurrent FOLFOXIRI + Bevacizumab | 11.86 |
| Arm B: Sequential FOLFOXIRI + Bevacizumab | 11.37 |
| Arm C: FOLFOX + Bevacizumab | 9.46 |
| Arms A + B: Pooled FOLFOXIRI + Bevacizumab | 11.70 |
The proportion of participants considered by the investigator to be unresectable at study enrollment who subsequently underwent attempted curative resections of metastases was calculated as follows: number of participants considered by the investigator to be unresectable at study enrollment who subsequently underwent attempted curative resections of metastases divided by total number of participants in each arm. This outcome represents a measure of the rate of conversion from unresectable to resectable disease. (NCT01765582)
Timeframe: Randomization up to approximately 3 years
| Intervention | Proportion of participants (Number) |
|---|---|
| Arm A: Concurrent FOLFOXIRI + Bevacizumab | 0.24 |
| Arm B: Sequential FOLFOXIRI + Bevacizumab | 0.17 |
| Arm C: FOLFOX + Bevacizumab | 0.14 |
| Arms A + B: Pooled FOLFOXIRI + Bevacizumab | 0.21 |
Reported here is the proportion of participants who underwent liver metastases resections calculated as follows: number of participants who underwent liver metastases resections divided by total number of participants in each arm. (NCT01765582)
Timeframe: Randomization up to approximately 3 years
| Intervention | Proportion of participants (Number) |
|---|---|
| Arm A: Concurrent FOLFOXIRI + Bevacizumab | 0.17 |
| Arm B: Sequential FOLFOXIRI + Bevacizumab | 0.10 |
| Arm C: FOLFOX + Bevacizumab | 0.08 |
| Arms A + B: Pooled FOLFOXIRI + Bevacizumab | 0.14 |
Time to PFS2 was defined as time from randomization to the first occurrence of disease progression after reinduction of second-line therapy, as assessed by the Investigator using RECIST v1.1, or death from any cause, whichever occurs first. Disease progression was defined as sum of longest diameters increased by at least 20% from the smallest value on study. The sum of longest diameters must also demonstrate an absolute increase of at least 5mm. (NCT01765582)
Timeframe: Randomization up to disease progression during second-line therapy or death, whichever occurs first (up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Arm A: Concurrent FOLFOXIRI + Bevacizumab | 18.76 |
| Arm B: Sequential FOLFOXIRI + Bevacizumab | 13.17 |
| Arm C: FOLFOX + Bevacizumab | 14.75 |
| Arms A + B: Pooled FOLFOXIRI + Bevacizumab | 15.08 |
DOR is defined as the time from date of first documented confirmed objective response to date of first documented progressive disease (PD). Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated. (NCT01191697)
Timeframe: 23.2 months (IQR: 11.0 - 46.9 months ).
| Intervention | months (Median) |
|---|---|
| Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine | 14.9 |
Overall survival based on the Kaplan-Meier method is defined as the time from randomization to death. Participants alive are censored at the last date of contact (including lost-to-follow-up) or at the date of withdrawal of consent, if relevant. (NCT01191697)
Timeframe: 23.2 months (IQR: 11.0 - 46.9 months ).
| Intervention | months (Median) |
|---|---|
| Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine | 23.2 |
PFS is defined as the duration of time from study entry to documented disease progression (PD) requiring removal from the study or death. Participants alive without PD were censored at the earliest of the date of the last disease evaluation or start of new anticancer therapy. Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated. (NCT01191697)
Timeframe: Patients received a median of 19 cycles of therapy (Interquartile range (IQR): 8 - 34.5 cycles). Median duration of follow up of 23.2 months (IQR: 11.0 - 46.9 months ).
| Intervention | months (Median) |
|---|---|
| Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine | 14.0 |
ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) on treatment based on RECIST 1.1 criteria. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions. (NCT01191697)
Timeframe: Patients received a median of 19 cycles of therapy (Interquartile range (IQR): 8 - 34.5 cycles). Median duration of follow-up of 23.2 months (IQR: 11.0 - 46.9 months ).
| Intervention | percentage of patients (Number) |
|---|---|
| Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine | 81 |
"Surgery was categorized as breast conserving surgery (Partial Mastectomy) or non-conserving surgery (Total Mastectomy or Modified Radical Mastectomy). Reported below is the percentage of patients receiving Partial Mastectomy. This was calculated by dividing the number of patients receiving Partial Mastectomy by the total number of patients undergoing surgery multiplied by 100 (to obtain the percentage)." (NCT00513292)
Timeframe: From time surgery to up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| FEC-75 Then Paclitaxel/Trastuzumab | 37.7 |
| Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 | 39.1 |
Difference from pretreatment LVEF (%) at 24 weeks [median change from baseline Inter Quartile Range (IQR)]. (NCT00513292)
Timeframe: Baseline, at 24 week
| Intervention | percent (Median) |
|---|---|
| FEC-75 Then Paclitaxel/Trastuzumab | -3 |
| Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 | -4 |
pCR Rate in the Breast and Axillary Lymph Nodes Defined as no Evidence of Invasive Tumor Remaining in Either the Breast or Axillary Nodes at Surgery Following Completion of Chemotherapy (among those with Metastasis to movable ipsilateral axillary lymph node(s) (cN1-3) disease). (NCT00513292)
Timeframe: Up to 5 years
| Intervention | Percentage (95% confidence Interval) (Number) |
|---|---|
| FEC-75 Then Paclitaxel/Trastuzumab | 48.3 |
| Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 | 46.7 |
DFS defined as inoperable progressive disease, gross residual disease following definitive surgery, local, regional or distant recurrence, contralateral breast cancer, other second primary cancers, and death prior to recurrence or second primary cancer. DFS of Arm I and Arm II patients will be estimated using the Kaplan-Meier method. (NCT00513292)
Timeframe: From time to registration to time of event, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| FEC-75 Then Paclitaxel/Trastuzumab | NA |
| Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 | NA |
All patients who had a MUGA or ECHO performed at week 12 are included in the summary of asymptomatic changed in LVEF at week 12. Difference from pretreatment LVEF (%) at 12 weeks [median change from baseline Inter Quartile Range (IQR)]. (NCT00513292)
Timeframe: At 12 week
| Intervention | percent (Median) |
|---|---|
| FEC-75 Then Paclitaxel/Trastuzumab | 2 |
| Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 | -3 |
OS of Arm I and Arm II patients will be estimated using the Kaplan-Meier method. (NCT00513292)
Timeframe: From time to registration to death, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| FEC-75 Then Paclitaxel/Trastuzumab | NA |
| Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 | NA |
Pathological complete response (pCR) rates will be based on institutional pathology reports. In the final analysis for publication, rates will be based on blinded central review of these institutional pathology reports. The Chi-squared test will be conducted at the two-sided 0.05 level. A 95% confidence interval will be computed for the difference in pCR rates. (NCT00513292)
Timeframe: Up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| FEC-75 Then Paclitaxel/Trastuzumab | 56.5 |
| Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 | 54.2 |
The summary of asymptomatic decrease in LVEF. (NCT00513292)
Timeframe: Baseline, at 12 week
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| no decrease or decrease < 10%, still above LLN | decrease < 10%, below lower limit of normal (LLN) | decrease 10-15%, still above lower limit of normal | decrease 10-15%, below lower limit of normal (LLN) | decrease > 15%, still above lower limit of norm | decrease > 15%, below lower limit of normal | |
| FEC-75 Then Paclitaxel/Trastuzumab | 92.3 | 0.8 | 6.2 | 0 | 0.8 | 0 |
| Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 | 82.5 | 0 | 11.7 | 0 | 2.9 | 2.9 |
The summary of asymptomatic changed in LVEF. (NCT00513292)
Timeframe: Baseline, at 24 week
| Intervention | Percentage of Participants (Number) | |||||
|---|---|---|---|---|---|---|
| no decrease or decrease < 10%, still above LLN | decrease < 10%, below lower limit of normal (LLN) | decrease 10-15%, still above lower limit of normal | decrease 10-15%, below lower limit of normal (LLN) | decrease > 15%, still above lower limit of normal | decrease > 15%, below lower limit of normal (LLN) | |
| FEC-75 Then Paclitaxel/Trastuzumab | 83.3 | 0.8 | 7.9 | 2.4 | 1.6 | 4.0 |
| Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 | 73.1 | 3.1 | 15.4 | 0.8 | 6.9 | 0.8 |
Disease control is defined as incidence of objective response or stable disease on study up to starting a new anti-tumor therapy. (NCT00418938)
Timeframe: From randomization up to 65 months.
| Intervention | % of participants (Number) | |
|---|---|---|
| Wild-type KRAS (n=91,91) | Mutant KRAS (n=36,32) | |
| Bevacizumab Plus FOLFIRI | 79.52 | 66.67 |
| Panitumumab Plus FOLFIRI | 72.41 | 52.94 |
Duration of response is defined as time from first confirmed objective response to disease progression per modified RECIST version 1.0 (by central assessment). (NCT00418938)
Timeframe: From randomization up to 65 months.
| Intervention | months (Median) | |
|---|---|---|
| Wild-type KRAS (n=91,91) | Mutant KRAS (n=36,32) | |
| Bevacizumab Plus FOLFIRI | 8.9 | 15.2 |
| Panitumumab Plus FOLFIRI | 12.7 | 10.2 |
Objective response rate is defined as incidence of either a confirmed complete response (CR) or partial response (PR) on study up to starting a new anti-tumor therapy and will be based on modified RECIST version 1.0 (responder) by central assessment. (NCT00418938)
Timeframe: From randomization up to 65 months.
| Intervention | % of patients (Number) | |
|---|---|---|
| Wild-type KRAS (n=91,91) | Mutant KRAS (n=36,32) | |
| Bevacizumab Plus FOLFIRI | 19.28 | 3.33 |
| Panitumumab Plus FOLFIRI | 32.18 | 11.76 |
Overall survival is defined as time from the date of randomization to the date of death due to any cause. Subjects who have not died or are lost to follow-up at the analysis cutoff date will be censored at their last contact date. (NCT00418938)
Timeframe: From randomization up to 65 months.
| Intervention | months (Median) | |
|---|---|---|
| Wild-type KRAS (n=91,91) | Mutant KRAS (n=36,32) | |
| Bevacizumab Plus FOLFIRI | 21.4 | 13.5 |
| Panitumumab Plus FOLFIRI | 18.0 | 8.7 |
Progression-free survival is defined as time from the date of randomization to the date of first progression per modified RECIST version 1.0 (based on central review of the radiographic scans), or death within 60 days after the last evaluable tumor assessment or randomization date (whichever is later). (NCT00418938)
Timeframe: From randomization up to 65 months.
| Intervention | months (Median) | |
|---|---|---|
| Wild-type KRAS (n=91,91) | Mutant KRAS (n=36,32) | |
| Bevacizumab Plus FOLFIRI | 9.2 | 6.4 |
| Panitumumab Plus FOLFIRI | 7.7 | 3.7 |
Time to progression is defined as time from the date of randomization to the date of radiographic disease progression per modified RECIST version 1.0 (per central assessment). (NCT00418938)
Timeframe: From randomization up to 65 months.
| Intervention | months (Median) | |
|---|---|---|
| Wild-type KRAS | Mutant KRAS | |
| Bevacizumab Plus FOLFIRI | 9.4 | 7.4 |
| Panitumumab Plus FOLFIRI | 11.1 | 4.5 |
Time to response is defined as time from the date of randomization to the date of first confirmed objective response (NCT00418938)
Timeframe: From randomization up to 65 months.
| Intervention | months (Median) | |
|---|---|---|
| Wild-type KRAS (n=91,91) | Mutant KRAS (n=36,32) | |
| Bevacizumab Plus FOLFIRI | 3.7 | 1.8 |
| Panitumumab Plus FOLFIRI | 2.1 | 2.2 |
A participant was considered to have had a DFS event if there was evidence of local, regional or metastatic recurrence, second primary cancer (with the exception of carcinoma of squamous cells or basal cells of the skin, cervical carcinoma in situ or lobular or ductal carcinoma in situ of the breast) or death for any reason. (NCT00129935)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: EC-T | 127 |
| Arm B: ET-X | 170 |
A participant was considered to have had a OS event if patient died from any cause. (NCT00129935)
Timeframe: Up to 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: EC-T | 70 |
| Arm B: ET-X | 83 |
"Time to taking off the wig was assessed by a specific Hair Toxicity Questionnaire were patients answered when they stop to use the wig.~The questionnaire was evaluated up to two years after the end of chemotherapy." (NCT00129935)
Timeframe: Up to 30 months
| Intervention | Months (Median) |
|---|---|
| Arm A: EC-T | 8.35 |
| Arm B: ET-X | 6.03 |
Safety was assessed by standard clinical and laboratory tests, and were evaluated using NCI-CTC criteria v2.0 (NCT00129935)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: EC-T | 665 |
| Arm B: ET-X | 699 |
Chireac tumour regression grade (NCT01362127)
Timeframe: Therapy followed in 14-16 weeks before surgery. After surgery the patients will be followed until 60 weeks after completed therapy.
| Intervention | Participants (Count of Participants) |
|---|---|
| Radiochemotherapy | 22 |
| Chemotherapy | 7 |
Safety profile of carrying out radical surgery after respective neoadjuvant therapy. (NCT01362127)
Timeframe: Five years follow up
| Intervention | Participants (Count of Participants) |
|---|---|
| Radiochemotherapy | 79 |
| Chemotherapy | 81 |
The European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire QLQ-C30 and disease specific questionnaires (QLQ-OES24/OG25). All items included in the questionnaires are analysed and also separate analysis of dysphagia questionnaires for oesophageal cancer were used, both clinically and psychometrically validated. All questions have four response alternatives (1, not at all; 2:a little, 3: quite a bit, 4: very much), except global scales which comprise seven response alternatives from poor to excellent. Questionnaire responses were transformed lineraly into scores ranging from 0 to 100 according to the EORTC scoring manual. A higher score indicates either more symotoms or better function, depending on the question. (NCT01362127)
Timeframe: Entry study up to Five years follow up
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Mean global QoL | Dysphagia score all | |
| Chemotherapy | 69 | 31 |
| Radiochemotherapy | 67 | 27 |
Response will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST 1.1 by independent radiology review) at 8 week intervals in patients with metastatic disease and in patients with locally advanced disease. (NCT01523457)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MPC Modified FOLFIRINOX | 35.1 |
| LAPC Modified FOLFIRINOX | 17.2 |
Overall survival will be determined in patients with metastatic disease and in patients with locally advanced disease. (NCT01523457)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MPC Modified FOLFIRINOX | 81 |
| LAPC Modified FOLFIRINOX | 100 |
The primary objective of this study is to determine the progression free survival in patients with metastatic pancreatic cancer and in patients with locally advanced unresectable non-metastatic pancreatic cancer treated with a dose-attenuated modification of FOLFIRINOX. Tumour response was determined according to RECIST 1.1 by independent radiology review. (NCT01523457)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MPC Modified FOLFIRINOX | 54 |
| LAPC Modified FOLFIRINOX | 97 |
The rate of surgical resection in the cohort of patients with locally advanced disease will be determined. (NCT01523457)
Timeframe: 24 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| Total | Unresectable | Borderline | |
| LAPC Modified FOLFIRINOX | 13 | 6 | 7 |
Toxicities will be assessed according to Common Terminology Criteria for Adverse Events (CTCAE) 4.0. Rates of grade 3 and 4 toxicities will be compared to historical controls. MPC and LAPC are combined because they were given the exact same medication. The study aimed to compare this dosage with historical dosage, so this comparison is the most appropriate. (NCT01523457)
Timeframe: 24 weeks
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia | Thrombocytopenia | Anaemia | Febrile neutropenia | Diarrhea | Fatigue | Alanine aminotransferase (ALT) increased | Thromboembolic event | Peripheral sensory neuropathy | Vomiting | |
| LAPC Modified FOLFIRINOX | 5 | 2 | 2 | 2 | 4 | 4 | 0 | 0 | 0 | 1 |
| MPC Modified FOLFIRINOX | 4 | 5 | 2 | 1 | 8 | 5 | 3 | 3 | 2 | 1 |
Disease recurrence will be defined as radiographic tumor evidence detected by surveillance imaging. Confirmation of recurrence by biopsy will be at the discretion of the treating physician. This study closed early on June 18, 2020. It was earlier than one planned because of the lack of accrual. (NCT03515941)
Timeframe: From the end of completion of assigned therapy, subjects undergo follow-up every 3 months for a total of 36 months(planned) after the date of surgery or until the study closure
| Intervention | months (Median) |
|---|---|
| Arm 1: Adjuvant Chemotherapy | NA |
| Arm 2: Adjuvant Chemoradiation | NA |
The number of patients who complete the recommended therapy will be counted for each arm. (NCT03515941)
Timeframe: From date of assigned therapy up to 17 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1: Adjuvant Chemotherapy | 3 |
| Arm 2: Adjuvant Chemoradiation | 2 |
"Per the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and by Spiral CT assessment:~Complete Response (CR) is the disappearance of all target lesions; Partial Response (PR) is a >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR" (NCT00573131)
Timeframe: Screening and Week 12
| Intervention | percentage of patients (Number) |
|---|---|
| Group 1 | 12.5 |
| Group 2 | 20.0 |
Response was evaluated using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000]. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter; Overall Response (OR) = CR + PR. (NCT00100815)
Timeframe: Pre-treatment and every 6 weeks from treatment.
| Intervention | percentage of participants (Number) |
|---|---|
| GEMCITABINE, CAPECITABINE and AVASTIN | 22.0 |
(NCT00100815)
Timeframe: every 2-4 months for 1 year and then every 6 months for 5 years
| Intervention | months (Median) |
|---|---|
| GEMCITABINE, CAPECITABINE and AVASTIN | 9.8 |
Grade 3, 4 or 5 toxicity rate (NCT00100815)
Timeframe: Subjects were evaluated for adverse events at each study visit for the duration of their participation in the study, up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| GEMCITABINE, CAPECITABINE and AVASTIN | 70 |
Quality of Life was assessed using EORTC QLQ-PAN26. All measures range in score from 1 to 4 as lower scores indicate better outcomes. The improved Quality of Life is defined as a greater than 5% decrease in 2 consecutive scores compared with the baseline score. (NCT00100815)
Timeframe: assessed at baseline then weekly for 3 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| GEMCITABINE, CAPECITABINE and AVASTIN | 56.0 |
Progressive Disease is defined using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000], as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions, or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. (NCT00100815)
Timeframe: every 2-4 months for 1 year and then every 6 months for 5 years
| Intervention | months (Median) |
|---|---|
| GEMCITABINE, CAPECITABINE and AVASTIN | 5.7 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments according to investigator (based on modified WHO criteria). (NCT00122460)
Timeframe: evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus Chemotherapy | 35.6 |
| Chemotherapy Alone | 19.5 |
The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments according to investigator (based on modified WHO criteria). (NCT00122460)
Timeframe: evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus Chemotherapy | 81.1 |
| Chemotherapy Alone | 60.0 |
"Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria." (NCT00122460)
Timeframe: time from first assessment of Complete Response or Partial Response to disease progression, death or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 5.6 |
| Chemotherapy Alone | 4.7 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00122460)
Timeframe: time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 10.1 |
| Chemotherapy Alone | 7.4 |
"Duration from randomization until radiological progression according to investigator (based on modified World Health Organisation (WHO) criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00122460)
Timeframe: time from randomization to disease progression, death or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 5.6 |
| Chemotherapy Alone | 3.3 |
Please refer to Adverse Events section for further details (NCT00122460)
Timeframe: time from first dose up to 30 after last dose of study treatment, reported between day of first dose of study treatment, 22 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | participants (Number) |
|---|---|
| Cetuximab Plus Chemotherapy | 218 |
| Chemotherapy Alone | 208 |
"Time from randomization to date of the first occurrence of; progression, discontinuation of treatment due to progression or adverse event, start of new anticancer therapy, withdrawal of consent, or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment." (NCT00122460)
Timeframe: Time from randomization to treatment failure or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 4.8 |
| Chemotherapy Alone | 3.0 |
Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL. (NCT00122460)
Timeframe: at baseline, day 1 of cycle 3, first 6-weekly evaluation following completion of chemotherapy, 6 & 12 months after randomization, reported between day of first patient randomised, 21 Dec 2004,until cut-off date, 12 Mar 2007
| Intervention | scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| At baseline | At cycle 3 | Month 6 | |
| Cetuximab Plus Chemotherapy | 50.74 | 52.68 | 55.30 |
| Chemotherapy Alone | 45.15 | 45.48 | 42.49 |
Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of social functioning. (NCT00122460)
Timeframe: at baseline, day 1 of cycle 3, first 6-weekly evaluation following completion of chemotherapy, 6 & 12 months after randomization, reported between day of first patient randomised, 21 Dec 2004,until cut-off date, 12 Mar 2007
| Intervention | scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| At baseline | At cycle 3 | Month 6 | |
| Cetuximab Plus Chemotherapy | 62.14 | 64.64 | 61.27 |
| Chemotherapy Alone | 62.05 | 60.67 | 65.72 |
The toxicity assessments were made according to the common terminology criteria for adverse events (CTCAE version 3.0) of the National Cancer Institute. Number of participants with Grade 1 to 5 adverse events are reported here. (NCT00193219)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bevacizumab/Cetuximab/FOLFOX | 31 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00193219)
Timeframe: 18 months
| Intervention | percentage of patients (Number) |
|---|---|
| Bevacizumab/Cetuximab/FOLFOX | 55 |
Measured from the date of first treatment until the date of death from any cause (NCT00193219)
Timeframe: 36 months
| Intervention | months (Median) |
|---|---|
| Bevacizumab/Cetuximab/FOLFOX | 25.7 |
Progression Free Survival (PFS) is defined as the interval between the start date of treatment and the date of occurrence of progressive disease or death. (NCT00193219)
Timeframe: 18 months
| Intervention | months (Median) |
|---|---|
| Bevacizumab/Cetuximab/FOLFOX | 9 |
The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment (NCT00308516)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Preoperative 5FU/Radiation/Bevacizumab | 85 |
| Postoperative 5FU/Radiation/Bevacizumab | 97 |
Overall Survival (OS) is defined ad the Length of time, in months, that patients were alive from their first date of protocol treatment until death. (NCT00308516)
Timeframe: 24 months
| Intervention | months (Median) |
|---|---|
| Preoperative 5FU/Radiation/Bevacizumab | NA |
| Postoperative 5FU/Radiation/Bevacizumab | NA |
The proportion of patients with best confirmed RECIST response of CR, PR, or duration of SD of at least 24 weeks (measured from first dose of trial treatment). (NCT02129556)
Timeframe: From the start of trial treatment until confirmed CR, PR, or SD lasting for 24 weeks or longer
| Intervention | proportion of participants (Number) |
|---|---|
| Phase Ib | 0.17 |
| Phase II PD-L1+ | 0.25 |
| Phase II PD-L1- | 0.00 |
"Determination of dose-limiting toxicity (DLT) which is defined as an adverse event or abnormal laboratory value assessed as suspected to be trial treatment related (possible, probable or definite) and unrelated to disease or disease progression. Toxicities and lab values will be graded according to the NCI CTCAE (v4.0).~Any grade-3 or greater non-hematological adverse event lasting at least one week;~Any grade-4 hematological toxicity; or,~Any adverse event resulting in a delay starting cycle 2 of more than 14 days." (NCT02129556)
Timeframe: Within the first 21 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase Ib 2 mg/kg | 0 |
| Phase Ib 10 mg/kg | 0 |
Duration of response (DoR) is defined among patients with objective response (confirmed CR or PR as best overall response) as the interval between dates of first documentation of objective response and first documentation of progressive disease. In the absence of documented progressive disease, follow-up will be censored at date of last disease assessment. (NCT02129556)
Timeframe: From date of first documentation of objective response until first documentation of progressive disease, up to 24 weeks after stop of treatment (=30 months)
| Intervention | months (Median) |
|---|---|
| Phase Ib | 23.1 |
| Phase II PD-L1+ | 3.5 |
Confirmed CR or PR as best overall response. At the time of each restaging, patients will be classified as achieving complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or non-evaluable for response according to RECIST (Version 1.1) criteria. (NCT02129556)
Timeframe: Clinical and radiological tumor assessment will be performed by CT scan or MRI at baseline, at weeks 12, 18 and 24, then every 12 weeks until progression, or 24 weeks after stop of treatment if before progression.
| Intervention | proportion of participants (Number) |
|---|---|
| Phase Ib | 0.17 |
| Phase II PD-L1+ | 0.15 |
| Phase II PD-L1- | 0.00 |
OS is defined as the time from the first dose of trial treatment to death from any cause. For patients who are lost to follow-up or who have no documentation of death at the time of final analysis, follow-up is censored at the date of last assessment of vital status. OS at 12 months by Kaplan-Meier estimates. (NCT02129556)
Timeframe: Time from start of trial treatment to death from any cause, assessed up to 30 months
| Intervention | proportion of participants (Number) |
|---|---|
| Phase Ib | 0.67 |
| Phase II PD-L1+ | .65 |
| Phase II PD-L1- | .12 |
The interval between the dates of the first dose of trial treatment until first documentation of disease progression or death, whichever occurs first. Patients with new non-breast cancer malignancy must continue to be followed for progression of the original breast cancer. For patients without progression, follow-up is censored at the date of last disease assessment without progression, unless death occurs within 12 weeks following the date last known progression-free, in which case the death will be counted as a PFS event. (NCT02129556)
Timeframe: From the date of first treatment dose until documented disease progression or death from any cause. whichever occur first, assessed up to 30 months
| Intervention | months (Median) |
|---|---|
| Phase Ib | 2.5 |
| Phase II PD-L1+ | 2.7 |
| Phase II PD-L1- | 2.5 |
Time to progression (TTP) defined as the interval between the dates of the start of trial treatment and first documentation of progressive disease. In the absence of documented progressive disease, follow-up will be censored at date of last disease assessment (NCT02129556)
Timeframe: From the first trial treatment until first documentation of progressive disease up to 24 weeks after stop of treatment (=30 months)
| Intervention | months (Median) |
|---|---|
| Phase Ib | 2.5 |
| Phase II PD-L1+ | 2.7 |
| Phase II PD-L1- | 2.5 |
The HFRDIS is a validated survey of 10 questions asking patients to rate ten hot flash-related symptoms on a scale of 0-10. The HFRDIS is a sum of the scores in each category, so that total score can range from 0 (no symptoms) to 100 (10 severe symptoms). These surveys were conducted at the time of enrollment (baseline), after four weeks of treatment, and at the conclusion of the study (8 weeks). All nine women who initiated hypnotherapy treatment completed the survey at the end of 8 weeks. One woman in the gabapentin arm did not submit a survey at 8 weeks. (NCT00711529)
Timeframe: Week 8
| Intervention | units on a scale (HFRDIS) (Median) |
|---|---|
| Hypnotherapy | 26 |
| Gabapentin | 22 |
The HFRDIS is a validated survey of 10 questions asking patients to rate ten hot flash-related symptoms on a scale of 0-10. The HFRDIS is a sum of the scores in each category, so that total score can range from 0 (no symptoms) to 100 (10 severe symptoms). These surveys were conducted at the time of enrollment (baseline), after four weeks of treatment, and at the conclusion of the study (8 weeks). Of 11 eligible women in the hypnotherapy arm, 2 never initiated treatment, and 3 did not complete the survey at this time point. Of the 14 eligible women in the gabapentin arm, 3 never initiated treatment, and 3 dropped out of the study before the 4 week time point. (NCT00711529)
Timeframe: Week 4
| Intervention | units on a scale (HFRDIS) (Median) |
|---|---|
| Hypnotherapy | 25.5 |
| Gabapentin | 21.5 |
The HFRDIS is a validated survey of 10 questions asking patients to rate ten symptoms on a scale of 0-10. The HFRDIS is a sum of the scores in each category, so that total score can range from 0 (no symptoms) to 100 (10 severe symptoms). These surveys were conducted at the time of enrollment (baseline), after four weeks of treatment, and at the conclusion of the study (8 weeks). All women who were randomized were included in the baseline analysis (with the exception of 2 women excluded from the hypnotherapy arm who were deemed ineligible after randomization). (NCT00711529)
Timeframe: Baseline
| Intervention | units on a scale (HFRDIS) (Median) |
|---|---|
| Hypnotherapy | 58 |
| Gabapentin | 45.5 |
The patients kept daily hot flash diaries, including the total number of hot flashes they characterized as mild, moderate,severe and very severe. Hot flash severity scores were calculated by assigning one point to each mild hot flash, two points for each moderate hot flash, three points for each severe hot flash and four points for each very severe hot flash. The hot flash severity score for a 24 hour period was the sum of these scores. The score was calculated for each day in the diary. For each subject, median scores were calculated for each week (7 day period) of participation. The median hot flash severity score for the first week was considered the baseline. The median hot flash severity score for the fourth week is considered the week 4 time point. The median hot flash severity score for the eighth week is considered the week 8 time point. The median result for the group was then calculated at each of the timepoints. (NCT00711529)
Timeframe: Baseline
| Intervention | units on a scale (severity score) (Median) |
|---|---|
| Hypnotherapy | 10 |
| Gabapentin | 7.5 |
The patients kept daily hot flash diaries, including the total number of hot flashes they characterized as mild, moderate,severe and very severe. Hot flash severity scores were calculated by assigning one point to each mild hot flash, two points for each moderate hot flash, three points for each severe hot flash and four points for each very severe hot flash. The hot flash severity score for a 24 hour period was the sum of these scores. The score was calculated for each day in the diary. For each subject, median scores were calculated for each week (7 day period) of participation. The median hot flash severity score for the first week was considered the baseline. The median hot flash severity score for the fourth week is considered the week 4 time point. The median hot flash severity score for the eighth week is considered the week 8 time point. The median result for the group was then calculated at each of the timepoints. (NCT00711529)
Timeframe: Week 4
| Intervention | units on a scale (severity score) (Median) |
|---|---|
| Hypnotherapy | 6.5 |
| Gabapentin | 4 |
The patients kept daily hot flash diaries, including the total number of hot flashes they characterized as mild, moderate,severe and very severe. Hot flash severity scores were calculated by assigning one point to each mild hot flash, two points for each moderate hot flash, three points for each severe hot flash and four points for each very severe hot flash. The hot flash severity score for a 24 hour period was the sum of these scores. The score was calculated for each day in the diary. For each subject, median scores were calculated for each week (7 day period) of participation. The median hot flash severity score for the first week was considered the baseline. The median hot flash severity score for the fourth week is considered the week 4 time point. The median hot flash severity score for the eighth week is considered the week 8 time point. The median result for the group was then calculated at each of the timepoints. (NCT00711529)
Timeframe: Week 8
| Intervention | units on a scale (severity score) (Median) |
|---|---|
| Hypnotherapy | 1.5 |
| Gabapentin | 5 |
"Patients kept daily diaries of their hot flashes. The absolute number of hot flashes in a 24 hour period is number of daily hot flashes. The median number was calculated for each week of data. The median number of daily hot flashes for the first week (7 days) of participation is used as baseline. The median number of daily hot flashes for the fourth week (over 7 day interval) is reported for the week four time point. The median number of daily hot flashes for the eighth week (over 7 day interval) is reported for the week eight time point (study completion). A total of 15 diaries were submitted (7 hypnotherapy, 8 gabapentin). One person in each arm stopped recording in her diary before the 4 week mark." (NCT00711529)
Timeframe: Week 4
| Intervention | daily hot flashes (Median) |
|---|---|
| Hypnotherapy | 4 |
| Gabapentin | 4 |
"Patients kept daily diaries of their hot flashes. The absolute number of hot flashes in a 24 hour period is number of daily hot flashes. The median number was calculated for each week of data. The median number of daily hot flashes for the first week (7 days) of participation is used as baseline. The median number of daily hot flashes for the fourth week (over 7 day interval) is reported for the week four time point. The median number of daily hot flashes for the eighth week (over 7 day interval) is reported for the week eight time point (study completion). Of the 13 women randomized to the hypnotherapy arm, 2 women were ineligible and therefore not included in analysis. Two women were unable to initiate treatment and did not submit diaries. An additional two women completed treatment but lost their diaries, leaving 7 diaries for analysis at baseline. Of the 14 randomized to receive gabapentin, 6 dropped out of the study and did not submit diaries." (NCT00711529)
Timeframe: Baseline
| Intervention | daily hot flashes (Median) |
|---|---|
| Hypnotherapy | 5 |
| Gabapentin | 4.5 |
"Patients kept daily diaries of their hot flashes. The absolute number of hot flashes in a 24 hour period is number of daily hot flashes. The median number was calculated for each week of data. The median number of daily hot flashes for the first week (7 days) of participation is used as baseline. The median number of daily hot flashes for the fourth week (over 7 day interval) is reported for the week four time point. The median number of daily hot flashes for the eighth week (over 7 day interval) is reported for the week eight time point (study completion). One woman in the hypnotherapy arm and 3 women in the gabapentin arm stopped keeping their diary before the 8 week mark." (NCT00711529)
Timeframe: Week 8
| Intervention | daily hot flashes (Median) |
|---|---|
| Hypnotherapy | 1 |
| Gabapentin | 3 |
The serum levels of anti-Müllerian hormone (AMH) were measured using human AMH ELISA kit (11351, Biofine)). POI (premature ovarian insufficiency) was defined as AMH<0.5ng/mL in this study. (NCT02518191)
Timeframe: 1 years
| Intervention | Participants (Count of Participants) |
|---|---|
| GnRHa (Gonadotrophin-releasing Hormone Analogues) Group | 10 |
| None GnRHa (Gonadotrophin-releasing Hormone Analogues) Group | 38 |
Overall Survival & Tumor Free Survival (NCT02518191)
Timeframe: 5 years
| Intervention | months (Mean) |
|---|---|
| GnRHa Group | 48.17 |
| None GnRHa Group | 49.33 |
Time in months from the start of study treatment to the date of first progression (PD) according to the RECIST criteria, or death due to any cause. PER RECIST, a PD is indicated when there is at least a 20% increase in the sum of the longest diameters from target lesions relative to the smallest sum recorded since treatment is initiated. Median PFS was estimated using a Kaplan-Meier curve, and is the time at which 50% of patients remain alive without disease progression. (NCT00447330)
Timeframe: 5 years from study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1- Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin | 6.97 |
Time in months from the start of study treatment to date of death due to any cause. Median survival was estimated using a Kaplan-Meier curve and is the time point at which 50% of patients remain alive. (NCT00447330)
Timeframe: 5 years after study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 10.51 |
The proportion of patients for whom the best overall response is complete response (CR) or partial response (PR). A CR occurs when all lesions disappear; whereas, a PR is indicated when there is at least a 30% decrease in the sum of the longest diameters (LD) of the target lesion. A PD (progressive disese) occurs when there is at least a 20% increase in the sum of the LD relative to the smallest sum LD recorded since treatment is initiated. Disease is considered stable if there is no response and no PD. All patients were assigned a best response for inclusion in this calculation in accordance with the protocol. (NCT00447330)
Timeframe: Every 9 weeks for up to 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 41.7 |
Number of subjects who experienced an adverse event (NCT00447330)
Timeframe: Every 21 days
| Intervention | participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 56 |
Disease-Free Survival (DFS)- are defined as local, regional or metastatic relapse or the date of second primary cancer or death from any cause whichever occurs first. (NCT00688740)
Timeframe: up to 10 year follow-up
| Intervention | Participants (Number) |
|---|---|
| TAC (Docetaxel) | 287 |
| FAC (5-fluorouracil) | 333 |
Overall Survival - time from the date of randomization up to the date of death of any cause. (NCT00688740)
Timeframe: up to 10 year follow-up
| Intervention | Participants (Number) |
|---|---|
| TAC (Docetaxel) | 188 |
| FAC (5-fluorouracil) | 241 |
Toxicity (second primary malignancies)- defined as histopathologically proven cancer, excluding nonmelanomatous skin cancer, in situ carcinoma of the cervix, and in situ carcinoma of the breast. (NCT00688740)
Timeframe: up to 10 year follow-up
| Intervention | Participants (Number) |
|---|---|
| TAC (Docetaxel) | 67 |
| FAC (5-fluorouracil) | 66 |
"The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) was used.~Questionnaires were self-administered to patients during the 14 days prior to randomisation baseline, at six prospective time points corresponding to chemotherapy cycles, with the time window related to each chemotherapy cycle defined as the period between the day following the first chemotherapy dose of the corresponding cycle and the day of the first dose of the following cycle, and then at 44, 68 and 120 weeks of the study.~The Global Health Status Scale has been used, which is calculated with questions 29 and 30 from the EORTC QLQ-C30. From this scale, the best score is the highest score observed during study (of all the questionnaires completed by patient). In this scale, scores range from 0 to 100 and a high score represents a high level of functioning or HRQoL." (NCT00121992)
Timeframe: 120 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Arm A: FAC | 79.30 |
| Arm B: TAC | 77.78 |
Hormone-receptor status and HER2 receptor status was analysed in Paraffin-embedded tumor samples obtained at the time of surgery, and were processed centrally. Disease-Free Survival (DFS) is defined as the interval from the date of randomization to the date of local, regional or metastatic relapse or the date of second primary cancer or death from any cause whichever occurs first. (NCT00121992)
Timeframe: 10 year
| Intervention | events (Number) |
|---|---|
| Arm A: FAC | 29 |
| Arm B: TAC | 28 |
Hormone-receptor status and HER2 receptor status was analysed in Paraffin-embedded tumor samples obtained at the time of surgery, and were processed centrally. (NCT00121992)
Timeframe: 10 year
| Intervention | events (Number) |
|---|---|
| Arm A: FAC | 6 |
| Arm B: TAC | 5 |
"Hormone-receptor status and HER2 receptor status was analysed in Paraffin-embedded tumor samples obtained at the time of surgery, and were processed centrally.~Disease-Free Survival (DFS) is defined as the interval from the date of randomization to the date of local, regional or metastatic relapse or the date of second primary cancer or death from any cause whichever occurs first." (NCT00121992)
Timeframe: 10 year
| Intervention | events (Number) |
|---|---|
| Arm A: FAC | 50 |
| Arm B: TAC | 37 |
DFS is calculated from the date of randomization until the first date of recurrence local, regional or distant, second primary tumor or death. (NCT00121992)
Timeframe: 10 years
| Intervention | events (Number) |
|---|---|
| Arm A: FAC | 127 |
| Arm B: TAC | 112 |
Hormone-receptor status and HER2 receptor status was analysed in Paraffin-embedded tumor samples obtained at the time of surgery, and were processed centrally. Disease-Free Survival (DFS) is defined as the interval from the date of randomization to the date of local, regional or metastatic relapse or the date of second primary cancer or death from any cause whichever occurs first. (NCT00121992)
Timeframe: 10 year
| Intervention | events (Number) |
|---|---|
| Arm A: FAC | 6 |
| Arm B: TAC | 6 |
"OS was determined from the date of randomization until the date of death for any reason.~OS is calculated from the date of randomization up to the first date of death by any cause." (NCT00121992)
Timeframe: 10 years
| Intervention | Participants with mortality event (Number) |
|---|---|
| Arm A: FAC | 57 |
| Arm B: TAC | 53 |
Safety was assessed by standard clinical and laboratory tests (haematology, serum chemistry). AE grade were defined by the NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) version 1.0. (NCT00121992)
Timeframe: Through study treatment, and average of 4 months
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Number patients with One AE | One G3-4 or severe treatment-emergent AE | One serious treatment-emergent AE | One serious G3-4 treatment-emergent AE | Number of patients discontinued due to AE | Number patients death due to AE | |
| Arm A: FAC | 519 | 88 | 22 | 10 | 4 | 0 |
| Arm B: TAC | 532 | 151 | 119 | 55 | 25 | 1 |
(NCT01167192)
Timeframe: 30 days post surgery (approximately 16-20 weeks from registration)
| Intervention | participant (Number) |
|---|---|
| Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation | 1 |
(NCT01167192)
Timeframe: Median follow-up was 59.9 months
| Intervention | percentage of participants (Number) |
|---|---|
| Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation | 75 |
Progression = at least a 20% increase in the sum of the longest diameter of the target lesions taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions, appearance of one or more new lesions, unequivocal progression of existing non-target lesions. (NCT01167192)
Timeframe: Up to 5 years from registration
| Intervention | months (Median) |
|---|---|
| Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation | 6.5 |
(NCT01167192)
Timeframe: 30 days post surgery (approximately 16-20 weeks after start of registration)
| Intervention | adverse event (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anemia | Leukocytosis | Cardiac arrest | Pulseless electrical activity | Sinus bradycardia | Fever | Wound infection | Radiation recall reaction (dermatologic) | Alanine aminotransferase increased | Creatinine increased | Lymphocyte count decreased | Neutrophil count decreased | Platelet count decreased | Weight gain | Hyponatremia | Back pain | Cerebrovascular accident | Acute kidney injury | Cellulitis | Hypertension | |
| Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
"Complete response (CR) = disappearance of all target lesions, disappearance of all non-target lesions and normalization of tumor marker level.~Partial response (PR) = at least a 30% decrease in the sum of the longest diameter (LD) of the target lesions taking as reference the baseline sum LD" (NCT01167192)
Timeframe: Prior to surgery (approximately 12-16 weeks from registration)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Pathologic complete response | Partial response | |
| Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation | 3 | 3 |
The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 will be utilized for all toxicity reporting. All detailed information regarding serious and other adverse events are listed in the Adverse Event module of these results. (NCT00603408)
Timeframe: 30 days post surgery (week 17-18)
| Intervention | participants (Number) |
|---|---|
| Cisplatin + Radiation + Recommended Surgery | 5 |
(NCT00603408)
Timeframe: 30 days post surgery (week 17-18)
| Intervention | participants (Number) |
|---|---|
| Cisplatin + Radiation + Recommended Surgery | 0 |
OS = Time from registration until death from any cause (NCT00603408)
Timeframe: Until study was terminated (23.5 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Cisplatin + Radiation + Recommended Surgery | 100 |
"Complete response: disappearance of all target lesions, non-target lesions, and normalization of tumor marker level~Partial response: at least a 30% decrease in the sum of the longest diameter (LD) of the target lesions taking as reference the baseline sum LD~Stable disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD since the treatment started,~Progressive disease: at least a 20% increase in the sum of the LD of the target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, appearance of one more new lesions, or unequivocal progression of existing non-target lesions." (NCT00603408)
Timeframe: At the time of surgery (week 13)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete response | Partial response | Stable disease | Progressive disease | |
| Cisplatin + Radiation + Recommended Surgery | 2 | 3 | 0 | 0 |
(NCT00375999)
Timeframe: One year
| Intervention | month (Median) |
|---|---|
| Treatment Group | 13.4 |
A reduction of 50% in heart volume exposed to radiation doses ≥ 5 Gy/CGE was considered preferred outcome in this study plan. (NCT01365845)
Timeframe: 2 weeks prior to starting radiation therapy.
| Intervention | % of heart receiving >= 5 Gray (Gy) (Median) |
|---|---|
| Conventional Photon Plan | 34.7 |
| 3D-Proton/Conventional Plan or 3D-proton Only | 2.7 |
Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Local Control Only | Local Control and Distant Metastasis | Distant Metastatsis Only | Secondary Primary - Site Unknown | Surgical Salvage | |
| Recurrence | 6 | 2 | 1 | 2 | 3 |
Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy
| Intervention | participants (Number) | ||
|---|---|---|---|
| Hematologic | Dermatitis | Mucositis/Dysphagia | |
| Acute Toxicity | 12 | 7 | 16 |
To determine biomarkers predictive of failure with either reduced or standard dose radiotherapy. (NCT01706939)
Timeframe: at 5 years
| Intervention | biomarkers (Number) |
|---|---|
| Reduced Dose Radiation | 0 |
| Standard Dose Radiation | 0 |
MDADI is a questionnaire of 20 questions and contains a global subscale, and three other categories of questions (emotional, functional, and physical). The scores are summed and a mean score is calculated. This mean score was multiplied by 20 to obtain a score, with a range of 0 (extremely low functioning) to 100 (high functioning). Thus, a higher MDADI score represented better day-to-day functioning and better QOL. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) |
|---|---|
| Reduced Dose Radiation | -8.12 |
| Standard Dose Radiation | -8.93 |
XQ is a nine questions survey developed specifically for xerostomia symptoms. The scores are summed and a mean score is calculated on a scale of 0 (low xerostomia interference) to 10 (high xerostomia interference). A lower or negative score reflects a better quality of life compared to baseline. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) |
|---|---|
| Reduced Dose Radiation | 2.18 |
| Standard Dose Radiation | 4.38 |
Number of participants with acute toxicity treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 3 |
| Standard Dose Radiation | 1 |
Local-regional control (LRC) at 3 years in patients with advanced HPV related oropharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 10 |
| Standard Dose Radiation | 7 |
Overall Survival (OS) 5 years treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 10 |
| Standard Dose Radiation | 7 |
The EORTC Head and Neck module was specifically designed and validated for head and neck cancer patients. This 35-item questionnaire contains 7 symptom scales (pain, swallowing, senses, speech, social eating, social contact, and sexuality), 6 single-item scales (difficulties of teeth, mouth opening, dry mouth, sticky saliva, coughing, and feeling ill), and 5 items about the additional use of pain medicine, nutritional supplements, and feeding tube and changes in body weight. All items were transformed to scales from 0 to 100, and divided into respective sub-scores of global health (GHS), functional (FS), and symptom scale (SS). Subscales from 0-100. A high score on global health and functional scale represents a better level of functioning, whereas a high score on a symptom scale and head and neck module indicates more severe symptoms. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| EORTC GHS | EORTC FS | EORTC SS | EORTC HN | |
| Reduced Dose Radiation | 5.95 | 5.14 | -3.91 | -2.80 |
| Standard Dose Radiation | -30.56 | -6.33 | 14.97 | 8.97 |
"MD Anderson Symptom Inventory Symptom Inventory and Severity (MDASI-HN SI and SS) MDASI Head and Neck is a site-specific MDASI module which includes the core MDASI 13 symptom severity items (SS) and 6 symptom interference items (SI), alongside 9 items relevant to head and neck cancer. The scores are summed and a mean score is calculated on a scale of 0 (low severity or interference) to 10 (high severity or complete interference). In order to calculate the mean score, a majority of the subscale's items must have been completed.~A lower or negative score reflects a better quality of life compared to baseline." (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) | |
|---|---|---|
| MDASI-HN SI | MDASI-HN SS | |
| Reduced Dose Radiation | 0.64 | 0.52 |
| Standard Dose Radiation | 1.56 | 1.48 |
Progression free survival (PFS) at 5 years in patients with advanced HPV related oropharynx cancer, nasopharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 and 5 years
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| at 3 years | at 5 years | |
| Reduced Dose Radiation | 10 | 10 |
| Standard Dose Radiation | 7 | 7 |
Dose related toxicity is defined as follows:1. luecopenia > grade 2; granular cell decrease > grade 2; anemia > grade 1; platelet > grade 1;SGPT/SGOT elevation > grade 1; ALP > grade 1; GGT > grade 1; Tbil > grade 1;renal function damag > grade 2;Non-gradular cell decreased fever > grade 1;nausea/vomiting > grade 1; fatigue > grade 2; weight loss > grade 2;gastritis > grade 2; dairrea > grade 2; abdominal pain > grade 2; upper gastrointestinal bleeding > grade 1;other toxic reaction > grade 2;KPS < 50 during the treatment (NCT01584544)
Timeframe: up to 7 weeks from start of the treatment
| Intervention | participants (Number) |
|---|---|
| 1000mg | 0 |
| 1200mg | 1 |
| 1350mg | 1 |
| 1500mg | 0 |
| 1650mg | 1 |
dose related toxicity is defined as follows:1. WBC damage >= grade 3; granular cell decrease >= grade 3; hemoglobin >= grade 2; platelet >= grade 2;SGPT/SGOT elevation >= grade 2; ALP >= grade 2; GGT >= grade 2; Tbil >= grade 2;renal function damage: BUN/Cr elevation >= grade 2;Non-gradular cell decreased fever >= grade 2;nausea/vomiting >= grade 2; fatigue >= grade 3; weight loss >= grade 3;gastritis >= grade 3; dairrea >= grade 3; abdominal pain >= grade 3; pancreatitis >= grade 2; upper gastrointestinal bleeding >= grade 2;other toxic reaction >= grade 3;KPS < 50 during the treatment (NCT01268943)
Timeframe: up to 9 weeks
| Intervention | event (Number) |
|---|---|
| 1000mg | 1 |
| 1200mg | 0 |
| 1400mg | 0 |
| 1500mg | 3 |
(NCT00537823)
Timeframe: 30 days following surgery
| Intervention | participants (Number) |
|---|---|
| Arm 1 - Wildtype | 0 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
-Compare total longest diameter from baseline to preoperative CT scan. (NCT00537823)
Timeframe: Completion of neoadjuvant therapy (approximately 8 weeks)
| Intervention | percentage of change of longest diameter (Median) |
|---|---|
| Arm 1 - Wildtype | -23.8 |
| Arm 2 K-Ras 12/13 Codon Mutation | -14.3 |
Number of participants whose tumor size decreased from baseline to completion of preoperative chemotherapy. (NCT00537823)
Timeframe: Upon completion of neoadjuvant chemotherapy (approximately 2 months)
| Intervention | participants (Number) |
|---|---|
| Arm 1 - Wildtype | 4 |
| Arm 2 K-Ras 12/13 Codon Mutation | 2 |
Fraction of patients with any complication grades IV and V (NCT00537823)
Timeframe: 30 days following surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 - Wildtype | 25 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
Fraction of patients with any grade of complication I-V (NCT00537823)
Timeframe: 30 days following surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 - Wildtype | 25 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
(NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Not reported on pathology report | Mild | Aborted surgery | None | |
| Arm 1 - Wildtype | 1 | 1 | 1 | 1 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 | 0 | 1 |
"NASH Scoring~Steatosis **<5% = 0~**5-33%=1~**>33-66%=2~**>66%=3~Lobular inflammation~**No foci=0~**<2 foci per x 200 field=1~**2-4 foci per x 200 field=2~**>4 foci per x 200 field=3~Hepatocellular ballooning **None=0 **Few balloon cells = 1 **Many cells/prominent ballooning=2" (NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Not reported on pathology report | Aborted surgery | Score 0 | |
| Arm 1 - Wildtype | 3 | 1 | 0 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 | 1 |
Liver only vs distant disease (NCT00537823)
Timeframe: Up to 5 years
| Intervention | participants (Number) | |
|---|---|---|
| Liver only | Distant disease | |
| Arm 1 - Wildtype | 0 | 1 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 |
96 reviews available for fluorouracil and Lymph Node Metastasis
| Article | Year |
|---|---|
Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma?
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase | 2018 |
Anal Cancer in the Era of Dose Painted Intensity Modulated Radiation Therapy: Implications for Regional Nodal Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Diagnostic Imagin | 2019 |
Adjuvant chemotherapy versus surgery alone for esophageal squamous cell carcinoma: a meta-analysis of randomized controlled trials and nonrandomized studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2014 |
Postoperative 5-FU based radiochemotherapy in rectal cancer: retrospective long term results and prognostic factors of a pooled analysis on 1,338 patients.
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Fluorouracil; Humans; Kap | 2013 |
[A case of advanced sigmoid colon cancer with metastases in the liver and the paraaortic lymph nodes successfully treated with 5-FU/l-LV and FOLFOX4 followed by S-1 leading to long-term complete response].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Fluorouracil; Human | 2014 |
Disseminated intravascular coagulation as clinical manifestation of colorectal cancer: a case report and review of the literature.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; De | 2014 |
[A case of cecum colon cancer with lymph node metastasis successfully treated with XELOX plus bevacizumab].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
[A Case of Descending Colon Adenocarcinoma with Neuroendocrine Differentiation Successfully Treated with FOLFIRI plus Bevacizumab].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Camptothe | 2016 |
[Neoadjuvant radiochemotherapy for rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose Fractionation, Radia | 2009 |
Contemporary issues and the potential uses of capecitabine in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2009 |
Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Chemoth | 2009 |
[Virchow's node as the form of onset of squamous cell carcinoma of the pancreas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplat | 2009 |
[Diagnosis and treatment of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Signet Ring Cell; Cisplatin; Endo | 2010 |
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2010 |
[Molecular subtypes and individualized treatment of breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2010 |
Adjuvant colon cancer chemotherapy: where we are and where we'll go.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colonic N | 2010 |
[A surgical (pancreatoduodenectomy) case of lymph node metastatic recurrence of colon cancer after chemotherapy].
Topics: Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Duoden | 2010 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorour | 2011 |
Adjuvant chemotherapy for localised colon cancer. Fluorouracil + folinic acid for node-positive, non-metastatic disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Co | 2011 |
[Multimodal therapy for colon cancer: state of the art].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dia | 2012 |
Takotsubo syndrome: an underdiagnosed complication of 5-fluorouracil mimicking acute myocardial infarction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 2013 |
[Recent advance in adjuvant therapy for breast cancer].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2002 |
[Progress in postoperative adjuvant chemotherapy in gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Drug Administrat | 2002 |
[Pancreatic cancer. The relative importance of neoadjuvant therapy].
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Case-Control Studies; Child; Ci | 2003 |
Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemother | 2003 |
[Cutaneous neoplasms].
Topics: Adjuvants, Immunologic; Aminoquinolines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bio | 2003 |
Focus on gastric cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cadheri | 2004 |
[Radiation and concomitant chemotherapy after surgery for breast cancer].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 2004 |
[Sequencing of adjuvant treatment after surgery for invasive breast cancer].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplas | 2004 |
Squamous cell carcinoma of the anal margin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2004 |
Adjuvant therapy for stage II colon cancer: an elephant in the living room?
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Leucovorin; Lymph No | 2004 |
Invasive ductal carcinoma within a fibroadenoma of the breast.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Breast Neoplasms; Carcin | 2004 |
[Effectiveness of chemoradiotherapy for three cases of squamous cell anal carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2004 |
Eliminating and suppressing local-regional disease in gastric cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Gastrectomy; Humans; Lymph | 2005 |
The development of clinical research in CRC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2005 |
[Management of rectal cancer in pregnant women].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Case Management; Cesarean Section; Chemotherapy, Adjuv | 2005 |
[Adjuvant chemotherapy based on evidence-based medicine for breast cancer patients].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2006 |
Bilateral axillary metastasis from a primary ethmoidal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Carcinoma, Squamous Cell; Cisplatin; Ethmoid | 2006 |
Surgical adjuvant therapy for colorectal cancer: current approaches and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trial | 2006 |
[Adjuvant chemotherapy in breast cancer: status in 1984].
Topics: Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Drug Th | 1984 |
The role of post-operative radiotherapy in the treatment of operable breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1984 |
Systemic adjuvant therapy with BCG versus BCG + 5FU in colorectal cancer Dukes' Class C: updated critical analysis.
Topics: Aged; BCG Vaccine; Carcinoembryonic Antigen; Clinical Trials as Topic; Colonic Neoplasms; Female; Fl | 1980 |
[Adjuvant chemotherapy in breast cancer].
Topics: Antineoplastic Agents; Axilla; Breast Neoplasms; Chlorambucil; Cyclophosphamide; Doxorubicin; Drug T | 1981 |
The case for adjuvant CMF chemotherapy in breast cancer. Has it been made?
Topics: Axilla; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Dose-Response Relationship, Dr | 1981 |
Intra-arterial chemotherapy for palliation of fungating breast cancer. A case report and review of the literature.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; | 1994 |
Adjuvant systemic therapy for breast cancer. Issues for primary care physicians.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1995 |
Role of adjuvant therapy in surgically resected colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined | 1995 |
[Targeting therapy of gastric and colorectal cancer].
Topics: Colorectal Neoplasms; Drug Delivery Systems; Fat Emulsions, Intravenous; Fluorouracil; Humans; Infus | 1994 |
Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta | 1994 |
[Cancer of the anal canal].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 1990 |
Anal canal cancer: current treatment and results.
Topics: Anal Canal; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ant | 1996 |
[Chemotherapy for advanced adenocarcinoma of the skin: experience with combination chemotherapy and a review of the literature].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Sch | 1997 |
Arterial infusion chemotherapy for peritoneal and liver metastasis in gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusions, Intra-Arterial; Liv | 1997 |
Selection of adjuvant chemotherapy for gastric cancer using objective criteria.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Carcinoembryonic Antigen; Chemotherap | 1997 |
[Benefits of adjuvant chemotherapy for breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; | 1997 |
Adjuvant therapy of colorectal cancer.
Topics: Adjuvants, Immunologic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemother | 1997 |
A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1997 |
[Paths of innovative surgery in gastrointestinal cancer in our department].
Topics: Antibodies, Monoclonal; Combined Modality Therapy; Drug Delivery Systems; Fluorouracil; Gastrointest | 1997 |
Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
Topics: Adult; Age Factors; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Chem | 1998 |
[Treatment of recurrent gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cis | 1998 |
[Treatment of patients with recurrent esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1998 |
[No advantage to using the CMF-regimen for node positive, postmenopausal, receptor-positive mammary carcinoma with adjuvant tamoxifen therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1998 |
[Successful multidisciplinary treatment for bladder cancer with priapism. A case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Comb | 1998 |
[Ways of improving long-term results of treatment in resectable pancreatic cancer].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Therapy; Evaluation | 1998 |
External beam radiotherapy for pelvic node recurrence after curative resection of colon cancer: report of a case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colectomy; Colonic Neopla | 1999 |
[A case of unresectable advanced gall bladder cancer successfully treated by hepatic arterial chemotherapy with reservoir (HACR) using CDDP and 5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Flu | 1999 |
[Standards, options and recommendations: concomitant radiochemotherapy for cancer of the cervix: a critical analysis of the literature and update of SOR].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1999 |
Recall phenomenon following epirubicin.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Ant | 1999 |
[Current trends in surgical treatment of esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Endoscopy; Eso | 2000 |
[Colon carcinoma. Consensus of therapeutic strategies].
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Che | 2000 |
[Outpatient treatment for gastrointestinal tract cancer in the Department of Surgery].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvan | 2000 |
[Postoperative adjuvant therapies for esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neopla | 2000 |
[Adjuvant therapy of breast cancer].
Topics: Adult; Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, H | 2001 |
Adjuvant treatment in node-negative, postmenopausal breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2001 |
Simultaneous radiochemotherapy in cervical cancer: recommendations for chemotherapy.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 2001 |
The worldwide perspective in the adjuvant treatment of primary lymph node positive breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 2001 |
Sustained complete remission of stage IV carcinoma of the pyriform fossa following chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2002 |
Invasive bladder cancer: organ preservation by radiochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carbopla | 2002 |
Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2001 |
The integration of chemotherapy into a combined modality approached to cancer therapy. V. Squamous cell cancer of the head and neck.
Topics: Bleomycin; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Therapy, Combination; Fluoro | 1975 |
The integration of chemotherapy into combined modality treatment of solid tumors. VIII. Cervical cancer.
Topics: Alkylating Agents; Altretamine; Antineoplastic Agents; Bleomycin; Cyclophosphamide; Drug Therapy, Co | 1977 |
[The state of hormone and chemotherapy in breast neoplasms].
Topics: Androgens; Brain Neoplasms; Breast Neoplasms; Castration; Cyclophosphamide; Doxorubicin; Drug Therap | 1978 |
[Hormone and chemotherapy of breast carcinoma].
Topics: Androgens; Breast Neoplasms; Castration; Cyclophosphamide; Drug Therapy, Combination; Estrogens; Fem | 1977 |
[Treatment possibilities of laryngeal cancer. Surgery--radiotherapy--chemotherapy].
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Chemotherapy, Cancer, Regional Perfusion; Co | 1975 |
Combined chemotherapy and surgery in breast cancer: a review.
Topics: Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mechloretham | 1975 |
Evolving concepts in the systemic adjuvant treatment of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical T | 1992 |
Squamous cell carcinoma in epidermolysis bullosa. Treatment with systemic chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheterization, Ce | 1990 |
Pancreatic cancer in 1988. Possibilities and probabilities.
Topics: Adenocarcinoma; Combined Modality Therapy; Diagnosis, Differential; Fluorouracil; Humans; Lymphatic | 1988 |
[5-Fluorouracil, adriamycin, and mitomycin C (FAM) combination chemotherapy in adenocarcinoma of the parotid gland].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; | 1989 |
Karnofsky memorial lecture. Conceptual and practical advances in the management of breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy | 1989 |
Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1988 |
[Adjuvant chemotherapy following radical operations for cancer of the large intestine].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Com | 1985 |
Patterns of metastasis and natural courses of breast carcinoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bre | 1985 |
Controversies in the management of potentially curable breast cancer.
Topics: Breast Neoplasms; Castration; Clinical Trials as Topic; England; Female; Fluorouracil; Humans; Lymph | 1974 |
[Use of optical quantum generators (lasers) in oncology].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Basal Cell; Carcinom | 1972 |
549 trials available for fluorouracil and Lymph Node Metastasis
| Article | Year |
|---|---|
Effect of Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide Followed by Paclitaxel on Disease-Free Survival Among Patients With Operable ERBB2-Negative and Lymph Node-Positive Breast Cancer: A Randomized Clinical Trial.
Topics: Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; | 2023 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter rando
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2019 |
High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial.
Topics: Adult; Axilla; Breast; Breast Neoplasms; Cardiovascular Abnormalities; Child; Cyclophosphamide; Dise | 2020 |
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neopla | 2020 |
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neopla | 2020 |
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neopla | 2020 |
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neopla | 2020 |
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; An | 2020 |
Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Flu | 2020 |
Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 Trial.
Topics: Aged; Chemoradiotherapy; China; Cisplatin; Confidence Intervals; Dose Fractionation, Radiation; Drug | 2021 |
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorect | 2022 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colore | 2017 |
Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, A | 2017 |
A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2018 |
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2019 |
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neo | 2019 |
The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2019 |
Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2019 |
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doub | 2019 |
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell-Free Nucleic Acids; Clinical | 2019 |
Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2019 |
A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capeci | 2013 |
Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; C | 2013 |
Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
Predictive factors determining neoadjuvant chemotherapy outcomes in breast cancer - a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cy | 2013 |
Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Base | 2013 |
Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2013 |
A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2014 |
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a random
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biom | 2013 |
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a random
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biom | 2013 |
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a random
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biom | 2013 |
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a random
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biom | 2013 |
Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 2014 |
Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docet | 2014 |
Circulating tumor cells predict survival in early average-to-high risk breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2014 |
Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradioth | 2014 |
Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2014 |
Epirubicin combined with oxaliplatin and 5-day continuous infusion of 5-fluorouracil as a first-line treatment for metastatic gastric cancer: treatment outcomes and analysis of prognostic factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Fluorou | 2015 |
A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of (18)FDG-PET scans: a phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2014 |
Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cape | 2015 |
Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
Topics: Adult; Aged; Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamou | 2015 |
Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2015 |
Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2015 |
Effects of high-intensity focused ultrasound for treatment of abdominal lymph node metastasis from gastric cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modal | 2015 |
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemother | 2015 |
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemother | 2015 |
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemother | 2015 |
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemother | 2015 |
Neutrophil-guided dosing of anthracycline-cyclophosphamide-containing chemotherapy in patients with breast cancer: a feasibility study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 2015 |
Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com | 2015 |
Prognostic value of HLA class I expression in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2015 |
SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2015 |
Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; | 2015 |
Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemoth | 2015 |
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; | 2016 |
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; | 2016 |
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; | 2016 |
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; | 2016 |
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy | 2016 |
Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; D | 2016 |
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Doc | 2016 |
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F | 2016 |
Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, | 2016 |
The Efficacy of Adjuvant FOLFOX6 for Patients With Gastric Cancer after D2 Lymphadenectomy: A Propensity Score-matched Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; China; Femal | 2016 |
Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla | 2016 |
LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Topics: AC133 Antigen; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Co | 2016 |
Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HOR
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemother | 2016 |
A Phase II/III randomized controlled trial comparing perioperative versus postoperative chemotherapy with mFOLFOX6 for lower rectal cancer with suspected lateral pelvic node metastasis: Japan Clinical Oncology Group Study JCOG1310 (PRECIOUS study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administrat | 2017 |
EUS-guided paclitaxel injection as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation before surgery for localized or locoregional esophageal cancer: a multicenter prospective randomized trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2017 |
Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Fluorouracil; F | 2016 |
Chemoradiation with concomitant boost followed by radical surgery in locally advanced cervical cancer: a dose-escalation study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dose | 2008 |
Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
Liver perfusion chemotherapy with 5-Fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Deoxycytid | 2009 |
The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Carcinoma, Renal | 2008 |
A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; C | 2009 |
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2009 |
[Preliminary study of biweekly regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2008 |
Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemo | 2008 |
Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2009 |
Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
[Impact of different extents of lymph node dissection on the survival in stage III esophageal cancer patients].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Carcinoma, Squamous Cell | 2008 |
[Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; | 2009 |
Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptot | 2009 |
Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy | 2009 |
Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2010 |
Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Adult; Antineoplastic Combined Chemotherapy Protocols; Ax | 2010 |
[FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
[Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2009 |
FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 2010 |
Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2009 |
Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2009 |
Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Disease Progression; E | 2009 |
Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and Capecitabine, Cisplatin for locally advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; | 2009 |
Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2010 |
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Bre | 2010 |
Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2010 |
Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 2010 |
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov | 2009 |
Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov | 2009 |
Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov | 2009 |
Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov | 2009 |
Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2010 |
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 2009 |
A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Resp | 2010 |
A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring | 2010 |
A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2010 |
Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2010 |
Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemothe | 2010 |
Influence of neoadjuvant chemoradiation on the number and size of analyzed lymph nodes in esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2010 |
Feasibility study of sentinel lymph node biopsy in esophageal cancer with conservative lymphadenectomy.
Topics: Adenocarcinoma; Aged; Antimony; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2011 |
Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Capecitabin | 2011 |
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epi | 2011 |
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Admin | 2011 |
Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; F | 2012 |
[Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capec | 2011 |
Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2011 |
Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasm | 2011 |
Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.
Topics: Adolescent; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tum | 2011 |
Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; | 2012 |
[Nedaplatin or cisplatin combined with 5-fluorouracil for treatment of stage III-IVa nasopharyngeal carcinoma: a randomized controlled study].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Lymp | 2011 |
[Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Campto | 2011 |
Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2012 |
Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2011 |
Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Female; Fl | 2011 |
Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
[Results of adjuvant chemotherapy (XELOX) of advanced colorectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2011 |
The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2012 |
Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2012 |
Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2012 |
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2012 |
Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diabe | 2012 |
Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetax | 2012 |
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modali | 2012 |
Is neck dissection necessary after induction plus concurrent chemoradiotherapy in complete responder head and neck cancer patients with pretherapy advanced nodal disease?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Long-term outcome of irradiation with or without chemotherapy for esophageal squamous cell carcinoma: a final report on a prospective trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2012 |
Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2012 |
Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Female; Flu | 2013 |
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brea | 2013 |
Sequential docetaxel as adjuvant chemotherapy for node-positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoradiotherapy; Ch | 2013 |
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2013 |
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2013 |
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2013 |
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2013 |
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2013 |
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2013 |
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2013 |
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2013 |
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2013 |
Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2002 |
Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2002 |
Selective lymph node dissection following hyperfractionated accelerated radio-(chemo-)therapy for advanced head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2002 |
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2002 |
Dose-dense anthracycline-based chemotherapy for node-positive breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2002 |
Pathologic changes related to CMF primary chemotherapy in breast cancer. Pathological evaluation of response predicts clinical outcome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2002 |
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroups.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2002 |
Block sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cyclophospham | 2002 |
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols | 2003 |
Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Axil | 2003 |
Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2003 |
Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 2003 |
Recurrent gastric adenocarcinoma with unusual metastatic localization and excellent response to docetaxel and 5-FU continuous infusion.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Doc | 2003 |
A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Dru | 2003 |
Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cause of Deat | 2003 |
[Concurrent chemotherapy and radiation therapy for unresectable locally advanced carcinoma of the esophagus. Phase II study and clinical review on literature].
Topics: Adult; Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 2003 |
Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcino | 2003 |
Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2003 |
A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorect | 2003 |
Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemother | 2003 |
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2003 |
Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 2003 |
[A prospective study of combined chemoradiotherapy followed by surgery in the treatment of esophageal carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2003 |
Postoperative chemotherapy vs chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cis | 2003 |
[The modern organ- and function-sparing surgical treatment in oncology].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci | 2003 |
Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2003 |
Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
Topics: Adult; Amenorrhea; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2003 |
[Appropriate duration of postoperative oral adjuvant chemotherapy with HCFU for colorectal cancer].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Diseas | 2004 |
Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 2004 |
Adjuvant oral 5-fluorouracil for cervical cancer: Japanese Gynecologic Oncology Group report.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; | 2004 |
[Radiation and concomitant chemotherapy after surgery for breast cancer].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 2004 |
[Rationale and progress of the phase III trial: intensification of the treatment of locally advanced squamous cell carcinoma of the anal canal].
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 2003 |
Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2004 |
Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2004 |
[Phase I study of capecitabine with concurrent radiotherapy in early-stage nasopharyngeal carcinoma].
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: a randomized controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Ch | 2004 |
Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized c
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2004 |
An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Canada; | 2005 |
Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemothe | 2004 |
Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2004 |
Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; British Columbia; Chemotherapy, Ad | 2005 |
Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; British Columbia; Chemotherapy, Ad | 2005 |
Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; British Columbia; Chemotherapy, Ad | 2005 |
Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; British Columbia; Chemotherapy, Ad | 2005 |
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Com | 2005 |
Long-term efficacy and toxicity of the FEC100 regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis | 2004 |
Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Humans; Leucovo | 2005 |
Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Fluorourac | 2005 |
Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2005 |
Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
A phase II study on the safety and efficacy of 5-fluorouracil, epirubicin, cyclophosphamide (FEC) followed by paclitaxel in the adjuvant treatment of breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2005 |
Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colonic Neoplasms; DNA, Neoplasm; Drug Administrati | 2005 |
[Pharmacokinetic modulating chemotherapy highly effective for colorectal carcinoma metastases to multiple organs].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chronothe | 2005 |
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2005 |
[Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Pr | 2005 |
Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2005 |
Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Brea | 2005 |
Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Ca
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 2005 |
Benefits of axillary radiotherapy unclear in women with early stage breast cancer undergoing conservative breast surgery without axillary dissection.
Topics: Antineoplastic Agents; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Female; F | 2005 |
A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Com | 2005 |
Prediction of mesorectal nodal metastases after chemoradiation for rectal cancer: results of a randomised trial: implication for subsequent local excision.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Fluorouracil; | 2005 |
[The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2005 |
Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biopsy, Needle | 2005 |
[A randomized controlled trail of taxol-based combination regimens for advanced gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; F | 2005 |
Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dise | 2006 |
Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dis | 2006 |
Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease Progression; Female; | 2006 |
Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Axilla; Bayes Theorem; Brea | 2006 |
A pilot phase II study of capecitabine in advanced or recurrent breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms | 2006 |
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2006 |
Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Ch | 2006 |
Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer.
Topics: Adenocarcinoma; Alkylating Agents; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic | 2006 |
A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; | 2006 |
[Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2006 |
Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 2006 |
Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 2006 |
Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 2006 |
Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 2006 |
[Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Ca | 2006 |
Ten-year follow-up results of a randomised controlled study comparing level-I vs level-III axillary lymph node dissection for primary breast cancer.
Topics: Antineoplastic Agents; Axilla; Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; F | 2006 |
[A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set
Topics: Anorexia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Ne | 2006 |
Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2007 |
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2006 |
Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: An analysis of outcomes in a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Confidence Intervals; Disea | 2007 |
[Evaluation of docetaxel, CDDP and 5-FU combined therapy as second-line chemotherapy for esophagus cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2007 |
Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2007 |
The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1-3 positive nodes: an analysis of prospective data from British Colum
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cyclophospham | 2007 |
Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitab | 2006 |
Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2007 |
[Concurrent chemoradiotherapy followed by adjuvant chemotherapy for stage III-IVa nasopharyngeal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2007 |
[Efficacy of docetaxel combined capecitabine on metastatic breast cancer].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2007 |
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Surv | 2007 |
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemothera | 2007 |
Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2007 |
Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2007 |
Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group.
Topics: Adult; Age Factors; Anemia; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Breast | 2008 |
Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Colorectal Neoplasms; | 2007 |
[Comparison of efficacy of docetaxel combined cisplatin (TP regimen) and cisplatin combined 5-fluorouracil (PF regimen) on locally advanced nasopharyngeal carcinoma].
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2007 |
A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2007 |
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci | 2008 |
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineo | 2008 |
A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma; Disease-Fre | 2007 |
U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2008 |
Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineo | 2007 |
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuva | 2008 |
Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; | 2008 |
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2008 |
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; | 2008 |
A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2008 |
A phase II trial of low-dose gemcitabine and radiation alternated to cisplatin and 5-fluorouracil: an active and manageable regimen for stage IV squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2008 |
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2008 |
Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Co | 1984 |
Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modali | 1984 |
Adjuvant chemotherapy of large bowel cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Floxu | 1982 |
Methyl-CCNU, 5-fluorouracil, vincristine, and streptozocin (MOF-STREP) in metastatic colo-rectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topi | 1983 |
The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1983 |
A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; BCG Vaccine; Breast Neoplasms; | 1983 |
Adjuvant chemotherapy in stage-II breast cancer: an overview of the NSABP clinical trials.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical | 1983 |
Multiple trials of adjuvant chemohormonal therapy in the treatment of breast cancer: preliminary results--the ECOG experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1983 |
Cancer and Leukemia Group B adjuvant chemotherapy trials in postmastectomy breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1983 |
Adjuvant therapy of breast cancer: the Southwest Oncology Group experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1983 |
Postmastectomy adjuvant chemotherapy with or without radiation therapy in women with operable breast cancer and positive axillary lymph nodes: the Southeastern Cancer Study Group experience.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as | 1983 |
Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage-II breast cancer: five-year results.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Clinical Trials as To | 1983 |
Treatment of primary breast cancer with L-PAM/5-FU and tamoxifen: an interim report.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1983 |
Breast cancer 1984: state of the art.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr | 1984 |
Ludwig Breast Cancer trial LBCS III: chemo- and endocrine adjuvant treatment in postmenopausal patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Co | 1984 |
Postmenopausal node-positive comparison of observation with CMFP and CMPF + tamoxifen adjuvant therapy: an Eastern Cooperative Oncology Group trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Co | 1984 |
Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Co | 1984 |
Current results of the University of Arizona Adjuvant Breast Cancer trials (1974-1984).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1984 |
Significance of drug dose, timing and radiotherapy in adjuvant therapy of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Clinical Trials as To | 1984 |
The use of a natural history data base to compare outcome among several trials of adjuvant chemotherapy for stage II breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1984 |
Adjuvant systemic therapy in postoperative node-positive patients with breast carcinoma: the CALGB trial and the ECOG premenopausal trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Clinical Trial | 1984 |
Adjuvant therapy of breast cancer: a Southwest Oncology Group experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1984 |
Short- or long-term chemotherapy for node-positive breast cancer: LMF 6 versus 18 cycles. SAKK study 27/76.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chlorambucil; Clinical Trials as T | 1984 |
Adjuvant programs for postmenopausal women with node-positive breast cancer: preliminary analysis of 5-year results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Co | 1984 |
Tamoxifen and combination chemotherapy as adjuvant treatment in postmenopausal women with breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chlorambucil; Clinical Trial | 1984 |
A controlled trial of adjuvant chemotherapy with melphalan versus cyclophosphamide, methotrexate, and fluorouracil for breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Co | 1984 |
Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 1984 |
Southeastern Cancer Study Group: breast cancer studies 1972-1982.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Cytarabin | 1983 |
[Follow-up study of preoperative oral administration of an antineoplastic agent as an adjuvant chemotherapy in stomach cancer].
Topics: Administration, Oral; Clinical Trials as Topic; Emulsions; Fluorouracil; Follow-Up Studies; Humans; | 1982 |
Adjuvant chemotherapy for breast cancer.
Topics: Age Factors; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Do | 1981 |
[Multihospital randomized study on the adjuvant chemotherapy with mitomycin-C and Futraful for gastric cancer V. Estimation of 5-year survival rate].
Topics: Drug Therapy, Combination; Fluorouracil; Gastrectomy; Humans; Lymphatic Metastasis; Mitomycin; Mitom | 1982 |
Systemic adjuvant therapy with BCG versus BCG + 5FU in colorectal cancer Dukes' Class C: updated critical analysis.
Topics: Aged; BCG Vaccine; Carcinoembryonic Antigen; Clinical Trials as Topic; Colonic Neoplasms; Female; Fl | 1980 |
Combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in advanced breast carcinoma.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; | 1980 |
A randomized comparative trial of chemotherapy and irradiation therapy for stage II breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Dr | 1981 |
[The results of 5 years of ancillary chemotherapy of carcinoma of the breast (author's transl)].
Topics: Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Flu | 1981 |
The case for adjuvant CMF chemotherapy in breast cancer. Has it been made?
Topics: Axilla; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Dose-Response Relationship, Dr | 1981 |
Divergent effect of adjuvant chemo-immunotherapy on recurrence rates in node-negative and node-positive breast cancer patients.
Topics: BCG Vaccine; Breast Neoplasms; Chlorambucil; Clinical Trials as Topic; Drug Therapy, Combination; Fe | 1980 |
Adjuvant combination chemotherapy for operable breast cancer. Trials in progress at the Istituto Nazionale Tumori of Milan.
Topics: Aged; Amenorrhea; Axilla; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy | 1981 |
Multimodal therapy with CMF in resectable breast cancer with positive axillary nodes: the Milan Institute experience.
Topics: Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Drug The | 1982 |
Adjuvant chemoimmunotherapy with LMF plus BCG in node-negative and node-positive breast cancer - intermediate report at 4 years.
Topics: Breast Neoplasms; Chlorambucil; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorou | 1982 |
Favorable factors in the adjuvant therapy of breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr | 1982 |
Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study.
Topics: Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Flu | 1982 |
Phase II trial of 5-fluorouracil and alpha-2b interferon in patients with hormone-refractory metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Drug Admini | 1994 |
[Intraperitoneal infusion therapy of MTX and 5-FU for advanced gastric cancer and its peritoneal metastasis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration | 1995 |
Randomized, comparative study of high-dose (with autologous bone marrow support) versus low-dose cyclophosphamide, cisplatin, and carmustine as consolidation to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for patients with operable stage II o
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carmu | 1995 |
Randomized cooperative study of perioperative chemotherapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1995 |
Neoadjuvant chemotherapy with etoposide, leucovorin, 5-fluorouracil and cisplatin for advanced esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1995 |
Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 1995 |
[A randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Sur | 1995 |
[High tissue concentration of 5-FU reduced local recurrence after administration of tegafur suppositories].
Topics: Chemotherapy, Adjuvant; Fluorouracil; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Neoplas | 1995 |
Combination 5-fluorouracil (5-FU) and alpha interferon (IFN) in metastatic colorectal cancer.
Topics: Adult; Aged; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Inter | 1995 |
[Combination therapy with interferon-alpha and continuous infusion of 5-fluorouracil for advanced renal cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Sch | 1995 |
Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles. The French Adjuvant Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Admi | 1993 |
Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collaborativ
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1993 |
Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control--preliminary results of a 4-arm randomised trial. The French Adjuvant Study Group.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 1993 |
Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an intergroup study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distributi | 1995 |
A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Epirubicin; Female; Fluoro | 1995 |
[Clinico-pathological study of preoperative chemotherapy of esophageal cancer by combined use of three drugs--cisplatin, 5-FU and leucovorin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Esophageal | 1995 |
Treating esophageal cancer with a combination of chemotherapy, radiation, and excision.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1995 |
[Chemotherapy against lymphatic metastases of gynecologic cancer via pelvic retroperitoneal cannulation: a preliminary report].
Topics: Adenocarcinoma; Adult; Aged; Animals; Catheterization; Endometrial Neoplasms; Female; Fluorouracil; | 1995 |
Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: a joint European Organization for Research and Treatment of Cancer-Dutch Breast Cancer Working Party Study. Cooperating Investigator
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1995 |
The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemother | 1994 |
Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1995 |
Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplati | 1995 |
Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Appendicea | 1995 |
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1995 |
[Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy].
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Admi | 1995 |
c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Ch | 1994 |
Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 1994 |
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ch | 1994 |
[A study of preoperative administration of 5'-DFUR in patients with colo-rectal cancer].
Topics: Administration, Oral; Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans | 1994 |
A clinical trial of continuous cisplatin-fluorouracil induction chemotherapy and supracricoid partial laryngectomy for glottic carcinoma classified as T2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemother | 1994 |
[Cisplatin/5-FU versus carboplatin/5-FU. 5 year follow-up].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoth | 1994 |
5-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes C colorectal cancer.
Topics: Aged; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Colonic Neoplasms; Confidence | 1994 |
[The usefulness of pre- and immediately postoperative chemotherapy in colorectal cancer].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 1994 |
A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
Chemotherapy and extended-field radiation therapy to para-aortic area in patients with histologically proven metastatic cervical cancer to para-aortic nodes: a phase II pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1994 |
Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modali | 1993 |
Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 1993 |
Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta | 1994 |
Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 1993 |
[5-fluorouracil, cisplatin and retinol palmitate in the management of advanced cancer of the oral cavity. Phase II study].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diterpenes; Female; Fluorouracil; | 1993 |
One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1993 |
Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma.
Topics: Abdominal Neoplasms; Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; F | 1993 |
Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Fem | 1993 |
A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin C and 5 fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1993 |
Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, | 1993 |
A preliminary report of a pilot randomized trial comparing cyclophosphamide, methotrexate and 5-fluorouracil with cyclophosphamide, mitoxantrone and 5-fluorouracil in the adjuvant therapy of stage II breast cancer with four or more positive axillary nodes
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubic | 1993 |
Maintenance tamoxifen after induction postoperative chemotherapy in node-positive breast cancer patients: the Eastern Cooperative Oncology Group Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1993 |
Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cycl | 1993 |
[Determination of 5-FU tissue concentrations after oral UFT administration in tumors of the head and neck].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1996 |
Adjuvant six cycles of high-dose adriamycin, cyclophosphamide, methotrexate, 5-fluorouracil (ACMF) vs. 12 cycles of low-dose ACMF with tamoxifen for premenopausal, node-positive breast cancer patients: results of a prospective randomized study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubic | 1995 |
Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemother | 1996 |
Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distribution; Combined | 1996 |
Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Neoplasms; Bone Marrow Tr | 1996 |
Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Adminis | 1996 |
Brachytherapy and continuous infusion 5-fluorouracil for treatment of locally advanced, lymph node negative, prostate cancer: a phase I trial.
Topics: Aged; Antineoplastic Agents; Brachytherapy; Combined Modality Therapy; Fluorouracil; Gold Radioisoto | 1996 |
Local hyperthermia of N2/N3 cervical lymph node metastases: correlationof technical/thermal parameters and response.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1996 |
Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer. A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modality Thera | 1996 |
Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.
Topics: Adult; Age Factors; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 1996 |
A long-term assessment of adjuvant chemotherapy on outcome of patients with extracapsular spread of cervical metastases from squamous carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1996 |
Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 1996 |
Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Com | 1996 |
Simultaneous radiochemotherapy for recurrent and metastatic breast carcinoma: evaluation of two treatment concepts.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Ant | 1996 |
Prognostic factors of colorectal cancer. Results of multivariate analysis of curative resection cases with or without adjuvant chemotherapy.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 1996 |
[Evaluation of chemotherapy in the treatment of advanced colorectal cancer--pilot study of 5-FU by biochemical modulation].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplas | 1996 |
[Effect of leucovorin and 5-FU for advanced colorectal cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 1996 |
Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Carcinoma in Situ; Carcino | 1996 |
Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of finding
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1996 |
Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. International Breast Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1996 |
[Administration method and recurrence-preventing effect of medroxyprogesterone acetate (MPA) as a postoperative adjuvant endocrine therapy for stage III breast cancer. Kitakyushu Collaborative Study Group for Breast Cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Breast Neoplasms; Che | 1996 |
Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1996 |
[Clinical study of ambulatory cancer chemotherapy for advanced colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Col | 1995 |
Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benef | 1996 |
[Sequencing of chemotherapy and radiotherapy following breast-preserving treatment of breast carcinoma].
Topics: Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alky | 1996 |
Chemotherapy for lymphatic metastatic gynecologic cancer via pelvic retroperitoneal cannulation: a preliminary report.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Catheterization, Peripheral; Feasibility Studies; Fema | 1996 |
Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 1996 |
Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ch | 1997 |
Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 1997 |
[The influence on prognosis of intraoperative chemotherapy for adenocarcinoma of gastric cardia].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cardia; Female; Fluorouracil; Humans; Intraop | 1996 |
Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergi | 1997 |
Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1997 |
[Preoperative adjuvant chemotherapy with oral anticancer agents for stomach cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, | 1997 |
Phase I-II study of combined 5-fluorouracil and cisplatin chemotherapy and altered fractionation radiotherapy for advanced squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 1997 |
Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Colorectal Neoplasms; Fe | 1997 |
Does information from axillary dissection change treatment in clinically node-negative patients with breast cancer? An algorithm for assessment of impact of axillary dissection.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; C | 1997 |
[Prospective controlled study on the usefulness of Carmofur as a postoperative adjuvant chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Admi | 1997 |
Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 1997 |
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; | 1997 |
Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Com | 1997 |
Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Com | 1997 |
Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Com | 1997 |
Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Com | 1997 |
Lack of effectiveness of adjuvant alternating chemotherapy in node-positive, estrogen-receptor-negative premenopausal breast cancer patients: results of a multicentric Italian study. The Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group (GROC
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 1997 |
Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Fem | 1998 |
Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
Topics: Cell Division; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Ge | 1998 |
[Sequential chemotherapy with methotrexate and 5-fluorouracil for advanced gastric cancer].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 1998 |
Neoadjuvant chemotherapy with accelerated CNF plus G-CSF in patients with breast cancer tumors larger than three centimeters: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1998 |
Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 1998 |
Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: Phase II study of the Radiation Therapy Oncology Group 92-10.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 1998 |
Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast | 1998 |
Squamous cell granulomas of the neck: histologic regression of metastatic squamous cell carcinoma following chemotherapy and/or radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1998 |
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-F | 1998 |
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI.
Topics: Adult; Age Distribution; Aged; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Ne | 1998 |
Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1998 |
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1998 |
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 1998 |
Chemoradiotherapy as an alternative to radiotherapy alone in fast proliferating head and neck squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Cycle; Cell Division; | 1997 |
Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free S | 1998 |
Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free S | 1998 |
Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free S | 1998 |
Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free S | 1998 |
Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free S | 1998 |
Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free S | 1998 |
Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free S | 1998 |
Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free S | 1998 |
Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free S | 1998 |
Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cyclophosphamide; Disease- | 1998 |
Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1999 |
Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by adjunctive chemotherapy.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 1999 |
Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1999 |
Adjuvant dose-intense chemotherapy with peripheral blood stem cell support in stage II-III breast cancer with five to nine involved axillary lymph nodes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuv | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Brachytherapy; Carcinoma; Cisplatin; Combined | 1999 |
Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Surv | 1999 |
[Influence of preoperative on gastric cancer tissues and cells].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 1997 |
Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineopl | 1999 |
Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1999 |
The effects of Chinese drugs for supporting healthy energy and removing blood stasis on postoperative metastasis of gastric carcinoma and ornithine decarboxylase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubic | 1998 |
Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1999 |
Intra-arterial 5-fluorouracil and intravenous folinic acid in the treatment of liver metastases from colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 1999 |
Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 1999 |
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1999 |
[Results of a prospective randomized trial with induction chemotherapy for cancer of the oral cavity and tonsils].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Moda | 1999 |
Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cycl | 1999 |
FILM (5-fluorouracil, ifosfamide, leucovorin and mitomycin C), an alternative chemotherapy regimen suitable for the treatment of advanced breast cancer in the 'out-patient' setting.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Brea | 1999 |
Adjuvant chemotherapy with a combination of mitoxantrone, methotrexate, 5-fluorouracil for node-positive breast cancer: phase II pilot study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; C | 1999 |
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2000 |
Value of estrogenic recruitment before chemotherapy: first randomized trial in primary breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Ant | 2000 |
Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 1999 |
A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2000 |
[Dose intensified adjuvant chemotherapy in high risk breast carcinoma with 4-9 positive lymph nodes].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2000 |
Phase II trial of adjuvant radiation and intraperitoneal 5-fluorouracil for locally advanced colon cancer: results with 10-year follow-up.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Disease-Free Survival; Female; Fluo | 2000 |
A phase III study of high-dose intensification without hematopoietic progenitor cells support for patients with high-risk primary breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Car | 2000 |
Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cell Division | 2000 |
[Biweekly low-dose cisplatin and 5-fluorouracil combination chemotherapy for advanced gastrointestinal carcinoma].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2000 |
[Randomized comparative study of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) and UFT-tamoxifen regimens as adjuvant chemotherapy after surgery for breast cancer: Tochigi Prefectural Study Group for Post-Breast Cancer Adjuvant Chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2000 |
Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2000 |
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Adminis | 2000 |
[Adjuvant therapy of colon cancer stage C MAC. Adverse effects and efficacy in the Department of Oncology, Soroka Medical Center in the years 1991-1994].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neop | 1999 |
Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Chemot | 2000 |
Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Renal Cell; Disease- | 2000 |
Effect of neoadjuvant chemotherapy for lymph node micrometastasis and tumor cell microinvolvement in the patients with esophageal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2000 |
The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Needle; Breast Neoplasm | 2000 |
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Needle; Breast Neoplasm | 2000 |
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
Topics: Acute Disease; Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2000 |
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
Topics: Acute Disease; Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2000 |
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
Topics: Acute Disease; Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2000 |
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
Topics: Acute Disease; Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2000 |
Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin | 2000 |
[Short-term hypofractionated radiotherapy followed by total mesorectal excision].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2000 |
Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2001 |
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 2001 |
Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cisplatin; Cy | 2001 |
[Usefulness of ambulatory adjuvant chemotherapy with low-dose epirubicin in patients with axially-node positive breast cancer: Chiba Epirubicin Cooperative Study Group].
Topics: Adult; Ambulatory Care; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; | 2001 |
The relationship between improved prognosis in gastric cancer patients in the last 25 years and changing methods of surgical and combined treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcino | 2000 |
Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Biomarkers; Breast Neoplasms; C | 2001 |
Prediction of node-negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry: an Eastern Cooperative Oncology Group Study (2192).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2001 |
Intra-arterial plus i.v. chemotherapy for advanced bulky squamous cell carcinoma of the buccal mucosa.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2001 |
Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvan | 2001 |
Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF.
Topics: Adult; Age Distribution; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyc | 2001 |
Adjuvant radiochemotherapy in the treatment of completely resected, locally advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; | 2001 |
[Cisplatin and vinorelbine therapy of previously treated advanced breast cancer (preliminary studies)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide | 2001 |
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
[Neoadjuvant chemotherapy for advanced gastric cancer with para-aortic lymph node metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Cisplatin; Drug Administrati | 2001 |
Postoperative chemoendocrine therapy for women with node-positive stage II breast cancer with combined cyclophosphamide, tamoxifen, and 1-hexylcarbamoyl-5-fluorouracil.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Ne | 2001 |
Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Sur | 2001 |
Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chi-Square Distributi | 2002 |
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
[Laryngeal Preservation with Induction Chemotherapy. Experience of two GETTEC Centers, Between 1985 and 1995].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2002 |
Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2002 |
The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative dos
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Belgium; Breast Neoplasms; Cyclophospha | 2002 |
Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2002 |
Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial.
Topics: Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality The | 2002 |
A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2002 |
Prolongation of postoperative disease-free interval and survival in human colorectal cancer by B.C.G. or B.C.G. plus 5-fluorouracil.
Topics: Administration, Oral; BCG Vaccine; Colonic Neoplasms; Evaluation Studies as Topic; Fluorouracil; Fol | 1976 |
Treatment of early breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Drug The | 1978 |
Advances in the staging and treatment of ovarian cancer.
Topics: Alkylating Agents; Altretamine; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Cyclophos | 1977 |
L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. An update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU).
Topics: Adenocarcinoma, Mucinous; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Clinical Trials | 1977 |
The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance.
Topics: Amenorrhea; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; | 1977 |
Five-year follow-up results of a collaborative study of therapies for carcinoma of the bladder.
Topics: Clinical Trials as Topic; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mal | 1977 |
Adjuvant chemotherapy in the primary management of breast cancer.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Clinica | 1977 |
Surgery and adjuvant chemotherapy in the treatment of operable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Clinical Trials as Topic; Cycloph | 1977 |
Adjuvant combination chemotherapy in primary mammary carcinoma: the CMF program.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, C | 1977 |
Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer patients. Intermediate report of a randomized trial in 242 patients.
Topics: Administration, Oral; Aged; BCG Vaccine; Breast Neoplasms; Chlorambucil; Clinical Trials as Topic; F | 1978 |
[Combined drug treatment of far-advanced forms of breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Castration; Clinical Trials as Topic; Cyclophosphamide; Dru | 1978 |
Pilot study on adjuvant chemotherapy and hormonal therapy for irradiated inoperable breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Dr | 1978 |
Adjuvant chemotherapy for large bowel cancer: an optimistic appraisal.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Lymphatic Metastasis; Postoperati | 1979 |
Immunology and adjuvant chemoimmunotherapy of breast cancer.
Topics: Aged; Animals; Antibodies, Neoplasm; BCG Vaccine; Breast Neoplasms; Carcinoma; Chick Embryo; Cycloph | 1976 |
[Chemotherapy of metastasizing breast cancers. Indications and results].
Topics: Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fema | 1975 |
[Neoadjuvant chemotherapy in combined treatment of breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 1992 |
Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: a South-Eastern Cancer Study Group (SEG) Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuv | 1992 |
A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Fema | 1992 |
Effectiveness of salvage neck dissection for advanced regional metastases when induction chemotherapy and radiation are used for organ preservation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Dr | 1992 |
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epi | 1992 |
Swiss adjuvant trials in women with node-negative breast cancer. OSAKO.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Chemotherapy, Adjuvan | 1992 |
Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1992 |
West Midlands Oncology Association trial of adjuvant chemotherapy in node-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Chlorambuc | 1992 |
Chemotherapy versus observation in high-risk node-negative breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Com | 1992 |
Cisplatin plus VP-16 combination chemotherapy in advanced refractory breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide | 1992 |
NSABP trials of adjuvant chemotherapy for breast cancer. A further look at the evidence.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, | 1991 |
The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1992 |
A randomized trial of chemotherapy (L-PAM vs CMF) and irradiation for node positive breast cancer. Eleven year follow-up of a Piedmont Oncology Association trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1991 |
[5-FU concentration in the tissue of gastric cancer, and evaluation of cancer chemotherapy with angiotensin-II].
Topics: Angiotensin II; Drug Administration Routes; Fluorouracil; Gastric Mucosa; Humans; Infusions, Intra-A | 1991 |
Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 1991 |
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1991 |
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1991 |
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1991 |
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1991 |
A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1991 |
Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1991 |
The role of intraluminal radiotherapy and concurrent 5-fluorouracil infusion in the management of carcinoma esophagus: a pilot study.
Topics: Adult; Aged; Brachytherapy; Brain Neoplasms; Combined Modality Therapy; Deglutition Disorders; Esoph | 1991 |
Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Mo | 1990 |
[Stage T4 bladder cancer. Impact of neoadjuvant chemotherapy on T4b tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1990 |
Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosphamide; D | 1990 |
Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administrat | 1990 |
Adjuvant treatment of operable stomach cancer with polyadenylic.polyuridylic acid in addition to chemotherapeutic agents: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Th | 1990 |
Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Proje
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubici | 1990 |
Evaluation of the worth of corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary breast cancer. Eight-year results from the National Surgical Adjuvant Breast and Bowel Project B-10.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bacterial Vaccines; Breast Neoplasms; Combined Modal | 1990 |
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1990 |
Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1990 |
[Combined radiotherapy and pre-radiation chemotherapy with cisplatin and 5-fluorouracil for advanced esophageal carcinoma. I. Clinical evaluation in cases with distant metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1990 |
[Adjuvant chemotherapy improves chances of survival in curative surgery of colon cancer, Dukes' stage C].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Fluoro | 1990 |
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1990 |
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1990 |
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1990 |
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1990 |
Prospective computerized simulation of breast cancer: comparison of computer predictions with nine sets of biological and clinical data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Computer | 1987 |
Prolonged adjuvant chemotherapy in breast cancer. The Scandinavian Adjuvant Chemotherapy Study 2.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1989 |
A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Co | 1989 |
Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1989 |
Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; C | 1989 |
Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1989 |
Levamisole with fluorouracil for colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Combine | 1989 |
Adjuvant radiotherapy and chemotherapy in resectable gastric cancer. A randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Human | 1989 |
Randomized multicenter 2 x 2-factorial design study of chemo/endocrine therapy in operable, node-positive breast cancer (protocol 2).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combined Modality | 1989 |
Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer patients: 10 year results.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Chlorambucil; Combine | 1989 |
Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Humans; Levamisole; Lymp | 1989 |
Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Castration; Clinical Trials | 1985 |
A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials | 1985 |
Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Combined Moda | 1988 |
Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1988 |
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; | 1989 |
Leucovorin and 5-fluorouracil as a treatment for disseminated cancer of the pancreas and unknown primary tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topi | 1988 |
Two years of cyclophosphamide and 5-fluorouracil as adjuvant chemotherapy for stage II and III breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1988 |
Performance of general hospitals in delivering adjuvant chemotherapy to breast cancer patients. G.I.V.I.O. (Interdisciplinary Group for Cancer Care Evaluation), Italy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Delivery of Heal | 1988 |
[A randomized controlled trial of surgical adjuvant therapy with mitomycin C, 5-fluorouracil and OK-432 in patients with gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Combined Modality Therapy | 1986 |
Tolerance of radiotherapy combined with adjuvant chemotherapy in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Combined Modality Therapy; | 1987 |
Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1988 |
Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1988 |
Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1987 |
Development and use of a natural history data base of breast cancer studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Clinical Tria | 1987 |
Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials | 1987 |
A clinical trial of mitoxantrone (novantrone) versus doxorubicin (adriamycin) in combination chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Clini | 1987 |
Combined treatment including postoperative chemotherapy in lung cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality T | 1988 |
Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; | 1986 |
Local control and survival in early breast cancer: the Milan trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Co | 1986 |
5-Fluorouracil chemotherapy and pelvic radiation in the treatment of large bowel cancer. Decreased toxicity in combined treatment with 5-fluorouracil administration through the intraperitoneal route.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule | 1986 |
Adjuvant chemo-immunotherapy in stage II carcinoma of the breast.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Cell Line; Clinical T | 1986 |
Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1986 |
Adjuvant therapy for breast cancer: a brief overview of the NSABP experience and some thoughts on neoadjuvant chemotherapy.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1986 |
Preoperative (neoadjuvant) chemotherapy for breast cancer: outline of the British Columbia Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Cell Division; Cli | 1986 |
Swiss adjuvant trial (OSAKO 06/74) with chlorambucil, methotrexate, and 5-fluorouracil plus BCG in node-negative breast cancer patients: nine-year results.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Chlorambucil; Clinica | 1986 |
A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; C | 1986 |
Adjuvant chemotherapy of breast cancer: a promising experiment or standard practice?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1985 |
Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1985 |
[Adjuvant chemotherapy following radical operations for cancer of the large intestine].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Com | 1985 |
The effects of multiple combination chemotherapy with vincristine, cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, adriamycin and prednisolone (VEMFAH) for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1985 |
Controversies in the management of potentially curable breast cancer.
Topics: Breast Neoplasms; Castration; Clinical Trials as Topic; England; Female; Fluorouracil; Humans; Lymph | 1974 |
Chemotherapy in primary therapy of cancer of the breast.
Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mast | 1967 |
Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation.
Topics: Adult; Aged; Axilla; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Female; Fluorouraci | 1968 |
1258 other studies available for fluorouracil and Lymph Node Metastasis
| Article | Year |
|---|---|
Intraoperative frozen section analysis of para-aortic lymph nodes after neoadjuvant FOLFIRINOX: will it soon become useless?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Frozen Sections; Human | 2022 |
PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma.
Topics: B7-H1 Antigen; Biomarkers, Tumor; Cell Line, Tumor; Cisplatin; Esophageal Neoplasms; Esophageal Squa | 2022 |
ypN0 in Patients With Definitive cN-positive Status After Preoperative Treatment Is a Prognostic Factor in Esophageal Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant | 2022 |
Protocols for the Evaluation of a Lymphatic Drug Delivery System Combined with Bioluminescence to Treat Metastatic Lymph Nodes.
Topics: Animals; Antineoplastic Agents; Drug Delivery Systems; Fluorouracil; Lymph Nodes; Lymphatic Metastas | 2022 |
[A Case of Long-Term Survival with S-1/Cisplatin for Liver Hilum Lymph Node Metastasis of Anal Canal Squamous Cell Carcinoma after Chemoradiotherapy].
Topics: Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamou | 2022 |
Protein Kinase D1 Correlates with Less Lymph Node Metastasis Risk, Enhanced 5-FU Sensitivity, and Better Prognosis in Colorectal Cancer.
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Lymphatic Metastasis; Prognosis; Protein Kinases | 2023 |
YpN0 rectal cancer patients with sterilized lymph nodes after neoadjuvant chemoradiotherapy are of greater risk of recurrence.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, A | 2020 |
Mystery of neck lump: an uncommon presentation of urachal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Diagnosis, | 2019 |
Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxe | 2019 |
PRDM14 promotes malignant phenotype and correlates with poor prognosis in colorectal cancer.
Topics: Adenocarcinoma; Adenoma; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; | 2020 |
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Prot | 2020 |
Prognostic Value of TWIST1 and EZH2 Expression in Colon Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Colonic Neoplas | 2021 |
Prognostic impact of residual lateral lymph node metastasis after neoadjuvant (chemo)radiotherapy in patients with advanced low rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Surv | 2019 |
Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati | 2020 |
[A Case of Lymph Node Recurrence with Invasion to the Trachea after the Resection of Esophageal Cancer Treated by Multidisciplinary Treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Sq | 2019 |
Morphological Study of Mesenteric Lymph Nodes in Rats with Experimental Breast Cancer Treated with Fragmented Double-Stranded DNA.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide | 2020 |
[PRIMARY SQUAMOUS CELL CARCINOMA OF THE PROSTATE: A CASE REPORT].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura | 2019 |
RHBDD2 overexpression promotes a chemoresistant and invasive phenotype to rectal cancer tumors via modulating UPR and focal adhesion genes.
Topics: Antimetabolites, Antineoplastic; Caco-2 Cells; Cell Adhesion; Cell Movement; Cell Proliferation; Dru | 2020 |
Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fema | 2020 |
Outcome of FOLFOX and Modified DCF Chemotherapy Regimen in Patients with Advanced Gastric Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Sectional Stu | 2020 |
Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cross- | 2020 |
Impact of Anatomic Extent of Nodal Metastasis on Adjuvant Chemotherapy Outcomes in Stage III Colon Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic | 2020 |
Five-year Outcomes of Chemotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Oesophagectomy in Oesophageal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel | 2020 |
Even a partial pathological response is associated with lower relapse rates in patients with operable rectal cancer undergoing neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase | 2021 |
Impact of microsatellite status on negative lymph node count and prognostic relevance after curative gastrectomy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2021 |
Improved response rate in patients with prognostically poor locally advanced rectal cancer after treatment with induction chemotherapy and chemoradiotherapy when compared with chemoradiotherapy alone: A matched case-control study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Case-Control Studie | 2021 |
Early prediction of response to neoadjuvant chemotherapy using contrast-enhanced ultrasound in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2021 |
Tumor Volume as Predictor of Pathologic Complete Response Following Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Capecitabine; Chemoradiotherapy; Female; Fluorouracil; Huma | 2021 |
The "Dextran-Magnetic Layered Double Hydroxide-Fluorouracil" Drug Delivery System Exerts Its Anti-tumor Effect by Inducing Lysosomal Membrane Permeability in the Process of Cell Death.
Topics: Adenocarcinoma; Antineoplastic Agents; Azure Stains; Blotting, Western; Cell Death; Cell Line, Tumor | 2021 |
Oncological Outcomes of Lateral Pelvic Lymph Node Metastasis in Rectal Cancer Treated With Preoperative Chemoradiotherapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Colectomy; Female; Fluorouracil; | 2017 |
Treatment of esophageal cancer with radiation therapy -a pan-Chinese survey of radiation oncologists.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvan | 2017 |
Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2017 |
Acute Disseminated Intravascular Coagulation after Oxaliplatin Infusion.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Creatinine; Disseminated In | 2017 |
The Role of Concomitant Radiation Boost in Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Fe | 2017 |
[Subacute cutaneous lupus erythematosus induced by 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Car | 2017 |
Clinical Outcomes of Resectable Esophageal Cancer with Supraclavicular Lymph Node Metastases Treated with Curative Intent.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Cisplatin; Esoph | 2017 |
Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone | 2017 |
[A Case of Perianal Squamous Cell Carcinoma with Left Inguinal Lymph Node Metastasis That Showed a Complete Response More Than Five Years after Chemotherapy and Concomitant Proton Beam Therapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Che | 2017 |
Combination of NRP1-mediated iRGD with 5-fluorouracil suppresses proliferation, migration and invasion of gastric cancer cells.
Topics: Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Fluoro | 2017 |
Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 2017 |
Subcutaneous Draining of Lower Extremity Edema in a Patient With Advanced Cancer Relieves Scrotal Swelling and Improves Mobility.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drainage; Edema; Fluoroura | 2018 |
Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Predictive Value of Circulating Tumor Cells for Evaluating Short- and Long-Term Efficacy of Chemotherapy for Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cy | 2017 |
Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2017 |
[A Case of Bilateral Lymph Node Metastases of Rectal Cancer Treated with Chemotherapy and Surgery].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Combined Modality Therapy; Fluoro | 2017 |
Effect of a Shortened Duration of FOLFOX Chemotherapy on the Survival Rate of Patients with Stage II and III Colon Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Survival; Drug | 2018 |
Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ducta | 2018 |
Anterior Mediastinal Lymph Nodes in Chemically Induced Breast Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinogens; Cell Proliferation; Cyclophosp | 2017 |
Apical Lymph Nodes in the Distant Metastases and Prognosis of Patients with Stage III Colorectal Cancer with Adequate Lymph Node Retrieval Following FOLFOX Adjuvant Chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2019 |
Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Adverse Prognostic Factors of Advanced Esophageal Cancer in Patients Undergoing Induction Therapy with Docetaxel, Cisplatin and 5-Fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Disease-Free Surviv | 2018 |
[A Case of Cecal Cancer with Para-Aortic Lymph Node Metastasis and Peritoneum Dissemination Treated with Curative Resection after mFOLFOX6 plus Panitumumab Chemotherapy].
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cecal Neoplasms | 2017 |
[Three-Year Survival after Lymphadenectomy for Residual Lymph Node Metastasis of Esophageal Cancer with Invasion into the Trachea and Carotid Artery after Chemoradiotherapy - A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carotid Arteries; Chemoradiotherapy; Cisplatin | 2017 |
KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neopl | 2018 |
Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colec | 2018 |
Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2018 |
Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Che | 2018 |
FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2018 |
Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chi | 2018 |
Indolent Nodal Relapse of Colon Carcinoma with Associated Tumor Thrombus Invading the Superior Mesenteric Vein.
Topics: Adenocarcinoma, Mucinous; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2019 |
How should BRAF V600E-mutated colorectal cancer be treated?
Topics: Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2018 |
Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma.
Topics: Aged; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neoplasms; Esophageal Squamou | 2018 |
[Five-Year Survival of Two Patients with Para-Aortic Lymph Node Metastasis Treated with Four FOLFOX6and Four FOLFIRI Courses in Combination with Bevacizumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Bevacizumab; Camptothecin; Colonic Neoplasms; | 2018 |
Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluo | 2018 |
C-Reactive Protein Level Predicts Survival Outcomes in Rectal Cancer Patients Undergoing Total Mesorectal Excision After Preoperative Chemoradiation Therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; C-Reactive Pr | 2018 |
FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biom | 2019 |
Neoadjuvant Capecitabine Results in Similar Total Lymph Node Harvests as 5-Fluorouracil but an Increased Number of Lymph Nodes Containing Adenocarcinoma on Resection.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Colorectal | 2018 |
The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant | 2019 |
Paclitaxel, 5-fluorouracil, and leucovorin combination chemotherapy as first-line treatment in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2019 |
"Sentinel lymph node imaging with sequential SPECT/CT lymphoscintigraphy before and after neoadjuvant chemoradiotherapy in patients with cancer of the oesophagus or gastro-oesophageal junction - a pilot study".
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Colloids; | 2018 |
[Second-line treatment with FOLFIRI plus aflibercept in a patient with right-sided, BRAF mutated metastatic colon cancer.]
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic | 2018 |
A novel miR-365-3p/EHF/keratin 16 axis promotes oral squamous cell carcinoma metastasis, cancer stemness and drug resistance via enhancing β5-integrin/c-met signaling pathway.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Fluor | 2019 |
Study of Thymidylate Synthase (TS) and Dihydropyrimidine Dehydrogenase (DPD) Expressions on 5-Fluorouracil in Oral Squamous Cell Carcinoma
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Squamous Cell; Case-Control Studies; | 2019 |
Tumor Size Improves the Accuracy of the Prognostic Prediction of Lymph Node-Negative Gastric Cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuv | 2019 |
Treatment of false-negative metastatic lymph nodes by a lymphatic drug delivery system with 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug | 2019 |
YWHAE promotes proliferation, metastasis, and chemoresistance in breast cancer cells.
Topics: 14-3-3 Proteins; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Moveme | 2019 |
Retrospective comparison of efficacy and safety of CAPOX and FOLFOX regimens as adjuvant treatment in patients with stage III colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Female | 2019 |
Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2019 |
Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bile Duc | 2019 |
Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2019 |
Lymph node invasion might have more prognostic impact than R status in advanced esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Card | 2013 |
The prognostic nutritional index predicts long-term outcomes of gastric cancer patients independent of tumor stage.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2013 |
Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2013 |
Which is the optimal response criteria for evaluating preoperative treatment in esophageal cancer: RECIST or histology?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2013 |
[A case of squamous cell carcinoma of the esophagogastric junction with bulky no.7-metastatic node successfully treatedby chemoradiation followed by surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Chemoradiotherapy; | 2013 |
CD24 expression predicts distant metastasis in extrahepatic bile duct cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Ex | 2013 |
Endoscopic ultrasound in staging esophageal cancer after neoadjuvant chemotherapy--results of a multicenter cohort analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2013 |
Routine defunctioning stoma after chemoradiation and total mesorectal excision: a single-surgeon experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Colostomy; Dose Fractiona | 2013 |
Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2013 |
The impact of glycemic levels in patients with colon cancer.
Topics: Antineoplastic Agents; Blood Glucose; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diet; Fluorourac | 2013 |
[Regional chemotherapy in locally advanced and metastatic gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Chemotherapy, Adjuva | 2012 |
The recurrence and survival of oral squamous cell carcinoma: a report of 275 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2013 |
Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis.
Topics: Animals; Antineoplastic Agents; Carbon Monoxide; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; C | 2013 |
The value of expression of M2-PK and VEGF in patients with advanced gastric cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; Follow-Up Studies; Gene Expression Regu | 2013 |
[Tolerance and efficacy of preoperative radiation therapy for elderly patients treated for rectal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Dose Fractionation, Radiatio | 2013 |
REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; C | 2013 |
Histopathological regression grading matches excellently with local and regional spread after neoadjuvant therapy of rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Chi-Square Distributio | 2013 |
Neoadjuvant-intensified treatment for rectal cancer: time to change?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2013 |
Virchow lymph node metastatic recurrence of sigmoid colon cancer with severe lymph node metastases successfully treated using systemic chemotherapy combined with radiotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2013 |
Evaluation of p53 protein as a prognostic factor for oral cancer surgery.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined C | 2013 |
Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2014 |
[Results of combined treatment of patients with metastatic gastric cancer. Case study].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2013 |
Hepatoid adenocarcinoma of the stomach: an unusual case of elevated alpha-fetoprotein with prior treatment for hepatocellular carcinoma.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2013 |
Significance of GSTP1 for predicting the prognosis and chemotherapeutic efficacy in esophageal squamous cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Chemotherapy, Adj | 2013 |
[A case of mediastinal lymph node gastric cancer recurrence during S-1 adjuvant therapy successfully treated with cisplatin + capecitabine as second-line chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2013 |
Treatment outcome of high-dose-rate interstitial radiation therapy for patients with stage I and II mobile tongue cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carboplatin; | 2013 |
Aggressive strategy for the treatment of synchronous metastatic anal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2013 |
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoembryoni | 2013 |
Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Fine-Ne | 2013 |
Metastatic lymph node ratio in stage III rectal carcinoma is a valuable prognostic factor even with less than 12 lymph nodes retrieved: a prospective study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Chemoradiotherapy; Colonoscop | 2014 |
DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisplatin; Disease-Free | 2013 |
Platinum-based combination chemotherapy vs. weekly cisplatin during adjuvant CCRT in early cervical cancer with pelvic LN metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinom | 2013 |
Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Biliary Tr | 2013 |
Early-onset brain metastases in a breast cancer patient after pathological complete response to neoadjuvant chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2013 |
[A "lymph node" of the hepatic hilum].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Ducts, Intrahepatic; Cholecystectomy; Cisplatin | 2013 |
The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemothera | 2014 |
[Impact of clinicopathological features and extent of lymph node dissection on the prognosis in early gastric cancer patients].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Carcinoma, Signet Ring Cel | 2013 |
Death associated protein 1 is correlated with the clinical outcome of patients with colorectal cancer and has a role in the regulation of cell death.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Mo | 2014 |
Preoperative chemoradiation with or without induction oxaliplatin plus 5-fluorouracil in locally advanced rectal cancer. Long-term outcome analysis.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Chemorad | 2014 |
The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adj | 2014 |
[Results of definitive radiotherapy for squamous cell carcinomas of the larynx patients with subglottic extension].
Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Antibodies, Monoclonal, Humanized; Antineoplasti | 2014 |
Combination chemotherapy for metastatic extramammary Paget disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone Neopla | 2014 |
Overexpression of S100P promotes colorectal cancer metastasis and decreases chemosensitivity to 5-FU in vitro.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Calcium-Binding Proteins; Cell Line, Tumor; Cell | 2014 |
[A case of recurrent duodenal carcinoma successfully controlled with FOLFOX treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Duodenal Neoplasms; Female; Fluorouracil; Humans; Le | 2013 |
[A case of advanced colon cancer successfully treated with combination therapy of cetuximab and oxaliplatin, leucovorin, and 5-fluorouracil].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
[A case of pathological complete response with neoadjuvant mFOLFOX6 chemotherapy for advanced lower rectal cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovor | 2013 |
[A case of good response in a rectal cancer patient with decreased dihydropyrimidine dehydrogenase activity because of strict control of the 5-fluorouracil dose].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Dihydrouracil Dehydrogenase (NADP); Fluo | 2013 |
[A case of rectal endocrine cell carcinoma treated by laparoscopic assisted intersphincteric resection after neoadjuvant chemotherapy].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Endocrine Cells; Fluorouraci | 2013 |
[A case of HER2-positive advanced gastric cancer successfully treated with a combination of capecitabine, cisplatin, and trastuzumab as first-line chemotherapy].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2013 |
[Multidisciplinary therapy for 3 patients with lymph node recurrence after curative gastrectomy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2013 |
Failure and success in the treatment of breast carcinoma in men: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Back Pain; Breast Neoplasms, Male; Carcinoma, Ductal | 2014 |
Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2013 |
Second primary pancreatic adenocarcinoma three years after successfully treated index esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Ad | 2014 |
Concomitant chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy as definitive, first line treatment of squamous cell carcinoma of the head and neck. A retrospective single center analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2014 |
Prognostic factors associated with primary cancer in curatively resected stage IV colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2014 |
Does pathologic response of rectal cancer influence postoperative morbidity after neoadjuvant radiochemotherapy and total mesorectal excision?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
Establishment and biological characterization of a novel cell line derived from hepatoid adenocarcinoma originated at the ampulla of Vater.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Ampulla of Vater; Animals; Antimetabolites, Antineoplastic | 2014 |
Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2014 |
Nrf2 is useful for predicting the effect of chemoradiation therapy on esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2014 |
Successful multimodal treatment for aggressive metastatic and recurrent fibrolamellar hepatocellular carcinoma in a child.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child; Cisplatin; Combine | 2014 |
Extracapsular lymph node involvement is associated with colorectal liver metastases and impact outcome after hepatectomy for colorectal metastases.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2014 |
A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2014 |
Retrospective analysis of 119 small bowel adenocarcinoma in Chinese patients.
Topics: Abdominal Pain; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cap | 2014 |
A complete response to mFOLFOX6 and panitumumab chemotherapy in advanced stage rectal adenocarcinoma: a case report.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil | 2014 |
Impending Carotid Blowout Syndrome.
Topics: Angiography; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Caro | 2015 |
Patterns of recurrence after trimodality therapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Anastomotic Leak; Antineoplastic Agents; Antineoplastic Combined Chemot | 2014 |
Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2014 |
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2014 |
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2014 |
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2014 |
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2014 |
The usefulness of neoadjuvant chemoradiation therapy for locally advanced esophageal cancer with multiple lymph-node metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2014 |
[A retrospective study of tegafur/uracil compared with cyclophosphamide, methotrexate, and fluorouracil as adjuvant chemotherapy in patients with node-negative, triple-negative breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamid | 2014 |
Clinical efficacy of alternating chemoradiotherapy by conformal radiotherapy combined with intracavitary brachytherapy for high-risk cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Chemoradiotherapy; Disea | 2014 |
Prognostic Significance of Nodal Ratio in Patients Undergoing Adjuvant Chemoradiotherapy After Curative Resection for Ampullary Cancer.
Topics: Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Ad | 2016 |
[Outcome and prognostic factors of 125 loco-regionally advanced head and neck squamous cell carcinoma treated with multi-modality treatment].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
[Adenoid cystic carcinoma of the breast:report of 25 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neopl | 2014 |
Inguinal lymph node recurrence in the untreated groin of patients with anal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Anus Neoplasms; Combined Modality Therapy; Fe | 2014 |
Can a biomarker-based scoring system predict pathologic complete response after preoperative chemoradiotherapy for rectal cancer?
Topics: Adenocarcinoma; Adult; Aged; Biomarkers, Tumor; Biopsy; Chemoradiotherapy; Combined Modality Therapy | 2014 |
Interval between neoadjuvant treatment and definitive surgery in locally advanced rectal cancer: impact on response and oncologic outcomes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Digestive | 2014 |
Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2014 |
Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma.
Topics: Adult; Aged; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 2014 |
The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2014 |
TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Relationship of body mass index with prognosis in breast cancer patients treated with adjuvant radiotherapy and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
[Adjuvant chemoradiotherapy in advanced gastric cancer: experience in 168 patients].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Fe | 2014 |
Prediction of concurrent chemoradiotherapy outcome in advanced oropharyngeal cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Fluorouracil; Human Papillomavirus | 2014 |
Intraarterial chemotherapy as the first-line therapy in penile cancer.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; | 2014 |
Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when, and for whom?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2014 |
Tranexamic acid and fibrinogen restore clotting in vitro and in vivo in cardiac thrombus associated hyperfibrinolysis with overt bleedings.
Topics: Adenocarcinoma; Aged; Anemia; Antifibrinolytic Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Selection of therapeutic treatment with alternating chemoradiotherapy for larynx preservation in laryngeal carcinoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Dose Frac | 2014 |
Impact of perineural and lymphovascular invasion on oncological outcomes in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy | 2015 |
CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 2014 |
Clinical Importance of Supraclavicular Lymph Node Metastasis After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Docetaxel; Doxorub | 2015 |
Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; C | 2014 |
Clinical resolution of vemurafenib-induced squamous cell carcinoma with topical 5-fluorouracil.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamo | 2015 |
Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2015 |
Lymph node enlargement after definitive chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2014 |
Expression of multidrug resistance-associated proteins and their relation to postoperative individualized chemotherapy in gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 2014 |
Epigenetic regulation of CD271, a potential cancer stem cell marker associated with chemoresistance and metastatic capacity.
Topics: Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; DNA Methylation; Drug Resi | 2015 |
Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bile Duct Neoplas | 2014 |
Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
Complete Neoadjuvant Treatment for Rectal Cancer: The Brown University Oncology Group CONTRE Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2017 |
[Gastric cancer with liver metastasis and peritoneal dissemination treated with conversion surgery to achieve r0 resection after capecitabine, cisplatin, and trastuzumab chemotherapy-a case report].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2014 |
FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2014 |
Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Cisplatin; | 2014 |
A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
Prognostic Significance of (18)F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2015 |
Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Proto | 2014 |
Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2015 |
Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses.
Topics: Adult; Aged; Drug Therapy; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Microsatellite | 2015 |
[Recurrence sites following definitive intensity-modulated conformational radiotherapy of squamous-cell carcinomas of the upper aerodigestive tract].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; | 2015 |
Treatment of locally advanced gastric cancer with the XELOX program of neoadjuvantchemotherapy combined with laparoscopic surgery: the experience in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Deoxycy | 2014 |
Semi-radical chemoradiotherapy for 53 esophageal squamous cell carcinomas with supraclavicular lymph node metastasis in a single institutional retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; D | 2014 |
[A case of metastatic gastric cancer originating from transverse colon cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colon, Transverse; Col | 2014 |
[A case of HER2-positive advanced gastric cancer with extensive lymph node metastasis treated via chemotherapy with a trastuzumab-containing regimen followed by conversion surgery].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cis | 2014 |
[A case of gastric cancer showing response to first-line XP regimen after lymph node recurrence during the administration of S-1 as postoperative adjuvant chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2014 |
[A feasibility study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for Japanese patients with advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2015 |
Prognostic significance of the concomitant existence of lymphovascular and perineural invasion in locally advanced gastric cancer patients who underwent curative gastrectomy and adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dise | 2015 |
Inverse association between Bmi-1 and RKIP affecting clinical outcome of gastric cancer and revealing the potential molecular mechanisms underlying tumor metastasis and chemotherapy resistance.
Topics: Aged; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Regulation, | 2016 |
[Preoperative chemoradiotherapy for rectal cancer: experience from one centre].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Pro | 2015 |
[A case of HER2-positive advanced gastric cancer successfully treated via capecitabine, cisplatin, and trastuzumab combination chemotherapy].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Prognostic factors and the role of adjuvant chemotherapy in post-curative surgery for Dukes B and C colon cancers and survival outcomes: a Malaysian experience.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2015 |
Loss of miR-200 family in 5-fluorouracil resistant colon cancer drives lymphendothelial invasiveness in vitro.
Topics: Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Endothelial Cells; Fluorouracil; Hom | 2015 |
Analyses of multiple factors for determination of "selected patients" who should receive rechallenge treatment in metastatic colorectal cancer: a retrospective study from Turkey.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colore | 2015 |
Anterior gradient protein 2 expression in high grade head and neck squamous cell carcinoma correlated with cancer stem cell and epithelial mesenchymal transition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; C | 2015 |
Advanced gastric cancer with liver and lymph node metastases successfully resected after induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Gastrectomy; Hum | 2014 |
A case of severe cerebral embolism after chemotherapy for HER2-positive gastric cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Cisplatin; Fatal Outcome; Fluorouracil; Gene Express | 2015 |
Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy.
Topics: Adult; Aldehyde Dehydrogenase 1 Family; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2016 |
MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms.
Topics: Adenoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Colorectal Neoplas | 2015 |
The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adju | 2015 |
[Study of the relationship among expression of Survivin and MRP and the drug resistance in human nasopharyngeal carcinoma].
Topics: Antineoplastic Agents; Carcinoma; Cisplatin; Drug Resistance, Neoplasm; Fluorouracil; Humans; Immuno | 2015 |
[Individualized therapy of synchronous ovarian and colon cancers with lymph].
Topics: Abdominal Pain; Adenocarcinoma; Adenocarcinoma, Papillary; Aged; Antineoplastic Agents, Phytogenic; | 2015 |
Analysis on clinical characteristics and influencing factors of patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2015 |
Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Pancreatic Du | 2015 |
Comparison of oncologic outcomes of metastatic rectal cancer patients with or without neoadjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2015 |
Neoadjuvant therapy does not affect lymph node ratio in rectal cancer.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluorouracil; Humans; I | 2016 |
Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2014 |
[A Case of Concurrent Cancer in a Giant Rectal Villous Adenoma That Resulted in Extensive Lymph Node Metastases].
Topics: Adenoma, Villous; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, | 2015 |
High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomark | 2016 |
Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cross-Sectional | 2015 |
Predictive Significance of VEGF and HIF-1α Expression in Patients with Metastatic Colorectal Cancer Receiving Chemotherapy Combinations with Bevacizumab.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2015 |
[Stage IV Gastric Cancer Made Resectable Following a Chemotherapy Regimen That Included Trastuzumab-A Case Report].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2015 |
A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings.
Topics: Adult; Aged; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Co | 2016 |
Correlation Between Nuclear Factor E2-Related Factor 2 Expression and Gastric Cancer Progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antioxidants; Carcinoma; Drug Resistance, Neo | 2015 |
Nuclear PRMT1 expression is associated with poor prognosis and chemosensitivity in gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Biomarke | 2016 |
Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2015 |
miR-125b Suppresses Proliferation and Invasion by Targeting MCL1 in Gastric Cancer.
Topics: Animals; Apoptosis; Base Sequence; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Female; Fl | 2015 |
Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Wester | 2016 |
Prostate Cancer Heterogeneous High-Metastatic Multi-Organ-Colonizing Chemo-Resistant Variants Selected by Serial Metastatic Passage in Nude Mice Are Highly Enriched for Multinucleate Giant Cells.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Doxorubi | 2015 |
[mFOLFOX6 chemotherapy enabling curative resection in a patient with locally advanced duodenal adenocarcinoma and lymph node metastases].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Duo | 2015 |
Down-regulation of SNX1 predicts poor prognosis and contributes to drug resistance in colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Colorec | 2016 |
MicroRNA-497 inhibits tumor growth and increases chemosensitivity to 5-fluorouracil treatment by targeting KSR1.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Movement; Cell Prolifer | 2016 |
Pediatric advanced stage nasopharyngeal carcinoma - case report.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Fluorouracil; Huma | 2015 |
[Characteristics of recurrence in patients with gastric cancer after radical gastrectomy and adjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Fluorouracil; Gas | 2015 |
Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2015 |
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2016 |
Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Agents; Azacitidine; Carcinoma, Ductal, Breast; Carcinoma, | 2016 |
[Efficacy and safety of antivascular drugs after anti-EFGR: aflibercept after cetuximab, a clinical case].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neo | 2015 |
A pilot study of an individualized comprehensive treatment for advanced gastric cancer with para-aortic lymph node metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Capecitabine; Chemotherapy, Adju | 2016 |
[A Case of Salvage Chemoradiotherapy for Regional Recurrence after Curative Esophagectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neopl | 2015 |
[A Case of Para-Aortic Lymph Node Metastases of Sigmoid Colon Cancer Treated with Complete Resection].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Capecitabine; Deoxycytidine; Fluorourac | 2015 |
[Recurrence of Rectal Cancer with Submucosal Invasion in the Bone and Lymph Nodes 89 Months after Surgery--A Case Report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptot | 2015 |
[A Case of Rectal Cancer with Multiple Liver, Lung, and Para-Aortic Lymph Node Metastases Successfully Treated with FOLFOX4 plus Bevacizumab].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Bevacizumab; Chemotherapy, Adjuvant; Fl | 2015 |
[A Case of Liver Metastasis of Descending Colon Cancer with a Pathological Complete Response to mFOLFOX6].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colon, Descending; Col | 2016 |
[Stage IB2, IIA and IIB cervical carcinoma without lymph node extension treated with neoadjuvant chemoradiotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 2016 |
A Digital Squamous Cell Carcinoma Mimicking a Diabetic Foot Ulcer, With Early Inguinal Metastasis and Cancer-Related Lymphedema.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Squamous Cell; | 2016 |
Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: exploratory analysis of the JCOG0303 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
ANXA11 regulates the tumorigenesis, lymph node metastasis and 5-fluorouracil sensitivity of murine hepatocarcinoma Hca-P cells by targeting c-Jun.
Topics: Animals; Annexins; Antineoplastic Agents; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumo | 2016 |
Impact of age on efficacy of postoperative oxaliplatin-based chemotherapy in patients with rectal cancer after neoadjuvant chemoradiotherapy.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Fluoro | 2016 |
Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Admin | 2017 |
Identification of a predictive factor for distant metastasis in esophageal squamous cell carcinoma after definitive chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2016 |
[Observance and results of concurrent chemoradiotherapy after induction chemotherapy by docetaxel, cisplatin and 5-fluoro-uracil for locally advanced head and neck cancers].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherap | 2016 |
[Analysis of clinical factors for the efficacy of TPF in treating hypopharyngeal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; Hypopharyngeal Neop | 2015 |
NOTCH1 inhibition enhances the efficacy of conventional chemotherapeutic agents by targeting head neck cancer stem cell.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2016 |
Oncologic Safety of Local Excision Compared With Total Mesorectal Excision for ypT0-T1 Rectal Cancer: A Propensity Score Analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2016 |
[A Case of Advanced Rectal Cancer Resected Successfully after Induction Chemotherapy with Modified FOLFOX6 plus Panitumumab].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil | 2016 |
[Surgical Resection and Adjuvant Chemotherapy with FOLFOX6 for Primary Duodenal Adenocarcinoma and Nodal Metastasis Resulted in Complete Remission].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Duodenal Neo | 2016 |
MicroRNA-874 inhibits growth, induces apoptosis and reverses chemoresistance in colorectal cancer by targeting X-linked inhibitor of apoptosis protein.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Down-Regulation; Female; Fluo | 2016 |
[Clinical study on locally advanced rectal cancer patients with pathological complete response after neoadjuvant chemoradiotherapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothe | 2016 |
Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell M | 2016 |
Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2016 |
ypN0: Does It Matter How You Get There? Nodal Downstaging in Esophageal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2016 |
Oxaliplatin, 5Fluorouracil and Leucovorin (FOLFOX4) as First Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; F | 2016 |
Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asth | 2016 |
Plasma microRNA profiles: identification of miR-23a as a novel biomarker for chemoresistance in esophageal squamous cell carcinoma.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Drug Resistance, Neoplasm; Esophageal | 2016 |
Primary Tumour Resection Could Improve the Survival of Unresectable Metastatic Colorectal Cancer Patients Receiving Bevacizumab-Containing Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine | 2016 |
Preoperative chemoradiotherapy for elderly patients with locally advanced rectal cancer-a real-world outcome study.
Topics: Age Factors; Aged; Aged, 80 and over; Capecitabine; Chemoradiotherapy; Diarrhea; Disease-Free Surviv | 2016 |
Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2017 |
Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies - experience of a community based hospital.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcin | 2016 |
Predictors of Survival in Esophageal Squamous Cell Carcinoma with Pathologic Major Response after Neoadjuvant Chemoradiation Therapy and Surgery: The Impact of Chemotherapy Protocols.
Topics: Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease Pro | 2016 |
Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2017 |
Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Proto | 2017 |
Glycoprotein 130 is associated with adverse postoperative clinical outcomes of patients with late-stage non-metastatic gastric cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cytokine Receptor | 2016 |
Prognostic Value of Sterilized Lymph Nodes After Preoperative Chemoradiotherapy for Patients with ypN0 Rectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Surv | 2017 |
Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorec | 2017 |
Positive feedback loop of IL-1β/Akt/RARα/Akt signaling mediates oncogenic property of RARα in gastric carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Cell Cycle; Cell Cycle Proteins; Cell Line, Tum | 2017 |
Target volume delineation for radical radiotherapy of early oesophageal carcinoma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squam | 2017 |
Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2017 |
[Two Cases of Metastatic Rectal Cancer Patients Who Received Chemotherapy with FOLFOXIRI plus Bevacizumab].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorourac | 2016 |
[Pathological Complete Response in a Case of Advanced Esophageal Cancer with Widespread Lymph Node Metastases Treated Using Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-FU(DCF therapy)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fe | 2016 |
[Long-Term Complete Response in Postoperative Multiple Lung and Mediastinal Lymph Node Metastases of Esophageal Cancer Using Systemic Chemotherapy with DCF Treatment - A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esop | 2017 |
Continuous infusion of a large dose of CF (folinic acid) and 5-FU combined with CDDP in the treatment of advanced esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Di | 2017 |
Inhibition of polypyrimidine tract-binding protein 3 induces apoptosis and cell cycle arrest, and enhances the cytotoxicity of 5- fluorouracil in gastric cancer cells.
Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Cycle C | 2017 |
Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemothe | 2017 |
FOLFOX and intensified split-course chemoradiation as initial treatment for rectal cancer with synchronous metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; F | 2017 |
Giant eccrine adenocarcinoma with skin and lymph node metastases: favourable response to chemotherapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2009 |
The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Age Factors; Aged; Chemotherapy, Adjuvant; Cohort Studies; Colectomy; Female; Fluoro | 2009 |
Survival for patients with pancreatic cancer after addition of gemcitabine to Fluorouracil chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycyti | 2008 |
Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2008 |
Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Deoxycytidine; F | 2008 |
Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2008 |
[Effect of Endostatin and SU6668 combined with 5-FU on human colon cancer xenograft in nude mice].
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Colonic Neoplasms; Endostatins; Fluorouracil; Hu | 2008 |
Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; C | 2009 |
A simple colostomy implantation model for evaluating colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Colostomy; Disease Mo | 2009 |
Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cisplatin; E | 2008 |
Combination chemotherapy of ifosfamide, 5-fluorouracil, etoposide and cisplatin as perioperative treatment in lymph node positive bladder carcinoma patients treated by radical cystectomy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2008 |
Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cis | 2009 |
The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; CA-19-9 Antigen; Combined Mod | 2008 |
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptotheci | 2009 |
Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2009 |
A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemother | 2009 |
A new neoadjuvant chemotherapy regimen for penile cancer with nodal metastases: a step forward.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2009 |
Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Dose Fractionation, Radiati | 2009 |
Sentinel lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Austrian Sentinel Node Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Breast Neoplasms; Cyclophospha | 2008 |
[A case of esophageal cancer with recurrent lymph-node metastasis successfully treated with chemo-radiotherapy after mediastinoscopy-assisted transhiatal esophagectomy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Esophageal Neoplasms; Eso | 2008 |
[Modified FOLFOX6 treatment for obstructive jaundice caused by hepatic lymph-node metastasis from liver metastases of rectal cancer--a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Fluorouracil; Huma | 2008 |
Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2009 |
[Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer].
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capec | 2008 |
Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colo | 2009 |
The prognostic impact of occult nodal metastasis in early breast carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axilla; Bone Marrow; | 2009 |
High-dose extended-field irradiation and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Carc | 2009 |
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2009 |
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2009 |
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2009 |
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2009 |
Neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: prognostic value of circumferential resection margin and stratification of N1 category.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2009 |
[A patient with axillary node metastasis from breast cancer who responded to trastuzumab/capecitabine combination therapy].
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combine | 2009 |
An unusual presentation of hand-foot syndrome at the hidden area: the scrotum and penis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedul | 2009 |
[A case report of complete response to RPMI regimen for multiple lymph node metastases following rectal cancer surgery].
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Fluorouracil; Humans; Leucovorin; Lymphatic Metastas | 2009 |
Role of adjuvant chemoradiotherapy for ampulla of Vater cancer.
Topics: Adult; Age Factors; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; | 2009 |
Lymph node harvest after proctectomy for invasive rectal adenocarcinoma following neoadjuvant therapy: does the same standard apply?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2009 |
Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2009 |
Current oncological treatment of patients with pancreatic cancer in germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combine | 2009 |
Chemosensitivity and survival in gastric cancer patients with microsatellite instability.
Topics: Aged; Antimetabolites, Antineoplastic; Disease Progression; Female; Fluorouracil; Humans; Lymphatic | 2009 |
[Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2009 |
[Efficacy of neoadjuvant chemotherapy with FEC and TEC regimen on breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2009 |
[Impact of adjuvant chemotherapy duration on 3-year disease-free survival of colorectal carcinoma patients after radical resection].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Age Factors; Aged; Antineoplastic Combined Chemothe | 2009 |
Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Ant | 2010 |
Impact of surgical staging in locally advanced cervical cancer and subsequent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Case-Control Studies; Cispla | 2009 |
Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2009 |
Metastatic colorectal cancer: is surgery necessary?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; | 2009 |
Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Multiple | 2009 |
[Prognostic analysis of 443 cases of stage II colorectal cancer and the value of adjuvant chemotherapy].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecita | 2009 |
[Risk factors related to lymph node metastases after neoadjuvant therapy for locally advanced rectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-1 | 2009 |
[Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Ant | 2009 |
Long-term outcome of unresectable metastatic colorectal cancer: does "adjuvant" chemotherapy play a role after resection?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C | 2009 |
Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherap | 2009 |
Preoperative chemoradiotherapy does not necessarily reduce lymph node retrieval in rectal cancer specimens--results from a prospective evaluation with extensive pathological work-up.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2010 |
Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineopl | 2009 |
Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; C | 2010 |
[Impact of changing gross tumor volume delineation of intensity-modulated radiotherapy on the dose distribution and clinical treatment outcome after induction chemotherapy for the primary locoregionally advanced nasopharyngeal carcinoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fl | 2009 |
Expression of livin in gastric cancer and induction of apoptosis in SGC-7901 cells by shRNA-mediated silencing of livin gene.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Apoptosis; | 2010 |
Axillary sentinel node biopsy after neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cyclophospham | 2010 |
Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcino | 2009 |
[Feasibility and short-term efficacy of simplified intensity-modulated radiotherapy and concurrent chemotherapy for neck and upper thoracic esophageal carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchitis; Carcinoma, Squamous Cell; Cisplati | 2009 |
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cl | 2010 |
First-generation genomic tests for breast cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamid | 2010 |
Relation between pathomorphological response in tumors after neoadjuvant chemotherapy and clinico-morphological and molecular prognostic factors in patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 2009 |
[Clinical impact of extracapsular extension of axillary lymph node metastases in breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cisplatin; Combined Modali | 2009 |
[Neoadjuvant chemotherapy of FLEEOX regimen for unresectable gastric cancer resulting from advanced abdominal lymph nodes metastases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Epirubicin; Fem | 2009 |
[A case of surgical approach to the recurrence of the para-aortic lymph nodes after resection of rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Combined Modality Therapy; Female; | 2009 |
[A case of sigmoid colon carcinoma accompanied with hydronephrosis caused by peritoneal dissemination and para-aortic lymph node metastases markedly responded to chemotherapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2009 |
[A case of advanced right colonic cancer successfully treated by surgery and post operative chemotherapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, | 2009 |
[Extended lymphadenectomy for gastric regional lymph node metastasis from transverse colon cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colon, Transverse; Colonic Neoplasms; | 2009 |
[A case of anal canal carcinoma with systemic lymph node metastases successfully treated by bevacizumab+mFOLFOX6 therapy].
Topics: Anal Canal; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anti | 2009 |
[A long-term survival case of hepatocellular carcinoma with lymph node metastasis on the posterior surface of the pancreas head and portal vein tumor thrombus successfully treated with hepatopancreatoduodenectomy and adjuvant interferon-alpha and 5-fluoro
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuv | 2009 |
Treatment results of FOLFOX chemotherapy before surgery for lymph node metastasis of advanced colorectal cancer with synchronous liver metastasis: the status of LN metastasis and vessel invasions at the primary site in patients who responded to FOLFOX.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2010 |
Diagnosis of lymph node metastases of head and neck cancer and evaluation of effects of chemoradiotherapy using ultrasonography.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2010 |
Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surg
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Combined Modality Therapy; | 2010 |
A case of esophageal cancer with multiple lymph node metastases which responded to neoadjuvant chemotherapy (DCF therapy).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2010 |
[A case of advanced ascending colon cancer, curatively resected after complete response in left supraclavicular and paraaortic lymph nodes and liver metastases to FOLFOX4 therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colonic Neoplasms; Combined Modality Therapy | 2010 |
Radiotherapy with or without concurrent chemotherapy for lymph node recurrence after radical surgery of thoracic esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Distribution; C | 2010 |
Significance of occult neoplastic cells on tumor metastasis: a case report of gastric cancer.
Topics: Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Signet Ring Cell; Cell Differentiation; Chemothe | 2010 |
Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemot | 2010 |
[In reference to the article: "Neck dissection following chemoradiation for node positive head and neck carcinomas" by Thariat et al. Cancer Radiother 2009;13:758-770].
Topics: Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplat | 2010 |
Obesity is an independent prognostic variable in colon cancer survivors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Composition; Body | 2010 |
Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispla | 2010 |
The combination of 5-FU, leucovorin and CPT-11 (FOLFIRI) prolongs survival through inhibition of metastasis in an orthotopic model of colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colonic Neo | 2010 |
[Pediatric nasopharyngeal carcinoma: Anatomoclinic aspects, therapeutic results and evolutive particularities].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Chemotherapy, Adju | 2010 |
Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2010 |
Pre- and post-therapy nodal status equally affects survival of patients with oesophageal squamous cell carcinoma receiving preoperative chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
A case of local advanced penile cancer treated with multimodality therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dose Fractionatio | 2010 |
Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2010 |
Trastuzumab beyond progression: a cost-utility analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Anal function and intersphincteric resection.
Topics: Adenocarcinoma; Anal Canal; Antineoplastic Agents; Combined Modality Therapy; Fluorouracil; Humans; | 2010 |
Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric carcinoma undergoing potentially curative resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 2010 |
Predictors of sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma.
Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarker | 2010 |
Sporotrichoid metastases to the skin from cutaneous squamous cell carcinoma in an immunocompetent patient.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arm; Carcin | 2010 |
A case of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Capecitabine; Carcinoma, D | 2011 |
Characterization of a novel lymph node metastasis model from human colonic cancer and its preclinical use for comparison of anti-metastatic efficacy between oral S-1 and UFT/ LV.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic Neoplasms; Drug C | 2010 |
Clinical impact of intesified 5-Fluorouracil-based chemotherapy using a prospective pharmacokinetically-guided dosing approach: comparative study in elderly and non-elderly patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Colorectal Neopla | 2010 |
[A case of ascending colon cancer with unresectable distant metastases treated by systemic chemotherapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2010 |
Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ato | 2011 |
BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, A | 2010 |
Adjuvant chemoradiation therapy in gallbladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplati | 2010 |
Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2011 |
TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2010 |
[A recurrence after surgery for colon cancer with metastases of the liver and periaortic lymph nodes, with CR achieved by using bevacizumab+mFOLFOX6].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2010 |
[A case of metastatic colorectal cancer suffering from hyperammonemic encephalopathy induced by 5-FU, continuously treated with FOLFOX therapy].
Topics: Amino Acids, Branched-Chain; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Comb | 2010 |
Outcome standards for an organ preservation strategy in stage II and III rectal adenocarcinoma after neoadjuvant chemoradiation.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoth | 2011 |
Comparison of three adjuvant chemotherapy regimes using an extended log-logistic model in women with operable breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridg | 2010 |
Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2011 |
Oncolytic adenovirus mediated Survivin RNA interference and 5-fluorouracil synergistically suppress the lymphatic metastasis of colorectal cancer.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal | 2010 |
Treatment of stage IB2, IIA bulky cervical cancer: a single-institution experience of neoadjuvant chemotherapy followed by radical hysterectomy and primary radical hysterectomy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Chemotherapy, Adj | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Metastatic lymph node targeted chemosensitivity test for gastric cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; An | 2011 |
Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Combined Moda | 2011 |
Increasing nodal ratio is a poor prognostic factor for survival in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant chemotherapy: a retrospective study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cis | 2011 |
One patient with metastastic colorectal cancer successfully treated by combination of targeted agents after failure of chemotherapy.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
Adjuvant 5-fluorouracil-induced colitis necessitating completion colectomy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; Colitis; Fluorou | 2011 |
[A case of recurrent esophageal cancer successfully treated by combined therapies].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophage | 2010 |
[A long-term survival case of rectal cancer with Virchow's lymph node metastasis by multimodality therapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2010 |
[A case of recurrent sigmoid colon cancer with adrenal and para-aortic lymph node metastasis successfully treated by operation and chemotherapy].
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, | 2010 |
[A long-term disease-free survival case of advanced rectal cancer with massive metastasis to the lateral pelvic and para-aortic lymph nodes].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined C | 2010 |
[A case of successfully treated lower rectal cancer with both inguinal lymph nodes by chemoradiotherapy].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
[A case report of primary adenocarcinoma of small intestine].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Squam | 2012 |
Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2011 |
Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; | 2011 |
The role of computed tomography in the management of the neck after chemoradiotherapy in patients with head-and-neck cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Decision | 2012 |
Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: a long-term single center experience.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; B | 2012 |
Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineo | 2011 |
Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2010 |
Scan? Cure? Sure!
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic | 2011 |
Improvement of oral intake following chemotherapy in gastric cancer patients with an inability to eat.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Feeding and Eating Di | 2010 |
[A case of multiple para-aortic lymph node metastases from squamous cell carcinoma of an unknown primary responding completely to chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Carcinoma, Squamous Cell; Cisplatin; Drug Com | 2011 |
Sentinel lymph node biopsy using dye alone method is reliable and accurate even after neo-adjuvant chemotherapy in locally advanced breast cancer--a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neopl | 2011 |
Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease | 2011 |
Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease | 2011 |
Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease | 2011 |
Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease | 2011 |
Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy after early failure of adjuvant systemic chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Combined Modalit | 2011 |
[A resected case of gastric regional lymph node metastasis from ascending colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colon, Ascending; Colonic Neoplasms; Combined M | 2011 |
5-Fluorouracil-induced acute dilated cardiomyopathy in a pediatric patient.
Topics: Acute Disease; Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pro | 2011 |
Evaluation of ¹⁸F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fema | 2011 |
Bevacizumab in the treatment of metastatic breast cancer: three case reports.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinoma.
Topics: Age Factors; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Chemo | 2011 |
The cell cycle profile test is a prognostic indicator for breast cancer patients treated with postoperative 5-fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2011 |
Type II radical hysterectomy and adjuvant therapy for pelvic lymph node metastasis with stage IB-IIB cervical carcinoma: a retrospective study of 288 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carcinoma, Sq | 2011 |
Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2011 |
HER-2 discordance between primary gastric carcinoma and paired lymph node metastasis.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2011 |
Identification of 14-3-3β in human gastric cancer cells and its potency as a diagnostic and prognostic biomarker.
Topics: 14-3-3 Proteins; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; | 2011 |
Off-label use of oxaliplatin in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast | 2011 |
Cervical nodal metastases of unresectable thoracic esophageal squamous cell carcinoma: characteristics of long-term survivors after concurrent chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Di | 2011 |
Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis.
Topics: Amputation, Surgical; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2011 |
Role of adjuvant chemoradiotherapy for duodenal cancer: a single center experience.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Chemoradiotherapy, Adj | 2012 |
Patterns of failure associated with involved field radiotherapy in patients with clinical stage I thoracic esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2011 |
FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2011 |
Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colo | 2011 |
Outcomes of radical surgery for gallbladder cancer patients with lymphatic metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribut | 2011 |
Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocol | 2011 |
Stereotactic radiosurgery in combination with chemotherapy as primary treatment for head and neck cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2012 |
Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2012 |
[A case of metastatic esophageal cancer - endoscopic resection of the primary site following systemic chemotherapies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Endoscopy; Eso | 2011 |
Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: can we trust the findings?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colonoscopy; Endosonography; | 2011 |
Risk of thromboembolic events after perioperative chemotherapy versus surgery alone for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Nonsurgical management of esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |
Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; | 2011 |
Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Ubc9 expression predicts chemoresistance in breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2011 |
Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2012 |
[Cetuximab-associated skin ulceration in patient with metastatic colorectal cancer: a case report].
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combine | 2011 |
Chemotherapy between the first and second stages of a two-stage hepatectomy for colorectal liver metastases: should we routinely recommend it?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Sur | 2012 |
A microfluidic system for testing the responses of head and neck squamous cell carcinoma tissue biopsies to treatment with chemotherapy drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopsy; Carcinoma, Squamous Cell; Cell Pr | 2012 |
[Primary systemic therapy in breast cancer patients (2007-2010)].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; | 2011 |
Endobronchial metastases of anal canal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bronchial Neoplasms; Bronchopneumoni | 2012 |
Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Loss, Surgical; Capecit | 2012 |
A prognostic model to predict outcome of patients failing to achieve pathological complete response after anthracycline-containing neoadjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brea | 2012 |
Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Ch | 2012 |
Long-term results of radiochemotherapy for solitary lymph node metastasis after curative resection of esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Docetaxel; Esophageal Neopl | 2012 |
Definitive chemoradiotherapy in patients with esophageal adenocarcinoma: an alternative to surgery?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2012 |
Concurrent chemoradiotherapy for locoregionally advanced salivary gland malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Female; Fl | 2012 |
Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2012 |
Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; F | 2012 |
[Preoperative chemoradiation (XELOX/RT) therapy for anal canal adenocarcinoma with the metastasis to inguinal lymph node].
Topics: Adenocarcinoma; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecita | 2011 |
[A case of recurrent rectal cancer with paraaortic lymph node metastasis treated by FOLFIRI therapy leading to complete response].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Female; Fluorouracil; Humans; L | 2011 |
[A case of metastatic rectal cancer in an extremely aged patient successfully treated with mFOLFOX6 plus bevacizumab].
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2011 |
[A case of no recurrence over 10 years in advanced rectal cancer with bleeding treated by urgent arterial embolization followed by synchronous liver resection and extended lymph node dissection].
Topics: Aged; Antimetabolites, Antineoplastic; Chemoembolization, Therapeutic; Combined Modality Therapy; Fe | 2011 |
Failure patterns and survival in patients with nasopharyngeal carcinoma treated with intensity modulated radiation in Northwest China: a pilot study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Child; C | 2012 |
Management of obstructive colorectal cancer: evaluation of preoperative bowel decompression using ileus tube drainage.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Colorectal | 2012 |
Optimal lymph node harvest in rectal cancer (UICC stages II and III) after preoperative 5-FU-based radiochemotherapy. Acetone compression is a new and highly efficient method.
Topics: Acetone; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Female; | 2012 |
Clinical evaluation of neoadjuvant chemotherapy followed by radical surgery in the management of stage IB2-IIB cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S | 2012 |
The role of chemoradiotherapy in patients with unresectable T4 breast tumors.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto | 2013 |
Analysis of local control in patients receiving IMRT for resected pancreatic cancers.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2012 |
Reduced lymph node harvest after neoadjuvant chemotherapy in gastric cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Demog | 2011 |
Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2012 |
Prognostic significance of intraoperative chemotherapy and extensive lymphadenectomy in patients with node-negative gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2012 |
MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells.
Topics: Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Protein | 2012 |
Prognostic factors in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiation therapy.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Esop | 2013 |
Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carbo | 2012 |
Adjuvant chemoradiation for gastric cancer: multicentric study of the Anatolian Society of Medical Oncology.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, A | 2012 |
Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2012 |
Reversible leukoencephalopathy with stroke-like presentation in a patient with 5-dihydropyrimidine dehydrogenase deficiency treated with continuous 5-fluorouracil infusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dihydropy | 2012 |
Effectiveness and safe use of modified FOLFOX-6 for metastatic gastric cancer with signet ring cell components complicated by disseminated intravascular coagulation and diffuse bone marrow carcinomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carcinoma; Carcinoma, Signet | 2012 |
[A case of resected rectal cancer with hepatic node and multiple liver metastases effectively treated by preoperative modified FOLFOX6 and sLV5FU2 chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Human | 2012 |
MR imaging of rectal cancer before and after chemoradiation therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Fema | 2012 |
[Combined radiochemotherapy of an irresectable carcinoma of the pancreas].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cholangiopancreat | 1998 |
Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2013 |
A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compo | 2012 |
Prognostic significance of CYFRA21-1, CEA and hemoglobin in patients with esophageal squamous cancer undergoing concurrent chemoradiotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryo | 2012 |
Role of positron emission tomography-computed tomography in the management of anal cancer.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 2012 |
Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Capecitabine; Carcinoma | 2012 |
Efficacy analysis of simplified intensity-modulated radiotherapy with high or conventional dose and concurrent chemotherapy for patients with neck and upper thoracic esophageal carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophageal Neop | 2012 |
Clinical outcome of endoscopic mucosal resection for esophageal squamous cell cancer invading muscularis mucosa and submucosal layer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemoradiotherap | 2013 |
Squamous cell carcinoma of the rectum: a single institution experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2012 |
Multidisciplinary therapy consisting of minimally invasive resection, irradiation, and intra-arterial infusion of 5-fluorouracil for maxillary sinus carcinomas.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Female; Fluorouracil; Follow-Up Studies; Humans; Infusio | 2013 |
[Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2012 |
Curative chemoradiotherapy in patients with stage IVB cervical cancer presenting with paraortic and left supraclavicular lymph node metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Chemoradiot | 2012 |
Clinicopathological significance of mesothelin expression in invasive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 2012 |
Ovarian metastasis is associated with retroperitoneal lymph node relapses in women treated for colorectal peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2013 |
Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets.
Topics: Adenocarcinoma; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Fluoroura | 2012 |
Metastatic human papillomavirus-positive nasopharyngeal carcinoma with an unusual pattern of aggressive hematogenous spread.
Topics: Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biomarkers, Tumor; Carb | 2012 |
Occurrence of Sjögren syndrome in a long-term survivor patient with metastatic colon carcinoma treated with GOLFIG regimen.
Topics: Adjuvants, Immunologic; Administration, Metronomic; Aged; Antineoplastic Combined Chemotherapy Proto | 2012 |
Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; | 2013 |
High and low dose folinic acid, 5-fluorouracil bolus and continuous infusion for poor-prognosis patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 2012 |
Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Blotting, Western; | 2013 |
[Effects of pre-chemotherapy hemoglobin and platelet levels in patients with stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy followed by radical hysterectomy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 2012 |
Chemosensitivity in ovarian metastases from gastric cancer: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Female; Fluorouracil | 2013 |
Laryngeal preservation in advanced piriform sinus squamous cell carcinomas using superselective intra-arterial chemoradiation therapy with three agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
What is the incidence of metastatic lymph node involvement after significant pathologic response of primary tumor following neoadjuvant treatment for locally advanced rectal cancer?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, A | 2013 |
Solitary bulky mediastinal lymph node metastasis from colon cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Cell Differentiation; Chemother | 2013 |
Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Femal | 2013 |
[A case of transverse colon cancer with multiple liver metastases and hepatic pedicle lymph node involvement showing pathological complete response by XELOX plus bevacizumab].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2012 |
Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2013 |
[Hypersensitivity to radiation therapy in a patient with tuberous sclerosis: biological considerations about a clinical case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2013 |
[Esophageal cancer: outcome according to therapeutic strategy].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2013 |
Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Flu | 2013 |
Larynx preservation for patients with locally advanced laryngeal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvan | 2013 |
Neoadjuvant therapy for rectal cancer decreases the number of lymph nodes harvested in operative specimens.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Female; Fluorour | 2013 |
Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2013 |
Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy?
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Irinotecan during pregnancy in metastatic colon cancer.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopl | 2012 |
Complete regression of esophageal cancer with concomitant liver metastasis achieved by concurrent chemoradiation therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2002 |
[A case of advanced esophageal cancer with multiple lymph node metastases successfully treated with induction chemotherapy consisting of nedaplatin and 5-FU followed by chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration Schedu | 2002 |
[Breast carcinoma in accessory gland: a case report].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neop | 2002 |
[A case of recurrent gastric cancer that responded dramatically to docetaxel and 5'-DFUR combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administr | 2002 |
Gender differences in the dihydropyrimidine dehydrogenase expression of colorectal cancers.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil | 2002 |
A case of advanced esophageal cancer with extensive lymph node metastases successfully treated with multimodal therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2002 |
Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Diarrhea; Dose-Response Relationship, Drug; D | 2002 |
Inverse treatment planning and stereotactic intensity-modulated radiation therapy (IMRT) of the tumor and lymph node levels for nasopharyngeal carcinomas. Description of treatment technique, plan comparison, and case study.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Effects of preoperative chemotherapy on metastatic lymph nodes in esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cel | 2002 |
Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorou | 2001 |
Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Colonic Diseases; D | 2002 |
Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Fluorourac | 2001 |
[Postoperative adjuvant immunochemotherapy using Lentinan for advanced gastric carcinoma patients with metastasis in the regional lymph nodes and serosal invasion].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2002 |
[Two patients with recurrent colon cancer who underwent surgery following a combination of irinotecan and UFT].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2002 |
Prognostic impact of reoxygenation in advanced cancer of the head and neck during the initial course of chemoradiation or radiotherapy alone.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma; Cell Hypoxia; Female; Fluorouracil; Head | 2003 |
[A case of stage IV diffusely infiltrating colon cancer treated by surgical resection and chemoradiation therapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Co | 2002 |
[A case report of primary hepatic carcinoid with lymph node metastasis--treatment of hepatic arterial infusion to post-reoperative liver and radiation to metastasis of para-aortic lymph nodes].
Topics: Carcinoid Tumor; Combined Modality Therapy; Doxorubicin; Electrocoagulation; Female; Fluorouracil; H | 2002 |
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
Topics: Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant | 2002 |
Adenocarcinoid of the appendix vermiformis: complete and persistent remission after chemotherapy (folfox) of a metastatic case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Female; Fluor | 2002 |
[A case of recurrent breast cancer with carcinomatous pleurisy successfully treated with combined chemoendocrine-therapy of CTF (CPA, THP and 5-FU) and anastrozole following instillation therapy 12 years after radical mastectomy].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carci | 2002 |
[A case of advanced gastric adenocarcinoma with mild elevation of serum SCC that responded remarkably to adjuvant chemotherapy of ADM, CDDP, ETP and 5-FU (ACVF)].
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chemothera | 2003 |
Chemoradiation for adenocarcinoma of the anus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Anus Neoplasms; Carcinoma, Sq | 2003 |
[A case report--TS-1/CDDP combined chemotherapy found effective for metastatic recurrence after operation for colon cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colon, Sigmoid; Combined Modality T | 2003 |
[A case of advanced colon cancer responding to treatment with levofolinate combined with 5-fluorouracil].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Admini | 2003 |
Distal intramural spread is an independent prognostic factor for distant metastasis and poor outcome in patients with rectal cancer: a multivariate analysis.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluoroura | 2003 |
Adjuvant chemotherapy for node-positive breast cancer patients: which is the reference today?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical T | 2003 |
[Preoperative diagnostic procedures in locally advanced rectal carcinoma (> or =T3 or N+). What does endoluminal ultrasound achieve at staging and restaging (after neoadjuvant radiochemotherapy) in contrast to computed tomography?].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2003 |
Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Belgium; B | 2003 |
Adjuvant chemotherapy in breast cancer: back to the future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; | 2003 |
Treatment of a patient with advanced esophageal cancer with a combination of mitomycin C and capecitabine: activation of the thymidine phosphorylase as active principle?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxy | 2003 |
S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug | 2003 |
Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehyd | 2003 |
Concurrent chemoradiotherapy for squamous cell carcinoma of the anus using a shrinking field radiotherapy technique without a boost.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Dise | 2003 |
Outpatient weekly 24-hour infusional adjuvant chemotherapy of cisplatin, 5-fluorouracil, and leucovorin for high-risk nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; | 2003 |
[Effect of nedaplatin, 5-FU, and leucovorin combined with radiation therapy in unresectable esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 2003 |
[A case of colon cancer with liver metastases and lymph node metastases successfully treated with surgery followed by CPT-11 and 5-FU chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Camptothecin; Colo | 2003 |
Response to preoperative chemotherapy affects prognosis in esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control | 2003 |
[Renal metastasis after curative resection of an epidermoid carcinoma of the esophagus].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined C | 2003 |
Volumetric and histologic responses to radiotherapy or radiochemotherapy of metastatic cervical lymph nodes of oral squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2003 |
[A case of advanced gastric cancer with liver and intra-abdominal lymph node metastasis treated by hypertensive selective chemotherapy with pharmacokinetic modulating chemotherapy].
Topics: Adenocarcinoma; Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; | 2003 |
Clinical benefit of chemosensitivity test for patients with regional lymph node-positive esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2003 |
Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fluoroura | 2003 |
ROLE OF THE INTERNIST IN CANCER.
Topics: Breast Neoplasms; Fluorouracil; Humans; Lymphadenitis; Lymphatic Metastasis | 1963 |
FURTHER CLINICAL COMPARISON BETWEEN 5-FLUOROURACIL (5-FU) AND 5-FLUORO-2' -DEOXYURIDINE (5-FUDR).
Topics: Brain Neoplasms; Breast Neoplasms; Diarrhea; Floxuridine; Fluorouracil; Geriatrics; Humans; Liver Ne | 1963 |
FLUORINATED PYRIMIDINE THERAPY OF ADVANCED GASTROINTESTINAL CANCER.
Topics: Alopecia; Colonic Neoplasms; Drug Eruptions; Esophagitis; Fluorouracil; Gallbladder Neoplasms; Human | 1964 |
[TREATMENT OF INOPERABLE BRONCHIAL CANCER WITH A COMBINATION OF CHEMOTHERAPY AND IRRADIATION].
Topics: Bronchial Neoplasms; Carcinoma, Bronchogenic; Cyclophosphamide; Fluorouracil; Humans; Idoxuridine; L | 1964 |
STUDIES IN THE TOXICITY AND CLINICAL APPLICATION OF 5-FLUOROURACIL.
Topics: Adenocarcinoma; Agranulocytosis; Biomedical Research; Diarrhea; Diverticulitis; Drug Eruptions; Fluo | 1964 |
REGIONAL ARTERIAL INFUSION OF ANTIMETABOLITES. AN ANALYSIS OF THE RESULTS OBTAINED IN 33 PATIENTS WITH MALIGNANT TUMORS OF THE HEAD AND NECK.
Topics: Antimetabolites; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; H | 1965 |
Pasteurella multocida infection following cisplatin and 5-fluorouracil chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Diseas | 2003 |
Reduced MLH1 expression after chemotherapy is an indicator for poor prognosis in esophageal cancers.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mism | 2003 |
[Dynamic magnetic resonance tomography (dMRT). It's value in advanced head-neck tumors treated with radiochemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Contrast Media; Disease-Fr | 2003 |
[A case of multiple advanced esophageal carcinomas with abdominal LN metastases showing complete response after chemoradiotherapy with concurrent cisplatin, 5-FU and adriamycin chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2003 |
[A case of locally extended rectal carcinoma quickly responding to local intraarterial infusion therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 2003 |
[Long-term survival after neck lymph node metastases from sigmoid colon cancer--a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colon, Sigmoid; Combined Modalit | 2003 |
[Two patients with metastatic ovarian tumor (Krukenberg's tumor) of gastric origin who underwent oophorectomy with paraaortic and intrapelvic lymph node dissection].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Carcinom | 2003 |
Anal canal cancer treatment: practical limitations of routine prescription of concurrent chemotherapy and radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2003 |
[Preliminary evaluation of chemotherapy with docetaxel, 5-FU, CDDP for recurrent esophageal cancer--a pilot study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Sche | 2003 |
[A case of advanced cancer with liver metastasis and paraaortic lymph node metastasis responding remarkably to combination chemotherapy of low-dose CDDP, 5-FU and CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Cisplatin; Drug Administration | 2003 |
[A case of advanced gastric cancer that responded to docetaxel with low-dose 5-FU and cisplatin combination chemotherapy after becoming chemoresistant to M-FLP].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administr | 2003 |
Modified pharmacokinetic modulating chemotherapy using 5-fluorouracil, UFT, and taxotere (docetaxel) for advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Docetaxel; Fluorouracil; Humans; Infusion | 2003 |
[A case of parotid carcinoma with hepatic metastasis that responded remarkably to combination chemotherapy of docetaxel, cisplatin and 5-fluorouracil].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administr | 2003 |
Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis.
Topics: Animals; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Humans; Image Interpretation, Computer-A | 2003 |
Adherence to the guidelines of the CCCE in the treatment of node-positive breast cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fl | 2004 |
[A case of rectal cancer with distant lymph node metastases completely responding to postoperative chemotherapy with levofolinate combined with 5-fluorouracil].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female | 2004 |
[Preoperative radiation with chemotherapy for rectal cancer: its impact on downstaging of disease and the role of endorectal ultrasound].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma in Situ; Chemotherapy, Adjuvant; | 2004 |
Using loco-regional recurrence as an indicator of the quality of breast cancer treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; C | 2004 |
Extracapsular spread of nodal metastasis as a prognostic factor in rectal cancer.
Topics: Actuarial Analysis; Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Combined Mod | 2004 |
[A case of advanced colon cancer with metastases to both the Virchow's and the paraaortic lymph nodes that achieved complete long-term response with levofolinate.5-FU therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Colonic Neoplasms; | 2004 |
Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2004 |
Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2004 |
[Estimation of level of enzyme induction of thymidine phosphorylase, dihydropyrimidine dehydrogenase, and thymidylate synthase in primary and recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dih | 2004 |
Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophospha | 2004 |
Toxic encephalopathy induced by capecitabine.
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Epil | 2004 |
[Thymidylate synthase and dihydropyrimidine dehydrogenase gene expressions in colorectal cancer using the Danenberg tumor profile method].
Topics: Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gene Expression Profiling; H | 2004 |
[Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin | 2004 |
[A case of curatively resected gastric cancer through an effective response to chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration | 2004 |
Quality of adjuvant CMF chemotherapy for node-positive primary breast cancer: a population-based study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Com | 2004 |
[Choice of chemotherapeutic drugs for colorectal cancers by DPD and OPRT activities in cancer tissues].
Topics: Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female | 2004 |
[A case of advanced colon cancer responding to l-LV+5-FU as neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; C | 2004 |
Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorourac | 2004 |
Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer?--a prospective clinical study.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X | 2004 |
[Single-agent Xeloda in the treatment of recurrent and metastatic breast cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxyc | 2004 |
[A case of recurrent stomach cancer treated with 5-fluorouracil responding to weekly paclitaxel therapy].
Topics: Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Resistance, Neoplasm; Fl | 2004 |
[Preoperative chemoradiation in esophageal cancer: experience of a single center in 102 patients].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2004 |
Pseudoneoplastic proliferation of histiocytes with paclitaxel-induced ultrastructural changes in a mastectomy specimen.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2004 |
[A case of rectal cancer with multiple liver and peritoneal metastases that responded dramatically to low-dose 5-FU plus LV and CDDP combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2004 |
Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2004 |
[A case of the 5-year survivor of ascending colon cancer associated with synchronous multiple liver metastasis and peritoneal dissemination successfully treated with combination therapy of systemic and hepatic arterial infusion chemotherapy].
Topics: Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Colonic Neoplasms; Embolization, Therapeutic | 2004 |
[Gastric cancer with liver metastasis effectively treated by intra-hepatic arterial infusion].
Topics: Administration, Oral; Adult; Aged; Agmatine; Antineoplastic Combined Chemotherapy Protocols; Cisplat | 2004 |
[Taxol based chemotherapy in the treatment of advanced gastric cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administratio | 2004 |
[Palliative surgery combined with oxaliplatin-based chemotherapy in treatment of patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2004 |
Dihydropyrimidine dehydrogenase expression predicts survival outcome and chemosensitivity to 5-fluorouracil in patients with oral squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Squam | 2005 |
[Efficacy of selective continuous transarterial infusion chemotherapy on advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Deoxycytidin | 2004 |
Adjuvant chemotherapy for lymph node-negative, estrogen receptor-negative breast cancer: a tale of three trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical T | 2004 |
Adjuvant portal vein cytotoxic infusion for curatively resected colon cancer--is it obsolete?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Admi | 2005 |
[Radio-chemotherapy for non-resectable primary esophageal malignant melanoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Esophageal | 2004 |
Concurrent proton beam radiotherapy and systemic chemotherapy for the metastatic liver tumor of gastric carcinoma: a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2005 |
Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Clinical Trials, Phase III | 2005 |
Correlation between histological effects on the main tumors and nodal status after chemoradiotherapy for squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2005 |
Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administrati | 2005 |
[Oxaliplatin plus capecitabine as a second line chemotherapy for patients with advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Admin | 2004 |
[A patient with metastatic breast cancer associated with retention of pleural effusion with no response to both CMF and exemestane, whose life was saved by high-dose toremifene].
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2005 |
Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2005 |
[Clinical analysis of resectable breast cancer: a report of 6 263 cases].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 2005 |
Lymph node micrometastasis in stage II distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2005 |
[A case of bilateral multiple liver metastases with distant lymph node metastases due to rectal cancer successfully treated with hepatic arterial infusion (HAI) of levofolinate (l-LV)/5-fluorouracil (5-FU) and radiotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dr | 2005 |
[Local failure-related factors of esophageal carcinoma after concurrent chemoradiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Female | 2005 |
[Minutes of the 23th meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO). Amsterdam, 24-28 October 2004].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents, Hormonal; Antineo | 2005 |
Lymph node metastasis in epithelial malignancies of the appendix with peritoneal dissemination does not reduce survival in patients treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Combine | 2005 |
Preoperative radio-chemotherapy treatment in locally advanced rectal carcinoma. Results of 8-year follow-up.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Disease-Free Survival; Dose Fractionat | 2005 |
[A case of advanced breast cancer markedly responding to chemo-endocrine therapy with only slight alopecia].
Topics: Adenocarcinoma, Scirrhous; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 2005 |
Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore | 2005 |
[Multivariate prognostic analysis for patients with unresectable esophageal carcinoma after concurrent chemoradiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
[A case of head and neck squamous cell carcinoma suffering from acute renal failure after methotrexate administrator].
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cispl | 2005 |
[A case of metastatic submandibular lymphnode treated successfully with palliative oral (5-FU + PSK) chemotherapy in the elderly].
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy | 2005 |
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, A | 2005 |
Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2006 |
Prognostic predictors in breast cancer patients with postoperative 5-fluorouracil-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Co | 2005 |
Rectal cancer clinical practice guidelines in oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Leucovorin; Live | 2005 |
[Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Admin | 2005 |
[Second-line chemotherapy with bi-weekly CPT-11 and cisplatin for recurrent colorectal cancer resistant to 5-FU based chemotherapy].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispl | 2005 |
Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis.
Topics: Adenocarcinoma, Sebaceous; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Eyelid Neopl | 2005 |
Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; | 2005 |
Intensity-modulated radiation therapy in head and neck cancers: dosimetric advantages and update of clinical results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2005 |
[Stage IV gastric cancer patient who underwent palliative gastrectomy showing complete response to induction therapy with methotrexate plus 5-fluorouracil and secondary treatment with oral TS-1].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2005 |
Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2005 |
Impact of orotate phosphoribosyl transferase activity as a predictor of lymph node metastasis in gastric cancer.
Topics: Aged; Antineoplastic Agents; Cell Proliferation; Female; Fluorouracil; Humans; Lymphatic Metastasis; | 2005 |
SMAD4 levels and response to 5-fluorouracil in colorectal cancer.
Topics: Allelic Imbalance; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Chrom | 2005 |
The reliability of lymph-node staging in rectal cancer after preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2005 |
[Two cases of advanced gallbadder cancer with para-aortic lymph node metastasis responding to intra-aortic infusion of gemcitabine and low-dose CDDP/5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Deoxycytidine; Drug Administration | 2005 |
Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2005 |
Recurrence and 5-FU sensitivity of stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Dihydrourac | 2005 |
Recurrence and 5-FU sensitivity of stage II/Dukes' B colorectal cancer with occult neoplastic cells in lymph node sinuses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Dihydrourac | 2005 |
Long-term survival after concomitant chemoradiotherapy prior to surgery in advanced cervical carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2006 |
Prognostic factors in patients with colorectal cancer receiving adjuvant chemotherapy or chemoradiotherapy: a pooled analysis of two randomized studies.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorourac | 2005 |
[Case report--postoperative continuous intraarterial infusion of small doses of 5-FU successfully controlled residual tumor and liver metastasis of stage IV gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Drug Combi | 2005 |
Recurrence and 5-FU sensitivity of stage II/III node-positive gastric cancer with occult neoplastic cells in lymph node sinuses.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Immunohis | 2005 |
Intratumoural expression of thymidylate synthase is an independent predictor of prognosis in patients with squamous cell carcinoma of the tongue: results from a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemother | 2006 |
[Complete disappearance of metastatic lung tumors and mediastinal lymphnode in a case of hepatocellular carcinoma treated by low-dose 5-fluorouracil/cisplatin therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Dose-Response | 2005 |
Detection of infraclavicular lymph node metastases using ultrasonography in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Du | 2005 |
Neoadjuvant chemoradiotherapy followed by esophagectomy for initially resectable squamous cell carcinoma of the esophagus with multiple lymph node metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Es | 2005 |
[A paclitaxel-resistant case of recurrent breast cancer responded to combination therapy of capecitabine and trastuzumab].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; An | 2005 |
Positron emission tomography scan to determine the need for neck dissection after chemoradiation for head and neck cancer: timing is everything.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy | 2005 |
Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemothe | 2006 |
Molecular factors of 5-fluorouracil metabolism in colorectal cancer: analysis of primary tumor and lymph node metastasis.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydr | 2006 |
Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2006 |
[Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabin | 2006 |
[A case of advanced rectal cancer responding to l-Leucovorin (LV)/5-fluorouracil( 5-FU) therapy as neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Adminis | 2006 |
Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2006 |
Long-term survival after three-field lymph-adenectomy for an adenocarcinoma in Barrett's esophagus with metastasis to Virchow's node.
Topics: Abdomen; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Ci | 2006 |
[Clinical examination of safety and effectiveness of primary chemotherapy with CEF followed by docetaxel in preoperative breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Breas | 2006 |
Recurrence and 5-FU sensitivity of stage I/II node-negative breast, lung, or gastric cancer with occult neoplastic cells in lymph node sinuses.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluor | 2006 |
Long-term survival and tumor 5-FU sensitivity in patients with stage IV colorectal cancer and peritoneal dissemination.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Huma | 2006 |
Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy).
Topics: Adenocarcinoma; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C | 2006 |
[Treatment efficacy of surgical management for liver metastasis from colorectal cancer--a report of 198 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2006 |
Effect of tamoxifen after chemotherapy in hormone receptor-positive, node-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Dru | 2006 |
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Ci | 2006 |
Prognostic factors and analysis of microsatellite instability in resected pulmonary metastases from colorectal carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemother | 2006 |
Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali | 2006 |
Adjuvant chemotherapy of colon cancer: lymph node involvement without metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Co | 2006 |
[Second-line chemotherapy with pharmacokinetic modulating chemotherapy for unresectable colorectal carcinoma recurrences resistant to 5-FU-based chemotherapy].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Co | 2006 |
Long-term results of maximally aggressive trimodality therapy in a high-risk subset of early-stage cervical cancer patients.
Topics: Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Hysterectomy; | 2006 |
Retrospective analysis on prognostic impact of adjuvant chemotherapy in the patients with advanced and resectable oral squamous cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2006 |
[Concurrent low-dose cisplatin/5-FU chemotherapy and radiation for the recurrent gastric carcinoma--case reports].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2006 |
Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience.
Topics: Adult; Aged; Aged, 80 and over; Ampulla of Vater; Analysis of Variance; Antimetabolites, Antineoplas | 2006 |
Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-F | 2006 |
[Successful antiemetic treatment of TSUMURA Rikkunshi-to Extract Granules for ethical use in addition to other antiemetic agents in neoadjuvant chemotherapy for an advanced breast cancer patient].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
[A case of advanced gastric cancer responding remarkably to paclitaxel + low-dose FP therapy in a neoadjuvant setting].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2006 |
Prognostic markers of local relapse in rectal cancer: are we any further forward?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Disease-F | 2006 |
Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuva | 2006 |
[Evaluation of weekly low-dose CPT-11 combined with 5-FU/l-LV therapy for advanced and recurrent colorectal cancer--preliminary study].
Topics: Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2006 |
Neoplastic mesorectal microfoci (MMF) following neoadjuvant chemoradiotherapy: clinical and prognostic implications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; F | 2006 |
[Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; C | 2006 |
A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Chemotherapy, A | 2007 |
Difference in Ki67 and thymidylate synthase expression in primary tumour compared with metastatic nodes in breast cancer patients.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Proliferation; Female; F | 2006 |
A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2006 |
Proteomic analysis identifies candidate proteins associated with distant recurrences in breast cancer after adjuvant chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Chemotherapy, A | 2007 |
Multiple cutaneous metastases from male breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; C | 2006 |
Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2007 |
[Successful treatment of an elderly patient with advanced gastric cancer using low-doses of 5-fluorouracil, levofolinate calcium, and cis-platinum with chronomodulation].
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aorta; Chronother | 2006 |
[A case of long-term survival of 3-years 4 months after combination chemotherapy of MTX, 5-FU and low-dose CDDP (MFP) for type 4 gastric cancer with pleuritis, peritoneal dissemination and Krukenberg tumor].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fema | 2006 |
[A case of intrahepatic cholangiocarcinoma effectively treated by hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Bone | 2006 |
[Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Antineoplastic Combined | 2006 |
Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2006 |
Infiltrating ductal carcinoma and synchronous malignant phyllodes tumour. Diagnostic and therapeutic approaches.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemoth | 2006 |
[Breast cancer in young women in the south of Tunisia].
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemot | 2006 |
[A case of metastatic lung cancer responding well from tongue carcinoma using a combination of stereotactic radiation therapy and docetaxel/cisplatin/5-FU chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2006 |
[A long-term survival case of liver and mediastinal LN metastases from colon cancer treated with intensive multimodal therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Co | 2006 |
[MTX-CDDP-5-FU double modulation intra aortic chemotherapy for advanced and metastatic gastric cancer--a comparison with an intra venous route].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Female; Fluorouracil; Humans; Infu | 2006 |
[A 42-month disease free survival case of combined hepatocellular-cholangiocarcinoma with lymph node metastases treated with multimodal therapy].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, | 2006 |
Concurrent chemoradiation for patients with squamous cell carcinoma of the cervical esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2007 |
Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplasti | 2007 |
[Prognosis analysis of nasopharyngeal carcinoma patients with distant metastasis].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, | 2007 |
Adjuvant chemotherapy in elderly patients (>or=75 yr) completely resected for colon cancer stage III compared to younger patients: toxicity and prognosis.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2006 |
Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Fine-Needle; Breast Neo | 2007 |
[A retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasm | 2007 |
[A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; C | 2007 |
Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Duodenal Neopl | 2007 |
[Pathological evaluation of neoadjuvant chemotherapy with low-dose FP therapy for advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2007 |
[A successful case of lower gingival cancer with pulmonary metastases by adjuvant chemotherapy including paclitaxel, cisplatin and 5-fluorouracil following a surgical procedure].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2007 |
[Clinical administration of FOLFOX regimens for patients with unresectable advanced or recurrent colorectal cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; C | 2007 |
Reduction rate of lymph node metastasis as a significant prognostic factor in esophageal cancer patients treated with neoadjuvant chemoradiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Es | 2007 |
[Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery].
Topics: Anastomosis, Surgical; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2008 |
Thymidylate synthase expression in primary colorectal tumours is correlated with its expression in metastases.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Female; Fluorouracil; Huma | 2007 |
The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus.
Topics: Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Esophageal Neoplasms; Fluo | 2007 |
The effect of chemotherapy on Ki-67, Bcl-2 and Bak expression in primary tumors and lymph node metastases of breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; bcl-2 Homologous Ant | 2007 |
Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2007 |
Salvage lymphadenectomy of the right recurrent nerve node with tracheal involvement after definitive chemoradiation therapy for esophageal squamous cell carcinoma: report of two cases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2007 |
One more change of paradigm in breast cancer treatment. Postmastectomy radiotherapy for patients with one to three lymph node metastases?
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2007 |
Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Adm | 2007 |
[A case of recurrent esophageal cancer successfully treated with concurrent radiochemotherapy with low-dose docetaxel plus 5-FU].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 2007 |
[A case of metastatic colon cancer to paraaortic lymph nodes and liver treated successfully with oxaliplatin combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administrati | 2007 |
[A case of severe hand-foot syndrome caused by capecitabine].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration | 2007 |
[Evaluation of combination therapy of high-dose toremifene and oral chemotherapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine | 2007 |
Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epi | 2008 |
Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2007 |
Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Therapy, | 2007 |
The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2007 |
Angiogenic effect of naive and 5-fluorouracil resistant colon carcinoma on endothelial cells in vitro.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Coculture Techniques; Colonic Neoplasms; Dru | 2007 |
[Clinical characteristics of cancer of unknown primary (CUP)--a summary of 22 cases].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 2007 |
[An elderly case of advanced cervical esophageal cancer successfully treated with UFT after chemoradiotherapy with docetaxel/5-FU/CDDP].
Topics: Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combi | 2007 |
[An effective treatment by chemoradiation therapy after stent insertion for advanced esophageal cancer with esophago-pulmonary fistula--report of a case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2007 |
Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2007 |
[Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2007 |
[Diagnosis and prognosis study of breast carcinoma with micropapillary component].
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone N | 2007 |
[Dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2007 |
Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinom | 2007 |
[Neoadjuvant and adjuvant chemotherapy in patients with advanced penile cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Adjuvant; Cisplatin; Combin | 2007 |
[Postoperative radiotherapy of the chest wall in patients with male breast cancer].
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Ch | 2007 |
[A case of elderly metastatic breast cancer with a complete response to treatment with capecitabine and cyclophosphamide].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Ch | 2007 |
Effect of neoadjuvant chemotherapy on circumferential margin positivity and its impact on prognosis in patients with resectable oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2008 |
Enzymatic activities of uridine and thymidine phosphorylase in normal and cancerous uterine cervical tissues.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; | 2007 |
Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cispl | 2007 |
[Clinical analysis of 108 cases with adenocarcinoma Barretts's esophagus].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Comb | 2007 |
Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Densi | 2007 |
Management of advanced nodal disease following chemoradiation for head and neck squamous cell carcinoma: role of magnetic resonance imaging.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2007 |
[Expression of livin in gastric cancer and effect of silencing of the livin gene on apoptosis in gastric cancer cells].
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apopto | 2007 |
ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Asian People; Chemotherapy, Adjuvant; Colectomy; Color | 2008 |
Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Co | 2008 |
Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cohort Studies; Combi | 2009 |
Administration of oxaliplatin to a pregnant woman with rectal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival | 2009 |
Correlation between clinical pathologic factors and activity of 5-FU-metabolizing enzymes in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasm | 2008 |
[A case of complete response in supraclavicular lymph node involvement from cancer of the sigmoid colon to FOLFOX4 therapy after laparoscopy-assisted colectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colectomy; Female; Fluorour | 2008 |
Evaluation of biological pathways involved in chemotherapy response in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2008 |
[Treatment of advanced maxillary sinus squamous carcinoma: an analysis of 92 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 2008 |
[A case of occult breast cancer successfully treated by capecitabine in combination with weekly paclitaxel followed by FEC (75)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2008 |
[A case of recurrent rectal cancer with lymphangiosis carcinomatosa successfully treated with modified FOLFOX6 therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovorin; Lung Neopl | 2008 |
Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2008 |
Disseminated melanoma. Biologic behavior and treatment.
Topics: Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Dactinomycin; Fluorouracil; Humans; Hydrazine | 1967 |
[2 cases of sebaceous cancer observed at the Holy Spirit Hospital in Casale Monferrato in 1980].
Topics: Adenoma; Aged; Anal Gland Neoplasms; Animals; Bleomycin; Diagnosis, Differential; Dinitrochlorobenze | 1982 |
Recurrent cervical cancer in the pelvis--intra-arterial infusion of oncostatics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Catheterization; Cisplatin; Combined Moda | 1983 |
Chemotherapy in advanced urinary bladder cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1984 |
Combination chemotherapy for the treatment of metastatic basal cell carcinoma of the scrotum. A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Basal Cell; Cisplatin; Fluorou | 1984 |
Nonsteroid antiinflammatory drugs and tamoxifen for desmoid tumors and carcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents; Cyclophosphamide; Drug Therapy, Combination; | 1983 |
Phase II study of methyl-CCNU, vincristine, 5-fluorouracil, and streptozotocin in advanced colorectal cancer. By the Gastrointestinal Tumor Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Female; Fluorour | 1984 |
Analysis of the results of our combined therapy for maxillary cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell | 1980 |
[Chemotherapy of small cell carcinoma of the lung in relation to lymph node metastasis and extending pattern of tumor].
Topics: Carcinoma, Small Cell; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Humans; Lung Neopl | 1983 |
Multimodality treatment of adenocarcinoma of the vagina Stage IV: potential for cure.
Topics: Adenocarcinoma, Mucinous; Adult; Combined Modality Therapy; Female; Fluorouracil; Humans; Lymphatic | 1983 |
Sequential methotrexate and 5-fluorouracil: improved response rate in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colonic Neoplasms; Drug | 1984 |
[Effect of extended chemotherapy using tegafur following surgery of stage III stomach cancer].
Topics: Aged; Drug Administration Schedule; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle | 1983 |
[Effective cases of advanced endometrial and recurrent ovarian cancers treated with oral administration of UFT].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Tra | 1984 |
[Preoperative immunochemotherapy for gastric cancer combined with perifocal administration of OK-432].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Female; Fluorourac | 1984 |
Spontaneous metastasis of highly metastatic variants of mouse tumors and the effect of drugs on the metastasis.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Doxorubicin; Fluorouracil; Lung Neoplasms; Lymphatic Met | 1984 |
Endoscopic intramural injection of anti-neoplastic emulsion.
Topics: Administration, Oral; Animals; Dogs; Emulsions; Fluorouracil; Gastric Mucosa; Gastroscopy; Lymph Nod | 1984 |
[Adriablastin (doxorubicin) in the combined chemotherapy of patients with disseminated forms of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1984 |
FAC + BCG as adjuvant therapy in breast cancer: an 8-year update.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Combined Modality The | 1984 |
Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer: 8 year results.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Chlorambucil; Combine | 1984 |
FAM2 regimen in disseminated gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; | 1984 |
Ludwig Breast Cancer trials LBCS III and IV: adjuvant endocrine treatment in postmenopausal patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Castration; Combined Modalit | 1984 |
CMF adjuvant programs at the Milan Cancer Institute.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; | 1984 |
[Initial therapeutic evaluations of 141 patients with carcinoma of the breast under 40 years of age].
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modal | 1984 |
[5 years' experiences with adjuvant chemotherapy in primary breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1984 |
Methotrexate and 5-fluorouracil in head and neck cancer.
Topics: Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Therapy, Combination; Endoscopy; Fluoro | 1983 |
Studies on the effect of oral administration of 5-FU emulsion as an adjuvant to surgical treatment of gastric cancer.
Topics: Administration, Oral; Combined Modality Therapy; Emulsions; Fluorouracil; Humans; Lymphatic Metastas | 1983 |
[A case of primary duodenal cancer. Diagnostic and therapeutic considerations].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug | 1983 |
[Bone scintigraphy in mastectomized patients with and without chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Breast Neoplasms; Cyclo | 1983 |
Oral and pharyngeal cancer: combined approach for multimodal therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cobalt Radioisotopes; Combined Modality | 1983 |
Prognostic factors in primary breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Combined Modality The | 1983 |
The natural history of gastric cancer and prognostic factors influencing survival.
Topics: Adenocarcinoma; Adult; Aged; Female; Fluorouracil; Gastrectomy; Humans; Liver Neoplasms; Lymphatic M | 1984 |
[Radiotherapy and combined modality treatment of advanced gastrointestinal tumors. Analysis of morbidity in 101 patients].
Topics: Aged; Combined Modality Therapy; Fluorouracil; Gastrointestinal Neoplasms; Humans; Hyperthermia, Ind | 1984 |
[Review of intra-arterial infusion-radiation therapy for lingual cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Combined Modality Th | 1984 |
Intratumor immunochemotherapy with 5-fluorouracil emulsion and BCG in C3H/HE mice transplanted with MH134.
Topics: Animals; BCG Vaccine; Cell Line; Fluorouracil; Hemolytic Plaque Technique; Liver Neoplasms, Experime | 1982 |
[Breast neoplasms. Progress by means of adjuvant chemotherapy?].
Topics: Age Factors; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Ly | 1980 |
[Endolymphatic polychemotherapy of ovarian cancer].
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Fluor | 1981 |
[Effect of immunochemotherapy on the cases of advanced gastric cancer stage III].
Topics: Drug Therapy, Combination; Fluorouracil; Gastrectomy; Humans; Levamisole; Lymphatic Metastasis; Mito | 1982 |
[Concentration of 5-FU level in the tissue and blood of the patients with breast cancer by preoperative administration of UFT].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Combin | 1982 |
[Renal cell carcinoma].
Topics: Adenocarcinoma; Cytarabine; Drug Therapy, Combination; Fluorouracil; Humans; Kidney Neoplasms; Lung | 1982 |
Pathologic findings from the National Surgical Adjuvant Breast Project. VIII. Relationship of chemotherapeutic responsiveness to tumor differentiation.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug | 1983 |
[Radiation and combination treatment of breast cancer metastases to the lungs].
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Evaluation Studies as To | 1983 |
Adjuvant CMF effect on site of first recurrence, and appropriate follow-up intervals, in operable breast cancer with positive axillary nodes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1981 |
[Juvenile carcinoma of the duodenum in two brothers (author's transl)].
Topics: Adenocarcinoma; Adult; Duodenal Neoplasms; Fluorouracil; Humans; Lymphatic Metastasis; Male | 1982 |
[Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer].
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinat | 1982 |
[Ancillary chemotherapy with trofosfamid, methotrexate and fluoro-uracil in cancer of the breast (author's transl)].
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lymphat | 1981 |
A study over a 5-year period of adjuvant chemotherapy after mastectomy for breast cancer.
Topics: Breast Neoplasms; Chlorambucil; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; | 1981 |
Multimodality approach to surgical management of locally advanced epidermoid carcinoma of the anorectum.
Topics: Aged; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Lymphat | 1981 |
[Results of, and indications for adjuvant chemotherapy in breast cancer].
Topics: Adult; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; | 1981 |
[Encouraging results with cytostatic therapy in metastasizing breast cancer (author's transl)].
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combina | 1981 |
Adjuvant therapy for stage II, estrogen receptor negative breast cancer.
Topics: Actuarial Analysis; Antineoplastic Agents; Axilla; Breast Neoplasms; Cyclophosphamide; Doxorubicin; | 1981 |
Adverse effect of radiotherapy on adjuvant chemotherapy for carcinoma of the breast.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; F | 1980 |
[Adjuvant chemotherapy in breast neoplasms. Clinical and immunologic results].
Topics: Adult; Aged; Breast Neoplasms; Concanavalin A; Cyclophosphamide; Female; Fluorouracil; Humans; Lymph | 1980 |
[Use of 5-fluorouracil in the radiation therapy of cervical cancer].
Topics: Adult; Aged; Cell Cycle; Cell Transformation, Neoplastic; Female; Fluorouracil; Humans; Lymphatic Me | 1980 |
[Drug pathomorphosis of breast cancer (proceedings)].
Topics: Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil | 1980 |
Clinical studies of intrarectal administration of 5-FU emulsion as an adjunct to surgical treatment of rectal cancer.
Topics: Emulsions; Fluorouracil; Humans; Lymphatic Metastasis; Preoperative Care; Rectal Neoplasms; Rectum; | 1980 |
Lymph node metastasis and effects of 1-beta-D-arabinofuranosylcytosine, 5-fluorouracil, and their lipophilic derivatives in an experimental model system using P388 leukemia.
Topics: Animals; Cytarabine; Female; Fluorouracil; Leukemia, Experimental; Lymphatic Metastasis; Mice; Solub | 1980 |
Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model.
Topics: Adenocarcinoma; Adrenal Glands; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Dis | 1995 |
Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity.
Topics: Antineoplastic Agents; Bleomycin; Carboplatin; Carmustine; Cisplatin; Dacarbazine; Dose-Response Rel | 1994 |
Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tum | 1994 |
[Hepatocellular carcinoma in pregnancy].
Topics: Adult; Carcinoma, Hepatocellular; Cesarean Section; Chemotherapy, Adjuvant; Combined Modality Therap | 1994 |
Treatment of invasive squamous cell carcinoma complicating anal Buschke-Löwenstein tumor: a case history.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Diseases; Anus Neoplasms; Carcinoma, Squamous C | 1995 |
Pericardiac metastasis from advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Fluorouracil; Heart Neoplasms; Human | 1995 |
[A case of advanced gastric cancer treated effectively with neo-adjuvant chemotherapy using l-leucovorin and 5-FU].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Adminis | 1995 |
Locally advanced non-metastatic breast cancer: analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 1995 |
[Advanced gastric carcinoma with extensive lymph node metastases successfully treated by sequential methotrexate/5-fluorouracil therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fluoro | 1995 |
[Effect of low dose CDDP/5-fluorouracil therapy on PCNA labeling index and TS inhibition rate of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cisplatin; DNA, Neoplasm; Flow Cytometry | 1995 |
Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclo | 1995 |
[Postoperative abdominal lymph node recurrence of intrathoracic esophageal cancer with a long-term complete response to radiation and split CF therapy (CDDP and 5-FU)--a case report].
Topics: Abdomen; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esoph | 1995 |
Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: a prospective longitudinal study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; | 1995 |
P-glycoprotein expression in primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 1995 |
[The immediate results of the combined treatment of rectal cancer using intra-arterial selective polychemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Female; Fluorou | 1994 |
[Two patients with far advanced gastric cancer responding to combination chemotherapy with 5-FU and CDDP].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 1995 |
[Combination therapy of 5-FU and low dose CDDP for advanced and recurrence gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Femal | 1995 |
[A case of meningeal carcinomatosis which occurred after treatment for recurrence of the cervical carcinoma].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combine | 1995 |
[A case of advanced gastric remnant carcinoma with Virchow's metastasis treated with neoadjuvant chemotherapy (low dose CDDP + 5-FU) followed by surgical resection].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; E | 1995 |
[Flow cytometric DNA analysis and chemosensitivity in squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Agents; Carbazilquinone; Carcinoma, Squam | 1994 |
Chemotherapeutic management of head and neck malignancies with positron emission tomography.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxyglucose; F | 1995 |
[Endolymphatic polychemotherapy with local ultra high frequency hyperthermia for the combined treatment of invasive rectal cancer].
Topics: Adenosarcoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; | 1993 |
[Adriamycin/cyclophosphamide: current standard in adjuvant therapy for breast carcinoma?].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1994 |
[A case report of rectal cancer with lymph node metastasis effectively treated by neoadjuvant chemotherapy of 5-FU oral and low-dose CDDP transarterial administration].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla | 1994 |
[Concomitant radiotherapy and chemotherapy with protracted low dose continuous infusion of 5-fluorouracil and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1994 |
[Tissue concentration of tegafur suppository in patients with head and neck cancer--concentration of 5-FU in cancer tissue].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Neopla | 1994 |
[Therapy of anal cancer].
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Therap | 1994 |
[The significance of intra-arterial infusion therapy for neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Doxorubici | 1994 |
Histologic grade of locally advanced infiltrating ductal carcinoma after treatment with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Needle; Breast Neoplasm | 1994 |
[The prognostic factors following the simultaneous radiochemotherapy of anal canal carcinoma in a multicenter series of 139 patients].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1994 |
Augmentation of 5-fluorouracil cytotoxicity by epidermal growth factor in a newly established human signet-ring cell carcinoma of the stomach in culture.
Topics: Carcinoma, Signet Ring Cell; Cell Division; Cell Line; Cell Survival; Dose-Response Relationship, Dr | 1994 |
[The tumor pathomorphosis and status of the regional lymph nodes after the preoperative polychemotherapy of patients with vulvar cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 1993 |
[Simultaneous radiochemotherapy in locoregional recurrent breast carcinoma after mastectomy. Results in patients with macroscopic residual tumor R2].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined M | 1994 |
Neoadjuvant therapy for unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Fluorouracil; Humans; Inf | 1993 |
[Postoperative immunochemotherapy for gastric carcinoma with peritoneal dissemination--the effects with the combination of CDDP, 5-FU and lentinan].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cel | 1994 |
Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1994 |
Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neo | 1994 |
[Successful treatment of advanced gastric cancer (Borrmann 1 type) with FTP chemotherapy after reduction surgery].
Topics: Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1994 |
Results of treatment of laryngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cobalt Radioisotopes; Female; Fluorouracil | 1994 |
Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 1993 |
Histocultures of patient head and neck tumors for pharmacodynamics studies.
Topics: Adult; Aged; Cisplatin; Culture Techniques; Drug Screening Assays, Antitumor; Female; Fluorouracil; | 1993 |
Acute tumor lysis syndrome with squamous cell carcinoma of the vulva.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; F | 1993 |
Small cell carcinoma of the esophagus with an esophago-mediastinal fistula successfully treated by chemoradiation therapy and intubation: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cobalt Radioisotop | 1993 |
[A case of nonresectable gastric cancer treated by sequential methotrexate and 5-fluorouracil].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Drug Admi | 1994 |
Epidermoid carcinoma of the anal canal: treatment by combined radiation and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neo | 1993 |
[Multimodality treatment of thoracic esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality | 1993 |
[Multimodality treatment of esophageal carcinoma: evaluation of preoperative (neoadjuvant) chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1993 |
[Tissue and serum levels of 5-FU in the patients with head and neck malignant tumors--influence of a streptococcal preparation OK-432].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Head and Neck Neo | 1993 |
PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 1993 |
[Intraarterial infusion chemotherapy for recurrent or unresectable gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Fluoroura | 1993 |
[A case report of an advanced esophageal carcinoma treated by neoadjuvant chemotherapy (CDDP + 5-FU) and evaluation of effect on metastatic lymph nodes].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1993 |
Respiratory failure due to pulmonary lymphangitis carcinomatosis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Fluorouracil; | 1993 |
[A case of advanced gastric cancer responding to an FAP (5-FU, ADM, platinum compounds) combined chemotherapy].
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplati | 1993 |
Induction chemotherapy and intensification with autologous bone marrow reinfusion in patients with locally advanced and disseminated breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1993 |
Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. The French Epirubicin Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1993 |
[Quandrantectomy in the conservative treatment of breast carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined Modality Thera | 1993 |
Postoperative radiation therapy for high-risk colon carcinoma.
Topics: Aged; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Lymphatic Metastas | 1993 |
[A patient with stage IV gastric cancer responding to combination chemotherapy with 5-FU, leucovorin and CDDP].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administratio | 1993 |
A case of advanced male breast cancer successfully treated by 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy combined with tamoxifen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms, Male; Carcin | 1995 |
[A case of advanced esophageal cancer showing good partial response by combination therapy of low dose 5-FU and low dose CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Cisplatin; Drug Admi | 1996 |
Surgical resection of pulmonary metastases from nasopharyngeal carcinoma.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemot | 1996 |
[5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?].
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Antimetabolites, Antineoplastic; Fatal Outcome; Female; Flu | 1996 |
Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy.
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic A | 1995 |
Preoperative adjuvant radiation with chemotherapy for rectal cancer: its impact on stage of disease and the role of endorectal ultrasound.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorour | 1996 |
Patterns of recurrence for advanced colon cancer modified by whole abdominal radiation and chemotherapy.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modality Therap | 1996 |
Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
Neoadjuvant chemotherapy with cisplatin-vindesine-5-fluorouracil and folinic acid for locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 1996 |
[A case report of small cell carcinoma of the esophagus with remarkable response to neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cispl | 1996 |
[A case of advanced gastric cancer with liver metastasis with no recurrence and long survival].
Topics: Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1996 |
[Successful neoadjuvant chemotherapy in a patient with advanced gastric cancer with periaortic lymph node metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Chemotherapy, Adjuvant; Cisplatin; Comb | 1996 |
Cyclophosphamide, methotrexate, and fluorouracil: still the gold standard?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1996 |
Nasopharyngeal carcinoma with metastatic disease to mediastinal and hilar lymph nodes: an indication for more aggressive treatment.
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemothe | 1996 |
Cisplatin-fluorouracil exclusive chemotherapy for T1-T3N0 glottic squamous cell carcinoma complete clinical responders: five-year results.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 1996 |
[Individual therapeutic procedure in metastatic carcinoid of the small intestine].
Topics: Carcinoid Tumor; Colectomy; Combined Modality Therapy; Female; Fluorouracil; Humans; Ileal Neoplasms | 1996 |
A retrospective study of the use of cisplatinum-5-fluorouracil neoadjuvant chemotherapy in cervical-node-positive nasopharyngeal carcinoma (NPC).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cis | 1995 |
Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy.
Topics: Appendiceal Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans | 1996 |
[Indication of prophylactic hepatic arterial-infusion chemotherapy after hepatic resection for liver metastases from colorectal cancer].
Topics: Colorectal Neoplasms; Doxorubicin; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusi | 1996 |
[Preoperative chemoradiation therapy for lower rectal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1996 |
Modified clearing technique to identify lymph node metastases in post-irradiated surgical specimens from rectal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Humans; Ly | 1996 |
A case of bone marrow recurrence from gastric carcinoma after a nine-year disease-free interval.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carcinoma, Signet Ring Cell; | 1996 |
Small intestinal cancer with extensive lymph node metastases showing complete remission by methotrexate/5-fluorouracil sequential therapy: report of a case.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 1997 |
[Results of adjuvant chemotherapy of operated high risk cervix carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 1996 |
[Clinical analysis of adjuvant chemotherapy using 5-fluorouracil, leucovorin and cis-diamminedichloroplatinum for patients with advanced and recurrent gastric cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Chem | 1997 |
Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Chemotherapy | 1997 |
[Preoperative synchronized chemoradiation therapy for advanced esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality | 1997 |
[Combined breast-preserving surgery, chemotherapy and radiotherapy in the treatment of breast carcinoma. Effect of the interval between surgery and the beginning of radiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 1997 |
[Continuous infusion high-dose leucovorin with cisplatin and 5-fluorouracil for a recurrent oropharynx carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administra | 1997 |
[A case of recurrent gastric cancer with liver metastasis responding to combination chemotherapy with cisplatin and carmofur].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluor | 1997 |
Nocturnal 5-fluorouracil infusion to patients with breast cancer prior to surgery: appearance of 5-fluorouracil-induced AgNORs aggregation (FAA).
Topics: Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Lymphatic Metastasis; | 1997 |
Pharmacokinetics of intrapericardial administration of 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Area Under Curve; Bre | 1997 |
[A case of advanced gastric cancer with carcinomatosa peritonitis effectively treated by 5-FU and low-dose CDDP therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplatin; Drug Administration | 1997 |
[Therapy pf cervical lymph node metastases of unknown primary tumor].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 1997 |
[The acute toxicity of the simultaneous radiochemotherapy of rectal carcinoma].
Topics: Acute Disease; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Female; Fluoroura | 1997 |
The role of radiation therapy and chemotherapy in the treatment of Merkel cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 1997 |
Breast conservation after induction chemotherapy for locally advanced breast cancer.
Topics: Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Al | 1997 |
[A case of papillary adenocarcinoma of the stomach with liver metastases and carcinomatous peritonitis treated effectively by methotrexate/5-fluorouracil sequential chemotherapy].
Topics: Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; D | 1997 |
Hyperplasia of axillary nodes in patients undergoing immunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Carcinoma, Renal Cell; Fluorouracil; Humans; | 1997 |
[High-dosage chemotherapy and autologous transplant of hematopoietic germ cells from peripheral blood in high-risk recurrence carcinoma of the breast (with >= or 10 involved axillary nodes at diagnosis) Preliminary results of the Solti 9301 cooperative st
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carboplatin; Combin | 1997 |
[Arterial infusion chemotherapy in pelvic space for advanced rectal cancer].
Topics: Antidotes; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Administration Schedule; Fl | 1997 |
[Liver metastases from breast cancer 14 years after radical mastectomy; successful treatment with hepatic arterial infusion chemotherapy and systemic endocrine therapy--a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Fadrozole; Femal | 1997 |
[A case of far-advanced gastric cancer treated with continuous 5-fluorouracil injection and intrahepatic arterial infusion of low-dose cisplatin].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasm | 1997 |
[Preoperative chemoradiation therapy for advanced rectal cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1997 |
[A case of advanced primary ureteral squamous cell carcinoma responding to combination chemotherapy with cisplatin and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1997 |
Feasibility of adjuvant chemotherapy for breast cancer patients.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 1997 |
A pilot study of multimodality therapy for initially unresectable liver metastases from colorectal carcinoma: hepatic resection after hepatic arterial infusion chemotherapy and portal embolization.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modal | 1997 |
Neoadjuvant chemotherapy followed by concurrent chemotherapy and radiotherapy for locally advanced esophageal carcinoma with bulky upper abdominal lymphadenopathy. Case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neopla | 1997 |
Lymph node recurrence of gallbladder carcinoma successfully managed by systemic chemotherapy with 5-fluorouracil and mitomycin C: report of a 5-year survivor.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 1997 |
[Polarographic detection of reoxygenation of lymph node metastases in the initial phase of primary radio- and radiochemotherapy in patients with advanced squamous epithelial carcinomas of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1997 |
[New combination therapy with FTM [5-FU, pirarubicin (THP) and MMC] for treatment of inoperable advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 1997 |
[Aortic stop flow and hypoxic perfusion chemotherapy for unresectable gallbladder cancer].
Topics: Anesthesia, General; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Chemotherapy, | 1998 |
[Effect of preoperative THP-FLPM (pirarubicin, 5-fluorouracil, leucovorin, cisplatin, mitomycin C) therapy on far advanced gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doxo | 1998 |
Angiogenesis and stromal fibronectin expression in invasive breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1998 |
Adjuvant cyclophosphamide, methotrexate and fluorouracil for node-positive breast cancer: a lifetime cost-utility analysis based on a modified Q-TWIST method.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benef | 1997 |
Conservative surgery and radiotherapy in early stage breast cancer: a comparison between tumourectomy and quadrantectomy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neopl | 1998 |
Radiotherapy alone or radiochemotherapy with platin derivatives following transurethral resection of the bladder. Organ preservation and survival after treatment of bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplasti | 1998 |
[Successful chemotherapy based on in vitro chemosensitivity testing in a case of recurrent thymic carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Adenosquamous; Cis | 1998 |
[A case of advanced gastric cancer with virchow's metastasis responding remarkably to combination chemotherapy of low-dose CDDP and 5-FU].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Chemotherapy, Adjuvant; | 1998 |
[Two patients with obstructive jaundice due to intra-abdominal lymph-node metastases of gastric cancer responding to combination chemotherapy with 5-FU and CDDP].
Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholestasis; Cisplatin; Drug Administ | 1998 |
Squamous cell carcinoma of the vulva in the south of Israel: a study of 50 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1998 |
[A case report of advanced breast cancer with remarkable response to chemoendocrine therapy (CTF + MPA)].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bre | 1998 |
[Advanced gastric cancer curatively resected following combined neoadjuvant chemotherapy--report of a case].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla | 1998 |
[Chemotherapy repeated injection via pelvic retroperitoneal cannulation].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Dogs; Endometrial Ne | 1997 |
Intranodal injection of anticancer drugs into fixed cervical metastatic lymph nodes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1997 |
Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 1998 |
[5-fluorouracil and low-dose leucovorin as surgical adjuvant therapy from viewpoint of long-term outcome].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Admi | 1998 |
[Evaluation of intra-arterial infusion chemotherapy for advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; Infusion Pumps, Imp | 1998 |
[Significance of full-thickness chest wall resection as a local treatment for sternum metastasis of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Fem | 1998 |
Clinical characteristics of patients with metastatic breast cancer with complete remission following systemic treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclo | 1998 |
Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 1998 |
[A case of stage IV (N4) esophageal cancer successfully treated with concurrent chemoradiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophage | 1998 |
p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy; Cell Dif | 1997 |
Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents, Hormonal; Antineoplasti | 1995 |
Adjuvant chemotherapy with CEF versus CMF for node-positive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Cytarabin | 1998 |
Detection of multiple hepatic micrometastases in pancreatic adenocarcinoma with a solitary liver metastasis by direct sequencing of the K-ras gene: a case report.
Topics: Adenocarcinoma; Aged; Base Sequence; Combined Modality Therapy; Dose Fractionation, Radiation; Femal | 1999 |
Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1998 |
Rationale of the so-called extended resection for pancreatic invasive ductal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Femal | 1999 |
[A case of advanced gastric cancer successfully treated by neoadjuvant chemotherapy with CPT-11, CDDP and 5-FU].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Fluorouracil; Gastre | 1999 |
Inguinal lymph node metastases from rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colostomy; Combined Mod | 1999 |
[A case report: modified PMUE therapy might be effective for advanced gastric carcinoma with pulmonary carcinomatous lymphangitis].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 1999 |
Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; beta-A | 1999 |
Metaplastic breast cancer: prognosis and response to systemic therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 1999 |
Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Combined Modality Thera | 1999 |
Estradiol receptor and prognostic parameters of human breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ch | 1999 |
FDG PET evaluation of residual masses and regrowth of abdominal lymph node metastases from colon cancer compared with CT during chemotherapy.
Topics: Abdominal Neoplasms; Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, | 1999 |
[The effect of the parameters of the therapeutic protocol on the efficacy of the adjuvant chemotherapy of breast cancer].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1999 |
[A case of multiple bone metastases from advanced breast cancer effectively treated with pamidronate].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1999 |
The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 1999 |
Resectable esophageal carcinoma: local control with neoadjuvant chemotherapy and radiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Invasive squamous cell carcinoma with sporotrichoid metastasis in a patient with cutaneous T cell lymphoma treated with chronic extracorporeal photopheresis.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Carci | 1999 |
Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1999 |
Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1999 |
Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1999 |
Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1999 |
Rectal cancer and inguinal metastases: prognostic role and therapeutic indications.
Topics: Abdominal Neoplasms; Adenocarcinoma; Aged; Aged, 80 and over; Biopsy; Female; Fluorouracil; Follow-U | 1999 |
Intra-arterial infusion chemotherapy for penile carcinoma with deep inguinal lymph node metastasis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1999 |
[5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer].
Topics: Actuarial Analysis; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 1999 |
[A case of advanced gastric cancer with abdominal para-aortic lymph node metastasis successfully treated with FLP therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Carcinoma, S | 1999 |
Adenocarcinoma of the head of the pancreas: effects of surgical and nonsurgical therapy on survival--a ten-year experience.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Life | 1999 |
Current trends in the surgical treatment of esophageal and cardia adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cardia; Chemother | 1999 |
[Effective and low toxicity chemoradiotherapy for distant metastatic esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Adm | 1999 |
[A case of stage IV esophageal cancer successfully treated by chemoradiation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Fluorouracil; Human | 1999 |
[A case of stage IV (A3) cervical and upper thoracic esophageal adenocarcinoma successfully treated with concurrent chemoradiotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 1999 |
Primary neuroendocrine small cell carcinoma of the breast.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Needle; Breast Neoplasms; Carcinoma, | 2000 |
Cisplatin-5-fluorouracil therapy with remarkable effect and 5-year survival for paraaortic lymph node metastases of rectal carcinoma in females: a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Female; Fluo | 1999 |
High dose chemotherapy and autologous blood stem cell support in women with breast carcinoma and isolated supraclavicular lymph node metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modal | 2000 |
Nodal volume reduction after concurrent chemo- and radiotherapy: correlation between initial CT and histopathologic findings.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2000 |
[A case of gastric cancer with liver metastasis responding to low-dose CDDP/5-FU combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Drug Admi | 2000 |
The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2000 |
The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with > or = 10 positive axillary nodes.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Axilla; Bone Marrow Transplant | 1999 |
Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience.
Topics: Adenocarcinoma; Age Factors; Analysis of Variance; Antimetabolites, Antineoplastic; Carcinoembryonic | 2000 |
[A case of far advanced breast cancer with distant metastases which had mostly disappeared after chemoendocrine therapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Mo | 2000 |
Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer.
Topics: Adult; Aged; Anal Canal; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorou | 2000 |
Chemosensitivity of advanced larynx carcinoma cells in vitro and significance of multidrug resistance markers in these tumors.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; C | 1998 |
The effect of nodal status on determinants of initial treatment response and patterns of relapse-free survival in nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma; Cisplatin; Disease- | 2000 |
Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cis | 2000 |
Antimetastatic intraoperative chemotherapy of human colon tumors in the livers of nude mice.
Topics: Animals; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorou | 2000 |
Epithelial cells in bone marrow of oesophageal cancer patients: a significant prognostic factor in multivariate analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Bone Marrow; Bon | 2000 |
Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma; Chemotherapy, A | 2000 |
Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Culture Media, Conditioned; Doxorubic | 2000 |
Wide-field radiation as adjunct to adjuvant chemotherapy in high-risk cases with early breast cancer: do it or not?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cause of Death; Chemotherapy, Adju | 2000 |
[Weekly low-dose CPT-11 and HCFU for advanced colorectal cancer on an outpatient treatment basis].
Topics: Adenocarcinoma; Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Pr | 2000 |
Feasibility of daily concurrent chemoradiation therapy as nonsurgical management for esophageal cancer: our experience and theoretical background.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose Fractionation, Radiation; Drug | 2000 |
[Cox proportion hazard model multivariate analysis of prognosis of 1,484 axillary node-negative breast cancer patients].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neopl | 1997 |
[A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 1998 |
[Lymph node and peritoneum metastases of bile duct cancer responding to chronochemotherapy--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin | 2000 |
[A patient with gastric cancer with para-aortic lymph node metastases surviving for 9 years after effective preoperative chemotherapy and radical operation].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aorta; Fluorouracil; Gastrectomy; Humans; Lymph Nod | 2000 |
[Two cases of advanced gastric cancer responding to TS-1: a novel oral formation of 5-fluorouracil].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sche | 2000 |
Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2000 |
[A case of effective chemotherapy using CAF followed by docetaxel for advanced breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2000 |
Postsurgical sequential methotrexate, fluorouracil, and leucovorin for stages 3 and 4 gastric carcinoma: A preliminary study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Administration Sc | 2000 |
Intratumoral pyrimidine nucleoside phosphorylase (PyNPase) activity predicts a selective effect of adjuvant 5'-deoxy-5-fluorouridine (5'DFUR) on breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combin | 2000 |
Malignant proliferating trichilemmal tumor in the skin over the breast: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Squamous | 2000 |
HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2000 |
[Postoperative simultaneous radiochemotherapy improves survival in patients with cervical carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Aden | 2000 |
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Du | 2000 |
A case of inoperable esophageal carcinoma with hepatic and nodal metastases which showed a long-term survival after chemoradiotherapy including nedaplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration Schedu | 2000 |
Treatment of neck nodes after induction chemotherapy in patients with primary advanced tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2000 |
[A case of breast cancer with multiple organ metastases responding remarkably to combination therapy of CAF (cyclophosphamide, adriamycin and 5-FU), 5'-DFUR and MPA (medroxyprogesterone acetate)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined M | 2000 |
[Induced hypertensive chemotherapy with angiotensin II found effective for mediastinal lymph node metastases of unknown origin].
Topics: Adenocarcinoma; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Doxo | 2000 |
[Appendiceal mucinous carcinoma].
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplas | 2000 |
Efficacy of intra-hepatectomy 5-FU on recurrence and metastasis of human hepatocellular carcinoma in nude mice.
Topics: Animals; Combined Modality Therapy; Female; Fluorouracil; Hepatectomy; Humans; Liver Neoplasms, Expe | 2001 |
Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 2001 |
[Anaphylactoid shock due to folinic acid during treatment of metastatic colorectal cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anaphylaxis; Antimetabolites, Antineoplastic; Colorectal Ne | 2000 |
[The prospects of the outpatient clinic or home anti-cancer chemotherapy for unresectable recurrence of colorectal cancer].
Topics: Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Ne | 2000 |
[A case of advanced gastric cancer with Virchow's and paraaortic lymph node metastases successfully resected after combined chemotherapy of low-dose CDDP and 5-FU].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Drug Administratio | 2001 |
[A patient with obstructive jaundice due to recurrence after gastric cancer surgery responding remarkably to FLP combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholestasis; Cisplatin; Drainage; Drug Adminis | 2001 |
Surgical and combined treatment of gastric cancer--own experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma; Chemotherapy, A | 2000 |
Base of tongue carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Brachytherapy; Carcinoma, Squamous Cell; Che | 2001 |
Metastatic in-situ perianal Paget's disease.
Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisplatin; Fluorourac | 2001 |
Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Resist | 2001 |
Gastric cancer with Virchow's and multiple lung metastases showing a remarkable response to preoperative chemotherapy: report of a case.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2001 |
[A case of inoperable advanced gall bladder cancer responding to intra-arterial infusion of 5-fluorouracil (5-FU) and leucovorin (LV)].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul | 2001 |
[Treatment of rectal carcinoma].
Topics: Antimetabolites, Antineoplastic; Brachytherapy; Combined Modality Therapy; Drug Therapy, Combination | 2001 |
Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Colectomy; Colorec | 2001 |
[Randomized trial on the effect of radiotherapy in addition to 6 cycles CMF in node-positive breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 2001 |
[The contrast between chemotherapy via pelvic retroperitoneal cannulation and intraperitoneal chemotherapy in gynecological malignancies cancers with lymph node metastases].
Topics: Antimetabolites, Antineoplastic; Endometrial Neoplasms; Female; Fluorouracil; Humans; Injections, In | 1999 |
[Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats].
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Combinations; Drug Screening Assays, Antitum | 2001 |
Node-positive mucosal gastric cancer: a follow-up study.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Female; Fluorourac | 2001 |
Pretreatment surgical lymph node staging predicts results of trimodality therapy in esophageal cancer.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Moda | 2001 |
Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Chemothe | 2001 |
The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Mo | 2001 |
[Clinical and histopathological characteristics of early Leser-Trélat syndrome].
Topics: Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Colon; Colonic Neoplasms; Colonosco | 2001 |
Second primary cardiac B-cell lymphoma after radiation therapy and chemotherapy--a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Cisp | 2001 |
Thymidine phosphorylase expression is useful in selecting adjuvant chemotherapy for stage III gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Female; | 2001 |
A case of bone metastasis from gastric carcinoma after a nine-year disease-free interval.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined | 2001 |
A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
[A case of postoperative multiple hepatic metastasis from esophageal cancer successfully treated by surgical resection and hepatic arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2001 |
[Lymph node excision with laparotomy and chemo-radiation therapy for a hepatocellular carcinoma patient with multiple lymph node metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorour | 2001 |
[Pharmacokinetics of "subselective" arterial infusion chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Catheters, Indwelling; Drug Administration Sc | 2001 |
Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Fe | 2002 |
[Adenocarcinomas of the distal esophagus and gastric cardia: what chemotherapy or chemoradiotherapy for recurrent or metastatic disease?].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Combined Modality | 2001 |
Chemoradiation for metastatic SCCA: role of comorbidity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Comorbidity; Fluorouracil; | 2001 |
P16INK4a protein expression is associated with poor survival of the breast cancer patients after CMF chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltr | 2001 |
[A complete response after neoadjuvant chemotherapy for advanced gastric cancer with esophageal invasion].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dihydrouracil Dehydrogenase (NADP); | 2002 |
Advanced gastric cancer effectively treated by neoadjuvant continuous low-dosage 5-fluorouracil and cisplatin (FP regimen): a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; Lymphatic Met | 2001 |
Docetaxel induced durable response in advanced extramammary Paget's disease: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; | 2002 |
Progesterone receptor status of breast cancer metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 2002 |
[Dormant chemotherapy by low-dose FP and low-dose UFT-E in recurrent gastric cancer with long-term survival--a case report].
Topics: Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administr | 2002 |
Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Chemothe | 2002 |
Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colon | 2002 |
Summary for patients. Survival of elderly patients with colon cancer treated with chemotherapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colon | 2002 |
[Chemotherapy-associated myelosuppression in gynecological oncology].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Chemothe | 2001 |
[Adjuvant simultaneous radiochemotherapy after operated uterine cervix carcinoma in high risk situation. Results of a pilot study].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined M | 2002 |
Resistance to apoptosis is increased during metastatic dissemination of colon cancer.
Topics: Annexin A5; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Apoptosis; bcl | 2002 |
[Prognostic factors in lymph node negative breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; | 2002 |
[Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic A | 2002 |
[A case of gastric cancer with paraaortic lymph node metastasis responding to preoperative chemotherapy and surviving 4 years and 4 months after total gastrectomy].
Topics: Adenocarcinoma, Scirrhous; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; D | 2002 |
[A case treated successfully with low-dose CDDP and 5-FU for the treatment of liver and para-aortic lymph node metastases and second metastasis to anterior mediastinum lymph nodes from gastric cancer after gastrectomy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Drug Administration Schedule; Fluo | 2002 |
[Three cases of recurrent gastric cancer responding to TS-1 therapy following combination therapy with 5-fluorouracil, mitomycin C and cisplatin].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administ | 2002 |
Trimodal combination therapy for maxillary sinus carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combin | 2002 |
Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2002 |
Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2002 |
Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2002 |
Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2002 |
Mesorectal microfoci adversely affect the prognosis of patients with rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2002 |
[A case of unresectable gastric cancer complicated by a serious hepatic disorder and Virchow lymph node metastasis in which FP therapy and TS-1 administration were effective].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
[A case of advanced colon cancer with para-aortic lymph node metastasis responding greatly to treatment by adjuvant chemotherapy of low-dose CPT-11 on an outpatient basis].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemot | 2002 |
Management of oral and pharyngeal cancer: a multidisciplinary approach.
Topics: Bleomycin; Carcinoma, Squamous Cell; Fluorouracil; Humans; Lymphatic Metastasis; Mouth Floor; Mouth | 1975 |
Esophageal carcinoma. The value of staging in long-term survival.
Topics: Administration, Oral; Cyclophosphamide; Esophageal Neoplasms; Esophagus; Female; Fluorouracil; Follo | 1975 |
Ovarian function in patients receiving adjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Androstenedione; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Dehydroepia | 1977 |
Chemotherapy for malignant Zollinger-Ellison tumors: successful treatment with streptozocin and fluorouracil.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Drug Therapy, Combination; Fluorouracil; Gastrins | 1976 |
[Preoperative administration of antineoplastic agents against gastric cancer. V. Clinical evaluation of combined chemotherapy with neocarzinostatin (NCS) and 5-fluorouracil (combined NF therapy) (author's transl)].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Drug Therapy, Combination; Female; Fluorouracil; Humans; L | 1979 |
[Determination of individual sensitivity of gastric cancer to 5-fluorouracil by tumor tissue respiratory and glycolytic indices].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Carcinoma; Fluorouracil; Glycol | 1975 |
Carcinoma of the rectum in adolescence.
Topics: Adenocarcinoma, Mucinous; Adolescent; Age Factors; Cyclophosphamide; Fluorouracil; Humans; Hydroneph | 1975 |
[Chemotherapy of breast cancer].
Topics: Adenocarcinoma, Scirrhous; Breast Neoplasms; Calcinosis; Cyclophosphamide; Drug Therapy, Combination | 1976 |
Mastectomy as an adjunct to combination chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Int | 1978 |
[A clinicopathological study on preoperative anticancer chemotherapy for gastric cancer (author's transl)].
Topics: Adult; Aged; Antineoplastic Agents; Cytarabine; Drug Synergism; Drug Therapy, Combination; Female; F | 1978 |
United States trials of adjuvant therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastect | 1977 |
[The period of time between operation and irradiation of a mamma carcinoma and its cytostatic treatment (author's transl)].
Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; | 1979 |
[A comparative study on the preoperative administration of 5-FU DS and FD-1 against gastric cancer--with special reference to histological findings (author's transl)].
Topics: Adult; Aged; Female; Fluorouracil; Furans; Humans; Lymphatic Metastasis; Male; Middle Aged; Preopera | 1979 |
5-drug adjuvant chemotherapy for breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluoro | 1979 |
Chemotherapeutic agents and estradiol receptor binding capacity.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Dianhydrogalactitol; Estradiol; Female; | 1979 |
Adjuvant chemotherapy of breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; F | 1979 |
Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED).
Topics: Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, C | 1979 |
Histological evaluation of the effect of 5-FU emulsion on lymph node metastasis of stomach cancer.
Topics: Adenocarcinoma; Administration, Oral; Carcinoma; Emulsions; Fluorouracil; Humans; Lymph Nodes; Lymph | 1978 |
Correlation of estrophilin content of primary mammary cancer to eventual endocrine treatment.
Topics: Adrenalectomy; Breast Neoplasms; Castration; Cyclophosphamide; Diethylstilbestrol; Drug Therapy, Com | 1978 |
[Combined irradiation and chemotherapy as postoperative treatment of breast cancer].
Topics: Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; L | 1978 |
[Continuous local application of cytostatics for bronchial carcinoma and mediastinal lymph node metastasisization (author's transl)].
Topics: Adenocarcinoma; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regi | 1976 |
Adjuvant combination chemotherapy with CMF in primary mammary carcinoma.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluoro | 1977 |
Therapy of primary breast cancer.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Female; Fluorouracil; Humans; Lymphatic Metasta | 1977 |
Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Carcinoma, Transitional Cell; Cyclophosphamide; Doxorubicin; | 1976 |
The role of chemotherapy in the treatment of breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combinatio | 1976 |
An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; | 1975 |
Intra-arterial infusion chemotherapy as preoperative treatment of locally advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Catheterization; Female; Fluorouracil; Humans; Lymphatic Metastasis; | 1975 |
Treatment of advanced bronchogenic carcinoma with adriamycin and 5-fluorouracil.
Topics: Alopecia; Carcinoma, Bronchogenic; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hum | 1975 |
Diagnositc and therapeutic patterns of bladder tumours.
Topics: Biopsy; Cystoscopy; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Postoperative Car | 1975 |
[Effect of amphotericin B and its combination with 5-fluorouracil on the development of transplantable rat lymphosarcoma].
Topics: Amphotericin B; Animals; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Lymphatic | 1975 |
Resolution of pulmonary lymphangitic carcinoma of the breast.
Topics: Adenocarcinoma; Adult; Breast Neoplasms; Castration; Female; Fluorouracil; Humans; Lung Neoplasms; L | 1976 |
Combination chemotherapy as an adjuvant treatment in operable breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; | 1976 |
Editorial: Major advance in breast-cancer therapy.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil | 1976 |
[Intra-arterial infusion chemotherapy for recurrent cervical lymph nodes after surgery in esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug | 1992 |
Chemosensitivity of head and neck cancer with the rapid thymidine incorporation assay and its clinical application.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Child; Cisplatin; Colonic Neopl | 1992 |
[Pancreatic endocrine tumor with metastases and increase of alpha-fetoprotein. A case report].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Fatal Outcome; Fluoroura | 1992 |
Adjuvant chemotherapy in high-risk breast cancer patients with ten or more positive lymph nodes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltr | 1992 |
Comparison of partial and modified radical mastectomy in the community setting--"10 years later".
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axilla; | 1992 |
[A case of metastatic urinary bladder tumor from gastric carcinoma].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fluorouracil; | 1992 |
Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Fem | 1992 |
Surgery for local recurrences following deficient radical mastectomy for breast cancer: a selected series of 39 cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1992 |
[Transanorectal ultrasonography in the evaluation of extension and the monitoring of epidermoid cancers of the anus treated by radiation or chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1992 |
T1 squamous cell carcinoma of the arytenoid.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arytenoid Cartilage; | 1992 |
[Preoperative administration of 5-FU emulsion for lymph nodes metastasis of pancreatic carcinoma].
Topics: Administration, Oral; Carcinoma; Emulsions; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; | 1992 |
Continuous infusion of low-dose 5-fluorouracil and radiation therapy for poor-prognosis squamous cell carcinoma of the uterine cervix.
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorouracil; Humans; Infusions, Intrav | 1992 |
[Borrmann 4 gastric cancer treated with l-LV and 5-FU combination--a case report].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; | 1992 |
Triple therapy for advanced squamous cell cancer of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
[Chemotherapy and thymostimulin in the treatment of advanced-stage breast neoplasms].
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cycl | 1992 |
Intravenous or oral adjuvant CMF for node-positive breast cancer.
Topics: Adjuvants, Pharmaceutic; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemot | 1992 |
Prognostic factors in node-positive operable breast cancer patients receiving adjuvant chemotherapy.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Lymphatic Metastasis; Melpha | 1992 |
Comparison of long-term survival of 1986 consecutive patients with breast cancer treated at the National Cancer Institute of Milano, Italy (1971 to 1972 and 1977 to 1978).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noni | 1991 |
[Clinical evaluation of intra-arterial infusion of hyperthermo-chemotherapy in gastric cancer].
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 1991 |
5-Fluorouracil, epirubicin, and BCNU (FEB) in advanced measurable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Epirubicin; | 1990 |
[Problems with topical therapies for extensive squamous cell carcinoma of the buttocks].
Topics: Administration, Topical; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Buttocks; Carcin | 1991 |
Preoperative radiation therapy for locally advanced carcinoma of the rectum. Clinicopathologic correlative review.
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Lymphatic Metastasis; Neoplasm Stag | 1992 |
Two simple indexes used to evaluate the impact of therapy on the quality of life of patients receiving primary chemotherapy for operable breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1991 |
Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carc | 1991 |
Complete response of a transitional cell carcinoma of the renal pelvis to leucovorin/5 fluorouracil chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Fluorouracil; | 1991 |
[Evaluation of effective neo-adjuvant chemotherapy (FLEP therapy) in the treatment of advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1991 |
[Interstitial hyperthermia (MINERVE) for perineal local recurrence of rectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cispl | 1991 |
Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1991 |
Combined modality treatment of advanced cancers of the oral cavity and oropharynx.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1991 |
The force of change in the management of squamous-cell cancer of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1991 |
Adjuvant therapy of stage II breast cancer treated with CMFVP, radiation therapy and VATH following lumpectomy. A pilot trial.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1991 |
[Effect, recurrence and prognosis of intra-arterial infusion chemotherapy with anticancer agents for advanced breast cancer--especially, the significance of tumor blood vessels].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Fluorouracil; | 1991 |
A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas.
Topics: Adenocarcinoma; Fluorouracil; Gastrointestinal Neoplasms; Leucovorin; Lymphatic Metastasis; Neoplasm | 1991 |
[Adjuvant chemotherapy in premenopausal women].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 1991 |
[Results of treatment following breast-saving therapy: analysis of intramammary recurrence].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, | 1990 |
Cisplatin, vindesine, and 96-h continuous infusion of 5-fluorouracil as initial chemotherapy for locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1991 |
High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1991 |
Preoperative multimodal therapy for locally advanced non-inflammatory breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cobalt Radioisotopes; Combined Mod | 1991 |
[Evaluation of subselective intraarterial infusion chemotherapy in advanced gastric cancer and recurrence case-evaluated on factors other than direct effects].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 1990 |
Clinical evaluation of chemotherapy under angiotensin II-induced hypertension in patients with advanced cancer.
Topics: Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Cisplatin; Dox | 1990 |
Effect of preoperative chemotherapy on mastectomy for locally advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1990 |
Combined modality therapy for locally advanced non-small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1990 |
Clinical study of pirarubicin for breast cancer in Japan. Clinical Study Group of THP for Breast Cancer in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1990 |
Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1990 |
Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1990 |
Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1990 |
Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1990 |
A phase II study of 5-fluorouracil/cisplatinum in recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1990 |
Acute non lymphoid leukemia following CMF treatment as adjuvant therapy in positive node breast cancer. Case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Fluoroura | 1990 |
[Adjuvant chemotherapy of breast cancer with the CMFV protocol].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1990 |
Adjuvant 5-FU and MeCCNU improves survival following curative gastrectomy for adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemot | 1990 |
Adjuvant chemotherapy and scar irradiation in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1990 |
[Drug therapy of pulmonary metastases of breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans | 1990 |
[Long-term arterial infusion chemotherapy in advanced and recurrent gastric cancer patients at home and an interesting autopsy case].
Topics: Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; D | 1990 |
Multicentric reticulohistiocytosis and cancer: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arthritis; Breast Neoplasms; Carcinoma, Intraductal, | 1985 |
Conventional fractionation radiotherapy combined with 5-fluorouracil for metastatic malignant melanoma.
Topics: Abdominal Neoplasms; Adult; Aged; Cobalt Radioisotopes; Female; Fluorouracil; Humans; Liver Neoplasm | 1987 |
[Chemotherapy and partial surgery in epithelioma of the pharyngo-larynx].
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; | 1988 |
Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleo | 1989 |
Tumor lysis syndrome in nonhematopoietic neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; Carcinoma, Intraductal, | 1989 |
[Plasma and tissue concentration of tegafur by a new soft capsule type suppository in colorectal carcinoma].
Topics: Aged; Aged, 80 and over; Capsules; Colorectal Neoplasms; Female; Fluorouracil; Humans; Lymph Nodes; | 1989 |
[Chemotherapeutic effect on metastatic tumors].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Doxorubicin; Fluorou | 1989 |
[Influence of OK-432 on intratumor 5-fluorouracil concentration in cases given UFT].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Products; Biotransformation; Colonic Neop | 1989 |
Distributions of tegafur in tissues of gastric adenocarcinoma patients: tissue uptakes and concentrations in plasma after oral and rectal administrations.
Topics: Adenocarcinoma; Administration, Oral; Administration, Rectal; Adult; Aged; Female; Fluorouracil; Hum | 1989 |
[Two cases of gastrointestinal cancers with major responses to sequential methotrexate 5-FU plus 5'-DFUR].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Ne | 1989 |
Clinical trials referral resource. Adjuvant therapy of breast cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Buserelin; | 1989 |
Advanced prostatic carcinoma: pulmonary manifestations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Fluorouracil; Hum | 1985 |
Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1989 |
[Optimization of chemotherapy of stomach cancer].
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; D | 1989 |
Use of serum squamous cell carcinoma antigen assays in chemotherapy treatment of cervical cancer.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1989 |
Metastatic extramammary Paget's disease: dramatic response to combined modality treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Lym | 1988 |
[Treatment methods for scirrhous carcinoma of the stomach--with special reference to total gastrectomy and chemotherapy in early postoperative period].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fluorouracil; | 1988 |
[Breast carcinoma and pregnancy. A case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Non | 1988 |
Aggressive resection of metastatic disease in selected patients with malignant gastrinoma.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Combin | 1986 |
Two cases with objective complete response to neo-adjuvant chemotherapy of breast carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noni | 1986 |
Clinical evidence of feasibility and efficacy of simultaneous irradiation and chemotherapy in advanced squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachytherapy; Carcinom | 1986 |
[Combined radio- and chemotherapy of anal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Colo | 1986 |
[The features of liver metastasis of breast cancer on imaging and its response to arterial infusion chemotherapy].
Topics: Adult; Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubi | 1986 |
[Serum and tissue concentrations of UFT in patients with lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Lung; Lung Neoplasms; Lymph No | 1986 |
Mitomycin C associated hemolytic uremic syndrome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Doxorubicin; Fluorouracil; Hemolyti | 1987 |
[A case of recurrent sigmoid colon cancer successfully treated with 5-FU and UFT].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Lympha | 1988 |
[Clinical study on the effect of chemotherapy in the treatment of pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Lymphatic Metastasis; | 1988 |
Cure of advanced gastric cancer by combined chemotherapy with cisplatinum, mitomycin C, and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorourac | 1988 |
Radiotherapy for the prevention of local-regional recurrence in high risk patients post mastectomy receiving adjuvant chemotherapy.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphami | 1988 |
[Inflammatory breast carcinoma--possibilities and results of surgical treatment and adjuvant chemotherapy, especially when done preoperatively].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Doxor | 1988 |
[Preoperative treatment of lymph node metastases of gastric cancer by local injection of 5-FU adsorbed on activated carbon--clinical study of 5-FU concentration in resected lymph nodes].
Topics: Adsorption; Carbon; Fluorouracil; Humans; Injections; Lymph Node Excision; Lymph Nodes; Lymphatic Me | 1988 |
[Preoperative treatment of lymph node metastasis in cases of gastric cancer by local injection of anticancer drugs--preliminary report].
Topics: Antineoplastic Agents; Charcoal; Fluorouracil; Humans; Lymphatic Metastasis; Preoperative Care; Stom | 1988 |
Comments on primary and adjuvant treatments of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1988 |
The follow up study of intra-arterial infusion chemotherapy with local vein blocking as a surgical neo-adjuvant treatment for locally advanced breast cancer.
Topics: Breast; Breast Neoplasms; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up St | 1988 |
Preoperative irradiation and 5-fluorouracil suppository for carcinoma of the rectum.
Topics: Aged; Combined Modality Therapy; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neop | 1988 |
Cisplatin and 5-fluorouracil in the primary management of squamous esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1987 |
Local management in primary breast cancer. Our experience of 331 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 1987 |
[Rational combinations of hormonal and cytostatic agents in disseminated forms of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosphamide; D | 1987 |
Neoadjuvant chemotherapy before definitive treatment for stage III carcinoma of the breast.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 1987 |
[Clinico-biochemical findings in malignant carcinoid during cytostatic therapy (description of a case)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; | 1986 |
Determinants of survival after intraarterial infusion of 5-fluorouracil for liver metastases from colorectal cancer: a multivariate analysis.
Topics: Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusion | 1986 |
[Chemotherapy of recurrent squamous cell carcinomas in the ENT area with cisplatin/adriamycin (DDP/ADM) and methotrexate/5-fluorouracil (MTX/5-Flu): a retrospective comparison of 2 protocols].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1986 |
[Compliance in adjuvant chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; | 1986 |
Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Combined Modality Therapy; | 1986 |
Management of locoregional recurrent breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Combined Modality T | 1986 |
[Adjuvant therapy of breast cancer. 1: Cytostatic therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1986 |
[4-component chemotherapy and radiation therapy of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Modality | 1986 |
Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1986 |
Analysis of the long-term results of our combination therapy for maxillary cancer, with particular reference to treatment of T4 and N1-3 maxillary cancer.
Topics: Adolescent; Adult; Age Factors; Aged; Carcinoma, Squamous Cell; Child; Child, Preschool; Combined Mo | 1985 |
Weight gain in patients receiving adjuvant chemotherapy for carcinoma of the breast.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Combined | 1985 |
Combined cryosurgical, chemotherapeutic, and radiotherapeutic management of T1-4N0M0 oral cavity cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cobalt Radioi | 1985 |
[Reduced-dose adjuvant CMF-chemotherapy combined with postoperative irradiation in breast cancer with lymphatic metastases. A prospective study of 45 patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cesium Radioisotopes; | 1985 |
[Radio-chemotherapy integration].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1985 |
Surgical treatment of carcinoma of the breast. V. Changes in patient population and therapeutic modalities at a metropolitan hospital (1971-1980).
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neop | 1985 |
Management of inflammatory carcinoma of the breast. A combined modality approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined M | 1985 |
[Therapy of recurrent squamous cell cancers in the ENT area with the sequential methotrexate (MTX)/5-fluorouracil (5-Fu) protocol].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Fluor | 1985 |
Maintenance chemotherapy for high-risk patients. A preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1985 |
The cyclophosphamide, hexamethylmelamine, 5 fluorouracil (CHF) regimen in the treatment of advanced and recurrent ovarian cancer.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1985 |
Treatment of anal canal carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachyt | 1985 |
[Preoperative combination therapy involving local administration of a non-specific immunoactivated preparation (OK-432) and chemotherapeutic preparations for patients with stomach cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Female; Fluorourac | 1985 |
[Preoperative cancer chemotherapy for gastric cancer].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fluorou | 1985 |
[Multimodality therapy of colorectal cancer].
Topics: Aged; Animals; Antibiotics, Antineoplastic; Colonic Neoplasms; Drug Administration Schedule; Emboliz | 1985 |
[A case of long-term survival of liver metastasis of breast cancer successfully treated with chemotherapy and endocrine therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Cy | 1985 |
Treatment of epidermoid carcinoma of the anal canal.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 1985 |
[Adjuvant mono- and polychemotherapy in breast cancer (a randomized study)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1985 |
[Preoperative treatment with 5-fluorouracil (5-FU) in gastric and colorectal cancer].
Topics: Administration, Oral; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Parenteral; Injections, In | 1985 |
Local-regional failure in patients treated with adjuvant chemotherapy for breast cancer.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphami | 1985 |
[Esophageal tumors--therapeutic problems].
Topics: Adenocarcinoma; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cobalt Isotopes; Esophageal Neoplasm | 1972 |
Cancer of the tongue.
Topics: Bleomycin; Carcinoma, Squamous Cell; Dental Caries; Electrocoagulation; Fluorides, Topical; Fluorour | 1973 |
Palliative treatment of mammary cancer. Response of soft tissue, pleural and pulmonary disease.
Topics: Adrenalectomy; Adult; Age Factors; Aged; Breast Neoplasms; Castration; Cyclophosphamide; Dexamethaso | 1973 |
Metastatic basal cell carcinoma: review, report of a case, and chemotherapy.
Topics: Aged; Antineoplastic Agents; Biopsy, Needle; Bleomycin; Carcinoma, Basal Cell; Cyclophosphamide; Dru | 1974 |
Second-look operation for colon carcinoma after fluorouracil therapy.
Topics: Colectomy; Colonic Neoplasms; Fluorouracil; Humans; Lymphatic Metastasis; Neoplasm Metastasis; Palli | 1970 |
[Late results of observing patients with extensive breast cancer who have undergone chemotherapy by infusion].
Topics: Breast Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Female; Fluorouracil; Follow-Up Studies; | 1974 |
Practical aspects of investigation and treatment of colorectal cancer.
Topics: Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Infusions, Parenteral; Liver Function | 1972 |
Widespread extracranial metastases of glioblastoma multiforme. Report of case and clinicopathological review of cases in literature.
Topics: Adolescent; Autopsy; Biopsy; Bone Neoplasms; Brain Neoplasms; Carotid Arteries; Cauda Equina; Cerebr | 1972 |
Axillary metastases from unknown primary sites.
Topics: Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Axilla; Breast Neoplasms; Carcinoma, Squamous Cel | 1973 |
Primary liver carcinoma.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Biopsy; Bone Neoplasms; Carcinoma, Hepatocellular; | 1974 |
[Determination of the individual sensitivity of gastric cancerous tumors to 5-fluorouracil according to respiratory and glycolytic indices].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Carcinoma; Drug Evaluation, Pre | 1974 |
A second look at the second operation in colonic cancer after the administration of fluorouracil.
Topics: Biopsy; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lymphat | 1974 |
In vitro estimate of sensitivity of individual human tumors to antitumor agents.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Arsenicals; Benzoates; Breast Neoplasms; Carbon Radi | 1974 |
Arterial infusion and radiation therapy in the treatment of advanced cancer of the nasal cavity and paranasal sinuses.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Carotid Artery, External; Carotid Artery, Internal; Chemot | 1973 |
Prognosis of uterine cervical cancer with extensive lymph node metastases. Special emphasis on the value of pelvic lymphadenectomy in the surgical treatment of uterine cervical cancer.
Topics: Cobalt Isotopes; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Mitomycins; Postop | 1972 |
[Topical administration of carcinostatics to mediastinal lymph node lesion metastasized lung cancer--an adjuvant therapy in surgery of lung cancer].
Topics: Animals; Dogs; Fluorouracil; Gold Colloid, Radioactive; Humans; Injections; Injections, Intra-Arteri | 1972 |
Increased concentration of anticancer agents in regional lymph nodes by fat emulsions, with special reference to chemotherapy of metastasis.
Topics: Animals; Emulsions; Fats; Fluorouracil; Histocytochemistry; Injections; Injections, Intravenous; Kid | 1973 |
The treatment of premalignant and malignant lesions of the vulva.
Topics: Administration, Topical; Adult; Aged; Carcinoma in Situ; Carcinoma, Squamous Cell; Female; Fluoroura | 1974 |
Synchronization of human tissues and its consequences for cancer therapy in ENT. Cell kinetic and clinical studies.
Topics: Aged; Animals; Carcinoma; Carcinoma, Squamous Cell; Cell Division; DNA Replication; DNA, Neoplasm; E | 1974 |
Therapeutic implications from a mathematical model characterizing the course of breast cancer.
Topics: Breast Neoplasms; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Mastectomy; | 1969 |
Prospects for the control of metastases.
Topics: Anticoagulants; Breast Neoplasms; Female; Fluorouracil; Humans; Lymphatic Metastasis; Neoplasm Recur | 1969 |
[Basic principles of percutaneous radiotherapy in cervical lymph node metastases].
Topics: Carcinoma, Squamous Cell; Cesium Isotopes; Cobalt Isotopes; Electrons; Fluorouracil; Head and Neck N | 1971 |
Experience with ftorafur treatment in breast cancer.
Topics: Breast Neoplasms; Diarrhea; Female; Fluorouracil; Furans; Humans; Injections, Intravenous; Leukopeni | 1972 |
[Combined application of drugs in cancer chemotherapy with special reference to the combination of mitomycin C, 5-fluorouracil, and cytosine arabinoside].
Topics: Cytarabine; Female; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Mitomycins; Neoplasm | 1972 |
[Villous tumors of the jejunum and ileum].
Topics: Adenocarcinoma; Cell Transformation, Neoplastic; Female; Fluorouracil; Humans; Ileum; Intestinal Neo | 1971 |
Xeroderma pigmentosum.
Topics: Adult; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Child, Preschool; Eyelid Neoplasms; Female; | 1971 |
Association of cancer of the breast and acute myelocytic leukemia.
Topics: Adenocarcinoma; Adult; Aged; Anti-Bacterial Agents; Breast Neoplasms; Carcinoma; Female; Fluorouraci | 1967 |
Combination chemotherapy in the management of breast cancer metastases.
Topics: Adult; Aged; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Synergism; Fe | 1970 |
[Experience with the treatment of patients with malignant tumors with 5-fluorouracil].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Duodenal Neoplasms; Female; Fluorouracil; Humans; In | 1967 |
Carcinoma of the colon and rectum.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic | 1968 |
A ten-year study of 5-flurouracil in disseminated breast cancer with clinical results and survival times..
Topics: Breast Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Prognosis; | 1969 |